Asciminib/ABL001 
Oncology Clinical Trial Protocol CABL001A2301  
A phase 3, multi -center, open -label, randomized study of oral 
ABL001 (asciminib)  versus bosutinib in patients with Chronic 
Myelogenous Leukemia in chronic phase (CML -CP), 
previously treated with 2 or more tyrosine kinase inhibitors  
Supplement 
 
This supplement contains 
 
1. Protocol CABL001A2301  
a. Protocol  – Global Initial version (Version 1.0)  
b. Protocol  – Global Final version (Version 3.0)  
c. Protocol  – US local version 
d. Protocol – Summary of changes 
 
 
2. Statistical Analysis Plan for Protocol CABL001A2301  
a. Statistical Analysis Plan – Initial version 
b. Statistical Analysis Plan – Final version (Version 3.0)  
c. Statistical Analysis Plan – Addendum  
d. Statistical Analysis Plan – Summary of changes  
   
 
 
 
 
1. Protocol  
  
Novartis Confidential Page 2
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 6
List of tables ........................................................................................................................ 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Protocol summary :............................................................................................................. 11
Amendment 1 (10 -Apr-2017) ............................................................................................ 17
1Background ........................................................................................................................ 19
1.1 Overview of disease pathogenesis, epidemiology and current treatment .............. 19
1.2 Introduction to investigational treatment ............................................................... 20
1.2.1 Overview of ABL001 ............................................................................ 20
1.2.2 Overview of bosutinib........................................................................... 26
2Rationale ............................................................................................................................ 27
2.1 Study  rationale and purpose ................................................................................... 27
2.2 Rationale for the stud y design ............................................................................... 28
2.2.1 Rationale for Biomarker Assessment.................................................... 29
2.3 Rationale for dose and regimen selection .............................................................. 29
2.4 Rationale for choice of combination drugs............................................................ 30
2.5 Rationale for choice of comparators drug bosutinib.............................................. 30
2.6 Risks and benefits .................................................................................................. 31
3Objectives and endpoints ................................................................................................... 31
4Study  design ...................................................................................................................... 34
4.1 Description of stud y design ................................................................................... 34
4.2 Timing of interim anal yses and design adaptations ............................................... 35
4.3 Definition of end of study ...................................................................................... 35
4.4 Early study termination .......................................................................................... 35
5Population .......................................................................................................................... 36
5.1 Patient population .................................................................................................. 36
5.2 Inclusion criteria .................................................................................................... 36
5.3 Exclusion criteria ................................................................................................... 38
6Treatment ........................................................................................................................... 40
6.1 Study  treatment ...................................................................................................... 40
6.1.1 Dosing regimen ..................................................................................... 40
6.1.2 Ancillary  treatments .............................................................................. 41
6.1.3 Rescue medication ................................................................................ 41

Novartis Confidential Page 3
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
6.1.4 Guidelines for continuation of treatment .............................................. 41
6.1.5 Treatment duration ................................................................................ 41
6.2 Dose escalation guidelines ..................................................................................... 41
6.3 Dose modifications ................................................................................................ 41
6.3.1 Dose modification and dose delay ........................................................ 41
6.3.2 Dose adjustments for QTcF prolongation ............................................. 51
6.3.3 Follow- up for toxicities ......................................................................... 51
6.3.4 Anticipated risks and saf ety concerns of the study drug ....................... 53
6.4 Concomitant medications for patients on ABL001 ............................................... 53
6.4.1 Permitted concomitant therap y ............................................................. 53
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... 53
6.4.3 Prohibited concomitant therap y ............................................................ 54
6.4.4 Other concomitant medications ............................................................. 55
6.5 Concomitant medications for patients on Bosutinib .............................................. 55
6.5.1 Prohibited concomitant medications ..................................................... 56
6.6 Patient numbering, treatment assignment or randomization ................................. 57
6.6.1 Patient numbering ................................................................................. 57
6.6.2 Treatment assignment or randomization............................................... 57
6.6.3 Treatment blinding ................................................................................ 58
6.7 Study  drug preparation and dispensation ............................................................... 58
6.7.1 Study  treatment packaging and labeling ............................................... 58
6.7.2 Drug supply  and storage ........................................................................ 58
6.7.3 Study  drug compliance and accountabilit y ........................................... 58
6.7.4 Disposal and destruction ....................................................................... 59
7 Visit schedule and assessments ......................................................................................... 59
7.1 Study  flow and visit schedule ................................................................................ 59
7.1.1 Molecular pre -screening ........................................................................ 69
7.1.2 Screening ............................................................................................... 69
7.1.3 Run- in period ........................................................................................ 70
7.1.4 Treatment period ................................................................................... 71
7.1.5 Visit windows ........................................................................................ 71
7.1.6 Discontinuation of study treatment ....................................................... 71
7.2 Assessment ty pes................................................................................................... 73
7.2.1 Efficacy  assessments ............................................................................. 73
7.2.2 Safety  and tolerability  assessments ....................................................... 75
7.2.3 Pharmacokinetics .................................................................................. 80

Novartis Confidential Page 4
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
7.2.4 Biomarkers ............................................................................................ 82
7.2.5 Resource utilization ............................................................................... 85
7.2.6 Patient reported outcomes ..................................................................... 85
8Safety  monitoring and reporting ........................................................................................ 87
8.1 Adverse events ....................................................................................................... 87
8.1.1 Definitions and reporting ...................................................................... 87
8.1.2 Laboratory  test abnormalities ................................................................ 88
8.1.3 Adverse events of special interest ......................................................... 89
8.2 Serious adverse events ........................................................................................... 89
8.2.1 Definitions............................................................................................. 89
8.2.2 Reporting............................................................................................... 90
8.3 Emergency  unblinding of treatment assignment ................................................... 90
8.4 Pregnancies ............................................................................................................ 90
8.5 Warnings and precautions ...................................................................................... 91
8.6 Data Monitoring Committee .................................................................................. 91
8.7 Steering Committee ............................................................................................... 91
9Data collection and management ....................................................................................... 92
9.1 Data confidentiality ............................................................................................... 92
9.2 Site monitoring ...................................................................................................... 92
9.3 Data collection....................................................................................................... 93
9.4 Database management and quality  control ............................................................ 93
10Statistical methods and data anal ysis................................................................................ 94
10.1 Analy sis sets .......................................................................................................... 94
10.1.1 Full Anal ysis Set ................................................................................... 94
10.1.2 Safety  set............................................................................................... 94
10.1.3 Per- Protocol set ..................................................................................... 94
10.1.4 Dose -determining anal ysis set............................................................... 95
10.1.5 Pharmacokinetic anal ysis set................................................................. 95
10.1.6 Other anal ysis sets ................................................................................. 95
10.2 Patient demographics/other baseline characteristics ............................................. 95
10.3 Treatments (stud y treatment, concomitant therapies, compliance) ....................... 95
10.4 Primary  objective ................................................................................................... 96
10.4.1 Variable ................................................................................................. 96
10.4.2 Statistical hypothesis, model, and method of analy sis.......................... 96
10.4.3 Handling of missing values/censoring/discontinuations ....................... 96
10.4.4 Supportive and Sensitivity anal yses...................................................... 97

Novartis Confidential Page 5
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
10.5 Secondary  objectives ............................................................................................. 97
10.5.1 Key secondary  objective(s) ................................................................... 97
10.5.2 Other secondary  efficacy objectives ..................................................... 98
10.5.3 Safety  objectives ................................................................................. 101
10.5.4 Secondary  PK objectives ..................................................................... 102
10.6 Exploratory  objectives ......................................................................................... 103
10.6.1 Exploratory  efficacy  objectives ........................................................... 103
10.6.2 Exploratory  PK objectives .................................................................. 104
10.6.3 Exploratory  biomarker objectives ....................................................... 104
10.6.4 Exploratory  Patient Reported Outcomes objectives ........................... 105
10.7 Interim anal ysis.................................................................................................... 106
10.8 Sample size calculation........................................................................................ 106
10.9 Power for anal ysis of key secondary  variables.................................................... 107
11Ethical considerations and administrative procedures .................................................... 107
11.1 Regulatory and ethical compliance ...................................................................... 107
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... 107
11.3 Informed consent procedures............................................................................... 108
11.4 Discontinuation of the study ................................................................................ 108
11.5 Publication of study  protocol and results ............................................................. 108
11.6 Study  documentation, record keeping and retention of documents ..................... 109
11.7 Confidentiality  of study  documents and patient records ..................................... 110
11.8 Audits and inspections......................................................................................... 110
11.9 Financial disclosures ............................................................................................ 110
12Protocol adherence .......................................................................................................... 110
12.1 Amendments to the protocol ................................................................................ 110
13References (available upon request) ................................................................................ 111
14Appendices ...................................................................................................................... 113
14.1 Appendix 1 L ist of CYP3A4 inducers, inhibitors and substrates ........................ 113

Novartis Confidential Page 6
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
List of figures
Figure 1 -1 KCL -22 CML Xenograft ....................................................................... 21
Figure 4 -1 Schematic of Study  Design ................................................................... 35
List of tables
Table 3 -1 Objectives and related endpoints .......................................................... 32
Table 6 -1 Dose and treatment schedule................................................................. 40
Table 6 -2 Criteria for dose reduction/interruption and re -initiation of ABL001 
and bosutinib treatment for adverse drug reactions .............................. 43
Table 6 -3 Dose reduction steps for ABL001 and bosutinib .................................. 51
Table 6 -4 Packaging and labeling ......................................................................... 58
Table 7 -1 Visit evaluation schedule ...................................................................... 60
Table 7 -2 Blood samples (efficacy  primary  endpoint).......................................... 74
Table 7 -3 ECOG Performance status scale ........................................................... 77
Table 7 -4 Central clinical labo ratory  parameters collection plan .......................... 77
Table 7 -5 Central ECG collection (all patients) .................................................... 79
Table 7 -6 Central ECG collection plan for patients in full PK ABL001 group ....79
Table 7 -7 Pharmacok inetic blood collection log (Sparse PK -group -ABL001 
arm) ....................................................................................................... 81
Table 7 -8 Pharmacokinetic blood collection log ( Full PK group -ABL001 
arm) ....................................................................................................... 82
Table 7 -9 Biomarker sample collection plan ......................................................... 84
Table 10 -1 Non compartmental pharmacokinetic pa rameters in full PK group.... 103
Table 10 -2 Detectable effect sizes for key  secondary  endpoint ............................ 107
Table 14 -1 CYP3A4 inducers ................................................................................ 113
Table 14 -2 CYP3A4 inhibitors .............................................................................. 114
Table 14 -3 CYP3A4 substrates: Narrow therapeutic index, sensitive, and 
others ................................................................................................... 115

Novartis Confidential Page 7
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
List of abbreviat ions
ABL Abelson proto -oncogene
AE Adverse Event
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
ANC Absolute neutrophil count
AP Accelerated phase
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
ATP Adenosine triphosphate
AUC Area under the curve
AV block Atrioventricular block
BC Blast crisis
BCRP Breast Cancer Resistant Protein
BID bis in diem /twice a day
BUN Blood urea nitrogen
CBC Complete Blood Count
CCA Clonal chromosome abnormalities
CCyR Complete Cytogenetic Response
CHR Complete Hematological Response
CI Confidence Interval
CMH Cochran –Mantel –Haenszel
CML Chronic myelogenous leukemia
CP Chronic phase
CRO Contract Research Organization
CSP Clinical study protocol
CSR Clinical study report
CT Computed tomography 
CTCAE Common Terminology Criteria for Adverse Events
CV Coefficient of variation
CYP3A4 Cytochrome P450 3A4
DDI Drug -drug interaction
DILI Drug -induced liver injury
DLCO Carbon monoxide diffusing capacity
DMC Data Monitoring Committee
DNA Desoxyribonucleic acid
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic Case Report Form
EDC Electronic data capture
ELN European Leukemia Network
EOT End of Treatment
eRT eResearchTechnology, Inc
hADME Human ADME study (Absorption, Distribution, Metabolism and Excretion) 
HDL High density lipoprotein
ICF Informed Consent Form

Novartis Confidential Page 8
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
ICH International Conference on Harmonization
IEC Independent Ethics Committee
INR International normalized ratio
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
K-M Kaplan -Meyer
LDL Low density lipoprotein
LFT Liver function test
LLN Lower limit of normal
LSC Leukemia stem cell
MCyR Major Cytogenetic Response
mCyR Minor Cytogenetic Response
MMR Major Molecular Response
MRI Magnetic resonance imaging
OS Overall survival
PAS Pharmacokynetic analysis set
PCR Polymerase Chain Reaction
PCyR Partial Cytogenetic Response
PD Pharmacodynamic
P-gp Permeability glycoprotein
Ph+ Philadelphia chromosome positive
PHI Protected Health Information
PK Pharmacokinetics
PLT Platelets
PPS Per-protocol set
QD Quaque die/once a day
QT Q to T interval (ECG)
QTcF QTc Fredericia
REB Research Ethics Board
RNA Ribonucleic acid
RQ-PCR Real time quantitative polymerase chain reaction
RU Resource Utilization
SAE Serious Adverse Event
SAP The Statistical Analysis Plan (SAP) is a regulatory document which provides evidence of 
preplanned analyses
SC Steering committee
SD Standard deviation
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic pyruvic transaminase
SOP Standard Operating Procedure
TBIL Total bilirubin
TKI Tyrosine Kinase Inhibitor
TTF Time to treatment failure
UGT Uridin diPhospho -glucuronosyltransferase
ULN Upper limit of normal

Novartis Confidential Page 9
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
USPI US prescribing information
WBC White blood cell count

Novartis Confidential Page 10
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biologic Sa mples A biological speci men including, for ex ample, blood (plas ma, serum), saliva, tissue,
urine, stool, etc. t aken fr om a study subject or study patient
Cycles Number and timing or recommended repetitions of therapy are usually expressed as 
number of days (e.g.: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed consent must 
be obtained (i.e. prior to starting any of the procedures described in the protocol)
Investigational drug The study treatment whose properties are being tested in the study; this definition is 
consistent with US CF R 21 Section 312.3 and is synonymous with “investigational 
new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indication/approved dosage, or that are tested 
in a fixed combination. Investigational treatment generally does not include other 
study treatments administered as concomitant background therapy required or 
allowed by the p rotocol when used in within approved indication/dosage
Medication number A unique identifier on the label of each study treatment package which is linked to 
one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study procedures that 
was not included in the investigational treatment
Subject Number ( Subject 
No.)A unique identifying number assigned to each patient/subject/healthy volunteer who 
enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional segments 
such as screening, baseline, titration, washout, etc.
Randomization number A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatmen t arm assignment
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administ ered to the 
patient (subject) as part of the required study procedures, including placebo and 
active drug run -ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatment combination; s tudy treatment in this case 
refers to the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any reason
Treatment group A treatment group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts. Cohorts are not expanded, new cohorts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified a ssessments at specified time points
Withdrawal of cons ent Withdrawal of co nsent occurs only wh en a patient d oes not want to partic ipate in the 
study any longer, a nd does not want any further visits or assessmen ts, and does not 
want any further study related cont act

Novartis Confidential Page 11
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
Protocol summary :
Title A phase 3, multi -center, open -label, randomized study of oral ABL001 versus 
bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML -
CP), previously treated with 2 or m ore tyrosine kinase inhibi tors
Brief title Study of efficacy of CML- CP patients treated with ABL001 versus bosutinib , 
previous ly treated with 2 or more TKIs
Sponsor and
Clinical PhaseNovartis;
Phase 3
Investigation ty pe Drug 
Study  type Interventional
Purpose and rationale Purpose:
The purpose of this pivotal study is to compare the efficacy of ABL001 with that of 
bosutinib in the treatment of patients with CML -CP having previously been treated 
witha minimum of two prior ATP- binding site TKIs with BCR -ABL ratios ≥ 1% IS at 
screening.
Rationale:
There remains an unmet need for new compounds in patients with CML who have 
failed at least two prior TKIs. Current practice suggests that a second generation 
TKI will have been used for first line therapy for about one half of patie nts with 
CML, meaning that most patients who have failed at least two prior TKIs will have 
failed at least one if not two second generation TKI s: dasatinib and/or nilotinib. 
Potentially, such patients may also have failed bosutinib and/or ponatinib ( Soverini 
2014 ). Patients having failed at least two TKIs may have limited sensitivity to the 
remaining available agents and, thus, there exists a need for new safe and 
effective therapy. In addition, mutations will have developed in 21 to 33% of 
patients that prevent the use of specific TKIs, increasing the need for a better and 
alternative compound ( Soverini 2014 ). Omacetaxine, a chemotherapeutic agent, is 
available for patients who have failed at least two prior TKIs under these conditions 
but only in the US and Canada. This agent is not available for most patients 
globally, where a bigger unmet medical need is present. Thus, there remains an 
unmet need for patients with CML who have failed at least two prior TKIs despite 
the existence of multiple agents.
Primary  Objective
and Key  Secondary  
ObjectivePrimary  Objective: To compare the Major Molecular Response ( MMR )rate at 24 
weeks of ABL001 versus bosutinib
Key Secondary  Objective: To compare MMR rate at 96 weeks of ABL001 versus 
bosutinib

Novartis Confidential Page 12
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
Secondary  Objectives ●To compare additional efficacy parameters of ABL001 versus bosutinib :
● cytogenetic response rate (Complete, Partial, Major, Minor, Minimal, no 
response) at and by all scheduled data collection time points, including 24, 48 
and 96 weeks
● MMR rate at all scheduled data collection time points (except 24 and 96 
weeks which are a lready covered by primary and key secondary endpoints)
● MMR rate by all scheduled data collection time points, including 24, 48 
and 96 weeks
● Time to MMR
● Duration of MMR
● Time to CCyR
● Duration of CCyR
● Time to treatment failure
● Progression free s urvival
● Overall survival
● To compare the safety and tolerability profile of ABL001 versus bosutinib by 
type, frequency and severity of adverse events, changes in laboratory values that 
fall outside the pre -determined ranges and clinically notable ECG an d other safety 
data (vital signs, physical examination)
●To characterize the PK of ABL001 in the CML -CP population (Trough plasma 
concentrations, PK parameters in full PK group: Cmax, Tmax, AUC0 -12h, CL/F)
Study  design This study is a randomized, phase 3, open -label, active -controlled multi -center 
study. Patients will be randomized to the novel BCR -ABL TKI ABL001 and 
bosutinib in a 2:1 ratio. The randomization is to be stratified to ensure the study 
population is balanced between the arms with respect to the patient’s cytogenetic 
response status at baseline (Major Cytogenetic response (complete or partial) vs 
No major cytogenetic response (minor, minimal or none) ).
The study design incorporates a 2:1 randomization, allocating more patients to the 
ABL001 arm in order to learn more about the safety profile of the experimental 
therapy, whereas the safety of bosutinib therapy is well documented. Treatment 
duration for each patient in the present study is for up to 96 weeks after the last 
patient received the first dose, which should be adequate to address both the 
primary objective of the study, i.e. determination of the MMR rate at 24 weeks, as 
well as secondary efficacy and safety objectives.
Population Two-hundred and twenty -two (222) patients with CML -CP who had prior treatment 
with two or more ATP binding site TKIs will be randomized on a 2:1 basis to 
receive either ABL001 or bosutinib. Patients with known history of T315I and/or
V299L mutations at study entry will be excluded from the trial since bosutinib, the 
comparator, is n ot approved for these patients.
Inclusion criteria Patients eligible for inclusion in this study have to meet allof the following criteria:
1.Male or female patients with a diagnosis of CML -CP ≥ 18 years of age
2.Patients must meet all of the following laboratory values at the screening visit:
● < 15% blasts in peripheral blood and bone marrow
● < 30% blasts plus promyelocytes in peripheral blood and bone marrow
● < 20% basophils in the peripheral blood
● ≥ 50 x 109/L (≥ 50,000/mm3) platelets
● Transient prior therapy related thrombocytopenia (< 50,000/mm3 for ≤30 
days pr ior to screening) is acceptable
● No evidence of extramedullary leukemic involvement, with the exception 
of hepatosplenomegaly
3.BCR -ABL ratio ≥ 1% IS according to central laboratory at the screening 
examination

Novartis Confidential Page 13
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
4.Prior treatment with a minimum of 2 prior ATP- binding site TKIs ( i.e.imatinib, 
nilotinib, dasatinib, radotinib or ponatinib)
5.Failure or intolerance to the last previous TKI therapy at the time of screening 
(adapted from the 2013 ELN Guidelines Bacarrani 2013 )
● Failure is defined for CML -CP patients (CP at the time of initiation of last 
therapy) as follows. Patients must meet a t least 1 of the following criteria.
● Three months after the initiation of therapy: No CHR or > 95% 
Ph+ metaphases
● Six months after the initiation of therapy: BCR -ABL ratio > 10% 
IS and/or > 65% Ph+ metaphases
● Twelve months after initiation of therapy : BCR -ABL ratio > 10% 
IS and/or > 35% Ph+ metaphases
● At any time after the initiation of therapy, loss of CHR, CCyR or 
PCyR
● At any time after the initiation of therapy, the development of new 
BCR -ABL mutations
● At any time after the initiation of therapy, confirmed loss of MMR 
in 2 consecutive tests, of which one must have a BCR -ABL ratio ≥ 1% IS
● At any time after the initiation of therapy, new clonal 
chromo some abnormalities in Ph+ cells :CCA/Ph+
● Intolerance is defined as:
● Non-hematologic in tolerance: Patients with grade 3 or 4 toxicity 
while on therapy, or with persistent grade 2 toxicity, unresponsive to 
optimal management, including dose adjustments (unless dose reduction 
is not considered in the best interest of the patient if response is already 
suboptimal)
● Hematologic intolerance: Patients with grade 3 or 4 toxicity 
(absolute neutrophil count [ANC] or platelets) while on therapy that is 
recurrent after dose reduction to the lowest doses recommended by 
manufacturer
6.Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 
or 2
7.Adequate end organ function as defined by (as per central laboratory tests ):
● Total bilirubin ≤ 1.5 x ULN except for patients with Gilbert’s syndrome who 
may only be included if to tal bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN
● Aspartate transaminase (AST) ≤ 3.0 x ULN
● Alanine transaminase (ALT) ≤ 3.0 x ULN
● Serum amylase ≤ ULN
● Serum lipase ≤ ULN
● Alkaline phosphatase ≤ 2.5 x ULN
● Creatinine clearance ≥ 50ml/min as calculated using Cockcroft -Gault 
formula
8.Patients must avoid consumption of grapefruit, Seville oranges or products 
containing the juice of each during the entire study and preferably 7 days before 
the first dose of study medications, due to potential CYP3A4 interaction with the 
study medications. Orange juice is allowed.
9.Written informed consent obtained prior to any screening procedures.
10.Patients must have the following electrolyte values (as per central laboratory
tests ) within normal limits or corrected to be within normal limits with supplements 
prior to first dose of study medication:
● Potassium
● Magnesium
● Total calcium (corrected for serum albumin)

Novartis Confidential Page 14
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
Exclusion criteria Patients eligible for this study must not meet anyof the following criteria:
1.Known presence of the T315I or V299L mutation at any time prior to study entry
2.Known second chronic phase of CML after previous progression to AP/BC
3.Previous treatment with a hematopoietic stem- cell transplantation
4.Patient planning to undergo allogeneic hematopoietic stem cell transplantation
5.Cardiac or cardiac repolarization abnormality, including any of the following:
● History within 6 months prior to starting study treatment of myocardial 
infarction (MI), angi na pectoris, coro nary artery bypass graft (CABG)
● Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), 
complete left bundle branch block, high -grade AV block (e.g., bifascicular block, 
Mobitz typ e II and third degree AV block)
● QTcF at screening ≥450 ms (male patients), ≥460 ms (fem ale patients)
● Long QT syndrome, family history of idiopathic sudden death or 
congenital long QT syndrome, or any of the following:
● Risk factors for Torsades de Pointe s(TdP) including uncorrected 
hypo kalemia or hypomagnesemia, history of cardiac failure, or history of 
clinically significant/symptomatic bradycardia
● Concomitant medication(s) with a known risk to prolong the QT 
interval and/or known to cause Torsades de Pointes that cannot be 
discontinu ed or replaced 7 days prior to starting study drug by saf e 
alternative medication.
● Inability to determine the QTcF interval
6.Severe and/or uncontrolled concurrent medical disease that in the opinion of 
the investigator could cause unacceptable safety r isks or compromise compliance 
with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, 
pulmonary hypertension)
7.History of acute pancreatitis within 1 year of study entry or past medical history 
of chronic pancreatitis
8.History of elevation in amylase or lipase (> ULN) within 1 year other than that 
which may have occurred with gallstones, trauma, or medical procedures
9.History of acute or chronic liver disease
10.Known presence of significant congenital or acquired bleeding di sorder 
unrelated to cancer
11.History of other active malignancy within 3 years prior to study entry with the 
exception of previous or concomitant basal cell skin cancer and previous 
carcinoma in situ treated curatively
12.Known history of Human Immunode ficiency Virus (HIV), chronic Hepatitis B 
(HBV), or chronic Hepatitis C (HCV) infection. Testing for Hepatitis B surface 
antigen (HBs Ag) and Hepatitis B core antibody (HBcAb / anti HBc) will be 
performed at screening
13.Impairment of gastrointestinal (GI ) function or GI disease that may significantly 
alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, 
vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric 
bypass surgery)
14.Treatment with medications that meet one of the following criteria and that 
cannot be discontinued at least one week prior to the start of treatment with study 
treatment
● Moderate or s trong inducers of CYP3A
● Moderate or s trong inhibitors of CYP3A and/or P -gp
● Substrates of CYP3A4/5, CYP2C8, or CYP2C9 with narrow therapeutic 
index
15.Previous treatment with or known/ suspected hypersensitivity to ABL001 or any 
of its excipients.
16.Previous treatment with or known/ suspected hypersensitivity to bosutinib or 
any of its excip ients.

Novartis Confidential Page 15
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
17.Participation in a prior investigational study within 30 days prior to 
randomization or within 5 half -lives of the investigational product, whichever is 
longer
18.Pregnant or nursing (lactating) women
19.Women of child -bearing potential, defin ed as all women physiologically capable 
of becoming pregnant, unless they are using highly effective methods of 
contraception during dosing and for 3 days after last dose of ABL001. Highly 
effective contraception methods include:
● Total abstinence (when t his is in line with the preferred and usual lifestyle 
of the subject ). Periodic abstinence (e.g., calendar, ovulation, symptothermal, 
post-ovulation methods) and withdrawal are not acceptable methods of 
contraception
● Female sterilization (have had surgic al bilateral oophorectomy (with or 
without hysterectomy) total hysterectomy or tubal ligation at least six weeks 
before taking study treatment ). In case of oophorectomy alone, only when the 
reproductive status of the woman has been confirmed by follow up hormone 
level assessment
● Male sterilization (at least 6 months prior to screening). The vasectomized 
male partner should be the sole partner for that subject.
● Use of oral, injected or implanted hormonal methods of contraception or 
placement of an intra uterine device (IUD) or intrauterine system (IUS) or other 
forms of hormonal contraception that have comparable efficacy (failure rate 
<1%), for example hormone vaginal ring or tra nsdermal hormone 
contraception.
● In case of use of oral contraception women should have been stable on 
the same pill for a minimum of 3 months before taking study treatment.
20.Women are considered post -menopausal and not of child bearing potential if 
they have had 12 months of natural (spontaneous) amenorrhea with an appropriat e 
clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had 
surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy 
or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only 
when t he reproductive status of the woman has been confirmed by follow up 
hormone level assessment is she considered not of child bearing potential.
21.Sexually active males unless they use a condom during intercourse while 
taking the drug during treatment and for 3 days after stopping treatment and should 
not father a child in this period. A condom is required to be used also by 
vasectomized men as well as during intercourse with a male partner in order to 
prevent delivery of the drug via semen.
Investigational and 
reference therapyABL001 40 mg BID
Bosutinib 500 mg QD
Efficacy  assessments Molecular response (RQ -PCR, mutational analysis)
Cytogen etic response ( Bone Marrow Aspirate)
Safety  assessments ●Physical examination
●Vital Sign
●Height and weight
●ECOG performance status
●Laboratory chemistry and hematology
●Serology
● Electrocardiogram (ECG)
●Echocardiogram
●Pulmonary function tests with DLCO

Novartis Confidential Page 16
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
Other assessments ●PK sampling (full/sparse)
●Bone Marrow Biopsy
●Patient Report Outcomes (MDASI -CML, PGIC, W PAI, EQ--5D-5L, resource 
utilization )
Data analy sis The primary efficacy variable of the study is the Major Molecular Response (MMR) 
rate at 24 weeks. A patient will be counted as having achieved MMR at 24 weeks if 
he meets th e MMR criteria (BCR -ABL ratio ≤0.1%) at 24 weeks.
The MMR rate at 24 weeks will be calculated based on the FAS and according to 
the Intent To Treat ( ITT)principle. MMR rate and its 95% confidence interval based 
on the Pearson -Clopper method will be presen ted by treatment group. Confidence 
interval for the difference in MMR rate between treatment groups will be provided 
using the W ald method .
The Mantel -Haenszel estimate of the common risk difference and the 
corresponding 95% confidence interval will also b e provided .
The key secondary endpoint is MMR rate at 96weeks.
Formal statistical testing of the key secondary endpoint will be performed only if the 
primary endpoint is significant by means of a gatekeeping procedure to control the 
overall alpha level. 
Key words Phase III, open -label, randomized trial, ABL001 bosutinib, CML -CP, prior treatment 
with 2 or more TKIs

Novartis Confidential Page 19
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
Chronic myeloid leukemia (CML) is a hematological stem cell disorder characterized bya 
specific chromosomal translocation leading to the Philadelphia (Ph) chromosome which is 
detected in 95% of patients (Nowell and Hungerford 1960 ; Rowley  1973). The molecular 
consequence of the translocation is the fusion of the ABL1 proto -oncogene to the BCR gene 
resulting in the production of an activated form of the ABL 1protein tyrosine kinase (TK)
(Bartram et al 1983 ; Heisterkamp et al 1983 ). BCR -ABL1 drives the growth factor 
independence, increased proliferation, genomic instability , suppression of apoptosis and 
alteration of the adhesive properties of CML cells (Hochhaus 2009 ) and the expression of 
BCR -
ABL1 in mice results in the development of a CML -like disease (Daley  et al 1990 ; 
Kelliher et al 1990 ).This evidence that BCR -ABL1 is a genetic driver of CML was 
subsequently  confirmed by the clinical efficacy  of imatinib in patient s[IRIS Study 
STI571A0106] .
Clinically , CML is characterized by overproduction of immature myeloid cells and mature 
granulocy tes in the spleen, bone marro w and peripheral blood. Most patients, however, 
present in the CP, characterized by splenomegal y and leukocy tosis with generall y few 
symptoms. CML  progresses through three distinct phases of increasing refractoriness to 
therap y: chronic phase (CP) ,acceler ated 
phase (AP), and blast crisis (BC). With conventional 
chemotherap y, such as busulfan or hy droxyurea, the median survival time commonly  reported 
for CML was about 4 years, but progression to AP and BP was only slightly  delayed. 
Interferon -alfa delay ed progression significantl y, with a median survival of approximately  6 
years. However, during the last decade , TKinhibitor (TKI)therapy  became the standard 
treatment for most patients with CML , with complete cy togenetic response rates 
of 70% to 90% 
and 5-year progression -free survival and overall survival of 80% to 95% commonly  reported 
(Vardiman 2009 ).
The National Comprehensive Cancer Network (NCCN) guideline on CML  (NCCN guideline 
v 
1.2014 ) and the European Leukemia Net (ELN) (Baccarani et al 2013 ) recommend 
continuing TKI treatment indefinit ely in all responding patients. The first TKI, imatinib 
mesy late (imatinib, STI571, Gleevec ™/Glivec™ ), an adenosine triphosphate (ATP) -
competitive TKIwith selectivity  towards BCR -ABL1, revolutionized treatment of CML and 
significantl y improved the prognosis of patients since its approv al in 2001. It is effective in 
most patients with CML atwell-tolerated doses , and is indicated as frontline therapy  for Ph+ 
CML -CP and in patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in CP 
after failure of interferon -alpha therap y. However, despite the remarkable efficacy  of imatinib, 
some patients are either intolerant to the drug or can develop resistance (O’Hare 2006 ). 
Imatinib resistance is primarily  due to nucleotide substi tutions in BCR -ABL, which encode 
mutant forms of protein’s tyrosine kinase domain that impair imatinib binding. Over -
expression of the BCR -ABL1 protein may also cause resistance. Rates of resistance increase 
with each stage of progression of CML  (CP < AP < BC) ( Branford 2003 ).

Novartis Confidential Page 20
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
Multiple agents, including nilotinib, dasatinib, ponatinib, bosutinib, radotinib (Korea) and 
omacetaxine (USA, Canada) are able to combat various forms of imatinib -resistant CML  and
are currently  approved for patients with CML -CP previously  treated with prior therap y.With 
the exception of omacetaxine, which is a cytotoxic chemotherapeutic agent, all of these drugs 
are ATP -competitive TKIs. Like imatinib, nilotinib and dasatinib are also indicated for the 
treatment of patients with newly  diagnosed CML. The activity  of nilotinib or dasatinib in 
patients previously  treated with a second generation TKI is not known. In contrast to the ATP -
competitive TKIs, ABL001 inhibits the enzymatic activity  of BCR -ABL1 through an 
allosteric mechanism.
There remains an unmet need for new compounds in patients with CML who have failed at 
least two prior TKIs. Current practice suggests that a second generation TKI will have been 
used for first line thera py for about one half of patients with CML , meaning that most patients 
who have failed at least two prior TKIs will have failed at least one if not two second 
generation TKIs: dasatinib and/or nilotinib. Potentially , such patients may also have failed 
bosu tinib and/or ponatinib (Soverini 2014 ). Patients having failed at least two TKIs may have 
limited sensitivity  to the remaining available agents and, thus, there exists a need for new safe 
and effective t herap y. In addition, mutations will have developed in 21 to 33% of patients that 
prevent the use of specific TKIs, increasing the need for a better and alternative compound 
(Soverini 2014 ). Omacetaxine, a chemotherapeutic agent, is available for patients who have 
failed at least two prior TKIs under these conditions but only in the US and Canada. This 
agent is not available for most patients globally , where a bigger unmet medical need is present. 
Thus, there remains an unmet need for active and safe drugs in patients with CML  who have 
failed at least two prior tyrosine kinase inhibitors (TKI), even in the presence of approved 
drugs, as described below.
1.2 Introduction to investigational treatment
1.2.1 Overview  ofABL001
ABL001 is anorally  bioavailable specific BCR -ABL inhibitor with a novel mechanism of 
action. In contrast to inhibitors such as imatinib, nilotinib and dasatinib that bind within the 
ATP -binding site of the ABL kinase domain, ABL001 inhibits ABL  tyrosine kinase activity 
by binding to a particular allosteric site on the kinase domain, which has only been 
identified 
on ABL1, ABL2 and BCR -ABL 1. Consequently, ABL001 is specifi c for the latter three 
enzymes.
ABL001 potentl y and selectivel y inhibits the proliferation of cell lines that express BCR -
ABL 1. By virtue of ABL001 not interacting with the ATP -binding site, the drug maintains 
activity  against cells expressing clinically  observed ATP -binding TKI resistance mutations.
1.2.1.1 Non-clinical experience
In vitro and in vivo pharmacology  data
ABL001 display s potent anti-tumor activity  in vivo with a clear pharmacokinetic 
(PK)/pharmacod ynamic (PD) /Efficacy  relationship [RD-2013-50145] . In a  K CL-22 CML 
blast crisis (CML -BC) cell line mouse subcutaneous xenog raft model, tumor regression was 

Novartis Confidential Page 21
Amended Protocol Version 01 ( Clean) Protocol No. CABL001A2301
observed at doses of 7.5mg/kg BID and above when ABL001 was administered alone. 
Efficacy  in the KCL -22 xenograft model correlated with stable inhibition of the downstream 
PD marker phospho -STAT5, consistent with finding that ABL1 inhibits STAT5 
phosphory lation in KCL22 cells with an I C90value of approximately  20 nM.
The KCL -22 xenograft model was also used to assess the activity  of ABL001 and nilotinib as 
single agents and in combination (Figure 1-1). In these experiments, when each agent was 
administered as monotherapy  in sequence, initial sensitivity  of the tumor was observed to 
each agent, bu t relapse occurred in each case .The mutations observed were as expected based 
on clinical experience (T315I  for nilotinib) or modeling (A337V) for ABL001. In contrast, 
animals treated upfront with the combination of ABL001 and nilotinib achieved sustained 
tumor regression with no evidence of disease relapse during the 70 day s of trea tment or for 80 
days following discontinuation of treatment. Note that in this KCL -22 model, the cells 
(derived from a blast crisis CML  patient) were grown as a solid tumor rather than as 
disseminated disease. Also, this model is much more aggressive than chronic phase CML in 
patients.
Figure 1-1 KCL-22 CML Xenograft
These data are consistent with ABL001 being active against nilotinib -resistant mutations and 
nilotinib being active against ABL 001-resistant mutations. Consequently , the findings support 
development of ABL001 both as single agent as well as in combination with TKIs as initial 
therap y of CML as well as therap y after progression on nilotinib.
In addition, due to ABL001 specific allytargeting the ABLkinase family  (ABL1, 
ABL2, 
BCR -ABL), ABL001 offers the potential for improved safet y and tolerability  when 
administered as monotherapy  when compared to TKIs binding to the ATP site of BCR -ABL, 
which are less specif ic towards ABL . Thus, there is the potential for an improved safet y 
profile of ABL0 01 in comparison to other TKIs.
Safety  pharmacology and toxicology
An extensive toxicology  safety evaluation program (subchronic, chronic, reproductive 
toxicology, phototoxi city and genotoxicity  studies) was conducted.
Safety  pharmacology  studies indicate that ABL001 is not expected to cause effects on the 
vital functions of the CNS, and the respiratory  systems. The IC50 for ABL001 in the hERG 
patch clamp is 11.4 μM (4498 ng/mL). No 
cardiovascular effects were observed in a single 
dose jacketed telemetry  study in dogs at doses up to 200 mg/kg or the invasive telemetry 

Novartis Confidential Page 22
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
cardiovascular safet y study  up to 60 mg/kg. Furthermore, no ECG related findings were noted 
in the 4 week GLP dog toxicology  study  at the end of treatment or recovery .
ABL001 does not show mutagenic, clastogenic, or aneugenic potential in the in vitro assay s or 
the MNT assessment in vivo; therefore, no potential risk for human is perceived.
As determined by  the results of the phototoxicity  assessment ( in vitro and in vivo ), phototoxic 
potential was identified in the mouse UV-LLNA assay . Given these data, patients should be 
advised to avoid prolonged exposure to sunlight (sunbathing) and to use sunscreen.
In the embryofetal development study  in rats, results indicate a risk of fetal malformations 
and/or visceral and skeletal variants. In the fertility  study, administration of ABL001 by da ily 
oral gavage at doses of 10, 50 and 200 mg/kg/day to males and females there was no evidence 
of effects on reproductive function (mean day to mating, mating and fertility  indices) at any 
dose. There was evidence of a slight effect on male sperm motility  and/or sperm count in 
individual animals and an embry o-lethal effect at 200 mg/kg/day . Based on these results, the 
no-observed -adverse- effect level (NOAEL) for paternal and maternal toxicity  was considered 
to be 200 mg/kg/day  and the no-observed- effect level (NOEL) for reproductive function and 
early embr yo-fetal development was cons idered to be 50 mg/kg/day .
Repeat dose toxicity  studies have been performed in rats, dogs and monkey s up to 26, 4 and 
13 weeks duration, respectivel y. Rat and dog toxicology  studies identified pancreas, liver, 
adrenal and harderian gland as potential targe t tissues. The cynomolgus monkey  did not 
recapitulate in short or long -term studies the pancreatic changes observed in the dog or the rat 
hepatic changes. All findings thus far have demonstrated a partial to complete reversibility 
during a 4-week recovery  phase, and can be readily  monitored in preclinical and clinical 
settings. The maximal doses evaluated in the 13/26 -week general toxicity  studies was 200 
mg/kg in rats and 100 mg/kg in monkey  and provide substantive safet y margins over the 40 
mg BID clinica l dose exposures.
Please refer to the latest [ABL001 Investigator’s Brochure ]for more details.
Non-clinical pharmacokinetics and metabolism
The preclinical pharmacokinetic profile of ABL001 has been investigated in three species: 
mouse, rat and dog. In these species, ABL001 exhibited low to moderate clearance, a 
moderate volume of distribution and a short apparent terminal half-life. Bioavailability  was 
found to be low in roden ts and moderate to high in dog.
ABL001 display ed high plasma protein binding across all teste d species (2- 6% free fraction).
The metabolite profile of ABL001 has been examined in vitro using rat, dog, monkey  and 
human hepatocy tes. Interspecies differences were observed. Direct glucuronidation occurred 
more readil y in human and dog tha n in monkey  and was noticeabl y absent in rat. However, no 
unique, major metabolites were identified in human hepatocy tes. The overall metabolic 
turnover was low.
The metabolite profile of ABL001 has also been examined in vivo in rats. Following 
intravenous and oral administration of [14C-ABL001] to intact rats, ABL001 was found to be 
the predominant component of plasma, accounting for ~86 - 91% of radioactivity  from 0 -8 h. 
ABL001 was excreted primarily  in the feces, with ~90% of radioactivity  detected in the feces 

Novartis Confidential Page 23
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
from 0 - 48 h. Renal elimination represented a minor route, with ~2.4% of radioactivity 
detected in the urine from 0 - 72 h. In the feces, ~58% (intravenous) and ~71% (oral) of the 
dose was associated with unchanged ABL001, with several oxidative metabolites accounting 
for the remaining radioactivity . The metabolites formed in vivo were consistent with those 
observed in vitro. Similar observations were noted in bile -duct cannulated rats.
To assess for potential drug-drug interactions (DDI), studie s have been conducted with 
cytochrome P450 (CYP) enzy mes and several transporters in vitro.
In human liver microsomes, the major metabolic route of ABL001 was found to be 
glucuronidation, followed by oxidative metabolism, consistent with findings from huma n 
hepatocy tes. Several UGT enzymes were found to be capable of ABL001 glucuronidation 
(UGT1A3, UGT1A4, UGT2B7, and UGT2B17). The oxidative metabolism of ABL001 was 
also catal yzed by several CYP enzymes. CYP3A4/5 appears to contribute the most, followed 
by CYP2C8, CYP4F12, and potentially  CYP2D6. Though the DDI risk with inhibitors of 
these enzymes is likely  to be minimal, inhibitors of CYP3A4/5 still have the potential to 
increase ABL001 concentration. Therefore, strong inhibitors of CYP3A4/5 should be avoided
and are prohibited in this study . Strong inducers of CYP3A4/5 have the potential to reduce 
ABL001 concentrations. Therefore, the use of strong inducers of CYP3A4/5 or UGT1A/ 2B is 
prohibited in this trial.
Transporter phenot yping studies have identified ABL001 to be a substrate of Breast Cancer 
Resistant Protein (BCRP) and Permeability  glycoprotein (P-gp). While inhibition of BCRP is 
not expected to result in any clinical relevant changes, inhibitors of P-gp may increase 
ABL001 concentration s significantl y and are prohibited in this study .
There is a potential for DDIs with co-medications metabolized by CYP3A4/5, CYP2C8 and 
CYP2C9 at the anticipated human efficacious dose. Therefore, narrow therapeutic index 
substrates of CYP3A4/5, CYP2C8 and CYP2C9 are prohibited. All other substrates of 
CYP3A4/5, CYP2C8 and CYP2C9 should be used with caution.
Please refer to the latest [ ABL001 Investigator Brochure ]version for more details.
1.2.1.2 Clinical experience
ABL001 is undergoing evaluation in a first-in-hum an (FIH) phase I clinical study , study 
[CABL 001X2101 ].
This study  evaluates patients with 1) CML who have been treated with at least 2 prior TKIs, 
or 2) who have the T315I mutation and have been treated with at least 1 prior TKI, or 3) who 
have Acute Lymphoblastic Leukemia (ALL)and have been treated with at least 1 prior TKI. 
The study  evaluates administration of ABL001 in a BID single agent dosing schedule, as well 
as in a QD single agent schedule, and in combination with nilotinib, imatinib, and dasatini b. 
In the present document, discussion will focus on data from CML  patients treated wit h 
ABL001 BID single agent only .
In this study , 101 patients have been enrolled as of 2 May 2016, and recruitment is still 
ongoing. For the most recent data cut-off of 2 May 2016, 67 CML patients had been treated 
with twice -daily (BID) doses of ABL001 of 10 mg (1 patient), 20 mg (14 patients), 40 mg (26 
patients), 80 mg (12 patients), 150 mg (9 patients), and 200 mg (5 patients). Of note, 66 of 

Novartis Confidential Page 24
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
those 67 patients had CML -CP, while one of the patients from the 40 mg cohort was in AP. 
This CML -AP patient discontinued after 20 days of treatment without any post screening 
efficacy  assessment.
The dose of ABL001 40mg BID has been selected for the proposed Phase 3 study  based on 
preliminary  MMR and CCyR results from the ongoing FIH study  [CABL001X2101] , as well 
as overall ABL001 safety  and pharmacokinetic information .
Efficacy :
Preliminary  data from the ongoing Phase 1 FIH study  [CABL001X2101 ]indicate that 
ABL001 has single -agent activity  in patients with CML  who have failed , relapsed, or are 
refractory  or intolerant after at least two prior TKIs, as demonstrated by  reduction in the BCR -
ABL transcript. ABL001 resulted in molecular and cytogene tic responses at doses ≥10 mg 
BID. In reporting the activity  of ABL001, the denominator at each time point represents the 
number of patients who, by that time point have either, achieved the endpoint, discontinued 
treatment, acquired an intra-patient dose escalation (ignoring assessments after escalation), or 
have suffici ent exposure .
Overall at an y dose of ABL001 BID, in p atients without T315I  mutation:
Molecular response:
In the subset of the n=47 patients treated at a dose level between 10mg -200mg BID who 
were not in MMR at screening:
6 out of 42 (14.3%) patients achieved MMR b y 3 months
10 out of 31 (32.3%) patients achieved MMR b y 6 months
12 out of 31 (38.7%) patients achieved MMR b y 9 months
13 out of 30 (43.3%) patients achieved MMR b y 12 months
Atthe dose of 40 mg BID, MMR was achieved in 1 out of 17 (5.9%) patients by  3 months, 
4 out of 11 (36.4%) patients by  6 months, 5 out of 11 (45.5%) patients b y 9 and 12 months
Cytogenetic response:
22 patients had >35% Ph+ metaphases at screening. Of these 22 patients, 5 patients were 
evaluable with 2 PCy R and 3 CCy R by  3 months. By  6, 9 and 12 months, 7 patients were 
evaluable with 1 minor c ytogenetic response and 5 CCy R.
33 patients did not have CCy R at screening. Of these 33 patients, 7 patients were 
evaluable with 3 PCy R and 4 CCy R by  3 months. By  6, 9 and 12 months, 10 patients were 
evaluable with 1 minor cytogenetic response, 1 PCy R and 7 CCy R.
15 of the above 33 patients who did not have CCyR at screening were treated at the dose 
of 40mg BID. Of these 15 patients, 3 patients were evaluable and with PCyR by  3 months. 
By 6, 9 and 12 months 4 patients were evaluable with 1 PCy R and 2 CC yR.
Please refer to the latest [ABL001 Investigator’s Brochure] for more details.

Novartis Confidential Page 25
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
Safety :
ABL001 was generall y well tolera ted in heavily  pre-treated CML patients resistant to or 
intolerant of prior TKI s. By  data cutoff of 2 May  2016, 67 CML  patients, including those with 
a T315I mutation (n=9), have been treated at an y dose of the ABL001 BID regimen.
There were no study  drug related deaths reported. One death was reported due to general 
physical health deterioration unrelated to the study  drug. Overall, 43 SAEs were reported in 
20 patients of the 67 patients. Six patients (9%) discontinued ABL001 due to adverse events 
Dose limiting toxicities in the study  included acute cardiac syndrome, lipase increase, 
arthralgia/m yalgia, and bronchospasm in 1 patient each.
Overall of 67 CML  patients, almost all (94%) patients reported at least one AE, including 45% 
reported grade 3/4 AEs. Th e most common AEs (>10%), regardless of study  drug -relationship, 
were headache, increased lipase (23.9%), rash (20.9), arthralgia, vomiting (both 19.4%), 
diarrhea, fatigue (both 17.9%), abdominal pain, pruritus (both 16.4%), constipation, myalgia, 
nausea, upper respiratory  tract infection (all 14.9%), thrombocy topenia (13.4%), peripheral 
edema (11.9%), increased amylase, dizziness, musculoskeletal pain (all 10.4%).
At 40 mg BID dose (n=26), the most common adverse events (>10%), regardless of study 
drug-relationship, were: increased lipase (30.8%), rash (26.9%), abdominal pain, fatigue, 
vomiting (all 23.1%), arthralgia, diarrhea (both 19.2%), increased amylase, upper respirator y 
tract infection (both 15.4%), cough, bone pain, pruritus, increased weight, abdo minal 
discomfort, anemia, constipation, dyspnea, ear pain, non- cardiac chest pain, and 
thrombocy topenia (all 11.5%).
Please refer to the latest [ABL001 Investigator’s Brochure] for more details.
Pharmacokinetics:
PK data from 61 patients (1 in 10 mg BID; 14 in 20 mg BID; 20 in 40 mg BID; 12 in 80 mg 
BID; 9 in 150 mg BID; 5 in 200 mg BID) were available from the [CABL001X2101 ]study , 
as of 2 May  2016.
Based on the available PK data, ABL001, administered orally  is rapidly  absorbed with a 
median time to maximum plasma concentration (Tmax) of 2 to 3 hours, independent of dose. 
Systemic exposure of ABL001, following oral administration of single and multiple doses, as 
measured by Cmax and AUC, increased in an approximate ly dose proportional manner. The 
variability  of exposure is low to moderate with inter -patient variability (geometric mean 
CV %) of 34 to 50% for Cycle 1 Day 1 AUC last and 36 to 60% for Cycle 1 Day 1 Cmax. 
With the twice daily dosing regimen, median plasm a ABL001 accumulation ratios ranged 
from 1.4 to 2.4. The median accumulation half -life was estimated to be 7 to 15 hours.
The emerging data of the hADME study [CABL001A2102] show that the relative 
contribution of the glucuronidation pathway  to the total clearance of ABL001 via metabolism 
is estimated to range from 30% to 61%, whereas the relative contribution of the oxidative 
pathway  is estimated to range from 35% to 63%. CYP3A4 was the main contributor for the 
clearance of ABL001 via the oxidative pathway  while UGT2B7 and UGT2B17 were 
responsible for the clearance of ABL001 via the glucuronidation pathway . There was no 

Novartis Confidential Page 26
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
metabolite detected with mean contribution to plasma radioactivity  AUC0 -24hours ≥ 10%. 
ABL001 was the predominant drug-related component in plasma at all time points analy zed, 
ranging from 91.9 to 94.2% of the total radioactivity  AUC0 -24 hours AUC, with an average 
value of 92.7%.
Please refer to the latest [ABL001 Investigator’s Brochure] for more details.
Exposure -response relationship:
Expos ure-efficacy
A preliminary  population PKPD model has been developed using data from the 
[CABL 001X2101 ]study  (cut-off 02May -2016). The time course of molecular response 
(change in BCR -ABL ratio %IS levels from baseline) was described using a semi -
physiolo gical model accounting for cell maturation, disease progr ession and existing 
resistance.
Simulations performed using an ABL001 population PK model revealed that a dose of 40 mg 
BID maintains Ctroughss above the clinical (0.07 to 61 ng/ml) threshold in > =95% of chronic 
phase CML patients without T315I  mutation having failed ≥ 2 TKI or intolerant to TKIs. The 
estimates from this clinical study  were found to be similar to the threshold trough 
concentration required for 90% inhibition of pSTAT5 derived from a preclinical PK -PD KCL -
22 mouse xenograft model (free IC90: 30 to 121 ng/mL, after correction for protein binding) 
and in vitro gIC50 assessed in the KCL -22 cell line (1 ng/mL = 2.1 nM after correction for 
protein binding).
Simulations performed using ABL 001 population PKPD model revealed that chronic phase 
CML  patients having failed ≥ 2 TKI or intolerant to TKIs are likely to exhibit a 1 log10 
reduction of (%) BCR -ABL mRNA transcript levels from baseline of ~33% (CI95%: 24 -42%) 
at 6 months, and ~42% (CI95%: 32-52%) at 12 months at a dose of 20 mg BID and ~41% 
(CI95%: 31-51%) at 6 months, and ~53% (CI95%: 43-63%) at 12 months at a dose of 40 mg 
BID.
Additional preliminary  exposure response analy ses (i.e. exploring the relationship between 
PK and both safet yand effic acy) support the selected dose.
Food effect
The effect of food on ABL001 PK was characterized in a Phase I study  [CABL001A2101 ]in 
healthy  volunteers. Food was found to influence the pharmacokinetics of ABL001. When 
administered with a low-fat meal, the exposure (AUC) decreased by approximately  30%. The 
overall exposure decreased by approximately  65% when administered with a high -fat meal.
Therefore, ABL001 will be administered in a fasted state.
1.2.2 Overview  of bosutinib
Bosutinib (Bosulif®) is indic ated for the treatment of adult patients with chronic, accelerated, 
or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance orintolerance to 
prior therapy  [Bosulif®USPI ], and in Europe for the treatment of adult patients with chronic 
phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive 

Novartis Confidential Page 27
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
chronic myelogenous leukemia (Ph+ CML ) previously  treated with one or more tyrosine 
kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered 
appropriate treatment options [EU SmPC ]. Bosutinib has been evaluated in patients treated 
with one or more prior TKI s.
For patients treated only  with prior imatinib, the MMR rate is approximately  15% at 24 weeks 
overall, and approximately  10% in resistant patients and 20% in intolerant patients 
(Gambacorti -Passerini 2014 ). The cytogenetic, molecular, and hematological response rates 
did not appear to differ greatly  between patients who were imatinib -resistant or imatinib -
intolerant ( Gambacorti -Passerini 2014 ).
When treated with bosutinib, the majority  of patients with CML -CP previously treated with at 
least 2 TKIs did not achieve Major Cytogenetic Respon se (MC yR); there was a 27% MCyR 
rate by Week 24 [Bosulif®USPI ]. For patients previously  treated with imatinib and either 
dasatinib or nilotinib, after a median of 28.5 months follow -
up, the cumulative rate of Major 
Molecular Response (MMR) is 15% (Khoury  2012). The cytogenetic, molecular, and 
hematological response rates appeared to be lower in patients who were resistant to dasatinib 
after imatinib treatment as compared to patients who 
were intolerant to dasatinib after 
imatinib treatment (Khoury  2012). In a small (30 patient) compassionate use trial of patients 
previously  treated with imatinib, dasatinib and nilotinib, after a median duration of treat ment 
of 9.3 months, the cumulative MMR rate was 14% (García -Gutiérrez 2015 ).Based on these 
data, the MMR rate at 6 month with bosutinib treatment in patients treated with at least 2 prior 
TKIs is estimated to be approximately  10
-15%.
Bosutinib has no activity  against the T315I and V299L mutant form of BCR -ABL. 
Accordingl y, the pivotal trial leading to the registration in the 3rdline setting excluded patients 
with a known history  of the T315I or V299L mutation [Bosulif®USPI ].
2 Rationale
2.1 Stud y rationale and purpose
ABL001 is an agent intended to be evaluated for the treatment of patients with CML .In the 
ongoing study  [CABL001X2101 ]study , ABL001 was found to produce clinically  meaningful 
and durable responses in patients who have had treatment failure after a minimum of 2 prior 
ATP -binding site TKIs, with an acceptable sa fety and tolerability profile.
The purpose of this pivotal study  is to compare the efficacy  of ABL001 with that of bosutinib 
in the treatment of patients with CML -CP having previously  been treated with a minimum of 
two prior ATP -binding site TKIs with BCR- ABL ratios ≥
1% I S at screening.
Imatinib, nilotinib and dasatinib are indicated for the treatment of patients with newl y 
diagnosed CML . Multiple agents, including nilotinib, dasatinib, ponatinib, bosutinib, 
radotinib (Korea) and omacetaxine (USA, Canada) are approved for patients with CML-CP 
previously  treated with prior therap y. Imatinib is a first generation TKI; nilotinib, dasatinib, 
bosutinib, ponatinib and radotinib are considered second generation TKIs and have activit y in 
patients previousl y treated with imatinib. The activity  of nilotinib or dasatinib in patients 
previously  treated with a second generation TKI is not known. All the currentl y approved 

Novartis Confidential Page 28
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
BCR -ABL TKIsare enzymatic site inhibitors, in distinction to ABL 001 which is an allosteric 
TKI. Omacetaxine is a cy totoxic chemotherapeutic agent.
2.2 Rationale for the study  design
ABL001 is anorally bioavailable specific BCR -ABL1 inhibitor with a novel mechanism of 
action. In contrast to other TKIs that bind within the ATP -binding site of the ABL  kinase 
domain, ABL001 inhibits ABL tyrosine kinase activity  by binding to a particular allosteric 
site on the kinase domain that is utilized by a  m yristate group to auto-regulate the native 
ABL1 kinase. With allosteric inhibition of BCR -ABL being a novel mechanism of action, 
ABL001 produces clinically  meaningful and durable responses in patients who have had 
treatment failure after a minimum of 2 prior ATP -binding site TKI s, with an acceptable safet y 
and tolerability  profile as demonstrated in study  [CABL001X2101 ].
The development of ABL001, presents an opportunity  to evaluate the beneficial effects of 
inhibition of BCR -ABL in the treatment of patients with CML .The proposed study  design is 
expected to adequatel y allow an assessment of the efficacy , safety  and tolerability  of ABL 001 
in a popul ation of patients with continuing medical need i.e., patients who have been treated 
with at least two prior TKI s and are in the need for further therapeutic intervention.
Bosutinib is one of the TKIs with proven clinical benefit in CP-CML  patients previous ly 
treated with one or more tyrosine kinase inhibitor(s) and is currentl y approved for this 
indication in many  countries, including the European Union. The proposed study  will evaluate 
ABL001 in comparison to bosutinib at the approved doses in the targeted population .
This study  is not being conducted as a blinded study ; the conditions for drug administration 
being distinct for the two treatments arms makes blinding complex and increases the 
likelihood of dosing errors. Bosutinib needs to be taken with food , whereas ABL001 needs to 
be taken fasted. The difference in administration of the two treatments, requiring double 
dummy  treatments, makes blinding difficult to put in place in practice and carries inherent 
risks of dosing errors and reduces patient compl iance. Additionally , the characteristic adverse 
event profile of bosutinib (frequent gastrointestinal AEs of diarrhea and vomiting in 78.5% 
and 37.1% patients, respectivel y) further preclude effective blinding. Randomization and use 
of objective efficacy  endpoints mitigate the risks of an open label study  design.
The study  design incorporates a 2:1 randomization, allocating more patients to the ABL001 
arm in order to learn more about the safet y profile of the experimental therap y ,whereas the 
safet y of bosu tinib therapy  is well documented.
Treatment duration for each patient in the present study  isforup to 96weeks after the last 
patient received the first dose, which should be adequate to address both the primary  objective 
of the study , i.e. determination of the MMR rate at 24 weeks, as well as secondary  efficacy  
and safet y objectives. Blood Samples will be taken in this study  from all patients randomized 
to ABL001 in order to describe the pharmacokinetics and possibly  identify  the sources of 
variabilities . Exploratory analysis may be performed to establish the relationship between 
exposure and efficacy  or safet y.

Novartis Confidential Page 30
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
With respect to overall exposure , the dose of 40 mg BID is expected to result in 
concentrations consistently  above IC90 in-vitro concentrations. The estimates from study 
[CABL 001X2101 ]were found to be above the threshold trough concentration required for 90% 
inhibiti on of pSTAT5 derived from a preclinical PK-PD KCL -22 mouse xenograft model 
(free IC90: 30 to 121 ng/mL , after correction for protein binding) and in vitro gIC50 assessed 
in the KCL -22 cell line (1 ng/mL = 2.1 nM after correction for protein binding).
A preliminary  population PK-PD model has been developed using data from the 
[CABL 001X2101 ]study  (cut-off 2 May 2016). The time course of molecular response 
(change in BCR -ABL ratio %IS levels from baseline) was described using a semi -
physiological model accounting for cell maturation, disease progression and existing 
resistance. Simulations performed (with 100 patients) using ABL001 population PK-PD 
model revealed that at a dose of 40 mg BID, ~41% (CI95%: 31-51%) of chronic phase CML 
patients having failed ≥ 2 TKI  or intolerant to TKIs are likely  to exhibit a 1 log10 reduction of 
(%) BCR -ABL mRNA transcript levels from baseline at 6 months, and 53% (CI 95%: 43 -63%) 
at 12 months, and predicting higher probability  of achieving BCR -ABL mRNA ≥1 log 
reduction at 6 and 12 months wi th 40 mg BID versus 20 mg BID.
Additional preliminary  PK-efficacy  and PK-safety  analyses to assess the exposure -response 
relationship for ABL001 were conducted (Section 1.2.1.2 ). The efficacy  measure used was 
Molecular Response (MR) which is defined as a decline in BCR -ABL transcript levels in 
clinical blood samples of patients with Chronic My eloid Leukemia (CML). MR was evaluated 
as both a continuous variable (BCR -ABL  transcript level s) and categorical variable (whether 
or not adequate decline in BCR -ABL was achieved). The safet y measures used were 
occurrence of Common Toxicity  Criteria (CTC) grade 2, 3 or 4 laboratory  values for lipase 
and am ylase.
Reviewing the totality  of the effica cy, safet y, and pharmacokinetic data derived from the 
[CABL 001X2101 ]study, the recommended dose for ABL001 in this phase 3 study  is 40 mg 
BID. Of note, the dose of ABL001 single agent BID is further being evaluated in patients with 
the T315I  mutation. At present the recommended dose of 40 mg BID is for patients without 
the T315I mutation. For this reason, patients with the T315I mutation are excluded from this 
study .
2.4 Rationale for choice of combination drugs
Not Applicable.
2.5 Rationale for choice of comparators drug bosutinib
The guidance provided by the NCCN and the ELN (Bacarrani 2013 ), recommends bosutinib 
as a treatment in CML -CP patients who fail first- line or second -line treatment with imatini b or 
nilotinib or dasatinib. Consistent with these recommendations and clinical practice, bosutinib 
was selected to be 
an appropriate comparator in a study  of 3rdline CML -CP patients after 
failure of at least 2 prior TKIs, and is the comparator that will be used in the present stud y.
It is to be noted that bosutinib has no activity  against the T315I  and V299L mutant form of 
BCR -ABL. Patients who have the T315I or V299L mutations documented in their medical 
record will alread y be excluded from this study. Bosutinib is known to be active against 

Novartis Confidential Page 31
Amended Protocol Version 01 ( Clean ) Protocol No. CABL001A2301
E255K/V, F317L/V/I/C, F359V/C/I, T315A, and Y253H and therefore, these mutations are 
not considered in the exclusion criteria for the current study .
Ponatinib is not selected as the comparator in the present clinical trial, because the comparator 
in this study  needs to be an approved agent administered at the approved dose. Currentl y, the 
ponatinib dose is being evaluated in a rando mized trial as a post-approval commitment due to 
the occurrence of vascular risks at the current approved dose of ponatinib. The dose of 
ponatinib that will be approved and will be used in practice at the completion of the present 
study  may  not be the appr oved dose at the time of initiation of the present study .
2.6 Risks and benefits
Appropriate eligibility  criteria, as well as specific dose modification and stopping rules in the 
event of expected toxicities , are included in this protocol. Recommended guidelin es for 
prophy lactic or supportive treatment for expected toxicities, including management of study -
drug induced adverse events are provided in Section 6.3.Patients who have failed 2 prior 
TKIs are at increased risk of progression to more advanced phases of CML such as CML -AP 
and CML -BC. Current lyavailable therapeutic agents in this setting are non-curative and 
patients remain at risk of progressing after short duration of remissions (Khoury  2012 ).
An important potential risk forpatients enrolling on the experimental arm of the study  with 
ABL001 will be that this agent may be ineffective .However, the evidence to date at the doses 
to be administered in a similar population of patients in the study  [CABL001X2101 ]suggests 
that ABL001 is an active agent. Further, the adverse event profile of ABL001 is similar 
qualitatively  to that observed with other TKIs targeting BCR -
ABL1 ( Section 1.2.1.2 ).The 
risk of ABL001 not being effective has been mitigated in that patients will be observed 
closely  for evidence of efficacy , based on assessment of hematologic , cytogenetic and 
molecular response data, which will permit rapid decision making as to discontinuation of 
therap y if necessary .
Other risks to subjects in this trial will be minimized by compliance with the eligibility 
criteria and study  procedures, close clinical monitoring, and adherence to dose modification 
and interruption guid ance provided in the protocol.
The currentl y available information suggests that there is equivalence between the two arms 
with respect to benefit / risk to enable inclusion of patients in this study .
There may be unforeseen risks with ABL 001 which could be serious. Refer to the latest 
[ABL 001 Investigator’s Brochure] for additional details.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3 -1below.

Novartis Confidential Page 32
Amended Protocol Version 01 (Clean) Protocol No. C ABL001A2301
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary
To compare the MMR rate at 24 weeks of ABL001 versus 
bosutinib Major Molecular Response (MMR) rate at 24 weeks Refer to Section 10.4
Key secondary
To compare additional parameters of the efficacy of ABL001 
versus bosutinib MMR rate at 96 weeks Refer to Section 10.5.1
Other secondary
To compare additional parameters of the efficacy of ABL001 
versus bosutinib●cytogenetic response rate (Complete, Partial, Major, Minor, Minimal, 
no response) at and by all scheduled data collection time points including 
24, 48 and 96 weeks
●MMR rate at all scheduled data collection time points (except 24 and 
96 weeks which are already covered by primary and key secondary 
endpoints)
●MMR rate by all scheduled data collection time points including 24, 48 
and 96 weeks
●Time to MMR
● D uration of MMR
●Time to CCyR
●Duration of CCyR
●Time to treatment failure
●Progression free survival
●Overall survivalRefer to Section 10.5.2
To compare the safety and tolerability profile of ABL001 versus 
bosutinibType, frequency and severity of adverse events,
Changes in laboratory values that fall outside the pre -determined ranges 
and clinically notable ECG and other safety data (vital signs, physical 
examination)
To characterize the PK of ABL001 in the CML -CP population Trough plasma concentrations,
PK parameters in full PK gr oup: Cmax, Tmax, AUC0 -12h, CL/F

Novartis Confidential Page 34
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
4 Study  design
4.1 Description of study  design
The study  is a phase 3, multi -center, open -label randomized study  of oral ABL001 versus 
bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML -CP), 
previously  treat ed with 2 or more t yrosine kinase inhibitors .
The trial is designed to compare the efficacy  and safet yof ABL001 with that of bosutinib in 
the treatment of patients with CML -CP having previously  been treated with a minimum of 
two prior ATP -binding site TKI s with a BCR -ABL ratio-IS≥ 1% at screening.
The study  will also investigate secondary  endpoints for efficacy , 
safet y and PK of single -
agent ABL001 compared to bosutinib. Tolerability, PK, PRO and exploratory  biomarker 
activities will also be assessed.
Patients meeting all of the inclusion and none of the exclusion criteria will be randomized into 
one of the 2 treatment arms, based on a 2:1 randomization between the ABL001 arm and the 
bosutinib arm.
The randomization will be stratified to ensure the study  population is balanced between the 
arms with respect to cytogene tic response status (See Section 7.2.1.2) at screening as follows:
Major Cy togenetic response ( complete or partial)
No major cy togenetic response (minor, minimal or none)
Patients will continue to receive the assigned study  treatments (ABL001 or bosutinib) for up 
to 96 weeks after the last patient received the first study  dose i.e., patients who are benefiti ng 
from their study  treatment can continue to receive the treatment for up to a period of 
approximately  2 years following the completion of study  enro llment. Patients who discontinue 
their study  treatment at any time during the study  will be followed up for survival and for 
progression to AP/BC for up to 5 years from the date the last patient received the first study 
dose.
Serial PK samples over 12 hours will be collected on Week 2Day 1 from at least 20 CML -CP 
patients (full PK group) on the ABL001 arm , inaddition to trough PK samples. These patients 
will be identified sequentially  at selected sites that are capable of serial PK sampling over 12 
hours. In the remaining patients in the ABL001 arm, sparse post-dose PK samples on Week 1
Day 1 and trough PK sa mples will be collected (sparse PK group) .

Novartis Confidential Page 35
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Figure 4-1 Schematic of Study  Design
4.2 Timing of interim analy ses and design adaptations
Not applicable. There are no formal interim analy ses or design adaptations planned for this 
study .See Section 8.6 for documentation of safety DMC.
4.3 Definition of end of study
The end of the study  will occur 5 years from the date when the last patient enrolled into the 
study  received the first dos e of the randomized treatment.
The primary  analysis (cut-offdate) is defined as the date when all randomized patients have 
been on treatment for 24 weeks (Section 10.4) or discontinued early .Subsequent to this 
analysis, the primary  clinical study  report (CSR) will be developed. Following the cut -off date 
for the primary  CSR, the study  will remain open. Patients who are ongoing at the time of the 
primary  analysis will continue to receive the assigned study  treatments (ABL001 or bosutinib) 
for up to 96 weeks after the last patient received the first study  dose i.e., patients who are 
benefiting from their study  treatment can continue to receive the treatment for up to a period 
of approximately  2 years following the completion of study  enrollment. The end of study  
treatment analysis will be conducted with a cut-off date 30 days after last patient receive sthe 
last study  dose to ensure all available treatment data from all patients in the study  is analyzed
and summarized in a CSR .
After the end of the study  treatment period the assigned study  treatment will be made 
available to patients who in the opinion of the Investigator are still deriving clinical benefit. 
This may be outside of this study  through alternative options including, but not limited to, an 
expanded access/compassionate use /managed access program or access to commercial 
supplies in applicable countries.
Patients will be followed up for survi val and progression for up to 5 years from the date the 
last patient received the first study  dose. Information on subsequent treatments will also be 
collected. An updated analy sis of OS and PFS will be performed at the end of the follow -up 
period.
4.4 Early  study  termination
The study  can be terminated at any  time for any  reason by  Novartis. Should this be necessary, 
the patient should be contacted as soon as possible and instructed to stop taking study 
medication .The end of treatment visit should be schedul ed and the same assessments should 

Novartis Confidential Page 36
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
be performed as described in Section 7 for a discontinued or withdrawn patient. The 
investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the patient’s interests. The investigator 
will be responsible for informing IRBs and/or ECs of the earl y termination of the trial.
5 Population
5.1 Patient population
Two-hundred and twent y-two (222) patients with CML -CP who had prior treatment with two 
or more ATP binding site TKIs will be randomized in a 2:1 fashion to recei ve either ABL001 
or bosutinib. No patients with a medical history of the T315I  or V299L mutation at study  
entry  will be include d in the trial. Previous medical records should be used to confirm the 
patient’s mutational status/history .
The definition of CML -CP will be according to the European Leukemia Network (ELN) 
criteria ( Baccarani et al 2013 ), and is outlined below in the inclusion criteria.
The investigator or designee must ensure that only patients who meet all the following 
inclusion and none of the exclusion criteria are offered treatment in the study.
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all of the following criteria:
1.Male or f emale patients with a diagnosis of CML -CP ≥ 18 y ears of ag
e
2.Patients must meet all of the following laboratory  values at the screening visit:
< 15% blasts in peripheral blood and bone marrow
< 30% blasts plus promyelocy tes in peripheral blood and bone marrow
< 20% basophils in the peripheral blood
≥ 50 x 109/L (≥ 50,000/mm3) platelets
Transient prior therap y related thrombocytopenia (< 50,000/mm3 for ≤ 30 day sprior 
to screening) is acceptable
No evidence of extramedullary  leukemic involvement, with the exception of 
hepatosplenomegal y
3.BCR -ABL ratio ≥
1% IS according to central laboratory  at the screening examination
4.Prior treatment with a minimum of 2 prior ATP -
binding site TKIs ( i.e. imatinib, nilotinib, 
dasatinib, radotinib or ponatinib)
5.Failure or intolerance to the last previous TKI therapy  at the time of screening (adapted 
from the 2013 ELN Guidelines Bacarrani 2013 )
Failure is defined for CML -CP patients (CP at the time of initiation of last therapy ) as 
follows. Patients must meet at least 1 of the following criteria .
Three months after the initiation of therap y: No CHR or > 95% Ph+ metaphases
Six months after the initiation of therapy : BCR -ABL  ratio > 10% IS and/or > 65% 
Ph+ metaphases

Novartis Confidential Page 37
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Twelve months after initiation of therapy : BCR -ABL ratio > 10% IS and/or > 35% 
Ph+ metaphases
At any  time after the initiation of therapy , loss of CHR, CCy R or PCy R
At any  time after the initiation of therapy , the development of new BCR -ABL 
mutations
At any  time after the initiation of therapy , confirmed loss of MMR in 2 
consecutive tests, of which one must have a BCR- ABL ratio ≥ 1% IS
At any  time after the initiation of therapy , new clonal chromosome abnormalities 
in Ph+ cells: 
CCA/Ph+
Intolerance is defined as:
Non-hematologic intolerance: Patients with grade 3 or 4 toxicity  while on therapy , 
or with persistent grade 2 toxicity , unresp onsive to optimal management, 
including dose adjustments (unless dose reduction is not considered in the best 
interest of the patient if response is alread y suboptimal)
Hematologic intolerance: Patients with grade 3 or 4 toxicity  (absolute neutrophil 
count [ANC] or platelets) while on therap y that is recurrent after dose reduction 
to the lowest doses recommended by  manufacturer
6.Eastern Cooperative Oncology  Group (ECOG) performance status (PS) of 0, 1, or 2
7.Adequate end organ function as defined b y (as per central laboratory tests):
Total bilirubin ≤ 1.5 x ULN except for patients with Gilbert’s sy ndrome who may  
only be included if total bilirubin ≤ 3.0 x UL N or direct bilirubin ≤ 1.5 x ULN
Aspartate transaminase (AST) ≤ 3.0 x ULN
Alanine transaminase (ALT) ≤ 3.0 x ULN
Serum amy lase ≤ ULN
Serum lipase ≤ ULN
Alkaline phosphatase ≤ 2.5 x ULN
Creatinine clearance ≥ 50 mL /min as calculated using Cockcroft- Gault formula
8.Patients must avoid consumption of grapefruit, Seville oranges or products containing the 
juice o f each during the entire study  and preferably  7 day s before the first dose of study  
medications, due to potential CYP3A4 interaction with the study  medications. Orange 
juice is allowed.
9.Written informed consent obtained prior to an y screening procedures .
10. Patients must have the following electrolyte values within normal limits (as per central 
laboratory tests)or corrected to be within normal limits with supplements prior to first 
dose of study  medication:
Potassium
Magnesium
Total calcium (corrected for serum albumin)

Novartis Confidential Page 38
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
5.3 Exclusion criteria
Patients eligible for this study  must not meet anyof the following criteria:
1.Known presence of the T315I  or V299L mutation at an y time prior to study entry
2.Known second chronic phase of CML after previous progression to AP/BC
3.Previous treatment with a hematopoietic stem -cell transplantation
4.Patient planning to undergo allogeneic hematopo ietic stem cell transplantation
5.Cardiac or cardiac repolarization abnormality , including an y of the following:
History  within 6 months pr ior to starting stud y treatment of my ocardial infarction 
(MI), angina pectoris, coro nary artery  bypass graft (CABG)
Clinically  significant cardiac arrhy thmias (e.g., ventricular tachy cardia), complete left 
bundle branch block, high -grade AV block (e.g., bi fascicular block, Mobitz ty pe II 
and third degree AV block)
QTcF at screening ≥450 ms (male patients), ≥460 ms (fem ale patients)
Long QT s yndrome, family  history  of idiopathic sudden death or congenital long QT 
syndrome, or an y of the following:
Risk factors for Torsades de Pointe s(TdP) including uncorrected h ypokalemia or 
hypomagnesemia, history  of cardiac failure, or history  of clinically  
significant/s ymptomatic brady cardia
Concomitant medication(s) with a known risk to prolong the QT interval and/or 
known to cause Torsades de Pointe sthat cannot be discontinued or replaced 7 
days prior to starting study  drug by safe alternative medication .
Inability to determine the QTcF interval
6.Severe and/or uncontrolled concurrent medical disease that in the opinion o f the 
investigator could cause unacceptable safet y risks or compromise compliance with the 
protocol (e.g. uncontrolled diabetes, active or uncontrolled infection , pulmonary  
hypertension)
7.History  of acute pancreatitis within 1 y ear of study  entry  or past me dical history  of chronic 
pancreatitis
8.History  of elevation in amy lase or lipase (> ULN) within 1 y ear other than that which may  
have occurred with gallstones, trauma, or medical procedures
9.History  of acute or chronic liver disease
10.Known presence of signifi cant congenital or acquired bleeding disorder unrelated to 
cancer
11.History  of other active malignancy  within 3 y ears prior to study  entry  with the exception 
of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated 
curativel y
12.Known history  of Human I mmunodeficiency  Virus (HIV), chronic Hepatitis B (HBV), or 
chronic Hepatitis C (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) 
andHepatitis B core antibody  (HBc Ab / anti HBc) will be performed at screening

Novartis Confidential Page 39
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
13.Impairm ent of gastrointestinal (GI) function or GI disease that may  significantly  alter the 
absorption of study  drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, 
malabsorption syndrome, small bowel resection, or gastric by pass surgery )
14.Treat ment with medications that meet one of the following criteria and that cannot be 
discontinued at least one week prior to the start of treatment with study  treatment
Moderate or s trong inducers of CYP3A
Moderate or s trong inhibitors of CYP3A and/or P -gp
Substrates of CYP3A4/5, CYP2C8, or CYP2C9 with narrow therapeutic index
15.Previous treatment with or k nown /suspected h ypersensitivity  to ABL001 or an y of its
excipients.
16.Previous treatment with or known/ suspected h ypersensitivity  to bosutinib or any  of its
excipients.
17.Participation in a prior investigational study within 30 days prior to randomization or 
within 5 half -lives of the investigational product, whichever is longer
18.Pregnant or nursing (lactating) women
19.Women of child- bearing potential, defined as all women phy siologicall y capable of 
becoming pregnant, unless they  are using highly  effective methods of contraception 
during dosing and for 3 day s after last dose of ABL001. Highl y effective contraception 
methods include:
Total abstinence (when this is i n line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilatera l oophorectom y (with or without 
hysterectom y) total h ysterectom y or tubal ligation at least six weeks before taking 
study  treatment ). In case of oophorectom y alone, only  when the reproductive status of 
the woman has been confirmed by follow up hormone leve l assessment
Male sterilization (at least 6 months prior to screening). The vasectomized male 
partner should be the sole partner for that subject.
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device ( IUD) or intrauterine s ystem (IUS) or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or tra nsdermal hormone contraception.
In case of use of oral contraception women should have been stable on the same pill 
for a minimum of 3 months before taking study  treatment.
20.Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ), total hy sterectom y or tubal ligation at least 
six weeks ago . In the case of oophorectomy  alone, only  when the reproductive status of 
the woman has been confirmed by follow up hormone level assessment is she considered 
not of child bearing potential.

Novartis Confidential Page 40
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
21.Sexually  active males unless they  use a condom during intercourse while taking the drug 
during treatment and for 3days after stopping treatment and should not father a child in 
this period. A condom is required to be used also by vasectomized men as well as during 
intercourse with a male partner in order to prevent delivery  of the drug via semen.
6 Treatment
6.1 Stud y treatment
The investigati onal treatments for this study  are ABL001 (40 mg BID) and bosutinib (500 mg 
QD).Novartis will supply  ABL001 to the 
investigational site as 20mgand 40 mg tablets.
Bosutinib will be supplied to the investigational site as 100 mg and 500 mg tablets.
6.1.1 Dosing regimen
ABL001
ABL001 20 or 40 mg strength tablets will be administered orall y twice -daily  (BID) , without 
food. ABL001 tablets should be ingested as follows:
ABL001 should be administered in the fasted state at least 1 h before or 2 h after a meal. 
Water is permitted during this period.
ABL001 should be taken with approximately  8 ounces (240 mL) of water.
ABL001 should be swallowed whole and not chewed or crushed.
If vomiting occurs within the first hour after taking the drug, re-dosing is allowed before 
the next scheduled dose
If the patient does not take ABL001 within 6 hours after the approximate time of the usual 
dosing time, that dose should be skipped and treatment should continue with the next dai ly 
dose at the prescribed level
Bosutinib
Bosutinib 500 mg or 100 mgtablets will be administered orally once daily (QD) with food. If 
a dose is missed beyond 
12 hours, the patient should skip the dose and take the usual dose on 
the following day .
Table 6-1 Dose and treatment schedule
Study  
treatmentsPharmaceutical form 
and route of 
administrationDose Frequency  and/or
RegimenFasting Condition
ABL001 Tablet for oral use 20 mgaTwice -daily Fasting
ABL001 Tablet for oral use 40 mg Twice -daily Fasting
Bosutinib Tablet for oral use 100 mgbOnce -daily Non-fasting
Bosutinib Tablet for oral use 500 mg Once -daily Non-fasting
a20 mg tablets will be dispensed to patients in the instance of dose reduction.
b100 mg tablets will be dispensed to patients in the instance of dose modifications .

Novartis Confidential Page 41
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
On days when serial blood samples are collected for ABL001 PK analysis, patients will be 
instructed tobring their drug suppl y to the site, and take the dose in the clinic, under 
supervision of the site personnel . The exact time for dose administration and meal intake must 
berecorded in the electronic Case Report Form (eCRF).
All dosages prescribed and dispensed to the patient and all dose changes during the study
must be recorded on the Dosage Administration Record eCRF.
6.1.2 Ancillary  treatments
Not applicable.
6.1.3 Rescue medication
Not applicable.
6.1.4 Guidelines for continuation of treatment
Not applicable. See Section 6.3 .
6.1.5 Treatment duration
Thereis no fixed duration of treatment planned per patient. All patients will be given the 
opportunity  to receive study  treatment until the date that corresponds to 96 weeksafter the l ast 
patient receive s the first study  dose. Patients may be discontinued from treatment with the 
study  drug at any time due to unacceptable toxicity , disease progression and/or at the 
discretion of the investigator or the patient.
6.2 Dose escalation guidelines
Dose escalation bey ond the standard doses of 40 mg BID for ABL001 is not permitted.
Dose escalation above 500 mg QD for bosutinib is permitted in this study . Bosutinib 
escalation guidelines are as follows:
Consider dose escalation to 600 mg once daily  in patients who are currently  taking 500 mg 
daily , did not have Grade 3 or higher adverse events and who:
Didnot reach complete hematological response (CHR) by  week 8
Did not reach complete cytogenetic response (CCyR) b y week 12
6.3 Dose mod ifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -
specified dosing schedule, dose interruptions 
and/or reductions are either recommended or mandated inorder to allow the patient to 
continue the study  treatment.
Thes e dose modifications are summarized in Table 6-2. The dose reduction indicated as 
“recommendations”
are provided to assist investigators in the event the patient experiences 
toxicity .However, deviations from “mandatory ” dose interruptions and/or reductions are not 

Novartis Confidential Page 42
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
allowed and mandatory  interruptions or reductions must be strictly  followed. Re-escalation to 
ABL001 40mg BID is permitted if a change in the patient’s individual benefit/risk assessme nt 
at the lower dose level is seen. Re-escalation will be allowed only once for any given patient 
on the ABL001 arm per protocol. Permanent treatment discontinuation is mandatory  for 
specific events indicated as such in Table 6-2. Any dose changes must be recorded on the 
Dosage Administration Record eCRF.
A patient must discontinue treatment with either ABL001 or bosutinib if, after treatment is 
resumed at a lower dose, the toxicity  recurs with the same or worse severity  (See Table 6 -2). 
If a patient requires a dose interruption of > 28 days,then the patient must be discontinued 
from the study treatment . Patients who discontinue the study treatment for a
nadverse event 
suspected to be related to study  drug or an abnormal laboratory  value suspected to be related 
to study  drug must be followed as described in Section 8 .

Novartis Confidential Page 43
Amended Protocol Version 01 (Clean) Proto col No. CABL001A2301
Table 6-2 Criteria for dose reduction/interruption and re -initiation of A BL001 and bosutinib treatment for adverse drug 
reactions
Dose modifications for both ABL001 and bosutinib
Worst toxicity
CTCAE Grade 4.03ABL001 bosutinib
Investigations (Hematologic)
Neutropenia (ANC)
Grade 1 (ANC < LLN –1.5 x 109/L) Recommendation : Maintain dose level Recommendation : Maintain dose level
Grade 2 (ANC < 1.5 –1.0 x 109/L) Recommendation : Maintain dose level Recommendation : Maintain dose level
Grade 3 (ANC < 1.0 –0.5 x 109/L) Mandatory : Hold dose until resolved to ≤ Grade 2 (recheck 
CBC 2 x/week), then:
if resolved in ≤ 14 days, then maintain dose level
If resolved in > 14 days, then reduce dose 1 dose level Mandatory : Hold dose until resolved to ≤ Grade 2 and platelets ≤ 
Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
If resolved in > 14 days, reduce dose 1 dose level 
Grade 4 (ANC < 0.5 x 109/L) Mandatory : Hold dose until resolved to ≤ Grade 2, 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level Mandatory :Hold dose until resolved to ≤ Grade 2 and platelets ≤ 
Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
Febrile neutropenia (ANC < 1.0 x 
109/L, fever ≥ 38.5°C)Mandatory :Hold dose until resolved, then reduce dose 
1 dose levelMandatory :Hold dose until resolved, then reduce dose 1 dose 
level
Thrombocytopenia
Grade 1 (PLT < LLN –75 X 109/L) Recommendation : Maintain dose level Recommendation: Maintain dose level
Grade 2 (PLT < 75 -50 x 109/L) Recommendation : Maintain dose level Recommendation: Maintain dose level

Novartis Confidential Page 44
Amended Protocol Version 01 (Clean) Proto col No. CABL001A2301
Dose modifications for both ABL001 and bosutinib
Worst toxicity
CTCAE Grade 4.03ABL001 bosutinib
Grade 3 (PLT < 50 -25 x 109/L) Mandatory :Hold dose until resolved to ≤ Grade 2 (recheck 
CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 2 and neutrophils 
≤ Grade 2 (re check CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
Grade 4 (PLT < 25 x 109/L) Mandatory :Hold dose until resolved to ≤ Grade 2 (recheck 
CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 2 and neutrophils 
≤ Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if reso lved in > 14 days, then reduce dose 1 dose level
Recurrence of all cytopenias Recommendation: Hold dose until resolved to ≤ Grade 2, 
then maintain current dose levelRecommendation: Hold dose until resolved to ≤ Grade 2, then 
reduce dose 1 additional level
Non-hematologic adverse reactions except where further specified in individual sections
Grade 1 Recommendation : Maintain dose level Recommendation: Maintain dose level
Grade 2 Recommendation: Hold dose until resolved to ≤ Grade 1, 
then maintain dose levelRecommendation: Maintain dose level
Grade 3 Mandatory :Hold dose until resolved to ≤ Grade 1, then 
reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 2, then reduce 
dose 1 dose level, If clinically appropriate, re -escalation of the 
dose back to baseline dose level (500 mg) should be considered
Grade 4 Mandatory : Permanently discontinue patient from study 
drug treatment.Mandatory :Hold dose until resolved to ≤ Grade 2, then reduce 
dose 1 dose level; If clinically appropriate, re -escalation of the 
dose back to baseline dose level (500 mg) should be considered
Investigations (Renal)
Serum creatinine
Grade 1 (> ULN -1.5 x ULN) Recommendation: Maintain dose level Recommendation: Maintain dose level
Grade 2 (> 1.5 -3.0 x ULN) Recommendation: Hold dose until resolved to ≤ Grade 1 
or baseline, then maintain dose levelRecommendation: Hold dose until resolved to ≤ Grade 1 or 
baseline, then maintain dose level
Grade 3 (> 3.0 -6.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
Grade 4 (> 6.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.

Novartis Confidential Page 45
Amended Protocol Version 01 (Clean) Proto col No. CABL001A2301
Dose modifications for both ABL001 and bosutinib
Worst toxicity
CTCAE Grade 4.03ABL001 bosutinib
Investigations (Hepatic)
Isolated total Bilirubin elevation
> ULN –1.5 x ULN Recommendation: Maintain dose level Recommendation: Maintain dose level
> 1.5 -3.0 x ULN Recommendation: Hold dose. Monitor LFTsb weekly, or 
more frequently if clinically indicated, until resolved to ≤ 1.5 
x ULN:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelRecommendation: Hold dose. Monitor LFTsb weekly, or more 
frequently if clinically indicated, until resolved to ≤ 1.5 x ULN:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
> 3.0 -10.0 x ULN*Mandatory :Hold dose. Monitor LFTsb weekly, or more 
frequently if clinically indicated, until resolved to ≤ 1.5 x 
ULN:
if resolved in ≤ 14 days, then reduce dose 1 dose level
if resolved in > 14 days, then discontinue patient from study 
drug treatment. The patient should be monitored weekly 
(including LFTsb), or more frequently if clinically indicated, 
until total bilirubin have resolved to baseline or stabilization 
over 4 weeks.Mandatory :Hold dose. Monitor LFTsb weekly, or more frequently if 
clinically indicated , until resolved to ≤ 1.5 x ULN:
if resolved in ≤ 14 days, then reduce dose 1 dose level
if resolved in > 14 days, then discontinue patient from study drug 
treatment. The patient should be monitored weekly (including 
LFTsb), or more frequently if clinica lly indicated, until total bilirubin 
have resolved to baseline or stabilization over 4 weeks.
> 10.0 x ULN* Mandatory :Permanently discontinue patient from study 
drug treatment. The patient should be monitored weekly 
(including LFTsb), or more frequently if clinically indicated, 
until total bilirubin have resolved to baseline or stabilization 
over 4 weeks.Mandatory :Permanently discontinue patient from study drug 
treatment. The patient should be monitored weekly (including 
LFTsb), or more frequently if cl inically indicated, until total bilirubin 
have resolved to baseline or stabilization over 4 weeks.
Isolated AST or ALT elevation
> ULN -3.0 x ULN Recommendation: Maintain dose level Recommendation: Maintain dose level
> 3.0 -5.0 x ULN Recommendation: Maintain dose level. Repeat LFTsbas 
soon as possible, preferably within 48 -72 hours from 
awareness of the abnormal results ; if abnormal lab values 
are confirmed upon the repeat test, then monitor LFTsb
weekly, or more frequently if clinically indicated, until 
resolved to ≤ 3.0 x ULNRecommendation: Maintain dose level. Repeat LFTsbas soon as 
possible, preferably within 48 -72 hours from awareness of the 
abnormal results; if abnormal lab values are confirmed upon the 
repeat test, then monitor LFTsbweekly, or more frequently if 
clinically indicated, until resolved to ≤ 3.0 x ULN

Novartis Confidential Page 46
Amended Protocol Version 01 (Clean) Proto col No. CABL001A2301
Dose modifications for both ABL001 and bosutinib
Worst toxicity
CTCAE Grade 4.03ABL001 bosutinib
> 5.0 -10.0 x ULN Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the 
abnormal results; monitor LFTsbweekly, or more frequently 
if clinically indicated, until resolved to ≤ 3.0 x ULN: Then
If resolved in ≤ 14 days, maintain dose level
If resolved in > 14 days, reduce dose 1 dose levelMandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤ 2.5 x ULN: Then
Recommendation: If resolved in ≤ 28 days, reduce dose 1 
dose level
Recommendation : If resolved in > 28 days, Discontinue patient 
from study drug treatment
> 10.0 -20.0 x ULN Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the 
abnormal results ; monitor LFTsbweekly, or more frequently 
if clinically indicated, until resolved to ≤ baseline. Then 
reduce dose 1 dose level.Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤ 2.5 x ULN. Then
Recommendation: If resolved in ≤ 28 days, reduce dose 1 
dose level maintain dose level
Recommendation: If resolved in > 28 days, Discontinue patient 
from study drug t reatment.
> 20.0 x ULN Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the 
abnormal results; monitor LFTsbweekly, or more frequently 
if clinically indicated, until resolved to ≤ 3 x ULN (or ≤ 5 x 
ULN for patients with baseline value > 3.0 -5.0 x ULN), 
then resume treatment at reduce dose 1 dose level. Only 
1 dose reduction is allowed; if reoccurs at > 5 x ULN, 
discontinue patient from study drug treatment.Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤ 2.5 x ULN (then
Recommendation: If resolved in ≤ 28 days, reduce dose 1 
dose level m aintain dose level
Recommendation: If resolved in > 28 days, Discontinue patient 
from study drug treatment

Novartis Confidential Page 47
Amended Protocol Version 01 (Clean) Proto col No. CABL001A2301
Dose modifications for both ABL001 and bosutinib
Worst toxicity
CTCAE Grade 4.03ABL001 bosutinib
Combined celevations of AST or ALT and total bilirubin
For patients with normal baseline 
ALT and AST and total bilirubin 
value:
AST or ALT >3.0 x ULN combined 
with total bilirubin >2.0 x ULN without 
evidence of cholestasisd
For patients with elevated baseline 
AST or ALT or total bilirubin value
[AST or ALT>2 x baseline AND > 3.0 
x ULN]Mandatory :Permanently discontinue patient from study 
drug treatment.
Mandatory :Repeat as soon as possible, preferably within 
48 hours from awareness of the abnormal results, then with 
weekly monitoring of LFTsb), or more frequently if clinically 
indicated, until AST, ALT, or bilirubin have resolved to 
baseline or stabilization over 4 weeks. Refer to Section 
6.3.3.1 for additional follow-up evaluations as applicable.Mandatory : Permanently discontinue patien t from study drug 
treatment.
Mandatory : Repeat as soon as possible, preferably within 48 
hours from awareness of the abnormal results, then with weekly 
monitoring of LFTsb), or more frequently if clinically indicated, until 
AST, ALT, or bilirubin have re solved to baseline or stabilization 
over 4 weeks. Refer to Section 6.3.3.1 for additional follow-up 
evaluations as applicable.
Investigation (metabolic)
Asymptomatic amylase and/or lipase elevation
Grade 1 (> ULN -1.5 x ULN) Recommendation: Maintain dose level, measure 2x week Recommendation: Maintain dose level, measure 2x week
Grade 2 (> 1.5 -2.0 x ULN) Recommendation: Maintain dose level, measure 2x week Recommendation: Maintain dose level, measu re 2x week
Grade 3 (> 2.0 -5.0 x ULN) Mandatory :Hold dose until resolved to Grade ≤ 1 or 
baseline, then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days, then discontinue treatment and 
obtain appropriate imaging (i.e., M RI, CT scan or 
ultrasound).Mandatory :Hold dose until resolved to Grade ≤ 1 or baseline, 
then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days, then discontinue treatment and obtain 
appropriate imaging (i.e., MRI, CT scan or ultrasound).
Grade 4 (> 5.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment. Obtain appropriate imaging (i.e., MRI, CT 
scan or ultrasound).Mandatory :Permanently discontinue patient from study drug 
treatment. Obtain appropriate imaging (i.e., MRI, CT scan or 
ultrasound).

Novartis Confidential Page 48
Amended Protocol Version 01 (Clean) Proto col No. CABL001A2301
Dose modifications for both ABL001 and bosutinib
Worst toxicity
CTCAE Grade 4.03ABL001 bosutinib
Vascular disorders
Hypertension
CTCAE Grade 3 Mandatory :Hold dose until resolved ≤ Grade 1, then 
reduce dose 1 dose levelMandatory :Hold dose until resolved ≤ Grade 1, then reduce dose 
1 dose level
CTCAE Grade 4 Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
Gastro intestinal
Pancreatitis
Grade 2 Mandatory :If asymptomatic radiologic pancreatitis (Grade 
2 pancreatitis), hold treatment until resolved to ≤ Grade 1 
or baseline. If treatment delay is ≤ 7 days, then reduce 
dose 1 dose level. If treatment delay >7 days, 
discontinue treatment and obtain appropriate imaging (i.e., 
MRI, CT scan or ultrasound).Mandatory : If asymptomatic radiologic pancreatitis (Grade 2 
pancreatitis), hold treatment until resolved to ≤ Grade 1 or 
baseline. If treatment delay is ≤ 7 da ys, then reduce dose 1 
dose level. If treatment delay >7 days, discontinue treatment and 
obtain appropriate imaging (i.e., MRI, CT scan or ultrasound).
Grade ≥ 3 Mandatory :Permanently discontinue patient from study 
drug treatment. Obtain appropriate im aging (i.e., MRI, CT 
scan or ultrasound).Mandatory :Permanently discontinue patient from study drug 
treatment. Obtain appropriate imaging (i.e., MRI, CT scan or 
ultrasound).
Diarrhea***
Grade 1 Recommendation: Maintain dose level but, initiate anti -
diarrhea treatmentRecommendation: Maintain dose level but, initiate anti -diarrhea 
treatment
Grade 2 Recommendation: Hold dose until resolved to ≤ grade 1, 
then maintain dose level.
If diarrhea returns as ≥ grade 2, then hold dose until 
resolved to ≤ grade 1 , then reduce dose 1 dose levelRecommendation: Hold dose until resolved to ≤ grade 1, then 
maintain dose level.
If diarrhea returns as ≥ grade 2, then hold dose until resolved to ≤ 
grade 1, then reduce dose 1 dose level
Grade 3 Recommendation: Hold dose and discontinue patient from 
study drug treatmentMandatory :Hold dose until recovery to ≤ grade 1. 
Recommendation: Bosutinib may then be resumed at 1 dose 
level
Grade 4 Mandatory :Permanently discontinue patient from study 
drug treatmentMandatory : Hold dose until recovery to ≤ grade 1. 
Recommendation: Bosutinib may then be resumed at 1 dose 
level

Novartis Confidential Page 49
Amended Protocol Version 01 (Clean) Proto col No. CABL001A2301
Dose modifications for both ABL001 and bosutinib
Worst toxicity
CTCAE Grade 4.03ABL001 bosutinib
Skin and subcutaneous tissue disorders
Rash/photosensitivity
Grade 1 Recommendation: Maintain dose level. Consider to 
initiate appropriate skin toxicity therapy (such as 
antihistamines, topical corticosteroids and low -dose 
systemic corticosteroids)Recommendation: Maintain dose level. Consider to initiate 
appropriate skin toxicity therapy (such as antihistamines, topical 
corticosteroids and low -dose systemic corticosteroids)
Grade 2 Recommendation : Maintain dose level, but 
initiate/intensify appropriate skin toxicity therapy (such as 
antihistamines, topical corticosteroids and low -dose 
systemic corticosteroids)Recommendation: Maintain dose level, but initiate/intensify 
appropriate skin toxicity therapy (such as antihistamines, topical 
corticosteroids and low -dose systemic corticosteroids)
Grade 3, despite skin toxicity therapy Recommen dation: Hold dose until resolved to Grade ≤ 1, 
then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days (despite appropriate skin toxicity 
therapy), then discontinue patient from study drug 
treatmentRecommendation: Hold dose until resolved to Grade ≤ 1, then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days (despite appropriate skin toxicity therapy), 
then discontinue patient from study drug treatment
Grade 4, despite skin toxicity therapy Mand atory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
General disorders and administration site conditions
Fatigue/ Asthenia
Grade 1 or 2 Recommendation: Maintain dose level Recommendation: Maintain dose level
Grade 3 Recommendation: Hold dose until resolved to ≤ grade 1, 
then :
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then reduce dose 1 dose levelRecommendation: Hold dose until resolved to ≤ grade 1, then :
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then reduce dose 1 dose level
Other adverse events
Grade 1 or 2 Recommendation : Maintain dose level Recommendation: Maintain dose level
Grade 3 Mandatory :Hold dose until resolved within 28 days to ≤ 
grade 1 then resume at 1 dose levelMandatory :Hold dose until resolved 1 within 28 days to ≤ grade, 
then resume at 1 dose level
Grade 4 Mandatory :Hold dose and then discontinue from st udy 
drug treatmentMandatory :Hold dose and then discontinue from study drug 
treatment

Novartis Confidential Page 50
Amended Protocol Version 01 (Clean) Proto col No. CABL001A2301
Dose modifications for both ABL001 and bosutinib
Worst toxicity
CTCAE Grade 4.03ABL001 bosutinib
All dose modifications should be based on the worst preceding toxicity.
aCommon Toxicity Criteria for Adverse Events (CTCAE Version 4.03)
bCore LFTs consist of ALT, AST, total bilirubin (fractionated [direct and indirect], if total bilirubin > 2.0 x ULN), and alka line phosphatase (fractionated [quantification of 
isoforms], if alkaline phosphatase > 2.0 x ULN.)
c“Combined” defined as total b ilirubin increase to the defined threshold concurrently with ALT/AST increase to the defined threshold
If combined elevations of AST or ALT and total bilirubin do not meet the defined thresholds, please follow the instructions f or isolated elevation of tot al bilirubin and 
isolated elevation of AST/ALT, and take a conservative action based on the degree of the elevations (e.g. discontinue treatme nt at the situation when hold dose is needed 
for one parameter and discontinue treatment is required for another p arameter). After all elevations resolve to the defined thresholds that allow treatment re -initiation, re -
start the treatment either at the same dose or at one dose lower if meeting a criterion for dose reduction
d “Cholestasis” defined as ALP elevation (> 2.0 x ULN and R value <2 ) in patients without bone metastasis, or elevation of ALP liver fraction in patients with bone 
metastasis
Note: The R value is calculated by dividing the ALT by the ALP, using multiples of the ULN for both values. It denotes wheth er the relative pattern of ALT and/or ALP 
elevation is due to cholestatic (R ≤ 2), hepatocellular ( R ≥ 5), or mixed (R >2 and < 5) liver injury
* Note: If total bilirubin > 3.0 x ULN is due to the indirect (non -conjugated) component only, and hemolysis as the etiology has been ruled out as per institutional guidelines 
(e.g., review of peripheral blood smear and haptoglobin determination), then ↓ 1 dose level and continue treatment at the dis cretion of the investigator.
** Note: A CT scan or other imaging s tudy to assess the pancreas, liver, and gallbladder must be performed within 1 week of the first occurrence of any ≥ Grade 3 of 
amylase and/or lipase. If asymptomatic Grade 2 elevations of lipase and/or amylase occur again at the reduced dose, patients will be discontinued permanently from 
study treatment.
*** Note: antidiarrheal medication is recommended at the first sign of abdominal cramping, loose stools or overt diarrhea

Novartis Confidential Page 51
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Table 6-3 Dose reduction steps for A BL001 and bosutinib
Dose reduction*
Starting dose level – 0 Dose level - 1
ABL001 BID 40 mg tablet BID (total daily 
dose 80 mg)20 mg tablet BID (total daily 
dose 40 mg)
*Dose reduction should be based on the worst toxicity demonstrated at the last dose.
ABL001 dose reduction below total daily 40 mg is not allowed. 20 mg tablets will be dispensed to patients in the 
instance of dose reduction.
Dose reduction*
Starting dose level – 0 Dose level - 1 Dose level – 2
Bosutinib QD 500 mg ( 1 -500 mg tablet QD) 400 mg (4 -100 mg tablets 
QD)300 mg (3 -100 mg 
tablets QD)
* Dose reduction should be based on the worst toxicity demonstrated at the last dose.
Bosutinib dose reduction below total daily 300 mg is not allowed. 100 mg tablets will be dispensed to patients in 
the instance of dose reduction.
6.3.2 Dose adjustments for QTcF prolongation
If QTcF >500 msec or QTcF prolongation >60 msec from baseline is observed at any point 
during stud y treatment, and confirmed, the below guidance must be followed:
1.Assess the quality of the ECG recording and th e QT value and repeat if needed
2.Interrupt stud y treatment until confirmed resolution of QTcF and as per dose reduction 
guidel ines for non- hematological AEs.
3.Determine the serum electroly te levels (in particular hy pokalemia, hy pomagnesemia). If 
abnormal, correct abnormalities before resuming study  drug tre atment.
4.Review concomitant medication use for other causes for QT prolongation (refer to 
qtdrugs.org for known QT prolonging drugs), and for drugs with the potential to increase 
the risk of drug exposure related QT prolongation (e.g., concomitant use of CY P3A4 
inhibitors, if the study  drug is a CYP3A4 substrate)
5.Check study drug dosing sc hedule and treatment compliance
6.Increased ECG safet y monitoring is recommended during or in -between subsequent visits.
6.3.3 Follow -up for toxicities
Patients whose treatment is permanently  discontinued due to a study  drug related adverse 
event or clinically  significant laboratory  value, must be followed up at least once a week for 4 
weeks, until resolution or stabilization of the event, whichever comes first. Appropriate 
clinical experts such as ophthalmologist, endocrinologist, dermatologist, psychiatrists etc. 
should be consulted as deemed necessary . All patients must be followed up for adverse events 
and serious adverse events for 30 day s following t he last dose of stud y treatment.

Novartis Confidential Page 52
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
6.3.3.1 Follow up on potential drug -induced liver injury (DILI) cases
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically  important events.
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
For patients with normal AL T and AST and TBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or ALT > 8.0 x ULN], combined with [TBIL > 2 x 
baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as ALP elevation > 2.0 x ULN with R value < 2 in patients without bone metastasis, or 
elevation of ALP liver fraction in patients with bone metastasis.
Note: (The R value is calculated b y dividing the ALT by  the ALP, using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferably  within 48 hours from 
the awareness of the abnormal results. The evaluation should include laboratory tests, detailed 
history , phy sical assessment and thepossibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
1.Laboratory tests should include ALT, AST, albumin, creatinine kinase, total bilirubin, 
direct and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase.
2.A detailed histo ry, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history of any  pre-existing liver 
conditions or risk factors, should be collected.
3. Further testing for acute hepatitis A, B, C or E infection and liver imaging (e .g.biliary  
tract) may be warranted.
4.Obtain PK sample, as close as possible to last dose of study  drug, if PK anal ysis is 
performed in th e stud y.
5.Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medically 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the 
term “potential drug -induced liver injury ”. All events should be followed up with the outcome 
clearl ydocumented.

Novartis Confidential Page 53
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
6.3.4 Anticipated risks and safety  concerns of the study  drug
Appropriate eligibility  criteria, as well as specific dose modification and stopping rules are 
included in this protocol. Recommended guidelines for proph ylactic or supportive treatment 
for expected toxicities, including management of study -drug 
induced adverse events, i.e., 
hypergly cemia, skin toxicity  and diarrhea are provided in Table 6-2. Refer to preclinical 
toxicity  and or clinical data found in the [I nvestigator’s Brochure].
6.4 Concomitant medications for patients on A BL001
The patient must be told 
to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug and including 
over-the-counter treatment and nutritional or vitamin supplements) and significant non-drug 
thera pies (including physical therapy , herbal/natural medications and blood transfusions) 
administered during the study  must be listed on the “Concomitant Medications/Significant 
non-drug therapies” section of the eCRF.
Chronic medication should be maintained at the same dose and schedule throughout the study
period, as medically  feasible.
All prior antineoplastic surgery , chemotherap y, biologic, immunologic and radiation therap y 
must be recorded in the “Prior antineoplasti c therapy ” section of the eCRF.
In gene ral, concomitant medications and therapies deemed necessary  for the supportive care 
and safet y of the patient are allowed, provided their use is documented in the patient records 
and on the appropriate case report form, 
including the medicati on’s duration (start and end 
dates or if continuing at final exam). These include blood and platelet transfusions for patients 
with anemia and with thrombocy topenia.
6.4.1 Permitted concomitant therapy
Drugs that affect gastric pH
ABL001 does not have a pH-dependent solubility . Drugs that elevate gastric pH will not 
affect ABL001 absorption. All ac id reducing agents are allowed.
6.4.2 Permitted concomitant therapy  requiring caution and/or action
There is a potential for DDIs with co-medications metabolized by CYP3A4/5, CYP2C8 and 
CYP2C9 at the anticipated human efficacious dose. Therefore, substrates of CYP3A4/5, 
CYP2C8 and CYP2C9 should be used with caution ( Section 14- Appendix ).
Additionally , transporter phenot yping studies have identified ABL001 to be a substrate of 
Breast Cancer Resistant Protein (BCRP). While the effect on 
ABL001 exposure via BCRP 
interaction is not likely , BCRP inhibitors should be administered wi th caution.

Novartis Confidential Page 54
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
6.4.3 Prohibited concomitant therapy
Strong CYP3A 4/5 and P -gpinhibitors
Every  effort should be made NOT to concomitantly  administer strong CYP3A4/5 and P-gp 
inhibitors (e.g., erythromy cin, ketoconazole, itraconazole, voriconazole, clarithrom ycin, 
telithromy cin, ritonavir, mibefradil). P-gp and CYP3A4/5 inhibitors may increase absorption 
or decrease the metabolism of ABL001 and resulting in increased serum concentrations and 
increased exposure. If administration of a strong CYP3A4/5 and P-gp inhibitor cannot be 
avoided during the study  and cannot be switc hed to an alternative therap y that does not 
strongl y inhibit CYP3A4/5 or P -gp, ABL001 must be stopped.
A list of cytochrome P450 isoenzy mes and CYP3A4/5 and P-gp inhibitors may be found at 
http://medicine.iupui.edu/CLINPHARM/ddis/clinical -table.
A classification of CYP3A4/5 and P- gp inhibitors can be found inSection 14 -Appendix .
Further information can also be found in the following reference ( Venkatakrishnan et al 2001 ).
Strong CYP3A 4/5, and UGT1A /2B inducers
Every  effort should be made NOT to concomitantly  administer strong CYP3A4 inducers 
during the stud y.
Additionally , the use of strong inducers of UGT1A/2B is prohibited during the study .
NTI substrates of CYP3A 4/5, CYP2C8 and CYP2C9
Based on the in vitro results, there is a potential for DDIs with co -medications metabolized by 
CYP3A4/5, CYP2C8 and CYP2C9 at the anticipated human efficacious dose. Therefore, 
narrow therapeutic index substra tes of CYP3A4/5, CYP2C8 and CYP2C9 are prohibited
QT prolonging agents
Every  effort should be made NOT to administer a QT prolonging agent. If during the course 
of the study , concomitant administration of an agent known to prolong the QT interval is 
requir ed and cannot be switched to an alternative therapy , ABL001 must be permanentl y 
discontinued.
Please see: http://www.torsades.org/medical -pros/drug
-lists/printable -drug-
list.cfmcrediblemeds.org/every one/composite -list-all-qtdrugs/ for a list of agents that prolong
the QT.
Herbal medications
Herbal preparations/medications are not allowed throughout the study . These herbal 
medications include, but are not limited to: St. John’s wort, Kava, ephedra (ma huang), 
gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. 
Patients should stop using these herbal medications 7 day s prior to first dose of study  drug.

Novartis Confidential Page 55
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
6.4.4 Other concomitant medications
Anti-emetics
Use of anti-emetics is allowed. Prophy lactic anti-emetics should be started only once the 
patient experiences nausea or vomiting, at the discretion of the investigator. It is 
recommended that patients use drugs that do not cause QT prolongation. Please note that 
some anti-emetics have a known risk for Torsade de Pointes and are prohibited ( refer to 
Section 6.4.2 and Section 14.1/Appendix 1).
Bisphosphonates
The use of bisphosphonates regar dless of indication is allowed.
Contraceptives
Hormonal contraceptives are allowed as contraception methods. Highl y effective 
contraception should be maintained throughout the study  and for 3 daysafter study  treatment 
discontinuation .
Anticoagulation agents
All anticoagulants or anti-aggregation agents may be administered under the discretion of the 
investigator.
Therapeutic 
doses of warfarin sodium (Coumadin®) or any other coumarin- derivative 
anticoagulants should be used with caution and fully  avoided whenever possible because of its 
known interaction with many  commonl y used medications and certain foods. As warfarin has 
a narrow therapeutic range, and ABL001 is possibly  an inhibitor of CYP2C9, the major 
metabolizing enzyme of S-warfarin (R-warfarin is metabolized by multiple CYP enzymes), 
warfarin should be caref ully monitored whenever used.
Caution is also advised when ABL001 is co-administered with anti-platelet pro-drugs such as 
clopidogrel, ticlopidine and prasugrel, which require metabolic activation by CYP3A4 and 
CYP2C9. While the weak reversible in vitro inhibition potential of ABL001 is unlikely  to 
translate into clinical significance as the stead y-state plasma concentrations at the maximum 
therapeutic doses are significantl y lower than the experimentally  determined inhibition 
constants, patient s using anti -platelet pro -drugs should still be carefull y monitored.
Direct Thrombin inhibitors (DTIs) and Factor Xa inhibitors are allowed as anticoagulants. 
Individual medications from each of the classes should be checked if they are not prohibited 
due to other drug-drug-interactions with ABL001. Alternativel y, therapeutic anticoagulation 
may be accomplished using low-molecular weight heparin.
6.5 Concomitant medications for patients on Bosutinib
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug and including 
over-the-counter treatment and nutritional or vitamin supplements) and significant non-drug 
therapies (including physical therapy , herbal/natural medications and blood transfusions) 

Novartis Confidential Page 56
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
administered during the study  must be listed on the “Concomitant Medications/Significant 
non-drug therapies” section of the eCRF.
Chronic medication should be maintained at the same dose and schedule throu
ghout the study
period, as medically  feasible.
All prior antineoplastic surgery , chemotherap y, biologic, immunologic and radiation therap y 
must be recorded in the “Prior antineoplasti c therapy ” section of the eCRF.
In general, concomitant medications and therapies deemed necessary  for the supportive care 
and safet y of the patient are allowed, provided their use is documented in the patient records 
and on the appropriate case report form, including the medicati on’s duration (start and end 
dates or if continuing at final exam). These include blood and platelet transfusions for patients 
with anemia and with thrombocy topenia
6.5.1 Prohibited concomitant medications
Concomitant use with CYP3A  inhibitors
Avoid the concomitant use of strong or moderate CYP3A inhibitors as an increase in 
bosutinib plasma concentration is expected. Strong CYP3A inhibitors include boceprevir, 
clarithrom ycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, 
mibefradil, nefazod one, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, 
telithromy cin, and voriconazole.
Moderate CYP3A inhibitors include amprenavir, aprepitant, atazanavir, ciprofloxacin, 
crizotinib, darunavir/ritonavir, diltiazem, erythromy cin, fluconazole, fosamprenavir, 
grapefruit products, imatinib and verapamil) [Bosulif®USPI ]. If administration of a strong or 
moderate CYP3A4/5 inhibitor cannot be avoided during the study  and cannot be switched to 
an alternative therap y, bosutinib must be stopped.
Concomi tant use with CYP3A  inducers
Avoid the concomitant use of strong or moderate CYP3A inducers as a large reduction in 
exposure is expected (strong CYP3A inducers include carbamazepine, pheny toin, rifampin 
and St. John's Wort. Moderate CYP3A inducers include bosentan, efavirenz, etravirine, 
modafinil and nafcillin) [ Bosulif®USPI ]. If administration of a strong or moderate CYP3A4/5 
inducer cannot be avoided during the study  and cannot be switched to an alternative therap y, 
bosutinib must be stopped.
P-gp Inhib itors
Avoid the concomitant use of P-gp inhibitors with BOSULIF as an increase in bosutinib 
plasma concentration is expected [ Bosulif®USPI ].
pH A ltering Medications
Bosutinib display s pH-dependent aqueous solubility , in vitro. In a  c ross-over trial in 23 
healthy  volunteers, a single oral dose of 400 mg of bosutinib was either administered alone or 
in combination with multiple -oral doses of 60 mg of lansoprazole (PPI) under fasting 
conditions. L ansoprazole decreased bosutinib Cmax and AU C by  46% and 26%, re spectively .

Novartis Confidential Page 57
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Concomitant administration with PPI s is not allowed.
Consider using short- acting antacids or H2 blockers instead of PPIs to avoid a reduction in 
bosutinib exposure. Separate antacid or H2 blocker dosing by more than 2 hours [Bosulif®
USPI ].
6.6 Patient numbering, treatment assignment or randomization
6.6.1 Patient numbering
Each patient is identified in the study  by a Subject Number (Subject No.), that is assigned 
when the patient is first enrolled for screening and is retained as the primary  identifier for the 
patient throughout his/her entire participation in the trial. The Subject No. consists of the 
Center Number (Center No.) (as assigned by Novartis to the investigative site) with a 
sequential patient number suffixed to it, so that each subject is numbered uniquely  across the 
entire database. Upon signing the informed consent form, the patient is assigned to the next 
sequential Subject No. available to the investigator through the Oracle Clinical RDC interface.
The investigator or designated staff will contact the IRT and provide the requested identify ing 
information for the patient to register them into the IRT. Once assigned, the Subject No. must 
not be reused for any other subject and the Subject No. for that individual must not be 
changed, even if the patient is re-screened. If the patient fails to be randomized or start 
treatment for any reason, the reason will be entered into the Screening Disposition page. IRT 
must be notified within 2 days that the patient was not randomized.
6.6.2 Treatment assignment or randomization
Patients will be assigned to one of the 2treatment arms ( Section 4.1 and Section 6.1 ) in a ratio 
of 2:1. Randomization will be stratified by  cytogenetic response status at screening.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients and investigator staff. A patient 
randomization list will be produced by the Interactive Response Technology  (IRT) provider 
using a validated system that automates the random assignment of patient numbers to 
randomization numbers. These randomization numbers are linked to the different treatment 
arms, which in turn are linked to medication numbers. A separate medication randomization 
list will be produced by or under the responsibility  of Novartis Drug Supply  Management 
using a validated system that automates the random assignment of medication numbers to 
medication packs containing each of the stud y treatments.
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be randomized via 
IRT to one of the treatment arms. The investigator or his/her delegate will call or log on to the 
IRT and confirm that the patient fulfills all the inclusion/exclusion criteria. The IRT will 
assign a randomization number to the patient, which will be used to link the patient to a 
treatment arm and will specify  a unique medication number for the first package of study 
treatment to be dispensed to the patient. The randomization number will not be communicated 
to the caller.

Novartis Confidential Page 58
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
6.6.3 Treatment blinding
Not applicable.
6.7 Stud y drug preparation and dispensation
The investigator or responsible site personnel must instruct the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by authorized site 
personnel only. All dosages prescribed to the patient and all dose changes during the study 
must be recorded on the Dosage Administration Record eCRF.
6.7.1 Study treatment packaging and labeling
Study  treatment, ABL001 and bosutinib tablets, will be provided as global clinical open -label 
supply  and will be packed and labeled under the responsibility  of Novartis, Drug Supply 
Managem ent.
Study  treatment labels will comply  with the legal requirements of each country  and will 
include storage conditions, a unique medication number (corresponding to study  treatment 
and strength). Responsible site personnel will identify  the study  treatmen t package(s) to 
dispense by the medication number(s) assigned by IRT to the patient. Site personnel will add 
the patient number on the label. If the label has 2-parts (base plus tear-off label), immediatel y 
before dispensing the package to the patient, site personnel will detach the outer part of the 
label from the package and affix it to the patient’s source document.
Table 6-4 Packaging and labeling
Study  treatments Packagin g Labeling (and dosing frequency )
ABL001 (20 mg and 40 mg) Tablets in bottle Labeled as ‘ABL001 20 mg/ABL001 40 
mg’(BID)
bosutinib (100 mg or 500 mg) Tablets in bottle or tablets in 
blisterLabeled as ‘bosutinib 100 mg or bosutinib 
500 mg’(QD)
6.7.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study site, handled and 
stored safel y and properly , and kept in a secured location to which only the investigator and 
designated site personnel have access. Upon receipt, the ABL001 and bosutinib should be 
stored according to the instruction s specified on the drug labels.
6.7.3 Study drug compliance and accountability
6.7.3.1 Study drug compliance
Total daily  dose of study treatment administered with start and end date will be collected on 
the Dose Administration Record eCRF page. Name, start and end dates of any Concomitant 
Medications and Surgical and Medical procedures will be collected on the Prior and 
Concomitant medications and Surgical and Medical procedures eCRFs respectivel y.
Compliance will be assessed by the investigator and/or study  personnel at each patient visit 
and information provided by the patient and/or caregiver will be captured in the Drug 

Novartis Confidential Page 59
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Accountability  Form. This information must be captured in the source document ateach 
patient visit.
6.7.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by the field 
monitor during site visits and at the completion of the study . Patients will be asked to return 
all unused study  treatment and packaging on a regular basis, at the end of the study  or at the 
time of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will 
return all used and unused study  treatment, packaging, drug labels, and a copy  of the 
completed drug accountability  logto the Novartis monitor or to the Novartis address provided 
in the investigator folder at each site.
6.7.3.3 Handling of other study  treatment
Not applicable.
6.7.4 Disposal and destruction
The study  drug suppl y can be destro yed at the local Novartis facility , Drug Supply  group or 
third party , or at the site only if permitted by  local regulations and authorized by Novartis in a 
prior agreement.
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
perfor med. All data obtained from these assessments must be supported in the patient’s source 
documentation. Patients can be consented for study participation prior to study  day 
-21.
No eCRF wil l be used as a source document.
(S) is defined as “Source”
(D) is de fined as “Data Based”

Novartis Confidential Page 69
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
7.1.1 Molecular pre -screening
Not applicable .
7.1.2 Screening
Written informed consent must be obtained before any study  specific medical procedures are 
performed (Day  -42) . All s creening /baseline assessments (with the exception of Bone Marrow 
Aspirates) should occur within 21 day s before randomization .
The screening visit window for bone marrow assessments is 42 days prior to randomization.
During the screening visit, inclusion and exclusion criteria will be assessed. Screening 
assessments to confirm eligibility  must be performed prior to randomization. The results of 
the RQ-PCR and the bone marrow aspirate must be available prior to randomization and first 
dose of study  treatmen t
For details of assessments required during screening please refer to Table 7 -1.
Laboratory  baseline assessments (including hematology , chemistry , coagulation and serum 
pregnancy  test), physical examina tion including extramedullary  involvement, performance 
status, ECG, height, weight and vital signs , evaluation of all relevant medical history  
including cardiovascular risk factors, CML disease history , including prior TKI therapy  and 
antineoplastic medica tion and prior and concomitant medication must be performed prior to 
the first dose of study  treatment. Patients with potassium, and/or magnesium and/or total 
calcium levels that are < LLN at screening, must have their potassium, and/or magnesium, 
and/or calcium replenished through supplementation and the levels must be within normal 
limits prior t o the first dose of study drug.
A patient who has a laboratory  test(peripheral blood test) results that do not satisfy  the 
entrance criteria may have the tests repeated. These tests may be repeated as soon as the 
investigator believes the re-test results are likely  to be within the acceptable range to satisfy  
the entrance criteria, but should be completed within approximately  2
 weeks of the original 
screening visit date. In this case, the subject will not be required to sign another ICF, and the 
original patient ID number assigned by the investigator will be used. In the event that the 
laboratory  tests cannot be performed within the screening visit window, or the re-tests do not 
meet the entrance criteria, or other eligibility  criteria have changed and are not met anymore, 
the patient is considered a screen failure, and must be discontinued from the study .
A new ICF will need to be signed if the investigator chooses to re-screen the patient after a 
patient has screen failed, however, the patient ID number will remain the same. All required 
screening activities must be performed when the patient is re-screened for participation in the 
study . An individual patient may only be re-screened once for the study . Once the number of 
patients screened and enrolled is likely  to ensure target enrollment, the Sponsor may  close the 
study  to further screening. In this case, the patients who screen failed will not be permitted to 
re-screen.

Novartis Confidential Page 70
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
7.1.2.1 Eligibility  screening
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed. The eligibility  check will be managed viaIRT system. 
Please refer and compl y with detailed guidelines in the I RT manual.
7.1.2.2 Information to be collected on screening failures
Patients who sign an informed consent but fail to be started on treatment for any reason will 
be considered a screen failure. The reason for not being started on treatment will be entered on 
the Screening Phase Disposition Page. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for Screen Failure patients. No other data 
will be e ntered into the clinical database for patients who are screen failures, unless the patient 
experienced a Serious Adverse Event during the Screening Phase (see Section 8 for SAE 
reporting details). If the patient fails to be randomized, the I RT must be notified within 2 day s 
of the screen fail that the patient was not randomized.
7.1.2.3 Patient demographics and other baseline characteristics
Patient demographics and baseline characteristics collected will includ e the following: date of 
birth, gender (and child bearing potential for female), race and ethnicity, height, weight, all 
relevant medical history  including cardiovascular disease history , CML disease history , 
including mutation status, and prior and concom itant medication including prior TKI therap y 
and antineoplastic medication.
Physical examination including extramedullary  involvement, performance status, vital signs, 
ECGs, and laboratory  assessments will be performed at screening.
Significant findings that were present prior to the signing of informed consent must be 
included in the Relevant Medical History /Current Medical Conditions page on the subject’s 
eCRF. Significant new findings that begin or worsen after informed consent must be recorded 
on the AE page of the patient’s eCRF.
Thecentral reading of the screening ECGs as well as the results of the RQ-PCR and the bone 
marrow aspirate must be available prior to randomization and first dose of study  treatment to 
evaluate eligibility  and to stratify  the patient.
7.1.2.4 Local recruitment procedures -Japan
Given the limited safet y data available in Japanese patients, specific recruitment and data 
monitoring procedures will be put in place for Japanese patients randomized to ABL 001.
Randomization of these patients w ill be staggered to avoid enrollment of more than one 
patient on the same day. Safety  parameters from a minimum of 2 patients treated on the 
ABL001 arm will be reviewed for determin ingthe appropriateness ofcontinuing patient 
enrollment in Japan
.
7.1.3 Run- in period
Not applicable.

Novartis Confidential Page 71
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
7.1.4 Treatment period
There is no fixed duration of treatment planned per patient. All patients will be given the 
opportunity  to receive study  treatment until the date that corresponds to 96 weeks after the last 
patient receives the first study  dose.
During the treatment phase, the patients will receive either ABL001 treatment 40 mg BID or 
bosutinib 500mg QD according to randomization. The dose can be modified, if required from 
the perspective of tolerance, following the guidance in Section 6.2 and Section 6.3 . Treatment 
is ongoing until patient experiences unacceptable toxicity , disease progression, death, lost to 
follow -up and/or treatment is discontinued at the discretion of the investigator or withdrawal 
of consent.
The patients are advised to adhere to the food restrictions during the treatment (fasting status 
regarding stud y treatment administration, avoidance of prohibited c oncomitant medication).
7.1.5 Visit windows
Study  visits from Day 1 to Week 16 should be completed every  2 w eeks on the designated 
date [with an allowed “visit window” of +/ -1 day ]
Study  visits from Week 16 to Week 96 should be completed every  4 weeks on the designated 
date [with an allowed “visit window” of +/ -2 day s]
Study  visits from Week 96 to EOT should be completed every  12 weeks on the designated 
date [with an allowed “visit window” of +/ -7 day s]
A delay ed visit will have no impact on the next planned visit. The next visit should be 
completed as scheduled in order to avoid 
accumulation of additional weeks.
7.1.6 Discontinuation of study treatment
Patients may voluntarily discontinue from thestudy  treatment forany reason at an ytime.If
apatient decides todiscontinue from the study treatment, theinvestigator should make a 
reasonable effort (e.g. telephone, e-mail,letter) tounderstand theprimary reason forthis
decision and record thisinform ation inthepatient ’schart andontheappropriate e CRF pages.
They maybe conside redwithdrawn ifthey state an intention towithdraw, failtor eturn for
visits,orbeco me lost tofollow - upfor an yother reason.
Theinvestigator should discontinue study treatmentfora given patient if,he/she believes that
continua tionwould bedetrimental tothe patie nt’sw e ll-being. Patients who discontinue study 
treatment should undergo an end of stud y visit.
For patients who discontinue treatment for reasons other than death, lost to follow -up, or 
withdrawal of consent, the patient should enter the survival follow -upphase. Survival visit
assessments (survival, antineoplastic therapies, stem cell transplant and progression) should 
be performed every12weeks until documented death, lost to follow -up, or withdrawal of 
consent.
Patients who discontinue the study  treatment for anadverse event suspected to be related to 
study  drug or an abnormal laboratory  value suspected to be related to study  drug must be 
followed as described in Section 8.

Novartis Confidential Page 72
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Patients may  also be discontinued from the study treatment if any of the following occur s:
discovery  of patient ineligibility
errors in treatment compliance [study  treatment, other prescribed or non -prescribed 
medications]
missed/unschedule d/off schedule/incomplete/incorrect assessments
major protocol deviation
pregnancy  during treatment phase
use of prohibited treatmentrefer toAppendix 1.
any other protocol deviation thatresults inasignificantrisk tothepatient’s saf ety
In addition to the general discontinuation criteria, the following study  specific criteria will 
also require discontinuation of study  treatment :
In the event of treatment failure the patient must be discontinued from the study treatment . 
The following events will constitute ‘treatment failure’, and are based on the ELN criteria
(Bacarrani 2013 )defining failure of a second line treatment:
No CHR or > 95% Ph+ metaphases at three months af ter randomization or thereafter
BCR -ABL ratio 
> 10% IS and/or > 65% Ph+ metaphases at six months af ter 
randomization or thereafter
BCR -ABL ratio > 10% IS and/or > 35% Ph+ metaphases at12 months after 
randomization or thereaft
er
Loss of CHR, CCy R or PCy R at any  time after randomization
Detection of new BCR -ABL mutations at any  time after randomization
Confirmed loss of MMR in 2 consecutive tests, of which one must have a BCR -ABL ratio 
≥ 1% I S 6 months after randomization
New cl onal chromosome abnormalities in Ph+ cells : CCA/Ph+: at any  time after 
randomization
In the event of disease progression the patient must be discontinued from the study treatment . 
The following events are considered disease progression.
1.CML -related death ( any death during treatment or follow -up if the principal cause of death 
is marked as “stud y indication” in the eCRF b y the investigator, or if the death occurred 
subsequent to documented progression to AP/BC and the cause of death is reported as 
“unknown” or not reported by  the investigator)
2.Accelerated phase (AP) as defined b y any of the following:
≥ 15% blasts in the peripheral blood or bone marrow aspirate, but < 30% blasts in 
both the peripheral blood and bone marrow aspirate
≥ 30% blasts plus promyeloc ytes in peripheral blood or bone marrow aspirate
≥ 20% basophils in the peripheral blood
Thrombocy topenia (<100 x 109/L) that is unrelated to therap y

Novartis Confidential Page 73
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
3. Blast crisis (BC) as defined by  any of the following:
≥ 30% blasts in peripheral blood or bone marrow aspirate
Appearance of extramedullary  involvement other than hepatosplenomegal y proven b y 
biopsy  (i.e., chloroma).
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
7.2.1.1 Molecular response
Molecular response (MR) will be assessed in all patients randomized to each treatmen t arm.
Levels of BCR -ABL transcripts will be determined by real-time quantitative PCR (RQ- PCR) 
testing of peripheral blood and anal yzed at a central testing laboratory . Log reduction in BCR -
ABL transcripts levels from the standardized baseline value, or th e percent ratio of BCR- ABL 
transcripts versus control gene (ABL) transcripts converted to a reference standard, 
international scale ( Hughes and Branford 2006 ), will be calculated for each sample.
Major m olecular response and related variables are defined as the following :
Rate of Major Molecular Response (MMR) where MMR is defined as a ≥ 3.0 log 
reduction in BCR -ABL transcripts compared to the standardized baseline equivalent to ≤ 
0.1 % BCR -ABL/ABL % by  international scale as measured by  RQ-PCR, confirmed by  
duplicate anal ysis of the same sample
Time to MMR defined as the time from the date of randomization to the date of the first 
documented MMR,
Duration of MMR defined as the time from the date of first documented MMR to the 
earliest date of loss of MMR, progression to AP or BC, or CML- related death.
Loss of MMR is defined as confirmed loss of a greater than or equal to 3.0 log reduction in 
BCR -ABL transcript levels compared to the standardized baseline value, or confirmed loss of 
a less than or equal to 0.1% BCR -ABL/ABL by international scale in association with a ≥ 5-
fold rise in BCR -ABL  from the lowest value achieved on study  treatment confirmed by a 
duplicate anal ysis of the same sample. This result ha s to be confirmed by  a subsequent sample 
within 4-6 weeks unless it is associated with confirmed loss of CHR or loss of CCyR or 
progression to AP/BC or CML -related death.
Mutational analy sis will be performed at a Novartis designated laboratory  by Sanger 
sequencing 
at baseline and at end of treatment . If the result at baseline is positive for a 
mutation, analy sis wi ll be performed every  12 weeks.
The blood samples will be taken as described in Table 7 -1and Table 7 -2.

Novartis Confidential Page 74
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Table 7-2 Blood samples (efficacy  primary  endpoint)
Sample Type Volume Visit Timepoint
Blood for BCR -ABL
quantification by RQ -PCR20 mL Screening/Baseline Pre-dose
20 mL Week 4 Pre-dose
20 mL Week 8 Pre-dose
20 mL Week12 Pre-dose
20 mL Week16 Pre-dose
20 mL Week24 Pre-dose
20 mL Week36 Pre-dose
20 mL Week48 Pre-dose
20 mL Week60 Pre-dose
20 mL Week72 Pre-dose
20 mL Week84 Pre-dose
20 mL Week96 Pre-dose
20 mL Every 12 weeks thereafter 
(W108,W120,W132, 
W144,W156,W168)Pre-dose
20 mL EndofTreatment Anytime
Blood for BCR -ABL Mutation
analysi sby Sanger Sequencing2.5 ml Week 1Day1 Pre-dose
2.5 ml End of Treatment Anytime
Blood for BCR -ABL Mutatio n
analysi s only for patients with
mutations at W1D12.5 ml Week12 Anytime
2.5 ml Week24 Anytime
2.5 ml Week36 Anytime
2.5 ml Week48 Anytime
2.5 ml Week60 Anytime
2.5 ml Week72 Anytime
2.5 ml Week84 Anytime
2.5 ml Week96 Anytime
2.5 ml Every 12 weeks thereafter 
(W108,W120,W132, 
W144,W156,W168)Anytime
During the study , peripheral blood samples will be collected into PAXgene ™Blood RNA 
tubes for all RQ-PCR assessments. Detailed instructions for the collection, handling, and 
shipment of RQ-PCR and mutation samples are outlined in the [CABL001A2301 Laboratory 
Manual ].
7.2.1.2 Bone marrow analy sis and cytogenetics
Cytogenetic response will be assessed as the percentage of Ph+ metaphases in the bone 
marrow and is defined as the following (a review of a minimum of 20 metaphases is required):
Complete (CCy R) -0% Ph+ metaphases
Partial (PCy R) ->0 to 35% Ph+ metaphases
Major (MCy R) -0 to 35% Ph+ metaphases

Novartis Confidential Page 75
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Minor (mCy R) ->35 to 65% Ph+ metaphases
Minimal ->65 to 95% Ph+ metaphases
None ->95 to 100% Ph+ metaphases.
Bone marrow aspirate for cytogenetic analyses will be performed at screening/ baseline
(performed up to 42 days prior to rando mization) , at week 24, 48, 72, 96 and at end of 
treatment. For patients on the bosutinib arm an unscheduled bone marrow assessment at week 
12 may be performed to evaluate cytogenetic response in consideration for potential dose 
escalation.
Quantification of the percentage of Ph+ chromosome metaphases, number of metaphases, 
number positive for Ph chromosome, additional chromosomal abnormalities as well as data 
from cytologic evaluation (microscopic analy sis) of percentage of blasts and prom yeloc ytes 
will berecorded on the Bone 
Marrow eCRF. These exams will be performed and analyzed 
locally . Fluorescent In- situ hy bridization (FISH) analy sis will not be accepted.
7.2.1.3 Hematologic response
A complete hematologic response (CHR) is defined as all of the following present for ≥ 4 
weeks:
WBC count <10 x 109/L
Platelet count <450 x 109/L
Basophils <5%
No blasts and prom yelocytes in peripheral blood
Myelocy tes + metam yelocytes < 5% in peripheral blood
No evidence of extramedullary  disease, including spleen and liver
7.2.2 Safet y and tolerability assessments
Safety  will be monitored by the assessments described below as well as collecting of the 
adverse events at every  visit. For details on AE collection and reporting, refer to Section 8.
Significant findings that were present prior to the signing of informed consent must be 
included in the Relevant Medical History /Current Medical Conditions page on the patient’s 
eCRF. Significant new findings that begin or worsen after informe d consent must be recorded 
on the AE page of the patient’s eCRF.
7.2.2.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular and neurological. Information about the physical examination must be 
present in the source documentation at the study  center and will be collected on the following 
visits:
Screening
Day 1
Every  2 weeks from Week 4 to Wee k 16

Novartis Confidential Page 76
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Every  4 weeks from Week 16 to Week 96
Every  12 weeks from Week 96 to EOT
End of treatment visit or early discontinuation visit in case of premature discontinuation.
Significant findings that were present prior to the signing of informed consent must be 
included in the Medical History  page on the patient’s eCRF. Significant new findings that 
begin or worsen after informed consent must be recorded on the Adverse Event page of the 
patient’s eCRF. Presence of extramedullary  leukemic involvement will be 
checked with each 
physical examination as outlined above. Findings on physical examination consistent with 
extra -medullary  leukemic involvement will be recorded (e.g. liver and spleen size, any other 
organ involvement)..
7.2.2.2 Vital signs
Vital signs include blood pressure (supine position preferred when ECG is collected), pulse 
measurement, and bod y temperature and must be performed at the following visits:
Screening
Day 1
Every  2 weeks from Week 2 to Week 16
Every  4 weeks from Week 16 to Week 96
Every  12 weeks from Week 96 to EOT
End of treatment visit or early discontinuation visit in case of premature discontinuation.
7.2.2.3 Height and weight
Height in centimeters (cm) will be measured at screening onl y.
Body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be 
measured at screening and at subsequent time points as specified in Table 7 -1:
Screening
Every  2 weeks from Wee
k 4 to Week 16
Every  4 weeks from Week 16 to Week 96
Every  12 weeks from Week 96 to EOT
End of treatment visit or early discontinuation visit in case of premature discontinuation.
7.2.2.4 Performance status
ECOG Performance status scale (Table 7 -2) will be used as described in the Table 7-1.
Screening
Day 1
Every  2 weeks from Week 4 to Week 16
Every  4 weeks from Week 16 to Week 96
Every  12 weeks from Week 96 to EOT
End of treatment visit or early discontinuation visit in case of premature discontinuation.

Novartis Confidential Page 77
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
More frequent examinations may be performed at the investigator’s discretion, if medically 
indicated.
Table 7-3 ECOG Performance status scale
Description Grade
Fully active, able to carry on all pre -disease activities without restriction. 0
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature e.g. light housework, office work.1
Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours.2
Capable of only limited self -care, confined to bed or chair more than 50% of waking hours. 3
Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair. 4
Dead. 5
7.2.2.5 Laboratory  evaluations
Central laboratory  will be used for analysis of hematology , biochemistry , coagulation, serum 
pregnancy  and hepatitis marker specimens collected (safety  monitoring). Details on the 
collections, shipment of the samples and reporting of results by the central laboratory  are 
provided to investigators in the [CABL 001A2301 Laboratory  Manual ]. The time windows 
granted for laboratory  evaluations are identical with the corresponding visit time windows for 
each visit (see Section 7.1.5 ).
Table 7-4 Central clinical laboratory parameters collection plan
Test Category Test Name Frequency
Hematology Hemoglobin, Platelets, Red blood cells, W hite 
blood cells, W BC Morphology with Differential 
(Basophils, Eosinophils, Lymphocytes, 
Monocytes, Neutrophils, Promyelocy tes, 
Myelocytes, Metamyelocytes , Blast and 
Other )Screening/Baseline, week 1 Day 1, week 
2 Day 1, every 2 weeks from week 4 up to 
week 16, every 4 weeks up to week 96 , 
and every 12 weeks thereafter, EOT and 
as clinically indicated
Chemistry Hemoglobin A1c Screening/Baseline, Week 12 and as 
clinically indicated
Chemistry Albumin, Alkaline phosphatase, ALT (SGPT), 
AST (SGOT), Total Calcium, Creatinine, 
Creat inine kinase, Potassium, Magnesium, 
Sodium, Phosphorus, Direct Bilirubin, Indirect 
Bilirubin, Total Bilirubin, Total Cholesterol, 
LDL, HDL, Total Protein, Triglycerides, Blood 
Urea or Nit rogen (BUN), Uric Acid, Amylase, 
Lipase , Glucose (fasting)Screening/Baseline, week 1 Day 1, week 
2 Day 1, every 2 weeks from week 4 up to 
week 16 , every 4 weeks up to week 96, 
and every 12 weeks thereafter, E OT, and 
as clinically indicated
Coagulation International normalized ratio (INR)
Hepatitis markers HbsAg, HbcAb /anti-Hbc Screening/Baseline 
Serum Pregnancy 
test (if applicable)Serum ß-HCG testing Screening/Baseline, every 4 weeks up to 
week 96, and every 12 weeks thereafter,
EOT, unscheduled

Novartis Confidential Page 78
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
7.2.2.5.1 Hematology
Hematology  labs are to be analy zed at each scheduled visit by a  c entral laboratory . 
Hematology  includes assessment of hemoglobin, platelets count, red blood cells, total white 
blood cell count (WBC) and a full manual differential count including basophils, eosinophils, 
lymphocy tes, monocy tes, neutrophils, prom yelocytes, myelocy tes, metamy elocy tes, blast and 
other cells ( Table 7 -4).
7.2.2.5.2 Clinical chemistry
Blood chemistry  labs are to be analyzed at each scheduled visits by a central laboratory . 
Chemistry  includes albumin, alkaline phosphatase, ALT (SGPT), 
AST (SGOT), total calcium, 
creatinine, creatinine kinase, potassium, magnesium, sodium, phosphorus, direct bilirubin, 
indirect bilirubin, total bilirubin, total cholesterol, LDL, HDL, total protein, triglycerides, 
blood urea or nitrogen (BUN), uric acid, amylase, lipase and fasting glucose. In addition the 
coagulation parameter INR is analy zed at each scheduled visit.
HbA1c is anal yzed at screening/ba seline, week 12 and as clinicall y indicated.
The hepatitis markers HbsAg, HbcAb/anti -Hbc are anal yzed at screening/baseline ( Table 7 -4).
7.2.2.5.3 Pregnancy and assessments of fertility
All women of childbearing potential have to complete a serum pregnancy  test at the screening 
visit, at every  monthl y visit until end of treatment visit. Pregnancy  testing is not required for 
patients who are determined to be post -menopausal. The time windows granted for pregnancy 
testing are identical with the corresponding visit time windows for each visit. Refer to Table 
7-1of the Visit evaluation schedule. Serum pregnancy  test will be performed by a  central 
laboratory .
After Week 96 monthl y urine pregnancy  testmust be performed by all women of child-
bearing potential between the three monthly  visits (beginning at Week 100). Urine pregnanc y 
tests may be performed at the investigational site or at home. Test results performed at home 
should be recorded onto a patient diary  and brought to each scheduled visit for the site to 
review. If a test result indicates a pregnancy , the patient must contact the investigator 
immediately .
All pregnancies (including female partners of male patients) should be recorded on a Clinical 
Trial Pregnancy  Form and reported by the investigator to the Oncology  Novartis Drug Safet y 
and Epidemiology  Department (DS&E).
During the whole study , women of childbearing potential should employ the use of highl y 
effective contraception. Highl y effective contraception methods are defined in Section 5.3.
Sexually  active males must use a condom during intercourse while taking the drug and for at 
least 3days after stopping treatment and should not father a child in this period. A condom is 
required to be used also by vasectomized men in order to prevent delivery  of the drug via 
seminal fluid.

Novartis Confidential Page 79
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
7.2.2.6 Cardiac assessments
7.2.2.6.1 Electrocardiogram (ECG)
After the subject has rested approximately  10 minutes in a semi -supine position, standard 12-
lead ECGs must be obtained in triplicate with a recommended minimal interval of 5minutes 
between each ECG at the time points specified in Table 7-5and Table 7 - 6. Blood samples for 
PK 
scheduled at the same time point should be taken after the ECGs are completed.
Table 7-5 Central ECG collection (all patients)
Week (or Day ) Number of ECGs (per visit) Time of ECG
Day -21 to -1 3 3 serial ECGs at the screening visit
Week 1 Day 1 3 3 serial ECGs at 2 h post dose
Week 2 Day 1 12 3 serial ECGs pre-dose and at 2, 3, 4 h post -
dose
Week 4 3 3 serial ECGs pre-dose
Week 12 3 3 serial ECGs pre-dose
Week 24 3 3 serial ECGs pre-dose
Week 96 3 3 serial ECGs 30 min *post-dose
Unscheduled 3 3 serial ECGs 30 min *post-dose
* 30 min +/ - 5min allowed
Table 7-6 Central ECG collection plan for patients in full PK A BL001 group
Week (or Day ) Number of ECGs (per visit) Time of ECG
Day -21 to -1 3 3 serial ECGs at the screening visi t
Week 1 Day 1 3 3 serial ECGs at 2 h post dose
Week 2 Day 1 24 3 serial ECGs pre -dose and at 1, 2, 3, 4, 6, 8, 12 
h post -dose
Week 4 3 3 serial ECGs pre-dose
Week 12 3 3 serial ECGs pre-dose
Week 24 3 3 serial ECGs pre-dose
Week 96 3 3 serial ECGs 30 min post -dose
Unscheduled 3 3 serial ECGs 30 min post -dose
* 30 min +/ - 5min allowed
All ECGs performed will be independently  reviewed. Instructions for the collection and 
transmission of these ECGs to the independent central reader (eRT) will be provided in the 
[CABL 001A2301 ECG Manual ].
Three serial ECGs (triplicate) should be performed ½ hour prior to dosing for pre-dose 
assessment. The serial ECGs should be taken approximately  5 m inutes apart. All 3 ECGs for 
each time point should be sent to eRT. Readings for QTc prolongation will be based on the 
average seen in the scans for each time point. The enrollment of patients has to be based on 
centrall y assessed QTcF time. If one of the 3 serial ECGs prior to dosing on day 1 shows a 
QTcF ≥450msec (male) or ≥ 460msec (female) by automated reading, an immediate manual 
central reading must be re quested by  calling eRT. The patient may  not be dosed if the average 
of the manuall y read ECGs confirms a QTcF ≥450msec (male) or ≥460msec (female) .

Novartis Confidential Page 80
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Dose adjustments in case of QTprolongation should be performed per Section 6.3.2 .
Additional unscheduled ECGs may  be repeated at the discretion of the investigator at any  time 
during the study  as clinically  indicated. Unscheduled ECGs with clinicall y significant findings 
should be collected in triplicate. Local cardiologist ECG assessment may  also be performed at 
any time during the study at the discretion of the investigator.
All ECGs, including unscheduled triplicate safety  ECGs with clinically relevant findings, 
collected during the study  should be trans mitted to the central core ECG laboratory  for review.
The results of the centrally  assessed ECGs are automatically  transferred into the clinical 
database .
Clinically  significant ECG abnormalities present at screening should be reported on the 
Medical History  eCRF page. New or worsened clinically  significant findings occurring after 
informed consent must be recorded on the Adverse Events e CRF page.
7.2.2.6.2 Cardi ovascular risk factor assessment
Cardiovascular events (CVE) including ischemic heart disease, peripheral arterial occlusive 
disease and ischemic cerebrovascular events have been reported in CML patients receiving 
TKI therapies. As both study  treatments in the trial are TKIs (ABL001 and bosutinib), the 
cardiovascul ar risk factors (hypertension, tobacco use, raised blood glucose (diabetes), 
physical inactivity , unhealthy  diet, cholesterol/lipids, overweight and obesity ) of each patient 
will be collected prior to randomization and end of treatment . This will also include the 
patient’s Famil y History.
7.2.2.6.3 Echocardiogram
Echocardiograms will be performed to monitor cardiac safety .Assessments are scheduled at 
screening/baseline, Week 20 and end of treatment visits. The echocardiogram will be 
performed and evaluated locally  to assess the left ventricular ejection fraction. Any clinicall y 
significant findings will be collected and reported in the database (i.e. reported as adverse 
events).
7.2.2.6.4 Pulmonary function test
Pulmonary  function test will be performed to monitor cardio -pulm onary  safet y.Assessments 
are scheduled at screening/baseline, Week 20 and end of treatment visits. The pulmonary 
function test with the plethy smograph includes the assessment of the lung volumes FEV1, 
FVC, FEV1/FVC, TLC and VC. In addition the DLCO to evaluate the gas exchange will be 
assessed at the same time points. Any clinically  significant findings will be collected and 
reported in the database (i. e. reported as adverse events).
7.2.3 Pharmacokinetics
Blood samples for ABL001 pharmacokinetics will be collected on all study subjects allocated 
to the ABL001 treatment arm.Blood samples for full PK profiles will be collected from at 
least 20 patients .These patients will be identified sequentially  at selected sites that are 
capable of serial PK sampling over 12 hours. ABL001 should be taken for at least 3 
consecutive day s without interruption or dose modifica tion prior to full PK day .

Novartis Confidential Page 81
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
For the assessment of ABL001 pharmacokinetics in plasma, serial blood samples will be 
collected following ABL001 administration at several time -points (see Table 7 -7and Table 7-
8below for further details). Remaining plasma 
samples may be used for identification and/or 
measurement of metabolites of ABL001.
Refer to the [CABL001A2301 Laboratory  Manual ]for detailed instructions for the collection, 
handling, and shipment of PK samples.
Table 7-7 Pharmacokinetic blood collection log (Sparse PK -group -ABL001 arm)
Week Day Scheduled Time Poi nt Dose 
Reference IDPK Sample No Blood Volume 
(mL)
1 1 2 h (± 10 min) 101 101 2
2 1 0 h (Pre -dose)a102/2001b102 2
1 2 h (± 10 min) 102 103 2
1 3 h (± 15 min) 102 104 2
1 4 h (± 15 min) 102 105 2
4 Any 0 h (Pre -dose)a103/3001b106 2
12 Any 0 h(Pre- dose)a104/4001b107 2
24 Any 0 h (Pre -dose)a105/5001b108 2
96 Any 0 h (Pre -dose)a106/6001b109 2
Unscheduled 1001+
aPre-dose PK sample should be taken immediately prior to the next administration of ABL001. PK samples on 
Week 2 Day 1 should be taken before and after the morning dose (i.e. 1stdose of the day). PK samples on other 
weeks may be taken immediately prior to the morning dose (i.e. 1stdose of the day) or the evening dose (i.e. 2nd
dose of the day).
bThe first dose reference ID refers to the first dose administered after PK sampling and the second dose 
reference ID refers to the last dose administered prior to the PK sampling.

Novartis Confidential Page 85
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
7.2.5 Resource utilization
The measures of healthcare Resource Utilization (RU) to be collected include: hospitalization
(H), emergency  room (ER) visit, general practitioner (GP) visits, specialist (Sp) visit and 
urgent care (UC) visit. These measures will be used to derive the economic impact of 
ABL001 and bosutinib.
Hospitalization visits will also record the number of days in ward and the type of ward 
(hospital unit) and the discharge status. At each RU collection, the reason for the visit (i.e. 
related to CML, AE or other reason) will be collected in order to quantify  the impact of 
ABL001 and bosutinib on healthcare resource s.
The RU assessment will be completed at each scheduled clinical trial visit; the RU will be 
completed by the investigator however information with respect to the number of GP, UC, Sp 
or ER visits will be ascertained from the patient.
All attempts to collect as much information from the patient as possible should be made in 
order to minimize selection bias.
7.2.6 Patient reported outcomes
The MDASI CML, PGIC , WPAI along with EQ-5D- 5L(EuroQol Group (1990) , Brooks 
(1996) ,Herdman et al (2011) )will be used to compare data on the patient’s disease -related 
symptoms and health -related quality  of life from base line to EOT between the treatment arms. 
The WPAI  will be used to assess work productivity  and activity  impairment related to the 
patient’s CML . All measures will assess differences between the treatment arms. All tools 
require patient’ s direct completion and will be administered utilizing electronic device for 
data collection .
Patients with an evaluable baseline score and at least one evaluable post baseline score during 
the treatment period will be included in the change from baseline analy ses. Missing dat a items 
in a scale will be handled according to the manual for each instrument. No imputation will be 
applied if the total or subscale scores are missing at a visit.
The patient should be given the questionnaire(s) to be completed at the scheduled visit before 
any clinical assessments are conducted. Patient’s refusal to complete all or any part of a 
questionnaire should be documented in the study  data capture system and should not be 
captured as a protocol deviation. Patient questionnaires should be completed in the language 
most familiar to the patient.
The patient should be given sufficient space and time to complete the questionnaire s and the 
administered questionnaire should be reviewed for completeness. If missing responses are 
noted, patients should be encouraged to complete any  missing responses.
Completed questionnaire(s) and any unsolicited comments written by the patient should be 
reviewed and assessed by the investigator for responses which may indicate potential AEs or 
SAEs before any  clinical st udy examinations. This assessment should be documented in study 
source records. If AEs or SAEs are confirmed, study  investigators should not encourage the 
patient to change responses reported in the completed questionnaires. Study  investigators 

Novartis Confidential Page 86
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
must follow reporting instructions outlined in Section 8 (e.g. reference “Adverse Events”
Section) of the study  protocol.
MDASI-CML
The M.D. Anderson Symptom Inventory  –Chronic Myeloid Leukemia (MDASI -CML) is a 
26 item self-administered questionnaire for adult CML  patients. Twent y of the items measure 
the severit y of disease -related sy mptoms and are scored from 0 (Not present) to 10 (As Bad as 
you can imagine) and 6 items that measure s ymptom interference with dai
ly life scored from 0 
(Did not interfere) to 10 (Interfered completel y).Descriptive statistics will be provided for the 
MDASI -CML  symptom score and interference score, and the change in the MDASI -CML 
symptom score and interference score from baseline to all available time points to the end of 
study . Additional anal ysis may  be performed and details will be described in the anal ysis plan.
EQ-5D-5L
EQ-5D- 5L is a two-part standardized instrument for measuring health outcomes in a wide 
range of health conditions and treatments. It consists of a descriptive system and a visual 
analogue scale (EQ 
VAS). The descriptive system comprises the following 5 dimensions: 
mobility , self-care, usual activities, pain/discomfort and anxiety /depression. Each dimension 
has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme 
problems (or unable to perform the activity ). The EQ VAS records the respondent’s self -rated 
health on a vertical, visual analogue scale where the endpoints are labeled ‘Best imaginable 
health state’ and ‘worst imaginable health state’. The health states derived from the 
descriptive system can be summarized into a single index score that provides a simple 
measure of health for clinical and economic appraisal. Descript ive statistics will be provided 
for EQ-5D- 5L health index score and for the EQ VAS, at each scheduled assessment time 
point. There should be only ONE response for each dimension. Missing values can be coded 
as ‘9’. Ambiguous values (e.g. 2 boxes are ticked for a single dimension) should be treated as 
missing values. Additional analysis may be performed and details will be described in a 
separate anal ysis plan.
WPA I
The Work Productivity  and Activity  Impairment Questionnaire (WPAI) is a four-item 
questionnai re which is intended to measure work and activity  impairment associated with 
CML for those who self-identify  as currently  employ ed for pay. This questionnaire measures 
self-reported productivity  loss associated with CML  during the past seven days. It consists of 
questions about absence from work due to CML , hours spent at work, the reduction in 
productivity  at work attributed to CML , and the reduction in productivity while performing 
regular activities. WPAI outcomes are expressed as impairment percentages, with higher 
numbers indicating greater impairment and less productivity , i.e., worse outcomes, Scoring 
will be done according to WPAI  instrument guidance resulting in four scores including: 
Percent work time missed due to problem; percent impairment while working due to problem; 
Percent overall work impairment due to problem; and, percent activity impairment due to 
problem. Change from baseline in WPAI  at each visit, where measured, will be done for each 
of the four derived scores.

Novartis Confidential Page 87
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
PGIC
The Patient Global Impression of Change is comprised of a single question intended to 
measure a patient’s perspective of improvement or deterioration over time relative to 
treatment. The PGIC uses a seven -point scale where one (1) equals very much improved and 
seven (7) equa ls very much worse. A summary  of Patient Global Impression of Change 
(PGI C) at each visit, where measured will be provided.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events t hat begin or worsen after informed consent should be recorded in the Adverse 
Events eCRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s eCRF. Adverse event monitoring sh ould 
be continued for at least 30 days (or 5 half-lives, whichever is longer) following the last dose 
of study  treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underly ing signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.
Adverse events will be assessed and graded according to the Common Terminology  Criteria 
for Adverse Events (CTCAE) version 4.03. Grade 1 to 5 will be used to characterize the 
severit y of the Adverse Event.
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderate, severe, 
and life-threatening, death related to the AEcorrespond ingrespectivel ytoGrades 1 - 5, will 
be used. Information about any deaths (related to an Adverse Event or not) will also be
collected through a Death form .
The occurrence of adverse events should be sought by  non-directive questioning of the patient 
(subject) during the screening process after signing 
informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screening process or between visits, or through physica l examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be 
evaluated to determine:

Novartis Confidential Page 88
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
1.The severit y grade (CTCAE Grade 1 -5)
2.Itsduration (Start and end dates)
3.Its relationship to the study treatment (Reasonable possi bility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non- drug therap y, 
concomitant medication/non -drug therap y)
6.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
and which seriousness criteria ha ve been met
7.
Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
If the event worsens the event should be reported a second time in the eCRF noting the start 
date when the event worsens in tox icity. For grade 3 and 4 adverse events only, if 
improvement to a lower grade is determined a new entry  for this event should be reported in 
the eCRF noting the start date when the event improved from h aving been Grade 3 or Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event eCRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be perma nent, and assessment should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.
Natural progression or deterioratio n ofthe malignancy under treatment (including loss of 
response, progression to accelerated phase or blast crisis and death due to disease progression ), 
will be recorded as part of the efficacy  evaluation and should NOT be reported as an AE/SAE.
Signs and symptoms clearly  associated with the disease under study  should NOT be reported 
as AEs unless they  are newly  emergent (i.e. not previously  observed in the patient), judged by 
the Investigator to be unusually  severe or accelerated, or if the Investigator considers 
deterioration of disease -related signs and symptoms to be caused directly  by the study  drug. If 
there is any uncertaint y about an AE being due solely  to the disease under study , it should be 
reported as an AE or SAE as appropriate.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in study  treatmen t), should be recorded on the Adverse Events eCRF . 
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia 
instead of low hemoglobin). Laboratory  abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality  is found. When an abnormal laboratory  or test result corresponds to a 

Novartis Confidential Page 89
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
sign/sy mptom of an already  reported adverse event, it is not necessary  to separately  record the 
lab/test result as an additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not 
automatically  indicate a SAE unless it meets the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality  may be 
required by the protocol in which case the lab abnormality  would still, by definition, be an 
adverse event and must be reported as such.
8.1.3 Adverse events of special interest
Adverse events of special interest (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitorin g and rapid communication by the investigator to the sponsor may 
be appropriate. Such events may require further investigation in order to characterize and 
understand them.
Adverse events of special interest are defined on the basis of an ongoing review ofthe safet y 
data. 
AESIs are discussed in detail in the [Investigator Brochure].
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpati ent hospitalization or prolongation of existing hospitalization,
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indication, not associated with any 
deter ioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event

Novartis Confidential Page 90
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
8.2.2 Reporting
Toensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study  treatment must be reported to Novartis within 24 hours of learnin g of its occurrence.
Any additional information for the SAE including complications, progression of the initial 
SAE, and recurrent episodes must be reported as follow -up to the original episode within 24 
hours of the investigator receiving the follow -up in formation. An SAE occurring at a different 
time interval or otherwise considered completely  unrelated to a previously  reported one 
should be reported separately as a new event.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to Novartis if the investigator suspects a causal relati onship to the study  treatment.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed inorder to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the compl eted form within 24 hours to Novartis .Detailed 
instructions regarding the SAE submission process and requirements for signatures are to be 
found in the investigator folder provided to each site.
Each re-occurrence, complication, or progression of the original event should be reported as a 
follow -up to that event regardless of when it occurs. The follow -up information should 
describe whether the event has resolved or continues, if and how it was treated, whether the 
blind was broken or not, and whether the patient continued or withdrew from study 
participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the Novartis study  treatment, an oncology 
Novartis Chief Medic al Office and Patient Safety  (CMO&PS) department associate may 
urgently  require further information from the investigator for Health Authority  reporting. 
Novartis may need to issue an Investigator Notification (IN), to inform all investigators 
involved in any study with the same drug that this SAE has been reported. Suspected 
Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the 
competent authorities and relevant ethics committees in accordance with Directive 
2001/20/EC or as per national regulatory  requirements in participating countries.
8.3 Emergency  unblinding of treatment assignment
Not applicable.
8.4 Pregnancies
To ensure patient safet y, each pregnancy  occurring while the patient is on study  treatment 
must be reported to Novartis
within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.

Novartis Confidential Page 91
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology  Novartis Drug Safety  and Epidemiology  Department (DS&E). 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment any pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes until delivery  must be collected for the fe male partners of any  males who
took study  treatment in this study . Consent to report information regarding these pregnancy
outcomes should be obtained from the mother.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator 
Brochure. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notificatio ns. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.6 Data Monitoring Committee
This study  will institute a data monitoring committee (DMC) which will function 
independentl y of all other individuals associated with the conduct of this clinical trial, 
including the site investigators participating in the study . The DMC will be constituted prior 
to the randomization of the first patient. The DMC will be responsible to review safety  data at 
approximately  6months after the first randomized patient has started study  treatment.
Subsequent reviews will be conducted approximately  every 6  m onths on an as and when 
needed basis thereafter (ie. if significant safet y findings are noted) .This includes but does not 
limit the role of the DMC to evaluate these data and to provide recommendations to the 
sponsor to continue, modify  or stop the study  early. The DMC will be in place at least until 
the c onduct of the primary  analy sis.
It is expected that the DMC will consist at a minimum of two physicians with appropriate 
disease area qualifications and one statistician. There will be a meeting with the DMC
describing their roles and responsibilities and discussing potential data format and process 
issues prior to the finalization of DMC charter.
It is envisioned that the DMC may  make certain types of recommendations, namely :
No safet y concerns, ethical to c ontinue the study  as planned
Serious safet y concerns precluding further study treatment, regardless of efficacy
Recommendation to continue the study  but proposing an amendment to the protocol (e.g., 
incorporate an additional safet y assessments)
8.7 Steering Committee
In order to monitor study conduct, a Steering Committee (SC) will be established comprising 
investigators participating in the trial. Additionally  two sponsor representatives (a physician 
and a statistician) will be active members of this committee .

Novartis Confidential Page 92
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
The SC will ensure transparent management of the study  according to the protocol through 
recommending and approving modifications as circumstances require. Novartis will make 
final decisions on trial conduct based on SC recommendations. Together with the clinical trial 
team, the SC will review protocol amendments as appropriate, and also develop 
recommendations for publications of study  results including authorship rules. The details of 
the role of the Steering Committee will be defined in a Steering Comm ittee charter.
9 Data collection and management
9.1 Data confidentiality
Information about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subject s that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the 
subject experienced an y new or worsened AEs) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individ ually  assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subject satisfies protocol age requirements 
and to enable appropriate age-related normal ranges to be used in assessing laboratory  test 
results.
9.2 Site monitoring
Before study  initiatio n, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and eCRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 

Novartis Confidential Page 93
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
treatment is being stored, dispensed, and accounted for according to specif ications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containi ng demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the eCRF entries. Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria 
and documentation of SAEs. Additional checks of the consistency  of the source data with the 
eCRFs are p erformed according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by the protocol into the Electronic Case Report Forms (eCRF). The eCRF s 
have been built using fully  validated secure web-enabled software that conforms to 21 CFR 
Part 11 requirements, Investigator site staff will not be given access to the EDC system until 
they have been trained. Automatic validation programs check for data discrepancies in the 
eCRFs and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF is 
complete, accurate, and that entry  and updates are p erformed in a timely  manner.
Data collected by third parties (biochemistry , PCR assessments, biomarkers, PK) will be sent 
electronically  to Novartis.
9.4 Database management and quality  control
For studies using eCRFs, Novartis personnel (or designated CRO) wi ll review the data entered 
by investigational staff for completeness and accuracy . Electronic data queries stating the 
nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC system. Designated 
investigator site staff are required to respond promptly  to queries and to make any necessary 
changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using 
the WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical 
classification system. Medical history /current medical conditions and adverse events will be 
coded using the Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data will be processed centrall y and the results will be sent electronically to 
Novartis (or a designated CRO).
Randomization codes and data about all study  treatments dispensed to the patient and all IRT 
assigned dosage changes will be tracked using the No vartis Interactive Response Technology .

Novartis Confidential Page 94
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copies 
of the patient data for archiving at the investigational site.
10 Statistical methods and data analy sis
The data will be anal yzed by  Novartis and/or designated CRO. It is planned that the data from 
participating centers in this protocol will be combined, so that an adequate number of patients 
will be available for analy sis.
Study  data will be summarized with respect to demographi c and baseline characteristics, 
efficacy  observations and measurements, safety  observations and measurements, and all 
relevant PK and PD measurements.
The cut-off date for the primary  analysis is defined as the date when all patients have been on 
study  for24 weeks or early discontinued. The cut-off date for the final treatment phase
analysis is defined as 30 days after last patient last study  drug to ensure that all available 
treatment phase data from all patients up to the last dose of study  drug taken in this study , will
be analy zed and summarized in a final treatment phase CSR. Patients will be further followed 
up for survival and progression for up to 5 years from the date the last patient received the 
first study  dose. A n update analy sis of OS and PFS will be performed at the end of the follow -
up period.
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Analysis Set (FAS) comprises all patients to whom study  treatment has been 
assigned b y randomization. According to the intent to treat principle, patients will be analy zed 
according to the treatment and stratumthey have been assigned to during the randomization 
procedure.
10.1.2 Safety  set
The Safety Setincludes all patients who received at least one dose of study  treatment. 
Patients will be analyzed according to the study  treatment received, where treatment received 
is defined as the randomized treatment if the patient took at l east one dose of that treatment or 
the first treatment received if the randomized treatment was never received.
10.1.3 Per-Protocol set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with requirements of the CSP. The PPS will be used for sensitivity  analyses on the primary 
endpoint only .
Oncology  standards for p rotocol deviations potentially  leading to exclusion from the PPS are:
Type of indication different from those required by  the CSP
If prior therap y does not match with CSP requirements in terms of number and types of 
previous therap y regimens

Novartis Confidential Page 95
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Another anti -neoplastic therap y administered after start of study  treatment and prior to 
first efficacy  assessment
Study  treatment received different from treatment assig ned b y randomization
10.1.4 Dose -determining analy sis set
Not applicable.
10.1.5 Pharmacokinetic analy sis set
The Pharmacokinetic analysis set (PAS) includes all patients who provide at least one 
evaluable PK concentration. For a concentration to be evaluable, patients are required to:
Take a dose of ABL001 prior to sampling,
Take the same dose of ABL001 for at least 3consecutive day s without dose interruption 
or dose modification prior to sampling,
For post -dose samples, do not vomit within 4 hours after the dosing of ABL001; For pre -
dose samples do not vomit within 4 hours after the dosing of ABL001 prior to sampling,
Havethepre-dose sample collected before thenext dose administration
10.1.6 Other analy sis sets
For duration of MMR and time to MMR, the MMR Responder Set will be usedthat includes 
patients who achieve MMR at any  time .
For CCyR rates at and by scheduled time points , the CCyR Anal ysis Set will be used that 
includes patients who are not in CCy R at baseline.
For duration of CCyR and time to CCyR, the Cytogenetic Responder Set will be use that 
includes patients who do not have CCy R at baseline and achieve CC yR at any  time.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed and 
summarized descriptively b y treatment group for the FAS or the Safet y Set .
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented.
Relevant medical histories and current medical conditions at baseline will be summarized 
separately by system organ class and preferred term, by treatment group.
10.3 Treatments (study  treatment, concomitant therapies, compliance)
The Safet y set will be used for the anal yses below.
Categorical data will be summarized as frequencies and percentages. For continuous data, 
mean, standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be 
presented.
The duration of exposure in days to ABL001 and bosutinib, as well as the dose intensity 
(computed as the ratio of actual cumulative dose received and actual duration of exposure) 

Novartis Confidential Page 96
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
and the relative dose intensity  (computed as the ratio of dose intensit y and planned dose 
intensity ) will be summarized by  means of descript ive statistics.
The number of patients with dose adjustments (reductions, interruption, or permanent 
discontinuation) and the reasons will be summarized bytreatment group and all dosing data 
will be listed.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification sy stem, by  treatment group.
10.4 Primary  objective
The primary  objective of the study  is to evaluate the efficacy  of ABL001 at the recommended 
dose in CML  patients in chronic phase, previously  treated with 2 or more tyrosine kinase 
inhibitors and to compare this efficacy  profile in this population with th at achieved b y patients 
receiving bosutinib .
10.4.1 Variable
The primary  efficacy  variable of the study  is the Major Molecular Response (MMR) rate at 24 
weeks. A patient will be counted ashaving achieved MMR at 24 weeks if he meets the MMR 
criteria 
(BCR -ABL rati o ≤0.1%) at 24 weeks.
10.4.2 Statistical hy pothesis, model, and method of analy sis
The MMR rate at 24 weeks will be calculated based on the FAS and according to the Intent 
To Treat (ITT)principle. MMR rate and its 95% confidence interval based on the Pearson -
Clopper method will be presented by treatment group. The confidence interval for the 
difference in MMR rate
between treatment groups will be provided using the Wald method.
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 24 weeks. The Cochrane -Mantel -Haenszel chi-square test, stratified by the 
randomization stratification factor, i.e. major cytogenetic response status (PCy R or CCyR vs 
others) at screening, will be used to compare MMR rate between the two treatment groups, at 
the two-sided 5% level of significance. The Mantel -Haenszel estimate of the common risk 
difference and the corresponding 95% confidence interval will also be provided.
10.4.3 Handling of missing values/censoring/discontinuations
Only  patients with MMR at 24 weeks are considered responders. In other words, any patient 
who achieves MMR before 24 weeks, but is no longer in MMR at 24 weeks, will be 
considered as a non-responder in this primary  analysis .Patients discontinuing the randomized 
treatment prior to 24 weeks due to an y reason will be considered as non -responders.
One exception to the rule above is if the 24-week PCR evaluation is missing, but both a PCR 
evalu ation at 16 weeks and a PCR evaluation at 36 weeks indicate MMR, the 24-week 
assessment is imputed as a ‘Response’.

Novartis Confidential Page 97
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
10.4.4 Supportive and Sensitivity analy ses
The analysis of the primary  endpoint will also be repeated on the PPS if the PPS is different 
from the F AS.
Subgroup analyses and a logistic regression analysis will be employ ed. Refer to the 
exploratory  objectives Section 10.6.1 for further details.
10.5 Secondary  objectives
The secondary  objective s in this study  are as follows:
To compare additional parameters of the efficacy of ABL001 versus bosutinib, defined as:
Key secondary endpoints
MMR rate at 96 weeks
Other efficacy endpoints
Cytogenetic response (Complete, Partial, Major, Minor, Minimal, no response ) rate at all 
scheduled data collection time points including 24, 48 and 96 weeks.
Cytogenetic response (Complete, Partial, Major, Minor, Minimal, no response) rate by  all 
scheduled data collection time points includin g, 24, 48 and 96 weeks.
MMR rate at 
allscheduled data collection time points (except 24 and 96 weeks which are 
alread y covered b y primary and key secondary  endpoints)
MMR rate by  all scheduled data collection time points including 24, 48 and 96 weeks.
Time to MMR
Duration of MMR
Time to CCy R
Duration of CCy R
Time to treatment failure
Progression free survival
Overall survival
To compare the safety  and tolerability  profile of ABL001 versus bosutinib
To characterize the PK of ABL001 in the CML- CP population
10.5.1 Key secondary  objective(s)
The key  secondary  endpoint to be evaluated isMMR rate at 96 weeks , which is defined as the 
proportion of patients with MMR at 96 weeks and derived in a similar f ashion to MMR rate at 
24 weeks.

Novartis Confidential Page 98
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
10.5.1.1 Analysis for key secondary  objectives
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 96 weeks. Formal statistical testing of the key secondary  endpoint will be 
performed with = 0.05 (two -sided) only if the primary  endpoint is signi ficant by means of a 
gatekeeping procedure to control the overall alpha level.
MMR rate at 96 weeks will be evaluated in a similar fashion to the primary  analysis of MMR 
rate at 24 weeks. The rate and the associated 95% confidence interval based on the Pearson-
Clopper method will be presented by treatment group. Confidence interval for the difference 
between treatment groups will be provided using the Wald method.
Statistical testing will be performed via CMH chi-square test stratified by the randomization 
strata. The Mantel -Haenszel estimate of the common risk difference and the corresponding 95% 
confidence interval will also be provided .
10.5.2 Other secondary  efficacy  objectives
Unless otherwise stated the FAS will be used for the analy sis of all other secondary  efficacy 
endpoints. The exception s are using the Molecular Responder Setfor duration of MMR and 
time to MMR, the CCyR Analy sis Set for CCyR rates, and the Cy togenetic Res ponder Set for 
duration of CCy R and time to CCy R.
No statistical testing of non-key secondary  efficacy endpoints will be performed , however a 
nominal p
-value will be presented for exploratory purposes.
Molecular Response
MMR ratesat scheduled time points (except 24 and 96 weeks which have been specified as 
primary  and key secondary  endpoints) will be evaluated in a similar fashion to the primar y 
analysis of MMR rate at 24 weeks. Patients discontinuing the randomized treatment prior to a 
specific time point due to any  reason will be considered as non -responders for that time point .
MMR ratesby scheduled time points are defined asthe proportion of patients who achieve 
MMR a t or before the specified visit, i.e. if a patient achieves an MMR but then loses it before 
or at the visit ,he/she will still be classed as achieving MMR by  that time point .
For each endpoint the rate and the associated 95% confidence interval based on the Pearson-
Clopper method will be presented b y treatment group. Confidence intervals for the differences 
in any  response rates between treatment groups will be provided using the Wald method.
Statistical testing will be performed via CMH chi-square tests stratified by the randomization 
strata. The Mantel -Haenszel estimate of the common risk difference and the corresponding 95% 
confidence interval will also be provided .
Duration of MMR isdefined in Section 7.2.1.1 as the time between the date of the first 
documented MMR and the earliest date of loss of MMR, progression to AP/BC, or CML -
related death for patients in the Molecular Responder Set. The time will be censored at the last 
molecular assessment (PCR) date on treatment for patients who have not experienced anyof 
the above events.

Novartis Confidential Page 99
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Duration of MMR will be analyzed by K-M method and presented by K-M plots. The 
estimated rates of patients who are still responding at various time points will also be 
provided using K -M method.
The cumulative incidence of MMR will be graphicall y display ed by an increasing step 
function. This curve will increase each time (after randomization) at which a new responder is 
observed and thus will increase up to the best observed response rate (e.g. up to 50% if half of 
the patients in the anal ysis population are able to achieve response).
Time to MMR is defined in Section 7.2.1.1 as: date of first MMR -date of randomization +1, 
for patients in the Molecular Responder Set . Descriptive statistics (range, median, quartiles, 
mean, sd) of time to MMR will be provided for the two treatment group s separately .
Cytogenetic Response
Patients in FAS will be categorized with counts and percentages provided for cytogenetic 
response (Complete, Partial, Major, Minor, Minimal, No Response) at and by (i.e. best 
response up to a specified time point ) scheduled time points . Shift tables will also be 
employ ed to examine the changes in cy togenetic response category  from baseline.
Since there are expected to be only very limited numbers who are actually  in CCyR at 
baseline (due to the inclusion criteria requiring BCR -ABL ratio ≥ 1%) the analysis of CCyR 
rate at and by scheduled time points will only include patients who are not in CCyR at
baseline , i.e. the CCy R Analy sis Set .
CCyR rates at and by scheduled time points etc. and the associated 95% confidence 
intervals based on the Pearson -Clopper method will be presented by treatment group with the 
analysis of these endpoints only  including patients who are not in CCy R at baseline.
Confidence intervals for the differences in any response rates between treatment groups will 
be provided using the Wald method.
Statistical testing will be performed via CMH chi-square tests stratified by the randomization 
strata. The Mantel -Haenszel estimate of the common risk difference and the co rresponding 95% 
confidence interval will also be provided .
Time to CCyR is defined for patients in the Cy togenetic Responder Set as: date of first CCy R 
-date of randomization +1.Descriptive statistics (range, median, quartiles, mean, sd) of time 
to CCy R will be provided for the two treatment groups separatel y.
The cumulative incidence of CCyR will also be graphicall y display ed by an increasing step 
function. This curve will increase each time (after randomization) at which a new responder is 
observed and thus will increase up to the best observed response rate.
Duration of CCyR is defined as the time between date of first documented CCyR and the 
earliest date of loss of CCyR, progression to AP/BC, or CML -related death for patients in the 
Cytogenetic Responder Set . The time will be censored at the last cytogenetic assessment date 
on treatment for patients for whom none of the above events is reported or last PCR 
evaluation on treatment indicating MMR.

Novartis Confidential Page 100
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Duration of CCyR response will be analyzed by K-M method and presented by K-M plots. 
The estimated rates of patients who are still responding at various time points will also be 
provided using K -M method.
Treatment failure, disease progression and survival
Time to treatment failure (TTF) is defined as the time from date of randomization to an 
event of treatment failure. The following events will constitute ‘treatment failure’, and are 
based on the ELN criteria (Bacarrani 2013 )defining failure of a second line treatment adapted 
to include discontinuation of randomized treatment as an event :
No CHR or > 95% Ph+ metaphases at three months after randomization or thereafte r
BCR -ABL ratio > 10% IS and/or > 65% Ph+ metaphases at six months af ter 
randomization or thereafter
BCR -ABL ratio > 10% IS and/or > 35% Ph+ metaphases at 12 months after 
randomization or thereafter
Loss of CHR, CCy R or PCy R at any  time after randomization
Detection of new BCR -ABL mutations at any  time after randomization
Confirmed loss of MMR in 2 consecutive tests, of which one must have a BCR -ABL ratio 
≥ 1% I S 6 months after randomization
New clonal chromosome abnormalities in Ph+ cells : CCA/Ph+: at any  time after 
randomization
Discontinuation from randomized treatment for any reason
For patients who have not reach treatment failure, their TTFs will be censored at the time of 
last study  assessment (PCR, cy togenetic, hematologic or extramedullary )
.
Progression -Free -Survival (PFS) is defined as the time from the date of randomization to 
the earliest occurrence of documented disease progression to AP/BC or the date of death from 
any cause (including progressions and deaths observed during the survival follow -up period).
The time wil l be censored at the date of last study  assessment (PCR, cy togenetic, hematologic 
or extramedullary ) or last post -treatment follow -up for patients without event.
Overall survival (OS) is defined as the time from the date of randomization to the date of 
death (including the survival follow -up period). Patients who are alive at the time of the 
analysis data cutoff date will be censored at the date of last contact before the cut -off date.
TTF, PFS and OSwill be estimated and graphically  display ed using the K-M approach. The 
estimated rates by K-M method at various time points will be provided and the endpoints will 
be compared between the two treatment groups using stratified log-rank test stratified by the 
randomization strata. The hazard ratio and 95% confid ence intervals will be computed from a 
stratified Cox model.

Novartis Confidential Page 101
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
10.5.3 Safety  objectives
10.5.3.1 Analysis set and grouping for the analy ses
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
treatment group.
The overall observation period will be divided into three mutually  exclusive segments:
1.pre-treatment period: from day  of subjec t’s first informed consent to the day  before first 
administration of study  treatment
2.
on-treatment period: from day  of first administration of study treatment to 30 day s after 
last 
actual administration of the same study  treatment (including start and stop date)
3.post-treatment period: starting at day  31 after last administration of any study  treatment
Summary  tables for safety  data will be presented for the on-treatment period. Comparative 
analysis will be performed only for the on-treatment period. Listings of safet y data will 
include pre-treatment, on-treatment, and post-treatment periods, with a flag to indicate data 
collected before or after the on -
treatment period.
10.5.3.2 Adverse events (A Es)
Summary  tables for adverse events (AEs) will include only AEs that started or worsened 
during the on -treatment period, the treatment- emergent AEs.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by system organ class and/or preferred term, severity  (based on CTCAE grades), 
type of adverse event, relation to study  treatment .
Serious adverse events, non-serious adverse events and adverse events of special interest
(AESI) during the on -treatment period will be tabulated.
All deaths (on
-treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including those from the pre-treatment , on-
treatment and post-treatment period
s) will be listed and those collected before or after the on-
treatment period will be flagged.
10.5.3.3 Laboratory  abnormalities
Grading of laboratory  values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) 
version 4.03. The calculation of CTCAE 
grades will be based on the observed laboratory  values only, clinical assessments will not be 
taken into account.
CTCAE Grade 0 will be assigned for all non-missing values not graded as1 or higher. Grade
5 will not be used.
For laboratory
 tests where grades are not defined by  CTCAE v4.03, results will be categorized 
as low/normal/high based on laboratory  normal ranges.
The following listings and summaries will be generated 
separatel y for hematology , and 
biochemistry  tests:

Novartis Confidential Page 102
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Listing of all laboratory  data with values flagged to show the corresponding CTCAE 
v4.03 grades if applicable and the classifications relative to the laboratory  normal ranges
For laboratory  tests where grades are defin ed by CTCAE v4.03
Worst post -baseline CTCAE grade (regardless of the baseline status). Each patient will be 
counted only once for the worst grade observed post -baseline in the on- treatment period .
Shift tables using CTCAE grades to compare respective 
basel ine to the worst on- treatment 
value
For laboratory  tests where grades are not defined by CTCAE v4.03,
Shift tables using the low/normal/high/ (low and high) classification to compare respective 
baseline to the worst on-treatment value.
10.5.3.4 Other safety  data
ECG
ECGs (12-lead) 
including PR, QRS, QT, QTcF, and HR intervals will be obtained for each 
subject during the study . ECG data will be read and interpreted centrall y.
Categorical analysis of QT/QTc interval data based on the number of patients meeting or 
exceeding predefined limits in terms of absolute QT/QTc intervals or changes from baseline 
will be presented. In addition, a listing of these patients will be produced b y treatment group.
Vital signs
Data on vital signs will be tabulated and listed, notable values will be flagged.
10.5.3.5 Supportive analy ses for secondary  objectives
Not applicable.
10.5.3.6 Tolerability
Tolerability  of each study  treatment will be assessed by summarizing the number of subjects
with dose interruptions and dose reductions. Reasons for dose interruptions and dose 
reductions will be listed by  subject and summarized.
10.5.4 Secondary  PK objectives
The PK objective is to characterize the PK of ABL001 in CML  population.
Using PAS, summary  statistics (n, mean, SD, coefficient of variation (CV) for mean, 
geometric mean, CV for geometric mean, median, minimum and maximum) will be presented 
for plasma concentration at each scheduled time point. The geometric mean with mean (SD) 
and individual plasma concentration versus time profiles of ABL001 will be display ed 
graphicall y.
Using Safet y set, concentration data will be listed. Concentration values below the limit of 
quantification (BLQ) will be set to zero by the Bioanal yst and display ed in listing s as zero 

Novartis Confidential Page 103
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
with a flag. BLQ values will be handled as zero in any calculations of summary  statistics, but 
handled as missing for the calculation of the geometric means and CVs.
Pharmacokinetic parameters will be determined by non-compartmental method(s) using the 
pharmacokinetic profile of ABL001 in patients with full PK sampling. PK parameters listed in 
Table 10
-1will be derived and reported, when feasible.
Population PKmodeling may be performed and theresults may be reported in a separate 
population PK report. Data from this study  may be combined with data from other studies for 
this analy sis.
Table 10-1 Non compartmental pharmacokinetic parameters in full PK group
AUC0 -12h The area under the plasma concentration -time curve from time zero to 12 h (mass x time x 
volume -1)a
Cmax The maximum (peak) observed plasma drug concentration after dose administration (mass x 
volume -1)
Tmax The time to reach maximum (peak) plasma drug concentration after dose administration (time)
CL/F The total body clearance of drug from the plasma after oral administration (volume x time -1)
10.6 Exploratory  objectives
10.6.1 Exploratory  efficacy  objectives
To evaluate the influence of factors such as major cy togenetic status at baseline, 
failure /intolerance to prior TKIs, line of therapy , gender , race and age on the effect of 
ABL001 with respect to the primary  efficacy  endpoint.
To characterize mutations in the BCR -ABL1 gene at baseline and at end of treatment and 
examine their association with molecular and cytogenetic response for ABL001 vs 
bosutinib
10.6.1.1 Data analy sis of exploratory  efficacy  objectives
Subgroup analyses will be performed to evaluate the influe nce of factors such as baseline 
major cytogenetic response status, baseline BCR- ABL ATP -binding site mutation status 
(from local historical record and from Sanger Sequencing), failure /intolerance to prior TKIs, 
line of therapy , gender, race and age on the primary  efficacy  endpoint. In addition ,a logistic 
regression analysis will incorporate the key baseline variables into the model to further 
evaluate the impact of these variables on the primary  endpoint and to provide a treatment 
effect estimate which is adjusted for imbalances in the treatment groups. An adjusted odds 
ratio for the treatment effect with associated 95% confidence intervals will be presented.
Mantel -Haenszel estimates of the common odds ratio and the corresponding 95% confidence 
interval wi ll also be provided.

Novartis Confidential Page 106
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
additional outpatient office visits gener al practitioner, specialist, and urgent care visits from 
Baseline up to End of Study . Hospitalization visits will also record the number of days on 
ward and the type of ward (hospital unit) and the discharge status. At each RU collected, the 
reason for thevisit, i.e. related to CML, AE or other reason, will be collected, in order to 
quantify  the impact of treatment on healthcare resources.
10.6.4.2 Patient Reported Outcomes
The MDASI  CML, PGIC along with EQ-5D- 5L will be used to compare data on the patient’s 
diseas e-related symptoms and health -related quality  of lifefrom baseline to EOT between the 
treatment arms . The WPAI will be used to assess work productivity  and activity  impairment 
related to the patient’s CML .All measures will assess differences between the treatment arms .
Patients with an evaluable baseline score and at least one evaluable post baseline score during 
the treatment period will be included in the change from baseline analy ses. Missing data items 
in a scale will be handled according to the manua l for each instrument. No imputation will be 
applied if the total or subscale scores are missing at a visit.
10.7 Interim analy sis
No formal interim analysis is planned for this trial. As described in Section 10, three formal 
analyses are planned: the primary  at week 24, another at the 96
-week end of study treatment 
and a PFS/OS update at year 5.
24-week primary  analy sis: Formal testing of the primary  endpoint with full alpha will be 
performed. Anal yses of ot her efficacy  endpoints at and by  24 weeks will also be 
performed.
96-week end of stud y treatment anal ysis: Formal statistical testing of the key  secondary  
endpoint will be performed with = 0.05 (two- sided) only  if the primary  endpoint is 
significant. Ana lyses of other efficacy  endpoints (including MMR rate at 48 weeks) will 
also be performed.
5-year PFS/OS update analy sis:PFS and OS
In addition DMC safet
y analyses will be conducted as described in Section 8.6.
10.8 Sample size calculation
To test the null hypothesis that the response rate is equal in the two groups, based on two-
sided 5% level of significance and with 90% power, 222 patients will be needed in total (i.e. 
148 
patients in the ABL001 arm and 74patients in the bosutinib arm based on 2:1 
randomization allocation). This assumes that ABL 001 leads to a 20% improvement in the 
MMR rate at 24 weeks over bosutinib from 15% to 35% which corresponds to an odds ratio 
of 3.05.
The assumed bosutinib MMR rate of 15% at 24 weeks is based on previous trials evaluating 
bosutinib therapy  (Khoury  2012 , Gambacorti - Passerini 2014 , García -Gutiérrez 2015 ).

Novartis Confidential Page 107
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
10.9 Power for analy sis of key secondary  variables
Ifthe primary  analysisofMMR rate at 24 weeks is statistically  significant , then the key 
secondary  endpoint MMR rate at 96 weeks will be tested, with the overall alpha controlled at 
the 5% two-sided level. The testing will use a gatekeeping strategy .Full details of the testing 
strategy  are provided in Section 10.5.1.
Table 10-2 below summarizes the treatment effects of the keysecondary  endpoint which can 
be detected with 80% and 90% power , based on the specified assumptions regarding the 
bosutinib effect. The calculat ions were made using the software package PASS (2008).
Table 10
-2 Detectable effect sizes for key  secondary  endpoint
Endpoint Anticipated effect 
with bosutinib2-sided alpha Power Detectable effect 
size§
MMR rate at 96 weeks 30%*0.05 90%
80%≥ 23%
≥ 20%
*: Gambacorti -Passerini et al. 2014 , Figure 1D.
§: Absolute difference from the anticipated effect with bosutinib.
For MMR rate at 96 weeks, if the anticipated effect with bosutinib is 30%, then the given 
sample size with 2-sided alpha=0.05 would allow to detect an absolute difference of at least 
23% (i.e. MMR rate at 96 weeks with ABL001 is at least 53%) for 90% power andof at least 
20% (i.e. MMR rate at 96 weeks with ABL001 is at least 50%) for 80% power.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent 
Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is 
required to sign a protocol signature page confirming his/her agreement to conduct the study 
in accordance with these documents and all of the instructions and procedures found in thi s 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.

Novartis Confidential Page 108
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
11.3 Informed consent proce dures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC/REB -approved informed consent.
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documented in the patient source documents. The date when a subject’s Informed 
Consent was actuall y obtained will be captured in their eCRFs.
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
Additional consent form
Not applicable.
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for terminating the study  are outlined in Section 
4.4.
11.5 Publication of study  protocol and results
Novartis is committed to following high ethical standards for reporting study results for its 
innovative medicine, including the timel y communication and publication of clinical trial 
results, whatever their outcome. Novartis assures that the key  design elements of this protocol 
will be posted on the publicly  accessible database, e.g. www.clinicaltrials.gov before study  
start. In addition, results of interventional clinical trials in adult patients are posted on 
www.novartisclinicaltrials.com, a publicl y accessible database of clinical study  results within 
1 year of study  completion (i.e., LPLV), those for interventional clinical trials involving 
pediatric patients within 6 months of study  completion.
Novartis follows the ICMJE authorship guidelines (www.icmje.org) and other specific 
guidelines of the journal or congress to which the publication will be submitted
Authors will not receive remuneration for their writing of a publication, either directl y from 
Novartis or through the professional medical writing agency . Author(s) may be requested to 
present poster or oral presentation at scientific congress; however, there will be no 
honorarium provided for such presentations.

Novartis Confidential Page 109
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
As part of its commitment to full transparency in publications, Novartis supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of interest of financial and non-financial nature by all authors, including 
medical writing/editorial support, if applicable.
For the Novartis Guidelines for the Publication of Results from Novartis -sponsored Research,
please refer to www.novartis.com.
11.6 Stud y documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulator y and institutional 
requirements for the protection of confidentiality of subjects. As part of participating in a 
Novartis -sponsored study , each site will permit authorized representatives of the sponsor(s) 
and regulatory  agencies to examine (and when required by applicable law, to copy) clinical 
records for the purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activiti es in a clinical trial necessary  for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospital 
records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copies or transcriptions certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media , x-rays, and subject files 
and records kept at the pharmacy , at the laboratories, and medico- technical departments 
involved in the clinical trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study  electronic case report form (eCRF) is the primary 
data collection instrument for the study . The investigator should ensure the accuracy , 
completeness, legibility , and timeliness of the data reported in the eCRFs and all other 
required reports. Data reported on the eCRF, that are derived from source documents, should 
be consistent with the source documents or the discrepancies should be explained. All data 
requested on the eCRF must be recorded. Any missing data must be explained. For electronic 
CRFs an audit trail will be maintained b y the s ystem.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
applicable regulations and/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.

Novartis Confidential Page 110
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by 
names in any documents submitted to Novartis. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at the site -prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the inves tigator contact Novartis or its agents, if any, monitoring the 
study  to request approval of a protocol deviation, as no authorized deviations are permitted. If 
the investigator feels a protocol deviation would improve the conduct of the study  this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, Novartis should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. UK requires the notification of 
urgent safet y measures within 3 day s) but not later than 1 0 working day s.

Novartis Confidential Page 111
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
13 References (available upon request)
[Baccarani M, Deininger DW, Rosti G, et al (2013)] European LeukemiaNet 
recommendations for the management of chronic my eloid leukemia: 2013. Blood; 
122(6):872-84.
[Bartram CR, de Klein A, Hagemeijer A, e t al (1983)] Translocation of c- ab1 oncogene 
correlates with the presence of a Philadelphia chromosome in chronic my elocy tic leukaemia. 
Nature; 306(5940):277 -80.
[Branford S, Rudzki Z, Walsh S, et al (2003)] Detection of BCR- ABL mutations in patients 
with CML  treated with imatinib is virtually  alway s accompanied by  clinical resistance, and 
mutations in the ATP phosphate -binding loop (P -loop) are associated with a poor prognosis. 
Blood; 102(1):276 -83.
[Brooks R (1996)] EuroQol: the current state of play . Hea lth Policy 37(1):53 -72.
[Daley  GQ, Van Etten RA, Baltimore D (1990)] Induction of chronic m yelogenous leukemia 
in mice by  the P210bcr/abl gene of the Philadelphia chromosome. Science; 247(4944):824 -30.
[EuroQol Group (1990)] EuroQol- a new facility  for the measurement of health -related quality  
of life. Health Policy  16(3):199 -208.
[Gambacorti -Passerini C, Brümmendorf TH, Kim DW, et al (2014)] Bosutinib efficacy  and 
safet y in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: 
Minimum 24 -month follow -up. Am J Hematol; 89(7):732-42.
[García -Gutiérrez V, Martinez -Trillos A, L opez Lorenzo JL , et al (2015)] Bosutinib shows 
low cross intolerance, in chronic m yeloid leukemia patients treated in fourth line. Results of 
the Spanish compassionate use program. Am J Hematol; 90(5):429-33.
[Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, et al (1983)] Localization of the c -ab1 
oncogene adjacent to a translocation break point in chronic m yeloc ytic leukaemia. Nature; 
306(5940):239 -42.
[Herdma n M, Gudex C, Llo yd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. (2011) ]
Development and preliminary testing of the new five -level version of EQ- 5D (EQ -5D- 5L). 
Quality  of Life Research 20(10):1727-1736.
[Hughes TP, Hochhaus A, Branford S, et al (201 0)] L ong-term prognostic significance of 
early molecular response to imatinib in newly  diagnosed chronic m yeloid leukemia: an 
analysis from the International Randomized Study  of Interferon and STI571 (I RIS). Blood; 
116(19):3758-3765.
[Hochhaus A, O'Brien S G, Guilhot F, et al (2009)] Six- year follow -up of patients receiving 
imatinib for the first -line treatment of chronic m yeloid leukemia. Leukemia; 23(6):1054-61.
[Kelliher MA, McLaughlin J, Witte ON, et al (1990)] I ntroduction of a chronic my elogenous 
leuke mia-like s yndrome in mice with v -Abl and BCR/ABL . Proc Natl Acad Sci USA 87; 
6649-53.
[Khoury  HJ, Kim D, Zaritskey  A, et al (2010)] Safety  and efficacy  of thirdline bosutinib in 
imatinib (I M) and dasatinib (DAS) resistant or intolerant chronic phase (CP) c hronic m yeloid 
leukemia (CML) [abstract]. J Clin Oncol; 28 (Suppl
; abstr 6514):15s.

Novartis Confidential Page 112
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
[Khoury  HJ, Cortes JE, Kantarjian HM, et al (2012)] Bosutinib is active in chronic phase 
chronic m yeloid leukemia after imatinib and dasatinib and/or nilotinib therapy fail ure. Blood; 
119(15):3403-12.
[Nowell Hungerford DA (1960)] A minute chromosome in chronic granulocy tic leukemia. 
Science; 132: 1497 -1501. [O’Brien S, Radich JP, Abboud CA, et al (2013)] Chronic 
Myelogenous Leukemia, Version 1.2014: Featured Updates to the NCCN Guidelines. J Natl 
Compr Canc Netw; 11(11):1327-40.
[O’Hare T, Corbin A S, Druker B J(2006)] Targeted CML therapy: controlling drug resistance, 
seeking cure. Current opinion in Genetics & development, 16:92 -99.
[Rowley  JD (1973)] A new consistent abno rmality in chronic my elogenous leukemia 
identified by  quinacrine, fluorescence and Giemsa staining. Nature; 243:290 -93.
[Soverini S, Branford S, Nicolini FE, et al (2014)] I mplications of BCR -ABL1 kinase 
domain -mediated resistance in chronic m yeloid leukem ia. Leuk Res; 38(1):10 -20.
[Vardiman J.W. (2009)] Chronic My elogenous Leukemia, BCR -ABL+. Am J Clin Pathol; 
132:250-260.
[Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2001)] Human drug metabolism and the 
cytochromes P450: application and relevance of in vitro models. The Journal of Clinical 
Pharmacology ; 41: 1149 -1179

Novartis Confidential Page 113
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
14 Appendices
14.1 Appendix 1 List of CYP3A 4 inducers, inhibitors and substrates
Table 14-1 CYP3 A4 inducers
Category Drug Names
Strong inducers 
of CYP3A41avasimibe, carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifabutin, 
rifampin, St. John’s wort (HYPERICUM PERFORATUM)5
Moderate 
inducers of 
CYP3A42bosentan, efavirenz, etravirine, lersivir ine, lopinavir, modafinil, nafcillin, ritonavir/tipranavir, 
semagacestat4, talviraline4, thioridazine
Weak inducers 
of CYP3A43amprenavir, aprepitant, armodafinil bexarotene, boceprevir, brivacetam, clobazam, danshen5, 
dexamethasone, echinacea5, eslicarba zepine, gingko (ginkgo biloba)5, ginseng5, glycyrrhizin5, 
honey6, quercetin6, methylprednisolone, nevirapine, oxcarbazepine, pioglitazone, pleconaril4, 
prednisone, primidone, raltegravir, ritonavir, rufinamide, sorafenib, Stribild (combo of 
elvitegravir, c obicistat, emtricitabine, and tenofovir), sulfinpyrazone, telaprevir, terbinafine, 
ticagleror, ticlopidine, topiramate, troglitazone4, vemurafenib, vicriviroc/ritonavir, vinblastine, 
yin zhi huang5
1A strong inducer for a specific CYP is defined as an inducer that decreases the AUC of a sensitive substrate for 
that CYP by equal or more than 80%.
2A moderate inducer for a specific CYP is defined as an inducer that decreases the AUC of a substrate for that 
CYP by 50 -80%.
3A weak inducer for a specific CYP is defined as an inducer that decreases the AUC of a substrate for that CYP 
by 20 -50%.
4Drugs not available in the US Market.
5Herbal product.
6Food product.
This list was based on information from the FDA’s “Guidance for Industry, Drug Interaction 
Studies”, from the Indiana Universit y School of Medicine’s “Clinicall y Relevant” Table, from 
the University  of Washington’s Drug Interaction Database. This list may not be 
comprehensive and may be updated periodically . Refer to Novartis Oncology  Clinical 
Pharmacology  Internal Memorandum, Drug -drug interactions (DDI) Database (last updated 
2016) for update or more details.

Novartis Confidential Page 114
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Table 14-2 CYP3 A4 inhibitors
Category Drug Names
Strong 
inhibitors of 
CYP3A41boceprevir, cobicistat (GS -9350), conivaptan, clarithromycin, danoprevir/ritonavir12, delalisib, 
darunavir/ritonavir12, elvitegravir/ritonavir12, grapefruit product11, indinavir, indinavir/ritonavir12, 
itraconazole, ketoconazole, LCL161, lopinavir/ritonavir12, mibefradil, nefazodone, nelfinavir, 
posaconazole, ritonavir, saquinavir, saquinavir/ritonavir12, telaprevir, telithromycin, 
tipranavir/ritonavir12, troleandomycin, VIEKIRA PAK2, voriconazole
Moderate 
inhibitors of 
CYP3A42ACT-178882, amprenavir, aprepitant, atazanavir, casopitant, cimetidine, ciprofloxacin, crizotinib, 
cyclosporine, Erythromycin, darunavir, diltiazem, dronedarone, FK1706Ferula asafetida resin 
(Feru la assa -foetida)4, faldaprevir, fluconazole7, imatinib, isavuconazole, netupitant, nilotinib, 
schisandra, sphenanthera, tofisopam, verapamil
Weak 
inhibitors of 
CYP3A43almorexant, alprazolam, AMD070, amiodarone, amlodipine, atorvastatin, AZD2327, 
azithrom ycin, berberine, bicalutamide, blueberry juice5, chlorzoxazone, cilostazol, clotrimazole, 
cranberry juice5, daclatasvir, delavirdine, evacetrapid, everolimus, fosaprepitant (IV), 
fluvoxamine8, fostamatinib, Garden Cress seeds (Lepidium sativum)5, ginkgo4, goldenseal4, 
Guan Mai Ning13, GSK1292263, GSK2248761, isoniazid, ivacaftor, lacidipine, linagliptin, 
lomitapide, M100240, oral contraceptives, palbociclib, pazopanib, peppermint oil, propiverine, 
ranitidine, ranolazine, resveratrol, roxithromycin, Seville orange juice5, simeprevir, sitaxentan, 
suvorexant, tabimorelin, tacrolimus, teriflunomide, ticagrelor, tolvaptan, Tong Xin Luo13
1A strong inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for 
that CY P by equal or more than 5 -fold.
2A moderate inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate 
for that CYP by less than 5 -fold bu t equal to or more than 2 -fold.
3A weak inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for 
that CYP by less than 2 -foldbut equal to or more than 1.25 -fold.
4Herbal product.
5Food product.
6Gemfibrozil also inhibits OATP1B1. Appl icable for another class of CYP inhibitor.
7Fluconazole is listed as a strong CYP2C19 inhibitor based on the AUC ratio of omeprazole, which is also 
metabolized by CYP3A; fluconazole is a moderate CYP3A inhibitor.
8Fluvoxamine strongly inhibits CYP1A2 and CYP2C19, but also inhibits CYP2C8/2C9 and CYP3A.
9Ticlopidine strongly inhibits CYP2C19, but also inhibits CYP3A, CYP2B6, and CYP1A2. The inhibition of 
CYP3A4 by ticlopidine is not strong although the actual class of its inhibition on CYP3A4 (moderate vs weak) has 
yet to be defined.
10Effect seems to be due to CYP2C19 inhibition by ethinyl estradiol. Applicable for another class of CYP inhibitor.
11The effect of grapefruit product varies widely among brands and is concentration -, dose -, and preparation -
dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation 
was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was 
used (e. g., low dose, single streng th).
12Combination therapy.(in some cases combinations with ritonavir have been listed as moderate inhibitors of 
CYP3A in the U W database, the have all been listed as strong in the DDI guide to avoid any potential confusion).
13Traditional Chinese medici ne.
This list is based on information from the FDA’s “Guidance for Industry , Drug Interaction 
Studies”, from the Indiana University  School of Medicine’s “Clinically  Relevant” Table and 
from the University  of Washington’s Drug Interaction Database. Please note that this is not an 
exhaustive list. Please refer to footnotes. Refer to Novartis Oncology  Clinical Pharmacology  
Internal Memorandum, Drug -drug interactions (DDI) Database (last updated 2016) for update 
or more details.

Novartis Confidential Page 115
Amended Protocol Version 01 (Clean) Protocol No. CABL001A2301
Table 14-3 CYP3 A4 substrates: Narrow therapeutic index, sensitive, and others
Category Drug Names
Narrow Therapeutic 
index substrates of 
CYP3A41alfentanil, astemizole, cisapride, cyclosporine, dihydroerg otamine, ergotamine, 
ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfanadine, thioridazine
Sensitive substrates 
of CYP3A42alpha -dihydroergocryptine, alfentanil, almorexant, alisoporivir, aplaviroc, aprepitant, 
atazanavir, atorvastatin, avanafil, bosutinib, brecanavir, brotizolam, budesonide, 
buspirone, capravirine, casopitant, conivaptan, danoprevir, darifenacin, darunavir, 
dasatinib, dronedarone, ebastine, eletriptan, elvitegravir, eplerenone, everolimus, 
felodipine, fluti casone, ibrutinib, indinavir, ivacaftor, levomethadyl, lomitapide, lopinavir, 
lovastatin, lumefantrine, lurasidone, maraviroc, midazolam, midostaurin, naloxegol, 
neratinib, nisoldipine, perospirone, quetiapine, ridaforolimus, saquinavir, sildenafil, 
simepr evir, simvastatin, tacrolimus, terfenadine, ticagrelor, tilidine,tipranavir, tolvaptan, 
triazolam, ulipristal, vardenafil, vicriviroc, voclosporin.
Other Substrates of 
CYP3A43alprazolam, ambrisentan, amlodipine, antipyrine, aripiprazole, artemether, avos entan, 
boceprevir, bosentan, buprenorphine, carbamazepine, dexloxiglumide, 
dextromethorphan, diazepam, docetaxel, enzalutamide, gemigliptin, halofantrine, 
imipramine, lansoprazole, lidocaine, linagliptin, loperamide, loratadine, losartan, 
lurasidone, macit entan, methadone, mirodenafil, montelukast, morphine, nelfinavir, 
netupitant, nevirapine, nifedipine, nilotinib, nitrendipine, omeprazole, ospemifene, 
oxycodone, paclitaxel, pazopanib, pioglitazone, quinine, ranolazine, repaglinide, rifabutin, 
ritonavir, roflumilast, saxagliptin, selegiline, sertraline, sibutramine, sotrastaurine, 
telaprevir, theophylline, tirilazad, tolterodine, udenafil, ulipristal, vincristine, voriconazole
Narrow Therapeutic 
index substrates of 
CYP2C9warfarin (also sensitive), phenyto in
Narrow Therapeutic 
index substrates of 
CYP2C8paclitaxel
1Sensitive substrates: Drugs that exhibit an AUC ratio (AUCi/AUC) of 5 -fold or more when co -administered with a 
known potent inhibitor.
2 Substrates with narrow therapeutic index (NTI): Drugs whose exposure -response indicates that increases in their 
exposure levels by the concomitant use of potent inhibitors may lead to serious safety concerns (e.g., Torsades 
de Pointes).
3Other substrates are these that have shown an in vivo ≥2-fold increase in AUC with co -administration of an 
inhibitor based on the U W database. 
This list of CYP substrates was compiled from the Indiana University  School of Medicine’s 
“Clinically  Relevant” Table; from the FDA’s “Guidance for Industry , Drug Interaction 
Studies” and from the University  of Washington’s Drug Interaction Database. This list may 
not be comprehensive and may be updated periodically . Refer to Novartis Oncology  Clinical 
Pharmacology  Internal Memorandum, Drug -drug interactions (DDI) Database (last updat ed 
2016) for update or more details.

Clinical Development
Asciminib/ABL001
Oncology Clinical Trial Protocol CABL001A2301
A phase 3, multi -center, open -label, randomized study  of 
oral ABL001 ( asciminib )versus bosutinib in patients w ith 
Chronic M yelogenous Leukemia in chronic phase (CML -
CP), pre viously  treated w ith 2 or more ty rosine kinase 
inhibitors
Document type Amended Protocol Version
EUDRACT number 2016 -002461 -66
Version number 03 (Clean )
Development phase III
Document status Final
Release date 14-Dec- 2018
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
Template version 19 -Nov-2015

Novartis Confidential Page 2
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 6
List of tables ........................................................................................................................ 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Protocol summary :
............................................................................................................. 11
Amendment 3 (14 -Dec-2018) ............................................................................................ 17
Amendment 2 (13 -Jul-
2018) ............................................................................................. 23
Amendment 1 (10 -Apr-2017) ............................................................................................ 29
1Background ........................................................................................................................ 31
1.1 Overview of disease pathogenesis, epidemiology
 and current treatment .............. 31
1.2 Introduction to investigational treatment ............................................................... 32
1.2.1 Overview of 
asciminib ( ABL001) ........................................................ 32
1.2.2 Overview of bosutinib........................................................................... 38
2Rationale ............................................................................................................................ 39
2.1 Study  rationale and purpose ................................................................................... 39
2.2 Rationale for the stud y design ............................................................................... 39
2.2.1
Rationale for Biomarker Assessment.................................................... 40
2.3 Rationale for dose and regimen selection .............................................................. 41
2.4
Rationale for choice of combination drugs............................................................ 42
2.5 Rationale for choice of comparators drug bosutinib .............................................. 42
2.6 Risks and benefits .................................................................................................. 42
3
Objectives and endpoints ................................................................................................... 43
4Study  design ................................ ................................ ................................ ...................... 47
4.1 Description of stud y design ................................................................................... 47
4.1.1 Study  treatment switch from bosutinib to asciminib ............................. 48
4.2 Timing of interim anal yses and design adaptations ............................................... 48
4.3 Definition of end of study ...................................................................................... 48
4.4 Early study termination .......................................................................................... 49
5Population .......................................................................................................................... 49
5.1 Patient population .................................................................................................. 49
5.2 Inclusion criteria .................................................................................................... 49
5.3 Exclusion criteria ................................................................................................... 51
6Treatment ................................ ................................ ................................ ........................... 53
6.1 Study  treatment ...................................................................................................... 53

Novartis Confidential Page 3
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
6.1.1 Dosing regimen ..................................................................................... 53
6.1.2 Ancillary  treatments .............................................................................. 54
6.1.3
Rescue medication ................................................................................ 54
6.1.4 Guidelines for continuation of treatment .............................................. 54
6.1.5 Treatment duration ................................................................................ 54
6.2 Dose escalation guidelines ..................................................................................... 55
6.3 Dose modifications ................................................................................................ 55
6.3.1 Dose modification and dose delay ........................................................ 55
6.3.2
Dose adjustments for QTcF prolongation............................................. 64
6.3.3 Follow -up for toxicities ......................................................................... 65
6.3.4 Anticipated risks and safety  concerns of the study drug ....................... 66
6.4 Concomitant medications for patients on asciminib.............................................. 66
6.4.1 Permitted concomitant therap y
............................................................. 66
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... 67
6.4.3 Prohibited concomitant therap y
............................................................ 67
6.4.4 Other concomitant medications ............................................................. 68
6.5
Concomitant medications for patients on bosutinib .............................................. 69
6.5.1 Permitted concomitant therap y requi ring caution ................................. 69
6.5.2 Prohibited concomitant therap y
............................................................ 70
6.6 Patient numbering, treatment assignment or randomization ................................. 70
6.6.1
Patient numbering ................................................................................. 70
6.6.2
Treatment assignment or randomization............................................... 71
6.6.3 Treatment blinding ................................................................................ 71
6.7 Study  drug preparation and dispensation ............................................................... 71
6.7.1 Study  treatment packaging and labeling ............................................... 72
6.7.2 Drug supply  and storage ........................................................................ 72
6.7.3 Study  drug compliance and accountabilit y
........................................... 72
6.7.4 Disposal and destruction ....................................................................... 73
7
Visit schedule and assessments ......................................................................................... 73
7.1 Study  flow and visit schedule ................................................................................ 73
7.1.1 Molecular pre -screening ........................................................................ 92
7.1.2 Screening ............................................................................................... 92
7.1.3 Run-in period ........................................................................................ 95
7.1.4 Treatment period ................................................................................... 95
7.1.5 Visit windows ........................................................................................ 95
7.1.6 Discontinuation of study treatment ....................................................... 96

Novartis Confidential Page 4
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
7.1.7 Withdrawal of consent .......................................................................... 97
7.2 Assessment ty pes................................................................................................... 98
7.2.1 Efficacy  assessments ............................................................................. 98
7.2.2 Safety  and tolerability  assessments ..................................................... 100
7.2.3 Pharmacokinetics ................................................................................ 107
7.2.4 Biomarkers .......................................................................................... 108
7.2.5 Resource utilization ............................................................................. 111
7.2.6 Patient reported outcomes ................................................................... 111
8Safety  monitoring and reporting ...................................................................................... 113
8.1 Adverse events ..................................................................................................... 113
8.1.1
Definitions and reporting .................................................................... 113
8.1.2 Laboratory  test abnormalities .............................................................. 114
8.1.3
Adverse events of special interest....................................................... 115
8.2 Serious adverse events ......................................................................................... 115
8.2.1
Definitions........................................................................................... 115
8.2.2
Reporting............................................................................................. 115
8.3 Emergency  unblinding of treatment assignment ................................................. 116
8.4 Pregnancies .......................................................................................................... 116
8.5 Warnings and precautions .................................................................................... 117
8.6 Data Monitoring Committee ................................................................................ 117
8.7 Steering Committee ............................................................................................. 117
9Data collection and management ................................ ................................ ..................... 118
9.1 Data confidentiality ............................................................................................. 118
9.2 Site monitoring .................................................................................................... 118
9.3
Data collection..................................................................................................... 119
9.4 Database management and quality  control .......................................................... 119
10Statistical methods and data anal ysis.............................................................................. 119
10.1 Analy sis sets ........................................................................................................ 120
10.1.1 Full Anal ysis Set ................................................................................. 120
10.1.2 Safety  set............................................................................................. 120
10.1.3
Per-Protocol set ................................................................................... 120
10.1.4 Dose -
determining anal ysis set............................................................. 120
10.1.5 Pharmacokinetic anal ysis set
............................................................... 121
10.1.6 Other anal ysis set
................................................................................ 121
10.2 Patient demographics/other baseline characteristics ........................................... 121
10.3 Treatments (stud y treatment, concomitant therapies, compliance) ..................... 121

Novartis Confidential Page 5
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
10.4Primary  objective ................................ ................................ ................................ .122
10.4.1 Variable ............................................................................................... 122
10.4.2 Statistical hypothesis, model, and method of analy sis........................ 122
10.4.3 Handling of missing values/censoring/discontinuations ..................... 122
10.4.4 Supportive and Sensitivity anal yses.................................................... 123
10.5 Secondary  objectives ........................................................................................... 123
10.5.1 Key secondary  objective(s) ................................................................. 123
10.5.2 Other secondary  efficacy objectives ................................................... 124
10.5.3 Safety  objectives ................................................................................. 127
10.5.4 Secondary  PK objectives ..................................................................... 128
10.6 Exploratory  objectives ......................................................................................... 129
10.6.1 Exploratory  efficacy  objectives ........................................................... 129
10.6.2 Exploratory  PK objectives .................................................................. 130
10.6.3 Exploratory  biomarker objectives ....................................................... 130
10.6.4 Exploratory  Patient Reported Outcomes objectives ........................... 131
10.7 Interim anal ysis.................................................................................................... 132
10.8 Sample size calculation........................................................................................ 132
10.9 Power for anal ysis of key secondary  variables
.................................................... 133
11Ethical considerations and administrative procedures .................................................... 133
11.1 Regulatory
 and ethical compliance ...................................................................... 133
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... 133
11.3 Informed consent procedures
............................................................................... 134
11.4 Discontinuation of the study ................................................................................ 134
11.5 Publication of study  protocol and results ............................................................. 134
11.6 Study  documentation, record keeping and retention of documents
..................... 135
11.7 Confidentiality  of study  documents and patient records ..................................... 136
11.8
Audits and inspections......................................................................................... 136
11.9 Financial disclosures ............................................................................................ 136
12Protocol adherence ................................ ................................ ................................ .......... 136
12.1 Amendments to the protocol ................................................................................ 136
13References (available upon request) ................................................................................ 137
14Appendices ...................................................................................................................... 139
14.1 Appendix 1 L ist of concomitant medications for patients on asciminib
............. 139
14.2 Appendix 2 L ist of concomitant medications for patients on bosutinib .............. 141

Novartis Confidential Page 6
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
List of figures
Figure 1 -1 KCL -22 CML Xenograft ....................................................................... 33
Figure 4 -
1 Schematic of Study  Design ................................................................... 48
List of tables
Table 3
-1 Objectives and related endpoints .......................................................... 44
Table 6
-1 Dose and treatment schedule................................................................. 54
Table 6
-2 Criteria for dose reduction/interruption and re -initiation of 
asciminib and bosutinib treatment for adverse drug re actions .............. 56
Table 6-3 Dose reduction steps for asciminib and bosutinib ................................. 64
Table 6
-4 Packaging and labeling ......................................................................... 72
Table 7
-1 Visit evaluation schedule ...................................................................... 74
Table 7
-2 Visit evaluation schedule (study  treatment switch phase) .................... 84
Table 7-3 Blood sampl es (efficacy  primary  endpoint).......................................... 99
Table 7
-4 ECOG Performance status scale ......................................................... 102
Table 7
-5 Central clinical laboratory  parameters collection plan ........................ 103
Table 7-6 Central ECG collect ion (all patients) .................................................. 105
Table 7
-7 Central ECG collection plan for patients in full PK asciminib group .105
Table 7-8 Pharmacokinetic blood collection log (Sparse PK -group -asciminib 
arm/ asciminib treatment switch patients)........................................... 107
Table 7-9 Pharmacokinetic blood collection log (Full PK group -asciminib 
arm) ..................................................................................................... 108
Table 7
-10 Biomarker sample collection plan ....................................................... 110
Table 10
-1 Non compartmental pharmacokinetic parameters in full PK group ....129
Table 10-2 Detectable effect sizes for key  secondary  endpoint ............................ 133
Table 14-1 Prohibited concomitant medications for asciminib arm...................... 139
Table 14-2 Concomitant medications to be used with caution in asciminib arm.. 140
Table 14-3 Prohibited concomitant med ications for bosutinib arm ...................... 141
Table 14-4 Concomitant medications to be used with caution in bosutinib arm ..141

Novartis Confidential Page 7
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
List of abbreviations
ABL Abelson proto -oncogene
ADME Absorption, Distribution, Metabolism, and Excretion
AE Adverse Event
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
ANC Absolute neutrophil count
AP Accelerated phase
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
ATP Adenosine triphosphate
AUC Area under the curve
AVblock Atrioventricular block
BC Blast crisis
BCR Breakpoint C luster Region gene
BCR -ABL BCR -ABL fusion gene (also called the Philadelphia chromosome)
BCRP Breast Cancer Resistant Protein
BID bis in diem /twice a day
BMA Bone marrow aspirate
BUN Blood urea nitrogen
CBC Complete Blood Count
CCA Clonal chromosome abnormalities
CCyR Complete Cytogenetic Response
CD8 Cluster of differentiation 8
CD34 Cluster of differentiation 34
CHR Complete Hematological Response
CI Confidence Interval
CMH Cochran –Mantel –Haenszel
CML Chronic Myelogenous Leukemia
CML-AP Chronic Myelogenous Leukemia -Accelerated Phase
CMO&PS Chief Medical Office and Patient Safety
CP Chronic phase
CRO Contract Research Organization
CSP Clinical study protocol
CSR Clinical study report
CT Computed tomography 
CTCAE Common Terminology Criteria for Adverse Events
CV Coefficient of variation
CYP3A4 Cytochrome P450 3A4
DDI Drug -drug interaction
DILI Drug -induced liver injury
DLCO Carbon monoxide diffusing capacity
DMC Data Monitoring Committee
DNA Desoxyribonucleic acid
DS&E Drug Safety and Epidemiology
ECG Electrocardiogram

Novartis Confidential Page 8
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
ECOG Eastern Cooperative Oncology Group
eCRF Electronic Case Report Form
EDC Electronic data capture
ELN European Leukemia Network
EOT End of Treatment
ERT Electronic Research Technology, Inc
EU European Union
FAS Full Analysis Set
FIH First In Human
GDPR General Data Protection Regulation
GFR Glomerular Filtration Rate
hADME Human ADME study (Absorption, Distribution, Metabolism and Excretion) 
HDL High density lipoprotein
ICF Informed Consent Form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
INN International Nonproprietary Name
INR International normalized ratio
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
K-M Kaplan -Meyer
Km Michaelis -Menten constant
LDL Low density lipoprotein
LFT Liver function test
LLN Lower limit of normal
MCyR Major Cytogenetic Response
mCyR Minor Cytogenetic Response
MDASI -CML MD Anderson Symptom Inventory – Chronic Myelogenous Leukemia
MMR Major Molecular Response
MRI Magnetic resonance imaging
NCCN National Comprehensive Cancer Network
NGS Next Generation Sequencing
NTI Narrow Therapeutic Index
OS Overall survival
PAS Pharmacokinetic analysis set
PBPK Physiologically based pharmacokinetic
PCR Polymerase Chain Reaction
PCyR Partial Cytogenetic Response
PD Pharmacodynamic
PGIC Patient Global Impression of Change
P-gp Permeability glycoprotein

Novartis Confidential Page 9
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Ph+ Philadelphia chromosome positive
PHI Protected Health Information
PK Pharmacokinetics
PLT Platelets
PPS Per-protocol set
QD Quaque die/once a day
QT Q to T interval (ECG)
QTcF QTc Fredericia
REB Research Ethics Board
RNA Ribonucleic acid
RQ-PCR Real time quantitative polymerase chain reaction
RU Resource Utilization
SAE Serious Adverse Event
SAP The Statistical Analysis Plan (SAP) is a regulatory document which provides evidence of 
preplanned analyses
SC Steering committee
SD Standard deviation
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic pyruvic transaminase
SmPC Summary of Product Characteristics
SOP Standard Operating Procedure
TBIL Total bilirubin
TdP Torsades de Pointes
TKI Tyrosine Kinase Inhibitor
TTF Time to treatment failure
UGT Uridin diPhospho -glucuronosyltransferase
ULN Upper limit of normal
US United States
USPI US prescribing information
WBC White blood cell count
WPAI Work Productivity and Activity Impairment

Novartis Confidential Page 10
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biologic Sa mples A biological speci men including, for ex ample, blood (plas ma, serum), saliva, 
tissue, urine, stool, etc. t aken fr om a study subject or study patient
Cycles Number and timing or recommended repetitions of therapy are usually expressed 
as number of days (e.g. q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed consent must 
be obtained (i.e. prior to starting any of the procedures described in the protocol)
Investigational drug The study treatment whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indication /approved dosage, or that are 
tested in a fixed combination. Investigational treatment generally does not include 
other study treatments administered as concomitant background therapy required 
or allowed by the protocol when used in within approved indicat ion/dosage
Medication number A unique identifier on the label of each study treatment package which is linked to 
one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study procedures th at 
was not included in the investigational treatment
Subject Number (Subject 
No.)A unique identifying number assigned to each patient/subject/healthy volunteer 
who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional 
segments such as screening, baseline, titration, washout, etc.
Personal Data Subject information collected by the Investigator that is transferred to Novartis for 
the purpose of the clinical trial. This data includes subject identifier information, 
study information and biological samples.
Randomization number A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient (subject) as part of the required study procedu res, including placebo and 
active drug run -ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any reason
Treatment group A treatment group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts. Cohorts are not expanded, new cohorts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified time points
Withdrawal of study 
consentWithdrawal of co nsent from the study oc curs only wh en a subject d oes not want 
to partic ipate in the study any longer, a nd does not allow any further collection of 
personal data

Novartis Confidential Page 11
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Protocol summary :
Title A phase 3, multi -center, open -label, randomized study o f oral ABL001 ( asciminib )versus 
bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML -CP), 
previously treated with 2 or more tyrosine kinase inhibitors
Brief title Study of efficacy of CML-CP patients treated with asciminib versus bosutinib, previously 
treated with 2 or more TKIs
Sponsor and
Clinical PhaseNovartis
Phase 3
Investigation ty pe Drug 
Study  type Interventional
Purpose and 
rationalePurpose:
The purpose of this pivotal study is to compare the efficacy of asciminib with that of 
bosutinib in the treatment of patients with CML-CP having previously been treated with a 
minimum of two prior ATP -binding site TKIs with BCR -ABL1 ratios ≥ 1% IS at screening.
Patients intolerant to the most recent TKI therapy must have BCR-ABL 1 ratio > 0.1% IS 
at screening and patients failing their most recent TKI therapy must meet the definition 
of treatment failure as per the 2013 ELN guidelines ( Baccarani et al 2013 ). No more 
than 66 pati ents (approximately 30% of the overall trial population) that are intolerant to 
their most recent TKI therapy with BCR-ABL 1< 1% will be recruited in order to ensure 
that the CML third line patient population is adequately represented.
Rationale:
There rem ains an unmet need for new compounds in patients with CML who have failed 
at least two prior TKIs. Current practice suggests that a second generation TKI will have 
been used for first line therapy for about one half of patients with CML, meaning that 
most patients who have failed at least two prior TKIs will have failed at least one if not 
two second generation TKIs (such as dasatinib and/or nilotinib ). Potentially, such 
patients may also have failed bosutinib and/or ponatinib ( Soverini 2014 ). Patients having 
failed at least two TKIs may have limited sensitivity to the remaining available agents 
and, thus, there exists a need for new safe and effective therapy. In addition, mutations 
will have developed in 21 to 33% of patients that prevent the use of specific TKIs, 
increasing the need for a better and alternative compound ( Soverini 2014 ). 
Omacetaxine, a chemotherapeutic agent, is available for patients w ho have failed at 
least two prior TKIs under these conditions but only in the US and Canada. This agent is 
not available for most patients globally, where a bigger unmet medical need is present. 
Thus, there remains an unmet need for patients with CML who h ave failed at least two 
prior TKIs despite the existence of multiple agents.
Primary  Objective
and Key  
Secondary  
ObjectivePrimary  Objective: To compare the Major Molecular Response (MMR) rate at 24 
weeks of asciminib versus bosutinib
Key Secondary  Objective: To compare MMR rate at 96 weeks of asciminib versus 
bosutinib
Secondary  
Objectives● To compare additional efficacy parameters of asciminib versus bosutinib:
● cytogenetic response rate (Complete, Partial, Major, Minor, Minimal, no 
response) at and by all scheduled data collection time points, including 24, 48 and 96 
weeks
● MMR rate at all scheduled data collection time points (except 24 and 96 weeks 
which are already covered by primary and key secondary endpoints)
● MMR rate by all scheduled d ata collection time points, including 24, 48 and 96 
weeks
● Time to MMR
● Duration of MMR
● Time to CCyR
● Duration of CCyR
● Time to treatment failure

Novartis Confidential Page 12
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
● Progression free survival
● Overall survival
●To compare the safety and tolerability profile of asciminib versus bosutinib by t ype, 
frequency and severity of adverse events, changes in laboratory values that fall outside 
the pre -determined ranges and clinically notable ECG and other safety data (vital signs, 
physical examination)
●To characterize th e PK of asciminib in the CML -CP population (Trough plasma 
concentrations, PK parameters in full PK group: Cmax, Tmax, AUC0 -12h, CL/F)
●    To assess the safety of asciminib when administered as treatment after bosutinib 
failure according to the 2013 ELN Gu idelines
Study  design This study is a randomized, phase 3, open -label, active -controlled multi -center study. 
Patients will be randomized to the novel BCR-ABL1 TKI asciminib and bosutinib in a 2:1 
ratio. The randomization is to be stratified to ensure the study population is balanced 
between the arms with respect to the patient’s cytogenetic response status at baseline 
(Major Cytogenetic response (complete or partial) vs. No major cytogenetic response 
(minor, minimal or none)).
The study design incorporate s a 2:1 randomization, allocating more patients to the 
asciminib arm in order to learn more about the safety profile of the experimental therapy, 
whereas the safety of bosutinib therapy is well documented. Treatment duration for each 
patient in the present study is for up to 96 weeks after the last randomized patient 
receive s the first dose, or up to 48 weeks after the last patient has switche d from 
bosutin ib to asciminib whichever is longer unless patients have discontinued treatment 
earlier, which should be adequate to address both the primary objective of the study, i.e. 
determination of the MMR rate at 24 weeks, as well as secondary efficacy and safety 
objectives. Patients on bosutinib will be able to switch to asciminib treatment up to 96 
weeks after th e last patient has been randomized.
If patients in the bosutinib arm have documented treatment failure according to the 2013
ELN Guidelines ( Baccarani et al 2013 ), they will have the option to receive asciminib.
Each patient who switches to asciminib after bosutinib failure can remain on asciminib 
treatment for up to 48 weeks after the last bosutinib failure patient has switched to 
asciminib during the treatment period unless patien tshave d iscontinued treatment 
earlier.
Population Two-hundred and twenty -two (222) patients with CML -CP who had prior treatment with 
two or more ATP binding site TKIs will be randomized on a 2:1 basis to receive either 
asciminib or bosutinib. Patients with known history of T315I and/or V299L mutations at 
study entry will be excluded from the trial since bosutinib, the comparator, is not 
approved for these patients.
Inclusion criteria Patients eligible for inclusion in this study have to meet allof the following criteria:
1.Male or female patients with a diagnosis of CML -CP ≥ 18 years of age
2.Patients must meet all of the following laboratory values at the screening visit:
● < 15% blasts in peripheral blood and bone marrow
● < 30% blasts plus promyelocytes in peripheral blood and bone marrow
● < 20% basophils in the peripheral blood
● ≥ 50 x 109/L (≥ 50,000/mm3) platelets
● Transient prior therapy related thrombocytopenia (< 50,000/mm3for ≤30 days 
prior to screening) is acceptable
● No evidenc e of extramedullary leukemic involvement, with the exception of 
hepatosplenomegaly
3a.Patients intolerant to the most recent TKI therapy, BCR -ABL1 ratio >0.1% IS 
according to central laboratory at the screening examination
4.Prior treatment with a minim um of 2 prior ATP -binding site TKIs (i.e. imatinib, 
nilotinib, dasatinib, radotinib or ponatinib)
5.Failure (adapted from the 2013 ELN Guidelines ;Baccarani et al 2013 ) or intolerance 
to the most recent TKI therapy at the time of screening 

Novartis Confidential Page 13
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
● Failure is defined for CML -CP patients (CP at the time of initiation of last 
therapy) as follows. Patients must meet at least 1 of the following criteria.
● Three months after the initiation of therap y: No CHR or > 95% Ph+ 
metaphases
● Six months after the initiation of therapy: BCR -ABL1 ratio > 10% IS 
and/or > 65% Ph+ metaphases
● Twelve months after initiation of therapy: BCR -ABL1 ratio > 10% IS 
and/or > 35% Ph+ metaphases
● At any time after the ini tiation of therapy, loss of CHR, CCyR or PCyR
● At any time after the initiation of therapy, the development of new 
BCR -ABL1 mutations which potentially cause resistance to study treatment 
● At any time after the initiation of therapy, confirmed loss of M MR in 2 
consecutive tests, of which one must have a BCR -ABL1 ratio ≥ 1% IS
● At any time after the initiation of therapy, new clonal chromosome 
abnormalities in Ph+ cells: CCA/Ph+
● Intolerance is defined as:
● Non-hematologic intolerance: Patients with grade 3 or 4 toxicity while 
on therapy, or with persistent grade 2 toxicity, unresponsive to optimal 
management, including dose adjustments (unless dose reduction is not 
considered in the best interest of the patient if response is already suboptimal)
● Hematologic intolerance: Patients with grade 3 or 4 toxicity (absolute 
neutrophil count [ANC] or platelets) while on therapy that is recurrent after dose 
reduction to the lowest doses recommended by manufacturer
6.Eastern Cooperative Oncology Group (ECOG) p erformance status (PS) of 0, 1, or 2
7.Adequate end organ function as defined by (as per central laboratory tests):
● Total bilirubin ≤ 1.5 x ULN) except for patients with Gilbert’s syndrome who may 
only be included if total bilirubin ≤ 3.0 x ULN or direc t bilirubin ≤ 1.5 x ULN
● Aspartate transaminase (AST) ≤ 3.0 x ULN
● Alanine transaminase (ALT) ≤ 3.0 x ULN
● Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN -  ≤ 1.5 x ULN, value must 
be considered not clinically significant and not associated with risk factors for acute 
pancreatitis
● Alkaline phosphatase ≤ 2.5 x ULN
● Creatinine clearance ≥ 50mL/min as calculated using Cockcroft -Gault formula
8.Patients must avoid consumption of grapefruit, Seville oranges or products 
containing the juice of each durin g the entire study and preferably 7 days before the first 
dose of study medications, due to potential CYP3A4 interaction with the study 
medications. Orange juice is allowed.
9.Written informed consent obtained prior to any screening procedures.
10a. Patie nts must have the following electrolyte values (as per central laboratory tests) 
within normal limits or corrected to be within normal limits with supplements prior to first 
dose of study medication:
 Potassium (potassium increase of up to 6.0 mmol/L is acc eptable at study entry
if associated with creatinine clearance within normal limits)
 Total calcium (corrected for serum albumin) ; (calcium increase of up to 12.5 
mg/dl or 3.1 mmol/L is acceptable at study entry if associated with creatinine 
clearance within normal limits)
 Magnesium, with the exception of magnesium increase > ULN - 3.0 
mg/dL; >ULN -1.23 mmol/L associated with creatinine clearance (calculated 
using Cockcroft -Gault formula) within normal limits
11. Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of 
screening which are amenable to standardized R Q-PCR quantification.
Exclusion criteria Patients eligible for this study must not meet anyof the following criteria:
1.Known presence of the T315I or V299L mutation at a ny time prior to study entry
2.Known second chronic phase of CML after previous progression to AP/BC

Novartis Confidential Page 14
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
3.Previous treatment with a hematopoietic stem-cell transplantation
4.Patient planning to undergo allogeneic hematopoietic stem cell transplantation
5.Cardiac or cardiac repolarization abnormality, including any of the following:
● History within 6 months prior to starting study treatment of myocardial infarction 
(MI), angina pectoris, coronary artery bypass graft (CABG)
● Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), 
complete left bundle branch block, high -grade AV block (e.g., bifascicular block, 
Mobitz type II and third degree AV block)
● QTcF at screening ≥450 msec (male patients), ≥460 msec (female patients)
● Long QT sy ndrome, family history of idiopathic sudden death or congenital long 
QT syndrome, or any of the following:
● Risk factors for Torsades de Pointes (TdP) including uncorrected 
hypokalemia or hypomagnesemia, history of cardiac failure, or history of 
clinicall y significant/symptomatic bradycardia
● Concomitant medication(s) with a “known risk of TdP” per 
www crediblemeds.org/ that cannot be discontinued or replaced 7 days prior to 
starting study drug by safe alternative medication.
● Inability to determine the Q TcF interval
6.Severe and/or uncontrolled concurrent medical disease that in the opinion of the 
investigator could cause unacceptable safety risks or compromise compliance with the 
protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pu lmonary 
hypertension)
7.History of acute pancreatitis within 1 year of study entry or past medical history of 
chronic pancreatitis
9.History of acute or chronic liver disease
10.Known presence of significant congenital or acquired bleeding disorder unre lated to 
cancer
11.History of other active malignancy within 3 years prior to study entry with the 
exception of previous or concomitant basal cell skin cancer and previous carcinoma in 
situ treated curatively
12.Known history of Human Immunodeficiency Vi rus (HIV), chronic Hepatitis B (HBV), 
or chronic Hepatitis C (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) 
and Hepatitis B core antibody (HBcAb / anti HBc) will be performed at screening
13.Impairment of gastrointestinal (GI) function or GI disease that may significantly alter 
the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, 
diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
14a. Treatment with medications that meet one of the following criteria and that 
cannot be discontinued at least one week prior to the start of treatment with study 
treatment
● Moderate or strong inducers of CYP3A
● Moderate or strong inhibitors of CYP3A 
15.Previous treatment with or known/ suspe cted hypersensitivity to asciminib or any of 
its excipients.
16.Previous treatment with or known/ suspected hypersensitivity to bosutinib or any of 
its excipients.
17.Participation in a prior investigational study within 30 days prior to randomization or
within 5 half -lives of the investigational product, whichever is longer
18.Pregnant or nursing (lactating) women
19a. Women of child -bearing potential, defined as all women physiologically capable 
of becoming pregnant, unless they are using highly effect ive methods of contraception 
during dosing and for 3 days after last dose of asciminib and one month after last dose 
of bosutinib . Highly effective contraception methods include:
● Total abstinence (when this is in line with the preferred and usual lifestyle of the 
subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -
ovulation methods) and withdrawal are not acceptable methods of contraception

Novartis Confidential Page 15
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
● Female sterilization (have had surgical bilateral oophorectomy (with or without 
hysterectomy) total hysterectomy or bilateral tubal ligation at least six weeks before 
taking study treatment). In case of oophorectomy alone, only when the reproductive 
status of the woman has been confirmed by follow up hormone level assessment
● Male sterilization (at least 6 months prior to screening). The vasectomized male 
partner should be the sole partner for that subject.
● Use of oral, injected or implanted hormonal methods of contraception or 
placement of an intrauterine device (IUD) or intrauteri ne system (IUS) or other forms 
of hormonal contraception that have comparable efficacy (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception.
● In case of use of oral contraception women should have been stable on the 
same pill for a minimum of 3 months before taking study treatment.
● Women are considered post -menopausal and not of child bearing potential if 
they have had 12 months of natural (spontaneous) amenorrhea with an appropriate 
clinical profile (e.g. age appropr iate, history of vasomotor symptoms) or have had 
surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or 
bilateral tubal ligation at least six weeks before taking study medication. In the case 
of oophorectomy alone, women are considered post -menopausal and not of child 
bearing potential only when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment.
Conditions to be 
fulfilled for 
asciminib switch1.Failure to bosutinib treatment up to 96 weeks after the last patient received the first 
dose (adapted from the 2013 ELN Guidelines; Baccarani et al 2013 ). Patients must 
meet at least 1 of the following criteria. Failure is defined as follows:
Three months after the initiation of therapy or thereafter : No CHR or > 95% Ph+ 
metaphases.
Six months after the initiation of therapy or thereafter: BCR -ABL1ratio > 10% 
IS and/or > 65% Ph+ metaphases.
Twelve months after initiation of therapy or thereaf ter: BCR -ABL1ratio > 10% 
IS and/or > 35% Ph+ metaphases.
At any time after the initiation of therapy, loss of CHR, CCyR or PCyR.
At any time after the initiation of therapy, detection of new BCR -ABL 1
mutations which potentially cause resistance to study treatment (asciminib or 
bosutinib) .
At any time after the initiation of therapy, confirmed loss of MMR in 2 
consecutive tests.
At any time after the initiation of therapy, new clonal chromosome abnormalities 
in Ph+ cells: CCA/Ph+.
Conditions preventing patients to switch to asciminib:
Any Grade 3 or 4 toxicity which has not resolved to Grade 2 or lower within 28
days and before starting asciminib treatment.
Asymptomatic (Grade 2)pancreatitis if not resolved within 28 days 
Disease progression while on bosutinib treatment. The following events are 
considered disease progression:
Accelerated phase (AP) as defined by any of the following:
 ≥15% blasts in the peripheral blood or bone marrow aspirate, but < 
30% blasts in both the peripheral blood and bone marrow aspirate.
 ≥30% blasts plus promyelocytes in peripheral blood or bone marrow 
aspirate.
 ≥20% basophils in the peripheral blood.
Thrombocytopenia (< 100 x 109/L) that is unrelat ed to therapy.
Blast crisis (BC) as defined by any of the following:
 ≥30% blasts in peripheral blood or bone marrow aspirate

Novartis Confidential Page 16
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Appearance of extramedullary involvement other than 
hepatosplenomegaly proven by biopsy (i.e., chloroma).
QTcF at time of switch >480msec or inability to determine QTc interval
Investigational 
and reference 
therapyAsciminib 40 mg BID
Bosutinib 500 mg QD
Efficacy  
assessmentsMolecular response (RQ -PCR, mutational analysis)
Cytogenetic response (Bone Marrow Aspirate)
Safety  
assessments●Physical examination
●Vital Sign
●Height and weight
●ECOG performance status
●Laboratory chemistry and hematology
●Serology
● Electrocardiogram (ECG)
●Echocardiogram
●Pulmonary function tests with DLCO
Other 
assessments●PK sampling (full/sparse)
●Bone Marrow Biopsy
●Patient Report Outcomes (MDASI -CML, PGIC, W PAI, EQ --5D-5L, resource 
utilization)
Data analy sis The primary efficacy variable of the study is the Major Molecular Response (MMR) rate 
at 24 weeks. A patient will be counte d as having achieved MMR at 24 weeks if he meets 
the MMR criteria (BCR -ABL1 ratio ≤0.1%) at 24 weeks.
The MMR rate at 24 weeks will be calculated based on the FAS and according to the 
Intent ionTo Treat (ITT) principle. MMR rate and its 95% confidence interval based on 
the Pearson -Clopper method will be presented by treatment group. Confidence interval 
for the difference in MMR rate between treatment groups will be provided using the W ald 
method.
The Mantel -Haenszel estimate of the common risk difference and the corresponding 
95% confidence interval will also be provided.
The key secondary endpoint is MMR rate at 96 weeks.
Formal statistical testing of the key secondary endpoint will be performed only if the 
primary endpoint is significant by means of a gate keeping procedure to control the 
overall alpha level. 
Key words Phase III, open -label, randomized trial, asciminib, bosutinib, CML-CP, prior treatment 
with 2 or more TKIs

Novartis Confidential Page 17
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Amendment 3 (14-Dec -2018 )
Amendment rationale 
As of 21-Nov- 2018, 13 7patients were screened and 8 6patients were randomized in the study , 
the study  is currentl y ongoing .
The primary  purpose of the amendment is:
Modification of the inclusion criterion of BCR -ABL 1transcript threshold required at study 
entry  from a BCR -ABL1 ratio ≥ 1% IS to BCR -ABL 1ratio >0.1% IS(i.e.not inMMR) for 
patients with intolerance to most recent TKItreatment. The threshold presented in this inclusion 
criteria affects only patients who are intolerant to prior treatment , since patients failing prior 
treatment must fulfill the criteria defined by ELN guidelines (Baccarani et al 2013). Although 
the number of treatment options is increasing, especiall y for patients with imatinib intolerance, 
alternatives for patients with resistance and/or intolerance to at least two previous TKIs are 
limited (NCCN 2018, ELN 2013). The reason of reducing the BCR -ABL 1ratio is that in routine 
clinical practice, physicians do not wait to observe increas
edBCR -ABL 1levels to switch 
treatment in patients with intolerance, which may increase the risk of disease progression, 
especiall y in patients with only limited further treatment options. This is in line with current 
CML  treatment guidelines where the switch to an alternative therapy  in intolerant patients is 
not linked to a BCR -ABL 1threshold (NCCN 2018 , Baccarani et al 2013 and Hochhaus et al 
2017). 
Therefore, the threshold of ≥1% BCR -ABL 1in the current trial is reduced to BCR -ABL 1ratio >
0.1% IS for patients with intolerance to most recent TKI treatment . No more than 66patients 
(approximately  30% of the overall trial population) that are intolerant to their most recent TKI 
therap y with BCR -ABL 1< 1% will be recruited in order to ensure that the CML  third line 
patient population is adequately represented. As the primary endpoint is the rate of MMR at 24 
weeks a baseline molecular response level > 0.1 % BCR -ABL1 is needed.
Patients experiencing documented treatment failure on bosutinib treatment will be allowed to 
switch to asciminib. Patients failing bosutinib treatment will have failed at least their third TKI 
treatment, with limited remaining treatment options. With this amendment patients who have 
failed bosutinib will be offered the po ssibility  to continue in the study  by receiving asciminib , 
if investigators consider that this treatment option is in the best interest of the patient. As of 15 -
Oct-2018, 4 patients could have potentially  benefited from this option. Treatment failure durin g 
study  treatment is assessed by measureable and pre-specified milestones defined by ELN 
criteria (Baccarani et al 2013 ), which are also used to define treatment failure as entry  criteria 
for the study . Only documented treatment failure in the bosutinib arm will be considered for a 
treatment switch. For the purpose of the primary  and secondary  endpoint analy ses, any  patient 
meeting the ELN failure criteria while receiving study  treatment, (either before or by the time 
of conducting the analysis and irrespective of treatment arm), will be considered as non
-
responders for the specific time point and for any subsequent time point. The switch to 
asciminib in case of bosutinib treatment failure is not expected to introduce bias as those 
patients will be regarded as non-responders irrespective of treatment switch and thedisease 
burden will certainly  not improve without further treatment . There is no option to switch 
patients failing on the asciminib treatment arm, as those patients can be offered approved 

Novartis Confidential Page 18
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
therapies outside of the context of the study . The efficacy  data collected after the switch from 
patients switching to asciminib following bosutinib failure will be analyz ed separatel y as 
exploratory  endpoints and will not be included for primary  and secondary  study endpoints. In 
addition, safety  data from patients receiving asciminib after bosutinib failure will be collected 
to further characterize ascimini b’s safet y profile .
Potassium increase of up to 6.0 mmol /L is acceptable at study  entry if associated with creatinin
e 
clearance within normal limits . Grade 2 increase of potassium is acceptable in case of normal 
creatinine clearance as this is not considered to be a risk factor for QTc prolongation. Total 
calci um (corrected for serum albumin) increase of up to 12.5 mg/dl or 3.1 mmol/L (Grade 2) is 
acceptable at study  entry if associated with creatinine clearance within normal limits as this is 
not considered to be a risk factor for QTc prolongation.
A change to creatinine clearance instead of GFR is being made in relation to the magnesium 
inclusion requirement as GFR in this study  is expressed by  creatinine clearance.
Exclusion criteria #19 is being modified under this amendment in order to define theduration 
of the use of highl y effective methods of contraception after the last dose of bosutinib under 
this study  (one month after last dose of bosutinib). This is being done in order to align with the 
latest Bosulif®USPI. 
Exclusion criteria #21 has also been removed under this amendment. In embry ofetal 
development studies with asciminib, fetal malformations (cardiac malformations) and increased 
visceral and skeletal variants were observed in rats and increased incidence of resorptions 
indicative of emb
ryo-fetal mortality  and a low incidence of cardiac malformations indicative of 
dysmorphogenesis were observed in rabbits. Asciminib is not genotoxic. As published in the 
literature, small molecules can distribute to seminal fluid and the seminal accumulati on 
suggested is semen/plasma ratios up to 11.3 ( Klemmt and Scialli 2005 ). According to the FDA 
guidance, in general, there is increased concern for reproductive or developmental toxicity  in 
humans for relative exposure ratios (animal: human) that are <
10 and decreased concern for 
exposure ratios > 25 (FDA Guidance for Industry 2011). The calculations for the asciminib 
safet y margin were done based on C max (plasma) seen in patients at a dose of 200mg BID
(Cmax 6843 ng/ml).  Safety  margin calculation based on the embry o-fetal development study 
in rats was 768 and safety  margin calculation based on the embry o
-fetal development study  in 
rabbits was 894. In conclusion, for asciminib, as outlined above, the safety margins are well 
above 25 and therefore no embry o-and fetotoxicity  effects can be anticipated via seminal fluid.
Removal of male contraception is in line with the Bosutinib USPI  and SmPC.
In addition, patients can be re-screened up to three times forthe study , instead of once.  The 
patient population being investigated in this study is heavil y pre -treated and patients might not 
have other treatment options outside the trial. There can be man y intolerance
-related temporary 
conditions resulting in ineligibility  for the trial.
Recruitment period extension has been reflected in the VES table. Study  length has changed 
with introduction of switch option for patients failing bosutinib treatment.
Patients enrolling in this trial will present a high disease burden after failure of previous 
therapies. Myelosuppression during TKI targeted treatment is a very common effect observed 
due to the suppression of the leukemic clone; this effect is also extended to hematopoiesis of 

Novartis Confidential Page 19
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
stem cells and progenitors (Steegmann et al 2016 ). For this reason, the recovery  period for 
cytopenias has been extended from 28 to 42 daysin order to allow for sufficient time to recover 
from suppression and to re-populate the bone marrow.
The biomarker sampling profile has been revised toremove the gene expression profile in 
leukemic stem cells in both blood and bone marrow due to technical limitations .  In addition, 
there is currentl y no validated assay available.
A clarification has been made to how thetests for blood urea and Blood Urea Nitrogen (BUN)
are noted. The text "blood urea, Blood Urea Nitrogen (BUN)" has been revised to “blood urea 
or Blood Urea Nitrogen (BUN)”
in order to note that either test is permitted .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Change of the purpose of the study  by decreasing the requirement of BCR -ABL1 ratio ≥
1% I S to BCR -ABL 1ratio > 0.1% IS at the time of screening for patients with 
intolerance :
Protocol summary .
Section 2.1 Study  rationale and purpose .
Section 4.1 Description of study .
Section 5.2 I nclusion criteria .
Section 10.5.2 Other secondary  efficacy  objectives .
Change of the stud y design b y introducing the switch to asciminib option for patients 
experiencing treatment failure on bosutinib treatment:
Protocol summary .
Section 2.2 Rationale for the study  design.
Section 4.1 Description of study .
Figure 4 -1 Schematic of Study  Design .
Addition of Section 4.
1.1 Study  treatment switch from bosutinib to asciminib
Section 4.3 Definition of end of study
.
Section 6.1.5 Treatment duration
Section 6.7.3.2 Study  drug accountabilit y.
Section 7 Visit schedule and assessments :
Addition of Table 7 -2 Visit evaluation schedule (study  treatment switch phase ).
Addition of Section 7.1.2.2 Conditions to be fulfilled for asciminib switch.
Section 7.1.5 Visit windows .
Section 7.1.6 Discontinuation of study  treatment.
Section 7.2.1.1 Molecular response .
Section 7.2.1.2 Bone marrow anal ysis and cy togenetics
Section 7.2.2.1 Phy sical examination .

Novartis Confidential Page 20
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Section 7.2.2.2 Vital signs .
Section 7.2.2.3 Height and weight.
Section 7.2.2.4 Performance status .
Section 7.2.2.5 L aboratory  evaluations .
Section 7.2.2.6 Cardiac assessments
.
Section 7.2.3 Pharmacokinetics.
Section 7.2.4 Biomarkers .
Section 10.1.6 Other analysis sets
.
Section 10.5.3.1 Analy sis set and grouping for the anal ysis
Addition of new exploratory  measure for patients that switch from bosutinib to asciminib :
Table 3
-1 Objectives and related endpoints .
Section 10.1.6 Other analysis sets.
Section 10.6 Exploratory objectives:
Section 10.6.1 Exploratory  efficacy  objectives.
Section 10.6.1.1 Data analy sis of exploratory  efficacy  objectives.
Reference for concomitant medications with a “known risk of TdP” has been updated to 
wwwcrediblemeds.org/
Protocol summary
Section 5.3 Exclusion criteria
Section 6.3.2 Dose adjustments for QTcF prolongation
Section 6.4.3 Prohibited concomitant therap y

Section 5.2 I nclusion criteria and protocol summary : updated inclusion criteria to reflect 
the changes below :
Inclusion Criteria #3: As referenced above, the requirement of BCR- ABL1 ratio ≥ 1% 
IS has been decreased to BCR -ABL 1ratio > 0.1% I S at the time of screening for 
patients intoleran t to previous TKI .
Inclusion Criteria #10: Potassium increase of up to 6.0 mmol/L is accepted at study  
entry if associated with creatine clearance within normal limits .  Calcium increase of 
up to 12.5 
mg/dl or 3.1 mmol/L  is acceptable at study  entry  if associated with 
creatinine clearance within normal limits .  GFR replaced b y Creatinine clearance 
(calculated using Cockcroft -Gault formula) in order to maintain consistency  
throughout the protocol as crea tinine clearance is already  calculated based on 
inclusion criteria #7 .
Inclusion 
Criteria #11: As study  eligibility  is assessed during screening with BCR-
ABL1 PCR quantification via international scale this requirement was added as 

Novartis Confidential Page 21
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
clarification. Measureme nt according to international scale is onl y possible for typical 
BCR -ABL1 transcripts .
Section 5.3 Exclusion Criteria and Protocol summary : updated exclusion criteria to reflect 
the following changes:
Exclusion Criteria #14: Removal of P -gp as a moderate o r strong inhibitor of CYP3A
as P-gp inhibitors are no longer prohibited per updated USPI , and SmPC
Exclusion Criteria #19: D uration of the use of highl y effective methods of 
contraception after the last do se of bosutinib has been defined to align with the latest 
bosutinib USPI .
Exclusion Criteria #21 Removal of this criteria in order to align with updated pre-
clinical data.
Section 6.3.1 Dose modification and dose delay: T he recovery  period for cytopenias has 
been extended from 28 to 42 day s in order to all ow for sufficient time to recover from 
suppression and to re -populate the bone marrow .
Table 7-1 Visit evaluation schedule: updates due to inadvertent omissions in previous 
protocols and to reflect extension of study  treatment period
ECOG Performance statu s: X has been replaced by “If needed” under Week 6, Week 
10 and Week 14.
Vital signs: added “If needed” under Week 6, Week 10 and Week 14.
Visit name: “W108, W120, W132, W144, W156” has been changed to “Every  12 
weeks up to end of stud y treatment ” to align with new extended recruitment timelines.
Section 7.1.2 Change of patient re-screening allowance from once to up to three times.
Section 7.1.2.2 Addition of new section with screening eligibility  criteria for patients 
switching from bosutinib to asciminib.
Section 7.1.4 Change of treatment duration for patients including those patients that 
switch to asciminib after failure on bosutinib. Patients can remain on ascimini b treatment 
for up to 96 weeks after the last patient received the first dose in the study  or up to 48
weeks after the last patient has switched to asciminib whichever islonger .
Section 7.1.6 Discontinuation of study  treatment: updated to specify  that the safet y follow -
up visit can be conducted by  telephone and replacement of “aft er randomization” by  “after 
initiation of therapy
” in the event that constitute sa treatment failure .
Section 7.2.2.5.3 Pregnancy and assessments of fertility :Change in requirement for 
reporting pregnancies under this study .  Pregnancies diagnosed in fema le partners of male 
participants are no longer required to be reported to CMO&PS.  Contraception use by  
sexually active males while on 
study  treatment is no longer required.
Table 7- 5 Central clinical laboratory  parameters collection plan: Clarification on blood 
urea and Blood Urea Nitrogen (BUN). The text " blood urea, Blood Urea Nitrogen (BUN) " 
has been revised to “ blood urea or Blood Urea Nitrogen (BUN)”.
Section 8.4 Pregnancies: removal of male contraception requirement due to new 
information of asciminib embry o and fetotoxicity .
Section 10.4.3 Handling of missing values/censoring/discontinuations: imputation rules 
updated to take in account unscheduled vi sits close to visit Week 24.

Novartis Confidential Page 22
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Section 10.5.1.1. Analy sis for key  secondary  endpoints: imputation rules updated to take 
in account unscheduled visits close to visit Week 96 .
Section 14 Appendices :updates to reflect that P -gp inhibitors are no longer prohibited
Section 14.2 Appendix List of concomitant medications for patients on bosutinib :
Removal of P -gp inhibitors from Table 14 -3Prohibited concomitant medications 
for bosutinib arm .
Addition of new medications to Category  Tors ade de pointe (TdP) TdP/QT ris k: 
Known .
Addition of new category , TdP/QT risk: Possible .
Addition of new category , TdP/QT risk: Conditional .
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes descri bed in this 
protocol amendment.

Novartis Confidential Page 23
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Amendment 2 (13-Jul -2018)
Amendment rationale 
As of 29-Jun- 2018, this study  has been submitted in 25 and approved in 24 countries. Eighty 
five (85) sites were initiated, 67 patien ts were screened and 38 patients were randomized in the 
study .
The primary  purposes of the amendment are:
The frequency  of bone marrow aspirate (BMA) to perform cytogenetic analysis has been 
decreased in accordance with treatment guidelines ( European Leuke mia Network (ELN) 
Guidelines (Baccarani et al 2013) , National Comprehensive Cancer Network (NCCN) (Clinical 
Practice Guidelines in Oncology -Chronic Myeloid Leukemia v4.2018). Initially  BMAs were 
foreseen at screening, every  24 weeks thereafter and at end of treatment. With the protocol 
amendment BMA is no longer needed for patients that have achieved MMR during study , 
however BMA asses sment is request ed at the time of end of treatment for biomarker anal ysis. 
Toxicity  studies performed in rats, dogs and cynomolgus monkey sidentified the pancreas as 
potential target tissues. Therefore the assessment for laboratory  parameters that are associated 
with pancreatitis were part of the inclusion criteria (amylase, lipase). Serum lipase is the 
preferred test due to its improved sensitivity , and a threshold concentration of 2-3 x ULN is 
recommended for the diagnosis of pancreatitis. There are a number of other co nditions that can 
elevate lipase, including TKI pretreatment, thus the screening threshold for lipase is increased 
from ≤ULN to ≤ 1.5 x ULN (CTCAE v4.03 grade 1), as patients with history  of acute 
pancreatitis within 1 y ear of study  and history  of chronic pancreatitis are excluded. Amylase is 
not a specific marker for pancreatitis, as up to 60% of total serum amylase originates from non -
pancreatic sources. Its short half-life reduces its value as a diagnostic test in the early clinical 
course. Lipase has r eplaced am ylase as the biochemical test of choice for acute pancreatitis due 
to its higher specificit y (Basnay ake 2015 ), therefore the requirement of amylase ≤ ULN at 
screening has been removed.
Assessme nts for visits at weeks 6, 10 and 14 will be limited to the monitoring of the bone 
marrow function to allow for adjustments of study  treatment. Assessments will comprise a 
complete blood count to detect neutropenia and thrombocy topenia which are among the most 
frequent adverse reactions [Asciminib Investigator ’sBrochure , Bosutinib label] .The physical 
examination must be done at site only  in case of previous or newl y occurring adverse events .
The concomitant medication section has been updated to reflect the most 
recent clinical updates 
on asciminib as well to align with the Bosutinib label .
In addition some minor inconsistencies (discrepancies between sections, typos) have been 
corrected.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
ABL001 has been replaced by International Nonproprietary  Name (INN) asciminib 
throughout the protocol amendment.

Novartis Confidential Page 25
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Section 6.3.1 Dose modification and dose delay : clarification made on treatment 
discontinuation.
Table 6-2 Criteria for dose reduction/ interruption an d re-initiation of asciminib and 
bosutinib treatment for adverse drug reactions: 
Gastro intestinal/ Pancreatitis/Grade 2 : precisions provided and treatment delay  
changed from 7 to 21 day s to give investigators sufficient time for re -assessment.
Removal of “other adverse event” section which was redundant with the section “non -
hematological adverse event reaction except where further specified in individual 
section”.
Mandatory  instructions for grade 3 and 4 “Non- hematological adverse event reaction 
except where further specified in individual section” for bosutinib have been aligned 
with those of asciminib: dose hold until resolved to ≤ grade 1 , to handle the patients 
identically  independent of the treatment assigned.
Section 
6.3.2 Dose adjustments for QTcF prolongation: adapting the dose adjustment
concerning QT prolonging agents to the classification known, possible or conditional risk 
for TdP, and adding the external web link to qtdrugs.org .
Section 6.4.2 Permitted concomitant therapy  requiring caution and/or action: updated with 
the most clinical data available.
Section 6.4.3 Prohibited concomitant therap y (asciminib ):
Section on other anticancer agent added,
Sections on strong CYP3A4/5 inhibitors and P- gp inhibitors: prohibition on P -gp 
inhibitors has been removed and moved under requiring caution and/or action section 
based on CABL001A2102 ADME study ,
Section on strong CYP3A4/5, UGT1A/2B inducers updated to provide instructions on 
action to be taken in case these inducers are taken,
Section on NTI subs trates of CYP3A4/5, CYP2C8 and CYP2C9 removed based on a 
most updated PBPK modeling predicting a negligible risk for sensitive CYP3A4/5, 
CYP2C8, or CYP2C9 substrates and moved under requiring caution and/or action 
section,
Section on QT prolonging agents u pdated to change agents known to prolong QT 
interval to agents with “known”, “possible” or “conditional” risk of Torsades de 
Pointes.
Section 6.5.1 Permitted concomitant therap y requiring caution (bosutinib): has been 
updated to reflect the bosutinib label information regarding the use of QT prolonging agents. 
Section 6.5.2 Prohibited concomitant therap y (bosutinib): 
Section on other anticancer agent added,
Concomitant use with CYP3A4/5 inhibitors/inducers: further clarifications on 
necessary  actions. 
Table 7- 1 Visit evaluation schedule: 
Exploratory  BCR -ABL1 mutation analy sis (Sanger Sequencing) for patients with 
mutations at Week 1 Day 1: rephrased to indicate that this assessment will be 
performed without any dedicated blood collection.

Novartis Confidential Page 28
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Section 10.5.2 Other secondary  efficacy  objectives: update of descriptive statistics 
definition and removal of presentation of p value as no formal sta tistical testing will be 
performed.
Section 10.6.1 Exploratory  efficacy  objectives and Section 10.6.3 Exploratory  biomarker 
objectives
: 
Correction of time points for BCR -ABL1 mutation characterization (baseline 
corrected to Week 1 Day 1, adding “upon confirmed loss of MMR, and changed 
“and” to “and/or” End of treatment).
  
Section 10.6.4.1 Resource utilization: c orrection on duration of resource utilization 
reporting.
Section 10.7 I nterim analy sis:clarification concerning the anal ysis of the key  secondary  
endpoint at week 96 if statistical significance is not reached for primary  endpoint at week 
24.
Section 14 Appendices: the lists of concomitant medications for patients on asciminib and 
bosutinib have been updated based on the internal Pharmacokinetic Sciences 
memorandum on Drug
-Drug Interaction (release date: January 2018).
Some minor inconsistencies (discrepancies between sections, ty pos) have been corrected.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes descri bed in this 
protocol amendment.

Novartis Confidential Page 31
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
Chronic myeloid leukemia (CML) is a hematological stem cell disorder characterized bya 
specific chromosomal translocation leading to the Philadelphia (Ph) chromosome which is 
detected in 95% of patients (Nowell and Hungerford 1960; Rowley  1973). The molecular 
consequence of the translocation is the fusion of the ABL1 proto- oncogene to the BCR gene 
resulting in the production of an activated form of the ABL1 protein tyrosine kinase (TK) 
(Bartram et 
al 1983; Heisterkamp et al 1983 ). BCR -ABL1 drives the growth factor 
independe nce, increased proliferation, genomic instability , suppression of apoptosis and 
alteration of the adhesive properties of CML  cells (Hochhaus 2009) and the expression of BCR -
ABL1 in mice results in the de velopment of a CML -like disease ( Daley  et al 1990; Kelliher et 
al 1990). This evidence that BCR -ABL1 is a genetic driver of CML was subsequently  
confi rmed b y the clinical efficacy of imatinib in patients [IRIS Study  STI571A0106] .
Clinically , CML is characterized by overproduction of immature myeloid cells and mature 
granulocy tes in the spleen, bone marrow and peripheral blood. Most patients, however, pr esent 
in the CP, characterized by splenomegaly and leukocy tosis with generall y few symptoms. CML  
progresses through three distinct phases of increasing refractoriness to therapy : chronic phase 
(CP), accelerated phase (AP), and blast crisis (BC). With conventional chemotherap y, such as 
busulfan or hydroxy urea, the 
median survival time commonly  reported for CML  was about 4 
years, but progression to AP and BP was only slightl y delay ed. Interferon -alfa delay ed 
progression significantl y, with a median survi val of approximately  6 years. However, during 
the last decade, TK inhibitor (TKI) therapy  became the standard treatment for most patients 
with CML , with complete cytogenetic response rates of 70% to 90% and 5-year progression -
free survival and overall surv ival of 80% to 95% commonly  reported ( Vardiman 2009 ).
The National Comprehensive Cancer Network (NCCN) guideline on CML ( NCCN guideline v 
1.2014) and the European L eukemia Net (ELN) ( Baccarani et al 2013 ) recommend continuing 
TKI treatment indefinit
ely in all responding patients. The first TKI, imatinib mesy late (imatinib, 
STI571, Gleevec ™/Glivec™), a n adenosine triphosphate (ATP) -competitive TKI with 
selectivity  towards BCR -ABL1, revolutionized treatment of CML  and significantly  improved 
the prognosis of patients since its approval in 2001. It is effective in most patients with CML at 
well-tolerated d oses, and is indicated as frontline therap y for Ph+ CML -CP and in patients with 
Ph+ CML in blast crisis (BC), accelerated phase (AP), or in CP after failure of interferon -alpha 
therap y. However, despite the remarkable efficacy  of imatinib, some patients are either 
intolerant to the drug or can develop resistance ( O’Hare 2006). Imatinib resistance is primaril y 
due to nucleotide substitutions in BCR -ABL 1, which encode mutant forms of protein’s tyrosine 
kinase domain that impair imatinib binding. Over -expression of the BCR -ABL1 protein may 
also cause resistance. Rates of resistance increase with each stage of progression of CML (CP 
< AP < BC) ( Branford 2003 ).
Multiple agents, including nilotinib, dasatinib, ponatinib, bosutinib, radotinib (Korea) and 
omacetaxine (USA, Canada) are able to combat 
various forms of imatinib -resistant CML  and 
are currently  approved for patients with CML -CP previously  treated with prior therap y. With 
the exception of omacetaxine, which is a cytotoxic chemotherapeutic agent, all of these drugs 

Novartis Confidential Page 32
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
are ATP -competitive TKIs. Like imatinib, nilotinib , dasatinib and most recently bosutinib are 
also indicated for the treatment of patients with newly  diagnosed CML. The activity  of nilotinib 
or dasatinib in patients previously  treated with a second generation TKI is not known. In 
contrast to the ATP -competitive TKIs, asciminib inhibits the enz ymatic activity of BCR -ABL1 
through an allosteric me chanism.
There remains an unmet need for new compounds in patients with CML  who have failed at least 
two prior TKI s. Current practice suggests that a second generation TKI will have been used for 
first line therapy for about one half of patients with CML, meaning that most patients who have 
failed at least two prior TKIs will have failed at least one if not two second generation TKIs: 
dasatinib and/or nilotinib. Potentially , such patients may also have failed bosutinib and/or 
ponatinib (Soverini 2014 ).Patients having failed at least two TKIs ma y hav e limited sensitivity 
to the remaining available agents and, thus, there exists a need for new safe and effective therap y. 
In addition, mutations will have dev eloped in 21 to 33% of patients that prevent the use of 
specific TKIs, increasing the need for a better and alternative compound (Soverini 2014). 
Omacetaxine, a chemotherapeutic agent, is available for patients who have failed at least two 
prior TKIs under these conditions but only in the US and Canada. This agent is not available 
for most patients globally, where a bigger unmet medical need is present. Thus, there remains 
an unmet need for active and safe drugs in patients with CML  who have failed at least two prior 
tyrosine kinase inhibitors (TKI), even in the presence of approved drugs, as described below.
1.2 Introduction to investigational treatment
1.2.1 Overview  of asciminib (ABL001 )
Asciminib is an orally bioavailable specific BCR -ABL 1inhibitor with a novel mechanism of 
action. In contrast to inhibitors such as imatinib, nilotinib ,
dasatinib and bosutinib that bind 
within the ATP -binding site of the ABL kinase domain, asciminib inhibits ABL tyrosine kinase 
activity  by binding to a particular allosteric site on the kinase domain, which has only been 
identified on ABL1, ABL2 and BCR -ABL1. Consequently , asciminib is specifi c for the latter 
three enz ymes.
Asciminib potently  and selectivel y inhibits the proliferation of cell lines that express BCR -
ABL1. By virtue of asciminib not interacting with the ATP -binding site, the drug maintains 
activity  against cells expressing clinically  observed ATP -binding TKI resistance mutations.
1.2.1.1 Non- clinical experience
In vitro and in vivo pharmacology  data
Asciminib display s potent anti-tumor activity in vivo with a clear pharmacokinetic 
(PK)/pharmacod ynamic (PD)/Efficacy  relationship [RD-2013-50145] . In a KC L -22 CML blast 
crisis (CML -BC) cell line mouse subcutaneous xenograft model, tumor regression was 
observed at doses of 7.5mg/kg BID and above when asciminib was administered alone. 
Efficacy  in the KCL -22 xenograft model correlated with stable inhibition of the downstream 
PD marker phospho- STAT5, consistent with finding that ABL1 inhibits STAT5 
phosphory lation in KCL22 cells with an I C90value of approximately  20 nM.

Novartis Confidential Page 33
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
The KCL -22 xenograft model was also used to assess the activity  of asciminib and nilotinib as 
single agents and in combination (Figure 1-1). In these experiments, when each agent was 
administered as monotherapy in sequence, initial sensitivity  of the tumor was observed to each 
agent, but relapse occurred in each case. The mutations observ ed were as expected based on 
clinical experience (T315I  for nilotinib) or modeling (A337V) for asciminib .In contrast, 
animals treated upfront with the combination of asciminib and nilotinib achieved sustained 
tumor regression with no evidence of disease r elapse during the 70 day s of treatment or for 80 
days following discontinuation of treatment. Note that in this KCL -22 model, the cells (derived 
from a blast crisis CML  patient) were grown as a solid tumor rather than as disseminated disease.
Also, this model is much more aggressive than chronic phase CML in patients.
Figure 1-1 KCL-22 CML Xenograft
These data are consistent with asciminib being active against nilotinib -resistant mutations and 
nilotinib being active against asciminib -resistant mutations. Consequently , the findings support 
development of asciminib both as single agent as well as in combination with TKIs as initial 
therap y ofCML as well as therap y after progression on nilotinib.
In addition, due to asciminib specifically  targeting the ABL kinase family  (ABL1, ABL2, BCR -
ABL 1), asciminib offers the potential for improved safet y and tolerability  when administered 
as monotherap y when compared to TKIs binding to the ATP site of BCR -ABL 1, which are less 
specific towards ABL. Thus, there is the potential for an improved safety  profile of asciminib
in comparison to other TKI s.
Safety  pharmacology and toxicology
An extensive toxicology safet y evaluation program (subchronic, chronic, reproductive 
toxicology , phototoxicity  and genotoxicity  studies) was conducted.
Safety  pharmacology  studies indicate that asciminib is not expected to cause effects on the vital 
functions of the CNS, and therespiratory  systems. The IC50 for asciminib in the hERG patch 
clamp is 11.4 μM (4498 ng/mL). No cardiovascular effects were observed in a single dose 
jacketed telemetry  study in dogs at doses up to 600 mg/kg or the invasive telemetry 
cardiovascular safet ystudy  up to 60 mg/kg. Furthermore, no changes in cardiovascular 
parameters related to QTc prolongation were observed using standard electrocardiograph y in 
the 4-week dog toxicity  study and in cynomolgus monkey  toxicity  studies (up to 39 weeks of 
treatment ).
Asciminib does not show mutagenic, clastogenic, or aneugenic potential in the in vitro assay s 
or the MNT assessment in vivo ; therefore, no potential risk for human is perceived.

Novartis Confidential Page 34
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
As determined by  the results of the phototoxicity  assessment ( in vitro and in vivo ), phototoxic 
potential was identified in the mouse UV-LLNA assay . Given these data, patients should be 
advised to avoid prolonged exposure to sunlight (sunbathing) , to avoid sunbed and to use 
sunscreen.
Toxicity  studies performed in rats, dogs and cynomolgus monkey s (up to 26, 4 and 39 weeks 
of treatment, respectively) identified the pancreas, liver, hematopoietic system, adrenal and 
gastro -intestinal tract as potential target tissues. 
Fetal malformations and increased visceral and skeletal variant s were observed in the rat 
embry o-fetal development study . There was no evidence of effects on reproductive function in 
the fertility stud y; however there was a slight effect on male sperm motility and/or sperm count 
in individual animals. Phototoxic potential was identified in the phototoxicity  (in vitro and in 
vivo) assessment.
Please refer to the latest [Asciminib Investigator’s Brochure] for more details.
Non- clinical pharmacokinetics and metabolism
The preclinical pharmacokinetic profile of asciminib has been investigated in three species: 
mouse, rat and dog. In these species, asciminib exhibited low to moderate clearance, a moderate 
volume of distribution and a short apparent terminal half-life. Bioavailability  was found to be 
low in rodents and mode rate to high in dog.
Asciminib display ed high plasma protein binding across all teste d species (2- 6% free fraction).
The metabolite profile of asciminib has been examined in vitro using rat, dog, monkey  and 
human hepatocy tes. Interspecies differences were observed in the in vitro metabolism of 
asciminib in hepatocy tes, with direct glucuronidation occurred more readily  in human , to a 
lesser extend in dog andmonkey ,and was noticeably  absent in rat. However, no unique, major 
metabolites were identified in hu man hepatocy tes. The overall metabolic turnover was low.
The metabolite profile of asciminib has also been examined in vivo in rats. Following 
intravenous and oral administration of [14C-asciminib ] to intact rats, asciminib was found to be 
the predominant component of plasma, accounting for ~86 -91% of radioactivity  from 0 -8 h. 
Asciminib was excreted primarily in the feces, with ~90% of radioactivity detected in the feces 
from 0 - 48 h. Renal elimination represented a minor route, with ~2.4% of radioacti vity detected 
in the urine from 0 - 72 h. In the feces, ~58% (intravenous) and ~71% (oral) of the dose was 
associated with unchanged asciminib , with several oxidative metabolites accounting for the 
remaining radioactivity. The metabolites formed in vivo were consistent with those observed in 
vitro. Similar observations were noted in bile -duct cannulated rats.
To assess for potential drug-drug interactions (DDI), studies have been conducted with 
cytochrome P450 (CYP) enzy mes and several transporters in vitro.
In human liver microsomes, the major metabolic route of asciminib was found to be 
glucuronidation, followed by oxidative metabolism, consistent with findings from human 
hepatocy tes. Several Uridin diPhospho- glucuronosy ltransferase (UGT )enzy mes were found to 
be capable of asciminib glucuronidation (UGT1A3, UGT1A4, UGT2B7, and UGT2B17). The 
oxidative metabolism of asciminib was also cataly zed by several CYP enzymes. CYP3A4/5 
appears to contribute the most, followed by CYP2C8, CYP4F12, and potentially  CYP2D 6.

Novartis Confidential Page 35
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Though the DDI risk with inhibitors of these enzy mes is likely to be minimal, inhibitors of 
CYP3A4/5 still have the potential to increase asciminib concentration. Therefore, strong 
inhibitors of CYP3A4/5 should be avoided and are prohibited in this study . Strong inducers of 
CYP3A4/5 have the potential to reduce asciminib concentrations. Therefore, the use of strong 
inducers of CYP3A4/5 or UGT1A/ 2B is prohibited in this trial.
In recombinant cellular expression systems, asciminib was identified as a substrate of Breast 
Cancer Resistant Protein (BCRP) ( Michaelis-Menten constant (Km) ≈ 4 µM) and permeability 
glycoprotein (P-gp) (Km could not be estimated due to insufficient saturation of efflux activity ). 
Late fecal metabolite analy sis in the human 
Absor ption, Distribution, Metabolism, and 
Excretion (ADME) study  [CABL001A2102] and estimated contributions of different enzyme 
pathway s (CYP vs. UGT) by  use of in vitro enzyme phenoty ping methods, do suggests that at 
least 24% of the parent drug in the feces is due to conversion of a glucuronide (M30.5) 
metabolite back to parent drug (absorption then being maximally  57%). However, this late fecal 
metabolite analy sis could also suggest that the 24% could be active secretion by P-gp (Drug 
Metabolism and Pharmacok inetics [DMPK R1700912] . This is a small percentage (< 25% of 
the clearance by this pathway ) with a weak expected impact on asciminib concentrations. 
Overall, inhibitors of BCRP and P -gpmay increase asciminib concentration. Therefore, BCRP 
and P -gp inhibi tors should be administered with caution.
Based on in vitro phenotyping studies and human ADME study  outcome, the physiologicall y 
based pharmacokinetic (PBPK) model was updated and predicted minimal to no DDI for 
sensitive substrates of CYP3A4, CYP2C8 and CYP2C9 (Drug Metabolism and 
Pharmacokinetics [DMPK -DDI-R1700912] . Indeed, the effect of asciminib 40 mg BID is 
expected to result in increased area under the curve (AUC) of CYP3A4, CYP2C8 and CYP2C9 
probe substrate by 1.21, 1.09 and 1.07. Therefore, the effect of asciminib is expected to be weak 
and hence substrates of CYP2C8, CYP2C9 and CYP3A4 with narrow therapeutic index (NTI) 
would be used with caution. 
Please refer to the latest [Asciminib Investigator ’sBrochure] version for more details.
1.2.1.2 Clinical experience
Asciminib is undergoing evaluation in a first-in-human (FIH) phase I clinical study , study 
[CABL 001X2101] .
This study  evaluates patients with 1) CML who have been treated with at least 2 prior TKIs, or 
2) who have the T315I mutation and have been treated with at least 1 prior TKI, or 3) who have 
Acute Lymphoblastic L eukemia (ALL) and have been treated with at least 1 prior TKI. The 
study  evaluates administration of asciminib in a BID single agent dosing schedule, as well as 
in a QD single agent schedule, and in combination with nilotinib, imatinib, and dasatinib. I n the 
present document, discussion will focus on data from CML  patients treated wit h asciminib BID 
single agent only .
As of 01-Sep-2017, a total of 239CML  or Ph+ ALL patients have been treated with either 
single agent oral asciminib or in combination cohorts. 150 CML patients have been treated with 
asciminib monotherap y. Based onthe preliminary  efficacy , safet y and tolerability  inpatients
with CML -CP or CML -APtreated with asciminib asa single agent on a BID schedule in 
study [CABL001X2101] and the results of a population PK/PD exposure -response model , the

Novartis Confidential Page 36
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
dose of 40mg BI D has been selected as therecommended dose to be used in future studies in
patients with CML -CP who do not harbor T315I mutations.
Efficacy :
Preliminary  data from the ongoing Phase I FIH study  [CABL001X2101] indicate that asciminib 
exhibits single -agent activity  in patients with CML who have failed at least two prior TKIs or 
are intolerant to TKIs, as demonstrated by major molecular response and reduction in the BCR -
ABL1 % IS. Asciminib has demonstrated anti -tumor activit y at doses greater or equal to 10 m g 
BID as well as dail y higher doses.
To date, efficacy  data in 141 patients with chronic -phase CML  treated with single agent 
asciminib therapy  (10-200 mg BID and 80-200 mg QD) are available (113 patients without 
T315I  mutation and 28 with T315I  mutation). 
Of the 62 
patients with BCR -ABL 1 no greater than 10 % IS at screening and without T315I 
mutation, 1-log reduction of BCRABL1 % IS was achieved in 16 of 62 (25.8%) patients by 6 
months and 19 of 62 (30.6%) patients by  12 months. For asciminib 40 mg BID dose, of the 17 
patients studied, 1 -log reduction of BCRABL1 % IS was achi eved in 5 of 17 (29.4%) patients 
by 6 months, and 12 months. 
Please refer to the latest [Asciminib Investigator’s Brochure] for more details.
Safety :
Asciminib was generally well tolerated in heavily  pre-treated CML  patients resistant to or 
intolerant of prior TKIs. All 239patients were evaluable for safety . Seventy  six study  
discontinuations have been reported; the most frequent reason for discontinuation was 
progressive disease, reported in 38 patients (15.9%). Adverse events leading to treatment 
discontinuation were reported in 15 patients (6.3%). Death leading to treatment discontinuation 
was reported in 3 patients (1.3%) (one patient in asciminib 20 mg BID due to aspiration 
pneumonia after b ypass procedure and two patients with ALL with 80 mg and 160 mg BID due 
to progressive disease ).
Among the 150 patients treated with asciminib monotherap y, almost all (94.7%) patients 
reported at least one AE, including 49.3% reported grade 3/4 AEs. The most common AEs (>
10%) among patients treated with 40mg BID (n=35), regardless of study  drug-relationship, 
were increased lipase, fatigue, diarrhea, thrombocy topenia, neutropenia, arthralgia, rash, 
headache, increased amylase, nausea, vomiting, abdominal pain, pyrexia, upper respiratory  tract 
infection, back pain, hypertension, cough, pruritus, pain in extremity , dyspnea, bone pain, 
peripheral oedema, non -cardiac chest pain and insomnia. The most common reported grade 3/4 
event was increased lipase (17.1%).
Forty-seven of 150 patients with CML -CP or CML -AP treated with asciminib single agent 
(31.3%) were reported with serious adverse events (SAE) .
Electrocardiogram (ECG )data shows no reported QT prolongation (increase > 60 msecor new >
500 msec) in 40 mg BID asciminib monotherapy  group. There was no reports of QT 
prolongation (increase > 60 msec) and two reports of new >500 msec(one each in 80 mg QD 
and 120 mg QD) among all asciminib monotherapy group.

Novartis Confidential Page 37
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Please refer to the latest [Asciminib Investigator’s Brochure] for more details.
Pharmacokinetics:
PK data from 190 patients were available from the [CABL 001X2101] study , as of 01-Sep-2017.
When given as a single agent on a twice daily schedule, patients received 
escalating doses of 
asciminib ranging from 10 to 200 mg .
Based on the available PK data, asciminib , administered orally  is rapidly  absorbed with a 
median time to maximum plasma concentration (Tmax) of 2 to 3 hours, independent of dose. 
Systemic exposure of asciminib , following oral administration of single and multiple doses, as 
measured by Cmax and AUC, increa sed in an approximately  dose proportional manner. The 
variability  of exposure is low to moderate with inter-patient variability  (geometric mean CV %) 
ranging from approximately  25 to 70% for both Cmax and AUClast . With the twice daily  dosing 
regimen, media n plasma asciminib accumulation ratios ranged from 1.3to 2.5.The median 
accumulation half -life was estimated to be 7 to 15 hours.
The data of the hADME study  [CABL001A2102] show that the relative contribution of the 
glucuronidation pathway  to the total clearance of asciminib via metabolism is estimated to range 
from 30% to 61%, whereas the relative contribution of the oxidative pathway  is estimated to 
range from 35% to 63%. CYP3A4 was the main contributor for the clearance of asciminib via 
the oxidative pathway  while UGT2B7 and UGT2B17 were responsible for the clearance of 
asciminib via 
the glucuronidation pathway . There was no metabolite detected with mean 
contribution to plasma radioactivity  AUC0- 24hours ≥ 10%. Asciminib was the predominant 
drug-related component in plasma at all time points analy zed, ranging from 91.9 to 94.2% of 
the total radioactivity  AUC0 -24 hours AUC, with an average value of 92.7%.
Please refer to the latest [Asciminib Investigator’s Brochure] for more details.
Exposure -response relationship:
Exposure -efficacy
A preliminary  population PKPD model has been developed using data from the 
[CABL 001X2101] study  (cut-off 02-May-2016). The time course of molecular response 
(change in BCR -ABL 1ratio % IS levels from baseline) was described using a semi -
physiological model accounting for cell maturation, disease progr ession and existing resistance.
Simulations performed using an asciminib population PK model revealed that a dose of 40 mg 
BID maintains Ctroughs above the clinical (0.07 to 61 ng/m L) threshold in ≥95% of chronic 
phase CML patients without T315I  mutation having failed ≥
2 TKI or intolerant to TKIs. The 
estimates from this clinical study  were found to be similar to the threshold trough concentration 
required for 90% inhibition of pSTAT5 derived from a preclinical PK-PD KCL - 22 mouse 
xenograft model (free IC90: 30 to 121 ng/mL, after correction for protein binding) and in vitro
gIC50 assessed in the KCL -22 cell line (1 ng/mL  = 2.1 nM after correction for protein binding).
Simulations performed using asciminib population PKPD model revealed that chronic phase 
CML  patients having failed ≥ 2 TKI or intolerant to TKIs are likely to exhibit a 1 log10 
reduction of (%) BCR -ABL 1mRNA transcript levels from baseline of ~33% (CI95%: 24-42%) 
at 6months, and ~42% (CI95%: 32-52%) at 12 months at a dose of 20 mg BID and ~41% 

Novartis Confidential Page 38
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
(CI95%: 31-51%) at 6 months, and ~53% (CI95%: 43-63%) at 12 months at a dose of 40 mg 
BID.
Additional preliminary  exposure response analy ses (i.e. exploring the relationship bet ween PK 
and both safet y and effic acy) support the selected dose.
Food effect
The effect of food on asciminib PK was characterized in a Phase I study  [CABL001A2101] in 
healthy  volunteers. Food was found to 
influence the pharmacokinetics of asciminib . When 
administered with a low-fat meal, the exposure (AUC) decreased by approximately  30%. The 
overall exposure decreased by approximately  65% when administered with a high-fat meal.
Therefore, asciminib will be administered in a fasted state.
1.2.2 Overview  of bosutinib
Bosutinib (Bosulif®) is indicated for the treatment of adult patients with newly -diagnosed 
chronic phase (CP) Philadelphia chromosome -positive chronic myelogenous leukemia (Ph+ 
CML ) and for the treatment of patients with chronic, accelerated, or blast phase Ph+ chronic 
myelogenous leukemia (CML ) with resistance orintolerance to prior therapy  (500 mg QD) 
[Bosulif®USPI ]as well as for newl y-diagnosed CML -CP (400 mg QD) , and in Europe for the 
treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase 
(BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML ) previously 
treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and 
dasatinib are not considered appropriate treatment options [EU Summary  of Product 
Characteristics (SmPC) ]. Bosutinib has been evaluated in patients treated with one or more prior 
TKIs.
For patients treated with bosutinib after prior imatinib only, the MMR rate is approximately 15% 
at 24 weeks ov erall, and approximately  10% in imatinib -resistant patients and 20% in imatinib -
intolerant patients ( Gambacorti -Passerini 2014 ). The cytogenetic, molecular, and hematological 
response rates did not appea r to differ greatl y between patients who were imatinib -resistant or 
imatinib -intolerant ( Gambacorti -Passerini 2014 ).
Twenty  seven percent of patients treated with bosutinib after at least 2 previous TKI s achieved 
MCy R rate by Week 24 [Bosulif®USPI ]. For patients previously  treated with imatinib and 
either dasatinib or nilotinib, after a median of 28.5 months follow -up, the cumulative rate of 
Major Molecular Response (MMR) is 15% (Khoury  2012). The cytogenetic, molecular, and 
hematological response rates appeared to be lower in patients who 
were resistant to dasatinib 
after imatinib treatment as compared to patients who were intolerant to dasatinib after imatinib 
treatment ( Khoury  2012). In a small (30 patient) compassionate use trial of patients previously 
treated wit
h imatinib, dasatinib and nilotinib, after a median duration of treatment of 9.3 months, 
the cumulative MMR rate was 14% (García -Gutiérrez 2015). Based on these data, the MMR 
rate at 6 month with bosutin
ib treatment in patients treated with at least 2 prior TKIs is estima ted 
to be approximately  10-15%.
Bosutinib has no activity  against the T315 I and V299L mutant form of BCR -ABL 1. 
Accordingl y, the pivotal trial leading to the registration in the 3rdline s etting excluded patients 
with a known history  of the T315I or V299L mutation [Bosulif®USPI ].

Novartis Confidential Page 39
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
2 Rationale
2.1 Stud y rationale and purpose
Asciminib is an agent intended to be evaluated for the treatment of patients with CML .In the 
ongoing study [CABL001X2101] study, asciminib was found to produce clinically meaningful 
and durable responses in patients who have had treatment failure after a minimum of 2 prior 
ATP -binding site TKIs, with an acceptable sa fety and tolerability profile.
The purpose of this pivotal st udy is to compare the efficacy  of asciminib with that of bosutinib 
in the treatment of patients with CML -CP having previously  been treated with a minimum of 
two prior ATP -binding site TKIs. Patients with intolerance to most recent TKI therapy  must 
have BCR -ABL 1ratio >  0.1% I S at screening and patients experiencing failure to most recent
therap y must meet the definition of treatment failure as per the 2013 ELN guideline s (Baccarani 
et al 2013 ).
Imatin ib, nilotinib and dasatinib are indicated for the treatment of patients with newly  diagnosed 
CML . Multiple agents, including nilotinib, dasatinib, ponatinib, bosutinib, radotinib (Korea) 
and omacetaxine (USA, Canada) are approved for patients with CML -CP previousl y treated 
with prior therap y. Imatinib is a first generation TKI; nilotinib, dasatinib, bosutinib, ponatinib 
and radotinib are considered second generation TKIs 
and have activity  in patients previousl y 
treated with imatinib. The activity  of nilotin ib or dasatinib in patients previously  treated with a 
second generation TKI is not known. All the currentl y approved BCR- ABL 1TKIsare 
enzy matic site inhibitors, in distinction to asciminib which is an allosteric TKI. Omacetaxine is 
a cytotoxic chemotherap eutic agent.
2.2 Rationale for the study  design
Asciminib is an orally bioavailable specific BCR -ABL1 inhibitor with a novel mechanism of 
action. In contrast to other TKIs that bind within the ATP -binding site of the ABL  kinase 
domain, asciminib inhibits ABL tyrosine kinase activity  by binding to a particular allosteric site 
on the kinase domain that is utilized by a m yristate group to auto- regulate the native ABL1 
kinase. With allosteric inhibition of BCR -ABL 1being a novel mechanism of action, asciminib
produces clinically  meaningful and durable responses in patients who have had treatment failure 
after a minimum of 2 prior ATP -binding site TKIs, with an acceptable safety  and tolerability 
profile as demonstrated in study  [CABL001X2101] .
The development of asciminib , presents an opportunity  to evaluate the beneficial 
effects of 
inhibition of BCR -ABL 1in the treatment of patients with CML .The proposed study  design is 
expected to adequatel y allow an assessment of the efficacy, safet y and to lerability  of asciminib
in a population of patients with continuing medical need i.e., patients who have been treated 
with at least two prior TKI s and are in the need for further therapeutic intervention.
Bosutinib is one of the TKIs with proven clinical benefit in CP-CML  patients previously  treated 
with one or more tyrosine kinase inhibitor(s) and is currentl y approved for 
this indication in 
many  countries, including the European Union. The proposed study  will evaluate asciminib in 
comparison to bosutinib at the approved doses in the targeted population.

Novartis Confidential Page 42
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Additional preliminary  PK-efficacy  and PK-safety  analyses to assess the exposure -response 
relationship for asciminib were conducted ( Section 1.2.1.2). The efficacy measure used was 
Molecular Response (MR) which is defined as a decline in BCR -ABL 1transcript levels in 
clinical blood samples of patie nts with Chronic My eloid Leukemia (CML). MR was evaluated 
as both a continuous variable (BCR -ABL 1transcript levels) and categorical variable (whether 
or not adequate decline in BCR -ABL 1was achieved). The safet y measures used were 
occurrence of Common Tox icity Criteria (CTC) grade 2, 3 or 4 laborator y values for lipase and 
amylase.
Reviewing the totality  of the efficacy , safet y, and pharmacokinetic data derived from the 
[CABL 001X2101] study, the recommended dose for asciminib in this phase 3 study  is 40 mg 
BID. Of note, the dose of asciminib single agent BID is further being evaluated in patients with 
the T315I mutation. At present the recommended dose of 40 mg BID is for patients without the 
T315I  mutation. For this reason, patient s with the T315I  mutation are excluded from this study .
2.4 Rationale for choice of combination drugs
Not Applicable.
2.5 Rationale for choice of comparators drug bosutinib
The guidance provided by the NCCN and the ELN (Baccarani et 
al 2013), recommends 
bosutinib as a treatment in CML -CP patients who fail first-line or second -line treatment with 
imatinib or nilotinib or dasatinib. Consistent with these recommendations and
clinical practice, 
bosutinib was selected to be an appropriate comparator in a study  of 3rdline CML -CP patients 
after failure of at least 2 prior TKIs, and is the comparator that will be used in the present study .
It is to be noted that bosutinib has no activity  against the T315I  and V299L mutant form of 
BCR -ABL 1. Patients who have the T315I  or V299L mutations documented in their medical 
record will alread y be excluded from this study. Bosutinib is known to be active against 
E255K/V, F317L/V/I/C, F359V/C/ I, T315A, and Y253H and therefore, these mutations are not 
considered in the exclusion criteria for the current study .
Ponatinib is not selected as the comparator in the present clinical trial, because the comparator 
in this study  needs to be 
an approved agent administered at the approved dose. Currentl y, the 
ponatinib dose is being evaluated in a randomized trial as a post-approval commitment due to 
the occurrence of vascular risks at the current approved dose of ponatinib. The dose of ponatinib 
that will be approved and will be used in practice at the completion of the present study  may 
not be the approved dose at the time of initiation of the present study .
2.6 Risks and benefits
Appropriate eligibility  criteria, as well as specific dose modification and stopping rules in the 
event of expected toxicities, are included in this protocol. Recommended guidelines for 
prophy lactic or supportive treatment for expected toxicities, including management of study -
drug induced adverse events are provided in Section 6.3. Patients who have failed 2 prior TKIs 
are at increased risk of progression to more advanced phases of CML such as CML -AP and 
CML -BC. Currentl y available therapeutic agents in this setting are non-curativ e and patients 
remain at risk of progressing after short duration of remission
s (Khoury  2012 ).

Novartis Confidential Page 43
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
An important potential risk for patients enrolling on the experimental arm of the study  with 
asciminib will be that this agent may be ineffective. However, the evidence to date at the doses 
to be administered in a similar population of patients in the study  [CABL001X2101] suggests 
that asciminib is an active agent. Further, the adverse event profile of asciminib is similar 
qualitatively  to that observed with other TKI s targeting BCR -ABL1 ( Section 1.2.1.2). The risk 
of asciminib not being effective has been mitigated in that patients will be observed closel y for 
evidence of efficacy , based on assessment of hematologic, cytogenetic and molecular response 
data, which will permit rapid decision making as to discontinuation of therapy  if necessary .
Other risks to subjects in this trial will be minimized by  complianc e with the eligibility  criteria 
and study  procedures, close clinical monitoring, and adherence to dose modification and 
interruption guid ance provided in the protocol.
The currentl y available information suggests that there is equivalence between the two a rms 
with respect to benefit / risk to enable inclusion of patients in this study .
There may be unforeseen risks with asciminib which could be serious. Refer to the latest 
[Asciminib Investigator’s Brochure] for additional details.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1 below.

Novartis Confidential Page 44
Amended Protocol Version 03 ( Clean ) Protocol No. C ABL001A2301
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary
To compare the MMR rate at 24 weeks of asciminib versus 
bosutinib Major Molecular Response (MMR) rate at 24 weeks Refer to Section 10.4
Key secondary
To compare additional parameters of the efficacy of asciminib 
versus bosutinib MMR rate at 96 weeks Refer to Section 10.5.1
Other secondary
To compare additional parameters of the efficacy of asciminib 
versus bosutinib● C ytogenetic response rate (Complete, Partial, Major, Minor, Minimal, 
no response) at and by all scheduled data collection time points 
including 24, 48 and 96 weeks
●MMR rate at all scheduled data collection time points (except 24 and 
96 weeks which are already covered by primary and key secondary 
endpoints)
●MMR rate by all scheduled data collection time points including 24, 
48 and 96 weeks
●Time to MMR
●Duration of MMR
●Time to CCyR
●Duration of CCyR
●Time to treatment failure
●Progression free survival
●Overall survivalRefer to Section 10.5.2
To compare the safety and tolerability profile of asciminib versus 
bosutinibType, frequency and severity of adverse events,
changes in laboratory values that fall outside the pre -determi ned ranges 
and clinically notable ECG and other safety data (vital signs, physical 
examination)
To characterize the PK of asciminib in the CML -CP population
To assess the safety of asciminib when administered as 
treatment after bosutinib failure according to the 2013 ELN 
GuidelinesTrough plasma concentrations,
PK parameters in full PK group: Cmax, Tmax, AUC0 -12h, CL/F
Type, frequency and severity of adverse events, c hanges in laboratory 
values that fall outsi de the pre -determined ranges and clinically notable 
ECG and other safety data (vital signs, physical examination)Refer to Section 10.6

Novartis Confidential Page 46
Amended Protocol Version 03 ( Clean ) Protocol No. C ABL001A2301
Objective Endpoint Anal ysis
Time to MMR
Duration of MMR
Time to CCyR
Duration of CCyR
Time to treatment failure

Novartis Confidential Page 47
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
4 Study  design
4.1 Description of study  design
The study  is a phase 3, multi- center, open -label randomized study  of oral asciminib versus 
bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML -CP), 
previously  treated with 2 or more tyrosine kinase inhibitors.
The trial is designed to compare the efficacy  and safet y of asciminib with that of bosutinib in 
the treatment of patients with CML -CP having previously  been treated with a minimum of two 
prior ATP -binding site TKIs. Patients intolerant to the most recent TKI therapy must have BCR -
ABL 1ratio > 0.1% ISat screening and patients failing their most recent TKI therapy must meet 
thedefinition of treatment failure as per the 2013 ELN guidelines (Baccarani et al 2013 ).No 
more than 6 6patients (approximately  30% of the overall trial population) that are intolerant to 
theirmost recent TKI therapy  with BCR -ABL 1< 1% will be recruited in order to ensure that 
the CML  third line patient population is adequately represented.
The study  will also investigate secondary  endpoints for efficacy , safety  and PK of single- agent 
asciminib compared to bosutinib. Tolerability , PK, PRO and exploratory  biomarker activities 
will also be assessed. Safet y and efficacy  data for patients switching to asciminib will be 
collected and analyzedseparatel y.
Patients meeting all of the inclusion and none of the exclusion criteria will be randomized into 
one of the 2 treatment arms, based on a 2:1 randomization betw een the asciminib arm and the 
bosutinib arm.
The randomization will be stratified to ensure the study  population is balanced between the 
arms with respect to cy togenetic response status (See Section 7.2.1.2
) at screening as follows:
Major c ytogenetic response (complete or partial)
No major cy togenetic response (minor, minimal or none)
Patients will continue to receive the assigned study  treatments (asciminib or bosutinib) until 
the end of study  treatment period as defined in Section 4.3. Patients who discontinue their study  
treatment at any time during the study  will be followed up for survival and for progression to 
AP/BC for up to 5 years from the date the lastrandomized patient receive sthe first dose 
(irrespective of treatment switch for patients failing bosutinib).
Serial PK samples over 12 hours will be collected on Week 2 Day  1 from at least 20 CML -CP 
patients (full PK group) on the asciminib arm, in addition to trough PK samples. These patients 
will be identified sequentially  at selected sites that are capable of serial PK sampling over 12 
hours. In the remaining patients in the asciminib arm and in patients that have switched to 
asciminib , 
sparse post-dose PK samples on Week 1 Day 1  and trough PK samples will be 
collected (sparse PK group).

Novartis Confidential Page 48
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Figure 4-1 Schematic of Study  Design
4.1.1 Study treatment switch from b osutinib to asciminib
Patients with documented treatment failure ( as per the 2013 ELN guidelines; Baccarani et al 
2013) while on bosutinib treatment will have the option to switch to asciminib treatment within
96 weeks after the last patient has been randomized on study . The patients who switch to 
asciminib will be able to receive asciminib up to end of study  treatment period .
At the end of 
the treatment period for patients who,in the opinion of the investigator still derive clinical 
benefit, asciminib treatment will be made available through alternative options including, but 
not limited to, an expanded access/compassionate use/managed access program or access to 
commercial supplies in applicable countries . Discontinuation of asciminib for patients who
have switched over from bosutinib must follow the guidelines provided in Section 7.1.6.
Eligibility  criteria for patients switch
ingto asciminib are described in Section 7.1 .
4.2 Timing of interim analy ses and design adaptations
Not applicable. There are no formal interim analy ses or design adaptations planned for this 
study . See Section 8.6 for documentation of safety DMC.
4.3 Definition of end of study
The patients are treated in the study  up to end of study  treatment period defined asup to96 
weeks after the last patient receives the first dose or up to 48 weeks after the last patient has 
switched to asciminib treatment whichever is longer unless patients have discontinued treatment 
earlier . The end of the study ,concluding the survival follow -up, will occur 5 years from the 
date when the last patient enrolled into the study  receive sthe first dose of the randomized 
treatment.
The primary  analysis (cut-offdate) is defined as the date when all randomized patients have 
been on study  treatment for 24 weeks (Section 10.4) or discontinued earl ier. Subsequent to this 

Novartis Confidential Page 49
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
analysis, the primary  clinical study  report (CSR) will be developed. Following the cut -off date 
for the primary  CSR, the study  will remain open. Patients who are ongoing at the time of the 
primary  analysis will continue to receive the assigned study  treatments (asciminib or bosutinib)
during the study  treatment period as defined above . The end of study  treatment analysis will be 
conducted with a cut-off date 30 days after the end of study  treatment period to ensure all 
available treatment data from all patients in the study  is anal yzedand summarized in a CSR .
After the end of the stud y treatment period the assigned study treatment will be made available 
to patients who in the opinion of the Investigators are still deriving clinical benefit. This may 
be outside of this study  through alternative options including, but not limited to, an expanded 
access/compassionate use /managed access program or access to commercial supplies in 
applicable countries.
Patients will be followed for survival and progression for up to 5 years from the date the last
randomized patient receive sthe first study  dose(irrespective of treatment switch for patients 
failing bosutinib) . Information on subsequent treatments will also be collected. An updated 
analysis of OS and PFS will be performed at the end of the follow -up period in the final study  
CSR.
4.4 Early study  termination
The study  can be terminated at any  time for any  reason by  Novartis. Shou ld this be necessary, 
the patient should be contacted as soon as possible and instructed to stop taking study 
medication. The end of treatment visit should be scheduled and the same assessments should 
be performed as described in Section 7 for a discontinued or withdrawn patient. The investigator 
may be informed of additional procedures to be followed in order to ensure that adequate 
consideration is given to the protection of the patient’s interests. The investigator will be 
responsible for informing I RBs and/or ECs of the earl y termination of the trial.
5 Population
5.1 Patient population
Two-hundred and twent y-two (222) patients with CML -CP who had prior treatment with two 
or more ATP binding site TKIs will be randomized in a 2:1 fashion to recei ve either asciminib 
or bosutinib. No patients with a medical history of the T315I or V299L mutation at study  entry 
will be included in the trial. Previous medical records should be used to confirm the patient’s 
mutati onal status/history .
The definition of CML -CP will be according to the European Leukemia Network (ELN) criteria 
(Baccarani et al 2013 ), and is outlined below in the inclusion criteria.
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered treatment in the study .
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all of the following criteri a:
1. Male or female patients with a diagnosis of CML- CP ≥ 18 y ears of age

Novartis Confidential Page 50
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
2.Patients must meet all of the following laboratory  values at the screening visit:
< 15% blasts in peripheral blood and bone marrow
< 30% blasts plus promyelocy tes in peripheral blood a nd bone marrow
< 20% basophils in the peripheral blood
≥ 50 x 109/L (≥ 50,000/mm3) platelets
Transient prior therap y related thrombocytopenia (< 50,000/mm3for ≤ 30 day s prior 
to screening) is acceptable
No evidence of extramedullary  leukemic involvement, with the exception of 
hepatosplenomegal y
3a.  BCR -ABL 1ratio >0.1% I S according to central laboratory  at the screening examination , 
for patients intolerant to the most recent TKI therapy
4.Prior treatment with a minimum of 2 prior ATP -binding site TKIs (i.e. imatinib, nilotinib, 
dasatinib, radotinib or ponatinib)
5.Failure (adapted from the 2013 EL N Guidelines ;Baccarani et al 2013) or intolerance to 
the 
most recent TKI therapy  at the time of screening 
Failure is defined for CML- CP patients (CP at the time of initiation of last therapy ) as 
follows. Patients must meet at least 1 of the following criteria.
Three months after the initiation of therap y: No CHR or > 95% Ph+ metaphases
Six months after the ini tiation of therap y: BCR -ABL 1ratio > 10% IS and/or > 
65% Ph+ metaphases
Twelve months after initiation of therap y: BCR -ABL 1ratio > 10% IS and/or > 
35% Ph+ metaphases
At any  time after the initiation of therapy , loss of CHR, CCy R or PCy R
At any  time after the initiation of therapy , the development of new BCR- ABL 1
mutations which potentially  cause resistance to current treatment 
At any  time after the initiation of therapy , confirmed loss of MMR in 2 
consecutive tests, of which one must have a BCR -ABL 1ratio ≥ 1% IS
At any  time after the initiation of therapy , new clonal chromosome abnormalities 
in Ph+ cells: CCA/Ph+
Intolerance is defined as:
Non-hematologic intolerance: Patients with grade 3 or 4 toxicity  while on 
therap y, or with persistent grade 2 toxicit y, unresponsive to optimal management, 
including dose adjustments (unless dose reduction is not considered in the best 
interest of the patient if response is alread y suboptimal)
Hematologic intolerance: Patients with grade 3 or 4 toxicity (absolute neutrophil 
count [ANC] or platelets) while on therap y that is recurrent after dose reduction 
to the lowest doses recommended by  manufacturer
6.Eastern Cooperative Oncology  Group (ECOG) performance status (PS) of 0, 1, or 2
7.Adequate end organ function as defined b y(as per central laboratory  tests):
Total bilirubin ≤ 1.5 x ULN except for patients with Gilbert’s sy ndrome who may  
only be included if total bilirubin ≤ 3.0 x UL N or direct bilirubin ≤ 1.5 x ULN

Novartis Confidential Page 51
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Aspartate transaminase (AST) ≤ 3.0 x ULN
Alanine transaminase (ALT) ≤ 3.0 x ULN
Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN -  ≤ 1.5 x UL N, value must be 
considered not clinically  significant and not associated with risk factors for acute 
pancreatitis
Alkaline phosphatase ≤ 2.5 x ULN
Creatinine clearance ≥ 50 m L/min as calculated using Cockcroft
-Gault formula
8.Patients must avoid consumption of grapefruit, Seville oranges or products containing the 
juice of each during the entire study  and preferably  7 day s before the first dose of study  
medications, due to poten tial CYP3A4 interaction with the study  medications. Orange 
juice is allowed.
9.Written informed consent obtained prior to an y screening procedures.
10a.Patients must have the following electrol yte values (as per central laboratory  tests) within 
normal limits or corrected to be within normal limits with supplements prior to first dose 
of study  medication:
Potassium (potassium increase of up to 6.0 mmol/L is acceptable at stud y entry if 
associated with creatinine clearance within normal limits)
Total calcium (c orrected for serum albumin) ; (calcium increase of up to 12.5 mg/dl or 
3.1 mmol/L  is acceptable at study  entry  if associated with creatinine clearance within 
normal limits)
Magnesium , with the exception of magnesium increase > ULN –3.0 mg/dL; > ULN -
1.23 mmol/L  associated with  creatinine clearance (calculated using Cockcroft- Gault 
formula )within normal limits.
11.Evidence of t ypical BCR -ABL1 transcript [e14a2 and/or e13a2] at the ti
me of screening 
which are amenable to standardized RQ- PCR quantification.
5.3 Exclusion criteria
Patients eligible for this study  must not meet anyof the following criteria:
1.Known presence of the T315I  or V299L mutation at an y time prior to study entry
2.Known second chronic phase of CML after previous progression to AP/BC
3.Previous treatment with a hematopoietic stem -cell transplantation
4.Patient planning to undergo allogeneic hematopo ietic stem cell transplantation
5.Cardiac or cardiac repolarization abnormality , including an y of the following:
History  within 6 months prior to starting study  treatment of my ocardial infarction 
(MI), angina pectoris, coro nary artery  bypass graft (CABG)
Clinically  significant cardiac arrhy thmias (e.g., ventricular tachy cardia), comple te left 
bundle branch block, high -grade AV block (e.g., bifascicular block, Mobitz ty pe II 
and third degree AV block)
QTcF at screening ≥450 ms ec(male patients), ≥460 ms
ec(fem ale patients)
Long QT s yndrome, family  history  of idiopathic sudden death or co ngenital long QT 
syndrome, or an y of the following:

Novartis Confidential Page 52
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Risk factors for Torsades de Pointe s(TdP) including uncorrected h ypokalemia or 
hypomagnesemia, history  of cardiac failure, or history  of clinically  
significant/s ymptomatic brady cardia
Concomitant medication(s) with a “K nown risk ofTorsades de Pointe s”per 
wwwcrediblemeds.org/ that cannot be discontinued or replaced 7 days prior to 
starting stud y drug b y safe alternative medication .
Inability to determine the QTcF interval
6.Severe and/or uncontrolled concu rrent medical disease that in the opinion of the 
investigator could cause unacceptable safet y risks or compromise compliance with the 
protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary  
hypertension)
7.History  of acute pancreati tis within 1 y ear of study  entry  or past medical history  of chronic 
pancreatitis
9.History  of acute or chronic liver disease
10. Known presence of significant congenital or acquired bleeding disorder unrelated to 
cancer
11.History  of other active malignancy  within 3 years prior to study  entry  with the exception 
of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated 
curativel y
12.Known history  of Human I mmunodeficiency  Virus (HIV), chronic Hepatitis B (HBV), or 
chronic Hepatitis C (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) 
and Hepatitis B core antibody  (HBcAb / anti HBc) will be performed at screening
13.Impairment of gastrointestinal (GI) function or GI disease that may  significantly  alter the 
absorption of study  drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, 
malabsorption syndrome, small bowel resection, or gastric by pass surgery )
14a. Treatment with medications that meet one of the following criteria and that cannot be 
discontinued at least one week prior to the start of treatment with study  treatment
Moderate or strong inducers of CYP3A
Moderate or strong inhibitors of CYP3A 
15.Previous treatment with or known/ suspected h ypersensitivity  to asciminib or an y of its
excipients.
16.Previous treatment with or known/ suspected h ypersensitivity  to bosutinib or any  of its
excipients.
17.Participation in a prior investigational study within 30 days prior to randomization or 
within 5 half -lives of the investigational product, whichever is lon ger
18.Pregnant or nursing (lactating) women
19a. Women of child- bearing potential, defined as all women phy siologically  capable of
becoming pregnant, unless they  are using highly  effective methods of contraception
during dosing and for 3 day s after last dose of asciminib and one month after last dose of
bosutinib. Highly  effective contraception methods include:

Novartis Confidential Page 53
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, sy mptoth ermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y (with or without 
hysterectom y) total h ysterectom y or bilateral tubal ligation at least six weeks before
taking stud y treatment ). In case of oophorectomy  alone, only  when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). The vasectomized male 
partner should be the sole partner for that subject.
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS) or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or tra nsdermal hormone contraception.
In case of use of oral contraception women should have been stable on the same pill 
for a minimum of 3 months before taking stud y treatment.
Women are considered post -menopausal and not of child bearing potential if they  
have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile (e.g. age appropriate, history  of vasomotor sy mptoms) or have had surgical 
bilateral oophorectomy  (with or with out hy sterectomy ), total h ysterectom y or bilateral 
tubal ligation at least six weeks before taking study  medication . In the case of 
oophorectom y alone, women are considered post- menopausal and not of child bearing 
potential only when the reproductive statu s of the woman has been confirmed by  
follow up hormone level assessment.
6 Treatment
6.1 Stud y treatment
The investigational treatments for this stud y are asciminib (40 mg BID) and bosutinib (500 mg 
QD). Novartis will supply  asciminib to the investigational siteas 20 mg and 40 mg tablets.
Bosutinib will be supplied to the investigational site as 100 mg and 500 mg tablets.
6.1.1 Dosing regimen
Asciminib
Asciminib 20 or 40 mg strength tablets will be administered orally  twice -daily  (BID), without 
food. Asciminib tablets should be ingested as follows:
Asciminib should be administered in the fasted state : avoid food for at least 2 hours before 
the dose is taken and for at least 1 hour after the dose is taken . Water is permitted during 
this period.
Asciminib should be taken with approximately  8 ounces (240 mL) of water.
Asciminib should be swallowed whole and not chewed or crushed.
If vomiting occurs within the first hour after taking the drug, re-dosing is allowed before 
the next scheduled dose

Novartis Confidential Page 54
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
If the patient does n ot take asciminib within 6 hours after the approximate time of the 
usual dosing time, that dose should be skipped and treatment should continue with the 
next dai ly dose at the prescribed level
Bosutinib
Bosutinib 500 mg or 100 mg tablets will be administer ed orally once daily (QD) with food. If 
a dose is missed beyond 12 hours, the patient should skip the dose and take the usual dose on 
the following day .
Table 6-1 Dose and tr eatment schedule
Study  
treatmentsPharmaceutical form 
and route of 
administrationDose Frequency  and/or
RegimenFasting Condition
Asciminib Tablet for oral use 20 mgaTwice -daily Fasting
Asciminib Tablet for oral use 40 mg Twice -daily Fasting
Bosutinib Tablet for oral use 100 mgbOnce -daily Non-fasting
Bosutinib Tablet for oral use 500 mg Once -daily Non-fasting
a20 mg tablets will be dispensed to patients in the instance of dose reduction.
b100 mg tablets will be dispensed to patients in the instance of dose modifications.
On days when serial blood samples are collected for asciminib PK analysis, patients will be 
instructed to bring their drug suppl y to the site, and take the dose in the clinic, under supervision 
of the site personnel. Th e exact time for dose administration and meal intake must be recorded 
in the electronic Case Report Form (eCRF).
All dosages prescribed and dispensed to the patient and all dose changes during the study must 
be recorded on the Dosage Administration Record eCRF.
6.1.2 Ancillary  treatments
Not applicable.
6.1.3 Rescue medication
Not applicable.
6.1.4 Guidelines for continuation of treatment
Not applicable. See Section 6.3 .
6.1.5 Treatment duration
There is no fixed duration of treatment planned per patient. The patients are treated in the study 
up to end of stud y treatment period defined as up to 96 weeks after the last patient receives the 
first dose or up to 48 weeks after the last patient has swi tched to asciminib treatment whichever 
is longer unless patients have discontinued treatment earlier .  Patients may be discontinued from 
treatment with the study drug at any time due to unacceptable toxicity , disease progression 
and/or at the discretion of the investigator or the patient.

Novartis Confidential Page 55
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
6.2 Dose escalation guidelines
Dose escalation bey ond the standard doses of 40 mg BID for asciminib is not permitted.
Dose escalation above 500 mg QD for bosutinib is permitted in this study. Bosutinib escalation 
guidelines ar e as follows:
Consider dose escalation to 600 mg once daily  in patients who are currently  taking 500 mg 
daily , did not have Grade 3 or higher adverse events and who:
Did not reach complete hematological response (CHR) by  week 8
Did not reach complete cytog enetic response (CCy R) by  week 12
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose interruptions 
and/or reductions are either recommended or mandated in order to allow the pat ient to continue 
the study  treatment.
These dose modifications are summarized in Table 6-2. The dose reduction indicated as 
“recommendations” are provided to assist investigators in the event the 
patient experiences 
toxicity .However, deviations from “mandatory ” dose interruptions and/or reductions are not 
allowed and mandatory  interruptions or reductions must be strictly  followed. Re-escalation to 
asciminib 40mg BID is permitted if a change in the patie nt’s individual 
benefit/risk assessment 
at the lower dose level is seen. Re-escalation will be allowed only once for any given patient on 
the asciminib arm per protocol. Permanent treatment discontinuation is mandatory  for specific 
events indicated as such in Table 6-2.Any dose changes must be recorded on the Dosage 
Administration Record eCRF.
A patient must discontinue treatment with either asciminib or bosutinib if, after treatment is 
resumed at a lowe r dose level , the toxicity  recurs with the same or worse severit y, except for 
recurrence of cytopenias (Table 6-2). If a patient requires a dose interruption of > 28 daysfor 
each non
-hematologic toxicity , then the patient must be discontinued from the study treatment. 
If a hematologic toxicity  (cytopenia Grade 3 or 4) lasts for more than 42 days without recovery 
to at least a Grade 2, despite TKI interruption and adequate management (including 
hematopoietic growth factors), then the patient must be discontinued from the study  treatment. 

Novartis Confiden tial Page 56
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Table 6-2 Criteria for dose reduction/interruption and re -initiation of asciminib and bosutinib treatment for adverse drug 
reactions
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontinued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Investigations (Hematologic) If a hematologic toxicity  (cytopenia Grade 3 or 4) lasts for more than 42 day s without recovery  to at least a Grade 2, despit e 
TKI interruption and adequate management (including hematopoietic growth factors), then the patient must be discontinued from the study  treatment.
Neutropenia (ANC)
Grade 1 (ANC < LLN –1.5 x 109/L) Recommendation : Maintain dose level Recommendation : Maintain dose level
Grade 2 (ANC < 1.5 –1.0 x 109/L) Recommendation : Maintain dose level Recommendation : Maintain dose level
Grade 3 (ANC < 1.0 –0.5 x 109/L) Mandatory : Hold dose until resolved to ≤ Grade 2 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
If resolved in > 14 days, then reduce dose 1 dose level Mandatory : Hold dose until resolv ed to ≤ Grade 2 and platelets ≤ 
Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
If resolved in > 14 days, reduce dose 1 dose level 
Grade 4 (ANC < 0.5 x 109/L) Mandatory : Hold dose until resolved to ≤ Grade 2, 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level Mandatory :Hold dose until resolved to ≤ Grade 2 and platelets ≤ 
Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
Febrile neutropenia (ANC < 1.0 x 
109/L, fever ≥ 38.5°C)Mandatory :Hold dose until resolved, then reduce dose 
1 dose levelMandatory :Hold dose until resolved , then reduce dose 1 dose 
level
Thrombocytopenia
Grade 1 (PLT < LLN –75 X 109/L) Recommendation : Maintain dose level Recommendation: Maintain dose level
Grade 2 (PLT < 75 -50 x 109/L) Recommendation : Maintain dose level Recommendation: Maintain d ose level

Novartis Confiden tial Page 57
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontinued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Grade 3 (PLT < 50 -25 x 109/L) Mandatory :Hold dose until resolved to ≤ Grade 2 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 2 and 
neutrophils ≤ Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
Grade 4 (PLT < 25 x 109/L) Mandatory :Hold dose unti l resolved to ≤ Grade 2 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 2 and 
neutrophils ≤ Grade 2 (recheck CBC 2x/wee k), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
Recurrence of all cytopenias Recommendation: Hold dose until resolved to ≤ Grade 2, 
then maintain current dose level . Recommendation: Hold dose until resolved to ≤ Grade 2, then 
reduce dose 1 additional level
Non-hematologic adverse reactions except where further specified in individual sections
Grade 1 Recommendation : Maintain dose level Recommendation: Maintain dose level
Grade 2 Recommendation: Hold dose until resolved to ≤ Grade 1, 
then maintain dose levelRecommendation: Maintain dose level
Grade 3 Mandatory :Hold dose until resolved to ≤ Grade 1, then 
reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 1, then reduce 
dose 1 dose level, If clinically appropriate, re -escalation of the 
dose back to baseline dose level (500 mg) should be considered
Grade 4 Mandatory : Permanently discontinue patient from study 
drug treatment.Mandatory :Hold dose until resol ved to ≤ Grade 1, then reduce 
dose 1 dose level; If clinically appropriate, re -escalation of the 
dose back to baseline dose level (500 mg) should be considered
Investigations (Renal)
Serum creatinine
Grade 1 (> ULN -1.5 x ULN) Recommendation: Maintain dose level Recommendation: Maintain dose level
Grade 2 (> 1.5 -3.0 x ULN) Recommendation: Hold dose until resolved to ≤ Grade 1 
or baseline, then maintain dose levelRecommendation: Hold dose until resolved to ≤ Grade 1 or 
baseline, then maintain dose level
Grade 3 (> 3.0 -6.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
Grade 4 ( > 6.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.

Novartis Confiden tial Page 58
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontinued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Investigations (Hepatic)
Isolated total Bilirubin elevation
> ULN –1.5 x ULN Recommendation: Maintain dose level Recommendation: Maintain dose level
> 1.5 -3.0 x ULN Recommendation: Hold dose. Monitor LFTsb weekly, or 
more frequently if clinically indicated, until resolved to ≤ 
1.5 x ULN:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelRecommendation: Hold dose. Monitor LFTsb weekly, or more 
frequently if clinically indicated, until resolved to ≤ 1.5 x ULN:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, th en reduce dose 1 dose level
> 3.0 -10.0 x ULN*Mandatory :Hold dose. Monitor LFTsb weekly, or more 
frequently if clinically indicated, until resolved to ≤ 1.5 x 
ULN:
if resolved in ≤ 14 days, then reduce dose 1 dose level
if resolved in > 14 days, then discontinue patient from 
study drug treatment. The patient should be monitored 
weekly (including LFTsb), or more frequently if clinically 
indicated, until total bilirubin have resolved to baseline or 
stabilization over 4 weeks.Mandatory :Hold dose. M onitor LFTsb weekly, or more frequently 
if clinically indicated, until resolved to ≤ 1.5 x ULN:
if resolved in ≤ 14 days, then reduce dose 1 dose level
if resolved in > 14 days, then discontinue patient from study drug 
treatment. The patient should be mo nitored weekly (including 
LFTsb), or more frequently if clinically indicated, until total bilirubin 
have resolved to baseline or stabilization over 4 weeks.
> 10.0 x ULN* Mandatory :Permanently discontinue patient from study 
drug treatment. The patient sh ould be monitored weekly 
(including LFTsb), or more frequently if clinically indicated, 
until total bilirubin have resolved to baseline or 
stabilization over 4 weeks.Mandatory :Permanently discontinue patient from study drug 
treatment. The patient should be monitored weekly (including 
LFTsb), or more frequently if clinically indicated, until total bilirubin 
have resolved to baseline or stabilization over 4 weeks.
Isolated AST or ALT elevation
> ULN -3.0 x ULN Recommendation: Maintain dose level Recommendation: Maintain dose level
> 3.0 -5.0 x ULN Recommendation: Maintain dose level. Repeat LFTsbas 
soon as possible, preferably within 48 -72 hours from 
awareness of the abnormal results ; if abnormal lab values 
are confirmed upon the repeat test, then monitor LFTsb
weekly, or more frequently if clinically indicated, until 
resolved to ≤ 3.0 x ULNRecommendation: Maintain dose level. Repeat LFTsbas soon 
as possible, preferably within 48 -72 hours from awareness of the 
abnormal results; if abnormal lab values are confirmed upon the 
repeat test, then monitor LFTsbweekly, or more frequently if 
clinically indicated, until resolved to ≤ 3.0 x ULN

Novartis Confiden tial Page 59
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontinued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
> 5.0 -10.0 x ULN Mandatory :Hold dose. Repeat LFTsbas soon as 
possible, preferably within 48 -72 hours from awareness of 
the abnormal results; monitor LFTsbweekly, or more 
frequently if clinically indicated, until resolved to ≤ 3.0 x 
ULN: Then
If resolved in ≤ 14 days, maintain dose level
If resolved in > 14 days, reduce dose 1 dose levelMandatory :Hold dos e. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤ 2.5 x ULN: Then
Recommendation: If resolved in ≤ 28 days, redu ce dose 1 
dose level
Recommendation : If resolved in > 28 days, Discontinue patient 
from study drug treatment
> 10.0 -20.0 x ULN Mandatory :Hold dose. Repeat LFTsbas soon as 
possible, preferably within 48 -72 hours from awareness of 
the abnormal results ; monitor LFTsbweekly, or more 
frequently if clinically indicated, until resolved to ≤ 
baseline. Then reduce dose 1 dose level.Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤ 2.5 x ULN. Then
Recommendation: If resolved in ≤ 28 days, reduce dose 1 
dose level maintain dose level
Recommendation: If resolved in > 28 days, Discontinue patient 
from study drug treatment.
> 20.0 x ULN Mandatory :Hold dose. Repeat LFTsbas soon as 
possible, preferably within 48 -72 hours from awareness of 
the abnormal results; monitor LFTsbweekly, or more 
frequently i f clinically indicated, until resolved to ≤ 3 x ULN 
(or ≤ 5 x ULN for patients with baseline value > 3.0 -5.0 x 
ULN), then resume treatment at reduce dose 1 dose 
level. Only 1 dose reduction is allowed; if reoccurs at > 5 x 
ULN, discontinue patient from study drug treatment.Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤ 2.5 x ULN (then
Recomm endation: If resolved in ≤ 28 days, reduce dose 1 
dose level maintain dose level
Recommendation: If resolved in > 28 days, Discontinue patient 
from study drug treatment

Novartis Confiden tial Page 60
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontinued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Combined celevations of AST or ALT and total bilirubin
For patients with normal baseline 
ALT and AST and total bilirubin 
value:
AST or ALT >3.0 x ULN combined 
with total bilirubin >2.0 x ULN without 
evidence of cholestasisd
For patients with elevated baseline 
AST or ALT or total bilirubin value
[AST or ALT>2 x baseline AND > 3.0 
x ULN]Mandatory :Permanently discontinue patient from study 
drug treatment.
Repeat as soon as possible, preferably within 48 hours 
from awareness of the abnormal results, then with weekly 
monitoring of LFTsb), or more frequently if clinically 
indicated, until AST, ALT, or bilirubin have resolved to 
baseline or stabilization over 4 weeks. Refer to Section 
6.3.3.1 for additional follow-up evaluations as applicable.Mandatory : Permanently discontinue p atient from study drug 
treatment.
Repeat as soon as possible, preferably within 48 hours from 
awareness of the abnormal results, then with weekly monitoring 
of LFTsb), or more frequently if clinically indicated, until AST, 
ALT, or bilirubin have resolved t o baseline or stabilization over 4 
weeks. Refer to Section 6.3.3.1 for additional follow-up 
evaluations as applicable.
Investigation (metabolic)
Asymptomatic amylase and/or lipase elevation
Grade 1 (> ULN -1.5 x ULN) Recommendation: Maintain dose level, measure 2x 
weekRecommendation: Maintain dose level, measure 2x week
Grade 2 (> 1.5 -2.0 x ULN) Recommendation: Maintain dose level, measure 2x 
weekRecommendation: Maintain dose level, measure 2x we ek
Grade 3 (> 2.0 -5.0 x ULN) Mandatory :Hold dose until resolved to Grade ≤ 1 or 
baseline, then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days, then discontinue treatment and 
obtain appropriate imaging (i.e., MRI, CT scan or 
ultrasound).Mandatory :Hold dose until resolved to Grade ≤ 1 or baseline, 
then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days, then discontinue treatment and obtain 
appropriate imaging (i.e., MRI, CT scan or ultr asound).
Grade 4 (> 5.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment. Obtain appropriate imaging (i.e., MRI, CT 
scan or ultrasound).Mandatory :Permanently discontinue patient from study drug 
treatment. Obtain appropriate imaging (i.e., MRI, CT scan or 
ultrasound).

Novartis Confiden tial Page 61
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontinued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Vascular disorders
Hypertension
CTCAE Grade 3 Mandatory :Hold dose until resolved ≤ Grade 1, then 
reduce dose 1 dose levelMandatory :Hold dose until resolved ≤ Grade 1, then reduce 
dose 1 dose level
CTCAE Grade 4 Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
Gastro intestinal
Pancreatitis
Grade 2 (radiologic findings for 
pancreatitis as per CTCAE v4.03, for 
increased enzymes please see table 
for asymptomatic amylase and/or 
lipase elevation)Mandatory :If asymptomatic radiologic pancreatitis, hold 
treatment until recovery of the radiologic findings. If 
treatment delay is ≤ 21 days, then reduce dose 1 dose 
level. If treatment delay > 21 days, discontinue treatment 
and keep monitoring with appropriate imaging (i.e., MRI, 
CT scan or ultrasound).Mandatory : If asymptomatic radiologic pancreatitis, hold 
treatment until recovery of the radiologic findings. If treat ment 
delay is ≤ 21 days, then reduce dose 1 dose level. If treatment 
delay > 21 days, discontinue treatment and keep monitoring with 
appropriate imaging (i.e., MRI, CT scan or ultrasound).
Grade ≥ 3 Mandatory :Permanently discontinue patient from study 
drug treatment. Obtain appropriate imaging (i.e., MRI, CT 
scan or ultrasound).Mandatory :Permanently discontinue patient from study drug 
treatment. Obtain appropriate imaging (i.e., MRI, CT scan or 
ultrasound).
Diarrhea***
Grade 1 Recommendation: Maint ain dose level but, initiate anti -
diarrhea treatmentRecommendation: Maintain dose level but, initiate anti -diarrhea 
treatment
Grade 2 Recommendation: Hold dose until resolved to ≤ grade 1, 
then maintain dose level.
If diarrhea returns as ≥ grade 2, then hold dose until 
resolved to ≤ grade 1, then reduce dose 1 dose levelRecommendation: Hold dose until resolved to ≤ grade 1, then 
maintain dose level.
If diarrhea returns as ≥ grade 2, then hold dose until resolved t o ≤ 
grade 1, then reduce dose 1 dose level
Grade 3 Recommendation: Hold dose and discontinue patient 
from study drug treatmentMandatory :Hold dose until recovery to ≤ grade 1. 
Recommendation: Bosutinib may then be resumed at 1 dose 
level
Grade 4 Mandatory :Permanently discontinue patient from study 
drug treatmentMandatory : Hold dose until recovery to ≤ grade 1. 
Recommendation: Bosutinib may then be resumed at 1 dose 
level

Novartis Confiden tial Page 62
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontinued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Skin and subcutaneous tissue disorders
Rash/photosensitivity
Grade 1 Recommendation: Maintain dose level. Consider to 
initiate appropriate skin toxicity therapy (such as 
antihistamines, topical corticosteroids and low -dose 
systemic corticosteroids)Recommendation: Maintain dose level. Consider to initiate 
appropriate skin t oxicity therapy (such as antihistamines, topical 
corticosteroids and low -dose systemic corticosteroids)
Grade 2 Recommendation : Maintain dose level, but 
initiate/intensify appropriate skin toxicity therapy (such as 
antihistamines, topical corticosteroids and low -dose 
systemic corticosteroids)Recommendation: Maintain dose level, but initiate/intensify 
appropriate skin toxicity therapy (such as antihistamines, topical 
corticosteroids and low -dose systemic corticosteroids)
Grade 3, despite skin toxicity the rapy Recommendation: Hold dose until resolved to Grade ≤ 1, 
then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days (despite appropriate skin toxicity 
therapy), then discontinue patient from study drug 
treatmentRecommendatio n:Hold dose until resolved to Grade ≤ 1, then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days (despite appropriate skin toxicity therapy), 
then discontinue patient from study drug treatment
Grade 4, despite skin toxicity therapy Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
General disorders and administration site conditions
Fatigue/ Asthenia
Grade 1 or 2 Recommendation: Maintain dose level Recommendation: Maintain dose level
Grade 3 Recommendation: Hold dose until resolved to ≤ grade 1, 
then :
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then reduce dose 1 dose levelRecommendation: Hold dose until resolved to ≤ grade 1, then :
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then reduce dose 1 dose level
All dose modifications should be based on the worst preceding toxicity.
aCommon Toxicity Criteria for Adverse Events (CTCAE Version 4.03)
bCore LFTs consist of ALT, AST, total bilirubin (fractionated [direct and indirect], if total bilirubin > 2.0 x ULN), and alka line phosphatase (fractionated [quantification of 
isoforms], if alkaline phosphatase > 2.0 x ULN.)
c“Combined” defined as total bilirubin increase to the defined threshold concurrently with ALT/AST increase to the defined thr eshold

Novartis Confiden tial Page 63
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontinued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
If combined elevations of AST or ALT and total bilirubin do not meet the defined thres holds, please follow the instructions for isolated elevation of total bilirubin and 
isolated elevation of AST/ALT, and take a conservative action based on the degree of the elevations (e.g. discontinue treatme nt at the situation when hold dose is 
needed fo r one parameter and discontinue treatment is required for another parameter). After all elevations resolve to the defined thr esholds that allow treatment re -
initiation, re -start the treatment either at the same dose or at one dose lower if meeting a criter ion for dose reduction
d “Cholestasis” defined as ALP elevation (>2.0 x ULN and R value <2) in patients without bone metastasis, or elevation of ALP l iver fraction in patients with bone 
metastasis
Note: The R value is calculated by dividing the ALT by the ALP, using multiples of the ULN for both values. It denotes whether the relative pattern of ALT and/or ALP 
elevation is due to cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury
* Note: If total bilirubin > 3.0 x ULN is due t o the indirect (non -conjugated) component only, and hemolysis as the etiology has been ruled out as per institutional 
guidelines (e.g., review of peripheral blood smear and haptoglobin determination), then ↓ 1 dose level and continue treatment at the discr etion of the investigator.
** Note: A CT scan or other imaging study to assess the pancreas, liver, and gallbladder must be performed within 1 week of the first occurrence of any ≥ Grade 3 of 
amylase and/or lipase. If asymptomatic Grade 2 elevations of lip ase and/or amylase occur again at the reduced dose, patients will be discontinued permanently from 
study treatment.
*** Note: antidiarrheal medication is recommended at the first sign of abdominal cramping, loose stools or overt diarrhea

Novartis Confidential Page 64
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Table 6-3 Dose reduction steps for asciminib and bosutinib
Dose reduction*
Starting dose level – 0 Dose level – 1
Asciminib BID 40 mg tablet BID (total daily 
dose 80 mg)20 mg tablet BID (total daily 
dose 40 mg)
*Dose reduction should be based on the worst toxicity demonstrated at the last dose.
Asciminib dose reduction below total daily 40 mg is not allowed. 20 mg tablets will be dispensed to patients in 
the instance of dose reduction.
Dose reduction*
Starting dose level – 0 Dose level – 1 Dose level – 2
Bosutinib QD 500 mg (1 -500 mg tablet QD) 400 mg (4-100 mg tablets 
QD)300 mg (3 -100 mg 
tablets QD)
* Dose reduction should be based on the worst toxicity demonstrated at the last dose.
Bosutinib dose reduction below total daily 300 mg is not allowed. 100 mg tablets will be dispensed to patients 
in the instance of dose reduction.
6.3.2 Dose adjustments for QTcF prolongation
If QTcF >500 msec or QTcF prolongation >60 msec from baseline is observed at any point 
during stud y treatment, and confirmed, the below guidance must be followed:
1.Assess the quality  ofthe ECG recording and the QT value and repeat if needed
2.Interrupt stud y treatment until confirmed resolution of QTcF and as per dose reduction 
guidel ines for non- hematological AEs.
3.Determine the serum electroly te levels (in particular hy pokalemia, hypomag nesemia). If 
abnormal, correct abnormalities before resuming study  drug treatment.
4. Review concomitant medication associated with QT prolongation, including drugs with a 
“Known”, “Possible”, or “Conditional risk of Torsades de Pointes” (refer to 
wwwcredible meds.org/ ), and drugs with the potential to increase the risk of study  drug 
exposure related QT prolongation .
5.Check study
 drug dosing sc hedule and treatment compliance.
After confirming ECG reading at site, if QTcF > 500 msec 
Interrupt stud y treatment 
Repeat ECG and confirm ECG diagnosis b y a cardiologist or central ECG lab 
If QTcF confirmed > 500 msec: 
Correct electrol ytes, eliminate culprit concomitant treatments, and identify  and 
address clinical conditions that could potentially  prolong the QT as per the ECG and 
QTc Clinical Safet y Standards Guidelines Section 3.3.1 . 
Consult with a cardiologist (or qualified specialist) 
Increase cardiac monitoring as indicated, until the QTcF returns to ≤ 480 msec. 
After resolution to ≤ 480 msec, consider re -introducing treatment at reduced dose, and 
increase ECG monitoring for the next treatment(s) , (e.g. pre-dose and 2 hours post dose 
after one week and two weeks of treatment re- introduction) : 

Novartis Confidential Page 65
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
If QTcF remains ≤ 500 msec after dose reduction, continue planned E CG monitoring 
during subsequent treatment 
If QTcF > 500 msec recurs after dose reduction, discontinue patient from trial. 
6.3.3 Follow -up for toxicities
Patients whose treatment is permanently discontinued due to a study drug related adverse event 
or clinicall y significant laboratory  value, must be followed up at least once a week for 4 weeks, 
until resolution or stabilization of the event, whichever comes first. Appropriate clinical experts 
such as ophthalmologist, endocrinologist, dermatologist, psy chiatrists etc. should be consulted 
as deemed necessary . All patients must be followed up for adverse events and serious adverse 
events for 30 day s following the last dose of study  treatment.
6.3.3.1 Follow up on potential drug -induced liver injury (DILI) cases
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically  important events.
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
For patients with normal ALT and AST and TBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or ALT > 8.0 x ULN], combined with [TBIL > 2 x 
baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as ALP elevation > 2.0 x ULN with R value < 2 in patients without bone metastasis, or elevation 
of AL P liver fraction in patients with bone metastasis.
Note: (The R value is calculated by  dividing the ALT by  the ALP, using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferabl y within 48 hours from the 
awareness of the abnormal results. The evaluation should include laboratory tests, detailed 
history , physical assessment and thepossibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
1.Laboratory tests should include ALT, AST, albumin, creatinine kinase, total bilirubin, 
direct and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase.
2.A detailed histo ry, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history of any  pre-existing liver 
conditions or risk factors, should be collected.
3. Further testing for acute hepatitis A, B, C or E infection and liver imaging (e .g.biliary  
tract) may be warranted.

Novartis Confidential Page 66
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
4.Obtain PK sample, as close as possible to last dose of study  drug, if PK anal ysis is 
performed in th e stud y.
5.Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medicall y 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the term 
“potential drug-induced liver injury ”. All events should be followed up with the outcome 
clearl y
documented.
6.3.4 Anticipated risks and safety  concerns of the study  drug
Appropriate eligibility  criteria, as well as specific dose modification and stopping rules are 
included in this protocol. Recommended guidelines for proph ylactic or supportive treatment for 
expected toxicities, including management of study -drug 
induced adverse events, i.e., 
hypergly cemia, skin toxicity  and diarrhea are provided in Table 6-2. Refer to preclinical toxicit y 
and or clinical data found in the [A sciminib Investigator’s Brochure] or bosutinib label .
6.4 Concomitant medications for patients on 
asciminib
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug and including 
over-the-counter treatment and nutritional or vitamin supplements) and significant non-drug 
therapies (including physical therapy , herbal/natural medications and blood transfusions) 
administered during the study  must be listed on the “Concomitant 
Medications/Significant non-
drug therapies” section of the eCRF.
Chronic medic
ation should be maintained at the same dose and schedule throughout the study
period, as medically  feasible.
All prior antineoplastic surgery , chemotherap y, biologic, immunologic and radiation therap y 
must be recorded in the “Prior antineoplasti c therapy ” section of the eCRF.
In general, concomitant medications and therapies deemed necessary  for the supportive care 
and safet y of the patient are allowed, provided their use is documented in the patient records 
and on the appropriate case report form, including the medicati on’s duration (start and end dates 
or if continuing at final exam). These include blood and platelet transfusions for patients with 
anemia and with thrombocy topenia.
6.4.1 Permitted concomitant therapy
Drugs that affect gastric pH
Asciminib does not have a pH -dependent solubility . Drugs that elevate gastric pH will not affect 
asciminib absorption. All ac id reducing agents are allowed.

Novartis Confidential Page 67
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
6.4.2 Permitted concomitant therapy  requiring caution and/or action
The in vivo potential of asciminib to interact with sensitive CYP3A4/5, CYP2C8 and CYP2C9 
substrates has been evaluated and would indicate a minimal or negligible risk ( Section 1.2.1.1). 
Therefore CYP3A4/5, CYP2C8 a
nd CYP2C9 substrates with narrow therapeutic index (NTI) 
should be used with caution. 
In recombinant cellular expression systems, asciminib was identified as a substrate of BCRP 
(Km ≈ 4 µM) and P-gP (Km could not be estimated due to insufficient saturation of efflux 
activity ). Inhibitors of BCRP and P -gP may  increase asciminib concentration. Based on human 
ADME study , P-gp may represent maximally  24% of the total clearance resulting in modest 
increase in AUC. Therefore, both BCRP and P-gp inhibitors should be administered with 
caution . If a medication listed in Section 14 appears on both the list of prohibited and the list of 
medications to be used with caution, the medication is prohibited.
6.4.3 Prohibited concomitant th erapy
Other anticancer agents
The administration of any  other anticancer agents including chemotherapy  and biologic agents 
isnotpermitted except for anti-cancer treatments of newl y diagnosed solid cancers (e.g. 
prostate cancer) that would not impact the level of minimal residual disease of patients. These 
patients may remain in the current study  after consultation with Novartis. The administration of 
other ty rosine kinase inhibitors indicated for treatment of CML  isnotallowed. 
Strong CYP3A 4/5 inhibitors
Every  effort should be made NOT to concomitantly  administer strong CYP3A4/5 inhibitors.
CYP3A4/5 inhibitors may decrease the metabolism of asciminib and resulting in increased 
serum concentrations and increased exposure. If administration of a strong CYP3A4/5 inhibitor 
cannot be avoided during the study  and cannot be switched to an alternative therap y that does 
not strongl y inhibit CYP3A4/5, asciminib must be interrupted .
A list of cytochrome P450 isoenzy mes and CYP3A4/5in hibitors may be found at 
medicine.iupui.edu/CLINPHARM/ddis/clinical- table .
A classification of CYP3A4/5 SmPC can be found 
inSection 14- Appendices .
Further information can also be found in the following referenc
e (Venkatakrishnan et al 2001).
Strong CYP3A 4/5, and UGT1A /2B inducers
Every  effort should be made NOT to concomitantly administer strong CYP3A4 inducers during 
the study .
Additionally , the use of strong in ducers of UGT1A/2B is prohibited during the study .
If administration of a strong CYP3A4/5 inducer or UGT1A/2B inducer cannot be avoided 
during the study  and cannot be switched to an alternative therapy , temporary  interruption of 
study  treatment is NOT needed .

Novartis Confidential Page 68
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
QT prolonging agents
As far as possible avoid co-administering drugs with a “Known”, “Possible” or “Conditional” 
risk of Torsades de Pointes (perwwwcrediblemeds.org/ )during the course of the study :
If concomitant administration of drugs with a “Known risk of Torsades de Pointe s” is 
required and cannot be avoided, study  drug must be interrupted. If, based on the investigator 
assessment and clinical need, study  treatment is resumed, close ECG monitoring is advised. 
If during the course of the study , concomitant administration of a drug with “Possible risk” 
or “Conditional risk of Torsades de Pointe s” is required, based on the investigator 
assessment and clinical need, study  treatment may be continued under close ECG 
monitoring to ensure patient safe ty.
A list of drugs associated with QT prolongation and/or Torsades de P ointe sis available online 
at wwwcrediblemeds.org/ .
Herbal medications
Herbal preparations/medications are not allowed throughout the study . These herbal 
medications include, but are not limited to: St. John’s wort, Kava, ephedra (ma huang), gingko 
biloba, dehy droepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. Patients should 
stop using these herbal medications 7 day s prior to first dose of study  drug.
6.4.4 Other concomitant med ications
Anti-emetics
Use of anti-emetics is allowed. Prophy lactic anti-emetics should be started only once the patient 
experiences nausea or vomiting, at the discretion of the investigator. It is recommended that 
patients use drugs that do not cause QT pr olongation. Please note that some anti -emetics have 
a known risk for T orsade de Pointes and are prohibited (refer to Section 6.4.2 and Section 14.1 
Appendix 1 ).
Bisphosphonates
The use of bisphosphonates regar dless of indication is allowed.
Contraceptives
Hormonal contraceptives are allowed as contraception methods. Highl y effective contraception 
should be maintained throughout the study  and for 3 daysafter study  treatment discontinuation .
Anticoagulation agents
All anticoagulants or anti-aggregation agents may be administered under the discretion of the 
investigator.
Therapeutic 
doses of warfarin sodium (Coumadin®) or any other coumarin- derivative 
anticoagulants should be used with caution and fully  avoided whenever possible because of its 
known interaction with many  commonl y used medications and certain foods. As warfarin has 
a narrow therapeutic range, and asciminib is possibly  an inhibitor of CYP2C 9, the major 

Novartis Confidential Page 69
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
metabolizing enzyme of S-warfarin (R-warfarin is metabolized by multiple CYP enzymes), 
warfarin should be caref ully monitored whenever used.
Caution is also advised when asciminib is co-administered with anti -platelet pro -drugs such as 
clopidogrel, ticlopidine and prasugrel, which require metabolic activation by CYP3A4 and 
CYP2C9. While the weak reversible in vitro inhibition potential of asciminib is unlikely  to 
translate into clinical significance as the stead y-state plasma concentrations at the maximum 
therapeutic doses are significantl y lower than the experimentally  determined inhibition 
constants, patients using anti- platelet pro -drugs should still be carefull y monitored.
Direc t Thrombin inhibitors (DTIs) and Factor Xa inhibitors are allowed as anticoagulants. 
Individual medications from each of the classes should be checked if they are not prohibited 
due to other drug-drug-interactions with asciminib . Alternatively , therapeutic anticoagulation 
may be accomplished usin
g low-molecular weight heparin.
6.5 Concomitant medications for patients on bosutinib
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug and including 
over-the-counter treatment and nutritional or vitamin supplements) and significant non-drug 
therapies (including physical therapy , herbal/natural medications and blood transfusions) 
administered during the study  must be listed on the “Concomitant 
Medications/Significant non-
drug therapies” section of the eCRF.
Chronic medication should be maintained at the same dose and schedule throughout the study
period, as medically  feasible.
All prior antineoplastic surgery , chemotherap y, biologic, immunologic and radiation therap y 
must be recorded in the “Prior antineoplasti c therapy ” section of the eCRF.
In general, 
concomitant medications and therapies deemed necessary  for the supportive care 
and safet y of the patient are allowed, provided their use is documented in the patient records 
and on the appropriate case report form, including the medicati on’s duration (start and end dates 
or if continuing at final exam). These include blood and platelet transfusions for patients with 
anemia and with thrombocy topenia
6.5.1 Permitted concomitant therapy  requiring caution
Bosutinib should be used with caution in patients who have or may develop prolongation of QT, 
including those patients who are taking medicinal products that are known to prolong the QTc 
(e.g., anti-arrhy thmic medicinal products such as amiodarone, disopy ramide, procainamide, 
quinidine and sotalol and other substances that may prolong QTc) (in accordance with EU 
SmPC dated 05/2018).
If a medication listed in Section 
14-Appendices appears on both the list of prohibited and the 
list of medications to be used with caution, the medication is 
prohibited.

Novartis Confidential Page 70
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
6.5.2 Prohibited concomitant therapy
Other anticancer agents
The administration of any  other anticancer agents including chemotherapy  and biologic agents 
isnotpermitted except for anti-cancer treatments of newl y diagnosed solid cancers (e.g. 
prostate cancer) that would not impact the level of minimal residual disease of patients. T hese 
patients may remain in the current study  after consultation with Novartis. The administration of 
other ty rosine kinase inhibitors indicated for treatment of CML  isnotallowed. 
Concomitant use with CYP3A  inhibitors
Avoid the concomitant use of stron g or moderate CYP3A inhibitors as an increase in bosutinib 
plasma concentration is expected. Strong CYP3A inhibitors include boceprevir, clarithrom ycin, 
conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, 
nelfina vir, posaconazole, ritonavir, saquinavir, telaprevir, t elithrom ycin, and voriconazole.
Moderate CYP3A inhibitors include amprenavir, aprepitant, atazanavir, ciprofloxacin, 
crizotinib, darunavir/ritonavir, diltiazem, ery thromy cin, fluconazole, fosamprenavir , grapefruit 
products, imatinib and verapamil) [Bosulif®USPI] . If administration of a strong or moderate 
CYP3A4/5 inhibitor cannot be avoided during the study  and cannot be switched to an alternative 
therap y, bosutinib must be interrupted .
Concomitant use with CYP3A  inducers
Avoid the concomitant use of strong or moderate CYP3A inducers as a large reduction in 
exposure is expected (strong CYP3A inducers include carbamazepine, phenytoin, rifampin and 
St. John's Wort. Moderate CYP3A inducers include bosentan, efavirenz, etravirine, modafinil 
and nafcillin) [ Bosulif®USPI ]. However, i f administration of a strong or moderate CYP3A4/5 
inducer cannot be avoided during the study  and cannot be switched to an alternative therap y, 
temporary  interruption of bosutinib is NOT required.
pH A ltering Medications
Bosutinib displays pH -dependent aqueous solubility , in vitro. In a cross -over trial in 23 healthy 
volunteers, a single oral dose of 400 mg of bosutinib was either administered alone or in 
combination with multiple -oral doses of 60 mg of lansoprazole (PPI ) under fasting conditions. 
Lansoprazole decreased bosutinib Cmax and AU C by  46% and 26%, respectivel y.
Concomitant administration with PPI s is not allowed.
Consider using short- acting antacids or H2 blockers instead of PPIs to avoid a reduction in 
bosutinib exposure. Separate antacid or H2 blocker dosing by more than 2 hours [Bosulif®
USPI ].
6.6 Patient numbering, treatment assignment or randomization
6.6.1 Patient numbering
Each patient is identified in the study  by a Subject Number (Subject No.), that is assigned when 
the patient is first enrolled for screening and is retained as the primary  identifier for the patient 

Novartis Confidential Page 71
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by Novartis to the investigative site) with a sequential patient 
number suffixed to it, so that each subject is numbered uniquel y across the entire database. 
Upon signing the informed con sent form, the patient is assigned to the next sequential Subject 
No. available to the investigator through the Oracle Clinical RDC interface.
The investigator or designated staff will contact the IRT and provide the requested identify ing 
information for the patient to register them into the IRT. Once assigned, the Subject No. must 
not be reused for an y other subject and the Subject No. for that individual must not be changed, 
even if the patient is re -screened. If the patient fails to be randomized or start treatment for an y 
reason, the reason will be entered into the Screening Disposition page. IRT must be notified 
within 2 day s that the patient was not randomized.
6.6.2 Treatment assignment or randomization
Patients will be assigned to one of the 2treatment arms ( Section 4.1 and Section 6.1 ) in a ratio 
of 2:1. Randomization will be stratified by  cytogenetic response status at screening.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients and investigator staff. A patient 
randomization list will be produced by the Interactive Response Technology  (IRT) provider 
using avalidated system that automates the random assignment of patient numbers to 
randomization numbers. These randomization numbers are linked to the different treatment 
arms, which in turn are linked to medication numbers. A separate medication randomization list 
will be produced by or under the responsibility  of Novartis Drug Supply  Management using a 
validated system that automates the random assignment of medication numbers to medication 
packs containing each of the study  treatments.
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be randomized via 
IRT to one of the treatment arms. The investigator or his/her delegate will call or log on to the 
IRT and confirm that the patient fulfills all the inclusion/exclusion criteria. The IRT will assign 
a randomization number to the patient, which will be used to link the patient to a treatment arm 
and will specify  a unique medication number for the first package of study  treatment to be 
dispensed to the patient. The randomization number will not be communicated to the caller.
6.6.3 Treatment blinding
Not applicable.
6.7 Stud y drug preparation and dispensation
The investigator or responsible site personnel must instruct the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by authorized site 
personnel only. All dosages prescribed to the patient and all dose changes during the study  must 
be recorded on the Dosage Administration Record eCRF.

Novartis Confidential Page 72
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
6.7.1 Study treatment packaging and labeling
Study  treatment, asciminib and bosutinib tablets, will be provided as global clinical open -label 
supply  and will be packed and labeled under the responsibility  of Novartis, Drug Supply 
Management.
Study  treatment labels will comply  with the legal requirements of each country  and will include 
storage conditions, a unique medication number (corresponding to study  treatment and strength).
Responsible site personnel will identify  the study  treatment package(s) to dispense by the 
medication number(s) assigned by IRT to the patient. Site personnel will add the patient number 
on the label. If the label has 2-parts (base plus tear-off label), immediately  before dispensing 
the package to the patient, site personnel will detach the outer part of the label from the package 
and aff ix it to the patient’s source document.
Table 6
-4 Packaging and labeling
Study  treatments Packaging Labeling (and dosing frequency )
asciminib (20 mg and 40 mg) Tablets in bottle Labeled as ‘ABL001 20 mg/ABL001 40 
mg’(BID)
bosutinib (100 mg or 500 mg) Tablets in bottle or tablets in 
blisterLabeled as ‘bosutinib 100 mg or bosutinib 
500 mg’(QD)
6.7.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, asciminib and bosuti nib should be stored according 
to the instruction s specified on the drug labels.
6.7.3 Study drug compliance and accountability
6.7.3.1 Study drug compliance
Total daily  dose of study  treatment administered with start and end date will be collected on the 
Dosage Administration Record eCRF page. Name, start and end dates of any Concomitant 
Medications and Surgical and Medical procedures will be collected on the Prior and 
Concomitant medications and Surgical and Medical procedures eCRFs respectivel y.
Compliance will be ass essed by the investigator and/or study  personnel at each patient visit and 
information provided by the patient and/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each 
dispensing pa tient visit.
6.7.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by the field 
monitor during site visits a nd at the completion of the study. Patients will be asked to return all 
unused study treatment and packaging on a regular basis, at the end of the study treatment or at 
the time of study  treatment discontinuation during the treatment period as well as during the 
switch treatment period with asciminib.

Novartis Confidential Page 73
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountabilit y logto the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.
6.7.3.3 Handling of other study  treatment
Not applicable.
6.7.4 Disposal and destruction
The study  drug suppl y can be destro yed at the local Novartis facility , Drug Supply  group or 
third party , or at the site only if permitted by  local regulations and authorized by  Novartis in a 
prior agreement.
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be sup
ported in the patient’s source 
documentation. Patients can be consented for study participation prior to stu dy day -21.
Table 7-2lists all of the assessments required by  patients that switch treatment from bosutinib 
to asciminib after documented treatment failure of bosutinib
.
No eCRF wil l be used as a source document.
(S) is defined as “Source”
(D) is defined as “Data Based”

Novartis Confidential Page 85
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301CategoryProtocol 
Section 
7Switch 
Screening 
PhaseTreatment Switch Phase
Visit name
EOT (Bosutinib)
/
S-Screening/
S-Baseline
S-Week 1 Day 1
S-Week 2 Day 1
S-Week 4
S-Week 6
S-Week 8
S-Week 10
S-Week 12
S-Week 14
S-Week 16
S-Week 20 S-Week 24
S-Week 28 S-Week 32
S-Week 36
S-Week 40 S-Week 44
S-Week 48
S-Week 52HematologyD 7.2.2.5.1 X
(if not done 
at EOT)X X X X X X X X X X X X X X X X X X
ChemistryD 7.2.2.5.2 X
(if not done 
at EOT)X X X X X X X X X X X X X X X
Chemistry -
Hemoglobin A1cD 7.2.2.5.2 X
(if not done 
at EOT)Week 12 and as clinically indicated
CoagulationD 7.2.2.5.2 X
(if not done 
at EOT)X X X X X X X X X X X X X X X
Serum 
Pregnancy test (if 
applicable)D 7.2.2.5.3 X
(if not done 
at EOT)X X X X X X X X X X X X X
Liver 
assessmentsDas clinically indicated

Novartis Confidential Page 92
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
7.1.1 Molecular pre -screening
Not applicable .
7.1.2 Screening
Written informed consent must be obtained before any study  specific medical procedures are 
performed. All screening/baseline assessments (with the exception of Bone Marrow Aspirates) 
should occur within 21 day s before Week 1 Day  1.
The screening visit window for bone marrow assessments is 56days prior to Week 1 Day 1.
Should bone marrow assessments have 
been performed before the main informed consent is 
signed but within 56 days of Week 1 Day 1, no further bone marrow sampling will be required 
at screening. Atend of treatment , abone marrow exploratory  aspirate and/or biopsy  must be 
collected even ifthe screening/baseline bone marrow exploratory  aspirate and/or biops y 
sample s were not collected .During the screening visit, inclusion and exclusion criteria will be 
assessed. Screening assessments to confirm eligibilit y must be performed prior to 
randomization. The results of the real time quantitative polymerase chain reaction (RQ-PCR)
and the bone marrow aspirate must be available prior to randomization and first dose of study  
treatment .
For details of assessments required during screening please refer to Table 7 -1.
Laboratory  baseline assessments (including hematology , chemistry , coagulation and serum 
pregnancy  test), physical examination including extramedullary involvement, performance 
status, ECG, height, weight and vital signs, evaluation of all relevant medical history including 
cardiovascular risk factors, CML  disease history , including prior TKI therapy  and antineoplastic 
medication and prior and concomitan t medication must be performed prior to the first dose of 
study  treatment. Patients with potassium, and/or magnesium and/or total calcium levels that are 
< LLN at screening, must have their potassium, and/or magnesium, and/or calcium replenished 
through supplementation and the levels must be within normal limits prior t
o the first dose of 
study  drug.
A patient who has a laboratory  test (peripheral blood test) results that do not satisfy  the entrance 
criteria may have the tests repeated. These tests may be repeated as soon as the investigator 
believes the re-test results are likely to be within the acceptable range to satisfy  the entrance 
criteria, but should be completed within approximately  2 weeks of the original screening visit 
date. In this case, the subject will not be required to sign another Informed Consent Form (ICF), 
and the original patient ID number assigned by the investigator will be used. In the event that 
the laboratory  tests cannot be performed within the screening visit window, or the re-tests do 
not meet the entrance criteria, or other eligibility  criteria have changed and are not met anymore, 
the patient is considered a screen failure, and must be discontinued from the study .
A new ICF will need to be signed if the investigator chooses to re-screen the patient after a 
patient has screen failed, however, the patient ID number will remain the same. All required 
screening activities must be performed when the patient is re-screened for participation in the 
study . No further bone marrow sampling will be done at re -screening if a previous assessment 
was done within 56 days of Week 1 Day 1. After 56 days, new bone marrow biops y and 
aspirates samples for cytogenetic assessment and exploratory  biomarker purpose should be re -

Novartis Confidential Page 93
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
collected at the time of the bone marrow assessment. An individual patient may be re -screened 
up to three times for the study . Once the number of patients screened and enrolled is likely to 
ensure target enrollment, the Sponsor may close the study  to further screening. In this case , the 
patients who screen failed will not be permitted to re- screen.
7.1.2.1 Eligibility  screening
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed. The eligibility  check will be manage d via IRT system. 
Please refer and compl y with detailed guidelines in the I RT manual.
7.1.2.2 Conditions to be fulfilled for asciminib switch
The eligibility  assessments of patients who are candidates for asciminib switch will start with 
the bosutinib EOT visit . Assessments conducted during the EOT visit will be used to evaluate 
if all conditions for asciminib switch are fulfilled and there are no conditions preventing patients 
from receiving asciminib treatment . Therefore all effort sMUST be made to ensure that all EOT 
assessments are completed per Table 7-1. In the event that all EOT assessments cannot be 
completed during the EOT visit, they must be completed within 42days(6 weeks) after the 
bosutinib EOT visit .For details of assessments r equired for patients that switch treatment from 
bosutinib to asciminib, please refer to Table 7-2.The maximum allowed time frame for patients 
failing bos utinib to start treatment with asciminib is 42 day s after bosutinib EOT.
In case a patient presents with a grade 3 or 4 adverse event at the time of the EOT visit or 
develops it after the EOT visit, the adverse event must be resolved to grade 2 or lower before 
startingasciminib treatment and within 28 days of the date of 
occurrence of the adverse event 
as outlined in the criteria listed below. 
However, a patient who has laboratory  test (peripheral blood test) results or ECG results that 
do not satisfy  thetreatment switch conditions may have the tests repeated multiple times during 
the treatment switch screening period. The last test performed before start of asciminib dosing 
must meet the conditions for treatment switch as listed below .
If apatient does not meet the conditions for treatment switch, they should enter the survival 
follow -up phase.
The conditions for treatment switch will be checked via the IRT system. Please refer and compl y 
with detailed guidelines in the I RT manual.
Conditions to fulfil l to allow the switch to asciminib:
1. Failure to bosutinib treatment up to 96 weeks after the last patient received the first dose 
(adapted from the 2013 ELN Guidelines; Baccarani et al 2013 ). Patients must meet at least 
1 of the following criteria. Failure is defined as follows:
Three months after the initiation of therapy or thereafter : No CHR or > 95% Ph+ 
metaphases.
Six months after the initiation of therap yor thereafter : BCR -ABL 1ratio > 10% I S 
and/or > 65% Ph+ metaphases.
Twelve months after initiation of therap yor thereafter : BCR -ABL 1ratio > 10% I S 
and/or > 35% Ph+ metaphases.

Novartis Confidential Page 94
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
At any  time after the initiation of therapy , loss of CHR, CCy R or PCy R.
At any  time after the initiation of therapy , detec tionof new BCR -ABL 1mutations
which potentially  cause resistance to study  treatment (asciminib or bosutinib) .
At any  time after the initiation of therapy , confirmed loss of MMR in 2 consecutive 
tests.
At any  time after the initiation of therapy , new clonal chromosome abnormalities in 
Ph+ cells: CCA/Ph+.
Conditions preventing patients to switch to asciminib
Any Grade 3 or 4 toxicity  which has not resolved to Grade 2 or lower within 28 days 
and before starting asciminib treatment.
Asymptomatic (Grade 2)pancreatitis if not resolved within 28 day s 
Disease progression while on bosutinib treatment. The following events are 
considered disease progression:
Accelerated phase (AP) as defined b y any of the following:
≥15% blasts in the peripheral blood or bon e marrow aspirate, but < 30% blasts 
in both the peripheral blood and bone marrow aspirate.
≥30% blasts plus promyelocy tes in peripheral blood or bone marrow aspirate.
≥20% basophils in the peripheral blood.
Thrombocy topenia (< 100 x 109/L) that is unrela ted to therapy .
Blast crisis (BC) as defined by  any of the following:
≥30% blasts in peripheral blood or bone marrow aspirate
Appearance of extramedullary  involvement other than hepatosplenomegal y 
proven b y biopsy (i.e. chloroma).
QTcF at time of switch > 480msec or inability  to determine QTc interval
7.1.2.3 Information to be collected on screening failures
Patients who sign an informed 
consent but fail to be randomized for any reason will be 
considered a screen failure. The reason for not being randomized will be entered on the 
Screening Phase Disposition Page. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for Screen Failure patients. No other data 
will be entered into the clinical database for patients who ar e screen failures, unless the patient 
experienced a Serious Adverse Event during the Screening Phase (see Section 
8for SAE 
reporting details). If the patient fails to be randomized, the I RT must be notified within 2 day s 
of the screen fail that the patient was not randomized.
7.1.2.4 Patient demographics and other baseline characteristics
Patient demographics and baseline characteristics collected will include the following: date of 
birth, gender (and child bearing potential for female), race and ethnicity, height, weight, all 
relevant medical history  including cardiovascular disease history , CML disease history , 

Novartis Confidential Page 95
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
including mutation status, and prior and concomitant medication including prior TKI therap y 
and a ntineoplastic medication.
Physical examination including extramedullary  involvement, performance status, vital signs, 
ECGs, and laboratory  assessments will be performed at screening.
Significant findings that were present prior to the signing of informed c onsent must be included 
in the Relevant Medical History /Current Medical Conditions page on the subject’s eCRF. 
Significant new findings that begin or worsen after informed consent must be recorded on the 
AE page of the patient’s eCRF.
The central reading of the screening ECGs as well as the results of the RQ-PCR and the bone 
marrow aspirate must be available prior to randomization and first dose of study  treatment to 
evaluate eligibility  and to stratify  the patient.
7.1.2.5 Local recruitment procedures -Japan
Given the limited safet y data available in Japanese patients, 
specific recruitment and data 
monitoring procedures will be put in place for Japanese patients randomized to asciminib.
Randomization of these patients will be staggered to avoid enrollment of more th an one patient 
on the same day. Safety parameters from a minimum of 2 patients treated on the asciminib arm 
will be reviewed for determin ingthe appropriateness of continuing patient enrollment in Japan .
7.1.3 Run
-in period
Not applicable.
7.1.4 Treatment period
There is no fixed duration of treatment planned per patient. All patients will be given the 
opportunity  to receive study  treatment until the end of study  treatment period as defined in 
(Section 4.3).
During the treatment phase, the patients will receive either asciminib treatment 40 mg BID or 
bosutinib 500 mg QD according to randomization. The dose can be modified, if required from 
the perspective of tolerance, following the guidance in Section 6.2 andSection 6.3 . Treatment 
will be administered until patient experiences treatment failure, unacceptable toxicity , disease 
progression, death, lost to follow -
up and/or treatment is discontinued at the discretion of the 
investigator or withdrawal of consent.
The patients are advised to adhere to the food restrictions during the treatment (fasting status 
regarding stud y treatment administration, avoidance of prohibi ted concomitant medication).
7.1.5 Visit windows
Study  visits from Week 1 Day 1 to Week 2 Day  1 / S-Week 1 Day  1 to S-Week 2 Da y 1  should 
be completed on the designated date [with an allowed “visit window” of +/ -1 day for Week 2 
Day 1 /
S-Week 2 Day  1]
Study  visits from Week 4to Week 16 / S
-Week 4to S-Week 16should be completed every  2 
weeks on the designated date [with an allowed “visit window” of +/ -1 day ]

Novartis Confidential Page 96
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Study  visits from Week 20to Week 96 / S-Week 20to S-Week 96should be completed every 
4 wee ks on the designated date [with an allowed “visit window” of +/ -2 day s]
Study  visits from Week 108to EOT / S-Week 108to S-EOT should be completed every  12 
weeks on the designated date [with an allowed “visit window” of +/ -7 day s]
A delay ed visit will have no impact on the next planned visit. The next visit should be completed 
as scheduled in order to avoid accumulation of additional weeks.
7.1.6 Discontinuation of study treatment
Patients m
ayvoluntarily discontinue from thestudy  treatment forany reason atanytime.Ifa
patient decides todiscontinue from the study  treatment, theinvestigator should make a 
reasonable effort (e.g. telephone, e-mail,letter) tounderstand theprimary reason forthis
decision and record thisinform ation inthepatient ’schart andontheappropriate e CRF pages.
They maybe conside redwithdrawn ifthey state an intention towithdraw, failtor eturnfor vis its,
orbeco me lost tofollow - upfor an yother reason.
The investigator should discontinue study  treat mentfora given patient if,he/she believes that
continua tionwould bedetrimental tothe patie nt’sw e ll-being. Patients who discontinue study 
treatment should undergo an end of treatment visit.
For patients who discontinue treatment in treatment period or switch treatmen t period for 
reasons other than death, lost to follow -up, or withdrawal of consent , the patient should enter 
the survival follow -up phase. Survival visit assessments (survival, antineoplastic therapies, stem 
cell transplant and progression) should be performed every  12 weeks until documented death, 
lost to follow -
up, withdrawal of consent or until the end of the study .This visit can be conducted 
by telephone.
Patients who discontinue the study  treatment for anadverse event suspected to be related to 
study  drug or an abnormal laboratory  value suspected to be related to study  drug must be 
followed as described in Section 8
Patients may  also be discontinued fro m the study  treatment if any of the following occurs:
discovery  of patient ineligibility
errors in treatment compliance [study  treatment, other prescribed or non- prescribed 
medications]
missed/unscheduled/off schedule/incomplete/incorrect assessments
major protocol deviation
use of prohibited treatmentrefer toSection 14 -Appendices
any other protocol deviation thatresults inasignif
icantrisk tothepatient’s saf ety
In addition to the general discontinuation criteria, the following study specific criteria will also 
require discontinuation of study  treatment :
In the event of detection of T315I or V299L mutations at any  time the patient must be 
discontinued from the study treatment .
In the event of a pregnancy  during study , if a patient wants to pursue the pregnancy  then 
patient must be discontinued from the study  treatment. However, in the event of a 

Novartis Confidential Page 97
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
spontaneous miscarriage or in the event of elective abortion, the patient is permitted to 
continue study  treatmen t.
In the event of treatment failure the patient must be discontinued from the study treatment . 
Patients randomized to bosutinib treatment experiencing treatment failure may  switch to 
asciminib treatment. The following events will constitute ‘treatment fai lure’, and are based 
on the ELN criteria (Baccarani et al 2013) defining failure of a second line treatment:
No CHR or > 95% Ph+ metaphases at three months af ter initiation of therapy or 
thereafter
BCR -ABL1 ratio > 10% IS and/or > 65% Ph+ metaphases at six months af ter 
initiation of therapy  or thereafter
BCR -ABL 1ratio > 10% IS and/or > 35% Ph+ metaphases at 12 months after 
initiation of therapy  or thereafter
Loss of CHR, CCy R or PCy R at any  time after initiation of therap y 
Detection of new BCR -ABL 1mutations which potentially  cause resistance to study  
treatment (asciminib or bosutinib) at any  time after initiation of therap y 
Confirmed loss of MMR in 2 consecutive tests (Section 7.2.1.1
)
New clonal chromosome abnormalities in Ph+ cells: CCA/Ph+: at any  time after 
initiation of therapy  
In the event of disease progression the patient must be discontinued from the study
treatment . The following events are considered disease progression.
1.CML -related death (an y death during treatment or follow -up if the principal cause of death 
is marked as “stud y indication” in the eCRF b y the investigator, or if the death occurred 
subsequent to documented progression to AP/B C and the cause of death is reported as 
“unknown” or not reported by  the investigator)
2.Accelerated phase (AP) as defined b y any of the following:
≥ 15% blasts in the peripheral blood or bone marrow aspirate, but < 30% blasts in 
both the peripheral blood an d bone marrow aspirate
≥ 30% blasts plus promyelocy tes in peripheral blood or bone marrow aspirate
≥ 20% basophils in the peripheral blood
Thrombocy topenia (<100 x 10 9/L) that is unrelated to therapy
3.
Blast crisis (BC) as defined by  any of the following:
≥ 30% blasts in peripheral blood or bone marrow aspirate
Appearance of extramedullary  involvement other than hepatosplenomegal y proven b y 
biopsy  (i.e., chloroma).
7.1.7 Withdrawal of consent
Subjects may voluntaril y withdraw consent toparticipate inthestudy foranyreason at any 
time.Withdrawal of consent occurs only when asubject:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data

Novartis Confidential Page 98
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
In this situation, the investigator should make a reasonable effort (e.g. t elephone, e- mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been col lected at subsequent visits will be considered missing. 
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table. 
Novartis will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples un til their time of withdrawal) according to applicable 
law.
For US and Japan: Allbiological samplesnot yet analyzed at the time of withdrawal may
still be used for further testing/anal ysis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and Rest of World : All biological samples not yet analy zed at the time of withdrawal 
will no longer be used, unless permitted by applicable law. They  will be stored according to 
applicable legal requirements.
7.2 Assessment ty pes
7.2.1 Efficacy assessments
7.2.1.1 Molecular response
Molecular response (MR) will be assessed in all patients randomized to each treatment arm as 
well as in patients that switch study  treatment from bosutinib to asciminib.
Levels of BCR -ABL 1transcripts will be determined by  real-time quantitative PCR (RQ -PCR) 
testing of peripheral blood and anal yzed at a central testing laboratory . Log reduction in BCR -
ABL 1transcripts levels from the standardized baseline value, or the percent ratio of BCR -ABL 1
transcripts versus control gene (ABL) transcripts converted to a reference standard, 
international scale ( Hughes and Branford 2006 ), will be calculated for each sample.
Major molecular response and related variables are defined as the following :
Rate of Major Molecular Response (MMR) where MMR is defined as a ≥ 3.0 log 
reduction in BCR -ABL 1transcripts compared to the standardized baseline equivalent to ≤ 
0.1 % BCR -ABL 1/ABL % by  international scale as measured by  RQ-PCR, confirmed by  
duplicate anal ysis of the same sample
Time to MMR defined as the time from the date of randomization to the date of the first 
documented MMR,
Duration of MMR defined as the time from the date of first documented MMR to the 
earliest date of loss of MMR, prog ression to AP or BC, or CML -related death.

Novartis Confidential Page 99
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Loss of MMR is defined as increase of BCR- ABL 1/ABL to >0.1% by international scale (IS) 
in association with a ≥ 5-fold rise in BCR -ABL 1from the lowest value achieved on study 
treatment and replicated by a second analysis of the same sample. Loss of MMR must be 
confirmed by subsequent sample analysis within 4to 6 weeks showing loss of MMR associated 
with a ≥ 5-fold rise in BCR -ABL1 from the lowest value achieved on study treatment, unless it 
is associated with confirmed loss of CHR or loss of CCyR or progression to AP/BC or CML -
related death. Mutational analy sis will be performed at a Novartis designated laboratory  by 
Sanger sequencing at 
Week 1 Day  1, upon confirmed loss of MMR and/orat end of treatment. 
If the result at Week 1 Day 1is positive for a mutation, analysis will be performed every  12 
weeks.
The blood samples will be taken as described in Table 7 -1,Table 7 - 2 and Table 7 -3.
Table 7
-3 Blood samples (efficacy  primary  endpoint)
Sample Type Volume Visit Timepoint
Blood for BCR -ABL1
quantification by RQ -PCR20 mL Screening/Baseline / S-Screening/ S-Baseline* Pre-dose
20 mL Week 4/ S-Week 4 Pre-dose
20 mL Week 8/  S-Week 8 Pre-dose
20 mL Week12/  S-Week 12 Pre-dose
20 mL Week16/  S-Week 16 Pre-dose
20 mL Week24/  S-Week 24 Pre-dose
20 mL Week36/  S-Week 36 Pre-dose
20 mL Week48/  S-Week 48 Pre-dose
20 mL Week60/  S-Week 60 Pre-dose
20 mL Week72/  S-Week 72 Pre-dose
20 mL Week84/  S-Week 84 Pre-dose
20 mL Week96/  S-Week 96 Pre-dose
20 mL Every 12 weeks thereafter up to end of study 
treatment     Pre-dose
20 mL EndofTreatment / S-End of Treatment Anytime
Blood for BCR -ABL1 Mutation
analysi s by Sanger 
Sequencing5 mL Week 1Day1 /S- Week 1 Day 1 * Pre-dose
No sample collected 
-  testing is 
performed on the 
“Blood for BCR -
ABL1 quantification 
by RQ -PCR” sampleUpon confirmed loss of MMR and/or End of 
Treatment / S-End of TreatmentAnytime
Blood for BCR -ABL1 Mutatio n
analysi s only for patients with
mutations at Week 1 Day 1No sample collected 
-  testing is 
performed on the 
“Blood for BCR -
ABL1 quantification 
by RQ -PCR” sampleWeek 12 and ever y 12 weeks thereafter up to 
end of study treatmentAnytime
*Assessment does not need to be completed during the visit for patients in the treatment switch if already 
collected during the EOT or the treatment switch screening visit .

Novartis Confidential Page 100
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
During the study , peripheral blood samples will be collected into PAXgene ™Blood RNA tubes 
for all RQ-PCR assessments. Detailed instructions for the collection, handling, and shipment of 
RQ-PCR and mutation samples are outlined in the [CABL 001A2301 Laboratory  Manual] .
7.2.1.2 Bone marrow analy sis and cytogenetics
Cytogenetic response will be assessed locally as the percentage of Ph+ metaphases in the bone 
marrow and is defined as the following (a review of a minimum of 20 metaphases is required):
Complete (CCy R) -0% Ph+ metaphases
Partial (PCy R) ->0 to 35% Ph+ metaphases
Major (MCy R) -0 to 35% Ph+ metaphas es
Minor (mCy R) ->35 to 65% Ph+ metaphases
Minimal ->65 to 95% Ph+ metaphases
None ->95 to 100% Ph+ metaphases.
Bone marrow 
aspirate for cytogenetic analyses will be performed at screening/baseline 
(performed up to 56days prior to Week 1 Day 1), at Week 24/S- Week 24, 48/S-48, 72/S-72, 
96/S-96 as long as patient has not achieved MMR and at end of treatment ( S-end of treatment 
as specified in Table 7-1 and Table 7 -2. For patients on the bosutinib arm an unscheduled bone 
marrow assessment at week 12 may be performed to evaluate cytogenetic response in 
consideration for potential dose escalation.
Quantification of the percentage of Ph+ chromosome metap
hases, number of metaphases, 
number positive for Ph chromosome, additional chromosomal abnormalities as well as data 
from cytologic evaluation (microscopic analy sis) of percentage of blasts and prom yeloc ytes 
will be recorded on the Bone Marrow eCRF. These exams will be performed and analyzed 
locally . Fluorescent In- situ hy bridization (FISH) analy sis will not be accepted.
7.2.1.3 Hematologic response
A complete hematologic response (CHR) is defined as all of the following present for ≥ 4 weeks:
WBC count <10 x 109/L
Platelet count <450 x 109/L
Basophils <5%
No blasts and prom yelocytes in peripheral blood
Myelocy tes + metam yelocytes < 5% in peripheral blood
No evidence of extramedullary  disease, including spleen and liver
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by the assessments described below as well as collecting of the adverse 
events at every  visit. For details on AE collection and reporting, refer to Section 8 .Significant 
findings that were present prior to the signing of informed consent must be included in the 
Relevant Medical History/Current Medical Conditions page on the patient’s eCRF. Significant 
new findings that begin or worsen after informed consent mu st be recorded on the AE page of 
the patient’s eCRF.

Novartis Confidential Page 101
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
7.2.2.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes , 
extremities, vascular and neurological. Information about the physical examination must be 
present in the source documentation at the study  center and will be collected on the following 
visits as specified in Table 7 -1and Table 7 -2:
Screening /
S-Screening
Week 1 Day  1/ S-Week 1 Day 1
Every  2 weeks from Week 4 to Week 16 / S-Week 4 to S- Week 16. Week 6, 10 and 14 / 
S
-Week 6, 10 and 14 assessments mus t be performed in case of previous or newl y 
occurring adverse events.
Every  4 weeks from Week 16 to Week 96 / S-Week 16 to S- Week 96
Every  12 weeks from Week 96 to EOT / S
-Week 96 to S- EOT
End of treatment / S
-End of treatment visit or early  discontinuation / S-early  
discontinuation visit in case of premature discontinuation.
Significant findings that were present prior to the signing of informed consent must be included 
in the Medical History  page on the patient’s eCRF. Significant new findings that begin or 
worsen after informed consent must be recorded on the Adverse Event page of the patient’s 
eCRF. Presence of extramedullary  leukemic involvement will be checked with each physical 
examination as outlined above. Findings on physical examination consistent with extra-
medullary  leukemic involvement will be recorded (e.g. liver and spleen size, any other organ 
involvement).
7.2.2.2 Vital signs
Vital signs include blood pressure (supine position preferred 
when ECG is collected), pulse 
measurement, and bod y temperature and must be performed at the following visits as specified 
in Table 7-1 and Table 7 -2:
Screening / S
-Screening
Week 1 Day  1/ S-Week 1 Day 1
Week 2 Day  1/ S-Week 2 Day  1
Every  2 weeks from Week 4 to Week 16 / S-Week 4 toS-Week 16
Every  4 weeks from Week 16 to Week 96 / S-Week 16 to S- Week 96
Every  12 weeks from Week 96 to EOT / S
-Week 96 to S- EOT
End of treatment / S
-End of treatment visit or early  discontinuation / S-early  
discontinuation visit in case of premature discontinuation.
7.2.2.3 Height and weight
Height in centimeters (cm) will be measured at screening onl y.
Body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be 
measured at screening and at subsequent time points as specified in Table 7 -1and Table 7 -2:
Screening / S
-Screening

Novartis Confidential Page 102
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Week 1 Day  1/ S-Week 1 Day 1
Every  12 weeks from Week 12 to EOT / S -Week 12 to S-EOT
End of treat ment visit / S-End of treatment or early  discontinuation / S-early  
discontinuation visit in case of premature discontinuation.
7.2.2.4 Performance status
ECOG Performance status scale (Table 7-4) will beused asdescribed in theTable 7-1, Table 
7-2andTable 7 - 4:
Screening / S
-Screening
Week 1 Day  1/ S-Week 1 Day 1
Every  2 weeks from Week 4 to Week 16 / S-Week 4 to S- Week 16
Every  4 weeks from Week 16 to Week 96 / S
-Week 16 to S- Week 96
Every  12 weeks 
from Week 96 to EOT / S-Week 96 to S- EOT
End of treatment / S
-End of treatment visit or early  discontinuation / S-early  
discontinuation visit in case of premature discontinuation.
More frequent examinations may be performed at the investigator’s discretion, if medically 
indicated.
Table 7-4 ECOG Performance status scale
Description Grade
Fully active, able to carry on all pre -disease activities without restriction. 0
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature e.g. light housework, office work.1
Ambulatory and capable of all self -care but unable to carry out any work activities. Up and 
about more than 50% of waking hours.2
Capable of only limited self -care, confined to bed or chair more than 50% of waking hours. 3
Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair. 4
Dead. 5
7.2.2.5 Laboratory  evaluations
Central laboratory  will be used for analysis of hematology , biochemistry , coagulation, serum 
pregnancy  and hepatitis marker specimens collected (safet y monitoring) as specified inTable 
7-1, Table 7 -2andTable 7 -5. Details on the collections, shipment of the samples and reporting 
of results by the central laboratory  are provided to investigators in the [CABL 001A2301 
Laboratory  Manual] . The time windows granted for laboratory  evaluations are identical with 
the corresponding visit time windows for each visit (see Section 7.1.5).
Local laboratory  analysis are allowed if there is a clinical suspi cion of abnormal laboratory
values which is supported by a reported adverse event and for hematology  assessments at Week 
6, 10 and 14.

Novartis Confidential Page 103
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Table 7-5 Central clinical laboratory  parameters collection plan
Test Category Test Name Frequency
Hematology Hemoglobin, platelets, red blood cells, white 
blood cells, W BC morphology with 
differential (basophils, e osinophils, 
lymphocytes, monocytes, n eutrophils, 
promyelocytes, myelocytes, 
metamyelocytes, blast and other)Screening/ baseline, Week 1 Day 1, 
Week 2 Day 1, every 2 weeks from week 
4 up to week 16, every 4 weeks up to 
week 96, and every 12 weeks thereafter, 
EOT and as clinically indicated / S-
Screening/ S-baseline* , S-Week 1 Day 1, 
S-Week 2 Day 1, every 2 weeks from S-
week 4 up to S-week 16, every 4 weeks 
up to S-week 96, and every 12 weeks 
thereafter, S-EOT and as clinically 
indicated
Chemistry Hemoglobin A1c Screening/ baseline, Week 12 and as 
clinically indicated / S-Screening/ S-
baseline* , S-Week 12 and as clinically 
indicated
Chemistry Creatinine clearance Screening/b aseline / 
S-Screening/S -baseline*
Chemistry Albumin, alkaline phosphatase, ALT (SGPT), 
AST (SGOT), total calcium, total calcium 
(corrected for albumin), c reatinine , creatine 
kinase, potassium, magnesium, s odium, 
phosphate (inorganic p hosphorus ), direct 
bilirubin, indirect bilirubin, total bilirubin, total 
cholesterol, LDL cholesterol , HDL
cholesterol , total protein, triglycerides, blood 
urea or Blood Urea Nitrogen (BUN) , uric 
acid, amylase, lipase, glucose (fasting)Screening/ baseline, Week 1 Day 1, 
Week 2 Day 1, every 4weeks from week 
4 up to week 96, and every 12 weeks 
thereafter, EOT, and as clinically 
indicated / S-Screening/ S-baseline *, S-
Week 1 Day 1, S-Week 2 Day 1, every 4
weeks from S-week 4 up to S-week 96, 
and every 12 weeks thereafter, S-EOT, 
and as clinically indicated
Coagulation International Normalized Ratio (INR)
Hepatitis markers HbsAg, HbcAb /anti -Hbc Screening/ baseline **
Serum Pregnancy 
test (if applicable)Serum ß-HCG testing Screening/ baseline, every 4 weeks up to 
week 96, and every 12 weeks thereafter, 
EOT, unscheduled / S-Screening/ S-
baseline* , every 4 weeks up to S-week 
96, and every 12 weeks thereafter, S-
EOT, unscheduled
*Assessment does not need to be completed during the screening visit for patients in the treatment switch if 
already collected during the EOT.
**Not applicable for patients being assessed for treatment switch as part of the treatment switch 
screening/baseline visit.
7.2.2.5.1 Hematology
Hematology  labs are to be anal yzed at each scheduled visit by  a central laboratory (Week 6, 10 
and 14 assessments can be performed at site or at any  peripheral local laboratory )as specified 
in Table 7-1and Table 7-2. Hematology  includes assessment of hemoglobin, platelets count, 
red blood cells, total white blood cell count (WBC) and a full manual differential count 
including basoph ils, eosinophils, lymphocy tes, monocy tes, neutrophils, promy elocy tes, 
myelocy tes, metam yelocytes, blast and other cells ( Table 7
-5).

Novartis Confidential Page 104
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
7.2.2.5.2 Clinical chemistry
Blood chemistry  labs are to be analyzed at each scheduled visits by a central laboratory as 
specified in Table 7 -1and Table 7-2. Chemistry  includes albumin, alkaline phosphatase, ALT 
(SGPT), AST (SGOT
), total calcium, total calcium (corrected for albumin), creatinine, 
creatinine clearance, creatine kinase, potassium, magnesium, sodium, phosphate (inorganic 
phosphorus ), direct bilirubin, indirect bilirubin, total bilirubin, total cholesterol, LDL
choles terol, HDL cholesterol, total protein, trigly cerides, blood urea,Blood Urea Nitrogen 
(BUN), uric acid, amylase, lipase and fasting glucose. In addition the coagulation parameter 
INR is anal yzed at each scheduled visit.
HbA1c is anal yzed at screening/baseline, week 12 and as clinicall y indicated.
The hepatitis markers HbsAg, HbcAb/anti -Hbc are anal yzed at screening/baseline ( Table 7 -5).
7.2.2.5.3 Pregnancy and assessments of fertility
All women of childbearing potential have to complete a serum pregnancy  test at the screening 
visit, at every  monthl y visit until end of treatment visit. Pregnancy  testing is not required for 
patients who are determined to be post -menopausal. The time windows granted for pregnancy 
testing are identical with the corresponding visit time windows
 for each visit. Refer to Table 7 -
1and Table 7-2of the Visit evaluation schedule s . Serum pregnancy  test will be per formed by 
a central laboratory .
After Week 96 / S-Week 96, monthly  urine pregnancy  test must be performed b y all women of 
child- bearing potential between the three monthly  visits (beginning at Week 100/ S-Week 100).
Urine pregnancy  tests may be performed at the investigational site or at home. Test results 
performed at home should be recorded onto a patient diary  and brought to each scheduled visit 
for the site to review. If a test result indicates a pregnancy , the patient must contact the 
investigator immediatel y.
Pregnancies diagnosed in female patients participating in the study   should be recorded on a 
Clinical Trial Pregnancy Form and reported b y the investigator to the Oncology Novartis Chief 
Medical Office and Patient Safety  (CMO&PS) Department.
During the whole study , women of childbearing potential should employ the use of highl y 
effective contraception. Highly effective contraception methods are defined in Section 5.3
7.2.2.6 Cardiac assessments
7.2.2.6.1 Electrocardiogram (ECG)
After the subject has rested approximately  10 minutes in a semi -supine position, standard 12-
lead ECGs must be obtained in triplicate with a recommended minimal interval of 5 minutes 
between each ECG at the time points specified in Table 7
-1, Table 7 -2,Table 7 - 6 and Table 7 -
7. ECGs should be taken before blood samples for PK if both assessments are scheduled at the 
same time point . In this case recording of ECGs should be planned according to the true time 
of blood sa mple for PK rather than to the scheduled time point.

Novartis Confidential Page 105
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Table 7-6 Central ECG collection (all patients)
Week (or Day ) Number of ECGs (per visit) Time of ECG
Screening/Baseline Day -21 
to -1/ S-Screening/ S-
Baseline Day -42 to -1 (all 
patients)3 3 serial ECGs at the screening visit
Week 1 Day 1 / S-Week 1 
Day 1 (all patients)3 3 serial ECGs at 2 h post dose
Week 2 Day 1 / S-Week 2 
Day 1 (asciminib /asciminib 
switch patients )12 3 serial ECGs pre -dose and at 2, 3, 4 h post -
dose
Week 2 Day 1 / S-Week 2 
Day 1 (bosutinib)3 3 serial ECGs pre-dose
Week 4 / S-Week 4 (all 
patients)3 3 serial ECGs pre-dose
Week 12 / S-Week 12 (all 
patients)3 3 serial ECGs pre-dose
Week 24 / S-Week 24 (all 
patients)3 3 serial ECGs pre-dose
Week 96 / S-Week 96 (all 
patients)3 3 serial ECGs 30 min* post-dose
Unscheduled (all patients) 3 3 serial ECGs 
* 30 min +/ - 5min allowed
Table 7-7 Central ECG collection plan for patients in full PK asciminib group
Week (or Day ) Number of ECGs (per visit) Time of ECG
Day -21 to -1 3 3 serial ECGs at the screening visit
Week 1 Day 1 3 3 serial ECGs at 2 h post dose
Week 2 Day 1 24 3 serial ECGs pre -dose and at 1, 2, 3, 4, 6, 8, 
12 h post- dose
Week 4 3 3 serial ECGs pre-dose
Week 12 3 3 serial ECGs pre-dose
Week 24 3 3 serial ECGs pre-dose
Week 96 3 3 serial ECGs 30 min *post-dose
Unscheduled 3 3 serial ECGs 
* 30 min +/ - 5min allowed
All ECGs performed will be independently  reviewed. Instructions for the collection and 
transmission of these ECGs to the independent central reader (ERT(Electronic Research 
Technology , Inc.) ) will be provided in the [CABL001A2301 ECG Manual] .
Three serial ECGs (triplicate) should be performed ½ hour prior to dosing for pre-dose 
assessment. The serial ECGs should be taken approximately  5 m inutes apart. All 3 ECGs for 
each time point should be sent to ERT. Readings for QTc prolongation will be based on the 
average seen in the scans for each time point. The enrollment of patients has to be based on 
centrall y assessed QTcF time. If one of the 3 serial ECGs prior to dosing on day 1 shows a 
QTcF ≥ 450 msec (male) or ≥ 460msec (female) by  automated reading, an immediate manual 

Novartis Confidential Page 106
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
central reading must be requested by  calling ERT. The patient may  not be dosed if the average 
of the manuall y read ECGs confirms a QTcF ≥ 450 msec (male) or ≥ 460 msec (female).
Dose adjustments in case of QT prolongation should be performed per Section 6.3.2 .
Additional unscheduled ECGs may  be repeated at the discretion of the investigator at any  time 
during the study  as clinically  indicated. Unsc heduled ECGs with clinicall y significant findings 
should be collected in triplicate. Local cardiologist ECG assessment may  also be performed at 
any time during the study at the discretion of the investigator.
All ECGs, including unscheduled triplicate safety  ECGs with clinically relevant findings, 
collected during the study should be transmitted to the central core ECG laboratory  for review.
The results of the centrally  assessed ECGs are automatically  transferr ed into the clinical 
database .
Clinically  significant ECG abnormalities present at screening should be reported on the Medical 
History  eCRF page. New or worsened clinically significant findings occurring after informed 
consent must be recorded on the Adver se Events e CRF page.
7.2.2.6.2 Cardiovascular risk factor assessment
Cardiovascular events (CVE) including ischemic heart disease, peripheral arterial occlusive 
disease and ischemic cerebrovascular events have been reported in CML patients receiving TKI 
therapies asspecified in Table 7 -1and Table 7 -2. As both study  treatments in the trial are TKI s 
(asciminib and bosutinib), 
the cardiovascular risk factors (hypertension, tobacco use, raised 
blood glucose (diabetes), physical inactivit y, unhealthy diet, cholesterol/lipids, overweight and 
obesity ) of each patient will be collected prior to randomization and end of treatment. This will 
also include the patient’s Fam ily History .
7.2.2.6.3 Echocardiogram
Echocardiograms will be performed to monitor cardiac safety .Assessments are scheduled at 
screening/baseline, Week 20 and end of treatment visits. The echocardiogram will be performed 
and evaluated locall y to assess the left ventricular ejection fraction. Any clinically  significant 
findings will be collected and reported in the database (i.e. reported as adverse events). For 
patients that switch from bosutinib to asciminib treatment , an echocardiogram willno longer
berequired.
7.2.2.6.4 Pulmonary function test
Pulmonary  function test will be performed to monitor cardio -pulmonary  safety.Assessments 
are scheduled at screening/baseline, Week 20 and end of treatment visits. The pulmonary 
function test with the plethy smograph includes the assessment of the lung volumes FEV1, FVC, 
FEV1/FVC, TL C and VC. I n addition the DLCO to evaluate the gas exchange will be assessed 
at the same time points. Any clinicall y significant findings will be collected and reported in the 
database (i.e. reported as adverse events). For patients that switch from bosutinib to asci minib
treatment , the pulmonary function testing will no longer be required.

Novartis Confidential Page 107
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
7.2.3 Pharmacokinetics
Blood samples for asciminib pharmacokinetics will be collected on all study subjects allocated 
to the asciminib treatment arm. Blood samples for full PK profiles will be collected from at 
least 20 patients. These patients will be identified sequentially at selected sites that are ca pable 
of serial PK sampling over 12 hours. Asciminib should be taken for at least 3 consecutive days 
without interruption or dose modification prior to full PK day .
Blood samples for asciminib pharmacokinetics will also be collected on patients switching from 
bosutinib to asciminib (see Table 7 -8). 
For the assessment of asciminib pharmacokinetics in plasma, serial blood samples will be 
collected following asciminib administration at several time-points (see Table 7-1, Table 7-2, 
Table 7 -
8and Table 7-9below for further details). Remaining plasma samples may be used for 
identification and/or measurement of metabolites of asciminib .
Refer to the [CABL001A2301 Laboratory  Manual ]for detailed instructions for the collection, 
handling, and shipment of PK samples.
Table 7-8 Pharmacokinetic blood collection log (Sparse PK -group -asciminib
arm/asciminib treatment switch patients )
Week /
S-WeekDay Scheduled Time 
PointDose 
Reference IDPK Sample No Blood Volume 
(mL)
1 1 2 h (± 10 min) 101 101 2
2 1 0 h (Pre -dose)a102/2001b102 2
1 2 h (± 10 min) 102 103 2
1 3 h (± 15 min) 102 104 2
1 4 h (± 15 min) 102 105 2
4 Any 0 h (Pre -dose)a103/3001b106 2
12 Any 0 h (Pre- dose)a104/4001b107 2
24 Any 0 h (Pre -dose)a105/5001b108 2
96 Any 0 h (Pre -dose)a106/6001b109 2
Unscheduled 1001+
aPre-dose PK sample should be taken immediately prior to the next administration of asciminib. PK samples 
on Week 2 Day 1 should be taken before and after the morning dose (i.e. 1stdose of the day). PK samples on 
other weeks may be taken immediately prior to the morning dose (i.e. 1stdose of the day) or the evening dose 
(i.e. 2nddose of the day).
bThe first dose reference ID refers to the first dose administered after PK sampling and the second dose 
reference ID refers to the last dose administered prio r to the PK sampling.

Novartis Confidential Page 111
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
7.2.5 Resource utilization
The measures of healthcare Resource Utilization (RU) to be collected include: hospitalization
(H), emergency  room (ER) visit, general practitioner (GP) visits, specialist (Sp) visit and urgent 
care (UC) visit. These measures will be used to derive the economic impact of asciminib and 
bosutinib.
Hospitalization visits will also record the number of days in ward and the type of ward (hospital 
unit) and the discharge status. At each RU collection, the reason for the visit (i.e. related to 
CML , AErelated to CML therapy or other reason) will be collected in order to quantify  the 
impact of asciminib and bosutinib on healthcare resources.
The RU assessment will be completed at each scheduled clinical trial visit as specified in Table 
7-1; the RU will be completed by the investigator however information with respect to the 
number of GP, UC, Sp or ER visits will be ascertained from the 
patient.
All attempts to collect as much information from the patient as possible should be made in order 
to minimize selection bias.
7.2.6 Patient reported outcomes
The MDASI CML, PGIC, WPAI  along with EQ-5D-5L (EuroQol Group (1990) , Brooks (1996) ,
Herdman et al (2011) ) will be used to compare data on the patient’s disease -related symptoms 
and health -related quality of life from baseline to EOT between the treatment arms. The WPAI 
will be used to ass ess work productivity  and activity  impairment related to the patient’s CML . 
All measures will assess differences between the treatment arms. All tools require patient’s 
direct completion and will be administered utilizing an electronic device for data coll ection .
Patients with an evaluable baseline score and at least one evaluable post baseline score during 
the treatment period will be included in the change from baseline analy ses. Missing data items 
in a scale will be handled according to the manual for each instrument. No imputation will be 
applied if the total or subscale scores are missing at a visit.
The patient should be given the questionnaire(s) to be completed at the scheduled visit before 
any clinical assessments are conducted as specified inTable 7-1. Completion of all 
questionnaires is mandatory ; they  cannot be skipped. In the event a patient refuses to complete 
the questionnaire(s), the patient’s refusal should be documented in the study  data capture system 
and should not be captured as a protocol deviation. Patient questionnaires should be completed 
in the language most familiar to the patient.
The patient should be given sufficient space and time to complete the questionnaires and the 
adminis
tered questionnaire should be reviewed for completeness. If missing responses are noted, 
patients should be encouraged to complete an y missing responses. 
Completed questionnaire(s) and any unsolicited comments written by the patient should be 
reviewed andassessed by the investigator for responses which may indicate potential AEs or 
SAEs before any  clinical study  examinations. This assessment should be documented in study 
source records. If AEs or SAEs are confirmed, study  investigators should not encourage the 
patient to change responses reported in the completed questionnaires. Study investigators must 
follow reporting instructions outlined in Section 8 (e.g. reference “Adverse Events” Section) of 
the study  protocol.

Novartis Confidential Page 112
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
MDASI-CML
The M.D. Anderson S ymptom I nventory  –Chronic M yeloid Leukemia (MDASI -CML) is a 26 
item self -administered questionnaire for adult CML  patients. Twenty  of the items measure the 
severit y of disease -related sy mptoms and are scored fr om 0 (Not present) to 10 (As Bad as you 
can imagine) and 6 items that measure s ymptom interference with daily life scored from 0 (Did 
not interfere) to 10 (Interfered completely ). Descriptive statistics will be provided for the 
MDASI -CML  symptom score and interference score, and the change in the MDASI -CML 
symptom score and interference score from baseline to all available time points to the end of 
study . Additional anal ysis may  be performed and details will be described in the anal ysis plan.
EQ-5D-5L
EQ-5D- 5L is a two-part standardized instrument for measuring health outcomes in a wide range 
of health conditions and treatments. It consists of a descriptive system and a visual analogue 
scale (EQ VAS). The descriptive system comprises the following 5 dimensio ns: mobility , self -
care, usual activities, pain/discomfort and anxiety /depression. Each dimension has 5 levels: no 
problems, slight problems, moderate problems, severe problems and extreme problems (or 
unable to perform the activity ). 
The EQ VAS records the respondent’s self-rated health on a 
vertical, visual analogue scale where the endpoints are labeled ‘Best imaginable health state’ 
and ‘worst imaginable health state’. The health states derived from the descriptive system can 
be summarized into a single index score that provides a simple measure of health for clinical 
and economic appraisal. Descriptive statistics will be provided for EQ-5D- 5L health index score 
and for the EQ VAS, at each scheduled assessment time point. There should be only ONE 
response for each dimension. Missing values can be coded as ‘9’. Ambiguous values (e.g. 2 
boxes are ticked for a single dimension) should be treated as missing values. Additional analy sis 
may be performed and details will be describ ed in a separate anal ysis plan.
WPA I
The Work Productivity  and Activity  Impairment Questionnaire (WPAI) is a four-item 
questionnaire which is intended to measure work and activity  impairment associated with CML  
for those who self-identify  as currently  employ ed for pay. This questionnaire measures self-
reported productivity  loss associated with CML during the past seven days. It consists of 
questions about absence from work due to CML , hours spent at work, the reduction in 
productivity  at work attributed to CML , and the reduction in produc tivity while performing 
regular activities. WPAI outcomes are expressed as impairment percentages, with higher 
numbers indicating greater impairment and less productivity , i.e., worse outcomes, Scoring will 
be done according to WPAI  instrument guidance resulting in four scores including: Percent 
work time missed due to problem; percent impairment while working due to problem; Percent 
overall work impairment due to problem; and, percent activity  impairment due to problem.
Change from baseline in WPAI  at each visit, where measured, will be done for each of the four 
derived scores.
PGIC
The Patient Global Impression of Change is comprised of a single question intended to measure 
a patient’s perspective of improvement or deterioration over time relative to treatment. The 

Novartis Confidential Page 113
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
PGIC uses a seven -point scale where one (1) equals very  much improved and seven (7) equals 
very much worse. A summary  of Patient Globa l Impression of Change (PGI C) at each visit, 
where measured will be provided.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), symptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent shoul d be recorded in the Adverse 
Events eCRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s eCRF. Adverse event monitoring should 
be continued for at least 30 days (or 5 half-lives, whichever is longer) following the last dose 
of study  treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underly ing signs and 
symptoms. When aclear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.
Adverse events will be assessed and graded according to the Common Terminology  Criteria for 
Adverse Events (CTCAE) version 4.03. Grade 1 to 5 will be used to characterize the severit y 
of the Adverse Event.
If CTCAE grading does not exist for an 
adverse event, the severit y of mild, moderate, severe, 
and life -threatening, death related to the AE corresponding respectively toGrades 1 -5, will be 
used. Information about any deaths (related to an Adverse Event or not) will also be collected 
through a Death form .
The occurrence of adverse events should be sought by  non-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1 -5)
2.Itsduration (Start and end dates)
3.Its relationship to the study  treatment (Reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)

Novartis Confidential Page 114
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant med ication/non -drug therap y)
6.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
and which seriousness criteria ha ve been met
7. Outcome (not recovered/not resolved, recovered/ resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
If the event worsens the event should be reported a second time in the eCRF noting the start 
date when the event worsens in toxicity . For grade 3 and 4 adverse events only, i f improvement 
to a lower grade is determined a new entr y for this event should be reported in the eCRF noting 
the start date when the event improved from h aving been Grade 3 or Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event eCRF.
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each vis
it (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Natural progression or deterioration of the malignancy  under treatment (including loss of 
response, progression to accelerated phase or blast crisis and death due to disease progression), 
will be recorded as part of the efficacy  evaluation and should NOT be reported as an AE/SAE.
Signs and symptoms clearly  associated with the disease under study  should NOT be reported 
as AEs unless they  are newly  emergent (i.e. not previously  observed in the patient), judged by 
the 
Investigator to be unusually  severe or accelerated, or if the Investigator considers 
deterioration of disease -related signs and symptoms to be caused directly  by the study  drug. If 
there is any uncertaint y about an AE being due solely  to the disease under study , it should be 
reported as an AE or SAE as appropriate.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laborat ory abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events eCRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalit ies, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality  may be required b y 

Novartis Confidential Page 115
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
the protocol in which case the lab abnormality  would still, by definition, be an adverse event 
and must be reported as such.
8.1.3 Adverse events of special interest
Adverse events of special interest (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitoring and rapid communication by  the investigator t o the sponsor may  be 
appropriate. Such events may require further investigation in order to characterize and 
understand them.
Adverse events of special interest are defined on the basis of an ongoing review of the safet y 
data. AESIs are discussed in detail
in the [ Asciminib Investigator ’sBrochure] .
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospitalization or prolongation of existin g hospitali zation,
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
Elective or pre -planned treatment for a pre
-existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an emergency  outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
8.2.2 Reporting
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study  treatment must be reported to Novartis within 24 hours of learning of its occurrence.
Any additional informatio n for the SAE including complications, progression of the initial SAE, 
and recurrent episodes must be reported as follow -up to the original episode within 24 hours of 
the investigator receiving the follow -up information. An SAE occurring at a different time 

Novartis Confidential Page 116
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
interval or otherwise considered completely  unrelated to a previousl y reported one should be 
reported separatel y as a new event.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to Novartis if the investiga tor suspects a causal relati onship to the study  treatment.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report . The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis. Detaile d 
instructions regarding the SAE submission process and requirements for signatures are to be 
found in the investigator folder provided to each site.
Each re-occurrence, complication, or progression of the original event should be reported as a 
follow -up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  parti cipation.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the Novartis study  treatment, an oncology  Novartis 
Chief Medical Office and Patient Safety  (CMO&PS) departme nt associate may urgently  require 
further information from the investigator for Health Authority  reporting. Novartis may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE hasbeen reported. Suspected Unexpected Serious Adverse 
Reactions (SUSARs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.
8.3 Emergency  unblinding of treatment assignment
Not applicable.
8.4 Pregnancies
To ensure patient safet y, each pregnancy occurring while the patient is on study treatment must 
be reported to Novartis within 24 hours of learning of its occurrence . The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology  Novartis Chief Medical Office and Patient Safety (CMO&PS ). 
Pregnancy  follow -up should be recorded on the same form and should include an assess ment 
of the possible relationship to the study  treatment any pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.

Novartis Confidential Page 117
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided asciminib 
Investigator ’sBrochure or bosutinib label . Additional safety  information collected between IB 
updates will be communicated in the form of Investigator Notifications. This information will 
be included in the patient informed consent and should be discussed with the patient during the 
study  as needed.
8.6 Data Monitoring Committee
This study  will institute a data monitoring committee (DMC) which willfunction independentl y 
of all other individuals associated with the conduct of this clinical trial, including the 
site 
investigators participating in the study . The DMC will be constituted prior to the randomization 
of the first patient. The DMC will be responsible to review safet y data at approximately  6
months after the first randomized patient has started study  treatment . Subsequent reviews will 
be conducted approximately  every 6 months on an as and when needed basis thereafter (i.e. if 
significant safety findings are noted) . This includes but does not limit the role of the DMC to 
evaluate these data and to provide recommendations to the sponsor to continue, modify  or stop 
the study  earl
y. The DMC will be in place at least until the c onduct of the primar y anal ysis.
It is expected that the DMC will consist at a minimum of two physicians with appropriate 
disease area qualifications and one statistician. There will be a meeting with the DMC 
describing their roles and responsibilities and discussing potential data format and process 
issues prior to the finalization of DMC charter.
It is envisioned that the DMC may  make certain ty pes of recommendations, namely :
No safet y concerns, ethical to continue the study as planned
Serious safet y concerns precluding further study  treatment, regardless of efficacy
Recommendation to continue the study  but proposing an amendment to the protocol (e.g., 
incorporate an additional safet y assessments)
8.7 Steering Committee
In order to monitor study conduct, a Steering Committee (SC) will be established comprising 
investigators participating in the trial. Additionally  two sponsor representatives (a physician 
and a statistician) will be active members of this committee.
The SC will ensure transparent management of the study  according tothe protocol through 
recommending and approving modifications as circumstances require. Novartis will make final 
decisions on trial conduct based on SC recommendations. Together with the clinical trial team, 
the SC will review protocol amendments as appro priate, and also develop recommendations for 
publications of study  results including authorship rules. The details of the role of the Steering 
Committee will be defined in a Steering Committee charter.

Novartis Confidential Page 118
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
9 Data collection and management
9.1 Data confidentiality
Information about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the subject 
experienced an y new or worsened AEs) at the end of their scheduled study period.
The data collection system for this study  uses built-in security  features to encry pt alldata for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected . If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subj ect satisfies protocol age requirements and 
to enable appropriate age -related normal ranges to be used in assessing laboratory  test results.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and eCRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field moni tor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiogr ams, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).

Novartis Confidential Page 119
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the eCRF entries. Novartis monitoring standards require full verification for 
the presence of informed consent, adherence to the incl usion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the eCRFs 
are performed according to the study -specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by the protocol into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully validated secure web-
enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they 
have been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF is complete, 
accurate, and that entry and updates are performed in a timely  manner.
Data collected by third parties (biochemistry , PCR assessments, biomarkers, PK) will be sent 
electr onically  to Novartis.
9.4 Database management and quality  control
For studies using eCRFs, Novartis personnel (or designated CRO) will review the data entered 
by investigational staff for completeness and accuracy . Electronic data queries stating the nature 
ofthe problem and requesting clarification will be created for discrepancies and missing values 
and sent to the investigational site via the EDC system. Designated investigator site staff are 
required to respond promptly  to queries and to make any  necessary changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical condition s and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data will be processed centrall y and the results will be sent electronically to 
Novartis (or a designated CRO).
Randomization codes and data about all study  treatments dispensed to the patient and all IRT 
assigned dosage changes will be tracked using the Novartis I nteractive Response Technology .
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper co pies 
of the patient data for archiving at the investigational site.
10 Statistical methods and data analy sis
The data will be anal yzed by  Novartis and/or designated CRO. It is planned that the data from 
participating centers in this protocol will be combined, so that an adequate number of patients 
will be available for analy sis.

Novartis Confidential Page 120
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Study  data will be summarized with respect to demographic and baseline characteristics, 
efficacy  observations and measurements, safety  observations and measurements, and all 
relevant P K and PD measurements.
The cut-off date for the primary  analysis is defined as the date when all patients have been on 
study  treatment for 24 weeks or discontinued earlier. The cut-off date for the end of study
treatment analysis is defined as 30 days after the end of study  treatment period (see Section 4.3)
to ensure that 
all available treatment phase data from all patients up to the last dose of study  
drug taken in this study , will be analy zed and summa rized in the end of study treatment phase 
CSR. Patients will be further followed  for survival and progression for up to 5 years from the 
date the last randomized patient receive sthe first study  dose. An update analy sis of OS and PFS 
will be performed at the end of the follow -up period in the final study  CSR .
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Analysis Set (FAS) comprises all patients to whom study  treatment has been assigne d 
by randomization. According to the intent ionto treat principle, patients will be analyzed 
according to the treatment and stratum they have been assigned to during the randomization 
procedure.
10.1.2 Safety  set
The Safety Set includes all patients who received at least one dose of study treatment. Patients 
will be anal yzed according to the stud y treatment received, where treatment received is defined 
as the randomized treatment if the patient took at least one dose of that treatment or the first 
treatment receiv ed if the randomized treatment was never received.
10.1.3 Per-Protocol set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with requirements of the CSP. The PPS will be used for sensitivity  analyses on the primary 
endp oint only .
Oncology  standards for protocol deviations potentially  leading to exclusion from the PPS are:
Type of indication different from those required by  the CSP
If prior therap y does not match with CSP requirements in terms of number and types of 
previous therap y regimens
Another anti -neoplastic therap y administered after start of study  treatment and prior to 
first efficacy  assessment
Study  treatment received different from treatment assigned by  randomization
10.1.4 Dose -determining analy sis set
Not appli cable.

Novartis Confidential Page 121
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
10.1.5 Pharmacokinetic analy sis set
The Pharmacokinetic analysis set (PAS) includes all patients who provide at least one 
evaluable PK concentration. For a concentration to be evaluable, patients are required to:
Take a dose of asciminib prior to sampling,
Take the same dose of asciminib for at least 3 consecutive day s without dose interruption 
or dose modification prior to sampling,
For post -dose samples, do not vomit within 4 hours after the dosing of asciminib (this is 
the current dose) ; for pre -dose sam plesdo not vomit within 4 hours after the dosing of 
asciminib prior to sampling (this is the previous dose),
Have thepre-dose sample collected before thenext dose administration.
10.1.6 Other analy sis set
For duration of MMR and time to MMR, the MMR Responder Set that will be used is a subset 
of FAS and includes patients who achieve MMR at any  time .
For CCyR rates at and by scheduled time points, the CCyR Anal ysis Set that will be used is a 
subset of FAS and includes patients who are not in CCy R at baseline.
For duration of CCy R and time to CCy R, the Cy togenetic Responder Set that will be use dis a 
subset of FAS andincludes patients who do not have CCyR at baseline and achieve CCyR at 
any time on study  treatment .
Patients who will receive at least one dose of asciminib after bosutinib failure will form the 
Switch Analy sis Set which will be used for safety  and exploratory  efficacy  endpoints defined 
on these patients
. 
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed and 
summarized descriptively b y treatment group for the FAS or the Safet y Set.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, an d maximum will be presented.
Relevant medical histories and current medical conditions at baseline will be summarized 
separately by system organ class and preferred term, by treatment group.
10.3 Treatments (study  treatment, concomitant therapies, 
compliance)
The Safet y set will be used for the anal yses below.
Categorical data will be summarized as frequencies and percentages. For continuous data, mean, 
standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be 
presented.
The duration of exposure in days to asciminib and bosutinib ,as well as the dose intensit y 
(computed as the ratio of actual cumulative dose received and actual duration of exposure) and 

Novartis Confidential Page 122
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
the relative dose intensity (computed as the ratio of dose intensity  and planned dose intensity ) 
will be summarized by  means of descriptive statistics.
The number of patients with dose adjustments (reductions, interruption, or permanent 
discontinuation) and the reasons will be summarized by treatment group and all dosing data 
will be listed.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification sy stem, by  treatment group.
10.4 Primary  objective
The primary  objective of the study  is to evaluate the efficacy  of asciminib at the recommended 
dose in CML  patients in chronic phase, previously  treated with 2 or more tyrosine kinase 
inhibitors and to compare this efficacy  profile in this populat ion with that achieved by  patients 
receiving bosutinib .
10.4.1 Variable
The primary  efficacy  variable of the study  is the Major Molecular Response (MMR) rate at 24 
weeks. A patient will be counted as having achieved MMR at 24 weeks if he meets the MMR 
criteria (B CR
-ABL 1ratio ≤0.1%) at 24 weeks.
10.4.2 Statistical hy pothesis, model, and method of analy sis
The MMR rate at 24 weeks will be calculated based on the FAS and according to the Intent ion-
ToTreat (ITT) principle. MMR rate and its 95% confidence interval based on the Pearson-
Clopper method will be presented by treatment group. The confidence interval for the difference 
in MMR rate between treatment groups will be provided using the Wald method.
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 24 weeks. The Cochrane -Mantel -Haenszel chi-square test, stratified by the 
randomization stratification factor, i.e. major cytogenetic response status (PCy R or CCyR vs.
others) at screening, will be used to compare MMR rate between the two treatment groups, at 
the two-sided 5% level of significance. The Mantel -Haenszel estimate of the common risk 
difference and the corresponding 95% confidence interval will also be provided.
10.4.3 Handling of missing values/censoring/discontinu ations
Only  patients with MMR at 24 week visit are considered responders. In other words, any patient 
who achieves MMR before 24 weeks, but is no longer in MMR at 24 weeks, will be considered 
as a non-responder in this primary  analysis. Patients discontinu ing the randomized treatment 
(having performed an EOT visit) prior to 24 weeks due to any reason will be considered as non-
responders. One exception to the rule above is if the 24-week PCR evaluation is missing, but 
both a PCR evaluation at 16 weeks and a PCR evaluation at 36 weeks indicate MMR, the 24-
week assessment is imputed as a ‘Response’. If PCR evaluations are performed at unscheduled 
visits closer to the Week 24 visit (before or after) , these will be taken into account for the 
imputation .

Novartis Confidential Page 123
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
10.4.4 Supportive and Sensitivity analyses
The analysis of the primary  endpoint will also be repeated on the PPS if the PPS is different 
from the FAS .
Subgroup anal yses and a logistic regression analy sis will be employ ed. Refer to the exploratory 
objectives Section 10.6.1 for further details.
10.5 Secondary  objectives
The secondary  objective s in this study  are as follows:
To compare additional parameters of the efficacy of asciminib versus bosutinib, defined 
as:
Key secondary endpoints
MMR rate at 96 weeks
Other efficacy endpoints
Cytogenetic response (Complete, Partial, Major, Minor, Minimal, no response) rate at all 
scheduled data collection time points including , 24, 48 and 96 weeks.
Cytogenetic response (Complete, Partial, Major, Minor, Minimal, no response) rate b y all 
scheduled data collection time points includin g, 24, 48 and 96 weeks.
MMR rate at all scheduled data collection time points (except 24 and 96 weeks which are 
alread y covered b y primary and key secon
dary endpoints)
MMR rate by  all scheduled data collection time points including 24, 48 and 96 weeks.
Time to MMR
Duration of MMR
Time to CCy R
Duration of CCy R
Time to treatment failure
Progression free survival
Overall survival
To compare the safety  and to lerability  profile of asciminib versus bosutinib
To characterize the PK of asciminib in the CML -CP population
10.5.1 Key secondary  objective(s)
The key  secondary  endpoint to be evaluated is MMR rate at 96 weeks, which is defined as the 
proportion of patients with MMR at 96 weeks and derived in a similar f ashion to MMR rate at 
24 weeks.

Novartis Confidential Page 124
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
10.5.1.1 Analysis for key secondary  objectives
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 96 weeks. Formal statistical testin g of the key secondary  endpoint will be 
performed with = 0.05 (two- sided) onl y if the primary  endpoint (i.e. MMR rate at 24 weeks)
is significant by means of a gatekeeping procedure to control the overall alpha level. Otherwise, 
no statistical testing will be performed , and any  analy sis will be considered exploratory .
MMR rate at 96 weeks will be evaluated in a similar fashion to the primary  analysis of MMR 
rate at 24 weeks. The rate and the associated 95% confidence interval based on the Pearson -
Cloppe r method will be presented by treatment group. Confidence interval for the difference 
between treatment groups will be provided using the Wald method.
Statistical testing will be performed 
via CMH chi-square test stratified by the randomization 
strata. TheMantel -Haenszel estimate of the common risk difference and the corresponding 95% 
confidence interval will also be provided.
If the PCR evaluation at 96 weeks is missing, but a PCR evaluation both at 84 weeks and 108 
weeks indicate MMR, the 96 week assessm ent is imputed as a “response”, assuming that MMR 
is maintained between 84 and 108 weeks. If PCR evaluations are performed at unscheduled 
visits closer to the Week 96 visit (before or after), these will be taken into account for the 
imputation.
10.5.2 Other secondary  efficacy  objectives
Unless otherwise stated the FAS will be used for the analy sis of all other secondary  efficacy 
endpoints. The exceptions are using the Molecular Responder Set for duration of MMR and 
time to MMR, the CCy R Analy sis Set for CCyR rates, and the Cy togenetic Responder Set for 
duration of CCy R and time to CCy R.
No statistical testing of non-key secondary  efficacy  endpoints will be performed, and any 
analysis will be considered exploratory .
Molecular Response
MMR rates at scheduled tim e points (except 24 and 96 weeks which have been specified as 
primary  and key secondary  endpoints) will be evaluated in a similar fashion to the 
primar y 
analysis of MMR rate at 24 weeks. Patients discontinuing the randomized treatment prior to a 
specific t ime point due to any  reason will be considered as non -responders for that time point.
MMR rates by scheduled time points are defined as the proportion of patients who achieve 
MMR at or before the specified visit, i.e. if a patient achieves an MMR but then loses it before 
or at the visit, he/she will still be classed as achieving MMR by  that time point.
For each endpoint the rate and the associated 95% confidence interval based on the Pearson-
Clopper method will be presented by  treatment group. Confidence in tervals for the differences 
in any  response rates between treatment groups will be provided using the Wald method.
Statistical testing will be performed via CMH chi-square tests stratified by the randomization 
strata. The Mantel -Haenszel estimate of the common risk difference and the corresponding 95% 
confidence interval will also be provided .

Novartis Confidential Page 125
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Duration of MMR is defined in Section 7.2.1.1 as the time between the date of the first 
documented MMR and the earlie st date of loss of MMR, progression to AP/BC, or CML -related 
death for patients in the Molecular Responder Set. The time will be censored at the last 
molecular assessment (PCR) date while on treatment for patients who have not experienced any 
of the above events.
Duration of MMR will be analyzed by K-M method and presented by K-M plots. The estimated 
rates of patients who are still responding at various time points will also be provided using K -
M method.
The cumulative incidence of MMR will be graphically  display ed by an increasing step function. 
This curve will increase each time (after randomization) at which a new responder is observed 
and thus will increase up to the best observed response rate (e.g. up to 50% if half of the patients 
in the anal ysis population are able to achieve response).
Time to MMR is defined in Section 7.2.1.1 and calculated as: date of first MMR -date of 
randomization +1, for patients in the Molecular Responder Set. Descriptive statistics (minimum, 
maximum , median, quartiles, mean, sd) of time to MMR will be provided for the two treatment 
groups separatel y.
Cytogenetic Response
Patients in FAS will be categorized with counts and percentages provided for cytogenetic 
response (Comp lete, Partial, Major, Minor, Minimal, No Response) at and by (i.e. best response 
up to a specified time point) scheduled time points. Shift tables will also be employ ed to 
examine the changes in cytogenetic response category from baseline.
Since there are expected to be only limited numbers who are actuall y in CCyR at baseline the 
analysis of CCyR rate at and by scheduled time points will only  include patients who are not in 
CCyR at baseline, i.e. the CCy R Anal ysis Set.
CCyR rates at and by scheduled time points etc.and the associated 95% confidence intervals 
based on the Pearson- Clopper method will be presented by treatment group with the analy sis of 
these endpoints only  including patients who are not in CCy R at baseline.
Confidence intervals for the diffe rences in an y response rates between treatment groups will be 
provided using the Wald method.
Statistical testing will be performed via CMH chi-square tests stratified by the randomization 
strata. The Mantel -Haenszel estimate of the common risk difference and the corresponding 95% 
confidence interval will also be provided.
Time to CCyR 
is defined for patients in the C ytogenetic Responder Set as: date of first CCy R 
-date of randomization +1. Descriptive statistics (minimum, maximum , median, quartiles, 
mean, sd) of time to CCyR will be provided for the two treatment groups separately .
The cumulative incidence of CCyR will also be graphicall y display ed by an increasing step 
function. This curve will increase each time (after randomization) at which a new respo nder is 
observed and thus will increase up to the best observed response rate.
Duration of CCyR is defined as the time between date of first documented CCyR and the 
earliest date of loss of CCyR, progression to AP/BC, or CML -related death for patients in the 

Novartis Confidential Page 126
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Cytogenetic Responder Set. The time will be censored at the last cytogenetic assessment date 
on treatment for patients for whom none of the above events is reported or last PCR evaluation 
on treatment indicating MMR.
Duration of CC yR response will be an alyzed by K-M method and presented b y K-M plots. The 
estimated rates of patients who are still responding at various time points will also be provided 
using K -M method.
Treatment failure, disease progression and survival
Time to treatment failure (TTF) is defined as the time from date of randomization to an event 
of treatment failure. The following events will constitute ‘treatment failure’, and are based on 
the ELN criteria (Baccarani et al 2013) defining failure of a second line treatment adapted to 
include discontinuation of randomized treatment as an event :
No CHR or > 95% Ph+ metaphases at three months after randomization or thereafte r
BCR -ABL 1
ratio > 10% IS and/or > 65% Ph+ metaphases at six months af ter 
randomization or thereafter
BCR -ABL 1ratio > 10% IS and/or > 35% Ph+ metaphases at 12 months after 
randomization or thereafter
Loss of CHR, CCy R or PCy R at any  time after randomization
Detecti on of new BCR -ABL 1mutations which potentially  cause resistance to study  
treatment at an y time after randomization
Confirmed loss of MMR
New clonal chromosome abnormalities in Ph+ cells: CCA/Ph+: at any  time after 
randomization
Discontinuation from random ized treatment for any reason
For patients who have not reach edtreatment failure, their TTFs will be censored at the time of 
last study  assessment (PCR, cytogenetic, hematologic or extramedullary )before the cut-off date.
Progression -Free -Survival (PFS) is defined as the time from the date of randomization to the 
earliest occurrence of documented disease progression to AP/BC or the date of death from any 
cause (including progressions and deaths observed during the survival follow -up period) before 
the cut -off date .
The time will be censored at the date of last study  assessment (PCR, cy togenetic, hematologic 
or extramedullary ) or last post -treatment follow -up for patients without event.
Overall survival (OS) is defined as the time from the date of randomization to the date of death 
(including the survival follow -up period). Patients who are alive at the time of the anal ysis data 
cutoff date will be censored at the date of last contact before the cut -off date.
TTF, PFS and OSwill be estimated and graphicall y displayed using the K-M approach on FAS. 
The estimated rates by K-M method at various time points will be provided and the endpoints 
will be compared between the two treatment groups using stratified log-rank test stratified by 
the randomization strata. The hazard ratio and 95% confidence intervals will be computed from 
a stratified Cox model.

Novartis Confidential Page 127
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
10.5.3 Safety  objectives
10.5.3.1 Analysis set and grouping for the analy ses
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
treatment group.
The overall observation period will be divided into three mutually  exclusive segments:
1.pre-treatment period: from day  of subject’s first informed consent to the day before first 
administration o f study  treatment
2. on- treatment period: from day  of first administration of study  treatment to 30 day s after 
last actual administration of the same stud y treatment (including start and stop date)
3.post-treatment period: starting at day
 31 after last administ ration of any  study  treatment
Summary  tables for safety  data will be presented for the on-treatment period. Comparative 
analysis will be performed only for the on -treatment period. Listings of safety data will include 
pre-treatment, on-treatment, and post-treatment periods, with a flag to indicate data collected 
before or after the on -treatment period.
The same analysis will be done for patients that switch to asciminib after treatment failure on 
bosutinib. However ,safety  events that initiated on or after start of asciminib during the switch 
treatment phase will be included.
10.5.3.2 Adverse events (A Es)
Summary  tables for adverse events (AEs) will include only AEs that started or 
worsened during 
the on- treatment period, the treatment- emergent AEs.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by system organ class and/or preferred term, severity  (based on CTCAE grades), 
type of adverse event, relation to study  treatment.
Serious adverse events, non-serious adverse events and adverse events of special interest (AESI)
during the on -treatment period will be tabulated.
All deaths (on- treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including those from the pre-treatment, on-
treatment and post-treatment periods) will be listed and those collected before or after the on-
treatment period will be flagged.
10.5.3.3 Laboratory  abnormalities
Grading of laboratory  values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) 
version 4.03. The calculation of CTCAE 
grades will be based on the observed laboratory  values only, clinical assessments will not be 
taken into account.
CTCAE Grade 0 will be assigned for all non -missing values not graded as 1 or higher. Grade 5 
will not be used.

Novartis Confidential Page 128
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
For laboratory tests where grades are not defined by  CTCAE v4.03, results will be categorized 
as low/normal/high based on laboratory  normal ranges.
The following listings and summaries will be generated separatel y for hematology , and 
biochemistry  tests:
Listing of all laboratory  data with values flagged to show the corresponding CTCAE 
v4.03 grades if applicable and the classifications relative to the laboratory  normal ranges
For laboratory  tests where grades are defin ed by CTCAE v4.03
Worst post -baseline CTCAE grade (regardless of the baseline status). Each patient will be 
counted only once for the worst grade observed post -baseline in the on -treatment period.
Shift tables using CTCAE grades to compare respective basel ine to the worst on- treatment 
value
For laboratory  tests where grades are not defined by  CTCAE v4.03,
Shift tables using the low/normal/high/ (low and high) classification to compare respective 
baseline to the worst on-treatment value.
10.5.3.4 Other safety  data
ECG
ECGs (12-lead) 
including PR, QRS, QT, QTcF, and HR intervals will be obtained for each 
subject during the study . ECG data will be read and interpreted centrall y.
Categorical analysis of QT/QTc interval data based on the number of patients meeting or 
exceeding predefined limits in terms of absolute QT/QTc intervals or changes from baseline 
will be presented. In addition, a listing of these patients will be produced b y treatment group.
Vital signs
Data on vital signs will be tabulated and listed, notable values will be flagged.
10.5.3.5 Supportive analy ses for secondary  objectives
Not applicable.
10.5.3.6 Tolerability
Tolerability  of each study  treatment will be assessed by summarizing the number of subjects
with dose interruptions and dose reductions. Reasons for dose interruptions and dose reductions 
will be listed by  subject and summarized.
10.5.4 Secondary  PK objectives
The PK objective is to characterize the PK of asciminib in CML  population.
Using PAS, summary statistics (n, mean, SD, coefficient of variation (CV) for mean, geometric 
mean, CV for geometric mean, median, minimum and maximum) will be presented for plasma 
concentration at each scheduled time point. The geometric mean with mean (SD) and individual 
plasma concentration versus time profiles of asciminib will be display ed graphicall y.

Novartis Confidential Page 129
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Using Safet y set, concentration data will be listed. Concentration values below the limit of 
quantification (BLQ) will be set to zero b y the Bioanal yst and displayed in l istings as zero with 
a flag. BLQ values will be handled as zero in any calculations of summary  statistics, but handled 
as missing for the calculation of the geometric means and CVs.
Pharmacokinetic parameters will be determined by non-compartmental method( s) using the 
pharmacokinetic profile of asciminib in patients with full PK sampling. PK parameters listed in 
Table 10
-1will be derived and reported, when feasible.
Population PKmodeling may be performe d and the results may be reported in a separate 
population PK report. Data from this study  may be combined with data from other studies for 
this analy sis.
Table 10-1 Non comp artmental pharmacokinetic parameters in full PK group
AUC0 -12h The area under the plasma concentration -time curve from time zero to 12 h (mass x time x 
volume -1)a
Cmax The maximum (peak) observed plasma drug concentration after dose administration (mass x
volume -1)
Tmax The time to reach maximum (peak) plasma drug concentration after dose administration (time)
CL/F The total body clearance of drug from the plasma after oral administration (volume x time -1)
10.6 Exploratory  objectives
10.6.1 Exploratory  efficacy  objectives
To evaluate the influence of factors such as major cytogenetic status at baseline, 
failure/intolerance to prior TKIs, line of therap y, gender, race and age on the effect of 
asciminib with respect to the primary  efficacy  endpoint.
To characterize mutations in the BCR -ABL1 gene at Week 1 Day  1, upon confirmed loss of 
molecular response and/orat end of treatment and examine their association with molecular 
and cy togenetic response for asciminib vs.bosutinib.
To assess the efficacy of asciminib when administered as treatment after bosutinib failure 
according to the 2013 ELN Guidelines.
10.6.1.1 Data analy sis of exploratory  efficacy  objectives
Subgroup analyses will be performed to evaluate the influence of factors such as baseline major 
cytogenetic response status, baseline /Week 1 Day 1BCR -ABL 1ATP -binding site mutation 
status (from local historical record and from Sanger Sequencing), failure/intolerance to prior 
TKIs, line of therapy , gender, race and age on the primary  efficacy  endpoint. In addition, a 
logistic regression anal ysis will incorporate the key baseline variables into the model to further 
evaluate the impact of these variables on the primar y endpoint and to provide a treatment effect 
estimate which is adjusted for imbalances in the treatment groups. An adjusted odds ratio for 
the treatment effect with associated 95% confidence intervals will be presented. Mantel -
Haenszel estimates of the common odds ratio and the corresponding 95% confidence interval 
will also be provided. The effect of asciminib when administered as treatment after bosutinib 
failure will be assessed using theSwitch Analy sis Set to estimate response rates (cytogenetic 
and molecular response )at all scheduled time points after switch, as well as time-to and duration 

Novartis Confidential Page 132
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
10.6.4.2 Patient Reported Outcomes
The MDASI  CML, PGIC along with EQ-5D- 5L will be used to compare data on the patient’s 
disease -related symptoms and health -related quality  of life from baseline to EOT between the 
treatment arms. The WPAI will be used to assess work productivity  and activity  impairment 
related to the patient’s CML .All measures will assess differences between the treatment arms.
Patients with an evaluable baseline score and at least one evaluable post baseline score during 
the treatment period will be included in the change from baseline analy ses. Missing data items 
in a scale will be handled according to the manual for each instrument. No imputation will be 
applied if the total or subscale scores are missing at a visit.
10.7 Interim analy sis
No formal interim analysis is planned for this trial. As described in Section 10, three or four
formal analyses are planned: the primary  at week 24, another at the 96-week end of study 
treatment and a PFS/OS update at year 5.
24-week primary  analy sis: Formal testing of the primary  endpoint with full alpha will be 
performed. Anal yses of other efficacy  endpoints at and by 24 weeks will also be 
performed.
96-week anal ysis: Formal statistical testing of the key  secondary  endpoint will be 
performed with = 0.05 (two
-sided) onl y if the primary endpoint (i.e. MMR rate at 24 
weeks) is significant. Otherwise, no statistical t esting will be performed, and any  anal ysis
will be considered exploratory . Anal yses of other efficacy  endpoints (including MMR rate 
at 48 weeks) will also be performed.
End of study  treatment analy sis (if required) similar to the 96 -week anal ysis without 
formal statistical testing.
5-year PFS/OS update analy sis:PFS and OS
In addition DMC safet
y analyses will be conducted as described in Section 8.6.
10.8 Sample size calculation
To test the null hy pothesis t hat the response rate is equal in the two groups, based on two-sided 
5% level of significance and with 90% power, 222 
patients will be needed in total (i.e. 148 
patients in the asciminib arm and 74 patients in the bosutinib arm based on 2:1 randomization 
allocation). This assumes that asciminib leads to a 20% improvement in the MMR rate at 24 
weeks over bosutinib from 15% to 35% which corresponds to an odds ratio of 3.05.
The assumed bosutinib MMR rate of 15% at 24 weeks is based on previous trials evaluati ng 
bosutinib therapy  (Khoury  2012 , Gambacorti - Passerini 2014 , García -Gutiérrez 2015 ).
No more than 66 patients (approximately 30% of the overall trial population) that are intolerant 
to their most recent TKI therap y with BCR -ABL 1 < 1% will be recruited in order to ensure that 
the CML  third line patient population is adequately  represented.

Novartis Confidential Page 133
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
10.9 Power fo r anal ysis of key  secondary  variables
If the primary  analysis of MMR rate at 24 weeks is statistically  significant, then the key 
secondary  endpoint MMR rate at 96 weeks will be tested, with the overall alpha controlled at 
the 5% two-sided level. The testing will use a gatekeeping strategy . Full details of the testing 
strategy  are provided in Section 10.5.1.
Table 10-2 below summarizes the treatment effects of the key secondary  endpoint which can 
be detected with 80% and 90% power , based on the specified assumptions regarding the 
bosutinib effect. The calculations were made using the software package PASS (2008).
Table 10
-2 Detectable effect sizes for key  secondary  endpoint
Endpoint Anticipated effect 
with bosutinib2-sided alpha Power Detectable 
effect size§
MMR rate at 96 weeks 30%*0.05 90%
80%≥ 23%
≥ 20%
*: Gambacorti -Passerini et al. 2014 , Figure 1D.
§: Absolute difference from the anticipated effect with bosutinib.
For MMR rate at 96 weeks, if the anticipated effect with bosutinib is 30%, then the given sample 
size with 2 -sided alpha=0.05 would allow to detect an absolute difference of at least 23% (i.e. 
MMR rate at 96 weeks with asciminib is at least 53%) for 90% power and of at least 20% (i.e. 
MMR rate at 96 weeks with asciminib is at least 50%) for 80% power.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is require d 
to sign a protocol signature page confirming his/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novartis monit ors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.

Novartis Confidential Page 134
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing writte n (witnessed, where 
required b y law or regulation), I RB/IEC/REB -approved informed consent.
Informed consent must be obtained before conducting an y stud y-specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining in formed consent should be 
documented in the patient source documents. The date when a subject’s Informed Consent was 
actuall y obtained will be captured in their eCRFs.
Novartis will provide to investigators, in a separate document, a proposed informed conse nt 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and acopy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
Additional consent form
Not applicable.
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study  are outlined in Section 4.3.
11.5 Publication of study  protocol and results
Novartis is committed to following high ethical standards for reporting study  results for its 
innovative medicine, including the timel y communication and publication of clinical trial 
results, whatever 
their outcome. Novartis assures that the key  design elements of this protocol 
will be posted on the publicly  accessible database, e.g. clinicaltrials.gov before study  start. In 
addition, results of interventional clinical trials in adult patients are posted on 
novartisclinicaltrials.com, a publicl y accessible database of clinical study  results within 1 year 
of study  completion (i.e., LPLV), those for interventional clinical trials involving pediatric 
patients with
in 6 months of study  completion.
Novartis follows the ICMJE authorship guidelines (icmje.org )and other specific guidelines of 
the journal or congress to which the publication will be submitted
Authors will not receive remuneration for their writing of a publication, either directl y from 
Novartis or through the professional medical writing agency . Author(s) may be requested to 
present poster or oral presentation at scientific congress; however, there will be no honorarium 
provided for such presentations.

Novartis Confidential Page 135
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
As part of its commitment to full transparency in publications, Novartis supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of interest of financial and non-financial nature by all authors, including 
medical writing/editorial support, if applicable.
For the Novartis Guidelines for the Publication of Results from Novartis -sponsored Research, 
please refer to novartis.com .
11.6 Stud y documentation, record keeping and retention of 
documen ts
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a Novartis -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by  applicable law, to copy ) clinical records for the purposes of 
quality  assurance reviews , audits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory  notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated in struments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x
-rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study  electronic case report form (eCRF) is the primary  data 
collection instrument for the study. The investigator should ensure the accuracy, completeness, 
legibility , and timeliness of the data reported in the eCRFs and all other required reports. Data 
reported on the eCRF, that are derived from source documents, should be consistent with the 
source documents or the discrepancies should be explained. All data requested on the eCRF 
must be recorded. Any  missing data must be explained. For electronic CRFs an audit trail will 
be maintained b y the s ystem.
The investigato r/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by applicable 
regulations and/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permis sion to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.

Novartis Confidential Page 136
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by names 
in any documents submitted to Novartis. Signed informed consent forms and patient enrollment 
log must be kept strictl y confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/do cuments must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at the site -prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the study 
to request approval of a protocol deviation, as no authorized deviations are permitted. If the 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
Novartis should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. UK requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working day
s.

Novartis Confidential Page 137
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
13 References (available upon request)
[Baccarani M, Deininger MW, Rosti G, et al (2013)] European LeukemiaNet 
recommendations for the management of chronic my eloid leukemia: 2013. Blood; 
122(6):872-84.
[Bartram CR, de Klein A, Hagemeijer A, et al (1983)] Translocation of c -ab1 oncogene 
correlates with the presence of a Philadelphia chr omosome in chronic my elocy tic leukaemia. 
Nature; 306(5940):277 -80.
[Basnay ake C, Ratnam D (2015)] Blood tests for acute pancreatitis. Aust Prescr 38:128 -30.
[Bosulif® SmPC ]
[Bosulif® USPI ]
[Branford S, Rudzki Z, Walsh S, et al (2003)] Detection of BCR- ABL mutations in patients 
with CML  treated with imatinib is virtually  alway s accompanied by  clinical resistance, and 
mutations in the ATP phosphate -binding loop (P -loop) are associated with a poor prognosis. 
Blood; 102(1):276 -83.
[Brooks R (1996)] EuroQol: th e current state of play . Health Policy  37(1):53 -72.
[Daley  GQ, Van Etten RA, Baltimore D (1990)] Induction of chronic m yelogenous leukemia 
in mice by  the P210bcr/abl gene of the Philadelphia chromosome. Science; 247(4944):824 -30.
[EuroQol Group (1990)] Eur oQol -a new facility  for the measurement of health- related quality  
of life. Health Policy  16(3):199 -208.
[Guidance for Industry  Reproductive and Developmental Toxicities - Integrating Study  
Results to Assess Concerns] Food and Drug Administration Center for Drug Evaluation and 
Research. September 2011.
[Gambacorti -Passerini C, Brümmendorf TH, Kim DW, et al (2014)] Bosutinib efficacy  and 
safet y in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: 
Minimum 24 -month follow -up. Am J Hematol; 89(7):732 -42.
[García -Gutiérrez V, Martinez -Trillos A, L opez Lorenzo JL , et al (2015)] Bosutinib shows 
low cross intolerance, in chronic m yeloid leukemia patients treated in fourth line. Results of 
the Spanish compassionate use program. Am J Hema tol; 90(5):429-33.
[Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, et al (1983)] Localization of the c -ab1 
oncogene adjacent to a translocation break point in chronic m yeloc ytic leukaemia. Nature; 
306(5940):239 -42.
[Herdman M, Gudex C, Llo yd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. (2011)]
Development and preliminary
 testing of the new five -level version of EQ- 5D (EQ -5D- 5L). 
Quality  of Life Research 20(10):1727-1736.
[Hughes TP, Hochhaus A, Branford S, et al (2010)] L ong-term prognosti c significance of 
early molecular response to imatinib in newly  diagnosed chronic m yeloid leukemia: an 
analysis from the International Randomized Study  of Interferon and STI571 (I RIS). Blood; 
116(19):3758-3765.
[Hochhaus A, Saussele S, Rosti G, et al (2017 )] Chronic my eloid leukaemia: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow -up. Ann Oncol (2017) 28 (suppl 4):
iv41–iv51.

Novartis Confidential Page 138
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
[Hochhaus A, O'Brien SG, Guilhot F, et al (2009)] Six -year follow -up of patients receiving 
imatinib for the first-line treatment of chronic m yeloid leukemia. Leukemia; 23(6):1054-61.
[Kelliher MA, McLaughlin J, Witte ON, et al (1990)] I ntroduction of a chronic my elogenous 
leukemia -like s yndrome in mice with v -Abl and BCR/ABL . Proc Natl Acad Sci USA 87; 
6649-53.
[Khoury  HJ, Kim D, Zaritskey  A, et al (2010)] Safety  and efficacy  of thirdline bosutinib in 
imatinib (I M) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic m yeloid 
leukemia (CML) [abstract]. J Clin Oncol; 28 (Suppl ;abstr 6514):15s.
[Klemmt L , Scialli AR. (2005)] The transport of chemicals in semen. Birth Defects Res (Pt
B); 74:119
–131.
[Khoury  HJ, Cortes JE, Kantarjian HM, et al (2012)] Bosutinib is active in chronic phase 
chronic m yeloid leukemia after imatinib and dasatinib and/or ni lotinib therapy failure. Blood; 
119(15):3403-12.
[National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in 
Oncology -Chronic My eloid L eukemia] v4.2018 –January  24, 2018.
[Nowell Hungerford DA (1960)] A minute chromosome in chronic granu locytic leukemia. 
Science; 132: 1497 -1501.
[O’Brien S, Radich JP, Abboud CA, et al (2013)] Chronic My elogenous Leukemia, Version 
1.2014: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw; 11(11):1327 -
40.
[O’Hare T, Corbin A S, Druker B J (2006)] Targeted CML  therapy : controlling drug 
resistance, seeking cure. Current opinion in Genetics & development, 16:92 -99.
[Rowley  JD (1973)] A new consistent abnormality in chronic my elogenous leukemia 
identified by  quinacrine, fluorescence and Giemsa sta ining. Nature; 243:290 -93.
[Soverini S, Branford S, Nicolini FE, et al (2014)] I mplications of BCR -ABL1 kinase 
domain -mediated resistance in chronic m yeloid leukemia. Leuk Res; 38(1):10 -20.
[Steegmann JL, Baccarani M, Breccia M, et al (2016) ]European Leuk emiaNet 
recommendations for the management and avoidance of adverse events of treatment in 
chronic m yeloid leukaemia. Leukemia; 30(8):1648 -
71.
[Vardiman J.W. (2009)] Chronic My elogenous Leukemia, BCR -ABL+. Am J Clin Pathol; 
132:250-260.
[Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2001)] Human drug metabolism and the 
cytochromes P450: application and relevance of in vitro models. The Journal of Clinical 
Pharmacology ; 41: 1149 -1179.

Novartis Confidential Page 139
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
14 Appendices
In general, the use of any concomitant medication deemed nec essary  for the care of the patient 
is permitted in this study, except as specificall y prohibited in Section 6.4for patients on 
asciminib and Section 6.5 for patients on bosutinib. 
The following lists are based on the 
internal [Pharmacokinetic Sciences memorandum on Drug -
Drug Interaction] (release date: January  2018), which was compiled from the Indiana University  
School of Medicine’s “Clinically  Relevant” Table and supplemented with the FDA Draft 
Guidance for Industry , Drug Interaction Studies –Study  Design, Data Anal ysis, and 
Implications for Dosing and Labeling (2017), and the Universit y of Washington’s Drug 
Interaction Database (2017). These lists are not comprehensive and are only meant to be used 
as a guide. Please contact the medical monitor with any questions. If a medication appears on 
both the list of prohibited and the list of medications to be used with caution, the 
medication is prohibited.
14.1 Appendix 1 List of concomitant medications for patients on 
asciminib
Table 14-1 Prohibited concomitant medications for asciminib arm
Category Drug Names
Strong inhibitors of 
CYP3Aatazanavir/ritonavir1, danoprevir/ritonavir1, darunavir/ritonavir1, elvitegravir/ritonavir1, 
indinavir/ritonavir1, lopinavir/ritonavir1, saquinavir/ritonavir1, tipranavir/ritonavir1, 
ombitasvir/paritaprevir/dasabuvir/ritonavir (Viekira Pak)1, boceprevir ,clarithromycin, 
cobicistat, conivaptan, grapefruit juice2, idelalisib, indinavir, itraconazole, ketoconazole, 
mibefradil, nefazodone, nelfinavir,  posaconazole, ritonavir, telaprevir, telithromycin, 
troleandomycin, voriconazole,
Strong inducers of 
CYP3Acarbamazepine, enzalutamide, lumacaftor, mitotane ,phenobarbital, phenytoin, rifabutin, 
rifampicin, St. John’s wort ( Hypericum perforatum )1
UGT1A1/2B7 
inducersUGT1A1: carbamazepine, cigarette smoke , rifampicin, testosterone propiate, 
UGT2B7: Barbiturates
Torsade de pointe 
(TdP) TdP/QT risk : 
Knownamiodarone, anagrelide, arsenic trioxide, astemizole (off us mkt), azithromycin, bepridil 
(off us mkt), chloroquine, chlorpromazine, cilostazol, cisapride (off us mkt), citalopram, 
clarithro mycin, cocaine, disopyramide, dofetilide, domperidone (not on us mkt), 
donepezil, dronedarone, droperidol, erythromycin, escitalopram, flecainide, fluconazole, 
grepafloxacin (off market worldwide), halofantrine, haloperidol, ibutilide, 
levofloxacin, levom ethadyl (off mkt worldwide), mesoridazine (off mkt worldwide), 
methadone, moxifloxacin, ondansetron, oxaliplatin, papaverine HCl, pentamidine, 
pimozide, probucol (off mkt worldwide), procainamide (oral off us mkt), propofol, 
quinidine, sevoflurane, sotalol , sparfloxacin (off us mkt), sulpiride (not on us mkt), 
terfenadine (off us mkt), thioridazine, vandetanib
TdP/QT risk: 
Possiblealfuzosin, apomorphine, aripiprazole, artenimol+piperaquine, asenapine, bedaquiline, 
bortezomib, buprenorphine, capecitabine, ceritinib, clomipramine, clozapine, crizotinib, 
cyamemazine (cyamepromazine) (Only on Non US Market), dabrafenib, dasatinib, 
degarilix, delamanid (off US mkt), desipramine, dexmedetomidine, dolas etron, eribulin, 
ezogabine, famotidine, felbamate, fingolimod , foscarnet, gemifloxacin, granisetron, 
hydrocodone -ER, iloperidone, imipramine (melipramine), isradipine, lapatinib, lenvatinib, 
leuprolide, lithium, mifepristone, mirabegron, mirtazapine, moexipril/hctz, nicardipine, 
nilotinib, norfloxacin, nortriptyline , ofloxacin, olanzapine, osimertinib, oxytocin, 
paliperidone, panabinostat, pasireotide, pazopanib, perflutren lipid microspheres, 
pipamperone (not on us mkt), promethazine, quetiapine, ranolazin e, rilpivirine, 
risperidone, roxithromycin (on non us mkt), s aquinavir, sertindole (on non us mkt), 
sorafenib, sunitinib, tacrolimus, tamoxifen, telavancin, telithromycin, tetrabenazine 

Novartis Confidential Page 140
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Category Drug Names
(orphan drug in us), tizanidine, tolterodine, toremifene, trimipramine, vardenafil, 
vemurafenib, venlafaxine, vorinostat, zotepine
TdP/QT risk: 
Conditionalamantadine, amisulpride, amitriptyline, atazanavir, chloral hydrate, diphenhydramine, 
doxepin, fluoxetine, furosemide (frusemide), galantamine, hydrochlorothiazide, 
hydroxyzine, hydroxychloroquine, indapamide, itraconazole, ivabra dine (on non us mkt), 
ketoconazole, loperamide, metoclopramide, metronidazole, nelfinavir,  pantoprazole, 
paroxetine, posaconazole, quinine sulfate, ritonavir, sertraline, solifenacin, telaprevir, 
torsemide, trazodone, voriconazole, ziprasidone
1Combinat ion ritonavir -boosted regimens are listed here in the DDI memo as strong CYP3A inhibitors (to avoid 
potential confusion), even though some are considered moderate CYP3A inhibitors in the UW  DDI Database.
2The effect of grapefruit juice varies widely among brands and is concentration -, dose -, and preparation -
dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation 
was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when anoth er preparation was 
used (e.g., low dose, single strength). 
Table 14-2 Concomitant medications to be used with caution in asciminib arm
Category Drug Names
Narrow Therapeutic 
index substrates of 
CYP2C8Paclitaxel
Narrow Therapeutic 
index substrates of 
CYP2C9phenytoin, warfarin (also sensitive)
Narrow Therapeutic 
index substrates of 
CYP3Aalfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, sirolimus, terfanadine, 
BCRP
Inhibitorsabacavir, amprenavir, atorvastatin, ,curcumin3, cyclosporine3,  daclatasvir, declatasvir3, 
delavirdine, efavirenz, elbasvir, eltrombopag3, elvitegravir3, erlotinib, fluvastatin, 
fostamatinib, fumitremorgin, gefitin ib, grazoprevir, lapatinib3, ledipasvir3, lopinavir, 
paritepravir3, pitavastatin, rosuvastatin, simvastatin, sulfasalazine, tipranavir3, velpatasvir, 
venetoclax
P-gp inhibitors alogliptin, amiodarone4, azithromycin4, canaglifozin, captopril4, carvedilol4, clopidrogel, 
cremophor RH40, curcumin, diltiazem4, dronedarone4, elacridar4, eliglustat, felodipine4, 
fluvoxamine4, fostamatinib,  ginko4,5, isavuconazole, ivacaftor, lopinavir,, milk thistle 
(silymarin, silibinin)4,5, nifedipine4, nitredipine4,ombitasvi r, paritaprevir, propafenone, 
quercetin,4, ritonavir4, sequinavir4, schisandra chinesis extract4,5, simepravir, St. John’s 
wort extract (HYPERICUM PERFORATUM)4,5,survorexant, talinolol4, telaprevir4, 
telmisartan4, ticagrelor4, tipranavir4, tolvaptan4, valspodar, vandetanib, verapamil4, 
voclosporin, vorapaxar.
3Evidence of in vivo DDI
4 Dual P -gp and CYP3A4 inhibitor
5 Herbal product

Novartis Confidential Page 141
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
14.2 Appendix 2 List of c oncomitant medications for patients on
bosutinib
Table 14-3 Prohibited concomitant medications for bosutinib arm
Category Drug Names
Strong inhibitors of 
CYP3Aboceprevir, clarithromycin, cobicistat, conivaptan, grapefruit juice2, idelalisib, indinavir, 
itraconazole, ketoconazole, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, 
telaprevir, telithromycin, troleandomycin, voriconazole, atazanavir/ritonavir1, 
danoprevir/ritonavir1, darunavir/ritonavir1, elvitegravir/ritonavir1, indinavir/ritonavir1, 
lopinavi r/ritonavir1, ombitasvir/paritaprevir/dasabuvir/ritonavir (Viekira Pak)1 , 
saquinavir/ritonavir1, tipranavir/ritonavir1
Moderate inhibitors of 
CYP3Aaprepitant, amprenavir, atazanavir, cimetidine, ciprofloxacin, crizotinib, cyclosporine, 
darunavir, diltiazem, dronedarone, erythromycin, faldaprevir, fluconazole, grapefruit 
juice2, imatinib, isavuconazole, netupitant, nilotinib, tofisopam, Schisandra sphenanthera
(nan wu wei zi)3, asafoetida resin ( Ferula asafoetida )3, verapamil
Strong inducers of 
CYP3Acarbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifabutin, 
rifampicin, St. John’s wort ( Hypericum perforatum )3
Moderate inducers of 
CYP3Abosentan, efavirenz, etravirine, modafinil, nafcillin, ritonavir/tipranavir, thior idazine, 
semagacestat4, talviraline4, lopinavir, lersivirine, 
Proton pump 
inhibitorsdexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. 
1Combination ritonavir -boosted regimens are listed here in the DDI memo as strong CYP3A inhibitors (to avoid 
potential confusion), even though some are considered moderate CYP3A inhibitors in the UW  DDI Database.
2The effect of grapefruit juice varies widely among brands and is concentration -, dose -, and preparation -
dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation 
was used (e.g., high dose, double stre ngth) or as a “moderate CYP3A inhibitor” when another preparation was 
used (e.g., low dose, single strength). 
3Herbal product
4 Dual P -gp and CYP3A4 inhibitor
Table 14-4 C oncomitant medications to be used with caution in bosutinib arm
Category Drug Names
Torsade de pointe 
(TdP) TdP/QT risk : 
Knownamiodarone, anagrelide, arsenic trioxide, astemizole (off us mkt), azithromycin, bepridil 
(off us mkt), chloroquine, chlorpromazine, cilostazol, cisapride (off us mkt), citalopram, 
clarithromycin, cocaine, disopyramide, dofetilide, domperidone (not on us mkt), 
donepezil, dronedarone, droperidol, erythromycin, escitalopram, flecainide, fluconazole, 
grepafloxacin  (off market worldwide), halofantrine, haloperidol, ibutilide, levofloxacin, 
levomethadyl (off mkt worldwide), mesoridazine (off mkt worldwide), methadone, 
moxifloxacin, ondansetron, oxaliplatin, papaverine HCl, pentamidine, pimozide, probucol 
(off mkt worldwide), procainamide (or al off us mkt), propofol, quinidine, sevoflurane, 
sotalol, sparfloxacin (off us mkt), sulpiride (not on us mkt), terfenadine (off us mkt),
thioridazine, vandeta nib
TdP/QT risk: 
Possiblealfuzosin, apomorphine, aripiprazole, artenimol+piperaquine, asenapin e, bedaquiline, 
bortezomib, buprenorphine, capecitabine, ceritinib, clomipramine, clozapine, crizotinib, 
cyamemazine (cyamepromazine) (Only on Non US Market), dabrafenib, dasatinib, 
degarilix, delamanid (off US mkt), desipramine, dexmedetomidine, dolas etron, eribulin, 
ezogabine, famotidine, felbamate, fingolimod, foscarnet, gemifloxacin, granisetron, 
hydrocodone -ER, iloperidone, imipramine (melipramine), isradipine, lapatinib, lenvatinib, 
leuprolide, lithium, mifepristone, mirabegron, mirtazapine, moexipril /hctz, nicardipine, 
nilotinib, norfloxacin, nortriptyline, ofloxacin, olanzapine, osimertinib, oxytocin, 
paliperidone, panabinostat, pasireotide, pazopanib, perflutren lipid microspheres, 
pipamperone (not on us mkt), promethazine, quetiapine, ranolazin e, rilpivirine, 
risperidone, roxithromycin (on non us mkt), saquinavir, sertindole (on non us mkt), 
sorafenib, sunitinib, tacrolimus, tamoxifen, telavancin, telithromycin, tetrabenazine 

Novartis Confidential Page 142
Amended Protocol Version 03 ( Clean ) Protocol No. CABL001A2301
Category Drug Names
(orphan drug in us), tizanidine, tolterodine, toremifene, trimipramine, va rdenafil, 
vemurafenib, venlafaxine, vorinostat, zotepine
TdP/QT risk: 
Conditionalamantadine, amisulpride, amitriptyline, atazanavir, chloral hydrate, diphenhydramine, 
doxepin, fluoxetine, furosemide (frusemide), galantamine, hydrochlorothiazide, 
hydroxyzine, hydroxychloroquine, indapamide, itraconazole, ivabradine (on non us mkt), 
ketoconazole, loperamide, metoclopramide, metronidazole, nelfinavir,  pantoprazole, 
paroxetine, posaconazole, quinine sulfate, ritonavir, sertraline, solifenacin, telapr evir, 
torsemide, trazodone, voriconazole, ziprasidone

Clinical Development
Asciminib/ABL001
Oncology Clinical Trial Protocol CABL001A2301
A phase 3, multi -center, open -label, randomized study  of 
oral ABL001 ( asciminib )versus bosutinib in patients w ith 
Chronic M yelogenous Leukemia in chronic phase (CML -
CP), pre viously  treated w ith 2 or more ty rosine kinase 
inhibitors
Document type Amended Protocol Version
EUDRACT number 2016 -002461 -66
Version number 03-US.01 (Clean )
Development phase III
Document status Final
Release date 05-Aug-2020
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
Template version 19 -Nov-2015

Novartis Confidential Page 2
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 6
List of tables ........................................................................................................................ 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Protocol summary :
............................................................................................................. 11
Amendment 03 -US.01 (05
-Aug-2020).............................................................................. 17
Amendment 3 (14 -Dec-2018) ............................................................................................ 18
Amendment 2 (13 -Jul-
2018) ............................................................................................. 24
Amendment 1 (10 -Apr-2017) ............................................................................................ 30
1Background ........................................................................................................................ 32
1.1 Overview of disease pathogenesis, epidemiology
 and current treatment .............. 32
1.2 Introduction to investigational treatment ............................................................... 33
1.2.1 Overview of 
asciminib ( ABL001) ........................................................ 33
1.2.2
Overview of bosutinib........................................................................... 39
2Rationale ................................ ................................ ................................ ............................ 40
2.1 Study  rationale and purpose ................................................................................... 40
2.2 Rationale for the stud y design ............................................................................... 40
2.2.1
Rationale for Biomarker Assessment.................................................... 41
2.3 Rationale for dose and regimen selection .............................................................. 42
2.4
Rationale for choice of combination drugs............................................................ 43
2.5
Rationale for choice of comparators drug bosutin ib.............................................. 43
2.6 Risks and benefits .................................................................................................. 43
3Objectives and endpoints ................................................................................................... 44
4Study  design ................................ ................................ ................................ ...................... 48
4.1 Description of stud y design ................................................................................... 48
4.1.1 Study  treatment switch from bosutinib to asciminib ............................. 49
4.2 Timing of interim anal yses and design adaptations ............................................... 49
4.3 Definition of end 
of study ...................................................................................... 49
4.4 Early study termination .......................................................................................... 50
5Population .......................................................................................................................... 50
5.1 Patient population .................................................................................................. 50
5.2 Inclusion criteria .................................................................................................... 50
5.3 Exclusion criteria ................................................................................................... 52
6Treatment ........................................................................................................................... 54

Novartis Confidential Page 3
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
6.1 Study  treatment ................................ ................................ ................................ ......54
6.1.1 Dosing regimen ..................................................................................... 54
6.1.2 Ancillary  treatments .............................................................................. 55
6.1.3
Rescue medication ................................................................................ 55
6.1.4 Guidelines for continuation of treatment .............................................. 55
6.1.5 Treatment duration ................................................................................ 55
6.2 Dose escalation guidelines ..................................................................................... 56
6.3 Dose modifications ................................................................................................ 56
6.3.1 Dose modification and dose delay ........................................................ 56
6.3.2
Dose adjustments for QTcF prolongation............................................. 65
6.3.3 Follow -up for toxicities ......................................................................... 66
6.3.4 Anticipated risks and safety  concerns of the study drug ....................... 67
6.4
Concomitant medications for patients on asciminib .............................................. 67
6.4.1 Permitted concomitant therap y
............................................................. 67
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... 68
6.4.3 Prohibited concomitant therap y
............................................................ 68
6.4.4 Other concomitant medications ............................................................. 69
6.5
Concomitant medications for patients on bosutinib .............................................. 70
6.5.1 Permitted concomitant therap y requiring caution ................................. 70
6.5.2 Prohibited concomitant therap y
............................................................ 71
6.6 Patient numbering, treatment assignment or randomization ................................. 71
6.6.1
Patient numbering ................................................................................. 71
6.6.2
Treatment assignment or randomization............................................... 72
6.6.3 Treatment blinding ................................................................................ 72
6.7 Study  drug preparation and dispensation ............................................................... 72
6.7.1 Study  treatment packaging and labeling ............................................... 73
6.7.2 Drug supply  and storage ........................................................................ 73
6.7.3 Study  drug compliance and accountabilit y
........................................... 73
6.7.4 Disposal and destruction ....................................................................... 74
7
Visit schedule and assessments ......................................................................................... 74
7.1 Study  flow and visit schedule ................................................................................ 74
7.1.1 Molecular pre -screening ........................................................................ 93
7.1.2 Screening ............................................................................................... 93
7.1.3 Run-in period ........................................................................................ 96
7.1.4 Treatment period ................................................................................... 96
7.1.5 Visit windows ........................................................................................ 96

Novartis Confidential Page 4
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
7.1.6 Discontinuation of study treatment ....................................................... 97
7.1.7 Withdrawal of consent .......................................................................... 98
7.2 Assessment ty pes................................................................................................... 99
7.2.1 Efficacy  assessments ............................................................................. 99
7.2.2 Safety  and tolerability  assessments ..................................................... 101
7.2.3 Pharmacokinetics ................................................................................ 108
7.2.4 Biomarkers .......................................................................................... 109
7.2.5 Resource utilization ............................................................................. 112
7.2.6 Patient reported outcomes ................................................................... 112
8Safety  monitoring and reporting ...................................................................................... 114
8.1 Adverse events ..................................................................................................... 114
8.1.1
Definitions and reporting .................................................................... 114
8.1.2 Laboratory  test abnormalities .............................................................. 115
8.1.3
Adverse events of special interest....................................................... 116
8.2 Serious adverse events ......................................................................................... 116
8.2.1
Definitions........................................................................................... 116
8.2.2
Reporting............................................................................................. 116
8.3 Emergency  unblinding of treatment assignment ................................................. 117
8.4 Pregnancies .......................................................................................................... 117
8.5 Warnings and precautions .................................................................................... 118
8.6 Data Monitoring Committee ................................................................................ 118
8.7 Steering Committee ............................................................................................. 118
9Data collection and management ................................ ................................ ..................... 119
9.1 Data confidentiality ............................................................................................. 119
9.2 Site monitoring .................................................................................................... 119
9.3
Data collection..................................................................................................... 120
9.4 Database management and quality  control .......................................................... 120
10Statistical methods and data anal ysis.............................................................................. 120
10.1 Analy sis sets ........................................................................................................ 121
10.1.1 Full Anal ysis Set ................................................................................. 121
10.1.2 Safety  set............................................................................................. 121
10.1.3
Per-Protocol set ................................................................................... 121
10.1.4 Dose -
determining anal ysis set............................................................. 121
10.1.5 Pharmacokinetic anal ysis set
............................................................... 122
10.1.6 Other anal ysis set
................................................................................ 122
10.2 Patient demographics/other baseline characteristics ........................................... 122

Novartis Confidential Page 5
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
10.3 Treatments (stud y treatment, concomitant therapies, compliance) ..................... 122
10.4 Primary  objective ................................................................................................. 123
10.4.1 Variable ............................................................................................... 123
10.4.2 Statistical hy pothesis, model, and method of analy sis........................ 123
10.4.3 Handling of missing values/censoring/discontinuations ..................... 123
10.4.4 Supportive and Sensitivity anal yses.................................................... 124
10.5 Secondary  objectives ........................................................................................... 124
10.5.1 Key secondary  objective(s) ................................................................. 124
10.5.2 Other secondary  efficacy objectives ................................................... 125
10.5.3 Safety  objectives ................................................................................. 128
10.5.4 Secondary  PK objectives ..................................................................... 129
10.6 Exploratory  objectives ......................................................................................... 130
10.6.1 Exploratory  efficacy  objectives ........................................................... 130
10.6.2 Exploratory  PK objectives .................................................................. 131
10.6.3 Exploratory  biomarker objectives ....................................................... 131
10.6.4 Exploratory  Patient Reported Outcomes objectives ........................... 132
10.7 Interim anal ysis.................................................................................................... 133
10.8
Sample size calculation........................................................................................ 133
10.9 Power for anal ysis of key secondary  variables
.................................................... 134
11Ethical considerations and administrative procedures ................................ .................... 134
11.1 Regulatory and ethical compliance ...................................................................... 134
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... 134
11.3 Informed consent procedures
............................................................................... 135
11.4 Discontinuation of the study ................................................................................ 135
11.5 Publication of study  protocol and results ............................................................. 135
11.6 Study  documentation, record keeping and retention of documents
..................... 136
11.7 Confidentiality  of stud y documents and patient records ..................................... 137
11.8
Audits and inspections......................................................................................... 137
11.9 Financial disclosures ............................................................................................ 137
12Protocol adherence .......................................................................................................... 137
12.1 Amendments to the protocol ................................................................................ 137
13References (available upon request) ................................................................................ 138
14Appendices ...................................................................................................................... 140
14.1 Appendix 1 L ist of concomitant medications for patients on asciminib
............. 140
14.2 Appendix 2 L ist of concomitant medications for patients on bosutinib .............. 142

Novartis Confidential Page 6
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
List of figures
Figure 1 -1 KCL -22 CML Xenograft ....................................................................... 34
Figure 4 -
1 Schematic of Study  Design ................................................................... 49
List of tables
Table 3
-1 Objectives and related endpoints .......................................................... 45
Table 
6-1 Dose and treatment schedule................................................................. 55
Table 6
-2 Criteria for dose reduction/interruption and re -initiation of 
asciminib and bosutinib treatment for adverse drug reactio ns.............. 57
Table 6-3 Dose reduction steps for asciminib and bosutinib ................................. 65
Table 6
-4 Packaging and labeling ......................................................................... 73
Table 7
-1 Visit evaluation schedule ...................................................................... 75
Table 7
-2 Visit evaluation schedule (study  treatment switch phase) .................... 85
Table 7-3 Blood samples (eff icacy  primary  endpoint)........................................ 100
Table 7
-4 ECOG Performance status scale ......................................................... 103
Table 7
-5 Central clinical laboratory  parameters collection plan ........................ 104
Table 7-6 Central ECG collection (all patients) .................................................. 106
Table 7
-7 Central ECG collection plan for patients in full PK asciminib group .106
Table 7-8 Pharmacokinetic blood co llection log (Sparse PK -group -asciminib 
arm/ asciminib treatment switch patients)........................................... 108
Table 7
-9 Pharmacokinetic blood collection log (Full PK group -asciminib 
arm) ..................................................................................................... 109
Table 7
-10 Biomarker sample collection plan ....................................................... 111
Table 10
-1 Non compartmental pharmacokinetic parameters in full PK group ....130
Table 10-2 Detectable ef fect sizes for key  secondary  endpoint ............................ 134
Table 14-1 Prohibited concomitant medications for asciminib arm...................... 140
Table 14-2 Concomitant medications to be used with caution in asciminib arm.. 141
Table 14-3 Prohibited concomitant medications for bosutinib arm ...................... 142
Table 14-4 Concomitant medications to be used with caution in bosutinib arm ..142

Novartis Confidential Page 7
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
List of abbreviations
ABL Abelson proto -oncogene
ADME Absorption, Distribution, Metabolism, and Excretion
AE Adverse Event
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
ANC Absolute neutrophil count
AP Accelerated phase
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
ATP Adenosine triphosphate
AUC Area under the curve
AVblock Atrioventricular block
BC Blast crisis
BCR Breakpoint C luster Region gene
BCR -ABL BCR -ABL fusion gene (also called the Philadelphia chromosome)
BCRP Breast Cancer Resistant Protein
BID bis in diem /twice a day
BMA Bone marrow aspirate
BUN Blood urea nitrogen
CBC Complete Blood Count
CCA Clonal chromosome abnormalities
CCyR Complete Cytogenetic Response
CD8 Cluster of differentiation 8
CD34 Cluster of differentiation 34
CHR Complete Hematological Response
CI Confidence Interval
CMH Cochran –Mantel –Haenszel
CML Chronic Myelogenous Leukemia
CML-AP Chronic Myelogenous Leukemia -Accelerated Phase
CMO&PS Chief Medical Office and Patient Safety
CP Chronic phase
CRO Contract Research Organization
CSP Clinical study protocol
CSR Clinical study report
CT Computed tomography 
CTCAE Common Terminology Criteria for Adverse Events
CV Coefficient of variation
CYP3A4 Cytochrome P450 3A4
DDI Drug -drug interaction
DILI Drug -induced liver injury
DLCO Carbon monoxide diffusing capacity
DMC Data Monitoring Committee
DNA Desoxyribonucleic acid
DS&E Drug Safety and Epidemiology
ECG Electrocardiogram

Novartis Confidential Page 8
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
ECOG Eastern Cooperative Oncology Group
eCRF Electronic Case Report Form
EDC Electronic data capture
ELN European Leukemia Network
EOT End of Treatment
ERT Electronic Research Technology, Inc
EU European Union
FAS Full Analysis Set
FIH First In Human
GDPR General Data Protection Regulation
GFR Glomerular Filtration Rate
hADME Human ADME study (Absorption, Distribution, Metabolism and Excretion) 
HDL High density lipoprotein
ICF Informed Consent Form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
INN International Nonproprietary Name
INR International normalized ratio
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
K-M Kaplan -Meyer
Km Michaelis -Menten constant
LDL Low density lipoprotein
LFT Liver function test
LLN Lower limit of normal
MCyR Major Cytogenetic Response
mCyR Minor Cytogenetic Response
MDASI -CML MD Anderson Symptom Inventory – Chronic Myelogenous Leukemia
MMR Major Molecular Response
MRI Magnetic resonance imaging
NCCN National Comprehensive Cancer Network
NGS Next Generation Sequencing
NTI Narrow Therapeutic Index
OS Overall survival
PAS Pharmacokinetic analysis set
PBPK Physiologically based pharmacokinetic
PCR Polymerase Chain Reaction
PCyR Partial Cytogenetic Response
PD Pharmacodynamic
PGIC Patient Global Impression of Change
P-gp Permeability glycoprotein

Novartis Confidential Page 9
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Ph+ Philadelphia chromosome positive
PHI Protected Health Information
PK Pharmacokinetics
PLT Platelets
PPS Per-protocol set
QD Quaque die/once a day
QT Q to T interval (ECG)
QTcF QTc Fredericia
REB Research Ethics Board
RNA Ribonucleic acid
RQ-PCR Real time quantitative polymerase chain reaction
RU Resource Utilization
SAE Serious Adverse Event
SAP The Statistical Analysis Plan (SAP) is a regulatory document which provides evidence of 
preplanned analyses
SC Steering committee
SD Standard deviation
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic pyruvic transaminase
SmPC Summary of Product Characteristics
SOP Standard Operating Procedure
TBIL Total bilirubin
TdP Torsades de Pointes
TKI Tyrosine Kinase Inhibitor
TTF Time to treatment failure
UGT Uridin diPhospho -glucuronosyltransferase
ULN Upper limit of normal
US United States
USPI US prescribing information
WBC White blood cell count
WPAI Work Productivity and Activity Impairment

Novartis Confidential Page 10
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biologic Sa mples A biological speci men including, for ex ample, blood (plas ma, serum), saliva, 
tissue, urine, stool, etc. t aken fr om a study subject or study patient
Cycles Number and timing or recommended repetitions of therapy are usually expressed 
as number of days (e.g. q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed consent must 
be obtained (i.e. prior to starting any of the procedures described in the protocol)
Investigational drug The study treatment whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is synonymous with
“investigational new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indicat ion/approved dosage, or that are 
tested in a fixed combination. Investigational treatment generally does not include 
other study treatments administered as concomitant background therapy required 
or allowed by the protocol when used in within approved indi cation/dosage
Medication number A unique identifier on the label of each study treatment package which is linked to 
one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study procedures that 
was not included in the investigational treatment
Subject Number (Subject 
No.)A unique identifying number assigned to each patient/subject/healthy volunteer 
who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional 
segments such as screening, baseline, titration, washout, etc.
Personal Data Subject information collected by the Investigator that is transferred to Novartis for 
the purpose of the clinical trial. This data includes subject identifier information, 
study information and biological samples.
Randomization number A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient (subject) as part of the required study procedu res, including placebo and 
active drug run -ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any reason
Treatment group A treatment group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts. Cohorts are not expanded, new cohorts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified time points
Withdrawal of study 
consentWithdrawal of co nsent from the study oc curs only wh en a subject d oes not want 
to partic ipate in the study any longer, a nd does not allow any further collection of 
personal data

Novartis Confidential Page 11
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Protocol summary :
Title A phase 3, multi -center, open -label, randomized study of oral ABL001 ( asciminib )versus 
bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML -CP), 
previously treated with 2 or more tyrosine kinase inhibitors
Brief title Study of efficacy of CML -CP patients treated with asciminib versus bosutinib, previously 
treated with 2 or more TKIs
Sponsor and
Clinical PhaseNovartis
Phase 3
Investigation ty pe Drug 
Study  type Interventional
Purpose and 
rationalePurpose:
The purpose of this pivotal study is to compare the efficacy of asciminib with that of 
bosutinib in the treatment of patients with CML-CP having previously been treated with a 
minimum of two prior ATP -binding site TKIs with BCR -ABL1 ratios ≥ 1% IS at screening.
Patients intolerant to the most recent TKI therapy must have BCR -ABL1 ratio > 0.1% IS 
at screening and patients failing their most recent TKI therapy must meet the definition 
of treatment failure as per the 2013 ELN guidelines ( Baccarani et al 2013 ). No more 
than 66 patients (approximately 30% of the overall trial population) that are intolerant to 
their most recent TKI therapy with BCR-ABL 1< 1% will be recruited in order to ensure 
that the CML third line patient population is adequately represented.
Rationale:
There remains an unmet need for new compounds in patients with CML who have failed 
at least two prior TKIs. Current practice suggests that a second generation TKI will have 
been used for first line therapy for about one half of patients with CML, meaning that 
most patients who have failed at least two prior TKIs will have failed at least one if not 
two second generation TKIs (such as dasatinib and/or nilotinib ). Potentially, such 
patients may also have faile d bosutinib and/or ponatinib ( Soverini 2014 ). Patients having 
failed at least two TKIs may have limited sensitivity to the remaining available agents 
and, thus, there exists a need for new safe and effective therapy. In addition, mutations 
will have developed in 21 to 33% of patients that prevent the use of specific TKIs, 
increasing the need for a better and alternative compound ( Soverini 2014 ). 
Omacetaxine, a chemotherapeutic agent, is available for patients who have failed at 
least two prior TKIs under these conditions but only in the US and Canada. This agent is 
not available for most patients globally, where a bigger unmet medical need is presen t. 
Thus, there remains an unmet need for patients with CML who have failed at least two 
prior TKIs despite the existence of multiple agents.
Primary  Objective
and Key  
Secondary  
ObjectivePrimary  Objective: To compare the Major Molecular Response (MMR) rate at 24 
weeks of asciminib versus bosutinib
Key Secondary  Objective: To compare MMR rate at 96 weeks of asciminib versus 
bosutinib
Secondary  
Objectives● To compare additional efficacy parameters of ascim inib versus bosutinib:
● cytogenetic response rate (Complete, Partial, Major, Minor, Minimal, no 
response) at and by all scheduled data collection time points, including 24, 48 and 96 
weeks
● MMR rate at all scheduled data collection time points (except 24 and 96 weeks 
which are already covered by primary and key secondary endpoints)
● MMR rate by all scheduled data collection time points, including 24, 48 and 96 
weeks
● Time to MMR
● Duration of MMR
● Time to CCyR
● Duration of CCyR
● Time to treatment failure

Novartis Confidential Page 12
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
● Progression free survival
● Overall survival
● To compare the safety and tolerability profile of asciminib versus bosutinib by t ype, 
frequency and severity of adverse events, changes in laboratory values that fall outside 
the pre -determined range s and clinically notable ECG and other safety data (vital signs, 
physical examination)
●To characterize the PK of asciminib in the CML -CP population (Trough plasma 
concentrations, PK parameters in full PK group: Cmax, Tmax, AUC0 -12h, CL/F)
●    To assess the safety of asciminib when administered as treatment after bosutinib 
failure according to the 2013 ELN Guidelines
Study  design This study is a randomized, phase 3, open -label, active -controlled multi -center study. 
Patients will be randomized to the novel BCR -ABL1 TKI asciminib and bosutinib in a 2:1 
ratio. The randomization is to be stratified to ensure the study population is balanced 
between the arms with respect to the patient’s cytogenetic response status at baseline 
(Major Cytogenetic response ( complete or partial) vs. No major cytogenetic response 
(minor, minimal or none)).
The study design incorporates a 2:1 randomization, allocating more patients to the 
asciminib arm in order to learn more about the safety profile of the experimental therapy,
whereas the safety of bosutinib therapy is well documented. Treatment duration for each 
patient in the present study is for up to 96 weeks after the last randomized patient 
receive s the first dose, or up to 48 weeks after the last patient has switche dfrom 
bosutin ib to asciminib whichever is longer unless patients have discontinued treatment 
earlier, which should be adequate to address both the primary objective of the study, i.e. 
determination of the MMR rate at 24 weeks, as well as secondary efficacy and safety 
objectives. Patients on bosutinib will be able to switch to asciminib treatment up to 96 
weeks after the last patient has been randomized.
If patients in the bosutinib arm have documented treatment failure according to the 2013
ELN Guidelines ( Baccarani et al 2013 ), they will have the option to receive asciminib.
Each patient who switches to asciminib after bosutinib failure can remain on asciminib 
treatment for up to 48 weeks after the last bos utinib failure patient has switched to 
asciminib during the treatment period unless patien tshave discontinued treatment 
earlier.
Population Two-hundred and twenty -two (222) patients with CML -CP who had prior treatment with 
two or more ATP binding site TKIs will be randomized on a 2:1 basis to receive either 
asciminib or bosutinib. Patients with known history of T315I and/or V299L mutations at 
study entry will be excluded from the trial since bosutinib, the comparator, is not 
approved for these patients.
Inclusion criteria Patients eligible for inclusion in this study have to meet allof the following criteria:
1.Male or female patients with a diagnosis of CML -CP ≥ 18 years of age
2.Patients must meet all of the following laboratory values at the screeni ng visit:
● < 15% blasts in peripheral blood and bone marrow
● < 30% blasts plus promyelocytes in peripheral blood and bone marrow
● < 20% basophils in the peripheral blood
● ≥ 50 x 109/L (≥ 50,000/mm3) platelets
● Transient prior therapy related thrombocy topenia (< 50,000/mm3for ≤30 days 
prior to screening) is acceptable
● No evidence of extramedullary leukemic involvement, with the exception of 
hepatosplenomegaly
3a.Patients intolerant to the most recent TKI therapy, BCR -ABL1 ratio >0.1% IS 
according to central laboratory at the screening examination
4.Prior treatment with a minimum of 2 prior ATP-binding site TKIs (i.e. imatinib, 
nilotinib, dasatinib, radotinib or ponatinib)
5.Failure (adapted from the 2013 ELN Guidelines ;Baccarani et al 2013 ) or intolerance 
to the most recent TKI therapy at the time of screening 

Novartis Confidential Page 13
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
● Failure is defined for CML -CP patients (CP at the time of initiation of last 
therapy) as follows. Patients must meet at least 1 of th e following criteria.
● Three months after the initiation of therapy: No CHR or > 95% Ph+ 
metaphases
● Six months after the initiation of therapy: BCR -ABL1 ratio > 10% IS 
and/or > 65% Ph+ metaphases
● Twelve months after initiation of therapy: BCR -ABL1 rat io > 10% IS 
and/or > 35% Ph+ metaphases
● At any time after the initiation of therapy, loss of CHR, CCyR or PCyR
● At any time after the initiation of therapy, the development of new 
BCR -ABL1 mutations which potentially cause resistance to study treatment 
● At any time after the initiation of therapy, confirmed loss of MMR in 2 
consecutive tests, of which one must have a BCR -ABL1 ratio ≥ 1% IS
● At any time after the initiation of therapy, new clonal chromosome 
abnormalities in Ph+ cells: CCA/Ph+
● Intolerance is defined as:
● Non-hematologic intolerance: Patients with grade 3 or 4 toxicity while 
on therapy, or with persistent grade 2 toxicity, unresponsive to optimal 
management, including dose adjustments (unless dose reduction is not 
considered in the best interest of the patient if response is already suboptimal)
● Hematologic intolerance: Patients with grade 3 or 4 toxicity (absolute 
neutrophil count [ANC] or platelets) while on therapy that is recurrent after dose 
reduction to the lowest doses re commended by manufacturer
6.Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
7.Adequate end organ function as defined by (as per central laboratory tests):
● Total bilirubin ≤ 1.5 x ULN) except for patients with Gilbert’s s yndrome who may 
only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN
● Aspartate transaminase (AST) ≤ 3.0 x ULN
● Alanine transaminase (ALT) ≤ 3.0 x ULN
● Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN -  ≤ 1.5 x ULN, value mus t 
be considered not clinically significant and not associated with risk factors for acute 
pancreatitis
● Alkaline phosphatase ≤ 2.5 x ULN
● Creatinine clearance ≥ 50mL/min as calculated using Cockcroft -Gault formula
8.Patients must avoid consumption of grapefruit, Seville oranges or products 
containing the juice of each during the entire study and preferably 7 days before the first 
dose of study medications, due to potential CYP3A4 interaction with the study 
medications. Orange juice is allowed.
9.Written informed consent obtained prior to any screening procedures.
10a. Patients must have the following electrolyte values (as per central laboratory tests) 
within normal limits or corrected to be within normal limits with supplements prior to first 
dose of st udy medication:
 Potassium (potassium increase of up to 6.0 mmol/L is acceptable at study entry
if associated with creatinine clearance within normal limits)
 Total calcium (corrected for serum albumin) ; (calcium increase of up to 12.5 
mg/dl or 3.1 mmol/L is acceptable at study entry if associated with creatinine 
clearance within normal limits)
 Magnesium, with the exception of magnesium increase > ULN - 3.0 
mg/dL; >ULN -1.23 mmol/L associated with creatinine clearance (calculated 
using Cockcroft -Gault formul a)within normal limits
11. Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of 
screening which are amenable to standardized R Q-PCR quantification.
Exclusion criteria Patients eligible for this study must not meet anyof the follow ing criteria:
1.Known presence of the T315I or V299L mutation at any time prior to study entry
2.Known second chronic phase of CML after previous progression to AP/BC

Novartis Confidential Page 14
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
3.Previous treatment with a hematopoietic stem-cell transplantation
4.Patient plannin g to undergo allogeneic hematopoietic stem cell transplantation
5.Cardiac or cardiac repolarization abnormality, including any of the following:
● History within 6 months prior to starting study treatment of myocardial infarction 
(MI), angina pectoris, coronary artery bypass graft (CABG)
● Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), 
complete left bundle branch block, high -grade AV block (e.g., bifascicular block, 
Mobitz type II and third degree AV block)
● QTcF at screenin g ≥450 msec (male patients), ≥460 msec (female patients)
● Long QT syndrome, family history of idiopathic sudden death or congenital long 
QT syndrome, or any of the following:
● Risk factors for Torsades de Pointes (TdP) including uncorrected 
hypokalemia o r hypomagnesemia, history of cardiac failure, or history of 
clinically significant/symptomatic bradycardia
● Concomitant medication(s) with a “known risk of TdP” per 
www crediblemeds.org/ that cannot be discontinued or replaced 7 days prior to 
starting study drug by safe alternative medication.
● Inability to determine the QTcF interval
6.Severe and/or uncontrolled concurrent medical disease that in the opinion of the 
investigator could cause unacceptable safety risks or compromise compliance with the 
protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary 
hypertension)
7.History of acute pancreatitis within 1 year of study entry or past medical history of 
chronic pancreatitis
9.History of acute or chronic liver disease
10.Known presence of significant congenital or acquired bleeding disorder unrelated to 
cancer
11.History of other active malignancy within 3 years prior to study entry with the 
exception of previous or concomitant basal cell skin cancer and previous carcinoma in 
situ treated curatively
12.Known history of Human Immunodeficiency Virus (HIV), chronic Hepatitis B (HBV), 
or chronic Hepatitis C (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) 
and Hepatitis B core antibody (HBcAb / anti HBc) will be performed at screening
13.Impairment of gastrointestinal (GI) function or GI disease that may significantly alter 
the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, 
diarrhea, malabsorption syndrome, small bowel resectio n, or gastric bypass surgery)
14a. Treatment with medications that meet one of the following criteria and that 
cannot be discontinued at least one week prior to the start of treatment with study 
treatment
● Moderate or strong inducers of CYP3A
● Moderate o r strong inhibitors of CYP3A 
15.Previous treatment with or known/ suspected hypersensitivity to asciminib or any of 
its excipients.
16.Previous treatment with or known/ suspected hypersensitivity to bosutinib or any of 
its excipients.
17.Participation in a prior investigational study within 30 days prior to randomization or 
within 5 half -lives of the investigational product, whichever is longer
18.Pregnant or nursing (lactating) women
19a. Women of child -bearing potential, defined as all women physiolo gically capable 
of becoming pregnant, unless they are using highly effective methods of contraception 
during dosing and for 3 days after last dose of asciminib and one month after last dose 
of bosutinib . Highly effective contraception methods include:
● Total abstinence (when this is in line with the preferred and usual lifestyle of the 
subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -
ovulation methods) and withdrawal are not acceptable methods of contraception

Novartis Confidential Page 15
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
● Female sterilization (have had surgical bilateral oophorectomy (with or without 
hysterectomy) total hysterectomy or bilateral tubal ligation at least six weeks before 
taking study treatment). In case of oophorectomy alone, only when the reproductive 
status of the woman has been confirmed by follow up hormone level assessment
● Male sterilization (at least 6 months prior to screening). The vasectomized male 
partner should be the sole partner for that subject.
● Use of oral, injected or implanted hormonal methods of contraception or 
placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms 
of hormonal contraception that have comparable efficacy (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception.
● In case of use of oral contraception women should have been stable on the 
same pill for a minimum of 3 months before taking study treatment.
● Women are considered post -menopausal and not of child bearing potential if 
they have had 12 months of natural (spont aneous) amenorrhea with an appropriate 
clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had 
surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or 
bilateral tubal ligation at least six weeks befo re taking study medication. In the case 
of oophorectomy alone, women are considered post -menopausal and not of child 
bearing potential only when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment.
Conditions to be 
fulfilled for 
asciminib switch1.Failure to bosutinib treatment up to 96 weeks after the last patient received the first 
dose (adapted from the 2013 ELN Guidelines; Baccarani et al 2013 ). Patients must 
meet at least 1 of the following criteria. Failure is defined as follows:
Three months after the initiation of therapy or thereafter : No CHR or > 95% Ph+ 
metaphases.
Six months after the initiation of therapy or thereafter: BCR -ABL1ratio > 10% 
IS and/or > 65% Ph+ metaphases.
Twelve months after initiation of therapy or thereafter: BCR -ABL1ratio > 10% 
IS and/or > 35% Ph+ metaphases.
At any time after the initiation of therapy, loss of CHR, CCyR or PCyR.
At any time after the initiation of therapy, detection of new BCR -ABL 1
mutations which potentially cause resistance to study treatment (asciminib or 
bosutinib) .
At any time after the initiation of therapy, confirmed loss of MMR in 2 
consecutive tests.
At any time after the initiation of therapy, new clonal chromosome abnormalities 
in Ph+ cells: CCA/Ph+.
Conditions preventing patients to switch to asciminib:
Any Grade 3 or 4 toxicity which has not resolved to Grade 2 or lower within 28
days and before start ing asciminib treatment.
Asymptomatic (Grade 2)pancreatitis if not resolved within 28 days 
Disease progression while on bosutinib treatment. The following events are 
considered disease progression:
Accelerated phase (AP) as defined by any of the following:
 ≥15% blasts in the peripheral blood or bone marrow aspirate, but < 
30% blasts in both the peripheral blood and bone marrow aspirate.
 ≥30% blasts plus promyelocytes in peripheral blood or bone marrow 
aspirate.
 ≥20% basophils in the peripheral blood.
Thrombocytopenia (< 100 x 109/L) that is unrelated to therapy.
Blast crisis (BC) as defined by any of the following:
 ≥30% blasts in peripheral blood or bone marrow aspirate

Novartis Confidential Page 16
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Appearance of extramedullary involvement other than 
hepatosplenomegaly proven by biopsy (i.e., chloroma).
QTcF at time of switch >480msec or inability to determine QTc interval
Investigational 
and reference 
therapyAsciminib 40 mg BID
Bosutinib 500 mg QD
Efficacy  
assessmentsMolecular response (RQ -PCR, mutational analysis)
Cytogenetic response (Bone Marrow Aspirate)
Safety  
assessments●Physical examination
●Vital Sign
●Height and weight
●ECOG performance status
●Laboratory chemistry and hematology
●Serology
● Electrocardiogram (ECG)
●Echocardiogram
●Pulmonary functi on tests with DLCO
Other 
assessments●PK sampling (full/sparse)
●Bone Marrow Biopsy
●Patient Report Outcomes (MDASI -CML, PGIC, W PAI, EQ --5D-5L, resource 
utilization)
Data analy sis The primary efficacy variable of the study is the Major Molecular Response (MMR) rate 
at 24 weeks. A patient will be counted as having achieved MMR at 24 weeks if he meets 
the MMR criteria (BCR -ABL1 ratio ≤0.1%) at 24 weeks.
The MMR rate at 24 weeks will be calculated based on the FAS and according to the 
Intent ionTo Tr eat (ITT) principle. MMR rate and its 95% confidence interval based on 
the Pearson -Clopper method will be presented by treatment group. Confidence interval 
for the difference in MMR rate between treatment groups will be provided using the W ald 
method.
The Mantel -Haenszel estimate of the common risk difference and the corresponding 
95% confidence interval will also be provided.
The key secondary endpoint is MMR rate at 96 weeks.
Formal statistical testing of the key secondary endpoint will be performed only if the 
primary endpoint is significant by means of a gatekeeping procedure to control the 
overall alpha level. 
Key words Phase III, open -label, randomized trial, asciminib, bosutinib, CML-CP, prior treatment 
with 2 or more TKIs

Novartis Confidential Page 17
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Amendment 03 -US.01 (05-Aug-2020 )
Amendment rationale 
As of 25-Jun-2020, 319 patients were screened, 233 patients were randomized in the study .
Patient recruitment has been completed on 22- Oct-2019. The stud y is currently  ongoing.
The primary  purpose of the amendment is:
Based on FDA request, requirement for male contraception has been reintroduced in the study .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The requirements for male contraception have been reintroduced in the following sections:
Section 7.2.2.5.3 Pregnancy  and assessments of fertility .
Section 8.4 Pregnancies.
Section 11.3 I nformed consent procedures.
The enrollment has been completed , thus the eligibility  criterion has not been updated .
IRBs/IECs
A copy  of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authority .
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 18
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Amendment 3 (14-Dec -2018 )
Amendment rationale 
As of 21-Nov- 2018, 13 7patients were screened and 8 6patients were randomized in the study , 
the study  is currentl y ongoing .
The primary  purpose of the amendment is:
Modification ofthe inclusion criterion of BCR -ABL 1transcript threshold required at study 
entry  from a BCR -ABL1 ratio ≥ 1% IS to BCR -ABL 1ratio >0.1% IS(i.e.not inMMR) for 
patients with intolerance to most recent TKItreatment. The threshold presented in this inclusion 
criteria affects only patients who are intolerant to prior treatment , since patients failing prior 
treatment must fulfill the criteria defined by ELN guidelines (Baccarani et al 2013). Although 
the number of treatment options is increasing, especiall y for patients with imatinib intolerance, 
alternatives for patients with resistance and/or intolerance to at least two previous TKIs are 
limited (NCCN 2018, ELN 2013). The reason of reducing the BCR -ABL 1ratio is that in routine 
clinical practice, physicians do not wait to observe increas
edBCR -ABL 1levels to switch 
treatment in patients with intolerance, which may increase the risk of disease progression, 
especiall y in patients with only limited further treatment options. This is in line with current 
CML  treatment guidelines where the switch to an alternative therapy  in intolerant patients is 
not linked toa BCR -ABL 1threshold (NCCN 2018 , Baccarani et al 2013 and Hochhaus et al 
2017). 
Therefore, the threshold of ≥1% BCR -ABL 1in the current trial is reduced to BCR -ABL 1ratio >
0.1% IS for patients with intolerance to most recent TKI treatment . No more than 66patients 
(approximately  30% of the overall trial population) that are intolerant to their most recent TKI 
therap y with BCR -ABL 1< 1% will be recruited in order to ensure that the CML  third line 
patient population is adequately represented. As the primary endpoint is the rate of MMR at 24 
weeks a baseline molecular response level > 0.1 % BCR -ABL1 is needed.
Patients experiencing documented treatment failure 
on bosutinib treatment will be allowed to 
switch to asciminib. Patients failing bosutinib treatment w ill have failed at least their third TKI 
treatment, with limited remaining treatment options. With this amendment patients who have 
failed bosutinib will be offered the possibility  to continue in the study  by receiving asciminib , 
if investigators consider that this treatment option is in the best interest of the patient. As of 15 -
Oct-2018, 4 patients could have potentially  benefited from this option. Treatment failure during 
study  treatment is assessed by measureable and pre-specified milestones defined by ELN 
criteria (Baccarani et al 2013 ), which are also used to define treatment failure as entry  criteria 
for the study . Only  documented treatment failure in the bosutinib arm will be considered for a 
treatment switch. For the purpose of the primary  and secondary  endpoint analy ses, any  patient 
meeting the ELN failure criteria while receiving study  treatment, (either before or by the time 
of conducting the analysis and irrespective of treatment arm), will be considered as non-
responders for the specific time point and for any subsequent time point. The switch to 
asciminib in case of bosutinib treatment failure is not expected to introduce bias as those 
patients will be regarded as non-responders irrespective of treatment switch and thedisease 
burden will certainly  not improve without further treatment . There is no option to switch 
patients failing on the asciminib treatment arm, as those patients can be offered approved 

Novartis Confidential Page 19
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
therapies outside of the context of the study . The efficacy  data collected after the switch from 
patients switching to asciminib following bosutinib failure will be analyz ed separatel y as 
exploratory  endpoints and will not be included for primary  and secondary  study endpoints. In 
addition, safet y data from patients receiving asciminib after bosutinib failure will be collected 
to further characterize ascimini b’s safet y profile .
Potassium increase of up to 6.0 mmol/L  is acceptable at study  entry if associated with creatinin
e 
clearance within normal limits . Grade 2 increase of potassium is acceptable in case of normal 
creatinine clearance as this is not considered to be a risk factor for QTc prolongation. Total 
calcium (corrected for serum albumin) increase of up to 12.5 mg/dl or 3.1 mmol/L (Grade 2) is 
acceptable at study  entry if associated with creatinine clearance within normal limits as this is 
not considered to be a risk factor for QTc prolongation.
A change to creatinine clearance instead of GFR is being made in relation to the magnesium 
inclusion requirement as GFR in this study  is expressed by  creatinine clearance.
Exclusion criteria #19 is being modified under this amendment in order to define the duration 
of the use of highl y effective methods of contraception after the last dose of bosutini b under 
this study  (one month after last dose of bosutinib). This is being done in order to align with the 
latest Bosulif®USPI. 
Exclusion criteria #21 has also been removed under this amendment. In embry ofetal 
development studies with asciminib, fetal malformations (cardiac malformations) and increased 
visceral and skeletal variants were observed in rats and increased incidence of resorptions 
indicative of embry o-fetal mortality  and a low incidence of cardiac malformations indicative of 
dysmorphogenesis were observed in rabbits. Asciminib is not genotoxic. As published in the 
literature, small molecules can distribute to seminal fluid and the seminal accumulation 
suggested is semen/plasma ratios up to 11.3 ( Klemmt and Scialli 2005 ). According to the FDA 
guidance, in general, there is increased concern for reproductive or developmental toxicity  in 
humans for relative exposure ratios (animal: human) that are <
10 and decreased concern for 
exposure ratios > 25 (FDA Guidance for Industry 2011). The calculations for the asciminib 
safet y margin were done based on C max (plasma) seen in patients at a dose of 200mg BID 
(Cmax 6843 ng/ml).  Safety  margin calculation based on the embry o-fetal development study 
in rats was 768 and safety  margin calculation based on the embry o
-fetal development study  in 
rabbits was 894. In conclusion, for asciminib, as outlined above, the safety  margins are well 
above 25 and therefore no embry o-and fetotoxicity  effects can be antici pated via seminal fluid.
Removal of male contraception is in line with the Bosutinib USPI  and SmPC.
In addition, patients can be re-screened up to three times for the study , instead of once.  The 
patient population being investigated in this study is heavi ly pre-treated and patients might not 
have other treatment options outside the trial. There can be man y intolerance
-related temporary 
conditions resulting in ineligibility  for the trial.
Recruitment period extension has been reflected in the VES table. Study length has changed 
with introduction of switch option for patients failing bosutinib treatment.
Patients enrolling in this trial will present a high disease burden after failure of previous 
therapies. Myelosuppression during TKI targeted treatment is avery common effect observed 
due to the suppression of the leukemic clone; this effect is also extended to hematopoiesis of 

Novartis Confidential Page 20
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
stem cells and progenitors (Steegmann et al 2016 ). For this reason, the recover y period for 
cytopenias has been extended from 28 to 42 daysin order to allow for sufficient time to recover 
from suppression and to re-populate the bone marrow.
The biomarker sampling profile has been revised toremove the gene expression profile in 
leukemic stem cells in both blood and bone marrow due to technical limitations .  In addition, 
there is currentl y no validated assay available.
A clarification has been made to how thetests for blood urea and Blood Urea Nitr ogen (BUN)
are noted. The text "blood urea, Blood Urea Nitrogen (BUN)" has been revised to “blood urea 
or Blood Urea Nitrogen (BUN)”
in order to note that either test is permitted .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Change of the purpose of the study  by decreasing the requirement of BCR -ABL1 ratio ≥
1% I S to BCR -ABL 1ratio > 0.1% IS at the time of screening for patients with 
intolerance :
Protocol summary .
Section 2.1 Study  rationale and purpose .
Section 4.1 Description of study .
Section 5.2 I nclusion criteria .
Section 10.5.2 Other secondary  efficacy  objectives.
Change of the stud y design by introducing the switch to asciminib option for patients 
experiencing treatment failure on bosutinib treatment:
Protocol summary .
Section 2.2 Rationale for the study  design.
Section 4.1 Description of study .
Figure 4 -1 Schematic of Study  Design .
Additio n of Section 4. 1.1 Study  treatment switch from bosutinib to asciminib
Section 4.3 Definition of end of study
.
Section 6.1.5 Treatment duration
Section 6.7.3.2 Study  drug accountabilit y.
Section 7 Visit schedule and assessments :
Addition of Table 7 -2 Visit evaluation schedule (study treatment switch phase ).
Addition of Section 7.1.2.2 Conditions to be fulfilled for asciminib switch.
Section 7.1.5 Visit windows .
Section 7.1.6 Discontinuation of study  treatment.
Section 7.2.1.1 Molecular response .
Section 7.2.1.2 Bone marrow anal ysis and cy togenetics
Section 7.2.2.1 Phy sical examination .

Novartis Confidential Page 21
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Section 7.2.2.2 Vital signs .
Section 7.2.2.3 Height and weight.
Section 7.2.2.4 Performance status .
Section 7.2.2.5 L aboratory  evaluations .
Section 7.2.2.6 Cardiac assessme nts.
Section 7.2.3 Pharmacokinetics.
Section 7.2.4 Biomarkers .
Section 10.1.6 Other analysis sets
.
Section 10.5.3.1 Analy sis set and grouping for the anal ysis
Addition of new exploratory  measure for patients that switch from bosutinib to asciminib :
Table 3- 1 Objectives and related endpoints .
Section 10.1.6 Other analysis sets.
Section 10.6 Exploratory objectives:
Section 10.6.1 Exploratory  efficacy  objectives.
Section 10.6.1.1 Data analy sis of exploratory  efficacy  objectives.
Reference for concomitant medications with a “known risk of TdP” has been updated to 
wwwcrediblemeds.org/
Protocol summary
Section 5.3 Exclusion criteria
Section 6.3.2 Dose adjustments for QTcF prolongation
Section 6.4.3 Prohibited concomitant therap y

Section 5.2 I nclusio n criteria and protocol summary : updated inclusion criteria to reflect 
the changes below :
Inclusion Criteria #3: As referenced above, the requirement of BCR- ABL1 ratio ≥ 1% 
IS has been decreased to BCR -ABL 1ratio > 0.1% I S at the time of screening for 
patients intoleran t to previous TKI .
Inclusion Criteria #10: Potassium increase of up to 6.0 mmol/L is accepted at study  
entry if associated with creatine clearance within normal limits .  Calcium increase of 
up to 12.5 mg/dl or 3.1 mmol/L
 is acceptable at study  entry  if associated with 
creatinine clearance within normal limits .  GFR replaced b y Creatinine clearance 
(calculated using Cockcroft -Gault formula) in order to maintain consistency  
throughout the protocol as creatinine clearance is already  calculate d based on 
inclusion criteria #7 .
Inclusion 
Criteria #11: As study  eligibility  is assessed during screening with BCR-
ABL1 PCR quantification via international scale this requirement was added as 

Novartis Confidential Page 22
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
clarification. Measurement according to international scale i s onl y possible for typical 
BCR -ABL1 transcripts .
Section 5.3 Exclusion Criteria and Protocol summary : updated exclusion criteria to reflect 
the following changes:
Exclusion Criteria #14: Removal of P -gp as a moderate or strong inhibitor of CYP3A
as P-gp inhibitors are no longer prohibited per updated USPI , and SmPC
Exclusion Criteria #19: D uration of the use of highl y effective methods of 
contraception after the last do se of bosutinib has been defined to align with the lat est 
bosutinib USPI .
Exclusion Cri teria #21 Removal of this criteria in order to align with updated pre-
clinical data.
Section 6.3.1 Dose modification and dose delay: T he recovery  period for cytopenias has 
been extended from 28 to 42 day s in order to allow for sufficient time to recover fr om 
suppression and to re -populate the bone marrow .
Table 7-1 Visit evaluation schedule: updates due to inadvertent omissions in previous 
protocols and to reflect extension of study  treatment period
ECOG Performance status: X has been replaced by “If needed ” under Week 6, Week 
10 and Week 14.
Vital signs: added “If needed” under Week 6, Week 10 and Week 14.
Visit name: “W108, W120, W132, W144, W156” has been changed to “Every  12 
weeks up to end of stud y treatment ” to align with new extended recruitment timelines.
Section 7.1.2 Change of patient re-screening allowance from once to up to three times.
Section 7.1.2.2 Addition of new section with screening eligibility  criteria for patients 
switching from bosutinib to asciminib.
Section 7.1.4 Change of treatment duration for patients including those patients that 
switch to asciminib after failure on bosutinib. Patients can remain on ascimini b treatment 
for up to 96 weeks after the last patient received the first dose in the study  or up to 48
weeks after the last patient has switched to asciminib whichever islonger .
Section 7.1.6 Discontinuation of study  treatment: updated to specify  that the safet y follow -
up visit can be conducted by  telephone and replacement of “after randomization” by  “after 
initiation of therapy
” in the event that constitute sa treatment failure .
Section 7.2.2.5.3 Pregnancy and assessments of fertility :Change in requirement for 
reporting pregnancies under this study .  Pregnancies diagnosed in female partners of male 
participants are n o longer required to be reported to CMO&PS.   Contraception use by  
sexually active males while on 
study  treatment is no longer required.
Table 7- 5 Central clinical laboratory  parameters collection plan: Clarification on blood 
urea and Blood Urea Nitrogen (BUN). The text "blood urea, Blood Urea Nitrogen (BUN) " 
has been revised to “ blood urea or Blood Urea Nitrogen (BUN)”.
Section 8.4 Pregnancies: removal of male contraception requirement due to new 
information of asciminib embry o and fetotoxicity .
Section 10.4.3 Handling of missing values/censoring/discontinuations: imputation rules 
updated to take in account unscheduled visits close to visit Week 24 .

Novartis Confidential Page 23
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Section 10.5.1.1. Analy sis for key  secondary  endpoints: imputation rules updated to take 
in account unschedu led visits close to visit Week 96 .
Section 14 Appendices :updates to reflect that P -gp inhibitors are no longer prohibited
Section 14.2 Appendix List of concomitant medications for patients on bosutinib :
Removal of P -gp inhibitors from Table 14 -3Prohibite d concomitant medications 
for bosutinib arm .
Addition of new medications to Category  Tors ade de pointe (TdP) TdP/QT risk : 
Known .
Addition of new category , TdP/QT risk: Possible .
Addition of new category , TdP/QT risk: Conditional .
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes descri bed in this 
protocol amendment.

Novartis Confidential Page 24
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Amendment 2 (13-Jul -2018)
Amendment rationale 
As of 29-Jun- 2018, this study  has been submitted in 25 and approved in 24 countries. Eighty 
five (85) sites were initiated, 67 patients were screened and 38 patients were randomized in the 
study .
The primary  purposes of the amendment are:
The frequency  of bone marrow aspirate (BMA) to perform cytogenetic analysis has been 
decreased in accordance with treatment guidelines ( European Leukemia Network (ELN) 
Guidelines (Baccarani et al 2013) , National Comprehensive Cancer Network (NCCN) (Clinical 
Practice Guidelines in Oncology -Chronic Myeloid Leukemia v4.2018). Initially  BMAs were 
foreseen at screening, every  24 weeks thereafter and at end of treatment. With the protocol 
amendment BMA isno longer needed for patients that have achieved MMR during study , 
however BMA asses sment is requested a t the time of end of treatment for biomarker anal ysis. 
Toxicity  studies performed in rats, dogs and cynomolgus monkey sidentified the pancreas as 
potential target tissues. Therefore the assessment for laboratory  parameters that are associated 
with pancreatitis were part of the inclusion criteria (amylase, lipase). Serum lipase is the 
preferred test due to its improved sensitivity , and a threshold concen tration of 2-3 x ULN is 
recommended for the diagnosis of pancreatitis. There are a number of other conditions that can 
elevate lipase, including TKI pretreatment, thus the screening threshold for lipase is increased 
from ≤ULN to ≤ 1.5 x ULN (CTCAE v4.03 grade 1), as patients with history  of acute 
pancreatitis within 1 y ear of study  and history  of chronic pancreatitis are excluded. Amylase is 
not a specific marker for pancreatitis, as up to 60% of total serum amylase originates from non -
pancreatic sources. Its short half-life reduces its value as a diagnostic test in the early clinical 
course. Lipase has replaced am ylase as the biochemical test of choice for acute pancreatitis due 
to its higher specificit y (Basnay ake 2015 ), therefore the requirement of amylase ≤ ULN at 
screening has been removed.
Assessments for visits at weeks 6, 10 and 14 will be limited to the monitoring of the bone 
marrow function to allow for adjustments of study  treatment. Assessments will comprise a 
complete blood count to detect neutropenia and thrombocy topenia which are among the most 
frequent adverse reactions [Asciminib Investigator ’sBrochure , Bosutinib label] .The physical 
examination must be done at site only  in case of previous or newl y occurring adverse events .
The concomitant medication section has been updated to reflect the most 
recent clinical updates 
on asciminib as well to align with the Bosutinib label .
In addition some minor inconsistencies (discrepancies betwee n sections, typos) have been 
corrected.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
ABL001 has bee n replaced by International Nonproprietary  Name (INN) asciminib 
throughout the protocol amendment.

Novartis Confidential Page 26
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Section 6.3.1 Dose modification and dose delay : clarification made on treatment 
discontinuation.
Table 6-2 Criteria for dose reduction/ interruption an d re-initiation of asciminib and 
bosutinib treatment for adverse drug reactions: 
Gastro intestinal/ Pancreatitis/Grade 2 : precisions provided and treatment delay  
changed from 7 to 21 day s to give investigators sufficient time for re -assessment.
Removal of “other adverse event” section which was redundant with the section “non -
hematological adverse event reaction except where further specified in individual 
section”.
Mandatory  instructions for grade 3 and 4 “Non- hematological adverse event reaction 
except where further specified in individual section” for bosutinib have been aligned 
with those of asciminib: dose hold until resolved to ≤ grade 1 , to handle the patients 
identically  independent of the treatment assigned.
Section 
6.3.2 Dose adjustments for QTcF prolongation: adapting the dose adjustment
concerning QT prolonging agents to the classification known, possible or conditional risk 
for TdP, and adding the external web link to qtdrugs.org .
Section 6.4.2 Permitted concomitant therapy  requiring caution and/or action: updated with 
the most clinical data available.
Section 6.4.3 Prohibited concomitant therap y (asciminib ):
Section on other anticancer agent added,
Sections on strong CYP3A4/5 inhibitors and P- gp inhibitors: prohibition on P -gp 
inhibitors has been removed and moved under requiring caution and/or action section 
based on CABL001A2102 ADME study ,
Section on strong CYP3A4/5, UGT1A/2B inducers updated to provide instructions on 
action to be taken in case these inducers are taken,
Section on NTI subs trates of CYP3A4/5, CYP2C8 and CYP2C9 removed based on a 
most updated PBPK modeling predicting a negligible risk for sensitive CYP3A4/5, 
CYP2C8, or CYP2C9 substrates and moved under requiring caution and/or action 
section,
Section on QT prolonging agents u pdated to change agents known to prolong QT 
interval to agents with “known”, “possible” or “conditional” risk of Torsades de 
Pointes.
Section 6.5.1 Permitted concomitant therap y requiring caution (bosutinib): has been 
updated to reflect the bosutinib label information regarding the use of QT prolonging agents. 
Section 6.5.2 Prohibited concomitant therap y (bosutinib): 
Section on other anticancer agent added,
Concomitant use with CYP3A4/5 inhibitors/inducers: further clarifications on 
necessary  actions. 
Table 7- 1 Visit evaluation schedule: 
Exploratory  BCR -ABL1 mutation analy sis (Sanger Sequencing) for patients with 
mutations at Week 1 Day 1: rephrased to indicate that this assessment will be 
performed without any dedicated blood collection.

Novartis Confidential Page 29
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Section 10.5.2 Other secondary  efficacy  objectives: update of descriptive statistics 
definition and removal of presentation of p value as no formal sta tistical testing will be 
performed.
Section 10.6.1 Exploratory  efficacy  objectives and Section 10.6.3 Exploratory  biomarker 
objectives
: 
Correction of time points for BCR -ABL1 mutation characterization (baseline 
corrected to Week 1 Day 1, adding “upon confirmed loss of MMR, and changed 
“and” to “and/or” End of treatment).
  
Section 10.6.4.1 Resource utilization: c orrection on duration of resource utilization 
reporting.
Section 10.7 I nterim analy sis:clarification concerning the anal ysis of the key  secondary  
endpoint at week 96 if statistical significance is not reached for primary  endpoint at week 
24.
Section 14 Appendices: the lists of concomitant medications for patients on asciminib and 
bosutinib have been updated based on the internal Pharmacokinetic Sciences 
memorandum on Drug
-Drug Interaction (release date: January 2018).
Some minor inconsistencies (discrepancies between sections, ty pos) have been corrected.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes descri bed in this 
protocol amendment.

Novartis Confidential Page 32
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and curren t 
treatment
Chronic myeloid leukemia (CML) is a hematological stem cell disorder characterized bya 
specific chromosomal translocation leading to the Philadelphia (Ph) chromosome which is 
detected in 95% of patients (Nowell and Hungerford 1960; Rowley  1973). The molecular 
consequence of the translocation is the fusion of the ABL1 proto- oncogene to the BCR gene 
resulting in the production of an activated form of the ABL1 protein tyrosine kinase (TK) 
(Bartram et al 1983; Heisterkamp et al 1983 ). BCR -ABL1 drives the growth factor 
independence, increased proliferation, genomic instability , suppression of apoptosis and 
alteration of the adhesive properties of CML  cells (Hochhaus 2009) and the expression of BCR -
ABL1 in mice results in the development of a CML -like disease ( Daley  et al 1990; Kelliher et 
al 1990). This evidence that BCR -ABL1 is a genetic driver of CML was subsequently  
confirmed b y the clinical efficacy of imatinib in patients [IRIS Study  STI571A0106] .
Clinically , CML is characterized by overproduction of immature myeloid cells and mature 
granulocy tes in the spleen, bone marro
w and peripheral blood. Most patients, however, present 
in the CP, characterized by splenomegaly and leukocy tosis with generall y few symptoms. CML  
progresses through three distinct phases of increasing refractoriness to therapy : chronic phase 
(CP), acceler ated phase (AP), and blast crisis (BC). With conventional chemotherap y, such as 
busulfan or hydroxy urea, the median survival time commonly  reported for CML  was about 4 
years, but progression to AP and BP was only slightl y delay ed. Interferon -alfa delay ed 
progression significantl y, with a median survival of approximately  6 years. However, during 
the last decade, TK inhibitor (TKI) therapy  became the standard treatment for most patients 
with CML , with complete cytogenetic response rates of 70% to 90% and 5-year progression -
free survival and overall survival of 80% to 95% commonly  reported ( Vardiman 2009 ).
The National Comprehensive Cancer Network (NCCN) guideline on CML ( NCCN guideline v 
1.2014) and the European L eukemia Net (ELN) ( Baccarani et al 2013 ) recommend continuing 
TKI treatment indefinit
ely in all responding patients. The first TKI, imatinib mesylate (imatinib, 
STI571, Gleevec ™/Glivec™), an adenosine triphosphate (ATP) -competitive TKI with 
selectivity  towards BCR -ABL1, revolutionized treatment of CML  and significantly  improved 
the prognosis of patients since its approval in 2001. It is effective in most patients with CML at 
well-tolerated doses, and is indicated as frontline therap y for Ph+ CML -CP and in patients with 
Ph+ CML in blast crisis (BC), accelerated phase (AP), or in CP after failure of interferon -alpha 
therap y. However, despite the rema rkable efficacy  of imatinib, some patients are either 
intolerant to the drug or can develop resistance ( O’Hare 2006
). Imatinib resistance is primaril y 
due to nucleotide substitutions in BCR -ABL 1, which encode mutant forms of protein’s tyrosine 
kinase domain that impair imatinib binding. Over -expression of the BCR -ABL1 protein may 
also cause resistance. Rates of resistance increase with each stage of progression of CML (CP 
< AP < BC) ( Branford 2003 ).
Multiple agents, including nilotinib, dasatinib, ponatinib, bosutinib, radotinib (Korea) and 
omacetaxine (USA, Canada) are able to combat various forms of imatinib -resistant CML  and 
are currently  approved forpatients with CML -CP previously  treated with prior therap y. With 
the exception of omacetaxine, which is a cytotoxic chemotherapeutic agent, all of these drugs 

Novartis Confidential Page 33
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
are ATP -competitive TKIs. Like imatinib, nilotinib , dasatinib and most recently bosutinib are 
also indicated for the treatment of patients with newly  diagnosed CML. The activity  of nilotinib 
or dasatinib in patients previously  treated with a second generation TKI is not known. In 
contrast to the ATP -competitive TKIs, asciminib inhibits the enz ymatic activity  of BCR -ABL1 
through an allosteric mechanism.
There remains an unmet need for new compounds in patients with CML  who have failed at least 
two prior TKI s. Current practice suggests that a second generation TKI will have been used for 
first line ther apy for about one half of patients with CML, meaning that most patients who have 
failed at least two prior TKIs will have failed at least one if not two second generation TKIs: 
dasatinib and/or nilotinib. Potentially , such patients may also have failed bosutinib and/or 
ponatinib (Soverini 2014 ).Patients having failed at least two TKIs ma y hav e limited sensitivity 
to the remaining available agents and, thus, there exists a need for new safe and effective therap y. 
In addition, mutations will have developed in 21 to 33% of patients that prevent the use of 
specific TKIs, increasing the need for a better and alternative compound (Soverini 2014). 
Omacetaxine, a chemotherapeutic agent, is available for patients who have failed at least two 
prior TKIs under these conditions but only in the US and Canada. This agent is not available 
for most patients globally, where a bigger unmet medical need is present. Thus, 
there remains 
an unmet need for active and safe drugs in patients with CML  who have failed at least two prior 
tyrosine kinase inhibitors (TKI), even in the presence of approved drugs, as described below.
1.2 Introduction to investigational treatment
1.2.1 Overview  ofasciminib (ABL001 )
Asciminib is an orally bioavailable specific BCR -ABL 1inhibitor with a novel mechanism of 
action. In contrast to inhibitors such as imatinib, nilotinib , dasatinib and bosutinib that bind 
within the ATP -binding site of the ABL kinase domain, asciminib inhibits ABL tyrosine kinase 
activity  by binding to a particular allosteric site on the kinase domain, which has only been 
identified on ABL1, ABL2 and BCR -ABL1. Consequently , ascimi nibis specifi c for the latter 
three enz ymes.
Asciminib potently  and selectivel y inhibits the proliferation of cell lines that express BCR -
ABL1. By virtue of asciminib not interacting with the ATP -binding site, the drug maintains 
activity  against cells exp ressing clinically  observed ATP -
binding TKI resistance mutations.
1.2.1.1 Non- clinical experience
In vitro and in vivo pharmacology  data
Asciminib display s potent anti-tumor activity in vivo with a clear pharmacokinetic 
(PK)/pharmacod ynamic (PD)/Efficacy  relationship [RD-2013-50145] . In a KC L -22 CML blast 
crisis (CML -BC) cell line mouse subcutaneous xenograft model, tumor regression was 
observed at doses of 7.5mg/kg BID and above when asciminib was administered alone. 
Efficacy  in the KCL -22 xenograft model correlated with stable inhibition of the downstream 
PD marker phospho- STAT5, consistent with finding that ABL1 inhibits STAT5 
phosphory lation in KCL22 cells with an I C90value of approximat ely 20 nM.

Novartis Confidential Page 34
Amended Protocol Version 03 -US.01 ( Clean ) Protocol No. CABL001A2301
The KCL -22 xenograft model was also used to assess the activity  of asciminib and nilotinib as 
single agents and in combination (Figure 1-1). In these experiments, when each agent was 
administer ed as monotherap y in sequence, initial sensitivity  of the tumor was observed to each 
agent, but relapse occurred in each case. The mutations observed were as expected based on 
clinical experience (T315I  for nilotinib) or modeling (A337V) for asciminib .In contrast, 
animals treated upfront with the combination of asciminib and nilotinib achieved sustained 
tumor regression with no evidence of disease relapse during the 70 day s of treatment or for 80 
days following discontinuation of treatment. Note that in th is KCL -22 model, the cells (derived 
from a blast crisis CML  patient) were grown as a solid tumor rather than as disseminated disease.
Also, this model is much more aggressive than chronic phase CML in patients.
Figure 1-1 KCL-22 CML Xenograft
These data are consistent with asciminib being active against nilotinib -resistant mutations and 
nilotinib being active against asciminib -resistant mutations. Consequently , the findings support 
development of asciminib both as single agent as well as in combination with TKIs as initial 
therap y of CML as well as therapy after progression on nilotinib.
In addition, due to asciminib specifical ly targeting the ABL kinase family  (ABL1, ABL2, BCR -
ABL 1), asciminib offers the potential for improved safet y and tolerability  when administered 
as monotherap y when compared to TKIs binding to the ATP site of BCR -ABL 1, which are less 
specific towards ABL. Thus, there is the potential for an improved safety  profile of asciminib
in comparison to other TKI s.
Safety  pharmacology and toxicology
An extensive toxicology  safety evaluation program (subchronic, chronic, reproductive 
toxicology , phototoxicity  and geno toxicity  studies) was conducted.
Safety  pharmacology  studies indicate that asciminib is not expected to cause effects on the vital 
functions of the CNS, and the respiratory  systems. The IC50 for asciminib in the hERG patch 
clamp is 11.4 μM (4498 ng/mL). Nocardiovascular effects were observed in a single dose 
jacketed telemetry  study in dogs at doses up to 600 mg/kg or the invasive telemetry 
cardiovascular safet y study  up to 60 mg/kg. Furthermore, no changes in cardiovascular 
parameters related to QTc prolo ngation were observed using standard electrocardiograph y in 
the 4-week dog toxicity  study and in cynomolgus monkey  toxicity  studies (up to 39 weeks of 
treatment) .
Asciminib does not show mutagenic, clastogenic, or aneugenic potential in the in vitro assay s
or the MNT assessment in vivo ; therefore, no potential risk for human is perceived.

Novartis Confidential Page 35
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
As determined by  the results of the phototoxicity  assessment ( in vitro and in vivo ), phototoxic 
potential was identified in the mouse UV-LLNA assay . Given these data, patients should be 
advised to avoid prolonged exposure to sunlight (sunbathing) , to avoid sunbed and to use 
sunscreen.
Toxicity  studies performed in rats, dogs and cynomolgus monkey s (up to 26, 4 and 39 weeks 
of treatment, respectively) identified the pancreas , liver, hematopoietic system, adrenal and 
gastro -intestinal tract as potential target tissues. 
Fetal malformations and increased visceral and skeletal variants were observed in the rat 
embry o-fetal development study . There was no evidence of effects on reproductive function in 
the fertility stud y; however there was a slight effect on male sperm motility and/or sperm count 
in individual animals. Phototoxic potential was identified in the phototoxicity  (in vitro and in 
vivo) assessment.
Please refer to thelatest [Asciminib Investigator’s Brochure] for more details.
Non- clinical pharmacokinetics and metabolism
The preclinical pharmacokinetic profile of asciminib has been investigated in three species: 
mouse, rat and dog. In these species, asciminib exhibite d low to moderate clearance, a moderate 
volume of distribution and a short apparent terminal half-life. Bioavailability  was found to be 
low in rodents and moderate to high in dog.
Asciminib display ed high plasma protein binding across all teste d species (2- 6% free fraction).
The metabolite profile of asciminib has been examined in vitro using rat, dog, monkey  and 
human hepatocy tes. Interspecies differences were observed in the in vitro metabolism of 
asciminib in hepatocy tes, with direct glucuronidation occu rred more readily  in human , to a 
lesser extend in dog andmonkey ,and was noticeably  absent in rat. However, no unique, major 
metabolites were identified in human hepatocy tes. The overall metabolic turnover was low.
The metabolite profile of asciminib has also been examined in vivo in rats. Following 
intravenous and oral administration of [14C-asciminib ] to intact rats, asciminib was found to be 
the predominant component of plasma, accounting for ~86 - 91% of radioactivity  from 0 -8 h. 
Asciminib was excret ed primarily in the feces, with ~90% of radioactivity detected in the feces 
from 0 - 48 h. Renal elimination represented a minor route, with ~2.4% of radioactivity  detected 
in the urine from 0 - 72 h. In the feces, ~58% (intravenous) and ~71% (oral) of thedose was 
associated with unchanged asciminib , with several oxidative metabolites accounting for the 
remaining radioactivity. The metabolites formed in vivo were consistent with those observed in 
vitro. Similar observations were noted in bile -duct cannulat ed rats.
To assess for potential drug-drug interactions (DDI), studies have been conducted with 
cytochrome P450 (CYP) enzy mes and several transporters in vitro.
In human liver microsomes, the major metabolic route of asciminib was found to be 
glucuronidati on, followed by oxidative metabolism, consistent with findings from human 
hepatocy tes. Several Uridin diPhospho- glucuronosy ltransferase (UGT )enzy mes were found to 
be capable of asciminib glucuronidation (UGT1A3, UGT1A4, UGT2B7, and UGT2B17). The 
oxidative metabolism of asciminib was also cataly zed by several CYP enzymes. CYP3A4/5 
appears to contribute the most, followed by CYP2C8, CYP4F12, and potentially  CYP2D6.

Novartis Confidential Page 36
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Though the DDI risk with inhibitors of these enzy mes is likely to be minimal, inhibitors of 
CYP3A4/5 still have the potential to increase asciminib concentration. Therefore, strong 
inhibitors of CYP3A4/5 should be avoided and are prohibited in this study . Strong inducers of 
CYP3A4/5 have the potential to reduce asciminib concentrations. Therefore, the use of strong 
inducers of CYP3A4/5 or UGT1A/ 2B is prohibited in this trial.
In recombinant cellular expression systems, asciminib was identified as a substrate of Breast 
Cancer Resist ant Protein (BCRP) ( Michaelis-Menten constant (Km) ≈ 4 µM) and permeability 
glycoprotein (P-gp) (Km could not be estimated due to insufficient saturation of efflux activity ). 
Late fecal metabolite analy sis in the human Absorption, Distribution, Metabolism, and 
Excretion (ADME) study  [CABL001A2102] and estimated contributions of different enzy
me 
pathway s (CYP vs. UGT) by  use of in vitro enzyme phenoty ping methods, do suggests that at 
least 24% of the parent drug in the feces is due to conversion of a glucuro nide (M30.5) 
metabolite back to parent drug (absorption then being maximally  57%). However, this late fecal 
metabolite analy sis could also suggest that the 24% could be active secretion by P-gp (Drug 
Metabolism and Pharmacokinetics [DMPK R1700912] . This isa small percentage (< 25% of 
the clearance by this pathway ) with a weak expected impact on asciminib concentrations. 
Overall, inhibitors of BCRP and P -gpmay increase asciminib concentration. Therefore, BCRP 
and P -gp inhibitors should be administered with caution.
Based on in vitro phenotyping studies and human ADME study  outcome, the physiologicall y 
based pharmacokinetic (PBPK) model was updated and predicted minimal to no DDI for 
sensitive substrates of CYP3A4, CYP2C8 and CYP2C9 (Drug Metabolism and 
Pharmacokinetics [DMPK -DDI-R1700912] . Indeed, the effect of asciminib 40 mg BID is 
expected to result in increased area under the curve (AUC) of CYP3A4, CYP2C8 and CYP2C9 
probe substrate by 1.21, 1.09 and 1.07. Therefore, the effect of asciminib is expected to be weak 
and hence substrates of C YP2C8, CYP2C9 and CYP3A4 with narrow therapeutic index (NTI) 
would be used with caution. 
Please refer to the latest [Asciminib Investigator ’sBrochure] version for more details.
1.2.1.2 Clinical experience
Asciminib is undergoing evaluation in a first-in-human (FIH) phase I clinical study , study 
[CABL 001X2101] .
This study  evaluates patients with 1) CML who have been treated with at least 2 prior TKIs, or 
2) who have the T315I mutation and have been treated with at least 1 prior TKI, or 3) who have 
Acute Lymphoblas tic Leukemia (ALL) and have been treated with at least 1 prior TKI. The 
study  evaluates administration of asciminib in a BID single agent dosing schedule, as well as 
in a QD single agent schedule, and in combination with nilotinib, imatinib, and dasatinib. In the 
present document, discussion will focus on data from CML  patients treated wit h asciminib BID 
single agent only .
As of 01-Sep-2017, a total of 239CML  or Ph+ ALL patients have been treated with either 
single agent oral asciminib or in combination cohorts. 150 CML patients have been treated with 
asciminib monotherap y. Based onthe preliminary  efficacy , safet y and tolerability  inpatients
with CML -CP or CML -APtreated with asciminib as a single agent on a BID schedule in 
study [CABL001X2101] and the results of a population PK/PD exposure -response model , the

Novartis Confidential Page 37
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
dose of 40mg BI D has been selected as therecommended dose to be used in future studies in
patients with CML -CP who do not harbor T315I mutations.
Efficacy :
Preliminary  data from the ongoing Phase I FIH study  [CABL001X2101] indicate that asciminib 
exhibits single -agent activity  in patients with CML who have failed at least two prior TKIs or 
are intolerant to TKIs, as demonstrated by major molecular response an d reduction in the BCR -
ABL1 % IS. Asciminib has demonstrated anti -tumor activit y at doses greater or equal to 10 m g 
BID as well as dail y higher doses.
To date, efficacy  data in 141 patients with chronic -phase CML  treated with single agent 
asciminib therapy (10-200 mg BID and 80-200 mg QD) are available (113 patients without 
T315I  mutation and 28 with T315I  mutation). 
Of the 62 
patients with BCR -ABL 1 no greater than 10 % IS at screening and without T315I 
mutation, 1-log reduction of BCRABL1 % IS was achieve d in 16 of 62 (25.8%) patients by 6 
months and 19 of 62 (30.6%) patients by  12 months. For asciminib 40 mg BID dose, of the 17 
patients studied, 1 -log reduction of BCRABL1 % IS was achieved in 5 of 17 (29.4%) patients 
by 6 months, and 12 months. 
Please re fer to the latest [Asciminib Investigator’s Brochure] for more details.
Safety :
Asciminib was generally well tolerated in heavily  pre-treated CML  patients resistant to or 
intolerant of prior TKIs. All 239patients were evaluable for safety . Seventy  six study 
discontinuations have been reported; the most frequent reason for discontinuation was 
progressive disease, reported in 38 patients (15.9%). Adverse events leading to treatment 
discontinuation were reported in 15 patients (6.3%). Death leading to treatme nt discontinuation 
was reported in 3 patients (1.3%) (one patient in asciminib 20 mg BID due to aspiration 
pneumonia after b ypass procedure and two patients with ALL with 80 mg and 160 mg BID due 
to progressive disease ).
Among the 150 patients treated with asciminib monotherap y, almost all (94.7%) patients 
reported at least one AE, including 49.3% reported grade 3/4 AEs. The most common AEs (>
10%) among patients treated with 40mg BID (n=35), regardless of study  drug-relationship, 
were increased lipase, fatigue, diarrhea, thrombocy topenia, neutropenia, arthralgia, rash, 
headache, increased amylase, nausea, vomiting, abdominal pain, pyrexia, upper respiratory  tract 
infection, back pain, hypertension, cough, pruritus, pain in extremity , dyspnea, bone pain, 
peripheral oedema, non -cardiac chest pain and insomnia. The most common reported grade 3/4 
event was increased lipase (17.1%).
Forty-seven of 150 patients with CML -CP or CML -AP treated with asciminib single agent 
(31.3%) were reported with serious adverse ev ents (SAE) .
Electrocardiogram (ECG )data shows no reported QT prolongation (increase > 60 msecor new >
500 msec) in 40 mg BID asciminib monotherapy  group. There was no reports of QT 
prolongation (increase > 60 msec) and two reports of new >500 msec(one each in 80 mg QD 
and 120 mg QD) among all asciminib monotherapy group.

Novartis Confidential Page 38
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Please refer to the latest [Asciminib Investigator’s Brochure] for more details.
Pharmacokinetics:
PK data from 190 patients were available from the [CABL 001X2101] study , as of 01-Sep-2017.
When given as a single agent on a twice daily schedule, patients received 
escalating doses of 
asciminib ranging from 10 to 200 mg .
Based on the available PK data, asciminib , administered orally  is rapidly  absorbed with a 
median time to maximum plasma concentration (Tmax) of 2 to 3 hours, independent of dose. 
Systemic exposure of asciminib , following oral administration of single and multiple doses, as 
measured by Cmax and AUC, increased in an approximately  dose proportional manner. The 
variabilit y of exposure is low to moderate with inter-patient variability  (geometric mean CV %) 
ranging from approximately  25 to 70% for both Cmax and AUClast . With the twice daily  dosing 
regimen, median plasma asciminib accumulation ratios ranged from 1.3to 2.5. The median 
accumulation half -life was estimated to be 7 to 15 hours.
The data of the hADME study  [CABL001A2102] show that the relative contribution of the 
glucuronidation pathway  to the total clearance of asciminib via metabolism is estimated to range 
from 30% to 61%, whereas the relative contribution of the oxidative pathway  is estimated to 
range from 35% to 63%. CYP3A4 was the main contributor for the clearance of asciminib via 
the oxidative pathway  while UGT2B7 and UGT2B17 were responsible for the clearance of 
asciminib via the glucuronidation pathway . There was no metabolite detected with mean 
contribution to plasma radioactivity  AUC0- 24hours ≥ 10%. Asciminib was the predominant 
drug-related component in plasma at all time points analy zed, ranging from 91.9 to 94.2% of 
the total radioactivity  AUC0 -24 hours AUC, with an average value of 92.7%.
Please refer to the latest [Asciminib Investigator’s Brochure] for more details.
Exposure -response relationship:
Exposure -efficacy
A preliminary  population PKPD model has been developed using data from the 
[CABL 001X2101] study  (cut-off 02-May-2016). The time course of molecular response 
(change in BCR -ABL 1ratio % IS levels from baseline) was described using a semi -
physiological model accounting for cell maturation, disease progr ession and existing resistance.
Simulations performed using an 
asciminib population PK model revealed that a dose of 40 mg 
BID maintains Ctroughs above the clinical (0.07 to 61 ng/m L) threshol d in ≥95% of chronic 
phase CML patients without T315I  mutation having failed ≥ 2 TKI or intolerant to TKIs. The 
estimates from this clinical study  were found to be similar to the threshold trough concentration 
required for 90% inhibition of pSTAT5 derived from a preclinical PK-PD KCL -22 mouse 
xenograft model (free IC90: 30 to 121 ng/mL, after correction for protein binding) and in vitro
gIC50 assessed in the KCL -22 cell line (1 ng/mL  = 2.1 nM after correction for protein binding).
Simulations performed using asciminib population PKPD model revealed that chronic phase 
CML  patients having failed ≥ 2 TKI or intolerant to TKIs are likely to exhibit a 1 log10 
reduction of (%) BCR -ABL 1mRNA transcript levels from baseline of ~33% (CI95%: 24-42%) 
at 6 months, and ~42% (CI95%: 32-52%) at 12 months at a dose of 20 mg BID and ~41% 

Novartis Confidential Page 39
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
(CI95%: 31-51%) at 6 months, and ~53% (CI95%: 43-63%) at 12 months at a dose of 40 mg 
BID.
Additional preliminary  exposure response analy ses (i.e. exploring the relationship between PK 
and bo
th safety and effic acy) support the selected dose.
Food effect
The effect of food on asciminib PK was characterized in a Phase I study  [CABL001A2101] in 
healthy  volunteers. Food was found to influence the pharmacokinetics of asciminib . When 
administered with a low-fat meal, the exposure (AUC) decreased by approximately  30%. The 
overall exposure decreased by approximately  65% when administered with a high-fat meal.
Therefore, asciminib will be administered in a fasted state.
1.2.2 Overview  of bosutinib
Bosutinib (Bosulif®) is indicated for the treatment of adult patients with newly -diagnosed 
chronic phase (CP) Philadelphia chromosome -positive chronic myelogenous leukemia (Ph+ 
CML ) and for the treatment of patients with chronic, accelerated, or blast phase Ph+ chronic 
myelogenous leukemia (CML ) with resistance orintolerance to prior therapy  (500 mg QD) 
[Bosulif®USPI ]as well as for newl y-diagnosed CML -CP (400 mg QD) , and in Europe for the 
treatment of adult patients with chronic phase (CP), accelerated phase (AP) , and blast phase 
(BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML ) previously 
treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and 
dasatinib are not considered appropriate treatment options [EU Summary  of Product 
Characteristics (SmPC) ]. Bosutinib has been evaluated in patients treated with one or more prior 
TKIs.
For patients treated with bosutinib after prior imatinib only, the MMR rate is approximately 15% 
at 24 weeks overall, and approximately  10% in imatinib -resistant patients and 20% in imatinib -
intolerant patients ( Gambacorti -Passerini 2014 ). The cytogenetic, molecular, and hematological 
response rates did not appear to differ greatl y between patients who were imatinib -resistant or 
imatinib -intolerant ( Gambacorti -Passerini 2014 ).
Twenty  seven percent of patients tre ated with bosutinib after at least 2 previous TKI s achieved 
MCy R rate by Week 24 [Bosulif®USPI ]. For patients previously  treated with imatinib and 
either dasatinib or nilotinib, after a median of 28.5 months follow -up, the cumulative rate of 
Major Molecul ar Response (MMR) is 15% (Khoury  2012). The cytogenetic, molecular, and 
hematological response rates appeared to be lower in patients who 
were resistant to dasatinib 
after imatinib treatment as compared to patients who were intolerant to dasatinib after imatinib 
treatment ( Khoury  2012). In a small (30 patient) compassionate use trial of patients previously 
treated with imatinib, dasatinib and nilotinib, after a median duration of treatment of 9.3 months, 
the cumulative MMR rate was 14% (García -Gutiérrez 2015). Based on these data, the MMR 
rate at 6 month with bosutinib treatment in patients treated wit
h at least 2 prior TKIs is estima ted 
to be approximately  10-15%.
Bosutinib has no activity  against the T315 I and V299L mutant form of BCR -ABL 1. 
Accordingl y, the pivotal trial leading to the registration in the 3rdline setting excluded patients 
with a know n history  of the T315I or V299L mutation [Bosulif®USPI ].

Novartis Confidential Page 40
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
2 Rationale
2.1 Stud y rationale and purpose
Asciminib is an agent intended to be evaluated for the treatment of patients with CML .In the 
ongoing study [CABL001X2101] study , asciminib was found to produce clinically meaningful 
and durable responses in patients who have had treatment failure after a minimum of 2 prior 
ATP -binding site TKIs, with an acceptable sa fety and tolerability profile.
The purpose of this pivotal study  is to compa re the efficacy  of asciminib with that of bosutinib 
in the treatment of patients with CML -CP having previously  been treated with a minimum of 
two prior ATP -binding site TKIs. Patients with intolerance to most recent TKI therapy  must 
have BCR -ABL 1ratio >  0.1% I S at screening and patients experiencing failure to most recent
therap y must meet the definition of treatment failure as per the 2013 ELN guideline s (Baccarani 
et al 2013 ).
Imatinib, nilotinib and dasatinib are indicated for the treatment of patients with newly  diagnosed 
CML . Multiple agents, including nilotinib, dasatinib, ponatinib, bosutinib, radotinib (Korea) 
and omacetaxine (USA, Canada) are approved for patients with CML -CP previousl y treated 
with prior therap y. Imatinib is a first generation TKI; nilotinib, dasatinib, bosutinib, ponatinib 
and radotinib are considered second generation TKIs and have activity  in patients previousl y 
treated with imatinib. The activity  of nilotinib or dasatinib in patients previously  treated with a 
second generation TKI is not known. All the currentl y approved BCR- ABL 1TKIsare 
enzy matic site inhibitors, in distinction to asciminib which is an allosteric TKI. Omacetaxine is 
a cytotoxic chemotherapeutic agent.
2.2 Rationale for the study  design
Asciminib is an orally bioavailable specific BCR -ABL1 inhibitor with a novel mechanism of 
action. In contrast to other TKIs that bind within the ATP -binding site of the ABL  kinase 
domain, asciminib inhibits ABL tyrosine kinase activity  by binding to a particular allosteric site 
on the kinase domain that is utilized by a m yristate group to auto- regulate the native ABL1 
kinase. With allosteric inhibition of BCR -ABL 1being a novel mechanism of action, asciminib
produces clinically  meaningful and durable responses in patients who have had treatment failure 
after a minimum of 2 prior ATP -binding site TKIs, with an acceptable safety  and tolerability 
profile as demonstrated in study  [CABL001X2101] .
The deve lopment of asciminib , presents an opportunity  to evaluate the beneficial 
effects of 
inhibition of BCR -ABL 1in the treatment of patients with CML .The proposed study  design is 
expected to adequatel y allow an assessment of the efficacy, safet y and tolerabili ty of asciminib
in a population of patients with continuing medical need i.e., patients who have been treated 
with at least two prior TKI s and are in the need for further therapeutic intervention.
Bosutinib is one of the TKIs with proven clinical benefit in CP-CML  patients previously  treated 
with one or more tyrosine kinase inhibitor(s) and is currentl y approved for this indication in 
many  countries, including the European Union. The proposed study  will evaluate asciminib in 
comparison to bosutinib at the approved doses in the targeted population.

Novartis Confidential Page 43
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Additional preliminary  PK-efficacy  and PK-safety  analyses to assess the exposure -response 
relationship for asciminib were conducted ( Section 1.2.1.2). The efficacy measure used was 
Molecular Response (MR) which is defined as a decline in BCR -ABL 1transcript levels in 
clinical blood samples of 
patients with Chronic My eloid Leukemia (CML). MR was evaluated 
as both a continuous variable (BCR -ABL 1transcript levels) and categorical variable (whether 
or not adequate decline in BCR -ABL 1was achieved). The safet y measures used were 
occurrence of Common Toxicity  Criteria (CTC) grade 2, 3 or 4 laborator y values for lipase and 
amylase.
Reviewing the totality  of the efficacy , safet y, and pharmacokinetic data derived from the 
[CABL 001X2101] study, the recommended dose for asciminib in this phase 3 study  is 40 mg 
BID. Of note, the dose of asciminib single agent BID is further being evaluated in patients with 
the T315I mutation. At present the recommended dose of 40 mg BID is for patients without the 
T315I  mutation. For this reason, patients with the T315I  mutation are excluded from this study .
2.4 Rationale for choice of combination drugs
Not Applicable.
2.5 Rationale for choice of comparators drug bosutinib
The guidance provided by the NCCN and the ELN (Baccarani et al 2013), recommends 
bosutinib as a treatment in CML -CP patients who fail first-line or second -line treatment with 
imatinib or nilotinib or dasatinib. Consistent with these recommendations 
and clinical practice, 
bosutinib was selected to be an appropriate comparator in a study  of 3rdline CML -CP patients 
after failure of at least 2 prior TKIs, and is the comparator that will be used in the present study .
It is to be noted that bosutinib has no activity  against the T315I  and V299L mutant form of 
BCR -ABL 1. Patients who have the T315I  or V299L mutations documented in their medical 
record will alread y be excluded from this study. Bosutinib is known to be active against 
E255K/V, F317L/V/I/C, F359V /C/I, T315A, and Y253H and therefore, these mutations are not 
considered in the exclusion criteria for the current study .
Ponatinib is not selected as the comparator in the present clinical trial, because the comparator 
in this study  needs to be 
an approve d agent administered at the approved dose. Currentl y, the 
ponatinib dose is being evaluated in a randomized trial as a post-approval commitment due to 
the occurrence of vascular risks at the current approved dose of ponatinib. The dose of ponatinib 
that will be approved and will be used in practice at the completion of the present study  may 
not be the approved dose at the time of initiation of the present study .
2.6 Risks and benefits
Appropriate eligibility  criteria, as well as specific dose modification and stopping rules in the 
event of expected toxicities, are included in this protocol. Recommended guidelines for 
prophy lactic or supportive treatment for expected toxicities, including management of study -
drug induced adverse events are provided in Section 6.3. Patients who have failed 2 prior TKIs 
are at increased risk of progression to more advanced phases of CML such as CML -AP and 
CML -BC. Currentl y available therapeutic agents in this setting are non-curative and patients 
remain at risk of progressing after short duration of remission
s (Khoury  2012 ).

Novartis Confidential Page 44
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
An important potential risk for patients enrolling on the experimental arm of the study  with 
asciminib will be that this agent may be ineffective. However, the evidence to date at the doses 
to be administered in a similar population of patients in the study  [CABL001X2101] suggests 
that asciminib is an active agent. Further, the adverse event profile of asciminib is similar 
qualitatively  to that observed with other TKI s targeting BCR -ABL1 ( Section 1.2.1.2). The risk 
of asciminib not being effective has been mitigated in that patients will be observed c losel y for 
evidence of efficacy , based on assessment of hematologic, cytogenetic and molecular response 
data, which will permit rapid decision making as to discontinuation of therapy  if necessary .
Other risks to subjects in this trial will be minimized by compliance with the eligibility  criteria 
and study  procedures, close clinical monitoring, and adherence to dose modification and 
interruption guid ance provided in the protocol.
The currentl y available information suggests that there is equivalence between the two arms 
with respect to benefit / risk to enable inclusion of patients in this study .
There may be unforeseen risks with asciminib which could be serious. Refer to the latest 
[Asciminib Investigator’s Brochure] for additional details.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1 below.

Novartis Confidential Page 45
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. C ABL001A2301
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary
To compare the MMR rate at 24 weeks of asciminib versus 
bosutinib Major Molecular Response (MMR) rate at 24 weeks Refer to Section 10.4
Key secondary
To compare additional parameters of the efficacy of asciminib 
versus bosutinib MMR rate at 96 weeks Refer to Section 10.5.1
Other secondary
To compare additional parameters of the efficacy of asciminib 
versus bosutinib● C ytogenetic response rate (Complete, Partial, Major, Minor, Minimal, 
no response) at and by all scheduled data collection time points 
including 24, 48 and 96 weeks
●MMR rate at all scheduled data collection time points (except 24 and 
96 weeks which are already covered by primary and key secondary 
endpoints)
●MMR rate by all scheduled dat a collection time points including 24, 
48 and 96 weeks
●Time to MMR
●Duration of MMR
●Time to CCyR
●Duration of CCyR
●Time to treatment failure
●Progression free survival
●Overall survivalRefer to Section 10.5.2
To compare the safety and tolerability profile of asciminib versus 
bosutinibType, frequency and severity of adverse events,
changes in laboratory values that fall outside the pre -determi ned ranges 
and clinically notable ECG and other safety data (vital signs, physical 
examination)
To characterize the PK of asciminib in the CML -CP population
To assess the safety of asciminib when administered as 
treatment after bosutinib failure according to the 2013 ELN 
GuidelinesTrough plasma concentrations,
PK parameters in full PK group: Cmax, Tmax, AUC0 -12h, CL/F
Type, frequency and severity of adverse events, c hanges in laboratory 
values that fall outside the pre -determined ranges and clinically notable 
ECG and other safety data (vital signs, physical examination)Refer to Section 10.6

Novartis Confidential Page 47
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. C ABL001A2301
Objective Endpoint Anal ysis
Time to MMR
Duration of MMR
Time to CCyR
Duration of CCyR
Time to treatment failure

Novartis Confidential Page 48
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
4 Study  design
4.1 Description of study  design
The study  is a phase 3, multi- center, open -label randomized study  of oral asciminib versus 
bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML -CP), 
previously  treated with 2 or more t yrosine kinase inhibitors.
The trial is designed to compare the efficacy  and safet y of asciminib with that of bosutinib in 
the treatment of patients with CML -CP having previously  been treated with a minimum of two 
prior ATP -binding site TKIs. Patients intolerant to the most recent TKI therapy must have BCR -
ABL 1ratio >
0.1% ISat screening and patients failing their most recent TKI therapy must meet 
thedefinition of treatment failure as per the 2013 ELN guidelines (Baccarani et al 2013 ).No 
more than 6 6patients (approximately  30% of the overall trial population) that are intolerant to 
theirmost recent TKI therapy  with BCR -ABL 1< 1% will be recruited in order to ensure that 
the CML  third line patient population is adequately  represented.
The study  will also investigate secondary  endpoints for efficacy , safety  and PK of single- agent 
asciminib compared to bosutinib. Tolerability , PK, PRO and exploratory  biomarker activities 
will also be assessed. Safet y and efficacy  data for patients switching to asciminib will be 
collected and analyzedseparatel y.
Patients meeting all of the inclusion and none of the exclusion criteria will be randomized into 
one of the 2 treatment arm
s, based on a 2:1 randomization between the asciminib arm and the 
bosutinib arm.
The randomization will be stratified to ensure the study  population is balanced between the 
arms with respect to cy togenetic response status (See Section 7.2.1.2) at screening as follows:
Major c ytogenetic response (complete or partial)
No major cy togenetic response (minor, minimal or none)
Patients will continue to receive the assigned study  treatments (asciminib or bosutinib) until 
the end of study  treatment period as defined in Section 4.3. Patients who discontinue their study  
treatment at any time during the study  will be followed up for survival and for progression to 
AP/BC for up to 5 years from the date the lastrandomized patient receive sthe first dose 
(irrespective of treatment switch for patients failing bosutinib).
Serial PK samples over 12 hours will be collected on Week 2 Day  1 from at least 20 CML -CP 
patients (full PK group) on the asciminib arm, in addition to trough PK samples. These patients 
will be identified sequentially  at selected sites that are capable of serial PK sampling over 12 
hours. In the remaining patients in the asciminib arm and inpatients that have switched to 
asciminib , sparse post-dose PK samples on Week 1 Day 1
 and trough PK samples will be 
collected (sparse PK group).

Novartis Confidential Page 49
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Figure 4-1 Schematic of Stu dy Design
4.1.1 Study treatment switch from b osutinib to asciminib
Patients with documented treatment failure ( as per the 2013 ELN guidelines; Baccarani et al 
2013) while on bosutinib treatment will have theoption to switch to asciminib treatment within
96 weeks after the last patient has been randomized on study . The patients who switch to 
asciminib will be able to receive asciminib up to end of study  treatment period .
At the end of 
the treatment period for patients who,in the opinion of the investigator still derive clinical 
benefit, asciminib treatment will be made available through alternative options including, but 
not limited to, an expanded access/compassionate use/managed access program or access to 
commercial supplies in applicable countries . Discontinuation of asciminib for patients who
have switched over from bosutinib must follow the guidelines provided in Section 7.1.6.
Eligibility  criteria for patients switch
ingto asciminib are described in Section 7.1 .
4.2 Timing of interim analy ses and design adaptations
Not applicable. There are no formal interim analy ses or design adaptations planned for this 
study . See Section 8.6 for documentation of safety DMC.
4.3 Definition of end of study
The patients are treated in the study  up to end of study  treatment period defined asup to96 
weeks after the last patient receives the first dose or up to 48 weeks after the last patient has 
switched to asciminib treatment whichever is longer unless patients have discontinued treatment 
earlier . The end of the study ,concluding the survival follow -up, will occur 5 years from the 
date when the last patient enrolled into the study  receive sthe first dose of the randomized 
treatment.
The primary  analysis (cut-offdate) is defined as the date when all randomized patients have 
been on study  treatment for 24 weeks (Section 10.4) or discontinued earl ier. Subsequent to this 

Novartis Confidential Page 50
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
analysis, the primary  clinical study  report (CSR) will be developed. Following the cut -off date 
for the primary  CSR, the study  will remain open. Patients who are ongoing at the time of the 
primary  analysis will continue to receive the assigned study  treatments (asciminib or bosutinib)
during the study  treatment period as defined above . The end of study  treatment analysis will be 
conducted with a cut-off date 30 days after the end of study  treatment period to ensure all 
available treatment data from all patients in the study  is anal yzedand summarized in a CSR .
After the end of the stud y treatment period the assigned study treatment will be made avai lable 
to patients who in the opinion of the Investigators are still deriving clinical benefit. This may 
be outside of this study  through alternative options including, but not limited to, an expanded 
access/compassionate use /managed access program or access to commercial supplies in 
applicable countries.
Patients will be followed for survival and progression for up to 5 years from the date the last
randomized patient receive sthe first study  dose(irrespective of treatment switch for patients 
failing bosut inib) . Information on subsequent treatments will also be collected. An updated 
analysis of OS and PFS will be performed at the end of the follow -up period in the final study  
CSR.
4.4 Early study  termination
The study  can be terminated at any  time for any  reason by Novartis. Should this be necessary, 
the patient should be contacted as soon as possible and instructed to stop taking study 
medication. The end of treatment visit should be scheduled and the same assessments should 
be performed as described in Section 7 for a discontinued or withdrawn patient. The investigator 
may be informed of additional procedures to be followed in order to ensure that adequate 
consideration is given to the protection of the pati ent’s interests. The investigator will be 
responsible for informing I RBs and/or ECs of the earl y termination of the trial.
5 Population
5.1 Patient population
Two-hundred and twent y-two (222) patients with CML -CP who had prior treatment with two 
or more ATP binding site TKIs will be randomized in a 2:1 fashion to receive either asciminib 
or bosutinib. No patients with a medical history of the T315I or V299L mutation at study  entry 
will be included in the trial. Previous medical records should be used to confirm the patient’s 
mutational status/history .
The definition of CML -CP will be according to the European Leukemia Network (ELN) criteria 
(Baccarani et al 2013 ), and is outlined below in the inclusion criteria.
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered treatment in the study .
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all of th e following criteria:
1. Male or female patients with a diagnosis of CML- CP ≥ 18 y ears of age

Novartis Confidential Page 51
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
2.Patients must meet all of the following laboratory  values at the screening visit:
< 15% blasts in peripheral blood and bone marrow
< 30% blasts plus promyelocy tes in peripheral blood and bone marrow
< 20% basophils in the peripheral blood
≥ 50 x 109/L (≥ 50,000/mm3) platelets
Transient prior therap y related thrombocytopenia (< 50,000/mm3for ≤ 30 day s prior 
to screening) is acceptable
No evidence of extramedullary  leukemic involvement, with the exception of 
hepatosplenomegal y
3a.  BCR -ABL 1ratio >0.1% I S according to central laboratory  at the screening examination , 
for patients intolerant to the most recent TKI therapy
4.Prior treatment with a minimum of 2 prior ATP -binding site TKIs (i.e. imatinib, nilotinib, 
dasatinib, radotinib or ponatinib)
5.Failure (adapted from the 2013 EL N Guidelines ;Baccarani et al 2013) or intolerance to 
the 
most recent TKI therapy  at the time of screening 
Failure is defined for CML- CP patients (CP at the time of initiation of last therapy ) as 
follows. Patients must meet at least 1 of the following criteria.
Three months after the initiation of therap y: No CHR or > 95% Ph+ metaphases
Six months after the initiation of therap y: BCR -ABL 1ratio > 10% IS and/or > 
65% Ph+ metaphases
Twelve months after initiation of therap y: BCR -ABL 1ratio > 10% IS and/or > 
35% Ph+ metaphases
At any  time after the initiation of therapy , loss of CHR, CCy R or P CyR
At any  time after the initiation of therapy , the development of new BCR- ABL 1
mutations which potentially  cause resistance to current treatment 
At any  time after the initiation of therapy , confirmed loss of MMR in 2 
consecutive tests, of which one must have a BCR -ABL 1ratio ≥ 1% IS
At any  time after the initiation of therapy , new clonal chromosome abnormalities 
in Ph+ cells: CCA/Ph+
Intolerance is defined as:
Non-hematologic intolerance: Patients with grade 3 or 4 toxicity  while on 
therap y, or with pers istent grade 2 toxicity , unresponsive to optimal management, 
including dose adjustments (unless dose reduction is not considered in the best 
interest of the patient if response is alread y suboptimal)
Hematologic intolerance: Patients with grade 3 or 4 toxi city (absolute neutrophil 
count [ANC] or platelets) while on therap y that is recurrent after dose reduction 
to the lowest doses recommended by  manufacturer
6.Eastern Cooperative Oncology  Group (ECOG) performance status (PS) of 0, 1, or 2
7.Adequate end organ f unction as defined by (as per central laboratory  tests):
Total bilirubin ≤ 1.5 x ULN except for patients with Gilbert’s sy ndrome who may  
only be included if total bilirubin ≤ 3.0 x UL N or direct bilirubin ≤ 1.5 x ULN

Novartis Confidential Page 52
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Aspartate transaminase (AST) ≤ 3.0 x ULN
Alanine transaminase (ALT) ≤ 3.0 x ULN
Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN -  ≤ 1.5 x UL N, value must be 
considered not clinically  significant and not associated with risk factors for acute 
pancreatitis
Alkaline phosphatase ≤ 2.5 x ULN
Creatinine clearance ≥ 50 mL /min as calculated using Cockcroft
-Gault formula
8.Patients must avoid consumption of grapefruit, Seville oranges or products containing the 
juice of each during the entire study  and preferably  7 day s before the first dose of study  
medications, due to potential CYP3A4 interaction with the study  medications. Orange 
juice is allowed.
9.Written informed consent obtained prior to an y screening procedures.
10a.Patients must have the following electrol yte values (as per central laboratory  tests)within 
normal limits or corrected to be within normal limits with supplements prior to first dose 
of study  medication:
Potassium (potassium increase of up to 6.0 mmol/L is acceptable at stud y entry if 
associated with creatinine clearance within normal limits)
Total calcium (corrected for serum albumin) ; (calcium increase of up to 12.5 mg/dl or 
3.1 mmol/L  is acceptable at study  entry  if associated with creatinine clearance within 
normal limits)
Magnesium , with the exception of magnesium increase > ULN –3.0 mg/dL; > ULN -
1.23 mmol/L  associated with  creatinine clearance (calculated using Cockcroft- Gault 
formula )within normal limits.
11.Evidence of t ypical BCR -ABL1 transcript [e14a2 and/or e13a2] at the time of screening 
which are amenable to standardized R
Q-PCR quantification.
5.3 Exclusion criteria
Patients eligible for this study  must not meet anyof the following criteria:
1.Known presence of the T315I  or V299L mutation at an y time prior to study entry
2.Known second chronic phase of CML after previous progress ion to AP/BC
3.Previous treatment with a hematopoietic stem -cell transplantation
4.Patient planning to undergo allogeneic hematopo ietic stem cell transplantation
5.Cardiac or cardiac repolarization abnormality , including an y of the following:
History  within 6 months prior to starting stud y treatment of myocardial infarction 
(MI), angina pectoris, coro nary artery  bypass graft (CABG)
Clinically  significant cardiac arrhy thmias (e.g., ventricular tachy cardia), complete left 
bundle branch block, high -grade AV block (e.g., bifascicular block, Mobitz ty pe II 
and third degree AV block)
QTcF at screening ≥450 ms ec(male patients), ≥460 msec (fem ale patients)
Long QT s yndrome, family  history  of idiopathic sudden death or congenital long QT 
syndrome, or an y of the following:

Novartis Confidential Page 53
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Risk factors for Torsades de Pointe s(TdP) including uncorrected h ypokalemia or 
hypomagnesemia, history  of cardiac failure, or history  of clinically  
significant/s ymptomatic brady cardia
Concomitant medication(s) with a “Known risk ofTorsades de Pointe s”per 
wwwcrediblemeds.org/ that cannot be discontinued or replaced 7 days prior to 
starting stud y drug b y safe alternative medication .
Inability to determine the QTcF interval
6. Severe and/or uncontrolled concurrent medical disease that in the opinion of the 
investigator could cause unacceptable safet y risks or compromise compliance with the 
protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary  
hypertension)
7.History  of acute pancreatitis within 1 y ear of study  entry  or past medical history  of chronic 
pancreatitis
9.History  of acute or chronic liver disease
10. Known presence of significant congenital or acquired bleeding disorder unrelated to 
cancer
11.History  of other active malignancy  within 3 y ears prior to study  entry  with the exc eption 
of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated 
curativel y
12.Known history  of Human I mmunodeficiency  Virus (HIV), chronic Hepatitis B (HBV), or 
chronic Hepatitis C (HCV) infection. Testing for Hepatitis B surfa ce antigen (HBs Ag) 
and Hepatitis B core antibody  (HBcAb / anti HBc) will be performed at screening
13.Impairment of gastrointestinal (GI) function or GI disease that may  significantly  alter the 
absorption of study  drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, 
malabsorption syndrome, small bowel resection, or gastric by pass surgery )
14a. Treatment with medications that meet one of the following criteria and that cannot be 
discontinued at least one week prior to the start of treatment with study  treatment
Moderate or strong inducers of CYP3A
Moderate or strong inhibitors of CYP3A 
15.Previous treatment with or known/ suspected h ypersensitivity  to asciminib or an y of its
excipients.
16.Previous treatment with or known/ suspected h ypersensitivity  to bosutinib or any  of its
excipients.
17.Participation in a prior investigational study within 30 days prior to randomization or 
within 5 half -lives of the investigational product, whichever is lon ger
18.Pregnant or nursing (lactating) women
19a. Women of child- bearing potential, defined as all women phy siologically  capable of
becoming pregnant, unless they  are using highly  effective methods of contraception
during dosing and for 3 day s after last dose of asciminib and one month after last dose of
bosutinib. Highly  effective contraception methods include:

Novartis Confidential Page 54
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, sy mptoth ermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y (with or without 
hysterectom y) total h ysterectom y or bilateral tubal ligation at least six weeks before
taking stud y treatment ). In case of oophorectomy  alone, only  when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). The vasectomized male 
partner should be the sole partner for that subject.
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS) or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or tra nsdermal hormone contraception.
In case of use of oral contraception women should have been stable on the same pill 
for a minimum of 3 months before taking stud y treatment.
Women are considered post -menopausal and not of child bearing potential if they  
have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile (e.g. age appropriate, history  of vasomotor sy mptoms) or have had surgical 
bilateral oophorectomy  (with or with out hy sterectomy ), total h ysterectom y or bilateral 
tubal ligation at least six weeks before taking study  medication . In the case of 
oophorectom y alone, women are considered post- menopausal and not of child bearing 
potential only when the reproductive statu s of the woman has been confirmed by  
follow up hormone level assessment.
6 Treatment
6.1 Stud y treatment
The investigational treatments for this stud y are asciminib (40 mg BID) and bosutinib (500 mg 
QD). Novartis will supply  asciminib to the investigational site as 20 mg and 40 mg tablets.
Bosutinib will be supplied to the investigational site as 100 mg and 500 mg tablets.
6.1.1 Dosing regimen
Asciminib
Asciminib 20 or 40 mg strength tablets will be administered orally  twice -daily  (BID), without 
food. Asciminib tablets should be ingested as follows:
Asciminib should be administered in the fasted state : avoid food for at least 2 hours before 
the dose is taken and f or at least 1 hour after the dose is taken . Water is permitted during 
this period.
Asciminib should be taken with approximately  8 ounces (240 mL) of water.
Asciminib should be swallowed whole and not chewed or crushed.
If vomiting occurs within the first h our after taking the drug, re-dosing is allowed before 
the next scheduled dose

Novartis Confidential Page 55
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
If the patient does not take asciminib within 6 hours after the approximate time of the 
usual dosing time, that dose should be skipped and treatment should continue with the 
next daily dose at the prescribed level
Bosutinib
Bosutinib 500 mg or 100 mg tablets will be administered orally once daily (QD) with food. If 
a dose is missed beyond 12 hours, the patient should skip the dose and take the usual dose on 
the following day .
Table 6-1 Dose and treatment schedule
Study  
treatmentsPharmaceutical form 
and route of 
administrationDose Frequency  and/or
RegimenFasting Condition
Asciminib Tablet for oral use 20 mgaTwice -daily Fasting
Asciminib Tablet for oral use 40 mg Twice -daily Fasting
Bosutinib Tablet for oral use 100 mgbOnce -daily Non-fasting
Bosutinib Tablet for oral use 500 mg Once -daily Non-fasting
a20 mg tablets will be dispensed to patients in the instance of dose reduction.
b100 mg tablets will be dispensed to patients in the instance of dose modifications.
On days when serial blood samples are collected for asciminib PK analysis, patients will be 
instructed to bring their drug supply to the site, and take the dose in the clinic, under supervision 
of the site personnel. The exact time for dose administration and meal intake must be recorded 
in the electronic Case Report Form (eCRF).
All dosages prescribed and dispensed to the patie nt and all dose changes during the study must 
be recorded on the Dosage Administration Record eCRF.
6.1.2 Ancillary  treatments
Not applicable.
6.1.3 Rescue medication
Not applicable.
6.1.4 Guidelines for continuation of treatment
Not applicable. See Section 6.3 .
6.1.5 Treatment duration
There is no fixed duration of treatment planned per patient. The patients are treated in the study 
up to end of stud y treatment period defined as up to 96 weeks after the l ast patient receives the 
first dose or up to 48 weeks after the last patient has switched to asciminib treatment whichever 
is longer unless patients have discontinued treatment earlier .  Patients may be discontinued from 
treatment with the study drug at any time due to unacceptable toxicity , disease progression 
and/or at the discretion of the investigator or the patient.

Novartis Confidential Page 56
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
6.2 Dose escalation guidelines
Dose escalation bey ond the standard doses of 40 mg BID for asciminib is not permitted.
Dose escalation above 500 mg QD for bosutinib is permitted in this study. Bosutinib escalation 
guidelines are as follows:
Consider dose escalation to 600 mg once daily  in patients who are currently  taking 500 mg 
daily , did not have Grade 3 or higher adverse events and who:
Did not reach complete hematological response (CHR) by  week 8
Did not reach complete cytogenetic response (CCyR) b y week 12
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose interr uptions 
and/or reductions are either recommended or mandated in order to allow the patient t o continue 
the study  treatment.
These dose modifications are summarized in Table 6-2. The dose reduction indica ted as 
“recommendations” are provided to assist investigators in the event the patient experiences 
toxicity .However, deviations from “mandatory ” dose interruptions and/or reductions are not 
allowed and mandatory  interruptions or reductions must be strictl y followed. Re-escalation to 
asciminib 40mg BID is permitted if a change in the patient’s individual 
benefit/risk assessment 
at the lower dose level is seen. Re-escalation will be allowed only once for any given patient on 
the asciminib arm per protocol. Permanent treatment discontinuation is mandatory  for specific 
events indicated as such in Table 6-2. Any dose changes must be recorded on the Dosage 
Administration Record eCRF.
A patient must discontinue treatment with either asciminib or bosutinib if, after treatment is 
resumed at a lower dose level , the toxicity  recurs with the same or worse 
severit y, except for 
recurrence of cytopenias (Table 6-2). I f a patient requires a dose interruption of > 28 daysfor 
each non
-hematologic toxicity , then the patient must be discontinued from the study treatment. 
If a hematologic toxicity  (cytopenia Grade 3 or 4) lasts for more than 42 days without recovery 
to at least a Grade 2, despite TKI interruption and adequate management (including 
hematopoietic growth factors), then the patient must be discontinued from the study  treatment. 

Novartis Confiden tial Page 57
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Table 6-2 Criteria for dose reduction/interruption and re -initiation of asciminib and bosutinib treatment for adverse drug 
reactions
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontin ued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Investigations (Hematologic) If a hematologic toxicity  (cytopenia Grade 3 or 4) lasts for more than 42 day s without recovery  to at least a Grade 2, despit e 
TKI interruption and adequate management (including hematopoietic growth factors), then the patient must be discontinued from the study  treatment.
Neutropenia (ANC)
Grade 1 (ANC < LLN –1.5 x 109/L) Recommendation : Maintain dose level Recommendation : Maintain dose level
Grade 2 (ANC < 1.5 –1.0 x 109/L) Recommendation : Maintain dose level Recommendation : Maintain dose level
Grade 3 (ANC < 1.0 –0.5 x 109/L) Mandatory : Hold dose until resolved to ≤ Grade 2 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
If resolved in > 14 days, then reduce dose 1 dose level Mandatory : Hold dose until resolv ed to ≤ Grade 2 and platelets ≤ 
Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
If resolved in > 14 days, reduce dose 1 dose level 
Grade 4 (ANC < 0.5 x 109/L) Mandatory : Hold dose until resolved to ≤ Grade 2, 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level Mandatory :Hold dose until resolved to ≤ Grade 2 and platelets ≤ 
Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
Febrile neutropenia (ANC < 1.0 x 
109/L, fever ≥ 38.5°C)Mandatory :Hold dose until resolved, then reduce dose 
1 dose levelMandatory :Hold dose until resolved, then reduce dose 1 dose 
level
Thrombocytopenia
Grade 1 (PLT < LLN –75 X 109/L) Recommendation : Maintain dose level Recommendation: Maintain dose level
Grade 2 (PLT < 75 -50 x 109/L) Recommendation : Maintain dose level Recommendation: Maintain dose level

Novartis Confiden tial Page 58
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontin ued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Grade 3 (PLT < 50 -25 x 109/L) Mandatory :Hold dose until resolved to ≤ Grade 2 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 2 and 
neutrophils ≤ Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
Grade 4 (PLT < 25 x 109/L) Mandatory :Hold dose until resolved to ≤ Grade 2 
(recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 2 and 
neutrophils ≤ Grade 2 (recheck CBC 2x/week), then:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
Recurrence of all cytopenias Recommendation: Hold do se until resolved to ≤ Grade 2, 
then maintain current dose level . Recommendation: Hold dose until resolved to ≤ Grade 2, then 
reduce dose 1 additional level
Non-hematologic adverse reactions except where further specified in individual sections
Grade 1 Recommendation : Maintain dose level Recommendation: Maintain dose level
Grade 2 Recommendation: Hold dose until resolved to ≤ Grade 1, 
then maintain dose levelRecommendation: Maintain dose level
Grade 3 Mandatory :Hold dose until resolved to ≤ Grade 1, then 
reduce dose 1 dose levelMandatory :Hold dose until resolved to ≤ Grade 1, then reduce 
dose 1 dose level, If clinically appropriate, re -escalation of the 
dose back to baseline dose level (500 mg) should be c onsidered
Grade 4 Mandatory : Permanently discontinue patient from study 
drug treatment.Mandatory :Hold dose until resolved to ≤ Grade 1, then reduce 
dose 1 dose level; If clinically appropriate, re -escalation of the 
dose back to baseline dose level (50 0 mg) should be considered
Investigations (Renal)
Serum creatinine
Grade 1 (> ULN -1.5 x ULN) Recommendation: Maintain dose level Recommendation: Maintain dose level
Grade 2 (> 1.5 -3.0 x ULN) Recommendation: Hold dose until resolved to ≤ Grade 1 
or baseline, then maintain dose levelRecommendation: Hold dose until resolved to ≤ Grade 1 or 
baseline, then maintain dose level
Grade 3 (> 3.0 -6.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
Grade 4 (> 6.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.

Novartis Confiden tial Page 59
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontin ued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Investigations (Hepatic)
Isolated total Bilirubin elevation
> ULN –1.5 x ULN Recommendation: Maintain dose level Recommendation: Maintain dose level
> 1.5 -3.0 x ULN Recommendation: Hold dose. Monitor LFTsb weekly, or 
more frequently if clinically i ndicated, until resolved to ≤ 
1.5 x ULN:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose levelRecommendation: Hold dose. Monitor LFTsb weekly, or more 
frequently if clinically indicated, until resolve d to ≤ 1.5 x ULN:
if resolved in ≤ 14 days, then maintain dose level
if resolved in > 14 days, then reduce dose 1 dose level
> 3.0 -10.0 x ULN*Mandatory :Hold dose. Monitor LFTsb weekly, or more 
frequently if clinically indicated, until resolved to ≤1.5 x 
ULN:
if resolved in ≤ 14 days, then reduce dose 1 dose level
if resolved in > 14 days, then discontinue patient from 
study drug treatment. The patient should be monitored 
weekly (including LFTsb), or more frequently if clinically 
indicated, until total bilirubin have resolved to baseline or 
stabilization over 4 weeks.Mandatory :Hold dose. Monitor LFTsb weekly, or more frequently 
if clinically indicated, until resolved to ≤ 1.5 x ULN:
if resolved in ≤ 14 days, then reduce dose 1 dose level
if res olved in > 14 days, then discontinue patient from study drug 
treatment. The patient should be monitored weekly (including 
LFTsb), or more frequently if clinically indicated, until total bilirubin 
have resolved to baseline or stabilization over 4 weeks.
> 10.0 x ULN* Mandatory :Permanently discontinue patient from study 
drug treatment. The patient should be monitored weekly 
(including LFTsb), or more frequently if clinically indicated, 
until total bilirubin have resolved to baseline or 
stabilization over 4 weeks.Mandatory :Permanently discontinue patient from study drug 
treatment. The patient should be monitored weekly (including 
LFTsb), or more frequently if clinically indicated, until total bilirubin 
have resolved to baseline or stabilization over 4 weeks.
Isolated AST or ALT elevation
> ULN -3.0 x ULN Recommendation: Maintain dose level Recommendation: Maintain dose level
> 3.0 -5.0 x ULN Recommendation: Maintain dose level. Repeat LFTsbas 
soon as possible, preferably within 48 -72 hours from 
awareness of the abnormal results ; if abnormal lab values 
are confirmed upon the repeat test, then monitor LFTsb
weekly, or more frequently if clinically indicated, until 
resolved to ≤ 3.0 x ULNReco mmendation: Maintain dose level. Repeat LFTsbas soon 
as possible, preferably within 48 -72 hours from awareness of the 
abnormal results; if abnormal lab values are confirmed upon the 
repeat test, then monitor LFTsbweekly, or more frequently if 
clinically indicated, until resolved to ≤ 3.0 x ULN

Novartis Confiden tial Page 60
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontin ued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
> 5.0 -10.0 x ULN Mandatory :Hold dose. Repeat LFTsbas soon as 
possible, preferably within 48 -72 hours from awareness of 
the abnormal results; monitor LFTsbweekly, or mo re 
frequently if clinically indicated, until resolved to ≤ 3.0 x 
ULN: Then
If resolved in ≤ 14 days, maintain dose level
If resolved in > 14 days, reduce dose 1 dose levelMandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 ho urs from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolved to ≤ 2.5 x ULN: Then
Recommendation: If resolved in ≤ 28 days, reduce dose 1 
dose level
Recommendation : If resolved in > 28 days , Discontinue patient 
from study drug treatment
> 10.0 -20.0 x ULN Mandatory :Hold dose. Repeat LFTsbas soon as 
possible, preferably within 48 -72 hours from awareness of 
the abnormal results ; monitor LFTsbweekly, or more 
frequently if clinically indicated, until resolved to ≤ 
baseline. Then reduce dose 1 dose level.Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicat ed, until resolved to ≤ 2.5 x ULN. Then
Recommendation: If resolved in ≤ 28 days, reduce dose 1 
dose level maintain dose level
Recommendation: If resolved in > 28 days, Discontinue patient 
from study drug treatment.
> 20.0 x ULN Mandatory :Hold dose. Re peat LFTsbas soon as 
possible, preferably within 48 -72 hours from awareness of 
the abnormal results; monitor LFTsbweekly, or more 
frequently if clinically indicated, until resolved to ≤ 3 x ULN 
(or ≤ 5 x ULN for patients with baseline value > 3.0 -5.0 x 
ULN), then resume treatment at reduce dose 1 dose 
level. Only 1 dose reduction is allowed; if reoccurs at > 5 x 
ULN, discontinue patient from study drug treatment.Mandatory :Hold dose. Repeat LFTsbas soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal 
results; monitor LFTsbweekly, or more frequently if clinically 
indicated, until resolve d to ≤ 2.5 x ULN (then
Recommendation: If resolved in ≤ 28 days, reduce dose 1 
dose level maintain dose level
Recommendation: If resolved in > 28 days, Discontinue patient 
from study drug treatment

Novartis Confiden tial Page 61
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontin ued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Combined celevations of AST or ALT and total bilirubin
For patients with normal baseline 
ALT and AST and total bilirubin 
value:
AST or ALT >3.0 x ULN combined 
with total bilirubin >2.0 x ULN without 
evidence of cholestasisd
For patients with elevated baseline 
AST or ALT or total bilirubin value
[AST or ALT>2 x baseline AND > 3.0 
x ULN]Mandatory :Permanently discontinue patient from study 
drug treatment.
Repeat as soon as possible, preferably within 48 hours 
from awareness of the abnormal results, then with weekly 
monitoring of LFTsb), or more freque ntly if clinically 
indicated, until AST, ALT, or bilirubin have resolved to 
baseline or stabilization over 4 weeks. Refer to Section 
6.3.3.1 for additional follow-up evaluations as applicable.Mandat ory: Permanently discontinue patient from study drug 
treatment.
Repeat as soon as possible, preferably within 48 hours from 
awareness of the abnormal results, then with weekly monitoring 
of LFTsb), or more frequently if clinically indicated, until AST, 
ALT, or bilirubin have resolved to baseline or stabilization over 4 
weeks. Refer to Section 6.3.3.1 for additional follow-up 
evaluations as applicable.
Investigation (metabolic)
Asymptomatic amylase and/o r lipase elevation
Grade 1 (> ULN -1.5 x ULN) Recommendation: Maintain dose level, measure 2x 
weekRecommendation: Maintain dose level, measure 2x week
Grade 2 (> 1.5 -2.0 x ULN) Recommendation: Maintain dose level, measure 2x 
weekRecommendation: Main tain dose level, measure 2x week
Grade 3 (> 2.0 -5.0 x ULN) Mandatory :Hold dose until resolved to Grade ≤ 1 or 
baseline, then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days, then discontinue treatment and 
obtain appropriate imaging (i.e., MRI, CT scan or 
ultrasound).Mandatory :Hold dose until resolved to Grade ≤ 1 or baseline, 
then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days, then discontinue treatment and obtain 
appropriate imaging (i.e., MRI, CT scan or ultrasound).
Grade 4 (> 5.0 x ULN) Mandatory :Permanently discontinue patient from study 
drug treatment. Obtain appropriate imaging (i.e., MRI, CT 
scan or ultrasound).Mandatory :Permanently discontinue patient from study drug 
treatment. Obtain appropriate imaging (i.e., MRI, CT scan or 
ultrasound).

Novartis Confiden tial Page 62
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontin ued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Vascular disorders
Hypertension
CTCAE Grade 3 Mandatory :Hold dose until resolved ≤ Grade 1, then 
reduce dose 1 dose levelMandatory :Hold dose until resolved ≤ Grade 1, then reduce 
dose 1 dose level
CTCAE Grade 4 Mandatory :Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
Gastro intestinal
Pancreatitis
Grade 2 (radiologic findings for 
pancreatitis as per CTCAE v4.03, for 
increased enzymes please see table 
for asymptomatic amylase and/or 
lipase elevation)Mandatory :If asymptomatic radiologic pancreatitis, hold 
treatment until recovery of the radiologic findings. If 
treatment delay is ≤ 21 days, then reduce dose 1 dose 
level. If treatment delay > 21 days, discontinue treatment 
and keep monitoring with appropriate i maging (i.e., MRI, 
CT scan or ultrasound).Mandatory : If asymptomatic radiologic pancreatitis, hold 
treatment until recovery of the radiologic findings. If treatment 
delay is ≤ 21 days, then reduce dose 1 dose level. If treatment 
delay > 21 days, discont inue treatment and keep monitoring with 
appropriate imaging (i.e., MRI, CT scan or ultrasound).
Grade ≥ 3 Mandatory :Permanently discontinue patient from study 
drug treatment. Obtain appropriate imaging (i.e., MRI, CT 
scan or ultrasound).Mandatory :Perma nently discontinue patient from study drug 
treatment. Obtain appropriate imaging (i.e., MRI, CT scan or 
ultrasound).
Diarrhea***
Grade 1 Recommendation: Maintain dose level but, initiate anti -
diarrhea treatmentRecommendation: Maintain dose level but, initiate anti -diarrhea 
treatment
Grade 2 Recommendation: Hold dose until resolved to ≤ grade 1, 
then maintain dose level.
If diarrhea returns as ≥ grade 2, then hold dose until 
resolved to ≤ grade 1, then reduce dose 1 dose lev elRecommendation: Hold dose until resolved to ≤ grade 1, then 
maintain dose level.
If diarrhea returns as ≥ grade 2, then hold dose until resolved to ≤ 
grade 1, then reduce dose 1 dose level
Grade 3 Recommendation: Hold dose and discontinue patient 
from study drug treatmentMandatory :Hold dose until recovery to ≤ grade 1. 
Recommendation: Bosutinib may then be resumed at 1 dose 
level
Grade 4 Mandatory :Permanently discontinue patient from study 
drug treatmentMandatory : Hold dose until recovery to ≤ grade 1. 
Recommendation: Bosutinib may then be resumed at 1 dose 
level

Novartis Confiden tial Page 63
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontin ued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
Skin and subcutaneous tissue disorders
Rash/photosensitivity
Grade 1 Recommendation: Maintain dose level. Consider to 
initiate appropriate skin toxicity therapy (such as 
antihistamines, topical corticosteroids and low -dose 
systemic corticosteroids)Recommendation: Maintain dose level. Consider to initiate 
appropriate skin toxicity therapy (such as antihistamines, topical 
corticosteroids and low -dose systemic corticosteroids)
Grade 2 Recommendation : Maintain dose level, but 
initiate/intensify appropriate skin toxicity therapy (such as 
antihistamines, topical corticosteroids and low -dose 
systemic corticosteroids)Recommendation: Maintain dose level, but initiate/intensify 
appropriate skin toxicity therapy (such as antihistamines, topical 
corticosteroids and low -dose systemic corticosteroids)
Grade 3, despite skin toxicity therapy Recommenda tion: Hold dose until resolved to Grade ≤ 1, 
then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days (despite appropriate skin toxicity 
therapy), then discontinue patient from study drug 
treatmentRecommendation: Hold dose un til resolved to Grade ≤ 1, then:
If resolved in ≤ 7 days, then reduce dose 1 dose level
If resolved in > 7 days (despite appropriate skin toxicity therapy), 
then discontinue patient from study drug treatment
Grade 4, despite skin toxicity therapy Mandat ory:Permanently discontinue patient from study 
drug treatment.Mandatory :Permanently discontinue patient from study drug 
treatment.
General disorders and administration site conditions
Fatigue/ Asthenia
Grade 1 or 2 Recommendation: Maintain dose level Recommendation: Maintain dose level
Grade 3 Recommendation: Hold dose until resolved to ≤ grade 1, 
then :
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then reduce dose 1 dose levelRecommendation: Hold dose until resolved to ≤ grade 1, then :
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then reduce dose 1 dose level
All dose modifications should be based on the worst preceding toxicity.
aCommon Toxicity Criteria for Adverse Events (CTCAE Version 4.03)
bCore LFTs consist of ALT, AST, total bilirubin (fractionated [direct and indirect], if total bilirubin > 2.0 x ULN), and alka line phosphatase (fractionated [quantification of 
isoforms], if alkaline phosphatase > 2.0 x ULN.)
c“Combined” defined as total bilirubin increase to the defined threshold concurrently with ALT/AST increase to the defined thr eshold

Novartis Confiden tial Page 64
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Dose modifications for both asciminib and bosutinib
Please note that if a patient requires a dose interruption of > 28 day s for each toxicity, then the patient must be discontin ued from the study  treatment
Worst toxicity
CTCAE Grade 4.03Asciminib Bosutinib
If combined elevations of AST or ALT and total bilirubin do not meet the defined thres holds, please follow the instructions for isolated elevation of total bilirubin and 
isolated elevation of AST/ALT, and take a conservative action based on the degree of the elevations (e.g. discontinue treatme nt at the situation when hold dose is 
needed fo r one parameter and discontinue treatment is required for another parameter). After all elevations resolve to the defined thr esholds that allow treatment re -
initiation, re -start the treatment either at the same dose or at one dose lower if meeting a criter ion for dose reduction
d “Cholestasis” defined as ALP elevation (>2.0 x ULN and R value <2) in patients without bone metastasis, or elevation of ALP l iver fraction in patients with bone 
metastasis
Note: The R value is calculated by dividing the ALT by the ALP, using multiples of the ULN for both values. It denotes whether the relative pattern of ALT and/or ALP 
elevation is due to cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury
* Note: If total bilirubin > 3.0 x ULN is due t o the indirect (non -conjugated) component only, and hemolysis as the etiology has been ruled out as per institutional 
guidelines (e.g., review of peripheral blood smear and haptoglobin determination), then ↓ 1 dose level and continue treatment at the discr etion of the investigator.
** Note: A CT scan or other imaging study to assess the pancreas, liver, and gallbladder must be performed within 1 week of the first occurrence of any ≥ Grade 3 of 
amylase and/or lipase. If asymptomatic Grade 2 elevations of lip ase and/or amylase occur again at the reduced dose, patients will be discontinued permanently from 
study treatment.
*** Note: antidiarrheal medication is recommended at the first sign of abdominal cramping, loose stools or overt diarrhea

Novartis Confidential Page 65
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Table 6-3 Dose reduction steps for asciminib and bosutinib
Dose reduction*
Starting dose level – 0 Dose level – 1
Asciminib BID 40 mg tablet BID (total daily 
dose 80 mg)20 mg tablet BID (total daily 
dose 40 mg)
*Dose reduction should be based on the worst toxicity demonstrated at the last dose.
Asciminib dose reduction below total daily 40 mg is not allowed. 20 mg tablets will be dispensed to patients in 
the instance of dose reduction.
Dose reduction*
Starting dose level – 0 Dose level – 1 Dose level – 2
Bosutinib QD 500 mg (1 -500 mg tablet QD) 400 mg (4 -100 mg tablets 
QD)300 mg (3 -100 mg 
tablets QD)
* Dose reduction should be based on the worst toxicity demonstrated at the last dose.
Bosutinib dose reduction below total daily 300 mg is not allowed. 100 mg tablets will be dispensed to patients 
in the instance of dose reduction.
6.3.2 Dose adjustments for QTcF prolongation
If QTcF >500 msec or QTcF prolongation >60 msec from baseline is observed at any point 
during stud y treatment, and confirmed, the below guidance must be followed:
1.Assess the quality  of the ECG recording and th e QT value and repeat if needed
2.Interrupt stud y treatment until confirmed resolution of QTcF and as per dose reduction 
guidel ines for non- hematological AEs.
3.Determine the serum electroly te levels (in particular hy pokalemia, h ypomagnesemia). If 
abnormal, correct abnormalities before resuming study  drug treatment.
4. Review concomitant medication associated with QT prolongation, including drugs with a 
“Known”, “Possible”, or “Conditional risk of Torsades de Pointes” (refer to 
wwwcrediblemeds.org/ ), and drugs with the potential to increase the risk of study  drug 
exposure related QT prolongation .
5.Check study
 drug dosing sc hedule and treatment compliance.
After confirming ECG reading at site, if QTcF > 500 msec 
Interrupt stud y treatment 
Repeat ECG and confirm ECG diagnosis b y a cardiologist or central ECG lab 
If QTcF confirmed > 500 msec: 
Correct electrol ytes, eliminate culprit concomitant treatments, and identify  and 
address clinical conditions that could potentially  prolong the QT as per the ECG and 
QTc Clinical Safet y Standards Guidelines Section 3.3.1 . 
Consult with a cardiologist (or qualified specialist) 
Increase cardiac monitoring as indicated, until the QTcF returns to ≤ 480 msec. 
After resolution to ≤ 480 msec, consider re -introducing treatment at reduced dose, and 
increase ECG monitoring for the next treatment(s) , (e.g. pre- dose and 2 hours post dose 
after one week and two weeks of treatment re- introduction) : 

Novartis Confidential Page 66
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
If QTcF remains ≤ 500 msec after dose reduction, continue planned ECG monitoring 
during subsequent treatment 
If QTcF > 500 msec recurs after dose reduction, discontinue pat ient from trial. 
6.3.3 Follow -up for toxicities
Patients whose treatment is permanently discontinued due to a study drug related adverse event 
or clinically significant laboratory value, must be followed up at least once a week for 4 weeks, 
until resolution or stabilization of the event, whichever comes first. Appropriate clinical experts 
such as ophthalmologist, endocrinologist, dermatologist, psy chiatrists etc. should be consulted 
as deemed necessary . All patients must be followed up for adverse events and ser ious adverse 
events for 30 day s following the last dose of study  treatment.
6.3.3.1 Follow up on potential drug -induced liver injury (DILI) cases
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be c onsidered as clinically  important events.
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
For patients with norma l ALT and AST and TBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or AL T > 8.0 x ULN], combined with [TBIL > 2 x 
baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as ALP elevation > 2.0 x ULN with R value < 2 in patients without bone metastasis, or elevation 
of AL P liver fraction in patients with bone metastasis.
Note: (The R value is calculated by  dividing the ALT by  the ALP, using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), o r mixed (R >2 and < 5) liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferabl y within 48 hours from the 
awareness of the abnormal results. The evaluation should include laboratory tests, detailed 
history , physical assessment and thepossibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
1.Laboratory tests should include ALT, AST, albumin, creatinine kinase, total bilirubin, 
direct and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase.
2.A detailed histo ry, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history of any  pre-existing liver 
conditions or risk factors, should be collected.
3. Further testing for acute hepatitis A, B, C or E infection and liver imaging (e .g.biliary  
tract) may be warranted.

Novartis Confidential Page 67
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
4.Obtain PK sample, as close as possible to last dose of study  drug, if PK anal ysis is 
performed in the study .
5.Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medicall y 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the term 
“potential drug-induced liver injury ”. All events should be followed up with the outcome 
clearl y
documented.
6.3.4 Anticipated risks and safety  concerns of the study  drug
Appropriate eligibility  criteria, as well as specific dose modification and stopping rules are 
included in this protocol. Recommended guidelines for proph ylactic or supportive treatment for 
expected toxicities, including management of study -drug induced adverse events, i.e., 
hypergly cemia, skin toxicity  and diarr hea are provided in Table 6-2. Refer to preclinical toxicit y 
and or clinical data found in the [A sciminib Investigator’s Brochure] or bosutinib label .
6.4 Concomitant medications for patients on asciminib
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug and including 
over-the-counter treatment and nutritional or vitamin supplements) and significant non-drug 
therapies (including physical therapy , herbal/natural medications and blood transfusions) 
administered during the study  must be listed on the “Concomitant 
Medications/Significant non-
drug therapies” section of the eCRF.
Chronic medic
ation should be maintained at the same dose and schedule throughout the study
period, as medically  feasible.
All prior antineoplastic surgery , chemotherap y, biologic, immunologic and radiation therap y 
must be recorded in the “Prior antineoplasti c therapy ” section of the eCRF.
In general, concomitant medications and therapies deemed necessary  for the supportive care 
and safet y of the patient are allowed, provided their use is documented in the patient records 
and on the appropriate case report form, including the medicati on’s duration (start and end dates 
or if continuing at final exam). These include blood and platelet transfusions for patients with 
anemia and with thrombocy topenia.
6.4.1 Permitted concomitant therapy
Drugs that affect gastric pH
Asciminib does not have a pH -dependent solubility . Drugs that elevate gastric pH will not affect 
asciminib absorption. All ac id reducing agents are allowed.

Novartis Confidential Page 68
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
6.4.2 Permitted concomitant therapy  requiring caution and/or action
The in vivo potential of asciminib to interact with sensitive CYP3A4/5, CYP2C8 and CYP2C9 
substrates has been evaluated and would indicate a minimal or negligible risk ( Section 1.2.1.1). 
Therefore CYP3A4/5, CYP2C8 and CYP2C9 substrates with narrow therapeutic index (NTI) 
should be used with caution. 
In recombinant 
cellular expression systems, asciminib was identified as a substrate of BCRP 
(Km ≈ 4 µM) and P-gP (Km could not be estimated due to insufficient saturation of efflu x 
activity ). Inhibitors of BCRP and P -gP may  increase asciminib concentration. Based on human 
ADME study , P-gp may represent maximally  24% of the total clearance resulting in modest 
increase in AUC. Therefore, both BCRP and P-gp inhibitors should be admini stered with 
caution . If a medication listed in Section 14 appears on both the list of prohibited and the list of 
medications to be used with caution, the medication is prohibited.
6.4.3 Prohibited concomitant therapy
Othe r anticancer agents
The administration of any  other anticancer agents including chemotherapy  and biologic agents 
isnotpermitted except for anti-cancer treatments of newl y diagnosed solid cancers (e.g. 
prostate cancer) that would not impact the level of m inimal residual disease of patients. These 
patients may remain in the current study  after consultation with Novartis. The administration of 
other ty rosine kinase inhibitors indicated for treatment of CML  isnotallowed. 
Strong CYP3A 4/5 inhibitors
Every  effort should be made NOT to concomitantly  administer strong CYP3A4/5 inhibitors.
CYP3A4/5 inhibitors may decrease the metabolism of asciminib and resulting in increased 
serum concentrations and increased exposure. If administration of a strong CYP3A4/5 inhibitor 
cannot be avoided during the study  and cannot be switched to an alternative therap y that does 
not strongl y inhibit CYP3A4/5, asciminib must be interrupted .
A list of cytochrome P450 isoenzy mes and CYP3A4/5inhibitors may be found at 
medicine.iupui.e du/CLINPHARM/ddis/clinical -table .
A classification of CYP3A4/5 SmPC can be found in Section 14- Appendices .
Further information can also be found in the following referenc
e (Venkatakrishnan et al 2001).
Strong CYP3A 4/5, and UGT1A /2B inducers
Every  effort should be made NOT to concomitantly administer strong CYP3A4 inducers during 
the study .
Additionally , the use of strong inducers of UGT1A/2B is prohibited during the study .
If administration of a strong CYP3A4/5 inducer or UGT1A/2B inducer cannot be avoided 
during the study  and cannot be switched to an alternative therapy , temporary  interruption of 
study  treatment is NOT needed
.

Novartis Confidential Page 69
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
QT prolonging agents
As far as possible avoid co-administering drugs with a “Known”, “Possible” or “Conditional” 
risk of Torsades de Pointes (perwwwcrediblemeds.org/ )during the course of the study :
If concomitant administration of drugs with a “Known risk of Torsades de Pointe s” is 
required and cannot be avoided, study  drug must be interrupted. If, based on the investigator 
assessment and clinical need, study  treatment is resumed, close ECG monitoring is advised. 
If during the course of the study, concomitant administration of a drug with “Possible risk” 
or “Conditional risk of Torsades de Pointe s” is required, based on the investigator 
assessment and clinical need, study  treatment may be continued under close ECG 
monitoring to ensure patient safet y.
Alist of drugs associated with QT prolongation and/or Torsades de P ointe sis available online 
at wwwcrediblemeds.org/ .
Herbal medications
Herbal preparations/medications are not allowed throughout the study . These herbal 
medications include, but are not l imited to: St. John’s wort, Kava, ephedra (ma huang), gingko 
biloba, dehy droepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. Patients should 
stop using these herbal medications 7 day s prior to first dose of study  drug.
6.4.4 Other concomitant medicati ons
Anti-emetics
Use of anti-emetics is allowed. Prophy lactic anti-emetics should be started only once the patient 
experiences nausea or vomiting, at the discretion of the investigator. It is recommended that 
patients use drugs that do not cause QT prolong ation. Please note that some anti -emetics have 
a known risk for T orsade de Pointes and are prohibited (refer to Section 6.4.2 and Section 14.1 
Appendix 1 ).
Bisphosphonates
The use of bisphosphonates regar dless of indication is allowed.
Contraceptives
Hormonal contraceptives are allowed as contraception methods. Highl y effective contraception 
should be maintained throughout the study  and for 3 daysafter study  treatment discontinuation .
Anticoagulation agents
All anticoagulants or anti-aggregation agents may be administered under the discretion of the 
investigator.
Therapeutic 
doses of warfarin sodium (Coumadin®) or any other coumarin- derivative 
anticoagulants should be used with caution and fully  avoided whenever possible because of its 
known interaction with many  commonl y used medications and certain foods. As warfarin has 
a narrow therapeutic range, and asciminib is possibly  an inhibitor of CYP2C 9, the major 

Novartis Confidential Page 70
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
metabolizing enzyme of S-warfarin (R-warfarin is metabolized by multiple CYP enzymes), 
warfarin should be caref ully monitored whenever used.
Caution is also advised when asciminib is co-administered with anti -platelet pro -drugs such as 
clopidogrel, ticlopidine and prasugrel, which require metabolic activation by CYP3A4 and 
CYP2C9. While the weak reversible in vitro inhibition potential of asciminib is unlikely  to 
translate into clinical significance as the stead y-state plasma concentrations at the maximum 
therapeutic doses are significantl y lower than the experimentally  determined inhibition 
constants, patients using anti- platelet pro -drugs should still be carefull y monitored.
Direc t Thrombin inhibitors (DTIs) and Factor Xa inhibitors are allowed as anticoagulants. 
Individual medications from each of the classes should be checked if they are not prohibited 
due to other drug-drug-interactions with asciminib . Alternatively , therapeutic anticoagulation 
may be accomplished usin
g low-molecular weight heparin.
6.5 Concomitant medications for patients on bosutinib
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug and including 
over-the-counter treatment and nutritional or vitamin supplements) and significant non-drug 
therapies (including physical therapy , herbal/natural medications and blood transfusions) 
administered during the study  must be listed on the “Concomitant 
Medications/Significant non-
drug therapies” section of the eCRF.
Chronic medication should be maintained at the same dose and schedule throughout the study
period, as medically  feasible.
All prior antineoplastic surgery , chemotherap y, biologic, immunologic and radiation therap y 
must be recorded in the “Prior antineoplasti c therapy ” section of the eCRF.
In general, 
concomitant medications and therapies deemed necessary  for the supportive care 
and safet y of the patient are allowed, provided their use is documented in the patient records 
and on the appropriate case report form, including the medicati on’s duration (start and end dates 
or if continuing at final exam). These include blood and platelet transfusions for patients with 
anemia and with thrombocy topenia
6.5.1 Permitted concomitant therapy  requiring caution
Bosutinib should be used with caution in patients who have or may develop prolongation of QT, 
including those patients who are taking medicinal products that are known to prolong the QTc 
(e.g., anti-arrhy thmic medicinal products such as amiodarone, disopy ramide, procainamide, 
quinidine and sotalol and other substances that may prolong QTc) (in accordance with EU 
SmPC dated 05/2018).
If a medication listed in Section 
14-Appendices appears on both the list of prohibited and the 
list of medications to be used with caution, the medication is 
prohibited.

Novartis Confidential Page 71
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
6.5.2 Prohibited concomitant therapy
Other anticancer agents
The administration of any  other anticancer agents including chemotherapy  and biologic agents 
isnotpermitted except for anti-cancer treatments of newl y diagnosed solid cancers (e.g. 
prostate cancer) that would not impact the level of minimal residual disease of patients. T hese 
patients may remain in the current study  after consultation with Novartis. The administration of 
other ty rosine kinase inhibitors indicated for treatment of CML  isnotallowed. 
Concomitant use with CYP3A  inhibitors
Avoid the concomitant use of stron g or moderate CYP3A inhibitors as an increase in bosutinib 
plasma concentration is expected. Strong CYP3A inhibitors include boceprevir, clarithrom ycin, 
conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, 
nelfina vir, posaconazole, ritonavir, saquinavir, telaprevir, t elithrom ycin, and voriconazole.
Moderate CYP3A inhibitors include amprenavir, aprepitant, atazanavir, ciprofloxacin, 
crizotinib, darunavir/ritonavir, diltiazem, ery thromy cin, fluconazole, fosamprenavir , grapefruit 
products, imatinib and verapamil) [Bosulif®USPI] . If administration of a strong or moderate 
CYP3A4/5 inhibitor cannot be avoided during the study  and cannot be switched to an alternative 
therap y, bosutinib must be interrupted .
Concomitant use with CYP3A  inducers
Avoid the concomitant use of strong or moderate CYP3A inducers as a large reduction in 
exposure is expected (strong CYP3A inducers include carbamazepine, phenytoin, rifampin and 
St. John's Wort. Moderate CYP3A inducers include bosentan, efavirenz, etravirine, modafinil 
and nafcillin) [ Bosulif®USPI ]. However, i f administration of a strong or moderate CYP3A4/5 
inducer cannot be avoided during the study  and cannot be switched to an alternative therap y, 
temporary  interruption of bosutinib is NOT required.
pH A ltering Medications
Bosutinib displays pH -dependent aqueous solubility , in vitro. In a cross -over trial in 23 healthy 
volunteers, a single oral dose of 400 mg of bosutinib was either administered alone or in 
combination with multiple -oral doses of 60 mg of lansoprazole (PPI ) under fasting conditions. 
Lansoprazole decreased bosutinib Cmax and AU C by  46% and 26%, respectivel y.
Concomitant administration with PPI s is not allowed.
Consider using short- acting antacids or H2 blockers instead of PPIs to avoid a reduction in 
bosutinib exposure. Separate antacid or H2 blocker dosing by more than 2 hours [Bosulif®
USPI ].
6.6 Patient numbering, treatment assignment or randomization
6.6.1 Patient numbering
Each patient is identified in the study  by a Subject Number (Subject No.), that is assigned when 
the patient is first enrolled for screening and is retained as the primary  identifier for the patient 

Novartis Confidential Page 72
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by Novartis to the investigative site) with a sequential patient 
number suffixed to it, so that each subject is numbered uniquel y across the entire database. 
Upon signing the informed con sent form, the patient is assigned to the next sequential Subject 
No. available to the investigator through the Oracle Clinical RDC interface.
The investigator or designated staff will contact the IRT and provide the requested identify ing 
information for the patient to register them into the IRT. Once assigned, the Subject No. must 
not be reused for an y other subject and the Subject No. for that individual must not be changed, 
even if the patient is re -screened. If the patient fails to be randomized or start treatment for an y 
reason, the reason will be entered into the Screening Disposition page. IRT must be notified 
within 2 day s that the patient was not randomized.
6.6.2 Treatment assignment or randomization
Patients will be assigned to one of the 2treatment arms ( Section 4.1 and Section 6.1 ) in a ratio 
of 2:1. Randomization will be stratified by  cytogenetic response status at screening.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients and investigator staff. A patient 
randomization list will be produced by the Interactive Response Technology  (IRT) provider 
using avalidated system that automates the random assignment of patient numbers to 
randomization numbers. These randomization numbers are linked to the different treatment 
arms, which in turn are linked to medication numbers. A separate medication randomization list 
will be produced by or under the responsibility  of Novartis Drug Supply  Management using a 
validated system that automates the random assignment of medication numbers to medication 
packs containing each of the study  treatments.
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be randomized via 
IRT to one of the treatment arms. The investigator or his/her delegate will call or log on to the 
IRT and confirm that the patient fulfills all the inclusion/exclusion criteria. The IRT will assign 
a randomization number to the patient, which will be used to link the patient to a treatment arm 
and will specify  a unique medication number for the first package of study  treatment to be 
dispensed to the patient. The randomization number will not be communicated to the caller.
6.6.3 Treatment blinding
Not applicable.
6.7 Stud y drug preparation and dispensation
The investigator or responsible site personnel must instruct the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by authorized site 
personnel only. All dosages prescribed to the patient and all dose changes during the study  must 
be recorded on the Dosage Administration Record eCRF.

Novartis Confidential Page 73
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
6.7.1 Study treatment packaging and labeling
Study  treatment, asciminib and bosutinib tablets, will be provided as global clinical open -label 
supply  and will be packed and labeled under the responsibility  of Novartis, Drug Supply 
Management.
Study  treatment labels will comply  with the legal requirements of each country  and will include 
storage conditions, a unique medication number (corresponding to study  treatment and strength).
Responsible site personnel will identify  the study  treatment package(s) to dispense by the 
medication number(s) assigned by IRT to the patient. Site personnel will add the patient number 
on the label. If the label has 2-parts (base plus tear-off label), immediately  before dispensing 
the package to the patient, site personnel will detach the outer part of the label from the package 
and aff ix it to the patient’s source document.
Table 6
-4 Packaging and labeling
Study  treatments Packaging Labeling (and dosing frequency )
asciminib (20 mg and 40 mg) Tablets in bottle Labeled as ‘ABL001 20 mg/ABL001 40 
mg’(BID)
bosutinib (100 mg or 500 mg) Tablets in bottle or tablets in 
blisterLabeled as ‘bosutinib 100 mg or bosutinib 
500 mg’(QD)
6.7.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, asciminib and bosuti nib should be stored according 
to the instruction s specified on the drug labels.
6.7.3 Study drug compliance and accountability
6.7.3.1 Study drug compliance
Total daily  dose of study  treatment administered with start and end date will be collected on the 
Dosage Administration Record eCRF page. Name, start and end dates of any Concomitant 
Medications and Surgical and Medical procedures will be collected on the Prior and 
Concomitant medications and Surgical and Medical procedures eCRFs respectivel y.
Compliance will be ass essed by the investigator and/or study  personnel at each patient visit and 
information provided by the patient and/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each 
dispensing pa tient visit.
6.7.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by the field 
monitor during site visits a nd at the completion of the study. Patients will be asked to return all 
unused study treatment and packaging on a regular basis, at the end of the study treatment or at 
the time of study  treatment discontinuation during the treatment period as well as during the 
switch treatment period with asciminib.

Novartis Confidential Page 74
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountabilit y logto the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.
6.7.3.3 Handling of other study  treatment
Not applicable.
6.7.4 Disposal and destruction
The study  drug suppl y can be destro yed at the local Novartis facility , Drug Supply  group or 
third party , or at the site only if permitted by  local regulations and authorized by  Novartis in a 
prior agreement.
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be sup
ported in the patient’s source 
documentation. Patients can be consented for study participation prior to stu dy day -21.
Table 7-2lists all of the assessments required by  patients that switch treatment from bosutinib 
to asciminib after documented treatment failure of bosutinib
.
No eCRF wil l be used as a source document.
(S) is defined as “Source”
(D) is defined as “Data Based”

Novartis Confidential Page 86
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301CategoryProtocol 
Section 
7Switch 
Screening 
PhaseTreatment Switch Phase
Visit name
EOT (Bosutinib)
/
S-Screening/
S-Baseline
S-Week 1 Day 1
S-Week 2 Day 1
S-Week 4
S-Week 6
S-Week 8
S-Week 10
S-Week 12
S-Week 14
S-Week 16
S-Week 20 S-Week 24
S-Week 28 S-Week 32
S-Week 36
S-Week 40 S-Week 44
S-Week 48
S-Week 52HematologyD 7.2.2.5.1 X
(if not done 
at EOT)X X X X X X X X X X X X X X X X X X
ChemistryD 7.2.2.5.2 X
(if not done 
at EOT)X X X X X X X X X X X X X X X
Chemistry -
Hemoglobin A1cD 7.2.2.5.2 X
(if not done 
at EOT)Week 12 and as clinically indicated
CoagulationD 7.2.2.5.2 X
(if not done 
at EOT)X X X X X X X X X X X X X X X
Serum 
Pregnancy test (if 
applicable)D 7.2.2.5.3 X
(if not done 
at EOT)X X X X X X X X X X X X X
Liver 
assessmentsDas clinically indicated

Novartis Confidential Page 93
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
7.1.1 Molecular pre -screening
Not applicable .
7.1.2 Screening
Written informed consent must be obtained before any study specific medical procedures are 
performed. All screening/baseline assessments (with the exception of Bone Marrow Aspirates) 
should occur within 21 day s before Week 1 Day  1.
The screening visit window for bone marrow assessments is 56days prior to Week 1 Day 1.
Should bone marrow assessments have been performed before the main informed consent is 
signed but within 56 days of Week 1 Day 1, no further bone marrow sampling will be required 
at screening. Atend of treatment , abone marrow exploratory  aspirat e and/or biopsy  must be 
collected even ifthe screening/baseline bone marrow exploratory  aspirate and/or biops y 
sample s were not collected .During the screening visit, inclusion and exclusion criteria will be 
assessed. Screening assessments to confirm eligibility  must be performed prior to 
randomization. The results of the real time quantitative polymerase chain reaction (RQ-PCR)
and the bone marrow aspirate must be available prior to randomization and first dose of study  
treatment .
For details of assessments required during screening please refer to Table 7 -1.
Laboratory  baseline assessments (including hematology , chemistry , coagulation and serum 
pregnancy  test), physical examination including extramedullary  involvement, performance 
status, ECG, height, weight and vital signs, evaluation of all relevant medical history including 
cardiovascular risk factors, CML  disease history , including prior TKI therapy  and antineoplastic 
medication and prior and concomitant medication must be performed prior to the first dose of 
study  treatment. Patients with potassium, and/or magnesium and/or total calcium levels that are 
< LLN at screening, must have their potassium, and/or magnesium, and/or calcium replenishe d 
through supplementation and the levels must be within normal limits prior t
o the first dose of 
study  drug.
A patient who has a laboratory  test (peripheral blood test) results that do not satisfy  the entrance 
criteria may have the tests repeated. These tests may be repeated as soon as the investigator 
believes the re-test results are likely to be within the acceptable range to satisfy  the entrance 
criteria, but should be completed within approximately  2 weeks of the original screening visit 
date. In this case, the subject will not be required to sign another Informed Consent Form (ICF), 
and the original patient ID number assigned by the investigator will be used. In the event that 
the laboratory  tests cannot be performed within the screening visit window, or the re-tests do 
not meet the entrance criteria, or other eligibility  criteria have changed and are not met anymore, 
the patient is considered a screen failure, and must be discontinued from the study .
A new ICF will need to be signed if the investigator chooses to re-screen the patient after a 
patient has screen failed, however, the patient ID number will remain the same. All required 
screening activities must be performed when the patient is re-screened for participation in the 
study . No further bone mar row sampling will be done at re -screening if a previous assessment 
was done within 56 days of Week 1 Day 1.
After 56 days, new bone marrow biops y and 
aspirates samples for cytogenetic assessment and exploratory  biomarker purpose should be re -

Novartis Confidential Page 94
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
collected at the time of the bone marrow assessment. An individual patient may be re -screened 
up to three times for the study . Once the number of patients screened and enrolled is likely to 
ensure target enrollment, the Sponsor may close the study  to further screening. In this case, the 
patients who screen failed will not be permitted to re- screen.
7.1.2.1 Eligibility  screening
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed. The eligibility  check will be managed via IRT system. 
Please refer and compl y with detailed guidelines in the I RT manual.
7.1.2.2 Conditions to be fulfilled for asciminib switch
The eligibility  assessments of patients who are candidates for asciminib switch will start with 
the bosutinib EOT visit. Assessments conducted during the EOT visit will be used to evaluate 
if all conditions for asciminib switch are fulfilled and there are no conditions preventing patients 
from receiving asciminib treatment . Therefore all effort sMUST be made to ensure that all EOT 
assessments are completed per Table 7-1. In the event that all EOT assessments cannot be 
completed during the EOT visit, they must be completed within 42days(6 weeks) after the 
bosutinib EOT visit .For details of assessments r equired for patients that switch treatment from 
bosutinib to asciminib, please refer to Table 7-2.The maximum allowed time frame for patients 
failing bos utinib to start treatment with asciminib is 42 day s after bosutinib EOT.
In case a patient presents with a grade 3 or 4 adverse event at the time of the EOT visit or 
develops it after the EOT visit, the adverse event must be resolved to grade 2 or lower before 
startingasciminib treatment and within 28 days of the date of 
occurrence of the adverse event 
as outlined in the criteria listed below. 
However, a patient who has laboratory  test (peripheral blood test) results or ECG results that 
do not satisfy  thetreatment switch conditions may have the tests repeated multiple times during 
the treatment switch screening period. The last test performed before start of asciminib dosing 
must meet the conditions for treatment switch as listed below .
If apatient does not meet the conditions for treatment switch, they should enter the survival 
follow -up phase.
The conditions for treatment switch will be checked via the IRT system. Please refer and compl y 
with detailed guidelines in the I RT manual.
Conditions to fulfil l to allow the switch to asciminib:
1. Failure to bosutinib treatment up to 96 weeks after the last patient received the first dose 
(adapted from the 2013 ELN Guidelines; Baccarani et al 2013 ). Patients must meet at least 
1 of the following criteria. Failure is defined as follows:
Three months after the initiation of therapy or thereafter : No CHR or > 95% Ph+ 
metaphases.
Six months after the initiation of therap yor thereafter : BCR -ABL 1ratio > 10% I S 
and/or > 65% Ph+ metaphases.
Twelve months after initiation of therap yor thereafter : BCR -ABL 1ratio > 10% I S 
and/or > 35% Ph+ metaphases.

Novartis Confidential Page 95
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
At any  time after the initiation of therapy , loss of CHR, CCy R or PCy R.
At any  time after the initiation of therapy , detec tionof new BCR -ABL 1mutations
which potentially  cause resistance to study  treatment (asciminib or bosutinib) .
At any  time after the initiation of therapy , confirmed loss of MMR in 2 consecutive 
tests.
At any  time after the initiation of therapy , new clonal chromosome abnormalities in 
Ph+ cells: CCA/Ph+.
Conditions preventing patients to switch to asciminib
Any Grade 3 or 4 toxicity  which has not resolved to Grade 2 or lower within 28 days 
and before starting asciminib treatment.
Asymptomatic (Grade 2)pancreatitis if not resolved within 28 day s 
Disease progression while on bosutinib treatment. The following events are 
considered disease progression:
Accelerated phase (AP) as defined b y any of the following:
≥15% blasts in the peripheral blood or bon e marrow aspirate, but < 30% blasts 
in both the peripheral blood and bone marrow aspirate.
≥30% blasts plus promyelocy tes in peripheral blood or bone marrow aspirate.
≥20% basophils in the peripheral blood.
Thrombocy topenia (< 100 x 109/L) that is unrela ted to therapy .
Blast crisis (BC) as defined by  any of the following:
≥30% blasts in peripheral blood or bone marrow aspirate
Appearance of extramedullary  involvement other than hepatosplenomegal y 
proven b y biopsy (i.e. chloroma).
QTcF at time of switch > 480msec or inability  to determine QTc interval
7.1.2.3 Information to be collected on screening failures
Patients who sign an informed 
consent but fail to be randomized for any reason will be 
considered a screen failure. The reason for not being randomized will be entered on the 
Screening Phase Disposition Page. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for Screen Failure patients. No other data 
will be entered into the clinical database for patients who ar e screen failures, unless the patient 
experienced a Serious Adverse Event during the Screening Phase (see Section 
8for SAE 
reporting details). If the patient fails to be randomized, the I RT must be notified within 2 day s 
of the screen fail that the patient was not randomized.
7.1.2.4 Patient demographics and other baseline characteristics
Patient demographics and baseline characteristics collected will include the following: date of 
birth, gender (and child bearing potential for female), race and ethnicity, height, weight, all 
relevant medical history  including cardiovascular disease history , CML disease history , 

Novartis Confidential Page 96
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
including mutation status, and prior and concomitant medication including prior TKI therap y 
and a ntineoplastic medication.
Physical examination including extramedullary  involvement, performance status, vital signs, 
ECGs, and laboratory  assessments will be performed at screening.
Significant findings that were present prior to the signing of informed c onsent must be included 
in the Relevant Medical History /Current Medical Conditions page on the subject’s eCRF. 
Significant new findings that begin or worsen after informed consent must be recorded on the 
AE page of the patient’s eCRF.
The central reading of the screening ECGs as well as the results of the RQ-PCR and the bone 
marrow aspirate must be available prior to randomization and first dose of study  treatment to 
evaluate eligibility  and to stratify  the patient.
7.1.2.5 Local recruitment procedures -Japan
Given the limited safet y data available in Japanese patients, 
specific recruitment and data 
monitoring procedures will be put in place for Japanese patients randomized to asciminib.
Randomization of these patients will be staggered to avoid enrollment of more th an one patient 
on the same day. Safety parameters from a minimum of 2 patients treated on the asciminib arm 
will be reviewed for determin ingthe appropriateness of continuing patient enrollment in Japan .
7.1.3 Run
-in period
Not applicable.
7.1.4 Treatment period
There is no fixed duration of treatment planned per patient. All patients will be given the 
opportunity  to receive study  treatment until the end of study  treatment period as defined in 
(Section 4.3).
During the treatment phase, the patients will receive either asciminib treatment 40 mg BID or 
bosutinib 500 mg QD according to randomization. The dose can be modified, if required from 
the perspective of tolerance, following the guidance in Section 6.2 andSection 6.3 . Treatment 
will be administered until patient experiences treatment failure, unacceptable toxicity , disease 
progression, death, lost to follow -
up and/or treatment is discontinued at the discretion of the 
investigator or withdrawal of consent.
The patients are advised to adhere to the food restrictions during the treatment (fasting status 
regarding stud y treatment administration, avoidance of prohibi ted concomitant medication).
7.1.5 Visit windows
Study  visits from Week 1 Day 1 to Week 2 Day  1 / S-Week 1 Day  1 to S-Week 2 Da y 1  should 
be completed on the designated date [with an allowed “visit window” of +/ -1 day for Week 2 
Day 1 /
S-Week 2 Day  1]
Study  visits from Week 4to Week 16 / S
-Week 4to S-Week 16should be completed every  2 
weeks on the designated date [with an allowed “visit window” of +/ -1 day ]

Novartis Confidential Page 97
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Study  visits from Week 20to Week 96 / S-Week 20to S-Week 96should be completed every 
4 wee ks on the designated date [with an allowed “visit window” of +/ -2 day s]
Study  visits from Week 108to EOT / S-Week 108to S-EOT should be completed every  12 
weeks on the designated date [with an allowed “visit window” of +/ -7 day s]
A delay ed visit will have no impact on the next planned visit. The next visit should be completed 
as scheduled in order to avoid accumulation of additional weeks.
7.1.6 Discontinuation of study treatment
Patients m
ayvoluntarily discontinue from thestudy  treatment forany reason atanytime.Ifa
patient decides todiscontinue from the study  treatment, theinvestigator should make a 
reasonable effort (e.g. telephone, e-mail,letter) tounderstand theprimary reason forthis
decision and record thisinform ation inthepatient ’schart andontheappropriate e CRF pages.
They maybe conside redwithdrawn ifthey state an intention towithdraw, failtor eturnfor vis its,
orbeco me lost tofollow - upfor an yother reason.
The investigator should discontinue study  treat mentfora given patient if,he/she believes that
continua tionwould bedetrimental tothe patie nt’sw e ll-being. Patients who discontinue study 
treatment should undergo an end of treatment visit.
For patients who discontinue treatment in treatment period or switch treatmen t period for 
reasons other than death, lost to follow -up, or withdrawal of consent , the patient should enter 
the survival follow -up phase. Survival visit assessments (survival, antineoplastic therapies, stem 
cell transplant and progression) should be performed every  12 weeks until documented death, 
lost to follow -
up, withdrawal of consent or until the end of the study .This visit can be conducted 
by telephone.
Patients who discontinue the study  treatment for anadverse event suspected to be related to 
study  drug or an abnormal laboratory  value suspected to be related to study  drug must be 
followed as described in Section 8
Patients may  also be discontinued fro m the study  treatment if any of the following occurs:
discovery  of patient ineligibility
errors in treatment compliance [study  treatment, other prescribed or non- prescribed 
medications]
missed/unscheduled/off schedule/incomplete/incorrect assessments
major protocol deviation
use of prohibited treatmentrefer toSection 14 -Appendices
any other protocol deviation thatresults inasignif
icantrisk tothepatient’s saf ety
In addition to the general discontinuation criteria, the following study specific criteria will also 
require discontinuation of study  treatment :
In the event of detection of T315I or V299L mutations at any  time the patient must be 
discontinued from the study treatment .
In the event of a pregnancy  during study , if a patient wants to pursue the pregnancy  then 
patient must be discontinued from the study  treatment. However, in the event of a 

Novartis Confidential Page 98
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
spontaneous miscarriage or in the event of elective abortion, the patient is permitted to 
continue study  treatmen t.
In the event of treatment failure the patient must be discontinued from the study treatment . 
Patients randomized to bosutinib treatment experiencing treatment failure may  switch to 
asciminib treatment. The following events will constitute ‘treatment fai lure’, and are based 
on the ELN criteria (Baccarani et al 2013) defining failure of a second line treatment:
No CHR or > 95% Ph+ metaphases at three months af ter initiation of therapy or 
thereafter
BCR -ABL1 ratio > 10% IS and/or > 65% Ph+ metaphases at six months af ter 
initiation of therapy  or thereafter
BCR -ABL 1ratio > 10% IS and/or > 35% Ph+ metaphases at 12 months after 
initiation of therapy  or thereafter
Loss of CHR, CCy R or PCy R at any  time after initiation of therap y 
Detection of new BCR -ABL 1mutations which potentially  cause resistance to study  
treatment (asciminib or bosutinib) at any  time after initiation of therap y 
Confirmed loss of MMR in 2 consecutive tests (Section 7.2.1.1
)
New clonal chromosome abnormalities in Ph+ cells: CCA/Ph+: at any  time after 
initiation of therapy  
In the event of disease progression the patient must be discontinued from the study
treatment . The following events are considered disease progression.
1.CML -related death (an y death during treatment or follow -up if the principal cause of death 
is marked as “stud y indication” in the eCRF b y the investigator, or if the death occurred 
subsequent to documented progression to AP/B C and the cause of death is reported as 
“unknown” or not reported by  the investigator)
2.Accelerated phase (AP) as defined b y any of the following:
≥ 15% blasts in the peripheral blood or bone marrow aspirate, but < 30% blasts in 
both the peripheral blood an d bone marrow aspirate
≥ 30% blasts plus promyelocy tes in peripheral blood or bone marrow aspirate
≥ 20% basophils in the peripheral blood
Thrombocy topenia (<100 x 10 9/L) that is unrelated to therapy
3.
Blast crisis (BC) as defined by  any of the following:
≥ 30% blasts in peripheral blood or bone marrow aspirate
Appearance of extramedullary  involvement other than hepatosplenomegal y proven b y 
biopsy  (i.e., chloroma).
7.1.7 Withdrawal of consent
Subjects may voluntaril y withdraw consent toparticipate inthestudy foranyreason at any 
time.Withdrawal of consent occurs only when asubject:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data

Novartis Confidential Page 99
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
In this situation, the investigator should make a reasonable effort (e.g. t elephone, e- mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been col lected at subsequent visits will be considered missing. 
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table. 
Novartis will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples un til their time of withdrawal) according to applicable 
law.
For US and Japan: Allbiological samplesnot yet analyzed at the time of withdrawal may
still be used for further testing/anal ysis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and Rest of World : All biological samples not yet analy zed at the time of withdrawal 
will no longer be used, unless permitted by applicable law. They  will be stored according to 
applicable legal requirements.
7.2 Assessment ty pes
7.2.1 Efficacy assessments
7.2.1.1 Molecular response
Molecular response (MR) will be assessed in all patients randomized to each treatment arm as 
well as in patients that switch study  treatment from bosutinib to asciminib.
Levels of BCR -ABL 1transcripts will be determined by  real-time quantitative PCR (RQ -PCR) 
testing of peripheral blood and anal yzed at a central testing laboratory . Log reduction in BCR -
ABL 1transcripts levels from the standardized baseline value, or the percent ratio of BCR -ABL 1
transcripts versus control gene (ABL) transcripts converted to a reference standard, 
international scale ( Hughes and Branford 2006 ), will be calculated for each sample.
Major molecular response and related variables are defined as the following :
Rate of Major Molecular Response (MMR) where MMR is defined as a ≥ 3.0 log 
reduction in BCR -ABL 1transcripts compared to the standardized baseline equivalent to ≤ 
0.1 % BCR -ABL 1/ABL % by  international scale as measured by  RQ-PCR, confirmed by  
duplicate anal ysis of the same sample
Time to MMR defined as the time from the date of randomization to the date of the first 
documented MMR,
Duration of MMR defined as the time from the date of first documented MMR to the 
earliest date of loss of MMR, prog ression to AP or BC, or CML -related death.

Novartis Confidential Page 100
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Loss of MMR is defined as increase of BCR- ABL 1/ABL to >0.1% by international scale (IS) 
in association with a ≥ 5-fold rise in BCR -ABL 1from the lowest value achieved on study 
treatment and replicated by a second analysis of the same sample. Loss of MMR must be 
confirmed by subsequent sample analysis within 4to 6 weeks showing loss of MMR associated 
with a ≥ 5-fold rise in BCR -ABL1 from the lowest value achieved on study treatment, unless it 
is associated with confirmed loss of CHR or loss of CCyR or progression to AP/BC or CML -
related death. Mutational analy sis will be performed at a Novartis designated laboratory  by 
Sanger sequencing at 
Week 1 Day  1, upon confirmed loss of MMR and/orat end of treatment. 
If the result at Week 1 Day 1is positive for a mutation, analysis will be performed every  12 
weeks.
The blood samples will be taken as described in Table 7 -1,Table 7 - 2 and Table 7 -3.
Table 7
-3 Blood samples (efficacy  primary  endpoint)
Sample Type Volume Visit Timepoint
Blood for BCR -ABL1
quantification by RQ -PCR20 mL Screening/Baseline / S-Screening/ S-Baseline* Pre-dose
20 mL Week 4/ S-Week 4 Pre-dose
20 mL Week 8/  S-Week 8 Pre-dose
20 mL Week12/  S-Week 12 Pre-dose
20 mL Week16/  S-Week 16 Pre-dose
20 mL Week24/  S-Week 24 Pre-dose
20 mL Week36/  S-Week 36 Pre-dose
20 mL Week48/  S-Week 48 Pre-dose
20 mL Week60/  S-Week 60 Pre-dose
20 mL Week72/  S-Week 72 Pre-dose
20 mL Week84/  S-Week 84 Pre-dose
20 mL Week96/  S-Week 96 Pre-dose
20 mL Every 12 weeks thereafter up to end of study 
treatment     Pre-dose
20 mL EndofTreatment / S-End of Treatment Anytime
Blood for BCR -ABL1 Mutation
analysi s by Sanger 
Sequencing5 mL Week 1Day1 /S- Week 1 Day 1 * Pre-dose
No sample collected 
-  testing is 
performed on the 
“Blood for BCR -
ABL1 quantification 
by RQ -PCR” sampleUpon confirmed loss of MMR and/or End of 
Treatment / S-End of TreatmentAnytime
Blood for BCR -ABL1 Mutatio n
analysi s only for patients with
mutations at Week 1 Day 1No sample collected 
-  testing is 
performed on the 
“Blood for BCR -
ABL1 quantification 
by RQ -PCR” sampleWeek 12 and ever y 12 weeks thereafter up to 
end of study treatmentAnytime
*Assessment does not need to be completed during the visit for patients in the treatment switch if already 
collected during the EOT or the treatment switch screening visit .

Novartis Confidential Page 101
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
During the study , peripheral blood samples will be collected into PAXgene ™Blood RNA tubes 
for all RQ-PCR assessments. Detailed instructions for the collection, handling, and shipment of 
RQ-PCR and mutation samples are outlined in the [CABL 001A2301 Laboratory  Manual] .
7.2.1.2 Bone marrow analy sis and cytogenetics
Cytogenetic response will be assessed locally as the percentage of Ph+ metaphases in the bone 
marrow and is defined as the following (a review of a minimum of 20 metaphases is required):
Complete (CCy R) -0% Ph+ metaphases
Partial (PCy R) ->0 to 35% Ph+ metaphases
Major (MCy R) -0 to 35% Ph+ metaphas es
Minor (mCy R) ->35 to 65% Ph+ metaphases
Minimal ->65 to 95% Ph+ metaphases
None ->95 to 100% Ph+ metaphases.
Bone marrow 
aspirate for cytogenetic analyses will be performed at screening/baseline 
(performed up to 56days prior to Week 1 Day 1), at Week 24/S- Week 24, 48/S-48, 72/S-72, 
96/S-96 as long as patient has not achieved MMR and at end of treatment ( S-end of treatment 
as specified in Table 7-1 and Table 7 -2. For patients on the bosutinib arm an unscheduled bone 
marrow assessment at week 12 may be performed to evaluate cytogenetic response in 
consideration for potential dose escalation.
Quantification of the percentage of Ph+ chromosome metap
hases, number of metaphases, 
number positive for Ph chromosome, additional chromosomal abnormalities as well as data 
from cytologic evaluation (microscopic analy sis) of percentage of blasts and prom yeloc ytes 
will be recorded on the Bone Marrow eCRF. These exams will be performed and analyzed 
locally . Fluorescent In- situ hy bridization (FISH) analy sis will not be accepted.
7.2.1.3 Hematologic response
A complete hematologic response (CHR) is defined as all of the following present for ≥ 4 weeks:
WBC count <10 x 109/L
Platelet count <450 x 109/L
Basophils <5%
No blasts and prom yelocytes in peripheral blood
Myelocy tes + metam yelocytes < 5% in peripheral blood
No evidence of extramedullary  disease, including spleen and liver
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by the assessments described below as well as collecting of the adverse 
events at every  visit. For details on AE collection and reporting, refer to Section 8 .Significant 
findings that were present prior to the signing of informed consent must be included in the 
Relevant Medical History/Current Medical Conditions page on the patient’s eCRF. Significant 
new findings that begin or worsen after informed consent mu st be recorded on the AE page of 
the patient’s eCRF.

Novartis Confidential Page 102
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
7.2.2.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes , 
extremities, vascular and neurological. Information about the physical examination must be 
present in the source documentation at the study  center and will be collected on the following 
visits as specified in Table 7 -1and Table 7 -2:
Screening /
S-Screening
Week 1 Day  1/ S-Week 1 Day 1
Every  2 weeks from Week 4 to Week 16 / S-Week 4 to S- Week 16. Week 6, 10 and 14 / 
S
-Week 6, 10 and 14 assessments mus t be performed in case of previous or newl y 
occurring adverse events.
Every  4 weeks from Week 16 to Week 96 / S-Week 16 to S- Week 96
Every  12 weeks from Week 96 to EOT / S
-Week 96 to S- EOT
End of treatment / S
-End of treatment visit or early  discontinuation / S-early  
discontinuation visit in case of premature discontinuation.
Significant findings that were present prior to the signing of informed consent must be included 
in the Medical History  page on the patient’s eCRF. Significant new findings that begin or 
worsen after informed consent must be recorded on the Adverse Event page of the patient’s 
eCRF. Presence of extramedullary  leukemic involvement will be checked with each physical 
examination as outlined above. Findings on physical examination consistent with extra-
medullary  leukemic involvement will be recorded (e.g. liver and spleen size, any other organ 
involvement).
7.2.2.2 Vital signs
Vital signs include blood pressure (supine position preferred 
when ECG is collected), pulse 
measurement, and bod y temperature and must be performed at the following visits as specified 
in Table 7-1 and Table 7 -2:
Screening / S
-Screening
Week 1 Day  1/ S-Week 1 Day 1
Week 2 Day  1/ S-Week 2 Day  1
Every  2 weeks from Week 4 to Week 16 / S-Week 4 toS-Week 16
Every  4 weeks from Week 16 to Week 96 / S-Week 16 to S- Week 96
Every  12 weeks from Week 96 to EOT / S
-Week 96 to S- EOT
End of treatment / S
-End of treatment visit or early  discontinuation / S-early  
discontinuation visit in case of premature discontinuation.
7.2.2.3 Height and weight
Height in centimeters (cm) will be measured at screening onl y.
Body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be 
measured at screening and at subsequent time points as specified in Table 7 -1and Table 7 -2:
Screening / S
-Screening

Novartis Confidential Page 103
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Week 1 Day  1/ S-Week 1 Day 1
Every  12 weeks from Week 12 to EOT / S -Week 12 to S-EOT
End of treat ment visit / S-End of treatment or early  discontinuation / S-early  
discontinuation visit in case of premature discontinuation.
7.2.2.4 Performance status
ECOG Performance status scale (Table 7-4) will beused asdescribed in theTable 7-1, Table 
7-2andTable 7 - 4:
Screening / S
-Screening
Week 1 Day  1/ S-Week 1 Day 1
Every  2 weeks from Week 4 to Week 16 / S-Week 4 to S- Week 16
Every  4 weeks from Week 16 to Week 96 / S
-Week 16 to S- Week 96
Every  12 weeks 
from Week 96 to EOT / S-Week 96 to S- EOT
End of treatment / S
-End of treatment visit or early  discontinuation / S-early  
discontinuation visit in case of premature discontinuation.
More frequent examinations may be performed at the investigator’s discretion, if medically 
indicated.
Table 7-4 ECOG Performance status scale
Description Grade
Fully active, able to carry on all pre -disease activities without restriction. 0
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature e.g. light housework, office work.1
Ambulatory and capable of all self -care but unable to carry out any work activities. Up and 
about more than 50% of waking hours.2
Capable of only limited self -care, confined to bed or chair more than 50% of waking hours. 3
Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair. 4
Dead. 5
7.2.2.5 Laboratory  evaluations
Central laboratory  will be used for analysis of hematology , biochemistry , coagulation, serum 
pregnancy  and hepatitis marker specimens collected (safet y monitoring) as specified inTable 
7-1, Table 7 -2andTable 7 -5. Details on the collections, shipment of the samples and reporting 
of results by the central laboratory  are provided to investigators in the [CABL 001A2301 
Laboratory  Manual] . The time windows granted for laboratory  evaluations are identical with 
the corresponding visit time windows for each visit (see Section 7.1.5).
Local laboratory  analysis are allowed if there is a clinical suspi cion of abnormal laboratory
values which is supported by a reported adverse event and for hematology  assessments at Week 
6, 10 and 14.

Novartis Confidential Page 104
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Table 7-5 Central clinical laboratory  parameters collection plan
Test Category Test Name Frequency
Hematology Hemoglobin, platelets, red blood cells, white 
blood cells, W BC morphology with 
differential (basophils, e osinophils, 
lymphocytes, monocytes, n eutrophils, 
promyelocytes, myelocytes, 
metamyelocytes, blast and other)Screening/ baseline, Week 1 Day 1, 
Week 2 Day 1, every 2 weeks from week 
4 up to week 16, every 4 weeks up to 
week 96, and every 12 weeks thereafter, 
EOT and as clinically indicated / S-
Screening/ S-baseline* , S-Week 1 Day 1, 
S-Week 2 Day 1, every 2 weeks from S-
week 4 up to S-week 16, every 4 weeks 
up to S-week 96, and every 12 weeks 
thereafter, S-EOT and as clinically 
indicated
Chemistry Hemoglobin A1c Screening/ baseline, Week 12 and as 
clinically indicated / S-Screening/ S-
baseline* , S-Week 12 and as clinically 
indicated
Chemistry Creatinine clearance Screening/b aseline / 
S-Screening/S -baseline*
Chemistry Albumin, alkaline phosphatase, ALT (SGPT), 
AST (SGOT), total calcium, total calcium 
(corrected for albumin), c reatinine , creatine 
kinase, potassium, magnesium, s odium, 
phosphate (inorganic p hosphorus ), direct 
bilirubin, indirect bilirubin, total bilirubin, total 
cholesterol, LDL cholesterol , HDL
cholesterol , total protein, triglycerides, blood 
urea or Blood Urea Nitrogen (BUN) , uric 
acid, amylase, lipase, glucose (fasting)Screening/ baseline, Week 1 Day 1, 
Week 2 Day 1, every 4weeks from week 
4 up to week 96, and every 12 weeks 
thereafter, EOT, and as clinically 
indicated / S-Screening/ S-baseline *, S-
Week 1 Day 1, S-Week 2 Day 1, every 4
weeks from S-week 4 up to S-week 96, 
and every 12 weeks thereafter, S-EOT, 
and as clinically indicated
Coagulation International Normalized Ratio (INR)
Hepatitis markers HbsAg, HbcAb /anti -Hbc Screening/ baseline **
Serum Pregnancy 
test (if applicable)Serum ß-HCG testing Screening/ baseline, every 4 weeks up to 
week 96, and every 12 weeks thereafter, 
EOT, unscheduled / S-Screening/ S-
baseline* , every 4 weeks up to S-week 
96, and every 12 weeks thereafter, S-
EOT, unscheduled
*Assessment does not need to be completed during the screening visit for patients in the treatment switch if 
already collected during the EOT.
**Not applicable for patients being assessed for treatment switch as part of the treatment switch 
screening/baseline visit.
7.2.2.5.1 Hematology
Hematology  labs are to be anal yzed at each scheduled visit by  a central laboratory (Week 6, 10 
and 14 assessments can be performed at site or at any  peripheral local laboratory )as specified 
in Table 7-1and Table 7-2. Hematology  includes assessment of hemoglobin, platelets count, 
red blood cells, total white blood cell count (WBC) and a full manual differential count 
including basoph ils, eosinophils, lymphocy tes, monocy tes, neutrophils, promy elocy tes, 
myelocy tes, metam yelocytes, blast and other cells ( Table 7
-5).

Novartis Confidential Page 105
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
7.2.2.5.2 Clinical chemistry
Blood chemistry  labs are to be analyzed at each scheduled visits by a central laboratory as 
specified in Table 7 -1and Table 7-2. Chemistry  includes albumin, alkaline phosphatase, ALT 
(SGPT), AST (SGOT
), total calcium, total calcium (corrected for albumin), creatinine, 
creatinine clearance, creatine kinase, potassium, magnesium, sodium, phosphate (inorganic 
phosphorus ), direct bilirubin, indirect bilirubin, total bilirubin, total cholesterol, LDL
choles terol, HDL cholesterol, total protein, trigly cerides, blood urea,Blood Urea Nitrogen 
(BUN), uric acid, amylase, lipase and fasting glucose. In addition the coagulation parameter 
INR is anal yzed at each scheduled visit.
HbA1c is anal yzed at screening/baseline, week 12 and as clinicall y indicated.
The hepatitis markers HbsAg, HbcAb/anti -Hbc are anal yzed at screening/baseline ( Table 7 -5).
7.2.2.5.3 Pregnancy and assessments of fertility
All women of childbearing potential have to complete a serum pregnancy  test at the screening 
visit, at every  monthl y visit until end of treatment visit. Pregnancy  testing is not required for 
patients who are determined to be post -menopausal. The time windows granted for pregnancy 
testing are identical with the corresponding visit time windows
 for each visit. Refer to Table 7 -
1and Table 7-2of the Visit evaluation schedule s . Serum pregnancy  test will be per formed by 
a central laboratory .
After Week 96 / S-Week 96, monthly  urine pregnancy  test must be performed b y all women of 
child- bearing potential between the three monthly  visits (beginning at Week 100/ S-Week 100).
Urine pregnancy  tests may be performed at the investigational site or at home. Test results 
performed at home should be recorded onto a patient diary  and brought to each scheduled visit 
for the site to review. If a test result indicates a pregnancy , the patient must contact the 
investigator immediatel y.
Pregnancies diagnosed in female patients participating in the study (including female partners 
of male patients) should be recorded on a Clinical Trial Pregnancy Form and reported by the 
investigator to the Oncology  Novartis Chief Medical Office and Patient Safety  (CMO&PS)
Department.
During the whole study , women of childbearing potential should employ the use of highl y 
effective contraception. Highly effective contraception methods are defined in Section 5.3.
Sexually  active males on asciminib treatment must use a condom during intercourse while 
taking the drug and for at least 3 days after stopping treatment and should not father a child 
within this period. A condom is required to be used also by vasectomized men in order to 
preven t delivery  of the drug via seminal fluid
. In addition, male participants must not donate 
sperm for the time period specified above.
7.2.2.6 Cardiac assessments
7.2.2.6.1 Electrocardiogram (ECG)
After the subject has rested approximately  10 minutes in a semi -supine position, standard 12-
lead ECGs must be obtained in triplicate with a recommended minimal interval of 5 minutes 

Novartis Confidential Page 106
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
between each ECG at the time points specified in Table 7-1, Table 7 -2,Table 7 -6and Table 7 -
7. ECGs should be taken before b lood samples for PK if both assessments are scheduled at the 
same time point . In this case recording of ECGs should be planned according to the true time 
of blood sample for PK rather than to the scheduled time point.
Table 7-6 Central ECG collection (all patients)
Week (or Day ) Number of ECGs (per visit) Time of ECG
Screening/Baseline Day -21 
to -1/ S-Screening/ S-
Baseline Day -42 to -1 (all 
patients)3 3 serial ECGs at the screening visit
Week 1 Day 1 / S-Week 1 
Day 1 (all patients)3 3 serial ECGs at 2 h post dose
Week 2 Day 1 / S-Week 2 
Day 1 (asciminib /asciminib 
switch patients )12 3 serial ECGs pre -dose and at 2, 3, 4 h post -
dose
Week2 Day 1 / S-Week 2 
Day 1 (bosutinib)3 3 serial ECGs pre-dose
Week 4 / S-Week 4 (all 
patients)3 3 serial ECGs pre-dose
Week 12 / S-Week 12 (all 
patients)3 3 serial ECGs pre-dose
Week 24 / S-Week 24 (all 
patients)3 3 serial ECGs pre-dose
Week 96 / S-Week 96 (all 
patients)3 3 serial ECGs 30 min* post-dose
Unscheduled (all patients) 3 3 serial ECGs 
* 30 min +/ - 5min allowed
Table 7-7 Central ECG collection plan for patients in full PK asciminib group
Week (or Day ) Number of ECGs (per visit) Time of ECG
Day -21 to -1 3 3 serial ECGs at the screening visit
Week 1 Day 1 3 3 serial ECGs at 2 h post dose
Week 2 Day 1 24 3 serial ECGs pre-dose and at 1, 2, 3, 4, 6, 8, 
12 h post- dose
Week 4 3 3 serial ECGs pre-dose
Week 12 3 3 serial ECGs pre-dose
Week 24 3 3 serial ECGs pre-dose
Week 96 3 3 serial ECGs 30 min *post-dose
Unscheduled 3 3 serial ECGs 
* 30 min +/ - 5min allowed
All ECGs performed will be independently  reviewed. Instructions for the collection and 
transmission of these ECGs to the independent central reader (ERT(Electronic Research 
Technology , Inc.) ) will be provided in the [CABL001A2301 ECG Manual] .
Three serial ECGs (triplicate) should be performed ½ hour prior to dosing for pre-dose 
assessment. The serial ECGs should be taken approximately  5 m inutes apart. All 3 ECGs for 
each time point should be sent to ERT. Readings for QTc prolongation will be based on the 

Novartis Confidential Page 107
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
average seen in the scans for each time point. The enrollment of patients has to be based on 
centrall y assessed QTcF time. If one of the 3 serial ECGs prior to dosing on day 1 shows a 
QTcF ≥ 450 msec (male) or ≥ 460 msec (female) by  automated reading, an immediate manual 
central reading must be requested by  calling ERT. The patient may  not be dosed if the average 
of the manuall y read ECGs confirms a QTcF ≥ 450 msec (male) or ≥ 460 msec (female).
Dose adjustments in case of QT prolongation should be performed per Section 6.3.2 .
Additional unscheduled ECGs may  be repeated at the discretion of the investigator at any  time 
during the study  as clinically  indicated. Unscheduled ECGs with clinicall y significant findings 
should be collected in triplicate. Local cardiologist ECG assessment may  also be performed at 
any time during the study at the discretion of the investigator.
All ECGs, including unscheduled triplicate safety  ECGs with clinically relev ant findings, 
collected during the study should be transmitted to the central core ECG laboratory  for review.
The results of the centrally  assessed ECGs are automatically  transferred into the clinical 
database .
Clinically  significant ECG abnormalities present at screening should be reported on the Medical 
History  eCRF page. New or worsened clinically significant findings occurring after informed 
consent must be recorded on the Adverse Events eCRF page.
7.2.2.6.2 Cardiovascular risk factor assessment
Cardiovascular events (CVE) including ischemic heart disease, peripheral arterial occlusive 
disease and ischemic cerebrovascular events have been reported in CML patients receiving TKI 
therapies as specified in Table 7 -1and Table 7 -2. As both study  treatments in the trial are TKI s 
(asciminib and bosutinib), 
the cardiovascular risk factors (hypertension, tobacco use, raised 
blood glucose (diabetes), physical inactivit y,unhealthy  diet, cholesterol/lipids, overweight and 
obesity ) of each patient will be collected prior to randomization and end of treatment. This will 
also include the patient’s Family  History .
7.2.2.6.3 Echocardiogram
Echocardiograms will be performed to monitor cardiac safety .Assessments are scheduled at 
screening/baseline, Week 20 and end of treatment visits. The echocardiogram will be performed 
and evaluated locall y to assess the left ventricular ejection fraction. Any clinically  significant 
findings will be collected and reported in the database (i.e. reported as adverse events). For 
patients that switch from bosutinib to asciminib treatment , an echocardiogram willno longer
berequired.
7.2.2.6.4 Pulmonary function test
Pulmonary  function test will be performed to monito r cardio -pulmonary  safety.Assessments 
are scheduled at screening/baseline, Week 20 and end of treatment visits. The pulmonary 
function test with the plethy smograph includes the assessment of the lung volumes FEV1, FVC, 
FEV1/FVC, TL C and VC. I n addition the DLCO to evaluate the gas exchange will be assessed 
at the same time points. Any clinicall y significant findings will be collected and reported in the 

Novartis Confidential Page 108
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
database (i.e. reported as adverse events). For patients that switch from bosutinib to asci minib
treatment , the pulmonary function testing will no longer be required.
7.2.3 Pharmacokinetics
Blood samples for asciminib pharm acokinetics will be collected on all study subjects allocated 
to the asciminib treatment arm. Blood samples for full PK profiles will be collected from at 
least 20 patients. These patients will be identified sequentially  at selected sites that are capable 
of serial PK sampling over 12 hours. Asciminib should be taken for at least 3 consecutive days 
without interruption or dose modification prior to full PK day .
Blood samples for asciminib pharmacokinetics will also be collected on patients switching from 
bosutinib to asciminib (see Table 7 - 8). 
For the assessment of asciminib pharmacokinetics in plasma, serial blood samples will be 
collected following asciminib administration at several time-points (see Table 7-1, Table 7-2, 
Table 7 -
8and Table 7 -9below for further details). Remaining plasma samples may be used for 
identification and/or measurement of metabolites of asciminib .
Refer to the [CABL001A2301 Laboratory  Manual ]for detailed instructions for the collection, 
handling, and shipment of PK samples.
Table 7-8 Pharmacokinetic blood collection log (Sparse PK -group -asciminib
arm/asciminib treatment switch patients )
Week /
S-WeekDay Scheduled Time 
PointDose 
Reference IDPK Sample No Blood Volume 
(mL)
1 1 2 h (± 10 min) 101 101 2
2 1 0 h (Pre -dose)a102/2001b102 2
1 2 h (± 10 min) 102 103 2
1 3 h (± 15 min) 102 104 2
1 4 h (± 15 min) 102 105 2
4 Any 0 h (Pre -dose)a103/3001b106 2
12 Any 0 h (Pre- dose)a104/4001b107 2
24 Any 0 h (Pre -dose)a105/5001b108 2
96 Any 0 h (Pre -dose)a106/6001b109 2
Unscheduled 1001+
aPre-dose PK sample should be taken immediately prior to the next administration of asciminib. PK samples 
on Week 2 Day 1 should be taken before and after the morning dose (i.e. 1stdose of the day). PK samples on 
other weeks may be taken immediately prior to the morning dose (i.e. 1stdose of the day) or the evening dose 
(i.e. 2nddose of the day).
bThe first dose reference ID refers to the first dose administered after PK sampling and the second dose 
reference ID refers to the last dose administered prior to the PK sampling.

Novartis Confidential Page 112
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
7.2.5 Resource utilization
The measures of healthcare Resource Utilization (RU) to be collected include: hospitalization
(H), emergency  room (ER) visit, general practitioner (GP) visits, specialist (Sp) visit and urgent 
care (UC) visit. These measures will be used to derive the economic impact of asciminib and 
bosutinib.
Hospitalization visits will also record the number of days in ward and the type of ward (hospital 
unit) and the discharge status. At each RU collection, the reason for the visit (i.e. related to 
CML , AErelated to CML therapy or other reason) will be collected in order to quantify  the 
impact of asciminib and bosutinib on healthcare resources.
The RU assessment will be completed at each scheduled clinical trial visit as specified in Table 
7-1; the RU will be completed by the investigator however information with respect to the 
number of GP, UC, Sp or ER visits will be ascertained from the 
patient.
All attempts to collect as much information from the patient as possible should be made in order 
to minimize selection bias.
7.2.6 Patient reported outcomes
The MDASI CML, PGIC, WPAI  along with EQ-5D-5L (EuroQol Group (1990) , Brooks (1996) ,
Herdman et al (2011) ) will be used to compare data on the patient’s disease -related symptoms 
and health -related quality of life from baseline to EOT between the treatment arms. The WPAI 
will be used to ass ess work productivity  and activity  impairment related to the patient’s CML . 
All measures will assess differences between the treatment arms. All tools require patient’s 
direct completion and will be administered utilizing an electronic device for data coll ection .
Patients with an evaluable baseline score and at least one evaluable post baseline score during 
the treatment period will be included in the change from baseline analy ses. Missing data items 
in a scale will be handled according to the manual for each instrument. No imputation will be 
applied if the total or subscale scores are missing at a visit.
The patient should be given the questionnaire(s) to be completed at the scheduled visit before 
any clinical assessments are conducted as specified inTable 7-1. Completion of all 
questionnaires is mandatory ; they  cannot be skipped. In the event a patient refuses to complete 
the questionnaire(s), the patient’s refusal should be documented in the study  data capture system 
and should not be captured as a protocol deviation. Patient questionnaires should be completed 
in the language most familiar to the patient.
The patient should be given sufficient space and time to complete the questionnaires and the 
adminis
tered questionnaire should be reviewed for completeness. If missing responses are noted, 
patients should be encouraged to complete an y missing responses. 
Completed questionnaire(s) and any unsolicited comments written by the patient should be 
reviewed andassessed by the investigator for responses which may indicate potential AEs or 
SAEs before any  clinical study  examinations. This assessment should be documented in study 
source records. If AEs or SAEs are confirmed, study  investigators should not encourage the 
patient to change responses reported in the completed questionnaires. Study investigators must 
follow reporting instructions outlined in Section 8 (e.g. reference “Adverse Events” Section) of 
the study  protocol.

Novartis Confidential Page 113
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
MDASI-CML
The M.D. Anderson S ymptom I nventory  –Chronic M yeloid Leukemia (MDASI -CML) is a 26 
item self -administered questionnaire for adult CML  patients. Twenty  of the items measure the 
severit y of disease -related sy mptoms and are scored fr om 0 (Not present) to 10 (As Bad as you 
can imagine) and 6 items that measure s ymptom interference with daily life scored from 0 (Did 
not interfere) to 10 (Interfered completely ). Descriptive statistics will be provided for the 
MDASI -CML  symptom score and interference score, and the change in the MDASI -CML 
symptom score and interference score from baseline to all available time points to the end of 
study . Additional anal ysis may  be performed and details will be described in the anal ysis plan.
EQ-5D-5L
EQ-5D- 5L is a two-part standardized instrument for measuring health outcomes in a wide range 
of health conditions and treatments. It consists of a descriptive system and a visual analogue 
scale (EQ VAS). The descriptive system comprises the following 5 dimensio ns: mobility , self -
care, usual activities, pain/discomfort and anxiety /depression. Each dimension has 5 levels: no 
problems, slight problems, moderate problems, severe problems and extreme problems (or 
unable to perform the activity ). 
The EQ VAS records the respondent’s self-rated health on a 
vertical, visual analogue scale where the endpoints are labeled ‘Best imaginable health state’ 
and ‘worst imaginable health state’. The health states derived from the descriptive system can 
be summarized into a single index score that provides a simple measure of health for clinical 
and economic appraisal. Descriptive statistics will be provided for EQ-5D- 5L health index score 
and for the EQ VAS, at each scheduled assessment time point. There should be only ONE 
response for each dimension. Missing values can be coded as ‘9’. Ambiguous values (e.g. 2 
boxes are ticked for a single dimension) should be treated as missing values. Additional analy sis 
may be performed and details will be describ ed in a separate anal ysis plan.
WPA I
The Work Productivity  and Activity  Impairment Questionnaire (WPAI) is a four-item 
questionnaire which is intended to measure work and activity  impairment associated with CML  
for those who self-identify  as currently  employ ed for pay. This questionnaire measures self-
reported productivity  loss associated with CML during the past seven days. It consists of 
questions about absence from work due to CML , hours spent at work, the reduction in 
productivity  at work attributed to CML , and the reduction in produc tivity while performing 
regular activities. WPAI outcomes are expressed as impairment percentages, with higher 
numbers indicating greater impairment and less productivity , i.e., worse outcomes, Scoring will 
be done according to WPAI  instrument guidance resulting in four scores including: Percent 
work time missed due to problem; percent impairment while working due to problem; Percent 
overall work impairment due to problem; and, percent activity  impairment due to problem.
Change from baseline in WPAI  at each visit, where measured, will be done for each of the four 
derived scores.
PGIC
The Patient Global Impression of Change is comprised of a single question intended to measure 
a patient’s perspective of improvement or deterioration over time relative to treatment. The 

Novartis Confidential Page 114
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
PGIC uses a seven -point scale where one (1) equals very  much improved and seven (7) equals 
very much worse. A summary  of Patient Global Impression of Change (PGI C) at each visit, 
where measured will be provided.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.
Abnorm al laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events eCRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s eCRF. Adverse event monitoring should 
be continued for at least 30 days (or 5 half-lives, whichever is longer) following the last dose 
of study  treatment. Adverse events (including lab abnormal ities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underly ing signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.
Adve rse events will be assessed and graded according to the Common Terminology  Criteria for 
Adverse Events (CTCAE) version 4.03. Grade 1 to 5 will be used to characterize the severit y 
of the Adverse Event.
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderate, severe, 
and life -threatening, death related to the AE corresponding respectively toGrades 1 -5, will be 
used. Information about any deaths (related to an Adverse Event or not) will also be collected 
through a Death form .
The occurrence of adverse events should be sought by  non-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunt eered by the patient 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1-5)
2.Itsduration (Start and end dates)
3.Its relationship to the study  treatment (Reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)

Novartis Confidential Page 115
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
and which seriousness criteria ha ve been met
7. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
If the event worsens the event should be reported a second time in the eCRF noting the start 
date when the event worsens in toxicity . For grade 3 and 4 adverse events only, if improvement 
to a lower grade is determined a new entr y for this event should be reported in the eCRF noting 
the sta rt date when the event improved from h aving been Grade 3 or Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event eCRF.
Once an adverse eve nt is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Natural progression or deterioration of the malignancy  under treatment (including loss of 
response, progression to accelerated phase or blast crisis and death due to disease progression), 
will be rec orded as part of the efficacy  evaluation and should NOT be reported as an AE/SAE.
Signs and symptoms clearly  associated with the disease under study  should NOT be reported 
as AEs unless they  are newly  emergent (i.e. not previously  observed in the patient), judged by 
the 
Investigator to be unusually  severe or accelerated, or if the Investigator considers 
deterioration of disease -related signs and symptoms to be caused directly  by the study  drug. If 
there is any uncertaint y about an AE being due solely  to thedisease under study , it should be 
reported as an AE or SAE as appropriate.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events eCRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality  may be required b y 

Novartis Confidential Page 116
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
the protocol in which case the lab abnormality  would still, by definition, be an adverse event 
and must be reported as such.
8.1.3 Adverse events of special interest
Adverse events of special interest (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitoring and rapid communication by  the investigator to the sponsor may  be 
appropriate. Such events may require further investigation in order to characterize and 
understa nd them.
Adverse events of special interest are defined on the basis of an ongoing review of the safet y 
data. AESIs are discussed in detail in the [Asciminib Investigator ’sBrochure] .
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospitalization or prolongation of existing hospitali zation,
Note that hospitalizations for the following reasons should not be reported as serious 
adve rse events:
Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened si nce signing the informed consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an emergency
 outpatient basis that does not result in hospital 
admission and involves an event no t fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
8.2.2 Reporting
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study  treatment must be reported to Novartis within 24 hours of learning of its occurrence.
Any additional information for the SAE including complications, progression of the initial SAE, 
and recurrent episodes must be reported as follow -up to the original episode within 24 hours of 
the investigator receiving the follow -up information. An SAE occurring at a different time 

Novartis Confidential Page 117
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
interval or otherwise considered completely  unrelated to a previousl y reported one should be 
reported separa tely as a new event.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to Novartis if the investigator suspects a causal relati onship to the study  treatment.
Information about all SAEs is collected and recorde d on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis. Detailed 
instructions regarding the SAE submission process and requirements for signatures are to be 
found in the inv estigator folder provided to each site.
Each re-occurrence, complication, or progression of the original event should be reported as a 
follow -up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurr ence) and is thought to be related to the Novartis study  treatment, an oncology  Novartis 
Chief Medical Office and Patient Safety  (CMO&PS) department associate may urgently  require 
further information from the investigator for Health Authority  reporting. No vartis may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (SUSARs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.
8.3 Emergency  unblinding of treatment assignment
Not applicable.
8.4 Pregnancies
To ensure patient s afety, each pregnancy occurring while the patient is on study treatment must 
be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology  Novartis Chief Medical Office and Patient Safety (CMO&PS ). 
Pregnancy  follow -up should be recorded on the same form and should include an assess ment 
of the possible relationship to the study  treatment any pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcome should be collected for the female partners of any male who received
asciminib treatment in this study . Consent to re port information regarding pregnancy  outcome
should be obtained from the mother.

Novartis Confidential Page 118
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
For all pregnancies with live birth and/or unknown outcome the newborn has to be followed up 
to obtain infant health status and developmen t up to twelve months after delivery .
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided asciminib 
Invest igator ’sBrochure or bosutinib label . Additional safety  information collected between IB 
updates will be communicated in the form of Investigator Notifications. This information will 
be included in the patient informed consent and should be discussed with the patient during the 
study  as needed.
8.6 Data Monitoring Committee
This study  will institute a data monitoring committee (DMC) which will function independentl y 
of all other individuals associated with the conduct of this clinical trial, including the 
site 
investigators participating in the study . The DMC will be constituted prior to the randomization 
of the first patient. The DMC will be responsible to review safet y data at approximately  6
months after the first randomized patient has started study  treatmen t. Subsequent reviews will 
be conducted approximately  every 6 months on an as and when needed basis thereafter (i.e. if 
significant safet y findings are noted) . This includes but does not limit the role of the DMC to 
evaluate these data and to provide recom mendations to the sponsor to continue, modify
 or stop 
the study  early. The DMC will be in place at least until the c onduct of the primary  anal ysis.
It is expected that the DMC will consist at a minimum of two physicians with appropriate 
disease area qualifications and one statistician. There will be a meeting with the DMC 
describing their roles and responsibilities and discussing potential data format and process 
issues prior to the finalization of DMC charter.
It is envisioned that the DMC may  make certain ty pes of recommendations, namely :
No safet y concerns, ethical to continue the study as planned
Serious safet y concerns precluding further study treatment, regardless of efficacy
Recommendation to continue the study  but proposing an amendment to the protocol (e.g., 
incorporate an additional safet y assessments)
8.7 Steering Committee
In order to monitor study conduct, a Steering Committee (SC) will be established comprising 
investigators participating in the trial. Additionally  two sponsor representatives (a physician 
and a statistician) will be active members of this committee.
The SC will ensure transparent management of the study  according to the protocol through 
recommending and approving modifications as circumstances require. Novartis will make final 
decisions on trial conduct based on SC recommendations. Together with the clinical trial team, 
the SC will review protocol amendments as appropriate, and also develop recommendations for 
publications of study  results including authorship rules. The details of the role of the Steering 
Committee will be defined in a Steering Committee charter.

Novartis Confidential Page 119
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
9 Data collection and management
9.1 Data confidentiality
Information about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose t hat information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collec ted prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the subject 
experienced an y new or wors ened AEs) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subject satisfies protocol age requirements and 
to enable appropriate age -related normal ranges to be used in assessin g laboratory  test results.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and eCRFs with the investigators and 
their staff. During the study, the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source d ocuments in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).

Novartis Confidential Page 120
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the eCRF entries. Novartis monitoring standards require full verification for 
the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the eCRFs 
are performed according to the study -specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by the protocol into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully validated secure web-enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they 
have been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF is complete, 
accurate, and that entry  and upda tes are performed in a timely  manner.
Data collected by third parties (biochemistry , PCR assessments, biomarkers, PK) will be sent 
electronically  to Novartis.
9.4 Database management and quality  control
For studies using eCRFs, Novartis personnel (or designate d CRO) will review the data entered 
by investigational staff for completeness and accuracy . Electronic data queries stating the nature 
of the problem and requesting clarification will be created for discrepancies and missing values 
and sent to the investig ational site via the EDC system. Designated investigator site staff are 
required to respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data will be processed centrall y and the results will be sent electronically to 
Novartis (or a designated CRO).
Randomization codes and data about all study  treatments dispensed to the patient and all IRT 
assigned dosage changes will be tracked usi ng the Novartis I nteractive Response Technology .
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copies 
of the patient data for archiving at the investigational site.
10 Statistical methods and data analy sis
The data will be analyzed by  Novartis and/or designated CRO. It is planned that the data from 
participating centers in this protocol will be combined, so that an adequate number of patients 
will be available for analy sis.

Novartis Confidential Page 121
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Study  data will be summarized with respect to demographic and baseline characteristics, 
efficacy  observations and measurements, safety  observations and measurements, and all 
relevant PK and PD measurements.
The cut-off date for the primary  analysis 
is defined as the date when all patients have been on 
study  treatment for 24 weeks or discontinued earlier. The cut-off date for the end of study
treatment analysis is defined as 30 days after the end of study  treatment period (see Section 4.3)
to ensure that all available treatment phase 
data from all patients up to the last dose of study  
drug taken in this study , will be analy zed and summarized in the end of study treatment phase 
CSR. Patients will be further followed  for survival and progression for up t o 5 years from the 
date the last randomized patient receive sthe first study  dose. An update analy sis of OS and PFS 
will be performed at the end of the follow -up period in the final study  CSR .
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Analysis Set (FAS) comprises all patients to whom study  treatment has been assigned 
by randomization. According to the intent ionto treat principle, patients will be analyzed 
according to the treatment and stratum they have been assigned to during the randomization 
procedure.
10.1.2 Safety  set
The Safety Set includes all patients who received at least one dose of study treatment. Patients 
will be anal yzed according to the stud y treatment received, where treatment received is defined 
as the randomized treatment if the patient took at least one dose of that treatment or the first 
treatment received if the randomized treatment was never received.
10.1.3 Per-Protocol set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with requirements of the CSP. The PPS will be used for sensitivity  analyses on the primary 
endpoint only .
Oncology  standards for protocol deviations potentially  leading to exclusion from th e PPS are:
Type of indication different from those required by  the CSP
If prior therap y does not match with CSP requirements in terms of number and types of 
previous therap y regimens
Another anti -neoplastic therap y administered after start of study treatment and prior to 
first efficacy  assessment
Study  treatment received different from treatment assigned by  randomization
10.1.4 Dose -determining analy sis set
Not applicable.

Novartis Confidential Page 122
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
10.1.5 Pharmacokinetic analy sis set
The Pharmacokinetic analysis set (PAS) includes all patients who provide at least one 
evaluable PK concentration. For a concentration to be evaluable, patients are required to:
Take a dose of asciminib prior to sampling,
Take the same dose of asciminib for at least 3 consecutive day s without dose interruption 
or dose modification prior to sampling,
For post -
dose samples, do not vomit within 4 hours after the dosing of asciminib (this is 
the current dose) ; for pre -dose samples do not vomit within 4 hours after the dosing of 
asciminib prior to sampling (this is the previous dose),
Have thepre-dose sample collected before thenext dose administration
.
10.1.6 Other analy sis set
For duration of MMR and time to MMR, the MMR Responder Set that will be used is a subset 
of FAS and includes patients who achieve MMR at any  time .
For CCyR rates at and by scheduled time points, the CCyR Anal ysis Set that will be used is a 
subset of FAS and includes patients who are not in CCy R at baseline.
For duration of CCy R and time to CCy R, the Cy togenetic Responder Set that will be use dis a 
subset of FAS andincludes patients who do not have CCyR at baseline and achieve CCyR at 
any time on study  treatment .
Patients who will receive at least one dose of asciminib after bosutinib failure will form the 
Switch Analy sis Set which will be used for safety  and exploratory  efficacy  endpoints defined 
on these patients. 
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed and 
summarized descriptively b y treatment group for the FAS or the Safet y Set.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented.
Relevant medical histories and current medical conditions at baseline will be summarized 
separately by system organ class and preferred term, by treatment group.
10.3 Treatments (study  treatment, concomitant therapies, 
compliance)
The Safet y set will be used for the anal yses below.
Categorical data will be summarized as frequencies and percentages. For continuous data, mean, 
standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be 
presented.
The duration of exposure in days to asciminib and bosutinib, as well as the dose intensit y 
(computed as the ratio of actual cumulative dose received and actual duration of exposure) and 

Novartis Confidential Page 123
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
the relative dose intensity (computed as the ratio of dose intensity  and planned dose intensity ) 
will be summarize d by means of descriptive statistics.
The number of patients with dose adjustments (reductions, interruption, or permanent 
discontinuation) and the reasons will be summarized by treatment group and all dosing data 
will be listed.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification sy stem, by  treatment group.
10.4 Primary  objective
The primary  objective of 
the study  is to evaluate the efficacy  of asciminib at the recommended 
dose in CML  patients in chronic phase, previously  treated with 2 or more tyrosine kinase 
inhibitors and to compare this efficacy  profile in this population with that achieved by  patients
receiving bosutinib .
10.4.1 Variable
The primary  efficacy  variable of the study  is the Major Molecular Response (MMR) rate at 24 
weeks. A patient will be counted as having achieved MMR at 24 weeks if he meets the MMR 
criteria (BCR -ABL 1ratio ≤0.1%) at 24 weeks.
10.4.2 Statistical hy pothesis, model, and method of analy sis
The MMR rate at 24 weeks will be calculated based on the FAS and according to the Intent ion-
ToTreat (ITT) principle. MMR rate and its 95% confidence interval based on the Pearson-
Clopper method will bepresented by treatment group. The confidence interval for the difference 
in MMR rate between treatment groups will be provided using the Wald method.
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 24 weeks. The Cochrane -Mantel -Haenszel chi-square test, stratified by the 
randomization stratification factor, i.e. major cytogenetic response status (PCy R or CCyR vs.
others) at screening, will be used to compare MMR rate between the two treatment groups, at 
the two-sided 5% level of significance. The Mantel -Haenszel estimate of the common risk 
difference and the corresponding 95% confidence interval will also be provided.
10.4.3 Handling of missing values/censoring/discontinuations
Only  patients with MMR at 24 week visit are considered responders. In other words, any patient 
who achieves MMR before 24 weeks, but is no longer in MMR at 24 weeks, will be considered 
as a non-responder in this primary  analysis. Patients discontinuing the randomized treatment 
(havi ng performed an EOT visit) prior to 24 weeks due to any reason will be considered as non-
responders. One exception to the rule above is if the 24-week PCR evaluation is missing, but 
both a PCR evaluation at 16 weeks and a PCR evaluation at 36 weeks indicat e MMR, the 24-
week assessment is imputed as a ‘Response’. If PCR evaluations are performed at unscheduled 
visits closer to the Week 24 visit (before or after) , these will be taken into account for the 
imputation .

Novartis Confidential Page 124
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
10.4.4 Supportive and Sensitivity analyses
The analysis of the primary  endpoint will also be repeated on the PPS if the PPS is different 
from the FAS .
Subgroup anal yses and a logistic regression analy sis will be employ ed. Refer to the exploratory 
objectives Section 10.6.1 for further details.
10.5 Secondary  objectives
The secondary  objective s in this study  are as follows:
To compare additional parameters of the efficacy of asciminib versus bosutinib, defined 
as:
Key secondary endpoints
MMR rate at 96 weeks
Other efficacy endpoints
Cytogenetic response (Complete, Partial, Major, Minor, Minimal, no response) rate at all 
scheduled data collection time points including , 24, 48 and 96 weeks.
Cytogenetic response (Complete, Partial, Major, Minor, Minimal, no respo nse) rate b y all 
scheduled data collection time points includin g, 24, 48 and 96 weeks.
MMR rate at all scheduled data collection time points (except 24 and 96 weeks which are 
alread y covered b y primary and key secondary  endpoints)
MMR rate by  all scheduled data collection time points
including 24, 48 and 96 weeks.
Time to MMR
Duration of MMR
Time to CCy R
Duration of CCy R
Time to treatment failure
Progression free survival
Overall survival
To compare the safety  and tolerability  profile of asciminib versus bosutinib
To characterize the PK of asciminib in the CML -CP population
10.5.1 Key secondary  objective(s)
The key  secondary  endpoint to be evaluated is MMR rate at 96 weeks, which is defined as the 
proportion of patients with MMR at 96 weeks and derived in a similar fashion to MMR rate at 
24 weeks.

Novartis Confidential Page 125
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
10.5.1.1 Analysis for key secondary  objectives
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 96 weeks. Formal statistical testing of the key secondary  endpoint will be 
performed with = 0.05 (two- sided) onl y if the primary  endpoint (i.e. MMR rate at 24 weeks)
is significant by means of a gatekeeping procedure to control the overall alpha level. Otherwise, 
no statistical testing will be performed , and any  analy sis will be considered exploratory .
MMR rate at 96 weeks will be evaluated in a similar fashion to the primary  analysis of MMR 
rate at 24 weeks. The rate and the associated 95% confidence interval based on the Pearson -
Clopper method will be presented by treatment group. Confidence interval for the difference 
between treatment groups will be provided using the Wald method.
Statistical testing will be performed 
via CMH chi-square test stratified by the randomization 
strata. The Mantel -Haenszel estimate of the common risk difference and the corresponding 95% 
confidence interval will also be provided.
If the PCR evaluation at 96 weeks is missing, but a PCR evaluation both at 84 weeks and 108 
weeks indicate MMR, the 96 week assessment is imputed as a “response”, assuming that MMR 
is maintained between 84 and 108 weeks. If PCR evaluations are performed at unscheduled 
visits closer to the Week 96 visit (before or after), these will be taken into account for the 
imputation.
10.5.2 Other secondary  efficacy  objectives
Unless otherwis e stated the FAS will be used for the analy sis of all other secondary  efficacy 
endpoints. The exceptions are using the Molecular Responder Set for duration of MMR and 
time to MMR, the CCy R Analy sis Set for CCyR rates, and the Cy togenetic Responder Set for 
duration of CCy R and time to CCy R.
No statistical testing of non-key secondary  efficacy  endpoints will be performed, and any 
analysis will be considered exploratory .
Molecular Response
MMR rates at scheduled time points (except 24 and 96 weeks which have been specified as 
primary  and key secondary  endpoints) will be evaluated in a similar fashion to the 
primar y 
analysis of MMR rate at 24 weeks. Patients discontinuing the randomized treatment prior to a 
specific time poin t due to any  reason will be considered as non -responders for that time point.
MMR rates by scheduled time points are defined as the proportion of patients who achieve 
MMR at or before the specified visit, i.e. if a patient achieves an MMR but then loses it before 
or at the visit, he/she will still be classed as achieving MMR by  that time point.
For each endpoint the rate and the associated 95% confidence interval based on the Pearson-
Clopper method will be presented by  treatment group. Confidence intervals for the differences 
in any  response rates between treatment groups will be provided using the Wald method.
Statistical testing will be performed via CMH chi-square tests stratified by the randomization 
strata. The Mantel -Haenszel estimate of the common risk difference and the corresponding 95% 
confidence interval will also be provided .

Novartis Confidential Page 126
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Duration of MMR is defined in Section 7.2.1.1 as the time between the date of the first 
documented MMR and the earliest date of loss of MMR, progression to AP/BC, or CML -related 
death for patients in the Molecular Responder Set. The time will be censored at the last 
molecular assessment (PCR) date while on treatment for patients who have not experienced any 
of the above events.
Duration of MMR will be analyzed by K-M method and presented by K-M plots. The estimated 
rates of patients who are still responding at various time points will also be provided using K -
M method.
The cumulative incidence of MMR will be graphically  display edby an increasing step function. 
This curve will increase each time (after randomization) at which a new responder is observed 
and thus will increase up to the best observed response rate (e.g. up to 50% if half of the patients 
in the anal ysis population are able to achieve response).
Time to MMR is defined in Section 7.2.1.1 and calculated as: date of first MMR -date of 
randomization +1, for patients in the Molecular Responder Set. Descriptive statistics (minimum, 
maximum , median, quartiles, mean, sd) of time to MMR will be provided for the two treatment 
groups separatel y.
Cytogenetic Response
Patients in FAS will be categorized with counts and percentages provided for cytogenetic 
response (Complete, Partial , Major, Minor, Minimal, No Response) at and by (i.e. best response 
up to a specified time point) scheduled time points. Shift tables will also be employ ed to 
examine the changes in cytogenetic response category from baseline.
Since there are expected to be only limited numbers who are actuall y in CCyR at baseline the 
analysis of CCyR rate at and by scheduled time points will only  include patients who are not in 
CCyR at baseline, i.e. the CCy R Anal ysis Set.
CCyR rates at and by scheduled time points etc.and the associated 95% confidence intervals 
based on the Pearson
-Clopper method will be presented by treatment group with the analy sis of 
these endpoints only  including patients who are not in CCy R at baseline.
Confidence intervals for the differences in an yresponse rates between treatment groups will be 
provided using the Wald method.
Statistical testing will be performed via CMH chi-square tests stratified by the randomization 
strata. The Mantel -Haenszel estimate of the common risk difference and the corre sponding 95% 
confidence interval will also be provided.
Time to CCyR is defined for patients in the C ytogenetic Responder Set as: date of first CCy R 
-date of randomization +1. Descriptive statistics (minimum, maximum , median, quartiles, 
mean, sd) of time to CCyR will be provided for the two treatment groups separately .
The cumulative incidence of CCyR will also be graphicall y display ed by an increasing step 
function. This curve will increase each time (after randomization) at which a new responder is 
obser ved and thus will increase up to the best observed response rate.
Duration of CCyR is defined as the time between date of first documented CCyR and the 
earliest date of loss of CCyR, progression to AP/BC, or CML -related death for patients in the 

Novartis Confidential Page 127
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Cytogeneti c Responder Set. The time will be censored at the last cytogenetic assessment date 
on treatment for patients for whom none of the above events is reported or last PCR evaluation 
on treatment indicating MMR.
Duration of CC yR response will be anal yzed by K-M method and presented b y K-M plots. The 
estimated rates of patients who are still responding at various time points will also be provided 
using K -M method.
Treatment failure, disease progression and survival
Time to treatment failure (TTF) is defined as the time from date of randomization to an event 
of treatment failure. The following events will constitute ‘treatment failure’, and are based on 
the ELN criteria (Baccarani et al 2013) defining failure of a second line treatment adapted to 
include discontinuation of randomized treatment as an event :
No CHR or > 95% Ph+ metaphases at three months after randomization or thereafte r
BCR -ABL 1
ratio > 10% IS and/or > 65% Ph+ metaphases at six mon ths af ter 
randomization or thereafter
BCR -ABL 1ratio > 10% IS and/or > 35% Ph+ metaphases at 12 months after 
randomization or thereafter
Loss of CHR, CCy R or PCy R at any  time after randomization
Detection of new BCR -ABL 1mutations which potentially  cause r esistance to study  
treatment at an y time after randomization
Confirmed loss of MMR
New clonal chromosome abnormalities in Ph+ cells: CCA/Ph+: at any  time after 
randomization
Discontinuation from randomized treatment for any reason
For patients who have not reach edtreatment failure, their TTFs will be censored at the time of 
last study  assessment (PCR, cytogenetic, hematologic or extramedullary )before the cut-off date.
Progression -Free -Survival (PFS) is defined as the time from the date of randomization to the 
earliest occurrence of documented disease progression to AP/BC or the date of death from any 
cause (including progressions and deaths observed during the survival follow -up period) before 
the cut -off date .
The time will be censored at the date of l ast study  assessment (PCR, cy togenetic, hematologic 
or extramedullary ) or last post -treatment follow -up for patients without event.
Overall survival (OS) is defined as the time from the date of randomization to the date of death 
(including the survival fol low-up period). Patients who are alive at the time of the anal ysis data 
cutoff date will be censored at the date of last contact before the cut -off date.
TTF, PFS and OSwill be estimated and graphicall y displayed using the K-M approach on FAS. 
The estimat ed rates by K-M method at various time points will be provided and the endpoints 
will be compared between the two treatment groups using stratified log-rank test stratified by 
the randomization strata. The hazard ratio and 95% confidence intervals will be computed from 
a stratified Cox model.

Novartis Confidential Page 128
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
10.5.3 Safety  objectives
10.5.3.1 Analysis set and grouping for the analy ses
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
treatment group.
The overall observation period will be di vided into three mutually  exclusive segments:
1.pre-treatment period: from day  of subject’s first informed consent to the day before first 
administration of study  treatment
2. on- treatment period: from day  of first administration of study  treatment to 30 day s after 
last actual administration of the same stud y treatment (including start and stop date)
3.post-treatment period: starting at day  31 after last administration of any  study  treatment
Summary  tables for safety  data will be presented for the on-treatment period. Comparative 
analysis will be performed only for the on -treatment period. Listings of safety data will include 
pre-treatment, on-treatment, and post-treatment periods, with a flag to indicate data collected 
before or after the on -treatment period.
The same analysis will be done for patients that switch to asciminib after treatment failure on 
bosutinib. However ,safety  events that initiated on or after start of asciminib during the switch 
treatment phase will be included.
10.5.3.2 Adverse events (A Es)
Summary  tables for adverse events (AEs) will include only AEs that started or 
worsened during 
the on- treatment period, the treatment- emergent AEs.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by system organ class and/or preferred term, severity  (based on CTCAE grades), 
type of adverse event, relation to study  treatment.
Serious adverse events, non-serious adverse events and adverse events of special interest (AESI)
during the on -treatment period will be tabulated.
All deaths (on- treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including those from the pre-treatment, on-
treatment and post-treatment periods) will be listed and those collected before or after the on-
treatment period will be flagged.
10.5.3.3 Laboratory  abnormalities
Grading of laboratory  values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) 
version 4.03. The calculation of CTCAE 
grades will be based on the observed laboratory  values only, clinical assessments will not be 
taken into account.
CTCAE Grade 0 will be assigned for all non -missing values not graded as 1 or higher. Grade 5 
will not be used.

Novartis Confidential Page 129
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
For laboratory tests where grades are not defined by  CTCAE v4.03, results will be categorized 
as low/normal/high based on laboratory  normal ranges.
The following listings and summaries will be generated separatel y for hematology , and 
biochemistry  tests:
Listing of all laboratory  data with values flagged to show the c orresponding CTCAE 
v4.03 grades if applicable and the classifications relative to the laboratory  normal ranges
For laboratory  tests where grades are defined b y CTCAE v4.03
Worst post -baseline CTCAE grade (regardless of the baseline status). Each patient wi ll be 
counted only once for the worst grade observed post -baseline in the on -treatment period.
Shift tables using CTCAE grades to compare respective baseline to the worst on -treatment 
value
For laboratory  tests where grades are not defined by  CTCAE v4.03,
Shift tables using the low/normal/high/ (low and high) classification to compare respective 
baseline to the worst on-treatment value.
10.5.3.4 Other safety  data
ECG
ECGs (12-lead) 
including PR, QRS, QT, QTcF, and HR intervals will be obtained for each 
subject durin g the study . ECG data will be read and interpreted centrall y.
Categorical analysis of QT/QTc interval data based on the number of patients meeting or 
exceeding predefined limits in terms of absolute QT/QTc intervals or changes from baseline 
will be presented. In addition, a listing of these patients will be produced by  treatment group.
Vital signs
Data on vital signs will be tabulated and listed, notable values will be flagged.
10.5.3.5 Supportive analy ses for secondary  objectives
Not applicable.
10.5.3.6 Tolerability
Tolerability  of each study  treatment will be assessed by summarizing the number of subjects
with dose interruptions and dose reductions. Reasons for dose interruptions and dose reductions 
will be listed by  subject and summarized.
10.5.4 Secondary  PK objectives
The PK objective is to characterize the PK of asciminib in CML  population.
Using PAS, summary  statistics (n, mean, SD, coefficient of variation (CV) for mean, geometric 
mean, CV for geometric mean, median, minimum and maximum) will be presented for plasma 
concentration at each scheduled time point. The geometric mean with mean (SD) and individual 
plasma concentration versus time profiles of asciminib will be display ed graphicall y.

Novartis Confidential Page 130
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Using Safet y set, concentration data will be listed. Concentration values below the limit of 
quantification (BLQ) will be set to zero b y the Bioanal yst and displayed in listings as zero with 
a flag. BLQ values will be handled as zero in any calculations of summary  statistics, but handled 
as missing for the calculation of the geometri c means and CVs.
Pharmacokinetic parameters will be determined by non-compartmental method(s) using the 
pharmacokinetic profile of asciminib in patients with full PK sampling. PK parameters listed in 
Table 10
-1will be derived and reported, when feasible.
Population PKmodeling may be performed and the results may be reported in a separate 
population PK report. Data from this study  may be combined with data from other studies for 
this analy sis.
Table 10-1 Non compartmental pharmacokinetic parameters in full PK group
AUC0 -12h The area under the plasma concentration -time curve from time zero to 12 h (mass x time x 
volume -1)a
Cmax The maximum (peak) observed plasma drug concentration after dose administration (mass x 
volume -1)
Tmax The time to reach maximum (peak) plasma drug concentration after dose administration (time)
CL/F The total body clearance of drug from the plasma after oral administration (volume x time -1)
10.6 Exploratory  objectives
10.6.1 Exploratory  efficacy  objectives
To evaluate the influence of factors such as major cytogenetic status at baseline, 
failure/intolerance to prior TKIs, line of therap y, gender, race and age on the effect of 
asciminib with respect to the primary  efficacy  endpoint.
To characterize mutations in the BCR-ABL1 gene at Week 1 Day  1, upon confirmed loss of 
molecular response and/orat end of treatment and examine their association with molecular 
and cytogenetic response for asciminib vs.bosutinib.
To assess the efficacy of asciminib when administered as treatment after bosutinib failure 
according to the 2013 ELN Guidelines.
10.6.1.1 Data analy sis of exploratory  efficacy  objectives
Subgroup analyses will be performed to evaluate the influence of factors such as baseline major 
cytogenetic response status, baseline /Week 1 Day 1BCR -ABL 1ATP -binding site mutation 
status (from local historical record and from Sanger Sequencing), failure/intolerance to prior 
TKIs, line of therapy , gender, race and age on the primary  efficacy  endpoint. In addition, a 
logistic regression anal ysis will incorporate the key baseline variables into the model to further 
evaluate the impact of these variables on the primar y endpoint and to provide a treatment effect 
estimate which is adjusted for imbalances in the treatment groups. An adjusted odds ratio for 
the treatment effect with associated 95% confidence intervals will be presented. Mantel -
Haenszel estimates of the common odds ratio and the corresponding 95% confidence interval 
will also be provided. The effect of asciminib when administered as treatment after bosutinib 
failure will be assessed using theSwitch Analy sis Set to estimate response rates (cytogenetic 
and molecular response )at all scheduled time points after switch, as well as time-to and duration 

Novartis Confidential Page 133
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
10.6.4.2 Patient Reported Outcomes
The MDASI  CML, PGIC along with EQ-5D- 5L will be used to compare data on the patient’s 
disease -related symptoms and health -related quality  of life from baseline to EOT between the 
treatment arms. The WPAI will be used to assess work productivity  and activity  impairment 
related to the patient’s CML .All measures will assess differences between the treatment arms.
Patients with an evaluable baseline score and at least one evaluable post baseline score during 
the treatment period will be included in the change from baseline analy ses. Missing data items 
in a scale will be handled according to the manual for each instrument. No imputation will be 
applied if the to tal or subscale scores are missing at a visit.
10.7 Interim analy sis
No formal interim analysis is planned for this trial. As described in Section 10, three or four
formal analyses are planned: the primary  at week 24, another at the 96-week end of study 
treatment and a PFS/OS update at year 5.
24-week primary  analy sis: Formal testing of the primary  endpoint with full alpha will be 
performed. Anal yses of other efficacy  endpoints at and by  24 weeks will also be
performed.
96-week anal ysis: Formal statistical testing of the key  secondary  endpoint will be 
performed with = 0.05 (two- sided) onl y if the primary endpoint (i.e. MMR rate at 24 
weeks) is significant. Otherwise, no statistical testing will be performed, and any  anal ysis
will be considered exploratory . Anal yses of other efficacy  endpoints (including MMR rate 
at 48 weeks) will also be performed.
End of study  treatment analy sis (if required) similar to the 96 -week anal ysis without 
formal statistical testing.
5-year PFS/OS update analy sis:PFS and OS
In addition DMC safet
y analyses will be conducted as described in Section 8.6.
10.8 Sample size calculation
To test the null hy pothesis that the response rate is e qual in the two groups, based on two-sided 
5% level of significance and with 90% power, 222 patients will be needed in total (i.e. 148 
patients in the asciminib arm and 74 patients in the bosutinib arm based on 2:1 randomization 
allocation). This assumes that asciminib leads to a 20% improvement in the MMR rate at 24 
weeks over bosutinib from 15% to 35% which corresponds to an odds ratio of 3.05.
The assumed bosutinib MMR rate of 15% at 24 weeks is based on previous trials evaluating 
bosutinib therapy  (Khoury  2012 , Gambacorti -Passerini 2014 , García -Gutiérrez 2015 ).
No more than 66 patients (approximately  30% of t he overall trial population) that are intolerant 
to their most recent TKI therap y with BCR -ABL 1 < 1% will be recruited in order to ensure that 
the CML  third line patient population is adequately  represented.

Novartis Confidential Page 134
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
10.9 Power for analy sis of key secondary  variables
If the primary  analysis of MMR rate at 24 weeks is statistically  significant, then the key 
secondary  endpoint MMR rate at 96 weeks will be tested, with the overall alpha controlled at 
the 5% two-sided level. The testing will use a gatekeeping strategy . Full details of the testing 
strategy  are provided in Section 10.5.1.
Table 10-2 below summarizes the treatment effects of the key secondary  endpoint which can 
be detected with 80% and 90% power , based on the specified assumptions regarding the 
bosutinib effect. The calculations were made using the software package PASS (2008).
Table 10
-2 Detectable effect sizes for key  secondary  endpoint
Endpoint Anticipated effect 
with bosutinib2-sided alpha Power Detectable 
effect size§
MMR rate at 96 weeks 30%*0.05 90%
80%≥ 23%
≥ 20%
*: Gambacorti -Passerini et al. 2014 , Figure 1D.
§: Absolute difference from the anticipated effect with bosutinib.
For MMR rate at 96 weeks, if the anticipated effect with bosutinib is 30%, then the given sample 
size with 2 -sided alpha=0.05 would allow to detect an absolute difference of at least 23% (i.e. 
MMR rate at 96 weeks with asciminib is at least 53%) for 90% po wer and of at least 20% (i.e. 
MMR rate at 96 weeks with asciminib is at least 50%) for 80% power.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the D eclaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature page confirming his/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.

Novartis Confidential Page 135
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
11.3 Informed con sent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC/REB -approved informed consent.
Informed consent must be obtained before conducting an y stud y-specific proc edures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a subject’s Informed Consent was 
actuall y obtained will be captured in their eCRFs.
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking thestudy  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any questi on that the patient will not reliably compl y, they 
should not be entered in the study .
Male subjects on asciminib treatment must be informed that if a female partner becomes 
pregnant while themale subject is enrolled in the study, contact with the female partner will be 
attempted to request her consent to collect pregnancy  outcome information.
Additional consent form
Not applicable.
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study  are outlined in Section 4.3.
11.5 Publicatio
n of study  protocol and results
Novartis is committed to following high ethical standards for reporting study  results for its 
innovative medicine, including the timel y communication and publication of clinical trial 
results, whatever their outcome. Novarti s assures that the key  design elements of this protocol 
will be posted on the publicly  accessible database, e.g. clinicaltrials.gov before study  start. In 
addition, results of interventional clinical trials in adult patients are posted on 
novartisclinicalt
rials.com, a publicl y accessible database of clinical study  results within 1 year 
of study  completion (i.e., LPLV), those for interventional clinical trials involving pediatric 
patients within 6 months of study  completion.
Novartis follows the ICMJE author ship guidelines (icmje.org )and other specific guidelines of 
the journal or congress to which the publication will be submitted
Authors will not receive remuneration for their writing of a publication, either directl y from 
Novartis or through the professio nal medical writing agency . Author(s) may be requested to 

Novartis Confidential Page 136
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
present poster or oral presentation at scientific congress; however, there will be no honorarium 
provided for such presentations.
As part of its commitment to full transparency in publications, Nova rtis supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of interest of financial and non-financial nature by all authors, including 
medical writing/editorial support, if applica ble.
For the Novartis Guidelines for the Publication of Results from Novartis -sponsored Research, 
please refer to novartis.com .
11.6 Stud y documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a Novartis -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by  applicable law, to copy ) clinical records for the purposes of 
quality  assurance reviews, audits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory  notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification asbeing accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collectio n is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study  electronic case report form (eCRF) is the primary  data 
collection instrument for the study. The investigator should ensure t he accuracy, completeness, 
legibility , and timeliness of the data reported in the eCRFs and all other required reports. Data 
reported on the eCRF, that are derived from source documents, should be consistent with the 
source documents or the discrepancies should be explained. All data requested on the eCRF 
must be recorded. Any  missing data must be explained. For electronic CRFs an audit trail will 
be maintained b y the s ystem.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by applicable 
regulations and/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additio nal period of time 
because of applicable laws, regulations and/or guidelines.

Novartis Confidential Page 137
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by names 
in any documents submitted to Novartis. Signed informed consent forms and patient enrollment 
log must be kept strictl y confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee orHealth 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at the site -prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the study 
to request approval of a protocol deviation, as no authorized deviations are permitted. If the 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
Novartis should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. UK requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working days.

Novartis Confidential Page 138
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
13 References (available upon request)
[Baccarani M, Deininger MW, Rosti G, et al (2013)] European LeukemiaNet 
recommendations for the management of chronic my eloid leukemia: 2013. Blood; 
122(6):872-84.
[Bartram CR, de Klein A, Hagemeijer A, et al (1983)] Translocation of c -ab1 oncogene 
correlates with the presence of a Philadelphia chromosome in chronic my elocy tic leukaemia. 
Nature; 306(5940):277 -80.
[Basnay ake C, Ratnam D (2015)] Blood tests for acute pancreatitis. Aust Prescr 38:128 -30.
[Bosulif® SmPC ]
[Bosulif® USPI ]
[Branford S, Rudzki Z, Walsh S, et al (2003)] Detection of BCR- ABL mutations in patients 
with CML  treated with imatinib is virtually  alway s accompanied by  clinical resistance, and 
mutations in the ATP phosphate -binding loop (P -loop) are associated with a poor prognosis. 
Blood; 102(1):276 -
83.
[Brooks R (1996)] EuroQol: the current state of play . Health Policy  37(1):53 -72.
[Daley  GQ, Van Etten RA, Baltimore D (1990)] Induction of chronic m yelogenous leukemia 
in mice by  the P210bcr/abl gene of the Philadelphia chromosome. Science; 247(4944):824 -
30.
[EuroQol Group (1990)] EuroQol- a new facility  for the measurement of health- related quality  
of life. Health Policy  16(3):199 - 208.
[Guidance for Industry  Reproductive and Developmental Toxicities - Integrating Study  
Results to Assess Concerns] Food and Drug Administration Center for Drug Evaluation and 
Research. September 2011.
[Gambacorti -Passerini C, Brümmendorf TH, Kim DW, et al (2014)] Bosutinib efficacy  and 
safet y in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: 
Minimum 24 -month follow -up. Am J Hematol; 89(7):732-42.
[García -Gutiérrez V, Martinez -Trillos A, L opez Lorenzo JL , et al (2015)] Bosutinib shows 
low cross intolerance, in chronic m yeloid leukemia patients treated in fourth line. Results of 
the Spanish compassionate use program. Am J Hematol; 90(5):429
-33.
[Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, et al (1983)] Localization of the c- ab1 
oncogene adjacent to a translocation break point in chronic m yeloc ytic leukaemia. Nature; 
306(5940):239 -42.
[Herdman M, Gudex C, Llo yd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. (2011) ]
Development and preliminary  testing of the new five -level version of EQ- 5D (EQ -5D- 5L). 
Quality  of Life Research 20(10):1727-1736.
[Hughes TP, Hochhaus A, Branford S, et al (2010)] L ong-term prognostic significance of 
early molecular response to imatinib in newly  diagnosed chronic m yeloid leukemia: an 
analysis from the International Randomized Study  of Interferon and STI571 (I RIS). Blood; 
116(19):3758-3765.
[Hochhaus A, Saussele S, Rosti G, et al (2017)] Chronic myeloid leukaemia: ESMO Clinical
Practice Guidelines for diagn osis, treatment and follow -up. Ann Oncol (2017) 28 (suppl 4):
iv41–iv51.

Novartis Confidential Page 139
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
[Hochhaus A, O'Brien SG, Guilhot F, et al (2009)] Six -year follow -up of patients receiving 
imatinib for the first -line treatment of chronic m yeloid leukemia. Leukemia; 23(6):1054-61.
[Kelliher MA, McLaughlin J, Witte ON, et al (1990)] I ntroduction of a chronic my elogenous 
leukemia -like s yndrome in mice with v -Abl and BCR/ABL . Proc Natl Acad Sci USA 87; 
6649-53.
[Khoury  HJ, Kim D, Zaritskey  A, et al (2010)] Safety  and efficacy  of thirdl ine bosutinib in 
imatinib (I M) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic m yeloid 
leukemia (CML) [abstract]. J Clin Oncol; 28 (Suppl ;abstr 6514):15s.
[Klemmt L , Scialli AR. (2005)] The transport of chemicals in semen. Birth Def ects Res (Pt
B); 74:119
–131.
[Khoury  HJ, Cortes JE, Kantarjian HM, et al (2012)] Bosutinib is active in chronic phase 
chronic m yeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood; 
119(15):3403-12.
[National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in 
Oncology -Chronic My eloid L eukemia] v4.2018 –January  24, 2018.
[Nowell Hungerford DA (1960)] A minute chromosome in chronic granulocy tic leukemia. 
Science; 132: 1497 -1501.
[O’Brien S, Radich JP, Abboud CA, et al (2013)] Chronic My elogenous Leukemia, Version 
1.2014: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw; 11(11):1327 -
40.
[O’Hare T, Corbin A S, Druker B J (2006)] Targeted CML  therapy : controlling drug 
resistance, seeking cure. Curr ent opinion in Genetics & development, 16:92 -99.
[Rowley  JD (1973)] A new consistent abnormality in chronic my elogenous leukemia 
identified by  quinacrine, fluorescence and Giemsa staining. Nature; 243:290 -93.
[Soverini S, Branford S, Nicolini FE, et al (20 14)] I mplications of BCR -ABL1 kinase 
domain -mediated resistance in chronic m yeloid leukemia. Leuk Res; 38(1):10 -20.
[Steegmann JL, Baccarani M, Breccia M, et al (2016) ]European LeukemiaNet 
recommendations for the management and avoidance of adverse events of treatment in 
chronic m yeloid leukaemia. Leukemia; 30(8):1648 -
71.
[Vardiman J.W. (2009)] Chronic My elogenous Leukemia, BCR -ABL+. Am J Clin Pathol; 
132:250-260.
[Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2001)] Human drug metabolism and the 
cytochromes P450: application and relevance of in vitro models. The Journal of Clinical 
Pharmacology ; 41: 1149 -1179.

Novartis Confidential Page 140
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
14 Appendices
In general, the use of any concomitant medication deemed necessary  for the care of the patient 
is permitted in this study, except as specificall y prohibited in Section 6.4for patients on 
asciminib and Section 6.5 for patients on bosutinib. 
The following lists are based on the internal [Pharmacokinetic Sciences memorandum on Drug -
Drug Interaction] (release date: January  2018), which was compiled from the Indiana University  
School of Medicine’s “Clinically  Relevant” Table and supplemented with the FDA Draft 
Guidance for Industry , Drug Interaction Studies –Study  Design, Data Anal ysis, and 
Implications for Dosing and Labeling (2017), and the Universit y of Washington’s Drug 
Interaction Database (2017). These lists are not comprehensive and are only meant to be used 
as a guide. Please con tact the medical monitor with any questions. If a medication appears on 
both the list of prohibited and the list of medications to be used with caution, the 
medication is prohibited.
14.1 Appendix 1 List of concomitant medications for patients on 
asciminib
Table 14-1 Prohibited concomitant medications for asciminib arm
Category Drug Names
Strong inhibitors of 
CYP3Aatazanavir/ritonavir1, danoprevir/ritonavir1, darunavir/ritonavir1, elvitegravir/ritonavir1, 
indinavir/ritonavir1, lopinavir/ritonavir1, saquinavir/ritonavir1, tipranavir/ritonavir1, 
ombitasvir/paritaprevir/dasabuvir/ritonavir (Viekira Pak)1, boceprevir ,clarithromycin, 
cobicistat, conivaptan, grapefruit juice2, idelalisib, indinavir, itraconazole, ketoconazole, 
mibefradil, nefazodone, nelfinavir,  posaconazole, ritonavir, telaprevir, telithromycin, 
troleandomycin, voriconazole,
Strong inducers of 
CYP3Acarbamazepine, enzalutamide, lumacaftor, mitotane ,phenoba rbital, phenytoin, rifabutin, 
rifampicin, St. John’s wort ( Hypericum perforatum )1
UGT1A1/2B7 
inducersUGT1A1: carbamazepine, cigarette smoke , rifampicin, testosterone propiate, 
UGT2B7: Barbiturates
Torsade de pointe 
(TdP) TdP/QT risk : 
Knownamiodarone, anagrelide, arsenic trioxide, astemizole (off us mkt), azithromycin, bepridil 
(off us mkt), chloroquine, chlorpromazine, cilostazol, cisapride (off us mkt), citalopram, 
clarithromycin, cocaine, disopyramide, dofetilide, domperidone (not on us m kt), 
donepezil, dronedarone, droperidol, erythromycin, escitalopram, flecainide, fluconazole, 
grepafloxacin (off market worldwide), halofantrine, haloperidol, ibutilide, 
levofloxacin, levomethadyl (off mkt worldwide), mesoridazine (off mkt worldwide), 
methadone, moxifloxacin, ondansetron, oxaliplatin, papaverine HCl, pentamidine, 
pimozide, probucol (off mkt worldwide), procainamide (oral off us mkt), propofol, 
quinidine, sevoflurane, sotalol, sparfloxacin (off us mkt), sulpiride (not on us mkt), 
terfenadin e (off us mkt), thioridazine, vandetanib
TdP/QT risk: 
Possiblealfuzosin, apomorphine, aripiprazole, artenimol+piperaquine, asenapine, bedaquiline, 
bortezomib, buprenorphine, capecitabine, ceritinib, clomipramine, clozapine, crizotinib, 
cyamemazine (cyamepromazine) (Only on Non US Market), dabrafenib, dasatinib, 
degarilix, delamanid (off US mkt), desipramine, dexmedetomidine, dolas etron, eribulin, 
ezogabine, famotidine, felbamate, fingolimod, foscarnet, gemifloxacin, granisetron, 
hydrocodone -ER, ilop eridone, imipramine (melipramine), isradipine, lapatinib, lenvatinib, 
leuprolide, lithium, mifepristone, mirabegron, mirtazapine, moexipril/hctz, nicardipine, 
nilotinib, norfloxacin, nortriptyline, ofloxacin, olanzapine, osimertinib, oxytocin, 
paliperidone , panabinostat, pasireotide, pazopanib, perflutren lipid microspheres, 
pipamperone (not on us mkt), promethazine, quetiapine, ranolazin e, rilpivirine, 
risperidone, roxithromycin (on non us mkt), saquinavir, sertindole (on non us mkt), 
sorafenib, sunitinib, tacrolimus, tamoxifen, telavancin, telithromycin, tetrabenazine 

Novartis Confidential Page 141
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Category Drug Names
(orphan drug in us), tizanidine, tolterodine, toremifene, trimipramine, vardenafil, 
vemurafenib, venlafaxine, vorinostat, zotepine
TdP/QT risk: 
Conditionalamantadine, amisulpride, amitripty line, atazanavir, chloral hydrate, diphenhydramine, 
doxepin, fluoxetine, furosemide (frusemide), galantamine, hydrochlorothiazide, 
hydroxyzine, hydroxychloroquine, indapamide, itraconazole, ivabradine (on non us mkt), 
ketoconazole, loperamide, metoclopramide, metronidazole, nelfinavir,  pantoprazole, 
paroxetine, posaconazole, quinine sulfate, ritonavir, sertraline, solifenacin, telaprevir, 
torsemide, trazodone, voriconazole, ziprasidone
1Combination ritonavir -boosted regimens are listed here in the DDI memo as strong CYP3A inhibitors (to avoid 
potential confusion), even though some are considered moderate CYP3A inhibitors in the UW  DDI Database.
2The effect of grapefruit juice varies widely among brands and is concentration -, dose -, and preparation -
depe ndent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation 
was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was 
used (e.g., low dose, single strength).
Table 14-2 Concomitant medications to be used with caution in asciminib arm
Category Drug Names
Narrow Therapeutic 
index substrates of 
CYP2C8Paclitaxel
Narrow Therapeutic 
index substrates of 
CYP2C9phenytoin, warfarin (also sensitive)
Narrow Therapeutic 
index substrates of 
CYP3Aalfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, sirolimus, terfanadine, 
BCRP
Inhibitorsabacavir, amprenavir, atorvastatin, ,curcumin3, cyclosporine3,  daclatasvir, declatasvir3, 
delavirdine, efavirenz, elbasvir, eltrombopag3, elvitegravir3, erlotinib, fluvastatin, 
fostamatinib, fumitremorgin, gefitinib, grazoprevir, lapatinib3, ledipasvir3, lopinavir, 
paritepravi r3, pitavastatin, rosuvastatin, simvastatin, sulfasalazine, tipranavir3, velpatasvir, 
venetoclax
P-gp inhibitors alogliptin, amiodarone4, azithromycin4, canaglifozin, captopril4, carvedilol4, clopidrogel, 
cremophor RH40, curcumin, diltiazem4, dronedarone4, elacridar4, eliglustat, felodipine4, 
fluvoxamine4, fostamatinib,  ginko4,5, isavuconazole, ivacaftor, lopinavir,, milk thistle 
(silymarin, silibinin)4,5, nifedipine4, nitredipine4,ombitasvir, paritaprevir, propafenone, 
quercetin,4, ritonavir4, sequinavir4, schisandra chinesis extract4,5, simepravir, St. John’s 
wort extract (HYPERICUM PERFORATUM)4,5,survorexant, talinolol4, telaprevir4, 
telmisartan4, ticagrelor4, tipranavir4, tolvaptan4, valspodar, vandetanib, verapamil4, 
voclosporin, vorapaxar.
3Evidence of in vivo DDI
4 Dual P -gp and CYP3A4 inhibitor
5 Herbal product

Novartis Confidential Page 142
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
14.2 Appendix 2 List of c oncomitant medications for patients on
bosutinib
Table 14-3 Prohibited concomitant medications for bosutinib arm
Category Drug Names
Strong inhibitors of 
CYP3Aboceprevir, clarithromycin, cobicistat, conivaptan, grapefruit juice2, idelalisib, indinavir, 
itraconazole, ketoconazole, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, 
telaprevir, telithromycin, troleandomycin, voriconazole, atazanavir/ritonavir1, 
danoprevir/ritonavir1, darunavir/ritonavir1, elvitegravir/ritonavir1, indinavir/ritonavir1, 
lopinavir/ritonavir1, ombitasvir/paritaprevir/dasabuvir/rit onavir (Viekira Pak)1 , 
saquinavir/ritonavir1, tipranavir/ritonavir1
Moderate inhibitors of 
CYP3Aaprepitant, amprenavir, atazanavir, cimetidine, ciprofloxacin, crizotinib, cyclosporine, 
darunavir, diltiazem, dronedarone, erythromycin, faldaprevir, fluconazole, grapefruit 
juice2, imatinib, isavuconazole, netupitant, nilotinib, tofisopam, Schisandra sphenanthera
(nan wu wei zi)3, asafoetida resin ( Ferula asafoetida )3, verapamil
Strong inducers of 
CYP3Acarbamazepine, enzalutamide, lumacaftor, mitotan e, phenobarbital, phenytoin, rifabutin, 
rifampicin, St. John’s wort ( Hypericum perforatum )3
Moderate inducers of 
CYP3Abosentan, efavirenz, etravirine, modafinil, nafcillin, ritonavir/tipranavir, thioridazine, 
semagacestat4, talviraline4, lopinavir, lersivirine, 
Proton pump 
inhibitorsdexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. 
1Combination ritonavir -boosted regimens are listed here in the DDI memo as strong CYP3A inhibitors (to avoid 
potential confusion), even though some are considered moderate CYP3A inhibitors in the UW  DDI Database.
2The effect of grapefruit juice varies widely among brands and is concentration -, dose -, and preparation -
dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation 
was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was 
used (e.g., low dose, single strength). 
3Herbal product
4 Dual P -gp and CYP3A4 inhibitor
Table 14-4 Concomitant medications to be used with caution in bosutinib arm
Category Drug Names
Torsade de pointe 
(TdP) TdP/QT risk : 
Knownamiodarone, anagrelide, arsenic trioxide, astemizole (off us mkt), azithromycin, bepridil 
(off us mkt), chloroquine, chlorpromazine, cilostazol, cisapride (off us mkt), citalopram, 
clarithromycin, cocaine, disopyramide, dofetilide, domperidone (not on us mkt), 
donepez il,dronedarone, droperidol, erythromycin, escitalopram, flecainide, fluconazole, 
grepafloxacin  (off market worldwide), halofantrine, haloperidol, ibutilide, levofloxacin, 
levomethadyl (off mkt worldwide), mesoridazine (off mkt worldwide), methadone, 
moxifloxacin, ondansetron, oxaliplatin, papaverine HCl, pentamidine, pimozide, probucol 
(off mkt worldwide), procainamide (oral off us mkt), propofol, quinidine, sevoflurane, 
sotalol, sparfloxacin (off us mkt), sulpiride (not on us mkt), terfenadine (off us m kt),
thioridazine, vandeta nib
TdP/QT risk: 
Possiblealfuzosin, apomorphine, aripiprazole, artenimol+piperaquine, asenapine, bedaquiline, 
bortezomib, buprenorphine, capecitabine, ceritinib, clomipramine, clozapine, crizotinib, 
cyamemazine (cyamepromazine) (Only on Non US Market), dabrafenib, dasatinib, 
degarilix, delamanid (off US mkt), desipramine, dexmedetomidine, dolas etron, eribulin, 
ezogabine, famotidine, felbamate, fingolimod, foscarnet, gemifloxacin, granisetron, 
hydrocodone -ER, iloperidone, imiprami ne (melipramine), isradipine, lapatinib, lenvatinib, 
leuprolide, lithium, mifepristone, mirabegron, mirtazapine, moexipril/hctz, nicardipine, 
nilotinib, norfloxacin, nortriptyline, ofloxacin, olanzapine, osimertinib, oxytocin, 
paliperidone, panabinostat, p asireotide, pazopanib, perflutren lipid microspheres, 
pipamperone (not on us mkt), promethazine, quetiapine, ranolazin e, rilpivirine, 
risperidone, roxithromycin (on non us mkt), saquinavir, sertindole (on non us mkt), 
sorafenib, sunitinib, tacrolimus, tamo xifen, telavancin, telithromycin, tetrabenazine 

Novartis Confidential Page 143
Amended Protocol Version 03- US.01 ( Clean ) Protocol No. CABL001A2301
Category Drug Names
(orphan drug in us), tizanidine, tolterodine, toremifene, trimipramine, vardenafil, 
vemurafenib, venlafaxine, vorinostat, zotepine
TdP/QT risk: 
Conditionalamantadine, amisulpride, amitriptyline, atazanavir, chloral hydrate, diphenhydramine, 
doxepin, fluoxetine, furosemide (frusemide), galantamine, hydrochlorothiazide, 
hydroxyzine, hydroxychloroquine, indapamide, itraconazole, ivabradine (on non us mkt), 
ketoconazole, loperamide, metoclopramide, metronidazole, nelfinavir,  pantoprazole, 
paroxetine, posaconazole, quinine sulfate, ritonavir, sertraline, solifenacin, telaprevir, 
torsemide, trazodone, voriconazole, ziprasidone

Clinical Development 
Asciminib/ABL001 
 
A phase 3, multi-center, open- label, randomized study of 
oral ABL001 (asciminib) versu s bosutinib in patients with 
Chronic Myelogenous Leukemia in chronic phase (CML-
CP), previously treated with 2 or more tyrosine kinase 
inhibitors 
Protocol – Summary of changes 
 
 
 
 
Property of Novartis 
Confidential 
May not be used, divulged, published or otherwise disclosed 
without the consent of Novartis 
 
Novartis Confidential Page 2 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
Amendment 3 (14-Dec-2018) 
Amendment rationale  
As of 21-Nov-2018, 137 patients were screened and 86 patients were randomized in the study, 
the study is currently ongoing. 
The primary purpose of the amendment is: 
Modification of the inclusion criterion of BCR-ABL1 transcript threshold required at study 
entry from a BCR-ABL1 ratio ≥ 1% IS to BCR-ABL1 ratio > 0.1% IS  (i.e. not in MMR) for 
patients with intolerance to most recent TKI treatment. The thr eshold presented in this inclusion 
criteria affects only patients who are intolerant to prior trea tment, since patients failing prior 
treatment must fulfill the criteria defined by ELN guidelines ( Baccarani et al 2013 ). Although 
the number of treatment options is increasing, especially for p atients with imatinib intolerance, 
alternatives for patients with resistance and/or intolerance to  at least two previous TKIs are 
limited ( NCCN 2018 , ELN 2013). The reason of reducing the BCR-ABL1 ratio is that in routine 
clinical practice, physicians do not wait to observe increased BCR-ABL1 levels to switch 
treatment in patients with intolerance, which may increase the risk of disease progression, 
especially in patients with only limited further treatment opti ons. This is in line with current 
CML treatment guidelines where the switch to an alternative the rapy in intolerant patients is 
not linked to a BCR-ABL1 threshold ( NCCN 2018 , Baccarani et al 2013  and Hochhaus et al 
2017 ).  
Therefore, the threshold of ≥ 1% BCR-ABL1 in the current trial is reduced to BCR-ABL1 ratio > 
0.1% IS for patients with intolerance to most recent TKI treatm ent. No more than 66 patients 
(approximately 30% of the overall trial population) that are in tolerant to their most recent TKI 
therapy with BCR-ABL1 < 1% will be recruited in order to ensure  that the CML third line 
patient population is adequately represented. As the primary en dpoint is the rate of MMR at 24 
weeks a baseline molecular response level > 0.1 % BCR-ABL1 is n eeded. 
Patients experiencing documented treatment failure on bosutinib  treatment will be allowed to 
switch to asciminib. Patients failing bosutinib treatment will have failed at least their third TKI 
treatment, with limited remaining treatment options. With this amendment patients who have 
failed bosutinib will be offered the possibility to continue in  the study by receiving asciminib, 
if investigators consider that this treatment option is in the best interest of the patient. As of 15-
Oct-2018, 4 patients could have potentially benefited from this  option. Treatment failure during 
s t u d y  t r e a t m e n t  i s  a s s e s s e d  b y  m e a s u r e a b l e  a n d  p r e - s p e c i f i e d  m i lestones defined by ELN 
criteria ( Baccarani et al 2013 ), which are also used to define treatment failure as entry cri teria 
for the study. Only documented treatment failure in the bosutin ib arm will be considered for a 
treatment switch. For the purpose of the primary and secondary endpoint analyses, any patient 
meeting the ELN failure criteria while receiving study treatmen t, (either before or by the time 
of conducting the analysis and irrespective of treatment arm), will be considered as non-
responders for the specific time point and for any subsequent t ime point. The switch to 
asciminib in case of bosutinib treatment failure is not expecte d to introduce bias as those 
patients will be regarded as non-responders irrespective of tre atment switch and the disease 
burden will certainly not improve without further treatment. Th ere is no option to switch 
patients failing on the asciminib treatment arm, as those patie nts can be offered approved 
Novartis Confidential Page 3 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
therapies outside of the context of the study. The efficacy dat a collected after the switch from 
patients switching to asciminib following bosutinib failure wil l be analyzed separately as 
exploratory endpoints and will no t be included for primary and secondary study endpoints. In 
addition, safety data from patie nts receiving asciminib after b osutinib failure will be collected 
to further characterize asciminib’s safety profile. 
Potassium increase of up to 6.0 mmol/L is acceptable at study e ntry if associated with creatinine 
clearance within normal limits. Grade 2 increase of potassium i s acceptable in case of normal 
creatinine clearance as this is not considered to be a risk fac tor for QTc prolongation. Total 
calcium (corrected for serum albumin) increase of up to 12.5 mg /dl or 3.1 mmol/L (Grade 2) is 
acceptable at study entry if associated with creatinine clearan ce within normal limits as this is 
not considered to be a risk factor for QTc prolongation. 
A change to creatinine clearance instead of GFR is being made i n relation to the magnesium 
inclusion requirement as GFR in this study is expressed by crea tinine clearance. 
Exclusion criteria #19 is being modified under this amendment i n order to define the duration 
of the use of highly effective me thods of contraception after t he last dose of bosutinib under 
this study (one month after last dose of bosutinib). This is being done in order to align with the 
latest Bosulif® USPI.  
Exclusion criteria #21 has also been removed under this amendme nt. In embryofetal 
development studies with asciminib, fetal malformations (cardia c malformations) and increased 
visceral and skeletal variants were observed in rats and increa sed incidence of resorptions 
indicative of embryo-fetal mortality and a low incidence of car diac malformations indicative of 
dysmorphogenesis were observed in rabbits. Asciminib  is not genotoxic. As published in the 
literature, small molecules can distribute to seminal fluid and  the seminal accumulation 
suggested is semen/plasma ratios up to 11.3 ( Klemmt and Scialli 2005 ). According to the FDA 
guidance, in general, there is increased concern for reproducti ve or developmental toxicity in 
humans for relative exposure ratios (animal: human) that are < 10 and decreased concern for exposure ratios > 25 (FDA Guidance for Industry 2011). The calc ulations for the asciminib 
safety margin were done based on Cmax (plasma) seen in patients  at a dose of 200 mg BID 
(Cmax 6843 ng/ml).  Safety margin calculation based on the embr yo-fetal development study 
in rats was 768 and safety margin calculation based on the embr yo-fetal development study in 
rabbits was 894. In conclusion, for asciminib, as outlined abov e, the safety margins are well 
above 25 and therefore no embryo - and fetotoxicity effects can be anticipated via seminal fluid. 
Removal of male contraception is  in line with the Bosutinib USP I and SmPC. 
In addition, patients can be re-screened up to three times for the study, instead of once.  The 
patient population being investigated in this study is heavily pre-treated and patients might not 
have other treatment options outside the trial. There can be ma ny intolerance-related temporary 
conditions resulti ng in ineligibility for the trial.  
Recruitment period extension has been reflected in the VES tabl e. Study length has changed 
with introduction of switch option for patients failing bosutin ib treatment. 
Patients enrolling in this trial will present a high disease bu rden after failure of previous 
therapies. Myelosuppression duri ng TKI targeted treatment is a very common effect observed 
due to the suppression of the le ukemic clone; this effect is al so extended to hematopoiesis of 
Novartis Confidential Page 4 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
stem  cells a nd progenit ors ( Steegmann et al 2016 ). For this reason, the recovery period for 
cytopenias has been extended from 28 to 42 days in order to all ow for sufficient time to recover 
from suppression and to re-populate the bone marrow. 
The biomarker sampling profile has been revised to remove the g ene expression profile in 
leukemic stem cells in both blood and bone marrow due to techni cal limitations.  In addition, 
there is currently no validated assay available. A clarification has been made to how the tests for blood urea a nd Blood Urea Nitrogen (BUN) 
are noted. The text "blood urea, Blood Urea Nitrogen (BUN)" has  been revised to “blood urea 
or Blood Urea Nitrogen (BUN)” in  order to note that either test  is permitted. 
Changes to the protocol 
Changes to specific sections of the protocol are shown in the t r a c k  c h a n g e s  v e r s i o n  o f  t h e  
protocol using strike through red font for deletions and red un derline for insertions. 
 Change of the purpose of the study by decreasing the requiremen t of BCR-ABL1 ratio ≥  
1% IS to BCR-ABL1 ratio > 0.1% IS at the time of screening for patients with 
intolerance: 
 Protocol summary. 
 Section 2.1 Study ra tionale and purpose. 
 Section 4.1 Description of study. 
 Section 5.2 Inclusion criteria. 
 Section 10.5.2 Other secondary efficacy objectives. 
 Change of the study design by introducing the switch to ascimin ib option for patients 
experiencing treatment failure on bosutinib treatment: 
 Protocol summary. 
 Section 2.2 Rationale for the study design. 
 Section 4.1 Description of study. 
 Figure 4-1 Schematic of Study Design. 
 Addition of Section 4.1.1 Study treatment switch from bosutinib  to asciminib 
 Section 4.3 Definitio n of end of study. 
 Section 6.1.5 Treatment duration 
 Section 6.7.3.2 Study drug accountability. 
 Section 7 Visit schedule and assessments: 
 Addition of Table 7-2 Visit evaluation schedule (study treatmen t switch phase). 
 Addition of Section 7.1.2.2 Conditions to be fulfilled for asci minib switch. 
 Section 7.1.5 Visit windows. 
 Section 7.1.6 Discontinuation of study treatment. 
 Section 7.2.1.1 Molecular response. 
 Section 7.2.1.2 Bone marrow analysis and cytogenetics 
 Section 7.2.2.1 Physical examination. 
Novartis Confidential Page 5 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
 Section 7.2.2.2 Vital signs. 
 Section 7.2.2.3 Height and weight. 
 Section 7.2.2.4 Performance status. 
 Section 7.2.2.5 Laboratory evaluations. 
 Section 7.2.2.6 Cardiac assessments. 
 Section 7.2.3 Pharmacokinetics. 
 Section 7.2.4 Biomarkers. 
 Section 10.1.6 Other analysis sets. 
 Section 10.5.3.1 Analysis set and grouping for the analysis 
 Addition of new exploratory measure for patients that switch fr om bosutinib to asciminib: 
 Table 3-1 Objectives and related endpoints. 
 Section 10.1.6 Other analysis sets. 
 Section 10.6 Exploratory objectives: 
 Section 10.6.1 Exploratory efficacy objectives. 
 Section 10.6.1.1 Data analysis of exploratory efficacy objectiv es. 
 Reference for concomitant medications with a “known risk of TdP ” has been updated to 
wwwcrediblemeds.org/ 
 Protocol summary 
 Section 5.3 Exclusion criteria 
 Section 6.3.2 Dose adjustm ents for QTcF prolongation 
 Section 6.4.3 Prohibited concomitant therapy 
  
  
  
  
  
 Section 5.2 Inclusion criteria and protocol summary: updated in clusion criteria to reflect 
the changes below: 
 Inclusion Criteria #3: As referenced above, the requirement of BCR-ABL1 ratio ≥ 1% 
IS has been decreased to BCR-ABL1  ratio > 0.1% IS at the time o f screening for 
patients intolerant to previous TKI. 
 Inclusion Criteria #10: Potassium increase of up to 6.0 mmol/L is accepted at study 
entry if associated with creatine clearance within normal limit s.  Calcium increase of 
up to 12.5 mg/dl or 3.1 mmol/L is acceptable at study entry if associated w ith 
creatinine clearance within norma l limits.  GFR replaced by Cre atinine clearance 
(calculated using Cockcroft-Gault formula) in order to maintain  consistency 
throughout the protocol as creatinine clearance is already calc ulated based on 
inclusion criteria #7. 
 Inclusion Criteria #11: As study eligibility is assessed during  screening with BCR-
ABL1 PCR quantification via inte rnational scale this requiremen t was added as 

Novartis Confidential Page 6 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
clarification. Measurement according to international scale is only possible for typical 
BCR-ABL1 transcripts. 
 Section 5.3 Exclusion Criteria and Protocol summary: updated ex clusion criteria to reflect 
the following changes: 
 Exclusion Criteria #14: Removal of P-gp as a moderate or strong  inhibitor of CYP3A 
as P-gp inhibitors are no longer prohibited per updated USPI, a nd SmPC 
 Exclusion Criteria #19: Duration of the use of highly effective  methods of 
contraception after the last dose of bosutinib has been defined  to align with the latest 
bosutinib USPI. 
 Exclusion Criteria #21 Removal of this criteria in order to ali gn with updated pre-
clinical data. 
 Section 6.3.1 Dose modification and dose delay: The recovery pe riod for cytopenias has 
been extended from 28 to 42 days in order to allow for sufficie nt time to recover from 
suppression and to re-populate the bone marrow. 
 Table 7-1 Visit evaluation schedule: updates due to inadvertent  omissions in previous 
protocols and to reflect extension of study treatment period 
 ECOG Performance status: X has been replaced by “If needed” und er Week 6, Week 
10 and Week 14. 
 Vital signs: added “If needed” under Week 6, Week 10 and Week 1 4. 
 Visit name: “W108, W120, W132, W144, W156” has been changed to “Every 12 
weeks up to end of study treatment” to align with new extended recruitment timelines. 
 Section 7.1.2 Change of patient re-screening allowance from onc e to up to three times. 
 Section 7.1.2.2 Addition of new section with screening eligibility criteria for patients 
switching from bosutinib to asciminib. 
 Section 7.1.4 Change of treatment duration for patients includi ng those patients that 
switch to asciminib after failure on bosutinib. Patients can re main on asciminib treatment 
for up to 96 weeks after the la st patient received the first do se in the study or up to 48 
weeks after the last patient has  switched to asciminib whicheve r is longer. 
 Section 7.1.6 Discontinuation of study treatment: updated to sp ecify that the safety follow-
up visit can be conducted by telephone and replacement of “afte r randomization” by “after 
initiation of therapy” in the eve nt that constitutes a treatmen t failure. 
 Section 7.2.2.5.3 Pregnancy and assessments of fertility: Chang e in requirement for 
reporting pregnancies under this study.  Pregnancies diagnosed in female partners of male 
participants are no longer required to be reported to CMO&PS.  Contraception use by 
sexually active males while on s tudy treatment is no longer req uired. 
 Table 7-5 Central clinical laboratory parameters collection pla n: Clarification on blood 
urea and Blood Urea Nitrogen (BU N). The text "blood urea, Blood  Urea Nitrogen (BUN)" 
has been revised to “blood urea or Blood Urea Nitrogen (BUN)”. 
 Section 8.4 Pre
gnancies: removal of male contraception requirem ent due to new 
information of asciminib embryo and fetotoxicity. 
 Section 10.4.3 Handling of missing values/censoring/discontinua tions: imputation rules 
updated to take in account unsched uled visits close to visit We ek 24. 
Novartis Confidential Page 7 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
 Section 10.5.1.1. Analysis for key secondary endpoints: imputation rules updated to take 
in account unscheduled visits close to visit Week 96. 
 Section 14 Appendices: updates to reflect that P-gp inhibitors are no longer prohibited 
 Section 14.2 Appendix List of concomitant medications for patie nts on bosutinib: 
 Removal of P-gp inhibitors from Table 14-3 Prohibited concomita nt medications 
for bosutinib arm. 
 Addition of new medications to Ca tegory Torsade de pointe (TdP) TdP/QT risk: 
Known. 
 Addition of new category, TdP/QT risk: Possible. 
 Addition of new category, T dP/QT risk: Conditional. 
IRBs/IECs 
A copy of this amended protocol will be sent to the Institution al Review Board 
(IRBs)/Independent Ethics Committ ee (IECs) and Health Authoriti es. 
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
The changes herein affect the Informed Consent. Sites are requi red to update and submit for 
approval a revised Informed Consent that takes into account the  changes described in this 
protocol amendment. 
Novartis Confidential Page 8 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
Amendment 2 (13-Jul-2018) 
Amendment rationale  
As of 29-Jun-2018, this study has been submitted in 25 and appr oved in 24 countries. Eighty 
five (85) sites were initiated, 67 patients were screened and 3 8 patients were randomized in the 
study. 
The primary purposes of the amendment are: 
The frequency of bone marrow aspirate (BMA) to perform cytogene tic analysis has been 
decreased in accordance with treatment guidelines (European Leu kemia Network (ELN) 
Guidelines ( Baccarani et al 2013) , National Comprehensive Cancer Network  (NCCN) (Clinical 
Practice Guidelines in Oncology-Chronic Myeloid Leukemia v4.201 8). Initially BMAs were 
foreseen at screening, every 24 weeks thereafter and at end of treatment. With the protocol 
amendment BMA is no longer needed for patients that have achiev ed MMR during study, 
however BMA assessment is requested at the time of end of treat ment for biomarker analysis.  
Toxicity studies performed in rats, dogs and cynomolgus monkeys  identified the pancreas as 
potential target tissues. Therefore the assessment for laborato ry parameters that are associated 
with pancreatitis were part of the inclusion criteria (amylase,  lipase). Serum lipase is the 
preferred test due to its improved sensitivity, and a threshold  concentration of 2-3 x ULN is 
recommended for the diagnosis of pancreatitis. There are a numb er of other conditions that can 
elevate lipase, including TKI pretreatment, thus the screening threshold for lipase is increased 
from ≤ ULN to ≤ 1.5 x ULN (CTCAE v4.03 grade 1), as patients wi th history of acute 
pancreatitis within 1 year of stu dy and history of  chronic panc reatitis are excluded. Amylase is 
not a specific marker for pancreatitis, as up to 60% of total s erum amylase originates from non-
pancreatic sources. Its short half-life reduces its value as a diagnostic test in the early clinical 
course. Lipase has replaced amylase as the biochemical test of choice for acute pancreatitis due 
to its higher specificity ( Basnayake 2015 ), therefore the requirement of amylase ≤ ULN at 
screening has been removed. 
Assessments for visits at weeks 6, 10 and 14 will be limited to  the monitoring of the bone 
marrow function to allow for adjustments of study treatment. As sessments will comprise a 
complete blood count to detect neutropenia and thrombocytopenia  which are among the most 
frequent adverse reactions [Asciminib Investigator’s Brochure , Bosutinib label] . The physical 
examination must be done at site only in case of previous or ne wly occurring adverse events. 
The concomitant medication section has been updated to reflect the most recent clinical updates 
on asciminib as well to align with the Bosutinib label. In addition some minor inconsiste ncies (discrepancies between s ections, typos) have been 
corrected. 
Changes to the protocol 
Changes to specific sections of the protocol are shown in the t r a c k  c h a n g e s  v e r s i o n  o f  t h e  
protocol using strike through red font for deletions and red un derline for insertions. 
 ABL001 has been replaced by International Nonproprietary Name ( INN) asciminib 
throughout the protocol amendment. 
Novartis Confidential Page 10 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
 Section 6.3.1 Dose modification and dose delay: clarification m ade on treatment 
discontinuation. 
 Table 6-2 Criteria for dose reduction/interruption and re-initi ation of asciminib and 
bosutinib treatment for adverse drug reactions:  
 Gastro intestinal/ Pancreatitis/ Grade 2: precisions provided an d treatment delay 
changed from 7 to 21 days to give investigators sufficient time for re-assessment. 
 Removal of “other adverse event” section which was redundant wi th the section “non-
hematological adverse event reaction except where further specified in individual 
section”. 
 Mandatory instructions for grade 3 and 4 “Non-hematological adv erse event reaction 
except where further specified in individual section” for bosut inib have been aligned 
with those of asciminib: dose hol d until resolved to ≤ grade 1,  to handle the patients 
identically independent of the treatment assigned. 
 Section 6.3.2 Dose adjustments for QTcF prolongation: adapting the dose adjustment 
concerning QT prolonging agents to the classification known, po ssible or conditional risk 
for TdP, and adding the external web link to qtdrugs.org.  
 Section 6.4.2 Permitted concomitant therapy requiring caution a nd/or action: updated with 
the most clinical data available. 
 Section 6.4.3 Prohibited concomitant therapy (asciminib): 
 Section on other anticancer agent added, 
 Sections on strong CYP3A4/5 inhibitors and P-gp inhibitors: pro hibition on P-gp 
inhibitors has been removed and moved under requiring caution a nd/or action section 
based on CABL001A2102 ADME study, 
 Section on strong CYP3A4/5, UGT1A/2B inducers updated to provid e instructions on 
action to be taken in case these inducers are taken, 
 Section on NTI substrates of CYP3A4/5, CYP2C8 and CYP2C9 remove d based on a 
most updated PBPK modeling predicting a negligible risk for sen sitive CYP3A4/5, 
CYP2C8, or CYP2C9 substrates and moved under requiring caution and/or action 
section, 
 Section on QT prolonging agents updated to change agents known to prolong QT 
interval to agents with “known”, “possible” or “conditional” ri sk of Torsades de 
Pointes. 
 Section 6.5.1 Permitted concomitant therapy requiring caution ( bosutinib): has been 
updated to reflect the bosutinib label information regarding th e use of QT prolonging agents.  
 Section 6.5.2 Prohibited concomitant therapy (bosutinib):  
 Section on other anticancer agent added, 
 Concomitant use with CYP3A4/5 inhibitors/inducers: further clar ifications on 
necessary actions.  
 Table 7-1 Visit evaluation schedule:  
 Exploratory BCR-ABL1 mutation analysis (Sanger Sequencing) for patient s with 
mutations at Week 1 Day 1: rephrased to indicate that this asse ssment will be 
performed without any dedicated blood collection. 
Novartis Confidential Page 13 
Protocol – Summary of changes  Protocol No. CABL001A2301 
 
 Section 10.5.2 Other secondary e fficacy objectives: update of descriptive statistics 
definition and removal of presentation of p value as no formal statistical testing will be 
performed. 
 Section 10.6.1 Exploratory efficacy objectives and Section 10.6 .3 Exploratory biomarker 
objectives:  
 Correction of time points for BC R-ABL1 mutation characterizatio n (baseline 
corrected to Week 1 Day 1, adding “upon confirmed loss of MMR, and changed 
“and” to “and/or” End of treatment). 
 .  
 Section 10.6.4.1 Resource utilization: correction on duration o f resource utilization 
reporting.  
 Section 10.7 Interim analysis: clarification concerning the ana lysis of the key secondary 
endpoint at week 96 if statistical significance is not reached for primary endpoint at week 
24. 
 Section 14 Appendices: the lists  of concomitant medications for  patients on asciminib and 
bosutinib have been updated based on the internal Pharmacokinet ic Sciences 
memorandum on Drug-Drug Interaction (release date: January 2018 ). 
 Some minor inconsistencies (discrepancies between sections, typos) have been corrected. 
IRBs/IECs 
A copy of this amended protocol will be sent to the Institution al Review Board 
(IRBs)/Independent Ethics Committ ee (IECs) and Health Authoriti es. 
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
The changes herein affect the Informed Consent. Sites are requi red to update and submit for 
approval a revised Informed Consent that takes into account the  changes described in this 
protocol amendment. 

2. Statistical Analysis Plan 
Clinical Development
ABL001 /asciminib
CABL001A2301
A phase 3, multi -center, open -label, randomized study  of 
oral ABL001 v ersus bosutinib in patients w ith Chronic 
Myelogenous Leukemia in chronic phase (CML -CP), 
previously  treated w ith 2 or more ty rosine kinase inhibitors
Statistical A nalysis Plan (SA P)
Author:Statistician, 
Document type: SAP Documentation
Document status: Final
Release date: 25-Aug-2017
Number of pages: 53
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis

Novartis Confidential Page 2
SAP 25-Aug-2017 (5:41) CABL001A2301
Document History  –Changes compared to previous final version of SAP
Date Time point Reason for 
updateOutcome for update Section and title 
impacted 
(Current)
25-
Aug-
2017Prior to DB 
lock for 
primary  
analysisCreation of 
final versionN/A -First version NA
Novartis Confidential Page 3
SAP 25-Aug-2017 (5:41) CABL001A2301
Table of contents
Table of contents ................................................................................................................. 3
1Introduction ......................................................................................................................... 7
1.1 Study  design ............................................................................................................. 7
1.2 Study  objectives and endpoints ............................................................................... 8
2Statistical met hods............................................................................................................... 9
2.1 Data analy sis general information ........................................................................... 9
2.1.1 General definitions ................................................................................ 11
2.2 Analy sis sets .......................................................................................................... 17
2.2.1 Subgroup of interest .............................................................................. 19
2.3 Patient disposition, demographics and other baseline characteristics ................... 20
2.3.1 Patient disposition ................................................................................. 21
2.4 Treatments (stud y treatment, rescue medication, concomitant therapies, 
compliance) ............................................................................................................ 22
2.4.1 Study  treatment / compliance ................................................................ 22
2.4.2 Prior, concomitant and post therapies ................................................... 24
2.5 Analy sis of the primary  objective .......................................................................... 25
2.5.1 Primary  endpoint ................................................................................... 25
2.5.2 Statistical hy pothesis, model, and method of an alysis .......................... 25
2.5.3 Handling of missing values/censoring/discontinuations ....................... 26
2.5.4 Supportive analy ses............................................................................... 26
2.6 Analy sis of the key  secondary  objective ............................................................... 26
2.6.1 Key secondary  endpoint ........................................................................ 26
2.6.2 Statistical hy pothesis, model, and method of analy sis.......................... 26
2.6.3 Handling of missing values/censoring/discontinuations ....................... 27
2.7 Analy sis of secondary  efficacy  objective(s) .......................................................... 27
2.7.1 Secondary endpoints ............................................................................. 27
2.7.2 Statistical hy pothesis, model, and method of analy sis.......................... 29
2.7.3 Handling of missing values/ce nsoring/discontinuations ....................... 31
2.8 Safety  anal yses....................................................................................................... 32
2.8.1 Adverse event s (AEs) ............................................................................ 32
2.8.2 Deaths .................................................................................................... 33
2.8.3 Laboratory  data ..................................................................................... 33
2.8.4 Other safety  data ................................................................................... 34
2.8.5 Additional Analy ses.............................................................................. 36
2.9 Pharmacokinetic endpoints.................................................................................... 36
Novartis Confidential Page 4
SAP 25-Aug-2017 (5:41) CABL001A2301
2.10 PD and PK/PD analy ses......................................................................................... 38
2.11 Patient- reported outcomes ..................................................................................... 38
2.11.1 MDASI -CML ........................................................................................ 39
2.11.2 EQ-5D- 5L............................................................................................. 39
2.11.3 WPAI -CML ........................................................................................... 40
2.11.4 PGIC...................................................................................................... 40
2.12 Resource utilization ............................................................................................... 41
2.13 Biomarkers ............................................................................................................. 41
2.13.1 Somatic mutation biomarker data handling and analy sis...................... 43
2.14 Other exploratory  anal yses.................................................................................... 44
2.15 Interim anal ysis...................................................................................................... 45
3 Sample size calculation ..................................................................................................... 45
3.1 Primary  anal ysis..................................................................................................... 45
3.2 Power for anal ysis of key secondary  variables...................................................... 46
4Change to protocol specified anal yses.............................................................................. 46
5Appendix ........................................................................................................................... 46
5.1 Imputation rules ..................................................................................................... 46
5.1.1 Study  drug ............................................................................................. 46
5.1.2 AE, ConMeds and safety assessment date imputation .......................... 47
5.2 AEs coding/grading ............................................................................................... 49
5.3 Laboratory  parameters derivations ........................................................................ 49
5.4 Derivation of PCR results and loss of response ..................................................... 50
5.5 Statistical models ................................................................................................... 51
5.5.1 Primary  anal ysis.................................................................................... 51
5.5.2 Key secondary  anal ysis......................................................................... 52
5.5.3 Other anal yses....................................................................................... 52
6Reference ........................................................................................................................... 53
Novartis Confidential Page 5
SAP 25-Aug-2017 (5:41) CABL001A2301
List of abbreviations
AE Adverse event
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AP Accelerated phase
AST Aspartate aminotransferase
ATC Anatomical therapeutic classification
AUC Area under the curve
BC Blast crisis
bid bis in diem/twice a day
CCyR Complete cytogenetic response
CHR Complete hematologic response
CMH Cochrane -Mantel -Haenszel
CML Chronic myelogenous leukemia
CML- CP Chronic myelogenous leukemia in chronic phase
CRO Contract research o rganization
CSP Clinical study protocol
CSR Clinical study report
CTCAE Common terminolog y criteria for adverse events
CV Coefficient of variation
DAR Dosage administration record
DI Dose intensity
DMC Data monitoring committee 
DRL Drug reference  listing
DSUR Development safety update report
ECG Electrocardiogram
eCRF Electronic case r eport f orm
EOT End of treatment
ER Emergency room
FAS Full analysis set
GP General practitioner
H Hospitalization
HCRU Health care resource utilization
HLT High level term
HLGT High level group term
IRT Interactive response technology
IS International scale
LLOQ Lower limit of quantitation
LPFT Last patient f irst treatment
LSC Leukemic stem cell
LVEF Left ventricular ejection fraction
MCyR Major cytogenetic response
Novartis Confidential Page 6
SAP 25-Aug-2017 (5:41) CABL001A2301
mCyR Minor cytogenetic response
MedDRA Medical d ictionary for regulatory activities
MMR Major molecular response
NCI National Cancer Institute
NGS Next g eneration sequencing
NMQ Novartis MedDRA Query
OS Overall survival
PAS Pharmacokinetic analysis s et
PCR Polymerase chain reaction
PCyR Partial cytogenetic response
PD Pharmacodynamic
PDI Planned dose i ntensity
PFS Progression -free rurvival
Ph+ Philadelphia chromosome positive
PK Pharmacokinetics
PPS Per-protocol set
PRO Patient -reported outcomes
PSUR Periodic safety  update report
PT Preferred term
qd Qua’que di’e / once a day
RDI Relative dose intensity
SAE Serious adverse event
SAP Statistical analysis plan
SD Standard deviation
SMQ Standardized MedDRA query
SOC System organ class
Sp Specialist
TBL Total b ilirubin
TKI Tyrosine kinase inhibitor
TTF Time to treatment failure
UC Urgent care
ULN Upper limit of norm
VAS Visual analogue scale
W1D1 Week 1Day 1
WBC White blood cell s
WHO-DD World Health Organization Drug Dictionary
Novartis Confidential Page 7
SAP 25-Aug-2017 (5:41) CABL001A2301
1 Introduction
This statistical analysis plan (SAP) describes all planned analysesof primary objective,
secondary  objectives and selected exploratory  objectives for the clinical study  report s(CSR) 
of study CABL001A2301, a phase 3, multi -center, open -label, randomized study  of oral 
ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase 
(CML -CP), previously  treated with 2 or more ty rosine kinase inhibitors . 
The content of this SAP is based on protocol CABL001A2301 version 01.All decisions 
regarding safet y monitoring analysis for the data monitoring committee, 24-week primary
analysis, 96
-week end of study  treatment analysis, 5-yearprogression -free survival 
(PFS)/overall survival (OS)update analysis,development safety  update report 
(DSUR )/periodic safety  update report (PSUR ), and postings for ClinTrial.gov and EudraCT,
as defined in thisSAP document, have been made prior to the first database lock of the study 
data for the primary  analy sis.
1.1 Stud y design
This is a randomized,  Phase III , open -label,  active -controlled, multi -center study   comparing  
safet y and efficacy  ofABL001 tobosutinib inpatients with CML -CP, previously  treated with 
2 or more tyrosine kinase inhibitors (Figure 1-1). Approximately 220 patients will be 
randomized to one of the following treatment arms in 2:1ratio:
ABL001
Bosutinib
Randomization will be stratified by the following factor: cytogenetic response status (with or 
without major cy togenetic response).
Figure 1
-1 Schematic of Study  Design
Patients will be treated for up to 96 weeks after the last patient received the first study  dose
(LPFT) , if they do not discontinue study  treatment earlier . After the study  treatment period 
(i.e. LPFT + 96 weeks ), the assigned study treatment will be made available to pati ents who in 
the opinion of the investigator sare still deriving clinical benefit. This may be outside of this 
study  through alternative options including, but not limited to, an expanded 

Novartis Confidential Page 8
SAP 25-Aug-2017 (5:41) CABL001A2301
access/compassionate use/managed access program or access to commercial supplies in 
applicable countries.
Major Molecular Response (MMR) rate at 24 weeks is the primary  endpoint in this study . 
MMR rate at 96 weeks is the key  secondary  endpoint.
The primary  analysis will be performed after all patien ts have been followed for at least 24 
weeks or have discontinued study earlier. The end of study  treatment analysis will be 
performed after all patients have been followed for at least 96 weeks or have discontinued 
study earlier. The PFS/OS update analy siswill be performed about 5 years after the date the 
last patient received the first study  dose.
No formal interim efficacy  analysis is planned in this study . A data monitoring committee 
(DMC )will monitor unblinded safet y data approximately  6months after the first randomized 
patient has started study  treatment. Subsequent reviews will be conducted approximately  
every  6 months on an as and when needed basis thereafter (ie. if significant safety  findings are 
noted) until the primary  analy sis.
1.2 Stud y objectiv esand endpoints
Table 1-1 Objectives and related endpoints
Objective Endpoint
Primary
To compare the MMR rate at 24 weeks of 
ABL001 versus bosutinib Major Molecular Response (MMR) rate at 24 weeks
Key secondary
To compare additional parameters of the 
efficacy of ABL001 versus bosutinib MMR rate at 96 weeks
Other secondary
To compare additional parameters of the 
efficacy of ABL001 versus bosutinibCytogenetic response rate (Complete, Partial, Major, 
Minor, Minimal, no response) at and by all scheduled data 
collection time points including 24, 48 and 96 weeks
MMR rate at all scheduled data collection time points  
(except 24 and 96 weeks which are already covered by 
primary and key secondary endpoints)
MMR rate by all scheduled data collection time points 
including 24, 48 and 96 weeks
Time to MMR
Duration of MMR
Time to CCyR
Duration of CCyR
Time to treatment failure
Progression free survival
Overall survival
To compare the safety and tolerability 
profile of ABL001 versus bosutinibType, frequency and severity of adverse events,
Changes in laboratory values that fall outside the pre -
determined ranges and clinically notable ECG and other safety 
data (vital signs, physical examination)
To characterize the PK of ABL001 in the 
CML-CP populationTrough plasma concentrations,
PK parameters in full PK group: Cmax, Tmax, AUC0 -12h, CL/F 
Novartis Confidential Page 9
SAP 25-Aug-2017 (5:41) CABL001A2301
Objective Endpoint
Exploratory
To evaluate the influence of factors such as 
cytogenetic response at baseline, 
failure/intolerance to prior TKIs, line of 
therapy, gender, race and age on the effect 
of ABL001 with respect to the primary 
efficacy endpoint Major Molecular Response (MMR) ra te at 24 weeks
To explore the exposure -response 
relationships of ABL001; evaluate the effect 
of population covariatesExposure -safety ,exposure -efficacy, and exposure -biomarker
analyses
To characterize mutations in the BCR -ABL1 
gene at baseline and at end of treatment 
and examine their association with 
molecular and cytogenetic r esponse for 
ABL001 vs bosutinibBCR -ABL1 gene mutations at baseline and at end of treatment 
as determined by Sanger Sequencing
To correlate gene expression profiles in 
leukemic stem cell (LSC) -enriched blood 
and bone marrow with r esponse to ABL001 
vs. bosutinibGene expression profile at baseline and changes to gene 
expression at end of treatment 
To characterize the effect of ABL001 vs. 
bosutinib treatment on CML LSC a nd 
normal progenitor cells (e.g. growth and 
differentiation) and their bone marrow 
microenvironment nichesAssess Week 1 Day1 pre -dose and at EOT correlation of 
molecular and cytogenetic response by f low cytometry analysis 
of:  1) LSCs; 2) T -cell maturatio n; 3) T -cell activation and 
differentiation; 4) myeloid derived suppressor cells in blood and 
bone marrow aspirates.
Bone marrow biopsies characterization for adaptive immune 
response by IHC (Immunohistochemistry) for PD -L1, CD8
To assess clonal evolution during trea tment 
with ABL001 vs. bosutinibLow level BCR -ABL1 mutation profiles assessed by mass 
spectrometry at baseline and at EOT.  
Clonal evolution of several genes implicated in CML assessed 
by Next Generation Sequencing (NGS) methods 
To evaluate soluble factors that correlate 
with response to ABL001 vs. bosutinib 
treatment in terms of tumor immunogenicity 
statusBaseline and changes from baseline of c ytokine expression in 
plasma  
To compare the impact of treatment on 
patient reported outcomes (PRO) including 
CML-specific symptoms, patient quality of 
life, and impact on work productivity and 
activity impairment from baseline and EOT 
between  treatment arms in all patientsChange in symptom burden and interference from baseline over 
time accordin g to the MDASI -CML PRO instrument
Change in patient’s impression of CML symptoms according to 
PGIC
Change in health utility from baseline over time according to 
EQ-5D-5L
To compare the impact of treatment on 
health care resource utilization between 
treatm ent arms in all patientsHealth care resource burden over time
2 Statistical methods
2.1 Data analy sisgeneral information
The planned analy ses will be performed by Novartis and/or a designated CRO . SAS version 
9.4 or later will be used to perform all data analy ses and to generate tables, figures and listings.
There is no planned interim efficacy  analysis. Prior to the database lock for the primary  
analysis, tables and figures aggregated by treatment arm for safet y data review by the data 
Novartis Confidential Page 10
SAP 25-Aug-2017 (5:41) CABL001A2301
monitoring committe e or for other reporting activities will be produced by an independent 
statistician and independent statistical programmers.
For between -treatment comparisons of efficacy  endpoints, randomization stratification factor, 
i.e. cytogenetic response status (MCyR vs no MCy R) at screening , will beincluded in
respective stratified statistical tests.
Data included in the analy ses
The anal ysis data cut-off date s for the planned analy ses are:
Primary  anal ysis:After all randomized patients have been on stud y treat ment for 24
weeks or  discontinued earlier , i.e., LPFT + 24 weeks . 
End of study  treatment analy sis:30 day s after all patients have been on treatment for 
at least 96 weeks or discontinued earlier , i.e., L PFT + 96 weeks + 30 day s. (Note: 
After the stud y treatment period, the assigned study  treatment will be made available, 
may be outside of this study , to patients who in the opinion of the investigators are 
still deriving clinical benefit. ) 
PFS/OS update analysis:5 years from the date when the last pati ent received the first 
study  dose .
All statistical analyseswill be performed using all data colle ctedinthe database upto th e
respective data cut-offdate. Alldata with an assessment date orevent start date (e.g. vital
sign assessment date orstart date ofanadverse event) prior toor on thecut-offdate will be
included intheanalysis.Any data collected beyond thecut-offdate will not be included in 
theanalysis and will not be used for a ny derivations.
All events with start date before or on the respective cut-off date and end date after the 
respective cut-off date will be reported as ongoing . The same rule will be applied to events 
starting before or on the respective cut-off date and not having documen ted end date. This 
approach applies, in particular, to adverse event and concomitant medication reports. For 
these events, the end date will not be imputed and therefore will not appear in the listings.
General analy sis conventions
Pooling of center s:Unle ss specified otherwise, data from all study  centers will be pooled for 
the anal ysis. Due to expected small number of patients enrolled at centers, no center effect 
will be assessed. 
Qualitative data (e.g., gender, race, etc.) will be summarized by  means of contingency  tables
by treatment group; a missing category  will be included as applicable. Percentages will be
calculated using the number of patients in the relevant population or subgroup as the
denominator.
Quantitative data (e.g., age, body  weight, etc.) will be summarized by appropriate
descriptive statistics (i.e. mean, standard deviation, median, minimum, and maximum) by 
treatment group .For pharmacokinetics (PK)concentration and parameters descriptive 
statistics also include coefficient of variation ( CV)%, geo -mean and geo -CV%.
Novartis Confidential Page 11
SAP 25-Aug-2017 (5:41) CABL001A2301
2.1.1 General d efinition s
Investigational drug and study  treatment
Investigational drug , will refer to the ABL001 only. Whereas, study treatment will refer to 
ABL001 orcontrol treatment , i.e. bosutinib .
Date of first administration of study  treatment 
The date of first administration of study  treatment is derived as the first date when a non- zero 
dose of study  treatment was administered as per the Dosage Administration Record (DAR)
electronic case report form (eCRF ). The date of first administration of study  treatment will 
also be referred as start of study treatment .
The date of first administration of study  treatment is the same as the date of first 
administration of investigational drug or control drug. 
Date of last administration of study  treatment 
The date of last administration of study  treatment is defined as the last date when a non- zero 
dose of study  treatment was administered as per DAR eCRF. 
The date of las t administration of study  treatment is the same as the date of last administration 
of investigational drug or control drug.
Study day
The study  day, describes the day  of the event or assessment date, relative to the reference start 
date. 
The study  day is defined as:
The date of the event (visit date, onset date of an event, assessment date ,etc.) −
reference start date + 1 if event is on or after the reference start dat e;
The date of the event (visit date, onset date of an event, assessment date ,etc.) − 
reference start date if event precedes the reference start date.
The reference start dateforsafety assessments (e.g.adverse event onset, laboratory 
abnormality occurrence, vital sign measurement, dose interruption, PK,etc.) isthestart of
study  treatment.
The reference start date forallother, non- safety assessments (e.g.molecular response, 
survival time, disease progression, ECOG performance status, patient reported outcomes
(PRO) , etc. )isthedate ofrandomization.
The study  day will be display ed in the data listings. I fanevent starts before thereference start 
date, thestudy day displa yed on the listing will be negative.
Time unit
A year length is defined as 365.25 days. A month length is 30.4375  (=365.25/12) days. If 
duration is reported in months, duration in days will be divided by 30.4375.  If duration is  
reported in years, duration in day s will be divided by  365.25.
Novartis Confidential Page 12
SAP 25-Aug-2017 (5:41) CABL001A2301
A week length is defined as 7 days. If duration is reported in weeks, duration in days will be 
divided by  7.
Baseline
For efficacy evaluations , the last non-missing assessment, including unscheduled assessments 
on or before the date of randomization is taken as “baseline” value or “baseline” assessment. 
In the context of baseline definition, the efficacy  evaluations also include PRO and
performance status. 
For safet y evaluations , the last available assessment on or before the date of start of study 
treatment is taken as‘‘baseline” assessment.
For pre-dose electrocardiogram (ECG ), the last availabl e assessment before the treatment start 
date/time is used for baseline.
For ECGs, where study requires multiple replicates per time point, the average of theses 
measurements would be calculated for baseline (if not alread y available in the database).
In rare cases where multiple laboratory measurements meet the baseline definition, with no 
further flag or label that can identify  the chronological order, then the following rule should 
be applied: If values are from central and local laboratories, the va lue from central assessment 
should be co nsidered as baseline.
If patients have no value as defined above, the baseline result will be missing.
On-treatment assessment/event and observation periods
For adverse event reporting the overall observation period will be divided into three mutually  
exclusive segments: 
1.pre-treatment period : from day of patient’s informed consent to the day before first 
administration of study  treatment
2.on-treatment period : from date of first administration of study  treatment to 30days 
after date of last actual administration ofany study  treatment (including start and stop 
date) . Note: Patients will be treated forup to LPFT + 96 weeks . This will be the last 
actual administration of study  treatment for each patient if the patient has not 
discontinue dstudy  treatment earlier. After this period, the assigned study  treatment 
will be made available, may be outside of this study , to patients who in the opinion of 
the investigators are still deriving clinical benefit.
3.post-treatment period : starting at day  31 after last administration of study  treatment .
If dates are incomplete in a way that clear assignment to pre-, on-, or post- treatment period 
cannot be made, then the respective data will be assigned to the on -treatment period.
Safety summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change 
from baseline summaries). In particular, summary  tables for adverse events (AEs ) will 
summarize only on-treatment events, with a start date during the on-treatment period 
Novartis Confidential Page 14
SAP 25-Aug-2017 (5:41) CABL001A2301
Table 2-2 Time windows for cy togenetic response
Assessment Target dayofassessment Time Interval
Baseline ≤ 1 ≤ Day 1#
Week 12* 78-84 Day 2 to day 122
Week 24 162-168 Day 123to day 248
Week 48 330-336 Day 249to day 416
Week 72 498-504 Day 417to day 584
Week 96 666-672 Day 585 to day 700
# Day 1 = Date of randomization
*Optional for patients in bosutinib arm to allow potential intra -patient dose escalation
Table 2-3 Time windows for ECG assessments
Assessment Target dayofassessment Time Interval
Baseline 1 ≤ Day 1#
Week 2 Day 1 8 Day 2 to day 14
Week 4 22-28 Day 15 to day 52
Week 12 78-84 Day 53 to day 122
Week 24 162-168 Day 123 to day 3 29
Week 96 666-672 Day 330 to day 700
# Day 1 = Date of first administration of study treatment
Table 2-4 Time windows for LVEF
Assessment Target dayofassessment Time Interval
Baseline ≤ 1 ≤ Day 1#
Week 20 134-140 Day 2 to day 168
# Day 1 = Date of first administration of study treatment
Table 2-5 Time windows for pharmacokinetic assessments
Assessment Target dayofassessment Time Interval
Baseline 1 ≤ Day 1#
Week 2 Day 1 8 Day 2 to day 14
Week 4 22-28 Day 15to day 52
Week 12 78-84 Day 53 to day 122
Week 24 162-168 Day 123 to day 329
Week 96 666-672 Day 330to day 700
# Day 1 = Date of first administration of study treatment
Novartis Confidential Page 15
SAP 25-Aug-2017 (5:41) CABL001A2301
For PRO data time windows will be defined for descriptive summary  by visit and longitudinal 
data analysis. If more than one assessment is available in the same time window, the 
assessment closest to the planned date will be considered. If two assessments are obtained 
with the same time difference compared to the scheduled visit day, the assessment obtained 
prior to visit will be considered.  
Table 2-6 Time windows for PRO : MDA SI-CML, EQ -5D-5L, PGIC
Assessment Target dayofassessment Time Interval
Baseline ≤ 1 ≤ Day 1#
Week 4 22-28 Day 2 to day 38
Week 8 50-56 Day 39 to day 66
Week 12 78-84 Day 67to day 94
Week 16 106-112 Day 95 to day 136
Week 24 162-168 Day 137 to day 206
Week 36 246-252 Day 207to day 290
Week 48 330-336 Day 291 to day 50 0
Week 96 666-672 Day 50 1to day 700
# Day 1 = Date of randomization
Table 2-7 Time windows for PRO : WPA I-CML
Assessment Target dayofassessment Time Interval
Baseline ≤ 1 ≤ Day 1#
Week 4 22-28 Day 2 to day 52
Week 12 78-84 Day 53 to day 122
Week 24 162-168 Day 123 to day 248
Week 48 330-336 Day 249 to day 50 0
Week 96 666-672 Day 50 1to day 700
# Day 1 = Date of randomization
Novartis Confidential Page 16
SAP 25-Aug-2017 (5:41) CABL001A2301
Last contact date 
The last contact date will be derived for patients not known to have died at the respective 
analysis data cut -off date using the last complete date among the following:
Table 2-8 Last contact date data sources
Source data Conditions
Date of r andom ization No condition
Last contac t date/last date patient was known to 
be alive from Survival Follow -up page Patient status is reported to be alive , lost to 
follow -up or unknown
Start/End dates from further antineoplastic 
therapyNon-missing medication/ procedure term
Start/End dates from drug administration record Non-missing dose. Doses of 0 are allowed
End of treatment date from end of treatment page No condition
Any specific efficacy  (molecular or cytogenetic) 
assessment date if availableEvaluation is marked as ‘done’
Laboratory/PK collection dates Sample collection marked as ‘done’
Vital signs da te At least one non-missing parameter value
Performance status date Non-missing performance status
Start/End dates of AE Non-missing verbatim term
The last contact date is defined as the latest complete date from the above list on or before the 
respective data cut-off date. The cut-offdate willnotbe used for last contact date, unless the
patient was seen or contacted on thatdate.No date post the cut-off date will be used. 
Completely  imputed dates (e.g. theanalysisdata cut-offdate programmaticall yimputed to
replac ethemissing enddate of a dose administration record) will not b e used toderive the 
last contact dat e. 
The last contact date will be used for censoring of patients in the anal ysis of overall survival.
Novartis Confidential Page 17
SAP 25-Aug-2017 (5:41) CABL001A2301
2.2 Analysis sets
Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all patients to whom study  treatment has been 
assigned b y randomization. According to the intent to treat principle, patients will be analy zed 
according to the treatment and stratumthey have been assigned to during the randomization 
procedure.
Per Protocol Set 
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with requirements of the clinical study  protocol (CSP).The PPS will be used for sensitivity 
analyses on the primary  endpoint only .
The followin g list of protocol deviations will lead to exclusion of the patient from the PPS:
Type of indication different from those required by the CSP , e.g., not CML -CP, BCR -
ABL ratio <1% International S cale(IS), with T315I  or V299L mutation (INC L03, 
INCL04, INCL05, EXCL01 )
If prior therapy  does not match with CSP requirements in terms of number and ty pes 
of previous therap y regimens (INCL06)
Study treatment received different from treatment assigned by randomization (TRT08)
Safety Set
The Safety Setincludes all subjects who received at least one dose of study  treatment. 
Subjects will be analy zed according to the study  treatment actuall y received.
The actual treatment received corresponds to:
the randomized treatment if patients took at least one dose of that treatment ;
the first treatment received if the randomized treatment was never received.
Pharmacokinetic Analysis Set
The Pharmacokinetic Analysis Set (PAS) includes all patients who provide at least one 
evaluable PK concentration. For a concentration to be evaluable, patients are required to:
Take a d ose of ABL001 prior to sampling
Take the same dose of ABL001 for at least 3consecutive day s without dose 
interruption or dose modification prior to sampling
For pre -dose samples , do n ot vomit within 4 hours after the dosing of ABL001 prior 
to sampling (this is the previous dose) ; for post -dose samples, do not vomit within 4 
hours after the dosing of ABL001 (this is the current dose)  
Have thepre-dose sample collected before thenext dose administration
Novartis Confidential Page 18
SAP 25-Aug-2017 (5:41) CABL001A2301
Other analy sis sets
For duration of MMR and time to MMR, the MMR Responder Set will be used that 
is a subset of FAS and includes patients who achieve MMR at any  time on study  
treatment .
For CCy Rrates at and b y scheduled time points, the CCyR Analysis Set will be used 
that is a subset of FAS and includes patients who are not in CCy R at baseline.
For duration of CCy R and time to CCy R, the Cytogenetic Responder Set will be use 
that is a subset of F AS and includes patients who do not have CCy R at baseline and 
achieve CC yR at any  time on study  treatment .
Patient Classification
Patients may be excluded from the analysis populations defined above based on the protocol 
deviations entered in the databas e and/or on specific subject classification rules defined in 
Table 2 -9. 
Table 2-9 Subject classification based on protoco l deviations and non protocol 
deviation criteria
Analy sis set Protocol deviations leading to 
exclusionNon protocol deviation 
leading to exclusion
FAS No written inform consent Not applicable
Safety  set No written inform consent No dose of stud y medication 
Per-protocol set See definition of PP S A nother anti-neoplastic 
therap y administered after 
start of study  treatment
PK analysis set No written inform consent See definition of PAS
MMR Responder Set Not applicable See definition of MMR 
Responder Set
CCyR Anal ysis Set Not applicable See definition of CCyR 
Analy sis Set
Cytogenetic Responder Set Not applicable See definition of Cytogenetic 
Responder Set
Withdrawal of Informed Consent
Any data collected in the clinical database after a subject withdraws informed consent from all 
further participation in the trial, will not be included in the analy sis.  The date on which a 
patient withdraws full consent is recorded in the eCRF. 
Novartis Confidential Page 19
SAP 25-Aug-2017 (5:41) CABL001A2301
2.2.1 Subgrou p of interest
Subgroup analy ses will use the same method as for the analysis in the respective overall 
analysis set. 
The objective forcarryingoutthese subgroup analysesis to identif ypotential issues that
may belimited toasubgroup of patients, or thataremore commonly  observed in a subgroup 
of patients.
Summary  tables and figures will be generated only if at least 15 patients are present in each 
subgroup. 
Efficacy
The primary  efficacy  endpoint will be summarized by  the following subgroups to examine the 
homogeneity  of treatment effect provided that the primary  efficacy  analysisbased on the FAS 
isstatistically  significant: 
Stratification factor (based on randomization data from Interactive Response 
Technology [IRT]): “Major Cy togenetic Respo nse” or “No Major Cy togenetic 
Response”
Sex: Female or male
Race : Asian, Caucasian, or others
Age category (< 65years, ≥ 65 years)
Reason for discontinuation of the last prior Tyrosine Kinase Inhibitor ( TKI): 
Failure (i.e. disease progression, lack of efficacy ) or intolerance (i.e. adverse event, 
lack of tolerability ). 
Note: Only  one reason for discontinuation is allowed for each prior therapy .
Number of prior TKI therapies: 2 or ≥3
Historical BCR -ABL1 mutation by  local lab: With or without mutation
Baseline BCR -ABL1 mutation by  Sanger Sequencing at central lab: W ild ty peor  
mutan t
No formal statistical test of hypotheses will be performed for the subgroups, only point 
estimate of the treatment effect and 95%- confidence intervals will be provided (see Section 
2.14 for further analysis details). The objective of the efficacy  subgroup analysis is to 
demonstrate homogeneity  of treatment effect in the above subgroups.
Safety
Subgroup anal yses for selected safet y endpoints will be defined when required.
Japan -specific subgroup analy ses
Two subgroups will be formed based on geographic region: Japan or other region (this is not 
based on ethinicity ). These subgroup analyses will be only used for submission to Japan 
health authority .
Summary  tables and figures will be presented for the two subgroups for the following 
outcome measures:
Novartis Confidential Page 20
SAP 25-Aug-2017 (5:41) CABL001A2301
Baseline characteristics :Tables of d emographics, diagnosis and extent of cancer ,
extramedullary  involvement , bone marrow anal ysis, patient disposition, analy sis sets
Exposure: Tables of d uration of exposure , dose received
Tables of c oncomitant medications as well as surgical and medical procedures
PK(only  in ABL001 arm): Table and figure of ABL001 concentration by time, figure 
of average trough ABL001 concentration from week 2, 4, 12 and 24 vs. BCR -ABL 
ratio IS (%)at 24 weeks
AEs: Tables of a ll AEs, treatment -related AEs, AEs requiring dose adjustment or 
interruption, AEs requiring additional therapies, seriou s adverse events ( SAEs ), 
adverse eve nts o f special interest ( AESIs )
ECG: Tables of Notable ECG values, c hange from baseline in ECG parameters values
Lab: Hematology  shift table, biochemistry  shift table
Efficacy : Tables of m olecular response categories at and b y each time point, MMR 
rate at and b y each time point, time to MMR, duration of MMR, cytogenetic response 
categories at and by each time point , time to CCy R, duration of CCy R, TTF, PFS, OS . 
Figures of cumulative incidence of MMR and of CCy R.
2.3 Patien t disposition, demographics and other baseline 
characteristics
The FAS will be used for all baseline and demographic summaries and listings unless 
otherwise specified. Summaries will be reported by treatment arm and for all patients ,and 
listings will be reported by treatment arm to assess baseline comparability . No inferential 
statistics will be provided.
Basic demographic and background data
All demographic and baseline disease characteristics data will be summarized and listed by 
treatment arm. Categorical data (e.g. age groups: 18 -<65, 65 -<85, and ≥ 85years, sex, race, 
ethnicity , ECOG performance status) will be summarized by frequency  counts and 
percentages ; the number and percentage of patients with missing data will be provided. 
Continuous data (e.g. age, weight, height, body  mass index ) will be summarized by 
descriptive statistics (N,mean, median, standard deviation, minimum and maximum ), where
BMI (kg/m2) will be calculated as weight[kg] / (height[m]2) using weight at screening .
In addition , a summary  table by sex, age group (18 -<65, 65 - <85, and ≥ 85 years) and 
treatment group and another summary  table by race and treatment grou p will be generated 
using the safet y set for DSUR/PSUR.
Baseline stratification factors
The number (%) of patients in each stratum ( “Major Cytogenetic Response” or “No Major 
Cytogenetic Response” ) based on data obtained from the IRT system will be summarized 
Novartis Confidential Page 21
SAP 25-Aug-2017 (5:41) CABL001A2301
overall and by treatment arm for the FAS. Discordances between the stratum recorded in IRT 
at the time of randomization and the actual stratum recorded in the clinical database through 
the dat a collected on eCRF will be cross- tabulated and listed.
Diagnosis and extent of cancer
All diagnosis and extent of cancer data will be summarized and listed by treatment arm. One
summary  table will include time (years) since initial diagnosis (descriptive statistics with N,
mean, median, standard deviation, minimum and maximum )and historical mutation
(frequency  counts and percentages ). Another table will include e xtramedullary  involvement
(frequency  counts and percentages ).
Medical history
Medical history  and ongoing conditions, including cancer -related conditions and symptoms 
entered on eCRF will be summarized and listed by treatment arm. The summar ywill be 
presented by primary  system organ class (SOC), preferred term (PT) and treatment arm. 
Medical histo ry and current medical conditions will be coded using the Medical Dictionary 
for Regulatory  Activities (MedDRA) terminology. The MedDRA version used for reporting 
will be specified in the CSR and as a footnote in the applicable tables/listings.
In addition, separate listings will be produced for medical history  possibly  contributing to 
liver dysfunction ,and medical history  of protocol solicited cardiovascular events .
Other
Alldata collected at baseline , including child bearing potential as well asinformed consent 
for additional research on study  data and biological samples, will be listed.
2.3.1 Patient disposition
Enrollment bycountr y and center will besummarized forallscreened patients and also
by treatment arm using the FAS. The number (%) of randomized patients included in the FAS 
will be presented overall and by treatment group. The number (%) of screened and not -
randomized patients and the reasons for screening failure will also be display ed. The number 
(%) of patients in the FAS who are still on treatment, who discontinued the study  phases and 
the reason for discontinuation will be presented overall and b y treatment group.
The following summaries will be provided (with % based on the total number of FAS 
patients ):
Number (%) of patients who were randomized (based on data from IRT s ystem)
Number (%) of patients who were randomized but not treated (based on DAR eCRF 
page not completed for any  study  treatment component)
Primary  reason for not being treated (based on “End of Screening Phase ” and 
“Withdrawl of Informed Consent(s) ” eCRF page s)
Number (%) of patients who were treat ed (based on DAR eCRF pages of each stud y 
treatment completed with non-zero dose administered)
Novartis Confidential Page 22
SAP 25-Aug-2017 (5:41) CABL001A2301
Number (%) of patient s who are still on -treatment ( based on the “End of Trea tment 
Disposition” page not completed); 
Number (%) of patient s who discontinued the study  treatment phase (based on the 
“End of Treatment Disposition” page) 
Primary  reason for study  treatment phase discontinuation (based on the “End of 
Treatment Disposit ion” page)
Number (%) of patient s who have entered the survival follow -up (based on the “End 
of Treatment Disposition” page);
Protocol de viations
The number (%) of patients in the FAS with any protocol deviation will be tabulated by 
deviation category  (as specified in the Study Specification Document ) overall and by 
treatment group for the FAS. All protocol deviations will be listed.
Analysis sets
The number (%) of patients in each analysis set (defined in Section 2.2 ) will be summarized  
by treatment group and stratum. Reason s leading to exclusion from analy sis sets will be listed 
by treatment group and stratum as well as tabulated overall and by treatment group.
2.4 Treatments (study  treatment, rescue medication, concomitant 
therapies, compliance)
2.4.1 Study treatment / compliance
Duration of exposure, actual cumulative dose, dose intensity  (DI) and relative dose intensity 
(RDI) will be summarized by treatment arm. Duration of exposure will be categorized into 
time intervals; frequency  counts and percentages will be presented for the number (%) of 
subjects in each interval. The number (%) of subjects who have dose reductions or 
interruptions, and the r easons, will be summarized by treatment group. 
Subject level listings of all doses administered on treatment along with dose change reasons 
will be produced.  
The safet y set will be used for all summaries and listings of study  treatment. 
Duration of exposure to study  treatment
Duration of exposure to study  treatment is considered by taking into account the duration of 
exposure to the investigational drug or control:
Duration of exposure to study  treatment (days) = (date of last administrat ion of  study 
treatment) –(date of first administration of study  treatment) + 1. 
The date of last administration of study  treatment is defined in Section 2.1.1 .
Novartis Confidential Page 23
SAP 25-Aug-2017 (5:41) CABL001A2301
Summary  of duration of exposure of study  treatment will include categorical summaries based 
on intervals (<24 weeks, ≥24 weeks, ≥48 weeks, ≥96 weeks) and continuous summaries (i.e. 
mean, standard deviation etc.).
Cumulative dose
Cumulative dose of a study  treatment is defined as the total dose given during the study  
treatment exposure. 
The planned cumulative dose for a study  treatment refers to the total planned dose as per the 
protocol up to the last date of study  treatment administration. The calculations for the two 
study  treatments are:
ABL001: 40 mg/administration × 2 (administration/day ) ×duration of exposure (day ) 
Bosutinib:  500 mg/day  × duration of exposure prior to dose escalation (day) 
+ 600 mg/day  ×duration of exposure since dose escalation (day ),
where the starting day  of dose escalation is identified as the first record in the DAR 
eCRF with dose increased and reason “As per protocol ”.
The actual cumulative dose refers to the total actual dose administered, over the duration for 
which the subject is on the study  treatment as documented in the DAR eCRF. It is the sum of 
the non-zero total daily doses recorded over the dosing period. For patients who did not take 
any drug the actual cumulative dose is by  definition equal to zero. The actual cumulative dose 
will be summarized for each of the study  treatment.
Dose intensity  and relative dose intensity
Dose intensity (DI) for patients with non -zero duration of exposure is defined as follows: 
DI (mg/day) = Actual cumulative dose (mg ) / Duration of exposure to study  treatment ( day).
For patients who did not take any drug the DI is by definition equal to zero. 
Planned dose intensity (PDI ) is defined as:
PDI (mg/day) = Planned cumulative dose (mg ) / Duration of exposure ( day).
Relative dose intensity (RDI) is defined as follows:
RDI = DI ( mg/day)  / PDI ( mg/day ).  
DI and RDI will be summarized separately  for the two study  treatment s. 
Dose change s,interruptions or permanent discontinuations
The number of subjects who have dose increase (allowed for bosutinib starting week 8, see 
protocol Section 6.2), dose reductions, dose interruptions or permanent discontinuations , and 
the reasons, will be summarized separately  for the two study  treatment s. 
‘Dose Changed’, ‘Dose Interrupted’ and ‘Dose Permanently  Discontinued’ fields from the 
DAR eCRF pages will be used to determine the dose change s, dose interruptions, and 
permanent discontinuations, respectivel y.
Novartis Confidential Page 24
SAP 25-Aug-2017 (5:41) CABL001A2301
The corresponding fields ‘Reason for Dose Change/ Dose Interrupted’ and ‘Reason for 
Permanent Discontinuation’ will be used to summarize the reasons.
A dose change occurs when total daily dose is different from the most recently  planned dose.
For patients in ABL001 arm, there is only one planned dose, i.e. 80 mg/day . For patients in 
bosutinib arm, the initial planned dose is 500 mg/day  and could be changed to 600 mg/day  in 
week 8 or later.
For the purpose of summarizing interruptions and reasons, multiple entries for interruption 
that are entered on consecutive days with different reasons will be counted as separate 
interruptions. However, if the reason is the same in thementioned multiple entries on 
consecutive day s, then it will be counted as one interru ption. 
Reduction : A dose change where the actual total daily  dose is lower than the most recently
planned dose. Therefore any dose change to correct a dosing error will not be considered a 
dose reduction. Only dose change is collected in the eCRF, while number of reductions will 
be derived programmatically  based on the change and the direction of the change.
Increase : A dose change where the actual total daily  dose is great er than the most recent ly
planned dose. Therefore any dose change to correct a dosin g error will not be considered a 
dose increase . Only dose change is collected in the eCRF, while number of increase will be 
derived programmatically  based on the change and the direction of the change.
2.4.2 Prior , concomitant and post therap ies
Prior anti -cancer thera py
The number and percentage of patients who received any prior anti-neoplastic medications 
will be summarized by treatment arm forsetting (e.g. adjuvant, metastatic, etc.) and also for
thelowest anatomical therapeutic classificati on (ATC )class andpreferred term. Summaries 
will in clude total number of regimens. A listing willalso be produced. 
Anti- neoplastic medications will be coded using the WHO Drug Dictionary  (WHO -DD). 
Details regarding WHO -DD version will be included in the footnote in the tables/listings. 
The above anal yses will be performed using the FAS.
Post treatment anti -cancer therapy
Anti- neoplastic therapies since discontinuation of study  treatment will be listed and 
summarized by ATC class, preferred term, overall and by treatment group by means of 
frequency  counts and percentages using FAS.
Anti- neoplastic medications will be coded using the WHO -DD. Details regarding WHO -DD 
version will be included in the footnote in the tables/listings. 
Concomitant therap ies
Concomitant therap ies aredefined as all interventions (therapeutic treatments and procedures) 
other than the study  treatment administered to a patient coinciding with the study  treatment 
period. Concomitant therap iesinclude medications (other than study  drugs) and medical 
Novartis Confidential Page 25
SAP 25-Aug-2017 (5:41) CABL001A2301
procedures starting on or after the start date of study  treatment, or starting prior to the start 
date of stud y treatment and continuing after the start date of stud y treatment. 
Concomitant medications will be coded using the World Health Organization (WHO) Drug 
Reference  Listing  (DRL)  dictionary   that  employ s  the  WHO  ATC classification system 
and summarized by the lowest ATC class and PTusing frequency  counts and percentages. 
Surgical and medical procedures will be coded using MedD RA and summarized by SOC and 
PT. These summaries will includ e:
1.Therapies starting on or after the start of study  treatment but no later than 30 days 
after last dose of study  treatment and
2.Therapies starting prior to start of study  treatment and continuing after the start of 
study  treatment .
Allconcomitant therapies willbelisted. Any concomitant therapies starting andending prior 
tothestart ofstudy treatment or starting morethan 30 days after thelastdate ofstudy 
treatment will be flagged in the listin g. The safetyset will be used for all concomitant 
medication tables and listings.
2.5 Analysis of the primary  objective
The primary  objective of the study  is to evaluate the efficacy  of ABL001 at the recommended 
dose in CML  patients in chronic phase, previously  treated with 2 or more tyrosine kinase 
inhibitors and to compare this efficacy  profile in this population with that achieved by  patients 
receiving bosutinib . 
2.5.1 Primary  endpoint
The primary  efficacy  variable of the study  is the Major Molecular Response (MMR) rate at 24 
weeks. A patient will be counted as having achieved MMR at 24 weeks if he/she meets the 
MMR criteri on(BCR -ABL ratio ≤0.1%) at 24 weeks. Details of derivation of Polymerase 
Chain Reaction (PCR )results and calculation of BCR -ABL ratio are presented in Section 5.4 .
Further categories of molecular response are defined below:
1% < BCR -ABL ratio ≤ 10%
0.1% < BCR -ABL ratio ≤ 1%
0.01% < BCR -ABL ratio ≤ 0.1%
0.0032% < BCR -ABL ratio ≤ 0.01%
BCR -ABL ratio ≤0.0032%
2.5.2 Statistical hy pothesis, model, and method of analy sis
The MMR rate at 24 weeks will be calculated based on the FAS and according to the Intent 
To Treat (ITT) principle. MMR rate and its 95% confidence interval based on the Pearson -
Clopper method will be presented b y treatment group. 
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 24 weeks. The Cochrane -Mantel -Haenszel (CMH) chi-square test, stratified by 
Novartis Confidential Page 26
SAP 25-Aug-2017 (5:41) CABL001A2301
the randomization stratification factor, i.e. cytogenetic response status (MCyR vs no MCy R) 
at screening , will be used to compare MMR rate between the two treatment groups, at the 
two-sided 5% level of significance. The 95% confi dence interval for the difference in MMR 
rate between treatment groups will be provided using the Wald method. The Mantel -Haenszel 
estimate of the common risk difference and the corresponding 95% confidence interval will 
also be present ed. 
2.5.3 Handling of mis sing values/censoring/discontinuations
Only  patients with MMR at 24 weeks are considered responders. In other words, any patient 
who achieves MMR before 24 weeks, but is no longer in MMR at 24 weeks, will be 
considered as a non-responder in this primary  analysis. Patients discontinuing the randomized 
treatment prior to 24 weeks due to an y reason will be considered as non -responders.
One exception to the rule above is if the 24-week PCR evaluation is missing, but both a PCR 
evaluation at 16 weeks and a PCR evaluation at 36 weeks indicate MMR, the 24-week 
assessment is imputed as a ‘Response’ ,assuming that MMR is maintained between 16 and 36 
weeks .
2.5.4 Supportive analy ses
The CMH chi-square test of MMR rate at 24 weeks , stratified by the randomization 
stratification factor (MCyR vs no MCy Rat screening ), will be repeated using the PPS, if the 
PPS is different from the FAS.
Additional exploratory  logistic regression and subgroup anal yses are described in Section 2.14 .
2.6 Analysis of the key  secondary  objective
The key secondary  objective of the study  is to compare additional parameters of the efficac y 
of ABL001 versus bosutinib.
2.6.1 Key secondary  endpoint
The key secondary  endpoint is MMR rate at 96 weeks, which is defined as the proportion of 
patients with MMR at 96 weeks and derived in a similar fashion to MMR rate at 24 weeks. 
2.6.2 Statistical hy pothesis, model, and method of analy sis
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 96 weeks. Following a gatekeeping procedure to control the overall alpha level , 
only if the primary  endpoint is significant , formal statistical testing of the key secondar y 
endpoint with two-sided 5% level of significance will be performed using the CMH chi-
square test, stratified by  the randomization stratification factor, i.e. cytogenetic response status 
(MCyR vs no MCy R) at screening .
MMR rate and its 95% confidence interval based on the Pearson -Clopper method will be 
presented by treatment group. The 95% confidence interval for the difference in MMR rate 
between treatment groups will be provided using the Wald method. The Mantel -Haenszel 
Novartis Confidential Page 27
SAP 25-Aug-2017 (5:41) CABL001A2301
estimate of the common risk d ifference and the corresponding 95% confidence interval will 
also be presented.
2.6.3 Handling of missing values/censoring/discontinuations
Only  patients with MMR at 96weeks are considered responders. In other words, any patient 
who achieves MMR before 96weeks, but is no longer in MMR at 96weeks, will be 
considered as a non-responder. Patients discontinuing the randomized treatment prior to 96
weeks due to an y reason will be considered as non -responders.
2.7 Analysis of secondary  efficacy  objective (s)
The other seco ndary  efficacy  objective is to compare additional parameters (defined below) of 
the efficacy  of ABL001 versus bosutinib .
2.7.1 Secondary  endpoints
2.7.1.1 Molecular response
MMR ratesat all scheduled data collection time points ,except for 24 weeks and 96 week s 
which are alread y covered by primary and key secondary  endpoints. In addition to baseline 
assessment, the time points include week 4, 8, 12, 16, 36, 48, 60, 72, 84, 108, 120, 132, 144, 
156, 168, and end of treatment.
MMR ratesby all scheduled data collection time points ,i.e., week 4, 8, 12, 16, 24, 36, 48, 
60, 72, 84, 96, 108, 120, 132, 144, 156 and 168, and end of treatment .These are cumulative 
MMR rates by time points and are defined as the proportion of patients who achieve MMR at 
or before specified visits, i.e. if a patient achieves an MMR but then loses it before or at a 
specific visit, he/she will still be classed as achieving MMR by  that specific time point.
Time to MMR is defined for patients in the Molecular Responder Set as: date of first MMR -
date of randomization + 1.
Duration of MMR is defined for patients in the Molecular Responder Set as the time 
between the date of the first documented MMR and the end date of MMR, i.e. the earliest date 
of loss of MMR, progression to accelerated phase (AP)/blast crisis (BC), or CML -related 
death . 
Loss of MMR is defined as confirmed loss of a greater than or equal to 3.0 log reduction in 
BCR -ABL transcript levels compared to the standardized baseline value (= confirmed loss of 
a less than or equal to 0.1% BCR -ABL/ABL by international scale )in association with a ≥ 5-
fold rise in BCR -ABL  from the lowest value achieved on study  treatment confirmed by a 
duplicate anal ysis of the same sample. This result has to be confirmed by  a subsequent sample 
within 4-6 weeks unless it is associated with confirmed loss of complete hematologic 
response (CHR )or loss of CCy R or progression to AP/BC or CML -related death.
For patients for whom none of the events above is reported , the duration will be censored (see 
Section 2.7.3 ).The duration of MMR is calculated as: end date or censoring date of MMR -
date of first MMR + 1.
Novartis Confidential Page 28
SAP 25-Aug-2017 (5:41) CABL001A2301
2.7.1.2 Cytogenetic response
At each assessment time point the cytogenetic response status of each patie nt is classified as 
complete, partial, major, minor, minimal response and none:
Complete response (CCyR) :0% Philadelphia chromosome positive (Ph+)metaphases
Partial response (PCyR):>0 to 35% Ph+ metaphases
Major response (MCy R= CCy R + PCy R):0 to 35% Ph+ metaphases
Minor response (mCyR):>35 to 65% Ph+ metaphases
Minimal response: >65 to 95% Ph+ metaphases
None :>95 to 100% Ph+ metaphases.
CCyR rates at all scheduled data collection time points ,i.e., week 24, 48, 72 and 96, and 
end of treatment . Such rates are defined as the proportion of patients inCCyR atthe 
respective time points among patients in the CCy R Analy sis Set ,which excludes patients who 
are in CCy R at baseline .
CCyR ratesby all scheduled data collection time points ,i.e., week 24, 48, 72 and 96, and 
end of treatment .Such rates are defined as the proportion of patients who achieve CCyRat or 
before the respective time points among patients in the CCy R Anal ysis Set .
Time to CCyR is defined for patients in the Cytogenetic Responder Set as: date of first 
documented CCyR -date of randomization + 1.
Duration of CCyR is defined for patients in the Cytogenetic Responder Set as the time 
between date of first documented CCy R and the end date of CC yR, i.e. the earliest date of loss 
of CCyR, progression to AP/BC, or CML -related death. For patients for whom none of the 
events above is reported or the last PCR evaluation on treatment indicating MMR , the 
duration will be censored (see Section 2.7.3 ).The duration of CCyR is calculated as: enddate 
or censoring date of CCyR -date of first CCy R + 1.
2.7.1.3 Other secondary  efficacy  endpoints
Time to treatment failure (TTF) is defined for patients in FAS as the time from date of 
randomization to an event of treatment failure. The following events will constitute ‘treatment 
failure’, and are based on the EL N criteria [Baccarani et al. 2013] defining failure of a second 
line treatment adapted to include discontinuation of randomized treatment as an event :
No CHR or > 95% Ph+ metaphases at three months after randomization or thereafter 
BCR -ABL ratio > 10% IS and/or > 65% Ph+ metaphases at six months after 
randomization or thereafter 
BCR -ABL ratio > 10% IS and/or > 35% Ph+ metaphases at 12 months after 
randomization or thereafter
Loss of CHR, CCy R or PCy R at any  time after randomization
Detection of new BCR -ABL 1mutations at any  time after randomization
Confirmed loss of MMR in 2 consecutive tests, of which one must have a BCR -ABL 
ratio ≥ 1% I S 6 months aft er randomization
Novartis Confidential Page 29
SAP 25-Aug-2017 (5:41) CABL001A2301
New clonal chromosome abnormalities in Ph+ cells: CCA/Ph+: at any  time after 
randomization
Discontinuation from randomized treatment for any reason
TTF is calculated as: date of treatment failure or censoring date (see Section 2.7.3 ) -date of 
randomization + 1.
Progression -Free- Survival (PFS) is defined for patients in FAS as the time from the date of 
randomization to the earliest occurrence of documented disease progression to AP/BC or the 
date of death from any cause (including progressions and deaths observed during the survival 
follow -up period). PFS is calculated as: date of disease progression/death or censoring date 
(see Section 2.
7.3) -date of randomization + 1.
Overall survival (OS) is defined for patients in FAS as the time from the date of 
randomization to the date of death (including the survival follow -up period). OS is calculated 
as: date of death or censoring date (see Section 2.7.3 ) -date of randomization + 1.
2.7.2 Statistical hy pothesis, model, and method of analy sis
No confirmatory  statistical testing of non -key secondary  efficacy  endpoints will be performed, 
however, nominal p-value swill be presented for exploratory  purposes (as specified in 
protocol Section 10.5.2) .
MMR rates at and by  time points
The FAS will be used for these endpoints. For each time point the MMR rate and the 
associated 95% confidence interval based on the Pearson -Clopper method will be presented 
by treatment group. The respective null hypothesis of each MMR rate is that there is no 
difference between treatment groups. Statistical testing will be performed via CMH chi -square 
tests stratified by the randomization strata ,i.e. MCyR vs no MCy R at screening .A 95% 
confidence interval for the difference in each MMR rate between treatment groups will be 
provided using the Wald method. The Mantel -Haenszel estimate of the common risk 
difference and the corresponding 95% confidence interval will also be provided .
The cumulative incidence of MMR by treatment group will be graphically  display ed by an 
increasing step function. Each curve will increase each time (after randomization) at which a 
new responder is observed and thus will increase up to the best observed response rate (e.g. up 
to 50% if half of the patients in the anal ysis population are able to achieve MMR ).
Molecular response at and by  time points
Frequency  and percentage of all molecular response categories (defined in Section 2.5.1 )by 
treatment arm using FAS will be presented for each time point.
For the by-time-points summary , the within -patient best molecular response category  up to 
the specific time points is used to calculate the frequency  and percentage.
Time to MMR
The MMR Responder Setwill be used. Descriptive statistics (minimum, maximum , median, 
quartiles, mean, sd) of time to MMR will be prov ided for the two treatment groups separately .
Novartis Confidential Page 30
SAP 25-Aug-2017 (5:41) CABL001A2301
Duration of MMR
The MMRResponder Setwill be used. The survival distribution of duration of MMR will be 
estimated using the Kaplan -Meier method, and Kaplan -Meier curves, medians and 95% 
confidence intervals [Brookmey er and Crowley  1982] of the medians , along with the 
proportion of patients who are still in MMR at 24, 48, 72 and 96 weeks and the associated 95% 
confidence intervals , will be presented for each treatment group.
CCyR rates at and by time points
TheCCyR Anal ysis Set will be used for these endpoints. 
For each time point the CCyR rate and the associated 95% confidence interval based on the 
Pearson -Clopper method will be presented by  treatment group. The respective null hy pothesis
of each CCyR rateisthat there is no difference between treatment groups. Statistical testing 
will be performed via CMH chi-square tests stratified by the randomization strata ,i.e. MCyR 
vs no MCy R at screening .A 95% confidence interval for the difference in each CCyR rate 
between treatment groups will be provided using the Wald method. The Mantel -Haenszel 
estimate of the common risk difference and the corresponding 95% confidence interval will 
also be provided .
The cumulative incidence of CCyR by treatment group will be graphically  display ed by an 
increasing step function. Each curve will increase each time (after randomization) at which a 
new responder is observed and thus will increase up to the best observed response rate (e.g. up 
to 50% if half of the patients in the ana lysis population are able to achieve CCyR).
Cytogenetic response at and by  time points
Frequency  and percentage of all cytogenetic response categories (defined in Section 2.7.1.2 ) 
by treatment arm using FAS will be presented for each time point. A shift table comparin g 
baseline and best post-baseline cytogenetic response categories by treatment will also be 
presented. All assessments of cytogenetic response categories will also be listed by treatment 
arm.
For the by-time-points summary , the within -patient best cytogenetic response category  up to 
the specific time points is used to calculate the frequency  and percentage.
Assessments of bone marrow aspirate at different time points will also be summarized.
Time to CCyR
The Cytogenetic Responder Setwill be used. Descriptive statistics (minimum, maximum , 
median, quartiles, mean, sd) of time to CCyR will be provided for the two treatment groups 
separately .
Duration of CCyR
The Cytogenetic Responder Setwill be used. The survival distribution of duration of CCyR 
will be estimated using the Kaplan -Meier method, and Kaplan -Meier curves, medians and 95% 
confidence intervals [Brookmey er and Crowley  1982] of the medians , along with the 
Novartis Confidential Page 31
SAP 25-Aug-2017 (5:41) CABL001A2301
proportion of patients who are still in CCyRat 24, 48, 72 and 96 weeks and the associated 95% 
confidence intervals , will be presented for each treatment group.
TTF, PFS and O S
For each endpoint t he respective null hypothesis is that there is no difference between 
treatment groups. Distribution of each endpoint will be compared between two treatments 
using astratified log-rank test at an overall two-sided 5% level of significance. The 
stratification will be based on the randomization stratification factor, i.e. cytogenetic response 
status ( MCyR vs no MCy R) at screening .
For each endpoint t he survival distribution will be estimated using the Kaplan -Meier method, 
and Kaplan -Meier curves, medians and 95% confidence intervals [Brookmey er and Crowle y 
1982] of the medians , along with the proportion of patients who have not experienced the 
respective events at 1, 3 and 5 years and the associated 95% confidence intervals ,will be 
presented for each treatment group. The hazard ratio will be calculated, along with its 95% 
confidence interval, using a stratified Cox model.
2.7.3 Handling of missing values/censoring/discontinuations
MMR ratesat specific time points :Patients discontinuing the randomized treatment prior to 
a specific time point due to any reason will be considered as non- responders for that time 
point .
Molecular response atspecific time points :The category  “Missing” will be assigned to
Ongoing cases, i.e. patients who have not discontinued study treatment and have not 
been treated sufficiently  long for a specific time point
Discontinued due to progressive disease /death prior to a specific time point
Discontinued due to other reasons prior to a specific time point
Duration of MMR : For patients who have not experienced any event (loss of MMR, 
progression to AP/BC, or CML -related death )the duration will be censored at the last 
molecular assessment (PCR) date on treatment.
CCyR rates at specific time points :Patients discontinuing the randomized treatment prior to 
a specific time point due to any reason will be considered as non - responders for that time 
point .
For the primary  analysis and the end of study  treatment analysis, the cytogentic response of 
patients who have not discontinued study  treatment and have not been treated sufficientl y 
long for a specific time point will be classified as “Missing”.
Cytogenetic response at specific time points :The category  “Missing” will be assigned to
Ongoing cases, i.e. patients who have not discon tinued study  treatment and have not 
been treated sufficiently  long for a specific time point
Discontinued due to progressive disease /death prior to a specific time point
Discontinued due to other reasons prior to a specific time point
Novartis Confidential Page 32
SAP 25-Aug-2017 (5:41) CABL001A2301
Duration of CCyR : For patients who have not experienced any event (loss of CCyR, 
progression to AP/BC, or CML -related death )the duration will be censored at the last 
cytogenetic assessment date on treatment or the last PCR evaluation on treatment indicating 
MMR. 
TTF :For patients who have not reach edtreatment failure, their TTFs will be censored at the 
time of last study  assessment (PCR, cytogenetic, hematologic or extramedullary )before the 
cut-off date .
PFS:For patients who have not experienced an event (disease progre ssion to AP/BC or death 
from any cause ), their PFS times will be censored at the date of last study  assessment (PCR, 
cytogenetic, hematologic or extramedullary ) before the cut- off date .
OS:Patients who are alive at the time of the analy sis data cutoff date will be censored at the 
date of last contact (see Section 2.1.1 ) before the cut -off date.
2.8 Safet y analyses
All safet y analyses will be based on the safety  set. All listings and tables will be presented by 
treatment group.
2.8.1 Adverse events (A Es)
AE summaries will include all AEs occurring during on treatment period. All AEs collected in 
the AE eCRF page will be listed along with the information collected on those AEs e.g. AE 
relationship to study  drug, AE outcome, etc. AEs with start date outside of on-treatment 
period will be flagged in the listings.
AEs will be summarized by  number and percentage of subjects having at least one AE, having 
at least one AE in each primary  system organ class (SOC) and for each preferred term (PT)
using MedDRA coding. A subject with multiple occurrences of an AE will be counted only 
once in the respective AE category . A subject with multiple CTCAE grades for the same 
preferred term will be summarized under the maximum CTCAE grade recorded for the event.
AE with missing CTCAE grade will be included in the ‘All grades’ column of the summary 
tables.
In AE summaries ,the primary  system organ class will be presented alphabeticall y and the 
preferred terms will be sorted within primary  SOC in descending frequency . The sort ingorder 
for the preferred term will be based on their frequency  in the ABL001 arm.
The following adverse event summaries will be produced by treatment arm:overview of 
adverse events and deaths, AEs by SOC and PT,summari zedby relationship, seriousness, 
leading to treatment discontinuation, leading to dose interruption/adjustment, requiring 
additional thera py,and leading to fatal outcome. For posting to ClinTrial.gov and EudraCT , a 
summary  table of on-treatment deaths and serious AEs and another summary  table of non 
serious AEs by treatment, both including occurrences (an occurrence is defined as >1 day 
between start and prior end date of record of same preferred term) and sorted by  SOC and PT, 
will be presented as well.
Novartis Confidential Page 33
SAP 25-Aug-2017 (5:41) CABL001A2301
2.8.1.1 Adverse events of special interest / grouping of A Es
Data analy sis of AESIs
An adverse event of special interest (AESI) is a grouping ofadverse events that are of 
scientific and medical concern specific to compound ABL001 . These groupings are defined 
using MedDRA terms, SMQs (standardized MedDRA queries), HLGTs (high level group 
terms), HLT (high level terms) and PTs (preferred terms). Customized SMQs (Novartis 
MedDRA queries, NMQ) may also be used. A NMQ is a customized group of search terms 
which defines a medical concept for which there is no official SMQ available or the available 
SMQ does not completely  fit the need. It may  include a combination of single terms and/or an 
existing SMQ, narrow or broad. The latest approved version of CRS prior to the respective 
database lock will be used.
For each specified AESI, number and percentage of patients with at least one event of the 
AESI  occur ring during on treatment period will be summarized.
Summaries of these AESI s will be provided by treatment arm (specify ing grade, SAE, 
relationship, leading to treatment discontinuation, leading to dose adjustment/interruption, 
hospitalization, death ,etc.).If sufficient number of events occurred, analy sis of time to first 
occurrence will be applied.
A listing of all grouping levels down to the MedDRA PTs used to define each AESI will be 
generated.
2.8.2 Deaths
Separate summaries for on-treatment and all deaths (including post-treatment death s)will be 
produced b y treatment arm, system organ class and preferred term. 
All deaths will be listed, where post treatment deaths will be flagged. A separate listing of 
deaths prior to starting treatment will be provided for all screened subjects.
2.8.3 Laboratory  data
Grading of laboratory  values will be assigned programmatically  as per National Cancer 
Institute (NCI)Common Terminology  Criteria for Adve rse Events (CTCAE) version 4.03.  
The calculation of CTCAE grades will be based on the observed laboratory  values only, 
clinical assessments will not be taken into account. CTCAE Grade 0 will be assigned for all 
non-missing values not graded as 1 or higher . Grade 5 will not be used. Details of CTC AE
grading and imputation rules are presented in Appendix 5.3 .
For laboratory tests where grades are not defined by  CTCAE v4.03, results will be categorized 
as low/normal/high based on laboratory  normal ranges.
On analy zing laboratory  data from all sources (central and local laboratories) will be 
combined. The summaries will include all assessments available for the lab parameter 
collected no later tha n 30 days after the last study  treatment administration date.
The following summaries will be produced separatel y for hematology and biochemistry 
laboratory  data (by  laboratory  parameter and treatment ):
Novartis Confidential Page 34
SAP 25-Aug-2017 (5:41) CABL001A2301
Worst post -baseline CTC AEgrade (regardless of the baseli ne status). Each subject will be 
counted only for the worst grade observed post -baseline in the on-treatment period.
Shift tables using CTC AEgrades to compare baseline to the worst on- treatment value . 
For laboratory  tests where CTC AEgrades are not defined, shift tables using the 
low/normal/high/(low and high) classification to compare baseline to the worst on-
treatment value.
The following listings will be produced separately  for hematology  and biochemistry  for the 
laboratory  data:
Listing sof all laboratory data, with CTC AEgrades and classification relative to the 
laboratory  normal range. Lab data collected during the post -treatment period willbe 
flagged .
Listing of all CTC AEgrade 3 or 4 laboratory  toxicities
Liver function parameters
Liver function parameters of interest are total bilirubin (TBL) , Alanine aminotransferase
(ALT ), Aspartate aminotransferase ( AST) and alkaline phosphatase (ALP). The number (%)
of patients with worst post -baseline values as per Novartis L iver To xicity  guidelines will be 
summarized:
The following summaries will be produced:
ALT or AST > 3x upper limit of norm ( ULN)
ALT or AST > 5xULN
ALT or AST > 8xULN
ALT or AST > 10xULN
ALT or AST > 20xULN
TBL > 2xULN
TBL > 3xULN
ALT or AST > 3xULN & TBL > 2xUL N
ALT or AST > 3xULN & TBL > 2xULN & AL P < 2xUL N  
2.8.4 Other safety  data
2.8.4.1 ECG and cardiac imaging data
12-lead ECGs including PR, QRS, QT, QTcF and RR intervals will be obtained centrall y for 
each subject during the study . ECG data will be read and interpreted centrally . 
The echocardiogram will be performed and evaluated locall y to assess the left ventricular 
ejection fraction (LVEF).
Data handling
The average of the triplicate ECG parameters at each time point will be used in the anal yses.
Novartis Confidential Page 35
SAP 25-Aug-2017 (5:41) CABL001A2301
Data analy sis
The number and percentage of subjects with notable ECG values will be presented by 
treatment arm. Notable values are defined below:
QT, QTcF
New value of > 450 and ≤ 480 ms
New value of > 480 and ≤ 500 ms
New value of > 500 ms
Increase from Baseline of > 30 ms to ≤  60ms
Increase from Baseline of > 60 ms
HR
Increase from baseline >25% and to a value > 100 bpm
Decrease from baseline >25% and to a value < 50 bpm
PR
Increase from baseline >25% and  to a value > 200 ms
New value of > 200 ms
QRS
Increase from baseline >25% and  to a value > 120 ms
New values of QRS > 120 ms
A listing of all ECG assessments will be produced by treatment arm and notable values will 
be flagged . A separate listing of only the subjects with notable ECG values will also be 
produced. In each listing the assessments collected during the post-treatment period will be 
flagged .
Change from baseline ECG parameters b y timepoint will also be summarized by  treatment.
A listing of all LVEF assessments will be produced by treatment arm. In the listing, the 
assessments collected outside of on-treatment period will be flagged. A summary  table by 
treatment arm with descriptive statistics for LVE F at different timepoints (baseline, week 20)
and for change from baseline will be presented. A shift table for LVEF categories (≤40%, 41-
49%, ≥50%) at baseline versus worst value on treatment will also be presented.
2.8.4.2 Cardiovascular risk factor assessment
Prior to randomization and at the end of treatment, for each patient information of the 
following risk factors is collected: heavy  smoking, low physical activity , unhealthy  diet, and 
other. A listing b y treatment arm will be presented. 
Family  medical history  of each patient for ischemic heart disease, cardiac arrhythmia, sudden 
death, high cholesterol, diabetes mellitus, heart defects (congenital heart disease), and heart 
failure is also collected prior to randomization and at the end of treatment .A listing by 
treatment arm will be presented.
Novartis Confidential Page 36
SAP 25-Aug-2017 (5:41) CABL001A2301
2.8.4.3 Vital signs
Vital sign assessments are performed in order to characterize basic body  function. The 
following parameters were collected: height (cm), weight (kg), body  temperature (°C), heart 
rate (beats per minute), systolic and diastolic blood pressure (mmHg).
Data handling
Vital signs collected on treatment will be summarized. Values measured outside of on 
treatment period will be flagged in t he listings.
Data analy sis
The number and percentage of subjects with notable vital sign values (high/low) in systolic 
blood pressure, diastolic blood pressure, pulse rate,weight and temperature will be presented 
by treatment arm.         
A listing of all vital sign assessments will be produced by treatment arm and notable values 
will be flagged. In the listing, the assessments collected outside of on -treatment period will be 
flagged. 
2.8.4.4 Liver events
There are separate eCRF pages to collect acetaminophen/paracetamol, autoimmune, drug use 
6 months prior to liver event, immunoglobulin, liver function tests, pathology , related imaging, 
viral serology  andpotential impact of alcohol use, and an overview eCRF page. Data on the 
overview eCRF p age will be listed by treatment arm. Assessments collected during the post-
treatment period willbe flagged .
2.8.4.5 Pulmonary  function tests
Data of pulmonary  function tests will be listed by treatment arm. Assessments collected 
during the post -treatment period willbe flagged .
2.8.5 Additional Analyses
Not applicable.
2.9 Pharmacokinetic endpoints
PK parameters
ThePK parameters that will be determined are shown in Table 2-10. The PK param eters for 
ABL001 are derived based on the non-compartmental methods using Phoenix WinNonlin®
software version 6.4in patients with full PK sampling in PAS .
Novartis Confidential Page 37
SAP 25-Aug-2017 (5:41) CABL001A2301
Table 2-10 Non-compartmental PK pa rameters for A BL001 in full PK group
AUC 0-12h The area under the plasma concentration -time curve from time zero to 12 
hours (ng*hr*mL-1)
AUClast The AUC from time zero to the last measurable plasma concentration 
sampling time (T last) (ng*hr*mL-1)
Cmax The maximum (peak) observed plasma concentration after dose 
administration (ng/mL)
Tmax The time to reach maximum (peak) plasma concentration after dose 
administration (hr)
Tlast The time to reach the last measurable plasma concentration after dose 
administration (hr)
CL/F The total apparent body clearance of drug from the plasma after oral 
administration (L *hr-1)
Descriptive statistics (n, arithmetic mean, CV% mean, standard deviation (SD) ,median, 
geometric mean, CV% geo- mean, minimum and m aximum ) will be presented by treatment for 
PASfor all PK parameters defined in Table 2-10 except Tmax, where only n, median, 
minimum and maximum will be presented. 
All individual PK parameters will be listed for patients treated with ABL001 and with full PK 
sampling in the safety  set.
PK concentrations 
Descriptive statistics ( n, m (number of non -zero concentrations), arithmetic mean, CV% mean, 
SD,median, geometric mean, CV% geo-mean, minimum and maxi mum ) forABL001
concentration will be presented at each scheduled time point for the PAS.
The mean (+/-SD) and geometric mean concentration -time profiles forABL001 over time 
will be display ed graphically  forPAS on the linear and semi -log view.
All indiv idual plasma ABL001 concentration data will be listed forpatients treated with 
ABL001 in the Safety  Set.
Handling of PK data below LLOQ or missing
All concentration values below thelower limit of quantitation (LLO Q, 1 ng/mL ) are set to 
zero by the Bioanal yst, and will be display ed in the listings as zero and flagged. LLOQ values
will be treated as zero in any calculations of summary  statistics, and treated as missing for the 
calculation of the geometric means and their CV%. The number of non-zero concentrations 
will also be reported in the summary statistics.
Missing values for an y PK data will not be imputed and will be treated as missing.
Novartis Confidential Page 38
SAP 25-Aug-2017 (5:41) CABL001A2301
2.10 PD and PK/PD analyses
The potential relationship between ABL001 exposure (e.g. trough concentration) and effica cy,
pharmacod ynamics (PD) or safet y endpoints may be assessed by graphic exploration and/or 
statistical modeling ,as appropriate ,including effect of population covariates. Additional 
exposure -response analyses for ECG may be conducted. The concentration data may be 
analyzed by  a population approach to evaluate the influence of covariates on drug exposure. If 
applicable, the details of the above -mentioned analy ses will be described in a separate
analysis plan and reported separately .
The relationship betwee n average trough plasma concentration up to 24 weeks and BCR -ABL 
ratio I S (%) at 24 weeks will be assessed by  graphic exploration. 
2.11 Patient -reported outcomes
The FAS will be used for analy zing PRO data unless specified differentl y. The MDASI CML, 
PGIC along with EQ-5D- 5L will be used to assess patient’s disease -related symptoms and 
health -related qualit y of life from baseline to EOT ; and the WPAI -CML will be used to assess 
work productivity  and activity  impairment related to the patient’s CML. All tools require 
patient’s direct completion and will be administered utilizing electronic device for data 
collection at scheduled time points from screening t o end of treatment .
The baseline is defined in Section 2.1.1 . Patients with an evaluable baseline score and at least 
one evaluable post-baseline score during the treatment period will be included in the change 
from baseline anal yses. Missing data items in a scale will be handled according to the manual 
for each instrument. No imputation will be applied if the total or subscale scores are missing 
at a visit. All measures will assess differences between the t reatment arms .
Compliance to the schedule of administration of each PRO questionnaire will be summarized 
by treatment group, forbaseline and scheduled post-baseline assessment time points . The 
following categories , as collected on the eCRF, will be used to describe whether the 
questionnaire was completed at a specific time point:
1.yes, fully  completed
2.yes, partl y completed
3. no
Repeated measures model for continuous scores
Tobest utilize the repeated assessments of a given PRO score , a repeated measures model for 
longitudinal data will be used toestimate differences between treatment arms. This repeated 
measures model will include terms for treatment, the stratification factor (major cytogenetic 
response status) , time, baseline value as main effects, and an interaction term for treatment b y 
time. This analy sis will be restricted to patients with an evaluable baseline score and at least 
one evaluable post-baseline score. All data collected until end of treatment (including the end 
of treatment assessment) will be included in the analy sis. Note that only data collected under 
treatment (i.e. while the patient is treated) will be included. The end of treatment assessment 
will be included if collected within 7 days of the last dose intake.
Novartis Confidential Page 39
SAP 25-Aug-2017 (5:41) CABL001A2301
Time will be conside red as a contin uous variable expressed in weeks , i.e. considering that the 
PRO score follow a linear trend.
As a first approach, an unstructured correlation matrix will be used to model the correlation 
within patients. The structure of the correlation matrix will be investigated and simplified 
using likelihood ratio tested if appropriate.
2.11.1 MDASI-CML
The M.D. Anderson Symptom Inventory  –Chronic Myeloid Leukemia (MDASI -CML)
questionnaire isplanned to be administered during screening, at weeks 4, 8, 12, 1 6, 24, 36, 48 
and 96 after randomization.
The MDASI -CML is a 26 item self-administered questionnaire for adult CML  patients. 
Twenty  of the items measure the severit y of disease -related symptoms and are scored from 0 
(Not present) to 10 (As bad as you can imagine) and 6 items that measure symptom 
interference with daily  life scored from 0 (Did not interfere) to 10 (Interfered completely ). 
The severit y score will be calculated when a patient scores at least 11 items out of the 20 
severit y items using the for mula: (sum of scores for the items answered) / ( number of items 
answered ).If a patient scores fewer than 11 items, the severit y score will be missing.
The interference score will be calculated when a patient scores at least 4 items out of the 6 
interference items using the formula: (sum of scores for the items answered) / (number of 
items answered ).If a patient scores fewer than 4 items, the interferenc e score will be missing.
For the severity  score and interference score , descriptive statistics (n, mean, SD, median, 25th 
and 75th percentiles) by treatment arm will be provided for the actual scores and change s
from baseline scores at each scheduled asses sment time point.
Between -treatment differences for the change in severit y and interference score s will be 
evaluated using the above -mentioned repeated measures model . 
2.11.2 EQ-5D-5L
EQ-5D- 5L is a two-part standardized instrument for measuring health outcomes in a wide 
range of health conditions and treatments. It consists of a descriptive system and a visual 
analogue scale (EQ VAS). The descriptive system comprises the following 5 dimensions: 
mobility , self-care, usual activities, pain/discomfort and anxiety /depression. Each dimension 
has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme 
problems (or unable to perform the activity ). The EQ VAS records the respondent’s self -rated 
health on a vertical, visual analogue scale where the endpoints are labeled ‘Best imaginable 
health state’ and ‘worst imaginable health state’.
The EQ-5D- 5L data will be used to calcutae utility  values forthe economic evaluation of 
ABL001 and bosutinib i n a separate anal ysis.
The EQ-5D- 5L questionna ire is planned to be administered during screening, at weeks 4, 8, 
12, 16, 24, 36, 48 and 96 after randomization .
Novartis Confidential Page 40
SAP 25-Aug-2017 (5:41) CABL001A2301
Descriptive sy stem
The number and percentage of subjects in the five levels of each EQ-5D demension will be 
presented b y treatment group at each assessment time point .
EQ VA S
The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale 
from 0, labeled as ‘worst imaginable health state’, to 100, labeled as ‘best imaginable health 
state’.
For the EQ VAS, descrip tive statistics (n, mean, SD, median, 25th and 75th percentiles) by 
treatment arm will be provided for actual values and forthe change from baseline at each 
assessment time point.
Between -treatment differences for the change sin EQ VAS score will be evaluated using the 
above -mentioned repeated measures model .
2.11.3 WPA I-CML
The Work Productivity  and Activity  Impairment Questionnaire –Chronic Myeloid Leukemia
(WPAI -CML ) questionnaire is planned to be administered during screening, at weeks 4, 12, 
24, 48 and 96 after randomization .
The WPAI -CML is a six-item questionnaire which is intended to measure work and activit y 
impairment associated with CML  for those who self-identify  as currentl y employ ed for pay. 
This questionnaire measures self-reported productivity  loss associated with CML  during the 
past seven days. It consists of questions about absence from work due to CML , hours spent at 
work, the reduction in productivity  at work attributed to CML, and the reduction in 
productivity  while performing regular activities. WPAI -CML outcomes are expressed as 
impairment percentages, with higher numbers indicating greater impairment and less 
productivity , i.e., worse outcomes .Scoring will be done according to WPAI -CML instrument 
guidance resulting in four scores including: Percent work time missed due to problem; percent 
impairment while working due to problem; Percent overall work impairment due to problem; 
and, percent activ ity impairment due to problem.
Descriptive statistics (n, mean, SD, median, 25th and 75th percentiles) for each of the four 
derived outcome scores and change sfrom baseline scores will be presented by treatment arm 
ateach scheduled assessment time point with .
Between -treatment differences for the change sin each of the four outcome scores will be 
evaluated using the above -mentioned repeated measures model . 
2.11.4 PGIC
The Patient Global Impression of Change (PGIC ) instrument i s planned to be administered 
during screening, at weeks 4, 8, 12, 16, 24, 36, 48 and 96 after randomization
The PGICis comprised of a single question intended to measure a patient’s perspective of 
improvement or deterioration over time relative to treatment. The PGIC uses a seven -point 
Novartis Confidential Page 41
SAP 25-Aug-2017 (5:41) CABL001A2301
scale where one (1) equals very much improved and seven (7) equals very much worse. 
Missing values will not be imputed.
The number and percentage of subjects in each of the seven categories for PGIC will be 
presented b y treatment group at each assessment time point .
2.12 Resource utilization
Data relating to resource utilization (described intrial protocol Section 7.2.5 )from the FAS 
will be used for the purpose of economic evaluation ,which will be carried out and reported as 
a separate activity  outside the CSR . 
The measures of healthcare resource utilization (HCRU) include: hospitalization (H), 
emergency  room (ER) visit, general practitioner (GP) visits, specialist (Sp) visit and urgent 
care (UC) visit. HCRUwill be assessed as follows: frequency  and duration of hospitalization 
from baseline up to end of treatmen t; frequency  of emergency  room visits from baseline up to 
end of treatment ; frequency  of additional outpatient office visits general practitioner, 
specialist, and urgent care visits from baseline up to end of treatment . Hospitalization visits 
will also record the number of days on ward and the type of ward (hospital unit) and the 
discharge status. At each HCRU collected, the reason for the visit, i.e. related to CML , AE 
related to CML therapy  or other reason, will be collected, in order to quantify  the impa ct of 
treatment on healthcare resources.
HCRU data by treatment arm will be summarized in the primary  analysis CSR and the end of 
study  treatment CSR, with descriptive statistics (n, mean, median, SD, min, max) for 
quantitative variables ,and count and per centage for qualitative variables .
2.13 Biomarkers
Asa projectstand ard,Nova rtiswillanalyze onl y biomarke rscollected inthe clinical da tabase.
For ex ploratory ma rkers,since thestudies a renot adequa tely powered to assess specific
bioma rker-related hy pothes es,thegoal of these exploratorystatistical analyse s should be
consid ered as thegeneration of new sc ientific hypothes es. Noadjustment formultiple
compa risons isusual ly plann edfor exploratory analyses. Fu rthermore, addit ional post hoc
exploratory assessments areexpected and may beperfor med.
Theremay be circ umstances when  adecision ismade tostop sample collection, or not 
perform or discontinue theiranaly sisdue toeither pract ical or strategicreasons. Under
such circumstance s,thenumber of sam ples may be inadequa te to perform a rigorous da ta
analy sis and the availa bledata will only be listed andpotential lysumma rized.
If not otherwise specified, t he FASwillbe used for allbiomarker analyses on patie nts with 
biomarker data.
Novartis Confidential Page 42
SAP 25-Aug-2017 (5:41) CABL001A2301
Exploratory  biomarkerobjectives
To characterize mutations in the BCR- ABL1 gene at baseline and at end of treatment 
and examine their association with molecular and cy togenetic r esponse for ABL001 
vs bosutinib
To correlate gene expression profiles in leukemic stem cell (L SC)-enriched blood and 
bone marrow with r esponse to ABL001 vs. bosutinib
To characterize the effect of ABL001 vs. bosutinib treatment on CML  LSC and 
normal progenitor cells (e.g. growth and differentiation) and their bone marrow 
microe nvironment niches
To assess clonal evolution during trea tment with ABL001 vs. bosutinib
To evaluate soluble factors that correlate with response to ABL001 vs. bosutinib 
treatment in terms of tumor immunogenicit y status
Only  some analyses for the first exploratory  biomarker objective about BCR -ABL1 mutation
listed above are described here and the results will be included in the respective CSRs. 
Additional analyses for this and other exploratory  biomarker objectives will bedescribed in 
separate analy ses plans, w ith results reported separa tely.
List ofbiom arkersevaluated a ndthecollection timepoints
The biomarkers evaluated in the study  are listed in Table 2 -11below.
Table 2-11 Sample biomarker summary  table
Biom arker Timepoint Sample Method
Immune markers PD -L1 
and CD8Screening and 
end of treatmentBone marrow biops y I mmunohisto -
chemistry
CD34+enriched leukemic 
stem cellsScreening, week 
24 and end of 
treatmentBone marrow aspirate RNA analysis
Leukemic stem cells
characterizationScreening, week 
24 and end of 
treatmentBone marrow aspirate Flow c ytometry
BCR -ABL1 gene mutation W1D1 pre-dose 
and end of 
treatment . If 
mutation is 
present at 
baseline, then 
also ever y 12 
weeks after 
baselinePeripheral blood Sanger 
Sequencing
CD34+enriched leukemic 
stem cellsW1D1 pre-dose 
and end of 
treatmentPeripheral blood RNA analysis
Low level mu tations in 
BCR -ABL1geneW1D1 pre-dose 
and end of Peripheral blood Mass 
spectrometry  
Novartis Confidential Page 43
SAP 25-Aug-2017 (5:41) CABL001A2301
Biom arker Timepoint Sample Method
treatment and NGS
ABL001 mode of action in 
patients treated with 
ABL001: T-cell maturation, 
activation and 
differentiation along with 
maturing myeloid and 
leukemic stem cell panelsW1D1 pre-dose, 
Week 4, 8, 12, 24, 
36, 48, 60, 72, 84, 
96 and end of 
treatmentPeripheral blood Flow c ytometry
Circulating cytokines in 
plasmaW1D1 pre-dose,
Week 48 and end 
of treatmentPeripheral blood MSD and ELISA
Genetic variant analysis of 
the UGT1A1 geneW1D1 Peripheral blood Sanger 
Sequencing
General data handling and preprocessing
For bone marrow samples the latest assessment during screening period will be used as the 
baseline value, while for blood samples the week 1 day  1 (W1D1) pre-dose assessment willbe
used as the baseline va lue.
When more than onebioma rker da tavalueare availa bleforasubject at an y timepoint,the 
mean of the replicate values will be us ed for allstatisti cal an alyse s.
2.13.1 Somatic mutation biomarker data handling and analy sis
Handli ng of somaticbiom arker data
Overall, somatic mutationstatus (wild ty pe or mutant) will be derivedfromthe mutationa l 
status oftheinterrogated exons fortheBCR -ABL1 gene by Sanger Sequencing .These
may be non-exc lusive and the presence of mutation across more than one exon will be
report ed in s eparate categori es.
Muta tion summ arystatistics
Allsomatic mutation data willbe reported using counts and pe rcentages b y themutation ty pe 
intheform of contingency ta bles with therows c ontaining thedifferent mutations a ssayed, 
and the treatment g roups inthe colum ns.Allthemutation categoriesfora gene will also be
aggregatedintomutant,wild type or missing/unknown groups and c ounts/pe rcentages willbe
reported by thesethree categor iesas well. A summary  table will be presented for baseline 
mutations and another summary  table for post-baseline new mutations (not present at 
baseline) .
All the mutation da ta will be listed for eac h subj ect ordered by tr eatment group.
Association betweenbiom arkers andclinicaloutcome
This analy sisdoes not a djust formultiplecomparisons and re sultsmay have higher fals e 
posit iverates.
Novartis Confidential Page 44
SAP 25-Aug-2017 (5:41) CABL001A2301
The relationship betweenbaseline BCR -ABL1 gene mutation data(wild type or muta nt)and 
outcome data(with or without MMR atand by24 and 96 weeks using FAS, with or without 
CCyR at and by 24 and 96 weeks using CCyR analysis set)will be explored b y reporti ng
contingency tables and by applying a logistic regression including treatment group, baseline 
BCR -ABL1 gene mutation and their interaction as covariates . Treatment group will be
includ ed in this summary table.
In addition, the same analy sis will be perform edfor
the relationship b etweenpost-baseline new BCR -ABL1 mutation (with or without 
new mutation) up to 48 weeks and outcome d ata(with or without MMR at 48 and 96 
weeks using FAS, with or without CCy R at 48 and 96 weeks using CCy R anal ysis 
set).
the relationship b etweenpost-baseline new BCR -ABL1 mutation (with or without 
new mutation) up to end of treatment and outcome d ata(with or without MMR at 96 
weeks using FAS, with or without CCy R at 96 weeks using CCy R anal ysis set).
The odds ratios bewteen treatment groups with 95% confidence intervals willbe repo rted, for 
each biomarker categor y and overall. If treatme nt by biomarkerinteractionis significant (e.g.
when p < 0.1), overa llodds ratio for tr eatment will not be report ed.
2.14 Other exploratory  analy ses
MMR rate at 24 weeks
The FAS will be used for the following exploratory  analy ses:
1.A logistic regression model adjusted for the stratification factor will be fit to assess 
treatment effect. An adjusted odds ratio for the treatment effect with associated 95% 
confidence intervals will be presented. M antel -Haenszel estimates of the common 
odds ratio and the corresponding 95% confidence interval will also be provided.
2.Based on the subgroups specified in Section 2.2.1 , the following analyses will be 
performed for each subgroup:
Proportion of patients with MMR at 24 weeks and its 95% confidence interval 
based on the Pearson -Clopper method within each treatment group
The difference in MMR rate at 24 weeks between treatment groups and the 
corresponding W ald95% confidence interval
Efficacy  anal yses in subgroups will be purel y exploratory  and are intended to explore 
the consistency  of treatment effect. Forest plot (n, risk difference, Wald 95% 
confidence interval ) will be produced to graphically  depict the treatment effect 
estimates in different subgroups. No inferential statistics (p- values) will be 
produced for the subgroups.
3.A logistic regression model adjusted for the stratification factor and other important 
variables identified b y the subgroup anal yses above will be fit to assess treatment 
effect. An adjusted odds ratio for the treatment effect with associated 95% confidence 
intervals will be presented .
Novartis Confidential Page 45
SAP 25-Aug-2017 (5:41) CABL001A2301
Association be tweenhistorical BCR -ABL1 mutations andclinicaloutcome
The relationship b etweenhistorical BCR -ABL1 gene mutation data(with or without mutation)
from local lab and outcome d ata(with or without MMR at and by  24 and 96 weeks using FAS, 
with or without CCyR at and by 24 and 96 weeks using CCyR analysis set) willbe explored
by reporti ng contingency tables and by applying a logistic regression including treatment 
group, baseline BCR -ABL1 gene mutation and their interaction as covariates . Treatment
group will beinclud ed in this summary table.
Influence of early  molecular response levels on long term molecular response 
levels
The relationship betweenMMR status at 24 weeks and MMR status at 48and 96 weeks will
be exploredusing FAS by reporting contingency  tables and by applying a logistic regression
including treatment group, MMR status at 24 weeks and their interaction as covariates . 
Treatment group will beinclud ed in this summary table. The odds ratios between treatment 
groups with 95% confidence interval swillbe repo rted,for each categor y of MMR status at 24 
weeks and overall. If the interaction of treatme nt byMMR status at 24 weeks is significant
(e.g. when p < 0.1), overa llodds ratio for tr eatment will not be report ed.
2.15 Interim analy sis
No formal interim anal ysis is planned for this trial.
3 Sample size calculation
3.1 Primary  analysis
To test the null hypothesis that the MMR rateat 24 weeks is equal in the two treatment arms, 
based on  two-sided 5% level of significance and with 90% power, 222 patients will be 
needed in total (i.e. 148 patients in the ABL001 arm and 74 patient s in the bosutinib arm 
based on 2:1 randomization allocation). The calculations were made using the software 
package PASS (2008).
It is assume dthat ABL001 leads to a 20% improvement in the MMR rate at 24 weeks over 
bosutinib from 15% to 35% which corresponds to an odds ratio of 3.05. The assumed 
bosutinib MMR rate of 15% at 24 weeks is based on previous trials evaluating bosutinib 
therap y ([Kuoury  et al. 2012] , [Gambacorti -Passerini et al. 2014] , [García -Gutiérrez et al. 
2015] ).
Novartis Confidential Page 46
SAP 25-Aug-2017 (5:41) CABL001A2301
3.2 Power for analy sis of key secondary  variables
If the primary  analysis of MMR rate at 24 weeks is statistically  significant, then the key 
secondary  endpoint MMR rate at 96 weeks will be tested, with the overall alpha controlled at 
the 5% two -sided level using a gatekeeping strategy .
Table 3 -1below summarizes the treatment effects of the key  secondary  endpoint which can be 
detected with 80% and 90% power , based on the specified assumptions regarding the 
bosutinib effect. The calculations were made using the software package PASS (2008).
Table 3-1 Detectable effect sizes for key  secondary  endpoint
Endpoint Anticipated effect 
with bosutinib2-sided alpha Power Detectable effect 
size§
MMR rate at 96 weeks 30%*0.05 90%
80%≥ 23%
≥ 20%
*:[Gambacorti -Passerini et al. 2014] , Figure 1D.
§: Absolute difference from the anticipated effect with bosutinib.
For MMR rate at 96 weeks, if the anticipated effect with bosutinib is 30%, then the given 
sample size with 2-sided alpha=0.05 would allow to detect an absolute difference of at least 
23% (i.e. MMR rate at 96 weeks with ABL001 is at least 53%) for 90% power and of at least 
20% (i.e. MMR rate at 96 weeks with ABL001 is at least 50%) for 80% power.
4 Change to protocol specified analyses
No change from protocol specified anal ysis was made.
5 Appendix
5.1 Imputation rules
5.1.1 Study drug
The following rulesshould be used for the imputation of the dose end date for a given study 
treatment component .
Scenario 1: If the dose end date is completel y missing and there is no EOT page and no death 
date, the patient is considered as on -going: 
The patient should be treated as on-going and the cut-off date should be used as the dose end 
date. 
Scenario 2: If the dose end date is completely or partially  missing and the EOT page is 
available:
Case 1: The dose end date is completely  missing, and the EOT completion date i s 
complete, then this latter date should be used.  
Case 2: Only  Year (yyyy) of the dose end date is available and yyyy < the year of EOT 
date:  
Use Dec31yyyy
Novartis Confidential Page 47
SAP 25-Aug-2017 (5:41) CABL001A2301
Case 3: Only  Year (yyyy) of the dose end date is available and yyyy  = the year of 
EOT date:
Use EOT date
Case 4: Both Year (yyyy) and Month (mm) are available for dose end date, and yyyy  
= the year of EOT date and mm < the mo nth of  EOT date: 
Use lastday of the Month (mm)
All other cases should be considered as a data issue and the statistician should contact 
the data manager of the study .
After imputation, compare the imputed date with start date of treatment, if the 
imputed da te is < start date of treatment:
Use the treatment start date
Patients with missing start dates are to be considered missing for all study  treatment 
component related calculations and no imputation will be made. If start date is missing then 
end-date should not be imputed.
5.1.2 AE, ConMeds and safety  assessment date imputation
The imputations specified inthis section are only used for analyses of time to and duration of 
AEs and concomitant medications. 
Novartis Confidential Page 48
SAP 25-Aug-2017 (5:41) CABL001A2301
Table 5 -1 Imputation of start dates (A E, CM) and assessments (LB, EG, VS)
Missing 
ElementRule
day, month,
and y earNo imputation will be done for completely  missing dates
day, month If available year = year of study  treatment start date then 
oIf stop date contains a full date and stop date is earlier than study  
treatment start date then set start date = 01JanYYYY
oElse set start date = stud y treatment start date. 
If available year > year of study  treatment start date then 01JanYYYY
If available year < year of study  treatment start date then 01JulYYYY
day If available month and year = month and year of study  treatment start 
date then 
oIf stop date contains a full date and stop date is earlier than study  
treatment start date then set start date= 01MONYYYY . 
oElse set start date = stud y treatment start date.
If available month and y ear > month and year of study  treatment start 
date then 01MONYYYY  
If available month and year < month year of stud y treatment start date 
then 15MONYYYY  
Table 5 -2 Imputation of end d ates (A E, CM) 
Missing 
ElementRule
(*=last treatment date plus 30days not > (death date, cut- off date, withdrawl 
of consent date))
day, month, 
and y earCompletely  missing end dates (incl. ongoing events) will be imputed by  
the end date of the on -treatment period* 
day, month If partial end date contains y ear onl y, set end date = earliest of 
31DecYYYY or end date of the on -treatment period * 
day If partial end date contains month and y ear, set end date = earliest of last 
day of the month or end date of the on -treatment period *
Any AEs and ConMeds with partial/missing dates will be display ed as such in the data 
listings .
Any AEs and ConMeds which are continuing as per data cut-off will be shown as ‘ongoing’ 
rather than the end date provided. 
Novartis Confidential Page 49
SAP 25-Aug-2017 (5:41) CABL001A2301
5.1.2.1 Other imputations
Incomplete date of initial diagnosis of cancer 
Missing day is defaulted to the 15thof the month and missing month and day is defaulted to 
01-Jan. 
5.2 AEs coding/grading
Adverse events are coded using the latest available version of Medical dictionary  for 
regulatory  activities (MedDRA) terminology .
AEs will be assessed according to the Common Terminology  Criteria for Adverse Events 
(CTCAE) version 4.03. 
The CTCAE represents a comprehensive grading system for reporting the acute and late 
effects of cancer treatments. CTCAE grading is by definition a 5-point scale generall y 
corresponding to mild, moderate, severe, life threatening, and death. This grading system 
inherently  places a value on the importance of an event, although there is not necessaril y 
proportionality  among grades (a grade 2 is not necessarily  twice as bad as a grade 1). 
5.3 Laboratory  parameters derivations
Grade categorization of lab values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) version 4.03. The calculation of CTCAE 
grades will be based on the observed laboratory  values only, clinical assessments will not be 
taken int o account. The criteria to assign CTCAE grades are given in Novartis internal criteria 
for CTCAE grading of laboratory  parameters (embedded below) . The latest available version 
of the document based on the underly ing CTCAE version v4.03 at the time of analysis will be 
used. For laboratory  tests where grades are not defined by CTCAE v4.03 , results will be 
graded by the low/normal/high (or other project -specific ranges, if more suitable)
classifications based on laboratory  normal ranges.
A severity  grade of 0 will be assigned for all non -missing lab values not graded as 1 or higher. 
Grade 5 will not be used. For laboratory  tests that are graded for both low and high values, 
summaries will be done separately  and labelled by direction, e.g., sodium will be summarized 
as hyponatremia and hy pernatremia.
EASE LA B - CTC 
grades in Novartis On  
Imputation Rules  
CTC AEgrading for blood differentials is based on absolute values. However,  this data may 
not be reported as absolute counts but rather as percentage of white blood cells ( WBC ). 
Novartis Confidential Page 50
SAP 25-Aug-2017 (5:41) CABL001A2301
If laboratory  values are provided as ‘<X’ (i.e. below limit of detection) or ‘>X’ , prior to 
conversion of laboratory  values to SI  unit, these numeric values are set to X. 
The following rules will be applied to derive the WBC differential counts when only 
percentages are available for a xxx differential
xxx count = (WBC count) * (xxx %value / 100)
The following rules will be applied to derive the WBC differential percentages when only 
differential co unts are available for a xxx differential
xxx %value = (xxx count 100) / WBC count
Further derivation of laboratory  parameters might be required for CTCAE grading. For 
instance, corrected calcium can be derived using the reported total calcium value and albumin 
at the same assessment using the following formula:
Corrected Calcium (mg/dL) = Calcium (mg/dL) –0.8 [Albumin (g/dL )-4]
In order to apply the above formula, albumin values in g/L will be converted to g/dL by  
multiply ing by 0.1andcalcium values in mmol/L will be converted to mg/dL  by dividing by 
0.2495. For calculation of laboratory  CTCAEgrades 0 and 1, the normal range for derived 
corrected calcium is set to the same limits (in mg/dL ) as for calcium.
CTC AEgrades for the derived absolute WBC differential counts (neutrophils, lymphocy tes) 
and corrected calcium will be assigned as described above for grading .
5.4 Derivation of PCR results and loss of response
Scaling towards an international standard will be performed for all molecular results using 
laboratory  specific conversion factors. In this process, the raw ratio between BCR -ABL and 
the control gene ABL is calculated and multiplied by the lab-specific conversion factor 
([Branford and Hughes 2006] ). Therefore, using the international unit, the BCR -ABL ratio 
will be presented in %. The MRDx assay  using PAXgeneTMBlood RNA tubes from MMD 
laboratory  will be used in this study . The lab conversion factor for this assay  is 1.1.  
The BCR -ABL  ratio in IS %is calculated by multiply ingthe raw BCR -ABL ratio with the 
lab-specific conversion factor and then b y 100: 
BCR -ABLratio (in %) = (BCR -ABL / ABL) * conversion factor * 100
For consistency  with elsewhere reported molecular response rates, the result may be 
expressed also as log -reduction. This is defined as the following: 
BCR -ABL Log-Reduction = -log 10(BCR -ABL rati o in %)
For example, -log 10(0.001) = 3 log reduction for a ratio of 0.1%.
The following binary  variables will be used when molecular response is reported.
Table 5-3 Response categories for molecular response
MR (Molecular Response) BCR -ABL ratio (%) Log-reduction category
Novartis Confidential Page 51
SAP 25-Aug-2017 (5:41) CABL001A2301
MMRYes ≤ 0.1% ≥ 3-log reduction
No > 0.1% < 3-log reduction
MR4.5Yes ≤ 0.0032% ≥ 4.5 -log reduction
No > 0.0032% < 4.5 -log reduction
Loss of MMR is defined in Section 2.7.1.1 .
5.5 Statistical models
5.5.1 Primary  analy sis
The null hypothesis of equality  of MMR rate at 24 weeks in the two treatment armswill be 
tested against two -sided alternative. The statistical hy potheses are:
H0: RA 24wk= RB 24wkversus HA: RA 24wk≠ RB 24wk, for a two -sided test
where RA 24wkis the probability  of MMR rate at 24 weeks in ABL001 arm and RB 24wkis the 
probability  of MMR rate at 24 weeks in bosutinib arm.
The Cochran- Mant el-Haenszel chi-square test X2
CMH (implement ed via S ASprocedure
FREQwithCMH op tion in the TABL ESstatem ent) will beused totestthedifference in
response rates between thetreatment arms. The p-value corresponding to the CMH test for 
“general association” will be used which follows a Chi -square distribution with one degree of 
freedom.
The 95% confidence interval for the difference in MMR rate at 24 weeks between treatment 
groups will be provided using the Wald method (implement ed via S ASprocedure FREQ
with RI SKDIFF op tion in the TABL ESstatem ent, under the default METHOD=WALD and 
VAR=SAMPLE ).If the 2×2 table is with ABL001 in row 1, bosutinib in row 2, MMR in 
column 1 and No MMR in column 2, then the SAS output will give the estimate of (risk 
for MMR at 24 weeks in ABL001 –risk for MMR at 24 weeks in bosutinib) . The 
corresponding Mant el-Haenszel estimate of common risk difference and 95% confidence 
interval will also be presented (with RISKDIFF( COMMON) option in the TABL ES
statem ent, taking the Mant el-Haenszel estimate from the SAS output table ).
If the sampling assumptions for chi-square test is not met (i.e. the expected frequencies
should ex ceed 5forall of tablecells), theexact Cochran -Mantel -Haenszel testwill be use d 
(imple mented via SAS procedure MULTTEST). The testisperform edbyrunni ng a stra tified
version ofthe Cochran -Armitage permutation test [Armitage et al. 1969] . In s tudies with
stratifie d randomi zation, the chi-square appro ximation is considered appropr iate for the 
X2
CMHstatistics iftheruleofMantelandFleiss[Mantel and Fleiss 1980] issatisfied.
Confidence inter valforMMR rate within each treatment arm
MMR will besumm arizedinterms of per centage rates with 95% confidence interval
using exact binomial confidence interval (implemented using SAS proced ure FREQwith
EXACT statement forone-way table [Clopper and Pearson 1934 ]).
Novartis Confidential Page 52
SAP 25-Aug-2017 (5:41) CABL001A2301
5.5.2 Key secondary  analysis
The null hypothesis of equality  of MMR rate at 96weeks in the two treatment armswill be 
tested against two -sided alternative. The statistical hy potheses are:
H0: RA 96wk= RB 96wkversus HA: RA 96wk≠ RB 96wk, for a two -sided test
where RA 96wkis the probability  of MMR rate at 96weeks in ABL001 arm and RB 96wkis the 
probability  of MMR rate at 96weeks in bosutinib arm.
The same approaches as for the primary  endpoint (Section 5.5.1 ) will be applied here for the 
Cochran-Mant el-Haen
szel chi-square testX2
CMH, the 95% Wald confidence interval for the 
difference in MMR rate at 96 weeks between treatment groups ,the Mant el-Haenszel
estimate of common risk difference with 95% confidence interval , and the confidence 
interval for MMR rate within each treatment arm .
Multiplicity  adjustment
Formal statistical testing of the key  secondary  endpoint will be performed with = 0.05 (two -
sided) only if the primary  endpoint is significant by means of a gatekeeping procedure to 
control the overall alpha level.
5.5.3 Other analy ses
Mantel -Haenszel comm on odds ratio
To obtain Mantel -Haenszel estimates of the common odds ratio and the corresponding 95% 
confidence interval in exploratory  analyses,  it requires SASprocedure FREQwithCMHand 
RELR ISK options in the TABL ESstatem ent. 
Logistic Regression 
Odds ratio will beused as a me asure of associati onbetw een tr eatment and response in 
exploratory  analyses (Section 2.14 ). The odds ratiowill be de rivedfrom thelogistic
regre ssionmodel(impl emented usingSASprocedure LOGISTIC, w ith tr eatment specified
as an explanatory vari able in the CLASS statem ent) which allows forincluding not only
thestratifi cation factor butalso foradjustments forother covaria tes(both categori caland
continuous). Theodds ratio willbepresented with 95% Wald confidence limits.
In ca ses wh ereanexact testhas been used tocompare response rates, the odds ratio should be 
determined using ex actlogisticregression, and theodds ratio presen tedwith exact 95% 
confidence limits. Inthesecases,SASPRO C LOGISTIC withEXACT ONLYoptio nwillbe 
used.
Kaplan- Meier estimates
Anestimate of the survival function in each treatment group w illbe constructed using
Kaplan -Meier (product-limit ) method as implemented inPROC LIFETEST with
Novartis Confidential Page 53
SAP 25-Aug-2017 (5:41) CABL001A2301
METHO D=KM option. The PROC LIFETEST statement will use the option
CON FTYP E=LOGL OG.
Median survival foreach treatment group will be obt ained along with 95% confide nce 
intervals calculated from PRO C LIFE TEST output using themethod of[Brookm eyer and 
Crowl ey 1982] . Kaplan-Mei er es timatesof the survivalfunction w ith 95% confidence
intervalsatspecifi c timepoints will be summ arized.Thestandard error of the Kaplan-
Meier estimatewill be calculated using Gr eenwood’s formula [Collett 1994].
Hazard ratio
Hazard ratio will be estimated by fitting the Cox proportional hazards model using SAS 
procedure PHREG (with TI ES=EXACT option in the MODEL statement). 
A st ratified unadjusted Cox model willbe, i.e.theMOD ELstatement will include the
treatment group va riable astheonly covar iateand theSTRATA statement will include
stratifi cation variable(s). Hazard ratio with two-sided 95% confidence interval will be based 
on Wald test.
6 Reference
1.Armitage P, McPherson CK and Rowe BC (1969). Repeated significance tests on 
accumulating data. J .R. Statist. Soc. A, 132, 232 -244. 
2.Baccarani M, Deininger DW, Rosti G, et al (2013). European LeukemiaNet 
recommendations for the management of chronic my eloid leukemia: 2013. Blood ;
122(6):872 -84.
3.Branford S, Hughes T (2006) Diagnosis and monitoring of chronic m yeloid leukemia b y 
qualitative and quantitative RT -PCR. Methods Mol Med; 125:69 -92.
4.Brookmeyer R and Crowley  J (1982). A Confidence Interval for the Median Survival 
Time. Biometrics, 38, 29 - 41. 
5.Clopper CJ and Pearson ES (1934).  The use of confidence or fiducial limits illustrated in 
the case of the binomial.  Biometrical , 26, 404- 413.
6.Collet D (1994). Modelling survi val data in medical research. London, Chapman & Hall.
7.Gambacorti -Passerini C, Brümmendorf TH, Kim DW, et al (2014). Bosutinib efficacy  and 
safet y in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: 
Minimum 24 -month follow -up. Am J Hematol; 89(7):732 -42.
8.García -Gutiérrez V, Martinez -Trillos A, L opez Lorenzo JL , et al (2015) .Bosutinib shows 
low cross intolerance, in chronic m yeloid leukemia patients treated in fourth line. Results 
of the Spanish compassionate use program. Am J Hematol; 90(5):429 -33.
9.Khoury  HJ, Cortes JE, Kantarjian HM, et al (2012). Bosutinib is active in chronic phase 
chronic m yeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. 
Blood; 119(15):3403 -12.
10.Mantel, N. and Joseph L  Fleisś ( 1980). Minimum expected cell size requirements for the 
Mantel -Haenszel one degree- of-freedom Chi -Square Test and a related rapid procedure. 
American Journal of Epidemiology , 112, 129- 134.
Novartis Confidential Page 54
SAP 25-Aug-2017 (5:41) CABL001A2301
Clinical Development
ABL001/asciminib
CABL001A2301
A phase 3, multi -center, open -label, randomized study  of 
oral ABL001 (asciminib) versus bosutinib in patients w ith 
Chronic M yelogenous Leukemia in chronic phase (CML -
CP), pre viously  treated w ith 2 or more ty rosine kinase 
inhibitors
Statistical A nalysis Plan (SA P)–Amendment 3
Author:Statistician, 
Document type: SAP Documentation
Document status: Final Amendment 3
Release date: 10-August -2020
Number of pages: 73
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis

Novartis Confidential Page 2
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Document History  –Changes compared to previous final version of SAP
Date Time point Reason for 
updateOutcome for update Section and title 
impacted 
(Current)
25-
Aug-
2017Prior to 
DB lock
for 
primary  
analysisCreation of 
final versionN/A -First version NA
26-
Mar-
2020Prior to 
DB lock 
for 
primary  
analysisImplementation 
of protocol 
amendment s 2 
and3. ABL001 has been replaced by  
International Nonproprietary  
Name (INN) asciminib.
Introduction of the switch to 
asciminib option for patients 
experiencing treatment failure 
on bosutinib treatment
Update of the definition of 
end of study  treatment
Added a potential End -of-
Study -Treatment anal ysis 
different from the 96 -week 
analysis
Addition /removal of
secondary  safet y objectives 
and exploratory efficacy  
objectivesThroughout the 
SAP amendment
Section  1.1, 
Figure 1-1
Sections 2.1, 
2.3
Analy ses added 
throughout the 
document
Section 1.1
Table 1-1
Additional 
analyses, 
clarificationClarification on which data are 
included in the analy ses, 
which assessments are 
considered for safety and 
efficacy  anal yses
Addition of the treatment arms 
and definition of the date of 
end of study  treatment
Removal of windows defined 
for ECGs, LVE F and PK 
assessments as they are not 
needed.Section 2.1
Section 2.1.1
Novartis Confidential Page 3
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
As per Health Authori ties 
request, addition of the 
breakdown per different time 
points of the number (%) of 
patients who discontinued the 
study  treatment phase and of 
the primary  reason for study 
treatment phase 
discontinuation
PAS: Removal of the 
condition related to vomiting
to consider a concentration 
evaluable as the occurrence 
and time of vomiting is not 
collected in the CRF.
Addition of asubgroup 
“Stratum reported in the CRF ” 
for the analy sis by subgroup of 
the primary  endpoint (to take 
into account the 
mistratification cases )
Removal of the subgroup 
“with or without historical 
BCR -ABL1 mutation by local 
lab” as this is not considered 
clinically  relevant
Additional analyses of prior 
TKI and non TKI 
antineoplastic therapies
Implementation of the 
estimand language for the 
primary  and key secondary 
objectives
Addition of a sensitivity  
analysis of the primary 
estimand stratify ing by the 
stratum recorded in the CRF to 
take into account that many 
stratification errors occurred
Addition of Time -to-event 
analyses for time to MMR and 
time to CCy RSection 
2.3.1
Section 2.2
Section 2.2.1
Section 2.4.2
Sections 2.5 and 
2.6
Section 
2.5.5
Section 2.7.2
Novartis Confidential Page 4
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Added how time is censored 
for time to MMR/CCy R, 
clarification on how to handle 
missing BMA assessments 
due to MMR being achieved
Added analyses AEs and 
SAEs incidence rates by 
adjusting for exposure and by 
reporting by time intervals to 
account for potential 
difference in exposure 
between the treatment arms
Clarified handling of 
unscheduled ECG 
measurements in the analy ses Section 2.7.3
Section 2.8.1
Section 2.8.4.1
4-
June-
2020Prior to 
DB lock 
for 
primary  
analysisCreation of 
amendment 2.0Clarified baseline for 
mutations
Clarified EOT is mapped to 
defined time points
Modified age subgroup, added 
Line of therapy  subgroup and 
moved Without T315I /V299L 
to Supplementary  analysis
(All patients with 
T315I /V299L  m utations 
identified at the Week 1 Day 1 
visit are discontinued from 
study  treatment when the 
mutation results become 
available) .
Clarified Mutation subgroup 
doesn’t include T315I /V299L 
mutations.
Modified age categories
Added COVID -
19 related PDs 
analysis
Added definitions of time on 
treatment, duration of 
exposure in patient -years and 
average dail y doseSection 2.1.1
Section 2.2.1
Section 2.3
Section 2.3.1
Section 2.4.1
Novartis Confidential Page 5
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Additional analyses of prior 
TKI therap y
Added summary of 
concomitant therapies for on-
switched treatment period.
Added COVID -
19 sensitivity  
analyses for the primary  and 
key secondary  endpoints
Added a supplementary 
analysis to the primary 
endpoint (Patients without 
T315I /V299L  mutations at 
Week 1 Day  1visit)
Added new graph for Ctrough 
values of asciminib
Updated the list of changes to 
the protocol specified analy ses
Added imputation rules for 
immature cells
Removed imputation rules for 
corrected calcium as corrected 
calcium is collected
Clarified all available values 
for BUN and UREA will be 
reported under the parameter 
name BUN in listing to avoid 
double reporting of same 
information
Definition of loss of MMR: 
Removed reference to 
confirmation of loss of 
CHR/CCy R
Loss of CHR: clarified 
“Progressive splenomegal y 
refractory  to therapy ” is ≥ 5cm
below left intercostal margin”
Implemented change to 
definition of treatment failure 
(Protocol amendment 3)Section 2.4.2
Sections 2.5.5, 
2.6.5
Section 2.5.6
Section 2.9
Section 4
Section 
5.3
Section 5.4.1
Section 5.4.3
Section 5.4.4
Section 5.4.5 
Novartis Confidential Page 6
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Clarified what 
“Thrombocy topenia (<100 x 
109/L ) that is unrelated to 
therap y” is.
Added derivation of response 
rates and categories sectionSection 5.5.
7-
Aug-
2020Prior to 
DB lock 
for 
primary  
analysisCreation of 
amendment 3.0
after FDA type 
C 
teleconference 
on 
28 July 2020As agreed with FDA, added 
sensitivity  analyses of the 
primary  and key secondary 
endpoints without the 
imputation rule used in the 
main analysesin case of 
missing PCR evaluations at 
24/96 weeks. 
Per FDA request, added 
another subgroup of interest: 
BCR -ABL ratio at basel ine ≥
1% or <1%.
Added calculation rules for 
duration of interrruption .
Added derivation rule for 
corrected calcium using the 
reported total calcium value 
and albumin.
Aligned the definition of loss 
of CCyR with the definition of 
loss of CHR by adding the 
requirement that loss of CCy R 
(Ph+ bone marrow cells to > 
0%)must have led to treatment 
discontinuation because of 
lack of efficacy .Section 2.5.5
Section 2.2.1
Section 2.4.1
Section 5.3
Section 5.4.2
Novartis Confidential Page 7
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Table of contents
Table of contents ................................................................................................................. 7
1Introduction ....................................................................................................................... 12
1.1 Study  design ........................................................................................................... 12
1.2 Study  objectives and endpoints ............................................................................. 13
2Statistical meth ods
............................................................................................................. 15
2.1 Data analy sis general information ......................................................................... 15
2.1.1 General definitions ................................................................................ 17
2.2 Analy sis sets .......................................................................................................... 25
2.2.1 Subgroup of interest .............................................................................. 26
2.3
Patient disposition, demographics and other baseline characteristi cs................... 28
2.3.1 Patient disposition ................................................................................. 29
2.4 Treatments (stud y treatment, rescu e medication, concomitant therapies, 
compliance) ............................................................................................................ 31
2.4.1 Study  treatment / compliance ................................................................ 31
2.4.2 Prior, concomitant and post therapies ................................................... 33
2.5 Analy sis of the primary  objective/estimand .......................................................... 35
2.5.1 Primary  endpoint/estimand ................................................................... 36
2.5.2 Statistical hy pothesis, model, and m ethod of analysis .......................... 36
2.5.3 Handling of remaining intercurrent events of primary  estimand
.......... 36
2.5.4 Handling of missing values not related to intercurrent event ............... 36
2.5.5 Sensitivity  analy ses............................................................................... 36
2.5.6 Supplementary  anal yses........................................................................ 37
2.6 Analy sis of the key  secondary  object ive/estimand
................................................ 37
2.6.1 Key secondary  endpoint/estimand ........................................................ 38
2.6.2 Statistical hy pothesis, model, and method of analy sis.......................... 39
2.6.3
Handling of remaining intercurre nt events of primary  estimand .......... 39
2.6.4 Handling of missing values not related to intercurrent event ............... 39
2.6.5 Sensitivity  analy sis................................................................................ 39
2.7 Analy sis of secondary  efficacy  objective(s) .......................................................... 39
2.7.1 Secondary
 endpoints ............................................................................. 39
2.7.2 Statistical hy pothesis, model, and method of analy sis.......................... 42
2.7.3 Handling of missing values/censoring/discontinuations ....................... 44
2.8 Safety  anal yses....................................................................................................... 45
2.8.1 Adverse events (AEs) ............................................................................ 45
2.8.2 Deaths .................................................................................................... 46
Novartis Confidential Page 8
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.8.3 Laboratory  data ..................................................................................... 47
2.8.4 Other safety  data ................................................................................... 48
2.8.5 Additional Analy ses.............................................................................. 50
2.9
Pharmacokinetic endpoints.................................................................................... 50
2.10 PD and PK/PD analy ses......................................................................................... 52
2.11
Patient- reported outcomes ..................................................................................... 52
2.11.1 MDASI -CML ........................................................................................ 53
2.11.2 EQ-
5D-5L............................................................................................. 53
2.11.3 WPAI -CML ........................................................................................... 54
2.11.4 PGIC
...................................................................................................... 54
2.12 Resource utilization ............................................................................................... 55
2.13 Biomarkers ............................................................................................................. 55
2.13.1 Somatic mutation biomarker data handling and analy sis...................... 57
2.14 Other exploratory  anal yses.................................................................................... 58
2.15 Interim anal ysis...................................................................................................... 59
3
Sample size calculation ..................................................................................................... 60
3.1 Primary  anal ysis..................................................................................................... 60
3.2 Power for anal ysis of key secondary  variables
...................................................... 60
4Change to protocol specified anal yses.............................................................................. 60
5Appendix ........................................................................................................................... 61
5.1 Imputation rules ..................................................................................................... 61
5.1.1 Study  drug ............................................................................................. 61
5.1.2 AE, ConMeds and safety assessment date imputation .......................... 61
5.2 AEs coding/grading ............................................................................................... 63
5.3 Laboratory  parameters derivations ........................................................................ 63
5.4 Efficacy  variables
.................................................................................................. 65
5.4.1 Molecular response ............................................................................... 65
5.4.2 Cytogenetic response ............................................................................ 66
5.4.3 Hematologic response ........................................................................... 67
5.4.4 Treatment Failure .................................................................................. 68
5.4.5 CML  progression to accelerated phase (AP) or blast crisis (BC) ......... 69
5.4.6 CML -related deaths ............................................................................... 69
5.4.7 Disease progression ............................................................................... 69
5.4.8 Overall survival ..................................................................................... 69
5.5 Derivation of response rates and categories .......................................................... 70
5.5.1
Response rate at a specific time point................................................... 70
Novartis Confidential Page 9
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
5.5.2 Response rate b y a specific time point (best response)......................... 70
5.6 Statis tical models................................................................................................... 70
5.6.1 Primary  anal ysis.................................................................................... 70
5.6.2 Key secondary  anal ysis......................................................................... 71
5.6.3 Other anal yses....................................................................................... 71
5.6.4
Calculation of exposure- adjusted incidence rate ................................... 72
6Reference ........................................................................................................................... 73
Novartis Confidential Page 10
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
List of abbreviations
AE Adverse event
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AP Accelerated phase
AST Aspartate aminotransferase
ATC Anatomical therapeutic classification
AUC Area under the curve
BC Blast c risis
bid bis in diem/twice a day
CCyR Complete cytogenetic response
CHR Complete hematologic r esponse
CMH Cochrane -Mantel -Haenszel
CML Chronic myelogenous leukemia
CML -CP Chronic myelogenous leukemia in chronic phase
CRO Contract r esearch organization
CSP Clinical s tudy protocol
CSR Clinical s tudy report
CTCAE Common terminolog y criteria for adverse events
CV Coefficient of variation
DAR Dosage administration r ecord
DI Dose intensity
DMC Data m onitoring c ommittee 
DRL Drug r eference  listing
DSUR Development safety update report
ECG Electrocardiogram
eCRF Electronic c ase report form
EOT End of treatment in the treatment phase (patient level)
EOsT End of study treatment (study level)
ER Emergency r oom
FAS Full analysis set
FD First dose date of study treatment during the treatment phase
FDswitch First dose date of asciminib during the treatment switch phase
GP General practitioner
H Hospitalization
HCRU Health care resource utilization
HLT High level term
HLGT High level group term
IRT Interactive response technology
IS International s cale
LD Last dose date of study treatment during the treatment phase
LDswitch Last dose date of asciminib during the treatment switch phase
Novartis Confidential Page 11
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
LLOQ Lower limit of quantitation
LPFT Last patient first treatment
LSC Leukemic stem cell
LVEF Left ventricular ejection fraction
MCyR Major cytogenetic r esponse
mCyR Minor cytogenetic r esponse
MedDRA Medical d ictionary for regulatory activities
MMR Major molecular r esponse
NCI National Cancer Institute
NGS Next generation sequencing
NMQ Novartis MedDRA Query
OS Overall s urvival
PAS Pharmacokinetic analysis set
PCR Polymerase chain reaction
PCyR Partial c ytogenetic r esponse
PD Pharmacodynamic
PDI Planned d ose intensity
PFS Progression -free rurvival
Ph+ Philadelphia chromosome positive
PK Pharmacokinetics
PPS Per-protocol set
PRO Patient-r eported outcomes
PSUR Periodic s afety  update report
PT Preferred term
qd Qua’que di’e / once a day
RDI Relative dose intensity
SAE Serious adverse event
SAP Statistical a nalysis plan
SD Standard deviation
S-EoT End of treatment in the treatment switch phase (patient level)
SMQ Standardized MedDRA q uery
SOC System organ c lass
Sp Specialist
TBL Total bilirubin
TKI Tyrosine kinase inhibitor
TTF Time to treatment failure
UC Urgent c are
ULN Upper limit of norm
VAS Visual a nalogue scale
W1D1 Week 1 Day 1
WBC White blood cell s
WHO-DD World Health Organization Drug Dictionary
Novartis Confidential Page 12
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
1 Introduction
This statistical analysis plan (SAP) describes all planned analysesof primary objective,
secondary  objectives and selected exploratory objectives for the clinical study report s(CSR) of 
study CABL001A2301, a phase 3, multi- center, open -label , randomized study  of oralasciminib
versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML -CP), 
previously  treated with 2 or more t yrosine kinase inhibitors. 
The content of this SAP is based on protocol CABL001A2301 version 03.All decisions 
regarding safet y monitoring analysis for the data monitoring committee, 24-week primary
analysis, 96-week analysis,end of study  treatment analysis, 5-year progression
-free survival 
(PFS)/overall survival (OS)update analysis,and postings for ClinTrial.gov and EudraCT, as 
defined in th isSAP document, have been made prior to the first database lock of the study data
for the primary  anal ysis.
1.1 Stud y design
This is a randomized,  Phase III , open -label,  active -controlled, multi- center study   comparing  
safet y and efficacy  ofasciminib tobosutinib inpatients with CML -CP, previously  treated with 
2 or more tyrosine kinase inhibitors (Figure 1-1). Approximately 220 patients will be 
randomized to one of the following treatment arms in 2:1ratio:
asciminib 40 mg BID
Bosutinib 500 mg QD
Randomization will be stratified by the following factor: cytogenetic response status (with or 
without major 
cytogenetic response).
Figure 1-1 Schematic of Study  Design
Patients with documented treatment failure (as per the 2013 ELN guidelines, Baccarani et al 
2013) while on bosutinib treatment will have the option to switch to asciminib treatment within 

Novartis Confidential Page 13
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
96 weeks after the last patient has been randomized on study . The patients who switch to 
asciminib will be able to receive asciminib up to the end of stud y treatment (EOsT) period.
Patients will be treated up to the EOsT defined as up to 96 weeks after the last patient received 
the first study  dose(LPFT) or up to 48 weeks after the last patient has switched to asciminib 
treatment whichever is longer , if they do not discontinue study  treatment earlier. After the EOsT, 
the assigned study  treatment will be made available to patients who in the opinion of the 
investigator sare still deriving clinical benefit. This may be outside of this study  through 
alternative options including, but not limited to, an expanded access/compassionate 
use/managed access program or access to commercial supplies in applicable countries.
Major Molecular Response (MMR) rate at 24 weeks is the primary  endpoint in this study . MMR 
rate at 96 weeks is the key secondary  endpoint.
Four analyses are planned for this study , including the 24 -week primary  analy sis, the 96 -week 
analysis, the End-of-Study -Treatment (EOsT) analy sis, and Progression- Free survival/Overall 
survival (PFS/OS) update analysis The timing when those analyses are conducted is 
summarized in Section 2.1. 
No formal interim efficacy  analysis is planned in this study . A data monitoring comm ittee 
(DMC )will monitor unblinded safet y data approximately  6months after the first randomized 
patient has started study treatment. Subsequent reviews will be conducted approximately  ever y 
6 months and when needed thereafter (ie. if significant safety  findings are noted) until the 
primary  anal ysis.
1.2 Stud y objectives and endpoints
Table 1-1 Objectives and related endpoints
Objective Endpoint
Primary
To compare the MMR rate at 24 weeks of
asciminib versus bosutinib Major Molecular Response (MMR) rate at 24 weeks
Key secondary
To compare additional parameters of the 
efficacy of asciminib versus bosutinib MMR rate at 96 weeks
Other secondary
To compare additional parameters of the 
efficacy of asciminib versus bosutinibCytogenetic response rate (Complete, Partial, Major, 
Minor, Minimal, no response) at and by all scheduled 
data collection time points including 24, 48 and 96 weeks
MMR rate at all scheduled data collection time points  
(except 24 and 96 weeks which are already covered by 
primary and key secondary endpoints)
MMR rate by all scheduled data collection time points 
including 24, 48 and 96 weeks
Time to MMR
Duration of MMR
Time to CCyR
Duration of CCyR
Time to treatment failure
Progression free survival
Novartis Confidential Page 14
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Objective Endpoint
Overall survival
To compare the safety and tolerability 
profile of asciminib versus bosutinibType, frequency and severity of adverse events,
changes in laboratory values that fall outside the pre-
determined ranges and clinically notable ECG and other 
safety data (vital signs)
To characterize the PK of asciminib in the 
CML-CP populationTrough plasma concentrations,
PK parameters in full PK group: Cmax, Tmax, AUC0 -12h, 
CL/F 
To assess the safety of asciminib when 
administered as treatment after bosutinib 
failure according to the 2013 ELN 
GuidelinesType, frequency and severity of adverse events, changes in 
laboratory values that fall outside the pre -determined ranges 
and clinically notable ECG and other safety data (vital signs )
Novartis Confidential Page 15
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Objective Endpoint
Exploratory
To evaluate the influence of factors such 
as cytogenetic response at baseline, 
failure/intolerance to prior TKIs, line of 
therapy, gender, race and age on the 
effect of asciminib with respect to the 
primary efficacy endpoint Major Molecular Response (MMR) rate at 24 weeks
To explore the exposure -response 
relationships of asciminib ; evaluate the 
effect of population covariatesExposure -safety ,exposure -PDanalyses
To characterize mutations in the BCR -
ABL1 gene at Week 1 Day 1, upon 
confirmed loss of MMR and/orat end of 
treatment and examine their association 
with molecular and cytogenetic r esponse 
forasciminib vs bosutinibBCR -ABL1 gene mutations at Week 1 Day 1, upom confirmed 
loss of MMR and/orat end of treatment as determined by 
Sanger Sequencing
To understand biology of CML and bone 
marrow microenvironment on leukemic 
stem cells (LSCs) eradication, including 
patients’ immunogenicityBone marrow biopsies cha racterization for adaptive immune 
response by immunohistochemistry (IHC); bone marrow 
aspirates to evaluate the effect of treatments on LSCs burden 
and immune cells subsets changes by flow cytometry
To assess clonal evolution during 
treatment with asciminib vs. bosutinibLow level BCR -ABL1 mutation profiles assessed by mass 
spectrometry at Week 1 Day 1, upon confirmed loss of MMR
and/orat EOT.  
Clonal evolution of several genes implicated in CML assessed 
by Next Generation Sequencing (NGS) method s 
To evaluate soluble /inflammarory factors 
that correlate with response to asciminib
vs. bosutinib treatmentBaseline and changes from baseline of c ytokine expression in 
plasma  
To compare the impact of treatment on 
patient reported outcomes (PRO) 
including CML -specific symptoms, patient 
quality of life, and impact on work 
productivity and activity impairment from 
baseline and EOT between  treatment 
arms in all patientsChange in symptom burden and interference from baseline 
over time according to t he MDASI -CML PRO instrument
Change in patient’s impression of CML symptoms according 
to Patient Global Impression of Change ( PGIC )
Change in health utility from baseline over time according to 
EQ-5D-5L
Change in work productivity and activity impairment ov er time 
according to W PAI
To compare the impact of treatment on 
health care resource utilization between 
treatment arms in all patientsHealth care resource burden over time
2 Statistical methods
2.1 Data analy sisgeneral information
The planned analyses willbe performed by Novartis and/or a designated CRO . SAS version 9.4 
or later will be used to perform all data anal yses and to generate tables, figures and listings.
There is no planned interim efficacy  analysis. Prior to the database lock for the primary  analysis, 
tables and figures aggregated by treatment arm for safet y data review by the data monitoring 
committee or for other reporting activities will be produced by  an independent statistician and 
independent st atistical programmers.
Novartis Confidential Page 16
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
For between -treatment comparisons of efficacy  endpoints, randomization stratification factor, 
i.e. cytogenetic response status (MCyR vs no MCyR) at screening , will beincluded inrespective
stratified statistical tests.
Data include d in the analy ses
The anal ysis data cut-off date s for the planned analy ses are:
Primary  anal ysis:After all randomized patients have been on stud y treatment for 24
weeks or  discontinued earlier , i.e., LPFT + 24 weeks . 
96-week analysis: After all randomized patients have been on study  treatment for 96
weeks or  discontinued earlier, i.e., LPFT + 96 weeks
End of study  treatment analy sis
:30 day s after the EOsT. (Note: After the study  
treatment period, the assigned stud y treatment will be made availa ble, may  be outside 
of this study , to patients who in the opinion of the investigators are still deriving 
clinical benefit. ) 
PFS/OS update analysis:5 years from the date when the last randomized patient 
received the first stud y dose (irrespective of trea tment switch for patients failing 
bosutinib) .
All statistical analyseswill be performed using all data colle ctedinthe database upto th e
respective data cut-offdate. Alldata with an assessment date orevent start date (e.g. vital sign
assessment date orstart date ofanadverse event) prior toor
onthecut-offdate will beincluded
intheanalysis.Any data collected beyondthecut-offdate willnot be included in the analysis 
and will not be used for a ny derivations.
All events with start date before or on the respective cut-off date and end date after the 
respective cut-off date will be reported as ongoing . The same rule will be applied to events 
starting before or on the respective cut-off date and not having documented end date. This 
approach applies, in particular, to adverse event and concomitant medication reports. For these 
events, the end date will not be imputed and therefore will not appear in the listings.
General analy sis conventions
Pooling of cente rs:Unless specified otherwise, data from all study  centers will be pooled for 
the anal ysis. Due to expected small number of patients enrolled at centers, no center effect 
will be assessed. 
Qualitative data (e.g., gender, race, etc.) will be summarized b y means of contingency  tables
by treatment group; a missing category  will be included as applicable. Percentages will be
calculated using the number of patients in the relevant population or subgroup as the
denominator.
Quantitative data (e.g., age, bod y weight, etc.) will be summarized by  appropriate descriptive 
statistics (i.e. mean, standard deviation, median, minimum, and maximum) by treatment group .
For pharmacokinetics (PK)concentration and parameters descriptive statistics also include 
coefficient o f variation ( CV)%, geo -mean and geo -CV%.
Novartis Confidential Page 17
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.1.1 General d efinition s
Investigational drug and study  treatment
Investigational drug , will refer to the asciminib only. Whereas, study treatment will refer to
asciminib orcontrol treatment , i.e. bosutinib, received during the treatment phase. Switched 
treatment will refer to asciminib received during treatment switch phase .
Treatment arms
Asciminib (Subjects randomized to asciminib arm at the beginning of the study )
Bosutinib (Subjects randomized to bosutinib arm at the beginning of the study )
Date of end of study  treatment (EOsT)
The EOsT date is the date that the study  treatment is ended for the entire study . On this date, 
patients are treated for at least 96 weeks if they are not eligible to switch study  treatment or are 
treated for at least 48 weeks after they have switched to asciminib treatment, unless patients 
have discontinued stud y treatment earlier
Date of first administration of randomized study treatment 
The date of first administration of randomized study  treatment (FD) is derived as the first date 
when a non-zero dose of study  treatment was administered as per the Dosage Administration
Record (DAR) electronic case report form (eCRF )
. The date of first administration of study  
treatment will also be referred as start of study treatment .
The date of first administration of randomized study  treatment is the same as the date of first 
administration of investigational drug or control drug.
Date of first administration of switched treatment 
For subjects switching from bosutinib to asciminib, the date of first administration of switched 
treatment (FD switch) is derived as the first date when a non-zero dose of asciminib was 
administered as per the DAR eCRF. The date of first administration of switched treatment 
(asciminib )will also be referred as start of switched treatment
.
Date of last administration of randomized study treatment 
The date of last administration of randomized study  treatme nt(LD) is defined as the last date 
when a non-zero dose of study  treatment was administered as per DAR eCRF . For subjects 
switching 
from bosutinib to asciminib, this includes the dose of bosutinib administered as 
bridging therap y between their treatment f ailure and the first dose of asciminib administered.
The date of last administration of randomized study  treatment is the same as the date of last 
administration of investigational drug or control drug.
Novartis Confidential Page 18
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Date of last administration of switched treatment 
The date of last administration of switched treatment (LD switch) is defined as the last date when 
a non -zero dose of switched treatment (asciminib) was administered as per DAR eCRF .
Study day
The study  day, describes the day  of the event or assessment date , relative to the reference start 
date. 
The study  day is defined as:
The date of the event (visit date, onset date of an event, assessment date ,etc.) −
reference start date + 1 if event is on or after the reference start dat e;
The date of the event (visit date, onset date of an event, assessment date ,etc.) − 
reference start date if event precedes the reference start dat e
.
Thereference start dateforsafety assessments (e.g.adverse event onset, laboratory  abnormality
occurrence, vital sign measurement, dose interruption, PK,etc.) isthestart ofstudy  treatment.
Thereference start date forallother, non- safety assessments (e.g.molecular response, survival 
time, disease 
progression, ECOG performance status, patient reported outcomes (PRO) , etc. )is
thedate ofrandomization.
The stud y day will be display ed in the data listings. If anevent starts before thereference start 
date, thestudy day displa yed on the listing will be negative.
Switch study  day
Theswitch study  day, describes the day  of the event or assessment date, relative to the start of 
switched treatment .
Switch study  day = date of event –start of switched treatment + 1, if event is on or after the
start of switched treatment
Switch study  day = date of event –start of switched treatment, if event precedes the start of
switched treatment
The switch study  day will be display ed in the data listings if an event starts on or after the start 
of switched treatment.
Time unit
A year length i s defined as 365.25 days. A month length is 30.4375  (=365.25/12) days. If 
duration is reported in months, duration in days will be divided by 30.4375.  If duration is  
reported in years, duration in day s will be divided by  365.25.
A week length is defined as 7 days. If duration is reported in weeks, duration in days will be 
divided by  7.
Baseline for the treatment period
For efficacy evaluations, the last non-missing assessment, including unscheduled assessments 
on or before the date of randomization is taken as “baseline” value or “baseline” assessment. In 
Novartis Confidential Page 19
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
the context of baseline definition, the efficacy  evaluations also include PRO andperforma nce 
status. 
For safet y evaluations, the last available assessment , including unscheduled assessments before 
the date of start of study  treatment is taken as‘‘baseline” assessment.
For pre-dose electrocardiogram (ECG ), the last available assessment befor e the treatment start 
date/time is used for baseline.
For ECGs, where study requires multiple replicates per time point, the average of theses 
measurements would be calculated for baseline (if not alread y available in the database).
For mutations, the Week 1 Day  1 assessment is taken as “baseline” assessment.
In rare cases where multiple laboratory
 measurements meet the baseline definition, with no 
further flag or label that can identify the chronological order, then the following rule should be 
applied: If values are from central and local laboratories, the value from central assessment 
should be considered as baseline.
If patients have no value as defined above , the baseline result will be missing .
Baseline for the treatment switch period
For subjects sw itching from bosutinib to asciminib, the last non- missing assessment, including
unscheduled assessments before the date of first administration of asciminib is taken as
‘‘baseline” assessment for the switched treatment period
, and denoted as baseline_switc h for 
short.
On-treatment assessment/event and observation periods
For adverse event reporting the overall observation period will be divided into three mutually 
exclusive segments for subjects without treatment switching and into up to five mutually  
exclusive segments for subjects switching treatment : 
For subjects without treatment switching:
1.pre-treatment period: from day of patient’s informed consent to the day before first 
administration of study  treatment (FD)
2.on-treatment period: from date of first administration of study  treatment to 30 days after 
date of last actual administration ofstudy  treatment (including start and stop date) (LD) . 
Note: Patients will be treated up to the end of study  treatment period (EOsT) . This will 
be the las t actual administration of study treatment for each patient if the patient hasnot 
discontinue dstudy  treatment earlier .On this date, all patients without treatment 
switching will have been treated for at least 96 weeks unless patients have discontinued 
study treatment earlier. After this period, the assigned study  treatment will be made 
available, may be outside of this study , to patients who in the opinion of the investigators 
are still deriving clinical benefit.
3.post-treatment period: starting at day  31 after last administration of study  treatment .
For subjects with treatment switching from bosutinib to asciminib:
Novartis Confidential Page 20
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
1.pre-treatment period: from day of patient’s informed consent to the day before first 
administration of study  treatment (FD)
2.on-treatment period: from date of first administration of study  treatment to either the 
day before the first administration of asciminib (FD switch) or  30 days after the date of 
last actual administration of bosutinib (L D), whichever comes first. 
3.post-treatment period
: from day 31 after last administration ofbosutinib to the day 
before  the first administration of asciminib (FD switch)
.If the end date is before the start 
date, this period is not applicable.
4.on-switched treatment period : from date of first administrati on of asciminib (FD switch) 
to 30 day s after date of last actual administration of asciminib (LD switch).
NOTE: Subjects are treated in the study  up to end of study  treatment period (EOsT). 
On this date, all subjects with treatment switching will have been treated for at least 48 
weeks after switching unless they  have discontinued the switched treatment earlier.
5.Post- switched treatment period :from day  31 after last actual administration of
asciminib (L Dswitch). 
If dates are incomplete in a way that clear assignment to pre-, on-, post- , on- switched -, post-
switched- treatment period cannot be made, then the respective data will be assigned to the on-
treatment period.
Safety  summaries (tables, figures) on the Safet y set (respectivel y on the Switch Anal ysis Set) 
include only data from the on-treatment (resp. on-switched treatment) period with the exception 
of baseline data which will also be summarized where appropriate (e.g. change from baseline 
summaries). In particular, summary  tables for adverse events (AEs) will summarize only on-
treatment (resp. on
-switched treatment) events, with a start date during the on-treatment (resp. 
on-switched treatment) period (treatment -emergent AEs) (resp. switched- treatment -emergent 
AEs) . In addition, a separate summary  for death including on-treatment and post-treatment 
deaths will be provided.
However, all safet y data (including those from the pre-treatment, post-treatment and post-
switched treatment period) will be listed and flagged as appropriate .
Efficacy  summaries on the FAS (apart from OS and PFS) include data from baseline up to either 
the last assessment on or before the EoT visit or before or on treatment failure, whichever is the 
earliest .
Efficacy  summaries on the Switch Analy sis Set include data from baseline_swit ch up to the last 
assessment on or before the S
-EoT visit or before or on treatment failure during the switched
treatment period, whichever is the earliest .
The efficacy  assessments collected post-treatment failure, post-EoT or post S -EoT visit are not 
included in any efficacy analyses(except for OS and PFS analyses).However, they will be 
listed and flagged as appropriate .
Novartis Confidential Page 21
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Windows for multiple assessments 
Data such as molecular response, cytogene tic response collected over time (including 
unscheduled visits) will be summarized by scheduled time point. As patients do not always 
adhere to the visit schedule, visits will be remapped according to visit windows defined in 
Table s 2-1 to Table 2-4of this document to enable by-visit analy sis. Only  those protocol -
defined visits will have the visit window defined. Each assessment (including the end of 
treatment assessment) , either scheduled or unscheduled, will have a mapped visit assigned, as 
long as study  day is available, according to the defined visit window up to the date with data 
included. 
If more than oneassessment isassigned to thesametime window, theassessment performed 
closest tothetarget date willbeused for by -visit statistical analy ses. If 2 assessments within a 
visit window are equidistant from the target date, then theaverage of the 2 assessments will be 
used. If multiple assessments on the same date ,then the the average will be used. Data from all 
assessments (scheduled and unscheduled), including multiple assessments, will be listed.
Table 2-1 Time windows for molecular response
Assessment Target dayofassessment Time Interval
Baseline ≤ 1 ≤ Day 1#
Week 4 29 Day 2 to day 43
Week 8 57 Day 44 - 71
Week 12 85 Day 72 - 99
Week 16 113 Day 100to day 141
Week 24 169 Day 142to day 211
Week k (k=36, 48, …) kx7 + 1 Day kx7-40 –kx7+43
# Day 1 = Date of randomization
EOT assessments are mapped to the time points as needed.
Novartis Confidential Page 22
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Table 2-2 Time windows for cy togenetic response
Assessment Target dayofassessment Time Interval
Baseline 1 ≤ Day 1#
Week 24 169 Day 2to day 253
Week 48 337 Day 254to day 421
Week72 505 Day 422to day 589
Week 96 673 Day 590 to day 7 00
# Day 1 = Date of randomization
EOT assessments are mapped to the time points as needed.
For PRO data time windows will be defined for descriptive summary  by visit and longitudinal 
data analysis. If more than one assessment is available in the same time window, the assessment 
closest to the planned date will be considered. If two assessments are obtained with the same 
time difference compared to the scheduled visit day , the assessment obtained prior to visit will 
be considered.  
Table 2-3 Time windows for PRO : MDA SI-CML, EQ -5D-5L, PGIC
Assessment Target dayofassessment Time Interval
Baseline 1 ≤ Day 1#
Week 4 29 Day 2 -43
Week 8 57 Day 44 - 71
Week 12 85 Day 72 - 99
Week 16 113 Day 100 -141
Week 24 169 Day 142 -211
Week 36 253 Day 212 -295
Week 48 337 Day 296 -505
Week 96 673 Day 506 -700
# Day 1 = Date of randomization
Table 2-4 Time windows for PRO : WPA I-CML
Assessment Target dayofassessment Time Interval
Baseline 1 ≤ Day 1#
Week 4 29 Day 2 -57
Week 12 85 Day 58 - 127
Week 24 169 Day 128- 253
Week 48 337 Day 254 -505
Week 96 673 Day 506 -700
# Day 1 = Date of randomization
Here’s the general rule for the target day of assessment and time interval: For Week k visit, 
target day of assessment is defined ask*7+1. For the time interval, “Lower limit” = “upper limit 
Novartis Confidential Page 23
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
of prior applicable visit” +1. “Upper limit” = “target day of current visit” + integer part of 
(“target day  of next applicable visit” – “target day  of current visit”)/2. 
Visit window for the switched treatment period will use the same rules as described above but 
with Day 1 being the date of first administration of asciminib . Visit name for the switched 
treatment period will be defined similarly  with annotated by  beginning with “S -“ (e.g. S -Week 
4) to differentiate from those used for the randomized treatment period.
Novartis Confidential Page 24
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Last contact date 
The last contact date will be derived for patients not known to have died at the respective 
analysis data cut-off date using the last complete date among the following:
Table 2-5 Last contact date data sources
Source data Conditions
Date of random ization No condition
Last contac t date/last date patient was known to 
be alive from Survival Follow -up page Patient status is reported to be aliv e, lost to 
follow -up or unknown
Start/End dates from further antineoplastic 
therapyNon-missing medication/ procedure term
Start/End dates from drug administration record Non-missing dose. Doses of 0 are allowed
End of treatment date from end of treatment page No condition
Any speci fic efficacy  (molecular or cytogenetic) 
assessment date if availableEvaluation is marked as ‘done’
Laboratory/PK collection dates Sample collection marked as ‘done’
Vital signs da te At least one non -missing parameter value
Performance status date Non-missing performance status
Start/End dates of AE Non-missing verbatim term
The last contact date is defined as the latest complete date from the above list on or before the 
respective data cut-off date. The cut-offdate willnotbe used for last contact date, unless the
patient was seen or contacted on thatdate . No date post the cut-off date will be used. 
Completely  imputed dates (e.g. theanalysisdata cut-offdateprogrammaticall yimputed to
replac ethemissing enddate of adose administration record) willnot b e used toderive the last 
contact dat e. 
The last contact date will be used for censoring of patients in the anal ysis of overall survival.
Novartis Confidential Page 25
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.2 Analysis sets
Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all pati ents to whom study  treatment has been assigned 
by randomization. According to the intent to treat principle, patients will be analyzed according 
to the treatment and strat umthey have been assigned to during the randomization procedure.
Safety Set
The Safety Setincludes all subjects who received at least one dose of study  treatment. Subjects 
will be anal yzed according to the study  treatment actuall y received.
The actual treatment received corresponds to:
the randomized treatment if patients took at least one dose of that treatment;
the first treatment received if the randomized treatment was never received.
Pharmacokinetic Analysis Set
The Pharmacokinetic Analysis Set (PAS) includes all patients who provide at least one 
evaluable PK concentration. For a co ncentration to be evaluable, patients are required to:
Take a d ose of asciminib prior to sampling
Take the same dose of asciminib for at least 3 consecutive day s without dose 
interruption or dose modification prior to sampling
Have thepre-dose sample collected before thenext dose administration
Other analy sis sets
For duration of MMR and time to MMR (descriptive anal ysis), the MMR Responder 
Setwill be used that is a subset of FAS and includes patients who achieve MMR at 
any time on study  treatment .
For CCy R rates at and by scheduled time points and time to CCyR(Kaplan
-Meier 
analysis), the CCyR Analysis Set will be used that is a subset of FAS and includes 
patients who are not in CCy R at baseline.
For duration of CCy R and time to CCy R(descriptive anal ysis), the C CyR Responder 
Setwill be use that is a subset of FAS and includes patients who do not have CCy R at 
baseline and achieve CCy R at any  time on study  treatment .
For analy ses of patients switched to asciminib, the Switch Analysis S etwill be used 
that is a subset of FAS and includes patients who switched from bosutinib to 
asciminib and received at least one dose of asciminib.
Patient Classification
Patients may be excluded from the analysis populations defined above based on the protoc ol 
deviations entered in the database and/or on specific subject classification rules defined in Table 
2-6. 
Novartis Confidential Page 26
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Table 2-6 Subject classification based on protocol deviations and non protocol 
deviation criteria
Analy sis set Protocol deviations leading 
to exclusionNon protocol deviation 
leading to exclusion
FAS No written inform consent Not applicable
Safety  set No written inform consent No dose of stud y medication 
PK a nalysis set No written inform consent See definition of PAS
MMR Responder Set Not applicable See definition of MMR 
Responder Set
CCyR Anal ysis Set Not applicable See definition of CCyR 
Analy sis Set
CCyRResponder Set Not applicable See definition of CCyR
Responder Set
Switch Analy sis Set Not applicable See definition of Switch 
Analy sis Set
Withdrawal of Informed Consent
Any data collected in the clinical database after a subject withdraws informed consent from all 
further participation in the trial, will not be included in the analy sis.  The date on which a patient 
withdraws full consent is recorded in the eCRF. 
2.2.1 Subgrou p of interest
Subgroup analyses will use the same method as for the analysis in the respective overall analysis 
set. 
The objective forcarryingoutthese subgroup analysesis toidentif ypotential issues that
may belimited toasubgroup ofpatients, orthataremore commonly  observed in a subgroup 
of patients.
Summary  tables and figures will be generated only for subgroups with at least 1 5 patients. 
Efficacy
The primary  efficacy  endpoint will be summarized by  the following subgroups to examine the 
homog eneity  of treatment effect provided that the primary  efficacy  analysisbased on the FAS 
isstatistically  significant: 
Stratification factor (based on randomization data from Interactive Response 
Technology [IRT]): “Major Cy togenetic Response” or “No Major Cytogenetic 
Response”
Stratum reported in the CRF ( derived using the data collected on theBone Marrow 
Aspirate eCRF at baseline : see Appendix): “Major Cytogenetic Response” or “No 
Major Cy togenetic Response”
Novartis Confidential Page 27
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Sex: Female or male
Race : Asian, Caucasian, or others
Age category  (≥18- < 65years, ≥65 years, ≥ 75 years, )
Reason for discontinuation of the last prior Tyrosine Kinase Inhibitor ( TKI): 
Failure (i.e. lack of efficacy ) or intolerance (i.e. adverse event, lack of tolerability ). 
Note: Only  one reason for discontinuation is allowed for each prior therap y.
Number of prior TKI therapies: 2 , 3or ≥4
Line of therap yof randomized treatment : 3rd, 4thor ≥5th
With or without Week 1 Day  1 BCR -ABL1 mutation (other than T315I or V299L) by 
Sanger Sequencing at central lab: W ild ty peor  mutan t
BCR -
ABL ratio at baseline ≥ 1% or <1%
No formal statistical test of hypotheses will be performed for the subgroups, only point estimate 
of the treatment effect and 95%- confidence intervals will be provided (see Section 2.14 for 
further analysis details) . The objective of the efficacy  subgroup analy sis is to demonstrate 
homogeneity  of treatment effect in the above subgroups.
Safety
Subgroup anal yses for select ed safet y endpoints will be defined when required.
Japan -specific subgroup analy ses
Two subgroups will be formed based on geographic region: Japan or other region (this is not 
based on ethinicity ). These subgroup anal yses will be only  used for submission t o Japan health 
authority .
Summary  tables and figures will be presented for the two subgroups for the following outcome 
measures:
Baseline characteristics :Tables of demographics, diagnosis and extent of cancer ,
extramedullary  involvement , bone marrow anal ysis, molecular response, prior TKI 
and non
-TKI, patient disposition, analy sis sets by stratum
Exposure: Tables of duration of exposure , dose received
Tables of c oncomitant medications as well as surgical and medical procedures
PK(only  inasciminib arm): Table and figure of asciminib concentration by time, 
table of asciminib PK parameters (patients with full PK sampling), figure of a verage 
trough asciminib concentration from week 2, 4, 12 and 24 vs. BCR -ABL ratio IS (%)
at 24 weeks
AEs: T ables of a ll AEs, treatment -related AEs, AEs requiring dose adjustment or 
interruption, AEs requiring additional therapies, serious adverse event s (SAEs ), 
adverse eve nts of special interest ( AESIs ), overview table of AEs and death
ECG: Tables of Notable ECG values , change from baseline in ECG parameters values
Lab: Hematology  shift table, biochemistry  shift table
Efficacy : Tables of m olecular response categories at and by  each time point, MMR 
rate at and b y each time point, time to MMR, duration of MMR, c ytogenetic response 
Novartis Confidential Page 28
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
categories at and by each time point , time to CCy R, duration of CCy R, TTF, PFS, OS . 
Figures of cumulative incidence of MMR and of CCy R, association between Week 1 
Day 1BCR -ABL1 gene mutation and clinical outcome .
2.3 Patient disposition, demographics and other baseline 
characteristics
The FAS will be used for all baseline and demographic summaries and listings unless otherwise 
specified. Summaries will be reported b y treatment arm and for all patients ,and listings will be 
reported by treatment arm to assess baseline comparability . No inferential statistics will be 
provided.
Basic demographic and background data
All demographic and baseline disease characteristics data will be summarized and listed by 
treatment arm. Categorical data (e.g. age groups: 18 - <65, 65 - <75, and ≥ 75yearsand 18 -
<65, ≥ 65 years, sex, race, ethnicity , ECOG performance status) will be summarized by 
frequency  counts and percentages ; the number and percentage of patients with missing data will 
be provided. Continuous data (e.g. age, weight, height, body  mass index ) will be summarized 
by descriptive statistics (N,mean, median, standard deviation, minimum and maximum ), where
BMI (kg/m2) will be calculated as weight[kg] / (heigh t[m]2) using weight at screening .
For the Switch Anal ysis Set, the initial baseline and “baseline_switch” value will be 
summarized. Weight, BMI , age and ECOG performance status will be summarized using the 
“baseline_switch” value defined in Section 2.1.2.
In addition , a summary  table by sex, age group (18 - <65, 65 -<85, and ≥ 85 years)and treatment 
group and another summary  table by race and treatment group will be generated using the safet y 
setfor DSUR/PSUR.
Baseline stratification factors
The number (%) of patients in each stratum ( “Major Cytogenetic Response” or “No Major 
Cytogenetic Response” ) based on data obtained from the IRT system will be summarized 
overall and by treatment arm for the FAS. Discordances between the stratum recorded in IRT 
at the time of randomization and the stratum recorded in the clinical database through the data 
collected on eCRF will be cross -tabulated and listed. In case the baseline bone marrow aspirate 
is missing or not evaluable (i.e. < 20 metaphases), the stratum record ed in the clinical database 
will be imputed following the rule described in Appendix 5.1. 2.1.
Baseline cytogenetic response and molecular response
Baseline and Baseline_switch will be summarized for cytogenetic response and molecular 
response for the FAS a nd Switch Analy sis Set respectivel y.
Diagnosis and extent of cancer
All diagnosis and extent of cancer data will be summarized and listed by treatment arm. One
summary  table will include time (years) since initial diagnosis (descriptive statistics with N,
mean, median, standard deviation, minimum and maximum )andhistorical mutation : present 
Novartis Confidential Page 29
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
(unknown, yes, no), historical CML -associated mutation status (E225K, E255V, E355G, etc.)
(frequency  counts and percentages ). Another table will include e xtramedullary involvement : 
any extramedullary  involvement (Yes/No) and location of extramedullary  involvement (Spleen, 
Liver) (frequency  counts and percentages ).
For the Switch Analy sis Set, the above information will be based on the last observation prior 
to the Baseline_switch.
Medical history
Medical history  and ongoing conditions, including cancer -related conditions and symptoms 
entered on eCRF will be summarized and listed by treatment arm. The summar ywill be 
presented by primary  system organ class (SOC), preferred term (PT) and treatment arm. 
Medical history  and current medical conditions will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA) terminology . The MedDRA version used for reporting will 
be specified in the CSR and as a footnote in the applicable tables/listings.
In addition, separate listings will be produced for medical history  possibly  contributing to liver 
dysfunction ,and medical history  of protocol solicited cardi ovascular events .
The cardiovascular risk factors, heav y smoking, low physical activity , unhealthy  diet, and other, 
are collected prior to randomization and the EoT visit. A listing by treatment arm will be 
presented. 
Family  medical history  of each patien t for ischemic heart disease, cardiac arrhythmia, sudden 
death, high cholesterol, diabetes mellitus, heart defects (congenital heart disease), and heart 
failure is also collected prior to randomization and at the EoT visit. A listing by  treatment arm 
will be presented.
Other
All data collected at baseline , including child bearing potential as well as informed consent for 
additional research on study  data and biological samples ,will be listed.
2.3.1 Patient disposition
Enrollment bycountr y and center will besummarized forallscreened patients andalso by 
treatment arm using the FAS. The number (%) of randomized patients included in the FAS will 
be presented overall and by  treatment group. The number (%) of screened and not -randomized 
patients and the reasons for screening failure will also be displayed. The eligibility  criteria will 
be also summarized. The number (%) of patients in the FAS who are still on treatment, who 
discontinued the study  phases and the reason for discontinuation will be presented overal l and 
by treatment group.
The following summaries will be provided (with % based on the total number of FAS patients):
Number (%) of patients who were randomized (based on data from IRT s ystem)
Number (%) of patients who were randomized but not treated (based on DAR eCRF 
page not completed for any  study  treatment component)
Primary  reason for not being treated (based on “End of Treatment P hase Disposition” 
eCRF page)
Novartis Confidential Page 30
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Number (%) of patients who were treat ed (based on DAR eCRF pages of each stud y 
treatment completed with non-zero dose administered)
Number (%) of patient s who are still on -treatment ( based on the “ End of Treatment 
Phase Disposition” page not completed); 
Number (%) of 
patient s who discontinued the study  treatment phase overall, before 
Week 24,   Week 48 and Week 96 (based on the “ End of Treatment Phase 
Disposition” page) 
Primary  reason for study  treatment phase discontinuation overall, before Week 24,  
Week 48 and Week 96 (based on the “ End of Treatment Phase Disposition” page)
Number (%) of pa tients who have entered the survival follow -up (based on the “ End 
of Treatment 
Phase Disposition” page)
Number (%) of patients in the FAS randomized to the bosutinib arm who switched to 
receive asciminib (based on DAR –ABL0001 eCRF page completed with non -zero 
dose administered during the Treatment switch phase );
The following summaries will be provided with % based on the total number patients in the 
Switch Analy sis Set :
Number (%) of patient s who switched from bosutinib arm t o receive asciminib and are 
still receiving asciminib (based on the “ End of Treatment Disposition” eCRF not 
completed during the Treatment switch phase );Number (%) of patient s who switched from 
bosutinib arm to receive asciminib and discontinued asciminib (based on the “ End of 
Treatment 
Disposition” eCRF during the Treatment switch phase );
Primary  reason for  treatment switch phase discontinuation (based on the “End of 
Treatment Disposition” eCRF during the Treatment switch phase )
Number (%) of patient s who have entered the survival follow -up (based on the “ End of 
Treatment 
Disposition” eCRF during the Treatment switch phase )
Protocol de viations
The number (%) of patients in the FAS with any protocol deviation will be tabulated by 
deviation category (as spec ified in the Study Specification Document ) overall and b y treatment 
group for the FAS. All protocol deviations will be listed. In addition, the number (%) of patients 
in the FAS with any COVID -19 related protocol deviation (COVI D-19 specific protocol 
deviations as well as non-specific COVID -19 protocol deviations with a COVID - 19 
relationship) will be tabulated by deviation category  (as specified in the Study Specification 
Document ) overall and by  treatment group .
Analysis se ts
The number (%) of patients in each anal ysis set (defined in Section 2.2 ) will be summarized  by 
treatment group and stratum. Reasons leading to exclusion from analy sis sets will be listed by 
treatment group and stratum as well as tabulated overall and b y treatment group .
Novartis Confidential Page 31
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.4 Treatments (study  treatment, rescue medication, concomitant 
therapies, compliance)
2.4.1 Study treatment / compliance
Duration of exposure, actual cumulative dose, average daily dose, dose intensity  (DI) and 
relative dose intensit y (RDI) will be summarized by treatment arm. Duration of exposure will 
be categorized into time intervals; frequency  counts and percentages will be presented for the 
number (%) of subjects in each interval. The number (%) of subjects who have dose reductions 
or interruptions, and the reasons, will be summarized by treatment group. 
Subject level listings of all doses 
administered on treatment along with dose change reasons 
will be produced.  
The safety  set and Switch Anal ysisSet will be used for all summaries and listings of randomized 
and switched treatment s respectivel y. 
To summarize exposure data for the randomized treatment period, this will be based on patients 
in the Safet y set with the date of last administration of study treatment and the date of first 
administration of stud y treatment being FD and LD respectively .
To summarize exposure data for the switched treatment period, this will be based on patients in 
the Switch Anal ysis Set with the date of last administration of  study  treatment and the date of 
first administration of stud y treatment being FD switchand LD switchrespectively.
Duration of exposure to study  treatment
Duration of exposure to study  treatment is considered by taking into account the duration of 
exposure to the investigational drug or control:
Duration of exposure to study treatment (weeks )= ((date of last administration of  study 
treatment) –(date of first administration of study  treatment) + 1) / 7. 
The duration of exposure inpatient -years is thetotal of the duration of exposure in years 
from all the patients in a treatment group. 
The date of last administration of study  treatment is defined in Section 2.1.1 .
Summary  of duration of exposure to study  treatment will include categorical summaries based 
on intervals (<24 weeks, ≥24 weeks, ≥48 weeks, ≥96 weeks) and continuous summaries (i.e. 
mean, standard deviation etc. ).
Cumulative dose
Cumulative dose of a study treatment is defined as the total dose given during the study  
treatment exposure. 
The planned cumulative dose for a study  treatment refers to the total planned dose as per the 
protocol up to the last date of study  treatment administration. The calculations for the two study 
treatments are:
ABL001: 40 mg/administration × 2 (administration/day ) ×duration of exposure (day ) 
Novartis Confidential Page 32
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Bosutinib:  500 mg/day  × duration of exposure prior to dose escalation (day) 
+ 600 mg/day  
× duration of exposure since dose escalation (day ),
where the starting day  of dose escalation is identified as the first record in the DAR 
eCRF with dose increased and reason “As per protocol ”.
The actual cumulative dose refers to the total actual dose administered, over the duration for 
which the subject is on the study  treatment as documented in the DAR eCRF. It is the sum of 
the non-zero total daily doses recorded over the dosing period. For patients who did not take 
any drug the actual cumulative dose is by  definition equal to zer o. The actual cumulative dose 
will be summarized for each of the study  treatment.
Dose intensity  and relative dose intensity
Average Daily Dose (ADD )is defined as:
ADD (mg/day ) = Actual cumulative dose (mg) / Time on treatment (day).
Time on treatment (weeks) = ((date of last administration of  study  treatment) –(date of first 
administration of study  treatment) + 1 –number of day s with dose interruption*) / 7
*For subjects in the ascimin ib arm, this includes the half day s before and after the period with 
0 dose if the treatment was interrupted after the morning dose and/or resumed in the evening (1 
day record with QD dose administered before or after a record with 0 dose).
Dose intensity (DI) for patients with non- zero duration of exposure is defined as follows: 
DI (mg/day) = Actual c umulative dose ( mg) / Duration of exposure to study  treatment ( day).
For patients who did not take any drug the DI is by definition equal to zero. 
Planned dose intensity (PDI ) is defined as:
PDI (mg/day) = Planned cumulative dose ( mg) / Duration of exposure ( day).
Relative dose intensity (RDI) is defined as follows:
RDI = DI ( mg/day)  / PDI ( mg/day ).  
ADD, DI and RDI will be summarized separatel y for the two study  treatment s . 
Dose change s,interruptions or permanen t discontinuations
The number of subjects who have dose increase (allowed for bosutinib starting week 8, see 
protocol Section 6.2), dose reductions, dose interruptions or permanent discontinuations
, and 
the reasons, as well as the duration of dose interruption due to any  reason will be summarized 
separately  for the two study  treatment s. For any subjects, duration of dose interruption will be 
calculated b y adding all individual episodes of dose interruption for that pa tient. For subjects in 
the asciminb arm, this includes the half days before and after the period with 0 dose if the 
treatment was interrupted after the morning dose and/or resumed in the evening (1 day record 
with QD dose administered before or after a rec ord with 0 dose) . 
‘Dose Changed’, ‘Dose Interrupted’ and ‘Dose Permanently  Discontinued’ fields from the DAR 
eCRF pages will be used to determine the dose change s, dose interruptions, and permanent 
discontinuations, respectively .
Novartis Confidential Page 33
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
The corresponding fields ‘Reason for Dose Change/ Dose Interrupted’ and ‘Reason for 
Permanent D iscontinuation’ will be used to summarize the reasons.
A dose change occurs when total daily dose is different from the most recently  planned dose.
For patients inasciminib arm, there isonly one planned dose, i.e. 80 mg/day. For patients in 
bosutinib arm, the initial planned dose is 500 mg/day  and could be changed to 600 mg/day  in 
week 8 or later.
For the purpose of summarizing interruptions and reasons, multiple entries for interruption that 
are entered on consecutive days with different reasons will be counted as separate interruptions. 
However, if the reason is the same in th ementioned multiple entries on consecutive day s, then 
it will be counted as one interruption. 
Reduction : A dose change where the actual total daily  dose is lower than the most recently
planned dose. Therefore any dose change to correct a dosing error will not be considered a dose 
reduction. Only dose change is collected in the eCRF, while number of reductions will be 
derived programmatically  based on the change and the direction of the change.
Increase : A dose change where the actual total daily  dose is great er than the most recent ly
planned dose. Therefore any dose change to correct a dosing error will not be considered a dose 
increase . Onl y dose change is collected in the eCRF, while number of increase will be derived 
programmaticall y based on the change and the direction of the change.
2.4.2 Prior, concomitant and post therap ies
Prior anti -cancer thera py
The number and percentage of patients who received an y prior anti -neoplastic medications will 
be summarized by treatment arm forthelowest anatomical therapeutic classification (ATC )
class andpreferred term. A listing willalso be produced. 
Anti- neoplastic medications will be coded using the WHO Drug Dictionary  (WHO -DD). 
Details regarding WHO -DD version will be included in the footnote in the tables/listings. 
The above anal yses will be performed using the FAS.
The following information will be summarized for the FAS and Switch Analysis Set:
Prior TKI b y medication (e.g. imatinib, dasatinib, nilotinib, ponatinib, bosutinib, etc.) 
Number of prior TKI (e.g. 2, 3, 4, etc.) 
Number of lines of prior TKI therap y (2, 3, 4, 5+)
A new line of therap yis considered each time a change in TKI occured .Multiple entries 
for the same TKI will be counted as separate lines of therapy if a different TKI is 
received between the different entries .
Time on each line of prior TKI therapy (in years)
Time on last 
prior TKI (in years)
Reason to discontinue the most recent TKI therapy  at the time of screening
Novartis Confidential Page 34
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Prior non- TKI therapies (Yes, No). 
A Sankey -
like plot showing the sequence of prior TKIs will be provided.
Note: In case the last TKI given prior to enrollment in the study  was a bridging therapy  (i.e. 
reason for discontinuation includes a wording related to bridging), it will not be considered in 
the analy sis of prior TKIs. I n particular, it will not be considered as the last or most recent TKI 
therap y at the t ime of screening and will not count as an additional line of therapy .
For the Switch Anal ysis Set, bosutinib received during the randomized treatment period and 
other TKIs received since discontinuation of bosutinib and before first administration of 
asciminib ( FD switch) should be considered as prior TKIs.
Post treatment anti -cancer therapy
Anti- neoplastic therapies since discontinuation of study  treatment will be listed and summarized 
by thelowest anatomical therapeutic classification (ATC )class, preferred term, overall and by 
treatment group by means of frequency  counts and percentages using FAS.
Anti- neoplastic medications will be coded using the WHO -DD. Details regarding WHO -DD 
version will be included in the footnote in the tables/listi ngs. 
Concomitant therap ies
Concomitant therap ies aredefined as all interventions (therapeutic treatments and procedures) 
other than the study  treatment administered to a patient coinciding with the study  treatment 
period. Concomitant therap iesinclude medications (other than study  drugs) and medical 
procedures starting on or after the start date of study treatment ,or starting prior to the start date 
of study  treatment and continuing after the start date of study  treatment. 
Concomitant medications will be coded using the World Health Organization (WHO) Drug 
Reference  Listing  (DRL)  dictionary   that  employs  the  WHO  ATC classification system and 
summarized by the lowest ATC class and PTusing frequency  counts and percentages. Surgical 
and medical proc edures will be coded using MedDRA and summarized by SOC and PT . 
The summaries for the on -treatment period using the Safet y Set will includ e:
Therapies starting on or after the start of randomized study  treatment but no later than 
the end of the on-treatment period and
Therapies 
starting prior to start of randomized study  treatment and continuing after 
the start of randomized study  treatment .
These summaries for the on-switched treatment period using the Switch Analy sis Set will 
includ e:
Medicatio ns starting on or after the start of switched treatment but no later than the 
end of the on- switched treatment period and
Medications starting prior to start of switched treatment and continuing after the start 
of switched treatment .
Novartis Confidential Page 35
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Allconcomitant therapies will belisted using the Safet y Set. Any concomitant therapies
starting andending prior to thestart ofrandomized study treatment or starting beyond end of 
the on-treatment period if not switched, or starting beyond end of on-switched treatment
period if switched will be flagged in the listin g. 
The prohibited concomitant medications will be summarized by lowest ATC class and preferred 
term up to the end of on -treatment and on-switched treatment periods, respectively.
2.5 Analysis of the primary  objective /estimand
In this section, the target edtreatment effect corresponding to the primary  objective as well as 
the primary  objective is clarified using the estimand language.
The primary  clinical question of interest is: Isthe efficacy of asciminib (40 mg bid) superior to 
bosutinib (500 mg qd) in CML  patients in chronic phase, previousl y treated with 2 or more 
tyrosine kinase inhibitors, with regards to achieving MMR at 24 weeks while on study  treatment
and without meeting any  treatment failure criteria (defined in section 5.4.4) prior to 24 weeks, 
regardless of dose 
modification,  dose interruption, or deviation in any intake of concomitant 
medications.
The primary  estimand is described by  the following attributes:
Population: CML  patients in chronic phase, previously  treated with 2 or more tyrosine kinase 
inhibitors. Further details about the population are provided in Section 5 of the protocol .
Endpoint: Major Molecular Response (MMR) achieved at 24 weeks while on study  treatment
without meeting any treatment failure criteria (defined in section 5.4.4) prior to 24 weeks . A 
patient will be counted as having achieved MMR at 24 weeks if he/shemeets 
the MMR criteri on
(BCR -ABL ratio ≤0.1%) at 24 weeks while on study  treatment unless the patient met any 
treatment failure criteria (defined in section 5.4.4 ) prior to 24 weeks .
Intercurrent events: 
Treatment discontinuation (i.e. having performed an EOT visit) prior to 24 weeks due to 
any reason (e.g. intolerance, treatment failure, death, etc.) : non response
Meeting any treatment failure criteria (defined in section 5.4.4 ) prior to 24 weeks: non 
response
Dose modification,  dose interruption, or deviation in any  intake of concomitant 
medications
: ignore (treatment policy  strategy )
Treatment of interest: the randomized treatment (the investigational trea tment asciminib or the 
control treatment bosutinib) received for at least 24 weeks with or without dose modification, 
dose interruption or deviation in any intake of concomitant medications. Further details about 
the investigational treatment and control t reatment are provided in Section 6 of the protocol.
Handling of remaining intercurrent events : no other IE foreseen
The summary  measure: difference in MMR rateand its 95% confidence interval at week 24 
between the two treatment arms .
Novartis Confidential Page 36
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.5.1 Primary  endpoint /estimand
The primary  endpoint is Major Molecular Response (MMR) achieved at 24 weeks while on 
study  treatment withoutmeeting an ytreatment failure criteria (defined in section 5.4.4) prior to 
24 weeks . A pa tient will be counted as having achieved MMR at 24 weeks if he /shemeets the 
MMR criteri on(BCR -
ABL ratio ≤0.1%) at 24 weeks while on study  treatment unless the 
patient met an y treatment failure criteria (defined in section 5.4.4 ) prior to 24 weeks .
MMR will be considered as a binary  variable with patients achieving MMR grouped as 
‘responders’ and patients not achieving MMR grouped as ‘non responders’. Only patients with 
MMR at 24 weeks are considered respon ders. In other words, any  patient who achieves MMR 
before 24 weeks, but is no longer in MMR at 24 weeks, will be considered as a non -responder 
in this primary  analy sis.
Patients discontinuing treatment (i.e. having performed an EOT visit) prior to 24 weeks due to 
any reason (e.g. intolerance, treatment failure, death, etc.) and patients meeting any treatment 
failure criteria (defined in section 5.4.4) prior to 24 weeks will be considered as not having 
achieved MMR at 24 weeks.
Details of derivation of Polymerase Chain Reaction (PCR )results and calculation of BCR -ABL 
ratio are presented in Section 5.4 .
2.5.2 Statistical hy pothesis, model, and method of analy sis
The MMR rate at 24 weeks will be calculated based on the FAS and according to the I ntent To 
Treat (ITT) principle. MMR rate and its 95% confidence interval based on the Pearson -Clopper 
method will be presented by  treatment group. The 95% confidence interval for the unstratified 
difference in MMR rate between treatment groups will be provided using the Wald method.
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 24 weeks. The Cochrane -Mantel -Haenszel (CMH) chi-square test, stratified by 
the randomization stratification factor, i.e. cytogenetic response status ( MCyR vs no MCy R) at 
screening , will be used to compare MMR rate between the two treatment groups, at the two-
sided 5% level of significance. TheMantel -Haenszel estimate of the common risk difference 
and the corresponding 95% confidence interval will be presented. 
2.5.3 Handling of remaining intercurrent events of primary  estimand
No remaining intercurrent events.
2.5.4 Handling of missing values not related to intercurrent event
Patients with missing PCR evaluations at 24 weeks will be considered as non-responders. 
However, if the 24-week PCR evaluation is missing, but both a PCR evaluation at 16 weeks 
and a PCR evaluation at 36 weeks indicate MMR, the 24-week assessment is imputed as a 
‘Response’ ,
assuming that MMR is maintained between 16 and 36 weeks.
2.5.5 Sensitivity analy ses
The following sensitivity anal yses will be performed:
Novartis Confidential Page 37
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
The CMH chi-square test of MMR rate at 24 weeks will be repeated stratifying by the 
stratum recorded in the CRF (MCy R vs no MC yRat baseline) .
Due to the C OVID -19 (Coronavirus) pandemic, there is a risk that planned hospital visits 
are cancelled, potentially resulting in missing PCR evaluations. In order to assess the 
impact of C OVID-19 (including potential missing data) on the primary endpoint, the 
CMH chi -square test of MMR rate at 24 weeks will be repeated on the FAS excluding the 
patients with planned 24 -week visit ( start of stud y treatment + 161 day s ) after the start 
date of COVID -19 epi demic. As per Novartis guidance, the start date, in a given country  
or region, is being defined as the approximate time point at which, according to the WHO 
situation reports and the Johns Hopkins database, the number of confirmed COVID -
19 
infections started to increase significantl y (around 100 confirmed cases) and/or 
governments started to take measures (such as stay -at-home orders) to contain the
epide mic, whichever occurred first (China: January  1, 2020; South Korea: February  20, 
2020; Japan: February  21, 2020; I taly: February  23, 2020 and Rest of the World: March 1, 
2020).
The CMH chi-square test of MMR rate at 24 weeks will be repeated without the 
imputation rule used in the main anal ysis in case of missing PCR eval uations at 24 weeks.
2.5.6 Supplementary  analyses
Additional supplemental logistic regression and subgroup analyses are described in Section 
2.14.
Assess whether the efficacy of asciminib (40 mg bid) is superio r to bosutinib (500 mg qd) in 
CML  patients in chronic phase, without T315I or V299L  mutation detected at Week 1 Day 1 
visit and previously  treated with 2 or more tyrosine kinase inhibitors, with regards to achieving 
MMR at 24 weeks while on study  treatment and without meeting any  treatment failure criteria 
(defined in section 5.4.4) prior to 24 weeks, regardless of dose modification,  dose interruption, 
or deviation in an y intake of concomita nt medications.
The corresponding estimand attributes are the same as the ones of the primary estimand except 
that the population excludes patients detected with T315I  or V299L  at Week 1 Day  1 visit (As 
per protocol, these patients were discontinued from study treatment when the mutation results 
became available ). 
The CMH chi-
square testof MMR rate at 24weeks will be repeated on the FAS excluding 
patients detected with T315I  or V299L at Week 1 Day  1visit.
2.6 Analysis of the key  secondary  objective /estimand
The key secondary clinical question of interest is: Isthe efficacy of asciminib (40 mg bid) 
superior to bosutinib (500 mg qd) in CML patients in chronic phase, previously  treated with 2 
or more tyrosine kinase inhibitors, with regards to achieving MMR at 96weeks while on stud y 
treatment and without meeting any treatment failure criteria (defined in section 5.4.4) prior to 
96 weeks, regardless of dose modification,  dose interruption, or deviation in any intake of 
concomitant medications.
The key secondary estimand is described b y the following attributes:
Novartis Confidential Page 38
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Population: CML  patients in chronic phase, previously  treated with 2 or more tyrosine kinase 
inhibitors. Further details about the population are pr ovided in Section 5 of the protocol .
Endpoint: Major Molecular Response (MMR) achieved at 96 weeks while being treated without 
meeting any treatment failure criteria (defined in section 5.4.4) prior to 96 weeks . A patient will 
be counted as having achieved MMR at 96weeks if he/she meets the MMR criteri on(BCR -
ABL ratio ≤0.1%) at 96weeks while on study  treatment unless the patient met any treatment 
failure criteria (defined in section 5.4.4 ) prior to 96 weeks . 
Intercurrent events: 
Treatment discontinuation (i.e. having performed an EOT visit) prior to 96weeks due to 
any reason (e.g. intolerance, treatment failure, death, etc.): non response
Meeting an y treatment failure criteria (defined in section 5.4.4 ) prior to 96 weeks: non 
response
Dose modification,  dose interruption, or deviation in any  intake of concomitant 
medications
: ignore (treatment policy  strate gy)
Treatment of interest: the randomized treatment (the investigational treatment asciminib or the 
control treatment bosutinib) received for at least 96 weeks with or without dose modification, 
dose interruption or deviation in any intake of concomitant medications. Further details about 
the investigational treatment and control treatment are provided in Section 6 of the protocol.
Handling of remaining intercurrent events : no other IE foreseen
The summary  measure: difference in MMR rateand its 95% confidence interval at week 96 
between the two treatment arms
The analy sis of the key secondary  objective will be performed at the time of the 96-week 
analysis.
2.6.1 Key secondary  endpoint /estimand
The key secondary  endpoint is MMR achieved at 96 weeks while on study  treatment without 
meeting any treatment failure criteria (defined in section 5.4.4) prior to96 weeks .A patient will 
be coun ted as having achieved MMR at 96weeks if he/she meets the MMR criteri on(BCR -
ABL ratio ≤0.1%) at 96weeks while on study  treatment unless the patient met any treatment 
failure criteria (defined in section 5.4.4 ) prior to 96 weeks .
MMR will be considered as a binary  variable with patients achieving MMR grouped as 
‘responders’ and patients not achieving MMR grouped as ‘non responders’. Only patients with 
MMR at 96weeks are considered responders. In other words, any  patient who achiev es MMR 
before 96weeks, but is no longer in MMR at 96weeks, will be considered as a non -responder 
in this key secondary analy sis.
Patients discontinuing treatment (i.e. having performed an EOT visit) prior to 96weeks due to 
any reason (e.g. intolerance, treatment failure, death, etc.) and patients meeting any treatment 
failure criteria (defined in section 5.4.4) prior to 96weeks will be considered as not having 
achieved MMR at 96 weeks.
Novartis Confidential Page 39
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.6.2 Statistical hy pothes is, model, and method of analy sis
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 96 weeks. Following a gatekeeping procedure to control the overall alpha level , 
only if the primary  endpoint is significant , formal statistical testing of the key secondary 
endpoint with two-sided 5% level of significance will be performed using the CMH chi -square 
test, stratified by the randomization stratification factor, i.e. cytogenetic response status (MCyR 
vs no MCy R) at screening .
MMR rate and its 95% confidence interval based on the Pearson- Clopper method will be 
presented by treatment group. The 95% confidence interval for the difference in MMR rate 
between treatment groups will be provided using the Wald method. The Mantel -Haenszel 
estimate of the common risk difference and the corresponding 95% confidence interval will 
also be presented.
2.6.3 Handling of remaining intercurrent events of primary  estimand
No remaining intercurrent events.
2.6.4 Handling of missing values not related to intercurrent event
Patients with missing PCR evaluations at 96 weeks will be considered as non-responders. 
However, ifthe 96-week PCR evaluation is missing, but both a PCR evaluation at 84 weeks 
and a PCR evaluation at 108 weeks indicate MMR, the 96-week assessment is imputed as a 
‘Response’, assuming that MMR is maintained between 84 and 108 weeks.
2.6.5 Sensitivity analy sis
In order to assess the impact of COVID -
19 (including potential missing data )on the key  
secondary  endpoint , the CMH chi-square test of MMR rate at 96 weeks will be repeated 
on the FAS excluding the patients with planned 96- week visit (start of stud y treatment + 
665 day s) between the start date of the COVID -19 epid
emic (China: January  1, 2020; 
South Korea: February  20, 2020; Japan: February  21, 2020; I taly: February 23, 2020 and 
Rest of the World: March 1, 2020) and itsend date (to be defined in the future). 
The CMH chi-square test of MMR rate at 96 weeks will be repeated without the 
imputation rule used in the main an alysis in case of missing PCR evaluations at 96 weeks.
2.7 Analysis of secondary  efficacy  objective (s)
The other secondary  efficacy  objective is to compare additional parameters (defined below) of 
the efficacy  ofasciminib versus bosutinib .
2.7.1 Secondary  endpoints
2.7.1.1 Molecular response
MMR ratesat all scheduled data collection time points, i.e., the protocol -planned visits 
except for 24 weeks and 96 weeks which are alread y covered by primary and key secondary 
endpoints. Such rates are defined as the proporti on of patients with MMR atthe respective time 
points.
Novartis Confidential Page 40
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
MMR ratesby all scheduled data collection time points, i.e., the protocol -planned visits .
These are cumulative MMR rates by time points and are defined as the proportion of patients 
who achieve MMR ator before specified visits, i.e. if a patient achieves an MMR but then loses 
it before or at a specific visit, he/she will still be classed as achieving MMR by that specific 
time point.
Molecular response category at specific time points, i.e., the protocol -planned visits. 
Categories of molecular response are defined in Appendix. 
Molecular response category by specific time points , i.e., the protocol -planned visits. This is 
defined as the best (lowest) molecular response category  up to the specific time points.
Time to MMR (in weeks) is defined as: (date of first documented MMR -date of randomization 
+ 1)/ 7.
Duration of MMR is defined for patients in the MMR Responder Set as the time between the 
date of the first documented MMR and the end date of MMR, i.e. the earliest date of confirmed 
loss of MMR, progression to accelerated phase ( AP)/blast crisis ( BC), or CML -related death . 
Loss of MMR and progression to accelerated phase (AP)/blast crisis (BC) are defined in 
Appendix .
For patie nts for whom none of the events above is reported , the duration will be censored (see 
Section 2.7.3). The duration of MMR (in weeks) is calculated as: (end date or censoring date of 
MMR -date of first MM R
+ 1)/ 7.
2.7.1.2 Cytogenetic response
At ea
ch assessment time point the cytogenetic response status of each patient is classified as 
complete, partial, major, minor, minimal response and none(a review of a minimum of 20 
metaphases is required) :
Complete response (CCyR) :0% Philadelphia chromosome positive (Ph+)metaphases
Partial response (PCyR):>0 to 35% Ph+ metaphases
Major response (MCy R= CCy R + PCy R): 0 to 35% Ph+ metaphases
Minor response (mCyR) :>35 to 65% Ph+ metaphases
Minimal response: >65 to 95% Ph+ m etaphases
None :>95 to 100% Ph+ metaphases.
As per protocol, bone marrow aspirate for cytogenetic analyses will be performed as long as 
subjects have not achieved MMR. Therefore, in case no bone marrow aspirate was performed 
but the subject is in MMR at a specific time-point, the subject is considered to have achieved
CCyR atthat time-point. The date of CCyR is imputed by the date of MMR at the same 
scheduled time -point.
CCyR rates at all scheduled data collection time points, i.e., the protocol -planned visits . 
Such rates are defined as the proportion of patients in CCyR atthe respective time points among 
patients in the CCy R Analy sis Set, which excludes patients who are in CCy R at baseline .
Novartis Confidential Page 41
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
CCy Rratesby all scheduled data collection time points, i.e.,the protocol -planned visits .
Such rates are defined as the proportion of patients who achieve CCyR at or before the 
respective time points among patients in the CCyR Analy sis Set .
Cytogenetic response category at specific time points, i.e., the protocol -planned visits. At 
each assessment time point the cytogenetic response status of each patient is classified as 
complete, partial, major, minor, minimal response and none (a review of a minimum of 20 
metaphase is required) as defined in Appendix.
Cytogenetic response category by specific time points , i.e., the protocol -planned visits. This 
is defined as the best (lowest) cy togenetic response category  up to the specific time points.
Time to CCyR (in weeks) is defined for patients as: (date of first documented CCyR -date of 
randomization + 1)/7.
Duration of CCyR is defined for patients in the CCyRResponder Set as the time between date 
of first documented CCyR and the end date of CCyR, i.e. the earliest date of loss of CCyR, 
progression to AP/BC, or CML -related death. Loss of CCyR and progression to AP/BC are 
defined in Appendix. For patients for whom none of the events above is reported , the duration
will be censored (see Section 2.7.3). The duration of CCyR (in weeks) is calculated as: (end
date or censoring date of CCy R -date of first CCyR + 1)/7.
2.7.1.3
Other secondary  efficacy  endpoints
Time to treatment failure (TTF) is defined for patients in FAS as the time from date of 
randomization to an event of treatment failure. The events thatconstitute ‘treatment failure’ are 
described in the Appendix. They are based on the ELN criteria [Baccarani et al. 2013] defining 
failure of a second line treatment adapted to include discontinuation of randomized treatment 
as an event .
TTF (in months) is calculated as: (date of treatment failure or censoring date (see Section 2.7.3) 
-date of 
randomization + 1)/30.4375.
Progression -Free -Survival (PFS) is defined for patients in FAS 
as the time from the date of 
randomization to the earliest occurrence of documented disease progression to AP/BC or the 
date of death from any cause (including progr essions and deaths observed during the survival 
follow -up period). 
PFS (in months) is calculated as: (date of disease progression/death or censoring date (see 
Section 2.7.3) -date of randomization + 1)/30.4375 .
Overall survival (OS) is defined for patients in FAS as the time from the date of randomization 
to the date of death (including 
the survival follow -up period).
OS (in months) is calculated as: (date of death or censoring date (see Section 2.7.3) -date of 
randomization +
1)/30.4375, regardless whether the patient switched from bosutinib to 
asciminib .
Novartis Confidential Page 42
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.7.2 Statistical hy pothesis, model, and method of analy sis
No confirmatory  statistical testing of non- key secondary  efficacy  endpoints will be performed, 
however ,nominal p- value swill be presented for exploratory  purposes (as specified in protocol 
Section 10.5.2).
MMR rates at and by  time points
The FAS will be used for these endpoints. For each time point the MMR rate and the associated 
95% confidence interval based on the Pearson -Clopper method will be presented by  treatment 
group. The descriptive p-value obtained via CMH chi-square tests stratified by the 
randomization strata ,i.e. MCyR vs no 
MCyR at screening , will be presented .A 95% confidence 
interval for the difference in each MMR rate between treatment groups will be provided using 
the Wald method. The Mantel -Haenszel estimate of the common risk difference and the 
corresponding 95% confide nce interval will also be provided .
The cumulative incidence of MMR by treatment group will be graphically  display ed by an 
increasing step function. Each curve will increase each time (after randomization) at which a 
new responder is observed and thus will increase up to the best observed response rate (e.g. up 
to 50% if half of the patients in the anal ysis population are able to achieve MMR ).
Molecular response at and by  time points
Frequency  and percentage of all molecular response categories (defined in Appendix ) by 
treatment arm using FAS will be presented for each time point.
For the b y-time-points summary , the within -patient best molecular response category  up to the 
specific time points is used to calculate the frequency and percentage.
Time to MMR
The MMR Responder Setwill be used. Descriptive statistics (minimum, maximum , median, 
quartiles, mean, sd) of time to MMR will be provided for the two treatment groups separately .
The FAS will be also used to perform similar Time -to-Event analy ses as described below for 
duration of MMR.
Duration of MMR
The MMRResponder Setwill be used. The survival distribution of duration of MMR will be 
estimated using the Kaplan -Meier method, and Kaplan -Meier curves, m edians and 95% 
confidence intervals [Brookmey er and Crowley  1982]of the medians, along with the proportion 
of patients who are still in MMR at 24, 48, 72 and 96 weeks and the associated 95% confidence 
intervals, will be presented for each treatment group.
CCyR rates at and by time points
The CCyR Anal ysis Set will be used for these endpoints. 
For each time point the CCyR rate and the associated 95% confidence interval based on the 
Pearson -Clopper method will be presented by treatment group. The descriptiv e p-value 
obtained via CMH chi-square tests stratified by the randomization strata ,i.e. MCyR vs no 
Novartis Confidential Page 43
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
MCy R at screening , will be presented .A 95% confidence interval for the difference in each
CCyR rate between treatment groups will be provided using the Wald method. The Mantel -
Haenszel estimate of the common risk difference and the corresponding 95% confidence 
interval will also be provided.
The cumulative incidence of CCyR by treatment group will be graphically  display ed by an 
increasing step function. Each curve will increase each time (after randomization) at which a 
new responder is observed and thus will increase up to the best observed response rate (e.g. up 
to 50% if half of the patients in the anal ysis population are able to achieve CCyR).
Cytogenetic response a t and by  time points
Frequency  and percentage of all cytogenetic response categories (defined in Section 2.7.1.2) by 
treatment arm using FAS will be presented for each time point. A shift table comparing baseline 
and best post -baseline cytogenetic response categories by treatment will also be presented. All 
assessments of cy togenetic response categories will also be listed by  treatment arm.
For the by-time-points summary , the withi n-patient best cytogenetic response category  up to 
the specific time points is used to calculate the frequency  and percentage.
Assessments of bone marrow aspirate at different time points will also be summarized.
Time to CCyR
The CCyRResponder Setwill beused. Descriptive statistics (minimum, maximum , median, 
quartiles, mean, sd) of time to CCyR will be provided for the two treatment groups separately .
The CCyR analysis set will be also used to perform similar Time -to-Event analy ses as described 
below for duration of CCy R. 
Duration of CCyR
The CCyRResponder Setwill be used. The survival distribution of duration of CCy
R will be 
estimated using the Kaplan -Meier method, and Kaplan -Meier curves, medians and 95% 
confidence intervals [Brookmey er and Crowley  1982]of the medians, along with the proportion 
of patients who are still in CCyRat 24, 48, 72 and 96 weeks and the associated 95% confidence 
intervals, will be presented for each treatment group.
TTF, PFS and OS
For each endpoint t he survival distribution will be estimated using the Kaplan -Meier method, 
and Kaplan -Meier curves, medians and 95% confidence intervals [Brookmey er and Crowle y 
1982] of the medians, along with the proportion of patients who have not experienced the 
respective events at 1, 3 and 5 years and the associated 95% confidence intervals, will be 
presented for each treatment group. The hazard ratio between the two treatments will be 
calculated, along with its 95% confidence interval, using a stratified Cox model. The descriptive 
p-value obtained using astratified log-rank testwill be also presented. The stratification will be 
based on the randomization stratification factor, i.e. cytogenetic response status (
MCyR vs no 
MCy R) at screening .
Novartis Confidential Page 44
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.7.3 Handling of missing values/ce nsoring/discontinuations
MMR rate sat specific time points :Patients discontinuing the randomized treatment prior to 
a specific time point due to any  reason or patients without an available assessment at that time 
point will be considered as non -responders for that time point .
MMR rate s by specific time points : 
Patients without any documented response for which an evaluable response assessment was 
never provided will be considered as non-responders for the period of time up to that time point.
Molecular re sponse atspecific time points :The category  “Missing” will be assigned to
Ongoing cases, i.e. patients 
without assessment at the specific time point who have 
not discontinued study  treatment and have not been treated sufficientl y long for a 
specific time point
Discontinued due to progressive disease /death prior to a specific time point
Discontinued due to other reasons prior to a specific time point
Molecular response category byspecific time points: The category  “Missing” will be 
assigned to p atients for whom an evaluable respons e assessment was never provided.
Time to MMR : For patients in the FAS who have not experienced an y MMR, the time will be 
censored as follows in the Kaplan- Meier anal ysis:
If a patient does not achieve the specified response before the cut -off date for the anal ysis,
censoring time will be the last molecular assessment (PCR) date on treatment prior to the 
cut-off date or the EoT visit, whichever comes first.
If a pat ient discontinues study  treatment prior to achieving a response for a reason other 
than disease progression or death, then the patient will be censored at the last molecular 
assessment (PCR) date on treatment prior to the cut -off date or the EoT visit, whichever 
comes first.
If a pat ient discontinues study  treatment prior to achieving a response due to pr ogression 
or death, then the censoring time will be set to the longest follow -up time in the treatment 
group , that is, consider the response is impossible to reach.
In case no on -treatment response assessment was performed, the patient will be censored 
at day  1.
Duration of MMR : For patients in the MMR responder set who have not experienced any event 
(loss of MMR, progression to AP/BC, or CML -
related death ),the duration will be censored at 
the last molecular assessment (PCR) date on treatment.
CCyR rates at specific time points :Patients discontinuing the randomized treatment prior to 
a specific time point due to any reason will be considered as non -responders for that time point .
CCyR rates by specific time points
: This will be handled similarly  as MMR, but with CCy R 
instead.
Cytogenetic response at specific time points: This will be handled similarly  as molecular 
response category .
Novartis Confidential Page 45
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Cytogenetic response category byspecific time points: This will be handled similarly  as 
molecular response category .
Time to CCyR : For patients in the CCyR analy sis setwho have not experienced any CCyR, 
the time will be censored in the same manner as Time to MMR.
Duration of CCyR: For patients in the CCyR responder set who have not experience d any 
event (loss of CCyR, progression to AP/BC, or CML -related death )the duration will be 
censored at the last cytogenetic assessment date on treatment or the last PCR evaluation on 
treatment indicating MMR, whichever is the latest . 
TTF :For patients in the FAS who have not reach edtreatment failure, their TTFs will be 
censored at the time of their last study  assessment (PCR, cytogenetic, hematologic or 
extramedullary ) before the cut- off date .
PFS:For patients who have not experienced an event (diseas e progression to AP/BC or death 
from any cause ), their PFS times will be censored at the date of last study  assessment (PCR, 
cytogenetic, hematologic or extramedullary )before the cut-off date, regardless of subsequent 
intake of treatment(s) after randomization.
OS:Patients who are alive at the time of the analy sis data cutoff date will be censored at the 
date of last contact (see Section 2.1.1) before the cut-off date,regardless of subsequent intake 
of treatment(s) after randomization
.
2.8 Safet y analyses
All safety  analyses will be based on the safety  set, except that the summary of safet y data during 
the switched treatment period will be based on the Switch Analy sis Set . All listings and tables 
will be presented b y treatment group.
2.8.1 Adverse events (A Es)
AE summaries will include all AEs occurring during the on-treatment period (or the on-
switched treatment period) . All AEs collected in the AE eCRF page will be listed along with 
the information collected on those AEs e.g. AE relationship to study  drug, AE outcome
,etc. 
AEs with start date outside of the on- treatment period will be flagged in the listings.
AEs will be summarized by  number and percentage of subjects having at least one AE, having 
at least one AE in each primary  system organ class (SOC) and for each preferred term (PT) 
using MedDRA coding. A subject with multiple occurrences of an AE will be counted only 
once in the respective AE category . A subject with multiple CTCAE grades or the same 
preferred term will be summarized under the maximum CTCAE grade recorded for the event.
AE with missing CTCAE grade will be included in the ‘All grades’ column of the summary 
tables.
In AE summaries, the primary  system organ class will be presented alphabeticall y and the 
preferred terms will be sorted within primary  SOC in descending frequency . The sort ingorder 
for the preferred term will be based on their frequency  in the asciminib arm.
The following adverse event summaries will be produced by treatment armfor the Safet y set 
and Switch Analy sis Set:overview of adverse events and deaths, AEs by SOC and PT,
Novartis Confidential Page 46
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
summari zedby relationship, seriousness, leading to treatment discontinuation, leading to dose 
interruption/adjustment, requiring additional therapy,and leading to fatal outcome. The study 
treatment -related AEs/SAEs/AEs leading to treatment discontinuation as well as SAE with fatal 
outcome are summarized for the Safet y set and Switch Anal ysis set. 
For posting to ClinTrial.gov and EudraCT , a summa ry table of on -treatment deaths and serious 
AEs and another summary  table of non serious AEs by treatment, both including occurrences 
(an occurrence is defined as >1 day between start and prior end date of record of same preferred 
term) and sorted b y SOC a nd PT, will be presented as well.
In order to account for differences in exposure between the treatment arms, incidence rates of 
AEs and SAEs will be presented by  adjusting for duration of treatment period in patient-years. 
They  will also be reported by time intervals (i.e. period of emergence : the event is assigned to 
the interval when it first started) : 0 to 2months, > 2months to 6 months, > 6 months to 12 
months, 
>12 months and more after the start of study  treatment . 
2.8.1.1 Adverse events of special inter est/ grouping of A Es
Data analy sis of AESIs
An adverse event of special interest (AESI) is a grouping of adverse events that are of scientific 
and medical concern specific to compound asciminib . These groupings are defined using 
MedDRA terms, SMQs (standa rdized MedDRA queries), HLGTs (high level group terms), 
HLT (high level terms) and PTs (preferred terms). Customized SMQs (Novartis MedDRA 
queries, NMQ) may also be used. A NMQ is a customized group of search terms which defines 
a medical concept for which there is no official SMQ available or the available SMQ does not 
completely  fit the need. It may  include a combination of single terms and/or an existing SMQ, 
narrow or broad. The latest approved version of CRS prior to the respective database lock will 
be used.
For each specified AESI, number and percentage of patients with at least one event of the AESI 
occurring during the on-treatment period (or the on-switched treatment period) will be 
summarized.
Summaries of these AESI s will be provided by treatment arm (specify ing grade, SAE, 
relationship, leading to treatment discontinuation, leading to dose adjustment/interruption, 
death ,etc.).If sufficient number of events occurred, analysis of time to first occurrence will be 
applied.
A listing of all grouping levels down to the MedDRA PTs used to define each AESI will be 
generated.
2.8.2 Deaths
Separate 
summaries for on-treatment and all deaths (including post-treatment death s)will be 
produced on the Safet y set by  treatment arm, s ystem org an class and preferred term. 
Similarly , a separate summary  for on-switched treatment deaths will be produced on the Switch 
Analy sis Set.
Novartis Confidential Page 47
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
All deaths will be listed, where deaths occurring during the post-treatment, the on-switched 
treatment or post -switche d treatment periods will be flagged.
A separate listing of deaths prior 
to starting treatment will be provided for all screened subjects.
2.8.3 Laboratory  data
Grading of laboratory  values will be assigned programmatically  as per National Cancer Institute 
(NCI)Common Terminology  Criteria for Adverse Events (CTCAE) version 4.03.  The 
calculation of CTCAE grades will be based on the observed laboratory  values only, clinical 
assessments will not be taken into account. CTCAE Grade 0 will be assigned for all non-missing 
values not graded as 1 or higher. Grade 5 will not be used. Details of CTC AEgrading and 
imputation rules are presented in Appendix 5.3
.
For laboratory  tests where grades are not defined by  CTCAE v4.03, results will be categorized 
as low/normal/high based on laboratory  normal ranges.
On anal yzing laboratory  data ,all sources (central and local laboratories) will be combined. The 
summaries will include allassessments available for the 
lab parameter collected no later than
30days after the last study  treatment administration date.
The following summaries will be produced on the Safet y set separatel y for hematology  and 
biochemistry  laboratory  data (by  labor atory  parameter and treatment ):
Worst post -baseline CTC AEgrade (regardless of the baseline status). Each subject will be 
counted only for the worst grade observed post -baseline in the on-treatment period.
Shift tables using CTC AEgrades to compare baseline to the worst on- treatment value . 
For laboratory  tests where CTC AEgrades are not defined, shift tables using the 
low/normal/high/(low and high) classification to compare baseline to the worst on-
treatment value.
The same summar ies will be produced on the Switch Anal ysis Set for the on-switched treatment 
period.
The following listings will be produced separately  for hematology  and biochemistry  for the 
laboratory  data:
Listing sof all 
laboratory data, with CTC AEgrades and classif ication relative to the 
laboratory  normal range. Lab data collected during the post -treatment period willbe 
flagged .
Listing of all CTC AEgrade 3 or 4 laboratory  toxicities
Liver function parameters
Liver function parameters of interest are total bilirubin (TBL), Alanine aminotransferase
(ALT), Aspartate aminotransferase ( AST )and alkaline phosphatase (ALP). The number (%)
of patients with worst post -baseline values as per Novartis DILI Clinical safety  guidelines will 
be summarized for the criteria defined b y single lab parameter. For combination of various 
parameters, the worst post-baseline values from each single parameter are taken into 
consideration, i.e. it may  not come from the concurrent measurement (i.e. same assessment). :
The following summaries will be produced:
Novartis Confidential Page 48
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
ALT or AST > 3x upper limit of norm ( ULN)
ALT or AST > 5xULN
ALT or AST > 10xULN
ALT or AST > 20xULN
TBL > 2xULN
TBL > 3xULN
ALT or AST > 3xULN & TBL > 2xULN
ALT or AST > 3xULN & TBL > 2xULN & AL P >=2xUL N
ALT or AST > 3xULN & TB L > 2xULN & AL P < 2xUL N  
2.8.4 Other safety  data
2.8.4.1 ECG and cardiac imaging data
12-lead ECGs including PR, QRS, QT, QTcF and RR intervals will be obtained centrall y for 
each subject during the study . ECG data will be read and interpreted centrally . 
The echocardiogram will be performed and evaluated locall y to assess the left ventricular 
ejection fraction (LVEF) .
Data handling
The average of the triplicate ECG parameters at each time point will be used in the anal yses.
For unscheduled visits, ECGs that are reported on the same day and within 30 minutes apart 
from each other will be assumed to be sequential ECGs and thus will be used to compute the 
mean of the ECG parameters.
Unscheduled ECG measurements will not be used in computing the summary  statist ics for 
change from Baseline at each post-baseline time point. However, they will be used in the outlier 
analyses (e.g. QTc >450 ms, > 480 ms,or >500 ms at any time point, or an increase from 
Baseline in QTc > 30 ms or > 60 ms). End of treatment ECG measurements for discontinued 
patients will be considered as an unscheduled measurement in case it occurs outside a scheduled 
visit.
Data analy sis
The number and percentage of subjects with notable ECG values will be presented by treatment 
armfor the Safet y set and Switched Anal ysis Set . Notable values are defined below:
QT, QTcF
New value of > 450 and ≤ 480 ms
New value of > 480 and ≤ 500 ms
New value of > 500 ms
Increase from Baseline of > 30 ms to ≤  60ms
Increase from Baseline of > 60 ms
H
R
Novartis Confidential Page 49
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Increase from baseline >25% and to a value > 100 bpm
Decrease from baseline >25% and to a value < 50 bpm
PR
Increase from baseline >25% and  to a value > 200 ms
New value of > 200 ms
QRS
Increase from baseline >25% and  to a value > 120 ms
New values of QRS > 120 ms
A listing of all ECG assessments will be produced by treatment arm and notable values will be 
flagged . A separate listing of only the subjects with notable ECG values willalso be produced.
In each listing the assessments collected during the post -treatment period willbe flagged.
Change from baseline ECG parameters b y timepoint will also be summarized by  treatment.
A listing of all LVEF assessments will be produced by treatment arm. In the listing, the 
assessments collected outside of on- treatment period will be flagged.
A summary  table by  treatment arm with descriptive statistics for LVEF at different timepoints
(baseline, week 20) and for change from baseline will be presented. A shift table for LVE F 
categories (
≤40%, 41-49%, ≥50%) at baseline versus worst value on treatment will also be 
presented.
2.8.4.2 Cardiovascular risk factor assessment
Prior to randomization and at the end of treatment, for each patient information of the following 
risk factors is collected: heav y smoking, low physical activity , unhealthy  diet, and other. A 
listing by  treatment arm will be presented. 
Family  medical history  of each patient for ischemic heart disease, cardiac arrhythmia, sudden 
death, high cholesterol, diabetes mellitus, heart defects (congenital heart disease), and heart 
failure is also collected prior to randomization and at the end of treatment .A listing by treatment 
arm will be presented.
2.8.4.3 Vital signs
Vital sign assessments are performed in order to characterize basic body  function. The 
following parame ters were collected: height (cm), weight (kg), body  temperature (°C), heart 
rate (beats per minute), systolic and diastolic blood pressure (mmHg).
Data handling
Vital signs collected on treatment will be summarized. Values measured outside of on treatment
period will be flagged in the listings.
Novartis Confidential Page 50
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Data analy sis
The number and percentage of subjects with notable vital sign values (high/low) in systolic 
blood pressure, diastolic blood pressure, pulse rate,weight and temperature will be presented 
by treatment arm.         
A listing of all vital sign assessments will be produced by treatment arm and notable values will 
be flagged. In the listing, the assessments collected outside of on-treatment period will be 
flagged. 
2.8.4.4 Liver even
ts
There are separate eCRF pages to collect acetaminophen/paracetamol, autoimmune, drug use 6 
months prior to liver event, immunoglobulin, liver function tests, pathology , related imaging, 
viral serology  andpotential impact of alcohol use, and an overview eCRF page. Data on the 
overview eCRF pag ewill be listed by treatment arm. A ssessments collected during the post-
treatment period willbe flagged.
2.8.4.5 Pulmonary  function tests
Data o f pulmonary  function tests will be listed by  treatment arm. Assessments colle cted during 
the post -treatment period willbe flagged.
2.8.5 Additional Analyses
2.8.5.1 ECOG performance status
ECOG performance status collected on treatment will be summarized. Shift tables will be 
provided comparing baseline with best and worst values during study for each treatment group.
2.9 Pharmacokinetic endpoints
PK parameters
The PK parameters that will be determined are shown inTable 2-7. The PK param eters for
asciminib are derived based on the non-compart mental methods using Phoenix WinNonlin®
software version 6.4in patients with full PK sampling in PAS .
Novartis Confidential Page 51
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Table 2-7 Non-compartmental PK parameters for asciminib in full PK group
AUC 0-12h The area under the plasma concentration -time curve from time zero to 12 
hours (ng*hr*mL-
1)
AUClast The AUC from time zero to the last measurable plasma concentration 
sampling time ( Tlast) (ng*hr*mL-1)
CtroughTrough plasma concentration (measured concentration at the end of a 
dosing interval at stead y state [taken directl y before next administration])
Cmax The maximum (peak) observed plasma concentration after dose 
administration (ng/mL)
Tmax The time to reach maximum (peak) plasma concentration after dose 
administration (hr)
Tlast The time to reach the last measurable plasma concentration after dose 
administration (hr)
CL/F The total apparent body clearance of drug from the plasma after oral
administration (L *hr-1)
Descriptive statistics (n, arithmetic mean, CV% mean, standard deviation (SD) ,median, 
geometric mean, CV% geo- mean, minimum and maximum) will be presented by treatment for 
PASfor 
all PK parameters defined in Table 2 -7except Tmax, where only n, median, minimum 
and maximum will be presented. 
All individual PK parameters will be listed for patients treated with asciminib and with full PK 
sampling in the safety  set.
PK concentrations 
Descriptive statistics ( n, m (number of non -zero concentrations), arithmetic mean, CV% mean, 
SD,median, geometric mean, CV% geo-mean, minimum and maximum ) forasciminib
concentration will be presented at each scheduled time point for th
e PAS.
The mean (+/-SD) and geometric mean concentration -time profiles forasciminib over time will 
be display ed graphically  forPAS on the linear and semi -log view (Week 2 Day  1; for patients 
with full PK sampling only ).
The mean (±SD) and median Ctrough values of asciminib over time will be display ed 
graphicall yfor PAS on the linear scale onl y (Patients with full and sparse PK sampling ).
All individual plasma asciminib concentration data will be listed forpatients treated with
asciminib inthe Safety  Set.
Handling of PK data below LLOQ or missing
All c oncentration values below the lower limit of quantitation (LLO Q, 1 ng/mL ) are set to zero 
by the Bioanaly st, and will be display ed in the listings as zero and flagged. LLOQ values will 
be treated a s zero in any calculations of summary  statistics, and treated as missing for the 
Novartis Confidential Page 52
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
calculation of the geometric means and their CV%. The number of non-zero concentrations will 
also be reported in the summary  statistics.
Missing values for an y PK data will not be imputed and will be treated as missing.
2.10 PD and PK/PD analyses
The potential relationship between asciminib exposure (e.g. trough concentration) and efficacy ,
pharmacod ynamics (PD) or safet y endpoints may be assessed by graphic exploration and/or 
statistical modeling ,as appropriate ,including effect of population covariates. Additional 
exposure -response analyses for ECG may be conducted. The concentration data may be 
analyzed by  a population approach to evaluate the influence of covariates on drug exposure. If 
applicable, the details of the above -mentioned analy ses will be described in a separate analysis 
plan and reported separately .
Therelationship between average trough plasma concentration up to 24 weeks and BCR-ABL 
ratio I S (%) at 24 weeks will be assessed by  graphic exploration. 
2.11 Patient-reported outcomes
The FAS will be used for analy zing PRO data unless specified differentl y. TheMDASI CML, 
PGIC along with EQ-5D- 5L will be used to assess patient’s disease -related symptoms and 
health- related qualit y of life from baseline to EOT ; and the WPAI -CML will be used to assess 
work productivity  and activity  impairment related to the patient ’s CML. All tools require 
patient’s direct completion and will be administered utilizing electronic device for data 
collection at scheduled time points from screening to end of treatment .
The baseline is defined in Section 2.1.1 . Patients with an evaluable baseline score and at least 
one evaluable post-baseline score during the treatment period will be included in the change 
from baseline anal yses. Missing data items in a scale will be handled according to the manual 
for each instrument. No imputation will be applied if the total or subscale scores are missing 
at a visit. All measures will assess differences between the treatment arms .
Compliance to the schedule of administration of each PRO questionnaire will be summarized 
by treatment group, forbaseline and scheduled post-baseline assessment time points. The 
following categories, as collected on the eCRF, will be used to describe whether the 
questionnaire was completed at a specific time point:
1.yes, full y completed
2.yes, partl y completed
3. no
Repeated measures model for continuous scores
Tobest utilize the repeated assessments of a given PRO score , a repeated measures model for 
longitudinal data will be used toestimate differences between treatment arms. This repeated 
measures model will include terms for treatment, the stratification factor (major cytogenetic 
response status) , time, baseline value as main effects, and an interaction term for treatment b y 
time. 
This analy sis will be restricted to patients w ith an evaluable baseline score and at least 
Novartis Confidential Page 53
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
one evaluable post-baseline score. All data collected until end of treatment (including the end 
of treatment assessment) will be included in the analy sis. Note thatonly data collected under 
treatment (i.e. while the patient is treated) will be included. The end of treatment assessment 
will be included if collected within 7 day s of the last dose intake.
Time will be considered as a contin uous variable expressed in weeks , i.e. considering 
thatthe 
PRO score follow a linear trend.
As a first approach, an unstructured correlation matrix will be used to model the correlation 
within patients. The structure of the correlation matrix will be investigated and simplified using 
likelihood ratio tested if appropriate.
2.11.1 MDASI-CML
The M.D. Anderson Symptom Inventory  –Chronic Myeloid Leukemia (MDASI -CML)
questionnaire isplanned to be administered during screening, at weeks 4, 8, 12, 16, 24, 36, 48 
and 96 after randomization.
The MDASI -CML is a 26 item self-administered questionnaire for adult CML  patients. Twent y 
of the items measure the severit y of disease -
related symptoms and are scored from 0 (Not 
present) to 10 (As bad as you can imagine) and 6 items that measure symptom interference with 
daily  life scored from 0 (Did 
not interfere) to 10 (Interfered completel y). 
The severit y score will be calculated when a patient scores at least 11 items out of the 20 
severit y items using the formula: (sum of scores for the items answered) / (number of items 
answered ).If a patient s cores fewer than 11 items, the severit y score will be missing.
The interference score will be calculated when a patient scores at least 4 items out of the 6 
interference items using the formula: (sum of scores for the items answered) / (number of 
items answered ) . If a patient scores fewer than 4 items, the interference score will be missing.
For the severity  score and interference score , descriptive statistics (n, mean, SD, median, 25th 
and 75th percentiles) by treatment arm will be provided for the actual scores and change sfrom 
baseline scores at each scheduled assessment time point.
Between -treatment differences for the change in severit y and interference score s will be 
evaluated using the above -mentioned repeated measures model . 
2.11.2 EQ-5D-5L
EQ-5D- 5L is a two- part standardized instrument for measuring health outcomes in a wide range 
of health conditions and treatments. It consists of a descriptive system and a visual analogue 
scale (EQ VAS). The descriptive system comprises the following 5 dimensions: mobi lity, self -
care, usual activities, pain/discomfort and anxiety /depression. Each dimension has 5 levels: no 
problems, slight problems, moderate problems, severe problems and extreme problems (or 
unable to perform the activity ). 
The EQ VAS records the respon dent’s self-rated health on a 
vertical, visual analogue scale where the endpoints are labeled ‘Best imaginable health state’ 
and ‘worst imaginable health state’.
The EQ-5D- 5L data will be used to calcutae utility  values forthe economic evaluation of
ascim iniband bosutinib i n a sepa rate anal ysis.
Novartis Confidential Page 54
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
The EQ -5D- 5L questionnaire is planned to be administered during screening, at weeks 4, 8, 12, 
16, 24, 36, 48 and 96 after randomization .
Descriptive sy stem
The number and percentage of subjects in the five levels of each EQ-5D demension will be 
presented b y treatment group at each assessment time point .
EQ VA S
The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale from 
0, labeled as ‘worst imaginable health state’, to 100, labele d as ‘best imaginable health state’.
For the EQ VAS, descriptive statistics (n, mean, SD, median, 25th and 75th percentiles) by 
treatment arm will be provided for actual values and forthe change from baseline at each 
assessment 
time point.
Between -treatment differences for the change sin EQ VAS score will be evaluated using the 
above -mentioned repeated measures model .
2.11.3 WPA I-CML
The Work Productivity  and Activity  Impairment Questionnaire –Chronic Myeloid Leukemia
(WPAI -CML ) questionnaire is planned to be administered during screening, at weeks 4, 12, 24, 
48 and 96 after randomization .
The WPAI -CML is a six-item questionnaire which is intended to measure work and activit y 
impairment associated with CML  for those who self-identify  as currentl y employ ed for pay. 
This questionnaire measures self-reported productivity  loss associated with CML during the 
past seven days. It consists of questions about absence from work due to CML , hours spent at 
work, the reduction in productivity  at work attributed to CML , and the reduction in productivity 
while performing regular activities. WPAI -CML outcomes are expressed as impairment 
percentages, with higher numbers indicating greater impairment and less productivity , i.e., 
worse outcomes .Scoring will be done according to WPAI -CML instrument guidance resulting 
in four scores including: Percent work time missed due to problem; percent impairment while 
working due to problem; Percent overall work impairment due to problem; and, percent activ ity 
impairment due to problem.
Descriptive statistics (n, mean, SD, median, 25th and 75th percentiles) for each of the four 
derived outcome scores and change sfrom baseline scores will be presented by treatment arm 
ateach scheduled assessment time point with .
Between -treatment differences for the change sin each of the four outcome scores will be 
evaluated using the above -mentioned repeated measures model . 
2.11.4 PGIC
The Patient Global Impression of Change (PGIC ) instrument i s planned to be administered 
during at weeks 4, 8, 12, 16, 24, 36, 48 and 96 after randomization
The PGICis comprised of a single question intended to measure a patient’s perspective of 
improvement or deterioration over time relative to treatment. The PGIC uses a seven -point scale 
Novartis Confidential Page 55
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
where one (1) equals very much improved and seven (7) equals very much worse. Missing 
values will not be imputed.
The number and percentage of subjects in each of the seven categories for PGIC will be 
presented b y treatment group at each assessment time point .
2.12 Resource utilization
Data relating to resource utilization (described in trial protocol Section 7.2.5) from the FAS will 
be used for the purpose of economic evaluation ,which will be carried out and reported as a 
separate activity  outside the CSR . 
The measures of healthcare resource utilization (HCRU) include: hospitalization (H), 
emergency  
room (ER) visit, general practitioner (GP) visits, specialist (Sp) visit and urgent care 
(UC) visit. HCRUwill be assessed as follows: frequency  and duration of hospitalization from 
baseline up to end of treatment ; frequency  of emergency room visits from baseline up to end of 
treatment ; frequency  of additional outpatient office visits general practitioner, specialist, and 
urgent care visits from baseline up to e nd of treatment . Hospitalization visits will also record 
the number of days on ward and the type of ward (hospital unit) and the discharge status. At 
each HCRU collected, the reason for the visit, i.e. related to CML, AE related to CML therapy  
or other reason, will be collected, in order to quantify  the impact of treatment on healthcare 
resources.
HCRU data by treatment arm will be summarized in the primary  analysis CSR and the end of 
study  treatment CSR, with descriptive statistics (n, mean, median, SD, min, max) for 
quantitative variables ,and count and percentage for qualitative variables .
2.13 Biomarkers
Asa
projec t standa rd,Novartiswillanalyze onl y biom arke rsc oll ected inthe clinical da tabase.
For ex ploratory ma rkers,since thestudies a renot adequa tel y po wered to assess specific
biomarker-related hy pothes es,thegoal of these e xploratorystatistical analyse s should be
considered as thegeneration of new sc ientific h ypothes es. Noadjustment formultiple
compa risons isusual ly planned for exploratory analyses. Fu rth ermore , addit ional post hoc
e
xploratory assessments areexpected and may beperfor med.
Therem
aybecircumstances when  a decis i on ismade tostop sample coll ection, or not 
perform or discontinue the ira nalysisdue toe ither p ractical or strategicreasons. Und e r such 
circumstance s,thenumber of sam ples may be inadequa te to perfor m a rigo rous da taa naly sis 
and the 
availa bledata will onlybe listed and potentially summa rized.
If not otherwise specified, the FASwillbe used for allbiomarker analyses on patie nts with 
biomar k er data.
Exploratory  biom
arkerobjectives
To characterize mutations in the BCR-ABL1 gene at Week 1 Day  1, upon confirmed 
loss of molecular response and/orat end of treatment and examine their association 
with molecular and cy togenetic r esponse for asciminib vs bosutinib
Novartis Confidential Page 56
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
To understand biology  of CML  and bone marrow microenvironment on leukemic 
stem c ells (L SCs) eradication, including patients’ immunogenicit y
To assess clonal evolution during trea tment with asciminib vs. bosutinib
To evaluate soluble /inflammatory factors that correlate with response to asciminib vs. 
bosutinib treatment 
Only  some analyses for the first exploratory  biomarker objective about BCR-ABL1 mutation
listed above are described here and the results will be included in the respective CSRs. 
Additional analyses for this and other exploratory biomarker objectives will bedescribed in 
separate analy ses plans, w i
th results reported separa tely.
List ofbiom arkersevaluated a ndthecollection timepoints
The biomarkers evaluated in the study  are listed in Table 2-8 below.
Table 2-8 Sample biomarker summary  table
Biom arker Timep
oint Sample Method
Immune markers PD -L1 
and CD8Screening and 
end of treatmentBone marrow biops y Immunohisto -
chemistry
Leukemic stem cells
characterizationScreening, week 
24 and end of 
treatmentBone marrow aspirate Flow c ytometry
BCR -ABL1 gene mutation W1D1 pre-dose 
and end of 
treatment . If 
mutation is 
present at 
baseline, then 
also ever y 12 
weeks after 
baselinePeripheral blood Sanger 
Sequencing
Low level mutations in 
BCR -ABL1geneW1D1 pre-dose 
and end of 
treatmentPeripheral blood Mass 
spectrometry  
and NGS
Circulating cytokines in 
plasmaW1D1 pre-dose,
Week 48 and end 
of treatmentPeripheral blood MSD and ELISA
Genetic variant analysis of 
the UGT 2B7 and 
UGT2B17 geneW1D1 Peripheral blood Genechip
General data handling and preprocessing
For bone marrow samples the latest assessment during screening period will be used as the 
baseline value, while for blood samples the week 1 day  1 (W1D1) pre -dose assessment willbe
used as the baseline va lue.
Novartis Confidential Page 57
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Whenmore than onebiomarker da tav a lueare availa bleforasubjec t at an y timepoint,the 
mean of the replicate va lues will be us ed for allstatistical analyse s.
2.13.1 Somatic mutation biomarker data handling and analy sis
Handli ng of somaticbiom ark
er data
Overall, somatic mutationstatus (wild ty pe or mutant) will be derivedfromthe mutationa l 
status oftheint
errogated exons fortheBCR -ABL1 gene by Sanger Sequencing .Thesemay
be non-exc lus ive and the p resence of mutation ac ross more than one exon will bereported in 
separate categori es.
Muta tion summary statistics
Allsomatic mutation data willbe reported using counts and pe rcentages b y themutation ty pe 
intheform of contingency ta bles with therows c ontaining thedifferent mutations a ssayed, 
and the treatment g roups inthe columns.Allthemutation categoriesfora gene will also be
aggreg a tedintomutant,wild type or missing/unknown groups and c ounts/pe rcentages willbe
reported b y thesethree categor iesas w ell. A summary  table will be presented for baseline 
mutations and another summary  table for post-baseline new mutations (not present at baseline) .
All themutation da ta will be listed for eac h subj ect ordered by tr eatment group.
Association be tweenbiom arkers a ndclinicaloutcome
This analy sisdoes not a djust formultiplecomp arisons and re sultsmay have higher fals e 
posit iverates.
The r elationship b etweenWeek 1 Day  1 BCR -ABL1 gene mutation data(wild ty pe or muta nt)
a
nd outcome data(with or without MMR atand by24 and 96 weeks using FAS, with or without 
CCyR at and by 
24 and 96 weeks using CCyR analysis set)will be explored b y reporti ng
contingency table s and by applying a logistic regression including treatment group, Week 1 
Day 1 BCR -
ABL1 gene mutation and their interaction as covariates . Treatment group willbe
includ ed in this summary table.
In addition, the same analy sis will be perform edfor
the relationship b etweenpost-baseline new BCR -ABL1 mutation (with or without 
new mutation) up to 48 weeks and outcome d ata(with or without MMR at 48 and 96 
weeks using FAS, with or without CCy R at 48 and 96 weeks using CCy R anal ysis 
set).
the relationship b etweenpost-baseline new BCR -ABL1 mutation (with or without 
new mutation) up to end of treatment and outcome d ata(with or without MMR at 96 
weeks using FAS, with or without CCy R at 96 weeks using CCy R anal ysis set).
The odds ratios bewteen treatment groups with 95% confidence intervals willbe repo rte d, for 
each biomark ercategor y and ov erall. If treatme nt by biomarkerinteractionis significant (e.g.
when p < 0.1), overa llodds ratio for tr eatment will not be re ported.
Novartis Confidential Page 58
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
2.14 Other e xploratory  analy ses
MMR rate at 24 weeks
The FAS will be used for the following exploratory  analy ses:
1.A logistic regression model adjusted for the stratification factor (based on the 
randomization platform data IRT) will be fit to assess treatment effect. An adjusted 
odds ratio for the treatment effect with associated 95% confidence intervals will be 
presented. Mantel -Haenszel estimates of the common odds ratio and the 
corresponding 95% confidence interval will also be provided.
Some subjects were mistratified . To assess the impact of this mistratification on the 
treatment effect assessment, alogistic regression adjusting for major cy togenetic
status at baseline based on CRF data will also 
be run .
2.Based on the subgroups specified in Section 2.2.1, the following analyses will be 
performed for each subgroup:
Proportion of patients with MMR at 24 weeks and its 95% confidence interval 
based on the Pearson -Clopper method within each treatment group
The difference in MMR rate at 24 weeks betwee n treatment groups and the 
corresponding Wald 95% confidence interval
Efficacy  anal yses in subgroups will be purel y exploratory  and are intended to explore 
the consistency  of treatment effect. Forest plot (n, risk difference, Wald 95% 
confidence interval ) will be produced to graphically  depict the treatment effect 
estimates in different subgroups. No inferential statistics (p- values) will be 
produced for the subgroups.
3.A logistic regression model adjusted for the stratification factor (baseline major 
cytogenetic response status based on randomization data ) and other important 
variables identified b y the subgroup anal yses above will be fit to assess treatment 
effect. An adjusted odds ratio for the treatment effect with associated 95% confidence 
intervals will be presented.
To assess the impact of mistratifications on the treatment effect assessment, the same 
analysis will be repeated, adjusting for major cy togenetic status at baseline based on 
CRF data instead of based on randomization data.
Influence of earl y molecular response levels on long term molecular response 
levels
The r elationship betwee nMMR status at 24 weeks and MMR status at 48 and 96 weeks willbe 
exploredusing FAS by reporting contingency  tables and by applying a logistic regression
including treatment group, MMR status at 24 weeks and their interaction as covariates . 
T
reatment group will beinclud ed in this summary table. The odds ratios between treatment 
groups with 95% confidence intervals willbe repo rte d, for each categor y of MMR status at 24 
weeks a
nd overall. If the interaction of tre atme nt byMMR status at 24 weeks is significant
(e.g. when p < 0.1), overa llodds ratio for tr eatment will not be re ported.
Novartis Confidential Page 59
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Efficacy  Analysis on Switch A nalysis Set
Efficacy  analyses on the Switch Analy sis Set will be performed at the time of the 96-week 
analysis. Unless otherwise specified, endpoints are defined and anal yzed similarly  as specified 
in Sections 2.5, 2.6, and 2.7 
on Switch Analy sis Set, but with baseline, FD, LD, and EoT 
replac ed by baseline_switch, FD switch, LD switch, and S-EoT. The below are the efficacy  endpoints 
to be anal yzed:
1.MMR rate at and b y all protocol -planned visits. 
2.CCyR rate at and by  all protocol -planned visits. 
3.Time to MMR
4.Duration of MMR
5.Time to CCy R
6.Duration of CCy R
7.Time to Treatment Failure
The analysis of time-to-event endpoints will be conducted only if at least 5 events are observed.
2.15 Interim analy sis
No formal interim anal ysis is planned for this trial.
Three to four analyses are planned with the analy sisdata cut-off dates and the scope of analyses 
as follows :
24-week Primary analysis :Formal testing of the primary  endpoint with full alpha will be 
performed. Anal yses of other efficacy  endpoints at and by  24 weeks will also be 
performed.
96-week analysis : Formal statistical testing of the key secondary endpoint will be 
performed with = 0.05 (two
-sided) onl y if the primary endpoint (i.e. MMR rate at 24 
weeks) is significant. Otherwise, no statistical testing will be performed, and any  anal ysis
will be considered exploratory . Anal yses of other efficacy  endpoints will also be 
performed.
End of study treatment (EO sT) analysis (if required) :similar to the 96 -week anal ysis 
without formal statistical testing.
NOTE: This anal ysis may  be conducted at the same time as 96 -week analy sis.
5-year PFS/OS update analysis :PFS and OS .
In addition
,DMC s afety analyses will be conducted . Prior to the database lock for the primary 
analysis, tables and figures aggregated by  treatment arm for safety  data review by  the DMC or 
for other reporting activities will be produced by an independent statistician and independent 
statistical programmers.
Novartis Confidential Page 60
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
3 Sample size calculation
3.1 Primary  analy sis
To test the null hypothesis that the MMR rateat 24 weeks is equal in the two treatment arms, 
based on  two -sided 5% level of significance and with 90% power, 222 patients will be needed 
in total (i.e. 148 patients in the asciminib arm and 74 patients in the bosutinib arm based on 2:1 
randomization allocation). The calculations were made using the software package PASS 
(2008).
It is assume dthatasciminib leads to a 20% improvement in the MMR rate at 24 weeks over 
bosutinib from 15% to 35% which corresponds to an odds ratio of 3.05. The assumed bosutinib 
MMR rate of 15% at 24 weeks is based on previous trials evaluating bosutinib therap y ([Kuour y 
et al. 2012] , [Gambacorti -Passerini et al. 2014] , [García -Gutiérrez et al. 2015] ).
3.2 Power for analy sis of key
 secondary  variables
If the primary  analysis of MMR rate at 24 weeks is statistically  significa nt, then the key 
secondary  endpoint MMR rate at 96 weeks will be tested, with the overall alpha controlled at 
the 5% two- sided level using a gatekeeping strategy .
Table 3-1 below summarizes the treatment effects of the key  secondary  endpoint which can be 
detected with 80% and 90% power , based on the specified assumptions regarding the bosutinib 
effect. The calculations were made using the software package PASS (2008).
Table 3-1 Detectable effect sizes for key  secondary  endpoint
Endpoint Anticipated effect 
with bosutinib2-sided alpha Power Detectable 
effect size§
MMR rate at 96 weeks 30%*0.05 90%
80%≥ 23%
≥ 20%
*:[Gambacorti -Passerini et al. 2014], Figure 1D.
§: Absolute difference from the anticipated effect with bosutinib.
For MMR rate at 96 weeks, if the anticipated effect with bosutinib is 30%, then the given sample 
size with 2 -sided alpha=0.05 would allow to detect an absolute difference of at least 23% (i.e. 
MMR rate at 96 weeks with asciminib is at least 53%) for 90% power and of at least 20% (i.e. 
MMR rate at 96 weeks with asciminib is at least 50%) for 80% power.
4 Change to protoco l specified analy ses
Pharmacokinetic analysis set: Removal of the condition related to vomiting to consider a 
concentration evaluable as the occurrence and time of vomiting is not collected in the CRF .
The estimand langage was implemented in sections 2.5 and 2.6. Then, the PPS and analy ses 
based on PPS were removed.
The subgroup considering historical BCR -ABL1 mutations was removed as not considered 
clinically  relevant.
A definition for loss of CHR was provided.
Novartis Confidential Page 61
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Definition of loss of MMR: removed any refer ence to confirmation of CHR and CCyR as 
confirmation of CHR and CCyR was not mandated by protocol and was therefore not performed 
in practise.
The following anal yses were added:
ECOG status, time to event analyses for duration of MMR and CCyR, exposure adjusted AE 
incidence and yearly AE incidence , COVID -19 related sensitivity  analy ses. 
5 Appendix
5.1 Imputation rules
5.1.1 Study drug
The following rulesshould be used for the imputation of the dose end date for a given study 
treatment component.
Scenario 1: I f the dose end date is completely  missing and there is no EOT page and no death 
date, the patient is considered as on -going: 
The patient should be treated as on-going and the cut-off date should be used as the dose end 
date. 
Scenario 2: If the dose e nd date is completel y missing and the EOT page is available:
The EOT completion date should be used.  
All other cases should be considered as a data issue and the statistician should contact 
the data manager of the study .
After imputation, compare the imp uted date with start date of treatment, if the 
imputed da te is < start date of treatment:
Use the treatment start date
Patients with missing start dates are to be considered missing for all study  treatment component 
related calculations and no imputation will be made. If start date is missing then end-date should 
not be imputed.
5.1.2 AE, ConMeds and safety  assessment date imputation
The imputations specified in this section are only used for analyses of time to and duration of 
AEs and concomitant medications. 
Table 5-1 Imputation of start dates (A E, CM) and assessments (LB, EG, VS)
Missing 
ElementRule
day, month, 
and y earNo imputation will be done for completely  missing dates
Novartis Confidential Page 62
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Missing 
ElementRule
day, month If available year = year of study  treatment start date then 
oIf stop date contains a full date and stop date is earlier than 
study  treatment start date then set start date = 01JanYYYY
oElse set start date = stud y treatment start date. 
If available year > year of study  treatment start date then 01JanYYYY
If available year < year of study  treatment start date then 01JulYYYY
day If available month and year = month and year of study  treatment start 
date then 
oIf stop date contains a full date and stop date is earlier than 
study  treatment start date then set start date= 01MONYYYY. 
oElse set start date = stud y treatment start date.
If available month and year > month and year of study  treatment start 
date then 01 MONYYYY  
If available month and year < month year of stud y treatment start date 
then 15MONYYYY  
Table 5-2 Imputation of end dates (A E, CM) 
Missing 
ElementRule
(*=last treatment date plus 30days not > (death date, cut -off date, 
withdraw al of consent date))
day, month, 
and y earCompletely  missing end dates (incl. ongoing events) will be imputed 
by the end date of the on -treatment period* 
day, month If partial end date contains y ear onl y, set end date = earliest of 
31DecYYYY or end date of the on -treatment period * 
day If partial end date contains month and y ear, set end date = earliest of 
last day  of the month or end date of the on -treatment period *
Any AEs and ConMeds with partial/missing dates wil l be displayed as such in the data listings .
Any AEs and ConMeds which are continuing as per data cut-off will be shown as ‘ongoing’ 
rather than the end date provided. 
5.1.2.1 Other imputations
Incomplete date of initial diagnosis of cancer 
Missing day is defaul ted to the 15thof the month and missing month and day is defaulted to 01 -
Jan. 
Stratum reported in the CRF
Novartis Confidential Page 63
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
This will be derived from the Bone Marrow Aspirate data recorded in the corresponding eCRF 
pages at baseline. In some case the baseline sample may be missing or not evaluable (i.e. <20 
metaphases). 
The following imputation rule will be applied to derive the missing or non evaluable values:
Major cytogenetic response (MCy R)(0 to 35% Ph+ metaphases )will be assumed if
BCR -ABL1 levels ≤10% (I S).
Rationale :
ELN 2013 recommendations are providing treatment milestones with response categories for 
cytogenetic and molecular response, whi ch we can refer to for the imputation:
MCy R is roughl y corresponding to BCR -ABL1 levels ≤10% (IS) (Ross et al 2009) .
5.2 AEs coding/grading
Adverse events are coded using the latest available version of Medical dictionary  for regulatory 
activities (MedDRA) terminology .
AEs will be assessed according to the Common Terminology  Criteria for Adverse Events 
(CTCAE) version 4.03. 
The CTCAE represents a comprehensive grading system for reporting the acute and late effects 
of cancer treatments. 
CTCAE grading is by definition a 5-point scale generally  corresponding 
to mild, moderate, severe, life threatening, and death. This grading system inherently  places a 
value on the importance of an event, although there is not necessaril y proportionality  among 
grades (a grade 
2 is not necessarily  twice as bad as a grade 1). 
5.3 Laboratory  parameters derivations
Grade categorization of lab values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) version 4.03. The calculation of CTC AE 
grades will be based on the observed laboratory  values onl
y, clinical assessments will not be 
taken into account. The criteria to assign CTCAE grades are given in Novartis internal criteria 
for CTCAE grading of laboratory  parameters (embedded below) . The latest available version 
of the document based on the underly ing CTCAE version v4.03 at the time of analysis will be 
used. For laboratory  tests where grades are not defined by CTCAE v4.03, results will be graded 
by the low/normal/high (or other project -
specific ranges, if more suitable) classifications based 
on laboratory  normal ranges.
A severity  grade of 0 will be assigned for all non -missing lab values not graded as 1 or higher. 
Grade 5 will not be used. For laboratory  tests that are graded for both low and high values, 

Novartis Confidential Page 64
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
summaries will be done separately  and labelled by direction, e.g., sodium will be summarized 
as hyponatremia and hy pernatremia.
EASE LA B - CTC 
grades in Novartis On  
Imputation Rules  
Hematology
Immature cells (prom yelocytes, my elocy tes, metamy elocy tes and blasts) will not be display ed 
in shift tables and will only  be listed.
Immature cells are manually  counted only if anomalies are detected during the automatic testing. 
Therefore, when the automatic testing was performed but no data is transferred for immature 
cells, this means there was no immature cells and theirvalue scan be imputed to 0. Note that 
there should not be any imputation in case the automatic testing was not performed or the test 
of immature cells is present with missing va lue in the database (this would mean the test was to 
be performed but couldn’t).
CTC AEgrading for blood differentials is based on absolute values. However,  this data may 
not be reported as absolute counts but rather as percentage of white blood cells ( WBC). 
If laboratory  values are provided as ‘<X’ (i.e. below limit of detection) or ‘>X’ , prior to 
conversion of laboratory  values to SI  unit, these numeric values are set to X. 
The following rules will be applied to derive the WBC differential counts when only 
percentages are available for a xxx differential
xxx count = (WBC count) * (xxx %value / 100)
The following rules will be applied to derive the WBC differential percentages when only 
differential counts are available for a xxx differential
xxx %value = (xxx count  100) / WBC count
Further derivation of laboratory  parameters might be required for CTCAE grading. For instance, 
corrected calcium can be derived using the reported total calcium value and albumin at the same 
assessment using the following f ormula:
Corrected Calcium (mmol/ L) = Calcium (m mol/L) +0.02 (40 – [Albumin (g/L )]
For calculation of laboratory  CTCAEgrades 0 and 1, the normal range for derived corrected 
calcium is set to the same limits (in mmol /L) as for calcium.
CTC AEgrades for the derived absolute WBC differential counts (neutrophils, lymphocy tes) 
and corrected calcium will be assigned as described above for grading .
Novartis Confidential Page 65
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Biochemistry
In order to avoid double reporting of the same information, all available values for BUN and 
UREA will be reported under the parameter name BUN (mmol/L) in listing using the following 
conversion rule: UREA (mmol/L)=2.14 BUN (mmol/L) ( [Lamb E et al 2012] ) . 
5.4 Efficacy  variables
5.4.1 Molecular response
Scaling towards an international standard will beperformed for all molecular results using 
laboratory  specific conversion factors. In this process, the raw ratio between BCR -ABL and the 
control gene ABL  is calculated and multiplied by  the lab -specific conversion factor ( [Branford 
and Hughes 2006] ). Therefore, using the international unit, the BCR -ABL ratio will be 
presented in %. The MRDx assay  using PAXgeneTMBlood RNA tubes from MMD laborator y 
will be used in this study . The lab conversion factor for this assay  was1.1until 1 June 2020 and 
1 there after.  
The BCR -ABL  ratio in IS % is calculated by m ultiply ingthe raw BCR -ABL ratio with the lab -
specific conversion factor and then b y 100: 
BCR -ABL ratio (in %) = ( BCR -
ABL / ABL) * conversion factor * 100
The BCR -ABL ratio in IS% provided by the centra l laboratory  will be use in the analyses. 
However, to calculate the fold change in BCR -ABL1/ABL used to derive the loss of MMR 
criteria, in case the BCR -ABL number of copies is reported as a 0 value and the patient doesn’t 
have atypical transcript at basel ine, then the value will be replaced by 1, and the BCR -ABL 
ratio will be calculated.
Molecular response is categorized as follows:
10% >BCR -ABL ratio
1% < BCR -ABL ratio ≤ 10%
0.1% < BCR -ABL ratio ≤ 1%
0.01% < BCR -ABL ratio ≤ 0.1%
0.0032% < BCR -ABL ratio ≤ 0.01%
BCR -ABL ratio 
≤ 0.0032%
Major molecular response (MMR)
Major molecular response (MMR) is defined as a value of ≤ 0.1% of BCR -ABL ratio on the IS. 
This endpoint corresponds to a ≥ 3 log reduction in BCR -ABL transcripts from a standardized 
baseline value for untreated CML  patients which was established in the IRIS study 
(STI5710106) . MMR will be considered as a binary  variable with patients achieving MMR 
grouped as ‘responders’ and patients not achieving MMR or patients with missing PCR 
evaluations grouped as ‘non- responders’.
Novartis Confidential Page 66
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Loss of MMR
Loss of MMR is defined as an increase in BCR -ABL1/ABL  to > 0.1% by international scale 
(IS) in association with a ≥ 5-fold rise in BCR -ABL1 /ABL from the lowest value achieved up 
to that time point on study  treatment and replicated by a second analy sis of the same sample. 
Loss of MMR must be confirmed by a subsequent sample analysis within 4-6 weeks showing 
loss of MMR associated with a ≥ 5-fold rise in BCR -ABL1 /ABL from the lowest value achieved
up to that time point on study  treatment.
If there is any assessment in between indicating a BCR -ABL ratio of ≤ 0.1% or a < 5
-fold 
increase in BCR -ABL ratio from the lowest value achieved up to that time point on study  
treatment, then the initial indication of loss of MMR canno t be confirmed. However, an 
assessment indicating (unconfirmed) loss of MMR will be considered as confirmed loss of 
MMR if the patient had loss of CHR or loss of complete cytogenetic response (CCyR) after the 
achievement of MMR. CML -related death or progression to AP or BC will be considered as 
confirmed loss of MMR in any case (if they occurred on treatment) (given that the patient 
achieved prior MMR). 
5.4.2 Cytogenetic response
Cytogenetic response will be based on the percentage of Ph+ metaphases in the bone marrow. 
Cytogenetic evaluations will be considered for response assessment only if the number of 
metaphases examined is ≥20 in each bone marrow sample . As per protocol, f luorescent in-situ
hybridization (FISH) assessments will not be considered for any evaluation of cytogenetic 
response during treatment.
Cytogenetic response is categorized as follows (a review of a minimum of 20 metaphase sis 
required):
Complete response (CCyR) :0% Philadelphia chromosome positive (Ph+)metaphases
Partial response (PCyR):>0 to 35% Ph+ metaphases
Major response (MCy R= CCy R + PCy R): 0 to 35% Ph+ metaphases
Minor response (mCyR) :>35 to 65% Ph+ metaphases
Minimal response: >65 to 95% Ph+ metaphases
None :>95 to 100% Ph+ metaphases.
If bone marrow aspirate blast percentage is provided as ‘<X’ (i.e. below limit of detection), the 
numeric value isset to X for summary  tables. In the listing ‘<X’ will be presented.
Complete cy togenetic response (CCy R)
CCyR is defined as a value of 0% Ph+ metaphases in bone marrow.
CCyR will be considered as a binary  variable with patients achieving CCyR grouped as 
‘responders’ and patients not achieving CCyR, patients with missing cytogenetic evaluations 
grouped as ‘non -responders’.
Loss of CCyR
Loss of CC yR is defined as an increas e in the Ph+ bone marrow cells to > 0%.
Novartis Confidential Page 67
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Loss of CC yR must have led to treatment discontinuation because of lack of efficacy ( based on 
the “End of Treatment Phase Disposition” eCRF or “End of Treatment Disposition” eCRF 
during the Treatment switch phase with Subject status=”lack of efficacy ” and Reason of 
treatment failure = “After start of therap y, loss of CHR, CCy R or PCy R”).
In addition, CML -related death or progression to AP or BC will be considered as loss of CCyR 
in any  case (if they  occurred on treat ment) .
Major cytogenetic response (MCyR)
MCy R is defined as a value of 0% to 35% Ph+ metaphases in bone marrow.
MCyR will be considered as a binary  variable with patients achieving MCyRgrouped as 
‘responders’ and patients not achieving MCyR, patients with missing cytogenetic evaluations 
grouped as ‘non -responders’.
Loss of MCy Ris defined as an increase in the Ph+ bone marrow cells to > 35%. For patients 
with response = PCy R, this would constitute loss of PCy R.
CML -related death or progre ssion to AP or BC will be considered as confirmed loss of MCy R
in any  case (if they  occurred on treatment) .
5.4.3 Hematologic response
Loss of CHR
Loss of CHR isdefined by  meeting any  of the following :
WBC count > 20 × 109/L
Platelet count ≥ 600 × 109/L
Appearance of blasts or promy elocy tes in peripheral blood
Appearance of m yeloc ytes + metam yeloc ytes ≥ 5% in peripheral blood
Progressive splenomegaly refractory  to therapy (i.e. ≥5cm below left intercostal margin) 
Loss of CHR must have ledto treatment d iscontinu ation because of lack of efficacy  (based on 
the “End of Treatment Phase Disposition” eCRF or “End of Treatment Disposition” eCRF 
during the Treatment switch phase with Subject status=”lack of efficacy ” and Reason of 
treatment failure = “After sta rt of therap y, loss of CHR, CCy R or PCy R”).
In addition, CML -related death or progression to AP or BC will be considered as loss of CHR 
in any  case (if they  occurred on treatment) .
Complete hematologic response (CHR)
CHR is defined when all of the followin g criteria are present at any assessment which is
confirmed b y another assessment at least after 4 weeks:
White blood cells ( WBC ) count < 10 × 109/L
Platelet count < 450 × 109/L
Basophils < 5%
No blasts and prom yelocytes in peripheral blood
Myelocy tes + metam yelocytes < 5% in peripheral blood
Novartis Confidential Page 68
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
No evidence of extramedullary  disease, including spleen and liver. As extramedullary
disease is evaluated less frequentl y than hematology, the results of these evaluations are
carried forward until the next assessmen t (unless extramedullary  disease was not present
at the current assessment but present at the next).
The assessment is not considered CHR, if there are any  values indicative of CML  in AP or BC 
(i.e. by blasts in bone marrow). The information used for hemat ological assessment will be
obtained from the laboratory , extramedullary  and bone marrow data, all merged b y patient and 
date. To accommodate for missing parameters, specific laboratory  results may be carried
forward up to 14 days such that assessments performed within a two-week period cancombined 
into one complete evaluation of hematological response. A value will be carried forward for no 
more than up to the subsequent valid assessment of the respective laborator yparameter. If even 
after apply ing this carry -forward algorithm, any of the above laboratory parameters is not 
available at a given assessment date, the response assessment will beconsidered missing, unless 
any of the available values (including those carried forward) indicates that there is no response 
in which case the assessment will be ‘No response’.
For confirmation of CHR, both the initial CHR as well as the confirming assessment (at least 4 
weeks after the initial assessment) must satisfy  all the criteria mentioned above and no
assessment in between indicates ‘No response’. The terms “confirmed CHR” and “CHR” are 
used as synony mous given that the definition of CHR mentioned above alread y includes a 
requirement for confirmation.
5.4.4 Treatment Failure
The following events will constitute ‘treatm ent failure’, and are based on the ELN criteria
(Baccarani et 
al 2013) defining failure of a second line treatment adapted to include 
discontinuation of randomized treatment as an event
:
No CHR or > 95% Ph+ metaphases at three months af ter initiation of therapy  or 
thereafter
BCR -ABL 1
ratio > 10% IS and/or > 65% Ph+ metaphases at six months af ter 
initiation of therapy or thereafter
BCR -ABL 1ratio > 10% IS and/or > 35% Ph+ metaphases at 12 months after 
initiation of therapy or thereafter
Loss of CHR, CCy R or PCy R at any  time after initiation of therap y
Detection of new BCR -ABL 1mutations which potentially  cause resistance to study  
treatment ( T315I and V299L ), at an y time after initiation of therap y  
Confi rmed loss of MMR in 2 consecutive tests
New clonal chromosome abnormalities in Ph+ cells: CCA/Ph+: at any  time after 
initiation of therapy
Discontinuation from randomized treatment for any reason * (Note that Reason for 
treatment discontinuation= ”completed ” doesn’t indicate a premature treatment 
discontinuation )
Novartis Confidential Page 69
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
5.4.5 CML progression to accelerated phase (AP) or blast crisis (BC)
For the evaluation of CML  progression to AP or BC, the following criteria will be used.
Accelerated phase (AP) isdefined b y any of th e following:
≥ 15% blasts in the peripheral blood or bone marrow aspirate, but < 30% blasts in 
both the peripheral blood and bone marrow aspirate
≥ 30% blasts plus promyelocy tes in peripheral blood or bone marrow aspirate, but < 
30% blasts in both the peripheral blood and bone marrow aspirate
≥ 20% basophils in the peripheral blood
Thrombocy topenia (<100 x 109/L) that is unrelated to therap y*
*As thrombocy topenia is a known adverse reaction to CML  therap y, platelets <100 × 109/L are 
only considered as CML -AP if the patient had these values within 30 days of treatment 
discontinuation due to disease progression. In this case, comments are to be provided on the 
termination page that thrombocy topenia is indicative of progression to AP and an adverse event 
(AE) entered with relationship to study treatment = ‘Not suspected’
Blast crisis (BC) is defined by  any of the following:
≥ 30% blasts in periphera l blood or bone marrow aspirate
Appearance of extramedullary  involvement other than hepatosplenomegal y proven b y 
biopsy  (i.e., chloroma).
The second bullet criteria can’t be considered in this study  as this information was not 
collected.
5.4.6 CML -related death s
CML -related death is considered as any death during treatment or follow -up(safet y or survival)
if the principal cause of death is marked as “stud y indication” in the eCRF by  the 
investigator,
or if the death occurred subsequent to documented progression to AP/BC and the cause of 
death is reported as “unknown” or not reported b y the investigator .
With respect to the second bullet, as “unknown” cause of death will be coded to the Medical 
Dictionary  for Regulatory  Activities (MedDRA) preferred term ‘Death’, this MedDRA coding 
will be used in the derivation of CML -related death.
5.4.7 Disease progression
The following events are considered disease progression
CML -related deaths
Accelerated phase (AP)
Blast crisis (BC)
5.4.8 Overall survival
This includes all- cause deaths.
Novartis Confidential Page 70
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
5.5 Derivation of response rates and categories 
5.5.1 Response rate at a specific time point
The molecular and cytogenetic response evaluations will be summarized by the following 
mutually  exclusive categories which are based on the respective assessment within the time 
window:
Response categories (sections 5.4.1 and 5.4.2 ):Patients with an available assessment at 
that time point (+/- time window) indicating an y of the response categories.
No response: Patients with assessment at that time point (+/- time window) indicating 'no 
response'
Missing: Patients without an evaluabl e response assessment at that time point (+/ -time 
window). This category  is then further split into patients who are ongoing without 
treatment failure at the beginning of the relevant time window, patients who are ongoing
with treatment failure at the beg inning of the relevant time window ,patients who 
discontinued due to lack of efficacy , disease progression (PD) or death and patients who 
discontinued due to other reasons.
5.5.2 Response rate by  a specific time point (best response)
In this analysis, patients w
ho had achieved any response at or before the time point will be 
display ed in their best response category , no matter if they lost the response/discontinued or not. 
Therefore this response rate represents the best observed response rate up to that specific time 
point (including the time window). 
Patients for whom an evaluable response assessment was never provided will be classified as 
‘Missing’. 
5.6 Statistical models
5.6.1 Primary  analy sis
The null hypothesis of equality  of MMR rate at 24 weeks in the two treatme nt armswill be 
tested against two -sided alternative. The statistical hy potheses are:
H0: RA 24wk= RB 24wkversus HA: RA 24wk≠ RB 24wk, for a two- sided test
where RA 24wkis the probability  of MMR rate at 24 weeks inasciminib arm and RB 24wkis the 
probability  of MMR rate at 24 weeks in bosutinib arm.
The Cochran- Mant e l- Haenszel chi-square testX2
CMH(im plement ed via S ASprocedure F REQ
withCMH option in t heT ABL ESstatem ent), stratified by the randomization stratification 
factor, i.e. cytogenetic response status ( MCyR vs no MCy R) at screening, willbeused totest
thediffer ence inresponse rates between the treatment arms. The p -value corresponding to the 
CMH test for “general association” will be used which follows a Chi -square distri bution with 
one degree of freedom.
The 95% confidence interval for the unstratified difference in MMR rate at 24 weeks between 
treatment groups will be provided using the Wald method (implement ed via S ASprocedure
F
REQ with RISKDIFF option in the TABL ES statem ent, under the default 
Novartis Confidential Page 71
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
METHOD=WALD and VAR=SAMP LE).If the 2×2 table is with asciminib in row 1, 
bosutinib in row 2, MMR in column 1 and No MMR in column 2, then the SAS output will 
give the estimate of (risk for MMR at 24 weeks inasciminib –risk for MMR at 24 weeks in 
bosutinib) . The corresponding Mant el-Haenszel estimate of common risk difference and 95% 
confidence interval will also be presented (with RISKDIFF( COMMON )option in the
TABL ESstatem ent, taking the Mant el-Haenszel estimate from the SAS output table ).
If the sampling assumptions for chi -square test is not met (i.e. the expected frequencies should
e
xceed 5forall of tablecells), theexact Cochran- Mantel -Haenszel test will be use d 
(imple mented via SAS procedure MULTTEST). The testisperform edbyrunni ng a stra ti fied
version ofthe Cochran- Armitage permutation test [Armitage et al. 1969] . In s tudies w ith
stratified randomi zation, the chi-square appro ximation is considered appropr iate for the 
X2
CMHstatistics iftheruleofMantelandFleiss[Mantel and Fleiss 1980] issatisfied.
Confidence inter
valforMMR rate within each treatment arm
MMR will besummarizedinterms of per centagerates with 95% confidence int erva lusing
exact binomial confidence interval (implemented using SAS proced ure FREQwith EXACT
statement forone-way table [ Clopper and Pearson 1934] ).
5.6.2 Key secondary  analysis
The null hypothesis of equality  of MMR rate at 96weeks in the two treatment armswill be 
tested against two -sided alternative. The statistical hy potheses are:
H0: RA 96wk= RB 96wkversus HA: RA 96wk≠ RB 96wk, for a two- sided test
where RA 96wkis the probability  of MMR rate at 96weeks inasciminib arm and RB 96wkis the 
probability  of MM R rate at 96 weeks in bosutinib arm.
The same approaches as for the primary  endpoint (Section 5.5.1) will be applied here for the 
Cochra
n-Mant el-Haenszel chi-square test X2
CMH, the 95% Wald confidence interval for the 
difference in MMR rate at 96 weeks between treatment groups ,the Mant e
l-Haenszel estimate 
of common 
risk difference with 95% confidence interval , and the confidence interval for MMR 
rate within each treatment arm .
Multiplicity  adjustment
Formal statistical testing of the key  secondary  endpoint will be performed with = 0.05 (two -
sided) only if the primary  endpoint is significant by means of a gatekeeping procedure to control 
the overall alpha level.
5.6.3 Other analy ses
Mantel -Haens zel comm on odds ratio
To obtain Mantel -Haenszel estimates of the common odds ratio and the corresponding 95% 
confidence interval in exploratory  analy ses,  it requires SASprocedure FREQwithCMHand 
RELR ISK options in the TABL ESstatem ent. 
Novartis Confidential Page 72
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
Logistic Regression 
Odds ratio will beused as a me asure of associati onbetw e en tr eatment and response in 
exploratory  anal yses (Section 2.14). The odds r atiowillbe derived from thelogisticregre ssion
model(impl emented usingSASprocedure LOGISTIC, w ith tr eatmentspecified as an
explanat ory vari abl e in the CLASS statem ent) which allows forincluding not only the
stratifi c
ation factor but also foradjustments forother covaria tes(both categoricaland
continuous). Theodds ratio willbepresented with 95% Wald confidence limits.
In ca ses wh ereanexact test hasbeen used tocompare response rates, the odds ratio should be 
determined using ex actlogisticregression, and theodds ratio presented with exact 95% 
confidence limits. I
nthesecases,SASPRO C LOGISTIC withEXACT ONLYoptio nwillbe 
used.
Kaplan -Meier estimates
Anestimate of the survival function in each treatment group w illbe constructed using Kaplan -
Meier (product-limit ) methodas implemented inPROC LIFETEST with METH OD=KM
option. The PROC LIFETEST statement will usetheoption CON FTYP E=LOGL OG.
Median survival foreachtreatment group will be obt ained along wit h 95% confide nce 
intervals ca lculated from PRO C LIFE TEST output using themethod of[Brookm eyer and 
Crowl ey 1982] . Kaplan- Mei er es timatesof the survivalfunction w ith 95% confidence
interval s atspecific timepoint swill besummarized.Thestandard error of the Kaplan-
Meier estimate will be calculated using Gr eenwood’s formula [Collett 1994].
Hazard ratio
Hazard ratio will be estimated by fitting the Cox proportional hazards model using SAS 
procedure PHREG (with TI ES=EXACT option in the MODEL statement). 
A stratified unadjusted Cox model willbe, i.e.theMOD ELstatement will include the
treatment group va riable astheonly covar iateand theSTRATA sta tement will include
stratification vari abl e(s). Hazard ratio with two-sided 95% confidence interval will be based 
on Wald test.
5.6.4 Calculation of exposure- adjusted incidence rate
To adjust for different durations of exposure across treatment arms, the incidence rate per 100 
patient -years of exposure (exposure -adjusted incidence rates of adverse events) will be 
calculated.
The I R/100 py r is defined as numerator/denominator, whe re
Numerator = number of patients with the adverse events of interest (not the number of 
events; one patient may  have more than one event).
Denominator = patient -years = total time at risk in y ears = among all patients in the 
population, sum of the duratio n of exposure (in day s) until the first onset of the event 
of interest, if the patient experienced the event, or until the date of last dose if the 
patient did not experience the event / 365.25.
The patient -years (i.e. total time at risk in y ears) will be calculated as the sum of times at risk 
in day s over all patients in the population / 365.25.
Novartis Confidential Page 73
SAP Amendment 3 10-Aug-2020 (8:52) CABL001A2301
The time at risk for a patient in day s will be calculated as follows:
If the patient experienced the event of interest, the time at risk for this patient is the 
duration of exposure from the first dose of treatment until the first onset of the event.
For patients without an event of interest, the time at risk is the total duration of 
exposure during core study , as applicable.
6 Reference
1.Armitage P, McPherson CK and Rowe BC (1969). Repeated significance tests on 
accumulating data. J .R. Statist. Soc. A, 132, 232 -
244. 
2.Baccarani M, Deininger DW, Rosti G, et al (2013). European LeukemiaNet 
recommendations for the management of chronic my eloid leukemia :2013. Blood ;
122(6):872-84.
3.Branford S, Hughes T (2006) Diagnosis and monitoring of chronic m yeloid leukemia b y 
qualitative and quantitative RT -PCR. Methods Mol Med; 125:69 -92.
4.Brookmey
er R and Crowley  J (1982). A Confidence Interval for the Me dian Survival 
Time. Biometrics, 38, 29 - 41. 
5.Clopper CJ and Pearson ES (1934).  The use of confidence or fiducial limits illustrated in 
the case of the binomial.  Biometrical , 26, 404- 413.
6.Collet D (1994). Modelling survival data in medical research. Lo ndon, Chapman & Hall.
7.Gambacorti -Passerini C, Brümmendorf TH, Kim DW, et al (2014). Bosutinib efficacy  and 
safet y in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: 
Minimum 24 -month follow -up. Am J Hematol; 89(7):732
-42.
8.García-Gutiérrez V, Martinez -Trillos A, L opez Lorenzo JL , et al (2015) .Bosutinib shows 
low cross intolerance, in chronic m yeloid leukemia patients treated in fourth line. Results 
of the Spanish compassionate use program. Am J Hematol; 90(5):429 -33.
9.Khoury  HJ, Cortes JE, Kantarjian HM, et al (2012). Bosutinib is active in chronic phase 
chronic m yeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. 
Blood; 119(15):3403 -12.
10.Lamb E, et al (2012) Kidney  Function Tests  In Elsevier Health Sciences (Ed), Tietz 
Textbook of Clinical Chemistry and Molecular Diagnostics (Chapter 25). Also retrieved 
from 
https://books.google.es/books?id=BBLRUI4aHhkC&lpg=PA685&hl=es&pg=PA685#v=o
nepage&q&f=false
11.Mantel, N. and Joseph L  Fleisś (1980). Minimum expected cell size requirements for the 
Mantel -Haenszel one degree- of-freedom Chi -Square Test and a related rapid procedure. 
American Journal of Epidemiology , 112, 129- 134.
12.Ross DM, Branford S, Moore S, et al (2006) Limited clinical value of regular bone 
marrow cy togenetic analy sis in imatinib -treated chronic phase CML patients monitored by 
RQ-
PCR for BCR- ABL. Leukemia; 20(4):664 -70.
Clinical Development
ABL001/asciminib
CABL001A2301
A phase 3, multi -center, open -label, randomized study  of 
oral ABL001 (asciminib) versus bosutinib in patients w ith 
Chronic M yelogenous Leukemia in chronic phase (CML -
CP), pre viously  treated w ith 2 or more ty rosine kinase 
inhibitors
Statistical A nalysis Plan (SA P)– Addendum 1
Document type: SAP Documentation
Document status: Addendum 1 
Release date: 14-October -2020
Number of pages: 75
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
Novartis Confidential Page 2
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Document History  –Changes compared to previous final version of SAP
Date Time point Reason for 
updateOutcome for update Section and title 
impacted 
(Current)
25-
Aug-
2017Prior to 
DB lock
for 
primary  
analysisCreation of 
final versionN/A -First version NA
26-
Mar-
2020Prior to 
DB lock 
for 
primary  
analysisImplementation 
of protocol 
amendment s 2 
and3. ABL001 has been replaced by  
International Nonproprietary  
Name (INN) asciminib.
Introduction of the switch to 
asciminib option for patients 
experiencing treatment failure 
on bosutinib treatment
Update of the definition of 
end of study  treatment
Added a potential End -of-
Study -Treatment anal ysis 
different from the 96 -week 
analysis
Addition /removal of
secondary  safet y objectives 
and exploratory  efficacy  
objectivesThroughout the 
SAP amendment
Section  1.1, 
Figure 1-1
Sections 2.1, 
2.3
Analy ses added 
throughout the 
document
Section 1.1
Table 1-1
Additional 
analyses, 
clarificationClarification on which data are 
included in the analy ses, 
which assessments are 
considered for safety and 
efficacy  anal yses
Addition of the treatment arms 
and definition of the date of 
end of study  treatment
Removal of windows defined 
for ECGs, LVE F and PK 
assessments as they are not 
needed.Section 2.1
Section 2.1.1
Novartis Confidential Page 3
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
As per Health Authorities 
request, addition of the 
breakdown per different time 
points of the number (%) of 
patients who discontinued the 
study  treatment phase and of 
the primary  reason for study 
treatment phase 
discontinuation
PAS: Removal of the 
condition related to vomiting 
to consider a concentration 
evaluable as the occurrence 
and time of vomiting is not 
collected in the CRF.
Addition of asubgroup 
“Stratum reported in the CRF ” 
for the analy sis by subgroup of 
the primary  endpoint (to take 
into account the 
mistratification cases )
Removal of the subgroup 
“with or without historical 
BCR -ABL1 mutation by local 
lab” as this is not considered 
clinically  relevant
Additional analyses of prior 
TKI and non TKI 
antineoplastic therapies
Implementation of the 
estimand language for the 
primary  and key secondary 
objectives
Addition of a sensitivity  
analysis of the primary 
estimand stratify ing by the 
stratum recorded in the CRF to 
take into account that many 
stratification errors occurred
Addition of Time -to-event 
analyses for time to MMR and 
time to CCy RSection 
2.3.1
Section 2.2
Section 2.2.1
Section 2.4.2
Sections 2.5 and 
2.6
Section 
2.5.5
Section 2.7.2
Novartis Confidential Page 4
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Added how time is censored 
for time to MMR/CCy R, 
clarification on how to handl e 
missing BMA assessments 
due to MMR being achieved
Added analyses AEs and 
SAEs incidence rates by 
adjusting for exposure and by 
reporting by time intervals to 
account for potential 
difference in exposure 
between the treatment arms
Clarified handling of 
unscheduled ECG 
measurements in the analy ses Section 
2.7.3
Section 2.8.1
Section 2.8.4.1
4-
June-
2020Prior to 
DB lock 
for 
primary  
analysisCreation of 
amendment 2.0Clarified baseline for 
mutations
Clarified EOT is mapped to 
defined time points
Modified age subgroup, added 
Line of therapy  subgroup and 
moved Without T315I /V299L 
to Supplementary  analysis
(All patients with 
T315I /V299L  m utations 
identified at the Week 1 Day 1 
visit are discontinued from 
study  treatment when the 
mutation results become 
available) .
Clarified Mutation subgroup 
doesn’t include T315I /V299L 
mutations.
Modified age categories
Added COVID -
19 related PDs 
analysis
Added definitions of time on 
treatment, duration of 
exposure in patient -years and 
average dail y doseSection 2.1.1
Section 2.2.1
Section 2.3
Section 2.3.1
Section 2.4.1
Novartis Confidential Page 5
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Additional analyses of prior 
TKI therap y
Added summary of 
concomitant therapies for on-
switched treatment period.
Added COVID -
19 sensitivity  
analyses for the primary  and 
key secondary  endpoints
Added a supplementary 
analysis to the primary 
endpoint (Patients without 
T315I /V299L  mutations at 
Week 1 Day  1visit)
Added new graph for Ctrough
values of asciminib
Updated the list of changes to 
the protocol specified analy ses
Added imputation rules for 
immature cells
Removed imputation rules for 
corrected calcium as corrected 
calcium is collected
Clarified all available values 
for BUN and UREA will be 
reported under the parameter 
name BUN in listing to avoid 
double reporting of same 
information
Definition of loss of MMR: 
Removed reference to 
confirmation of loss of 
CHR/CCy R
Loss of CHR: clarified 
“Progressive splenomegal y 
refractory  to therapy ” is ≥ 5cm
below left intercostal margin”
Implemented change to 
definition of treatment failure 
(Protocol amendment 3)Section 2.4.2
Sections 2.5.5, 
2.6.5
Section 2.5.6
Section 2.9
Section 4
Section 5.3
Section 5.4.1
Section 5.4.3
Section 5.4.4
Section 5.4.5 
Novartis Confidential Page 6
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Clarified what 
“Thrombocy topenia (<100 x 
109/L ) that is unrelated to 
therap y” is.
Added derivation of response 
rates and categories sectionSection 5.5.
7-
Aug-
2020Prior to 
DB lock 
for 
primary  
analysisCreation of 
amendment 3.0
after FDA type 
C 
teleconference 
on 
28 July 2020As agreed with FDA, added 
sensitivity  analyses of the 
primary  and key secondary 
endpoints without the 
imputation rule used in the 
main analysesin case of 
missing PCR evaluations at 
24/96 weeks. 
Per FDA request, added 
another subgroup of interest: 
BCR -ABL ratio at baseline ≥
1% or <1%.
Added calculation rules for 
duration of interrruption .
Added deriv ation rule for 
corrected calcium using the 
reported total calcium value 
and albumin.
Aligned the definition of loss 
of CCyR with the definition of 
loss of CHR by adding the 
requirement that loss of CCy R 
(Ph+ bone marrow cells to > 
0%)must have led to treatment 
discontinuation because of 
lack of efficacy .Section 2.5.5
Section 2.2.1
Section 2.4.1
Section 5.3
Section 5.4.2
14-
Oct-
2020Post DB 
lock for 
primary  
analysisCreation of 
addendum 1.0 
to include post-
hoc analyses
added after FIR 
results reviewAdded that protocol deviations 
during the treatment switch 
period will be reported 
separately  and clarified .
Clarified how to identify 
prohibited concomitant 
medications.
Addedan analy sisof time to 
MMR considering Section 2.3.1
Section 2.4.2
Sections 2.7.2 
and 5.6.3
Novartis Confidential Page 7
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
discontinuation from 
treatment due to any reason, 
without prior achievement of 
MMR as a competing risk.
Added an analysis of the 
MMR rate using the number of 
subjects with adequate follow -
up as the denominator, i.e. for 
each time point (week x), only 
patie nts randomized at least x 
weeks prior to the cut-off date 
will be considered.
Added that post-hoc 
exploration of the treatment 
effect in different subgroups 
and assessment of the possible 
effect of differences in 
distribution of baseline 
characteristics were conducted 
(e.g. distribution of reasons for 
discontinuation of last prior 
TKI by gender and treatment, 
distribution of MCy R status at 
baseline by reasons for 
discontinuation of last prior 
TKI, distribution of mutation 
status at Week 1 Day 1 by 
reasons for discontinuation of 
last prior TKI).Section 2.14
Novartis Confidential Page 8
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Table of contents
Table of contents ................................................................................................................. 8
1Introduction ....................................................................................................................... 13
1.1 Study  design ........................................................................................................... 13
1.2 Study  objectives and endpoints ............................................................................. 14
2Statistical methods ............................................................................................................. 16
2.1 Data analy sis general information ......................................................................... 16
2.1.1 General definitions ................................................................................ 18
2.2 Analy sis sets .......................................................................................................... 26
2.2.1 Subgroup of interest .............................................................................. 27
2.3
Patient disposition, demographics and other baseline characteristics ................... 29
2.3.1 Patient disposition ................................................................................. 30
2.4 Treatments (stud y treatment, rescue medication, concomitant therapies, 
compliance) ............................................................................................................ 32
2.4.1 Study  treatment / compliance ................................................................ 32
2.4.2 Prior, concomitant and post therapies ................................................... 34
2.5 Analy sis of the primary  objective/estimand .......................................................... 36
2.5.1 Primary  endpoint/estimand ................................................................... 36
2.5.2 Statistical hy pothesis, model, and method of analy sis.......................... 37
2.5.3 Handling of remaining intercurrent events of primary  estimand
.......... 37
2.5.4 Handling of missing valu es not related to intercurrent event ............... 37
2.5.5 Sensitivity  analy ses............................................................................... 37
2.5.6 Supplementary  anal yses........................................................................ 38
2.6 Analy sis of the key  secondary  objective/estimand ................................................ 38
2.6.1 Key secondary  endpoint/estimand ........................................................ 39
2.6.2 Statistical hy pothesis, model, and method of analy sis.......................... 39
2.6.3
Handling of remaining intercurre nt events of primary  estimand .......... 40
2.6.4 Handling of missing values not related to intercurrent event ............... 40
2.6.5 Sensitivity  analy sis................................................................................ 40
2.7 Analy sis of secondary  efficacy  objective(s) .......................................................... 40
2.7.1 Secondary
 endpoints ............................................................................. 40
2.7.2 Statistical hy pothesis, model, and method of analy sis.......................... 42
2.7.3 Handling of missing values/censo ring/discontinuations ....................... 45
2.8 Safety  anal yses....................................................................................................... 46
2.8.1 Adverse events (AEs) ............................................................................ 46
2.8.2 Deaths .................................................................................................... 47
Novartis Confidential Page 9
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
2.8.3 Laboratory  data ..................................................................................... 48
2.8.4 Other safety  data ................................................................................... 49
2.8.5 Additional Analy ses.............................................................................. 51
2.9
Pharmacokinetic endpoints.................................................................................... 51
2.10 PD and PK/PD analy ses......................................................................................... 53
2.11
Patient- reported outcomes ..................................................................................... 53
2.11.1 MDASI -CML ........................................................................................ 54
2.11.2 EQ-
5D-5L............................................................................................. 54
2.11.3 WPAI -CML ........................................................................................... 55
2.11.4 PGIC
...................................................................................................... 55
2.12 Resource utilization ............................................................................................... 56
2.13 Biomarkers ................................ ................................ ................................ ............. 56
2.13.1 Somatic mutation biomarker data handling and analy sis...................... 58
2.14 Other exploratory  anal yses.................................................................................... 59
2.15 Interim anal ysis...................................................................................................... 60
3
Sample size calculation ..................................................................................................... 61
3.1 Primary  anal ysis..................................................................................................... 61
3.2 Power for anal ysis of key secondary  variables
...................................................... 61
4Change to protocol specified anal yses.............................................................................. 61
5Appendix ........................................................................................................................... 62
5.1 Imputation rules ..................................................................................................... 62
5.1.1 Study  drug ............................................................................................. 62
5.1.2 AE, ConMeds and safety assessment date imputation .......................... 62
5.2 AEs coding/grading ............................................................................................... 64
5.3 Laboratory  parameters derivations ........................................................................ 64
5.4 Efficacy  variables
.................................................................................................. 66
5.4.1 Molecular response ............................................................................... 66
5.4.2 Cytogenetic response ............................................................................ 67
5.4.3 Hematologic response ........................................................................... 68
5.4.4 Treatment Failure .................................................................................. 69
5.4.5 CML  progression to accelerated phase (AP) or blast crisis (BC) ......... 70
5.4.6 CML -related deaths ............................................................................... 70
5.4.7 Disease progression ............................................................................... 70
5.4.8 Overall survival ..................................................................................... 71
5.5 Derivation of response rates and categories .......................................................... 71
5.5.1 Response rate at a specific time point
................................................... 71
Novartis Confidential Page 10
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
5.5.2 Response rate b y a specific time point (best response)......................... 71
5.6 Statistical models ................................................................................................... 71
5.6.1 Primary  anal ysis.................................................................................... 71
5.6.2 Key secondary  anal ysis......................................................................... 72
5.6.3 Other anal yses....................................................................................... 73
5.6.4
Calculation of exposure- adjusted incidence rate ................................... 74
6Reference ........................................................................................................................... 74
Novartis Confidential Page 11
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
List of abbreviations
AE Adverse event
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AP Accelerated phase
AST Aspartate aminotransferase
ATC Anatomical therapeutic classification
AUC Area under the curve
BC Blast c risis
bid bis in diem/twice a day
CCyR Complete cytogenetic response
CHR Complete hematologic r esponse
CMH Cochrane -Mantel -Haenszel
CML Chronic myelogenous leukemia
CML -CP Chronic myelogenous leukemia in chronic phase
CRO Contract r esearch organization
CSP Clinical s tudy protocol
CSR Clinical s tudy report
CTCAE Common terminolog y criteria for adverse events
CV Coefficient of variation
DAR Dosage administration r ecord
DI Dose intensity
DMC Data m onitoring c ommittee 
DRL Drug r eference  listing
DSUR Development safety update report
ECG Electrocardiogram
eCRF Electronic c ase report form
EOT End of treatment in the treatment phase (patient level)
EOsT End of study treatment (study level)
ER Emergency r oom
FAS Full analysis set
FD First dose date of study treatment during the treatment phase
FDswitch First dose date of asciminib during the treatment switch phase
GP General practitioner
H Hospitalization
HCRU Health care resource utilization
HLT High level term
HLGT High level group term
IRT Interactive response technology
IS International s cale
LD Last dose date of study treatment during the treatment phase
LDswitch Last dose date of asciminib during the treatment switch phase
Novartis Confidential Page 12
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
LLOQ Lower limit of quantitation
LPFT Last patient first treatment
LSC Leukemic stem cell
LVEF Left ventricular ejection fraction
MCyR Major cytogenetic r esponse
mCyR Minor cytogenetic r esponse
MedDRA Medical d ictionary for regulatory activities
MMR Major molecular r esponse
NCI National Cancer Institute
NGS Next generation sequencing
NMQ Novartis MedDRA Query
OS Overall s urvival
PAS Pharmacokinetic analysis set
PCR Polymerase chain reaction
PCyR Partial c ytogenetic r esponse
PD Pharmacodynamic
PDI Planned d ose intensity
PFS Progression -free rurvival
Ph+ Philadelphia chromosome positive
PK Pharmacokinetics
PPS Per-protocol set
PRO Patient-r eported outcomes
PSUR Periodic s afety  update report
PT Preferred term
qd Qua’que di’e / once a day
RDI Relative dose intensity
SAE Serious adverse event
SAP Statistical a nalysis plan
SD Standard deviation
S-EoT End of treatment in the treatment switch phase (patient level)
SMQ Standardized MedDRA q uery
SOC System organ c lass
Sp Specialist
TBL Total bilirubin
TKI Tyrosine kinase inhibitor
TTF Time to treatment failure
UC Urgent c are
ULN Upper limit of norm
VAS Visual a nalogue scale
W1D1 Week 1 Day 1
WBC White blood cell s
WHO-DD World Health Organization Drug Dictionary
Novartis Confidential Page 13
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
1 Introduction
This statistical analysis plan (SAP) describes all planned analysesof primary objective,
secondary  objectives and selected exploratory objectives for the clinical study report s(CSR) of 
study CABL001A2301, a phase 3, multi- center, open -label, randomized study  of oralasciminib
versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML -CP), 
previously  treated with 2 or more t yrosine kinase inhibitors. 
The content of this SAP is based on protocol CABL001A2301 version 03.All decisions 
regarding safet y monitoring analysis for the data monitoring committee, 24-week primary
analysis, 96-week analysis,end of study  treatment analysis, 5-year progression
-free survival 
(PFS)/overall survival (OS)update analysis,and postings for ClinTrial.gov and EudraCT, as 
defined in th isSAP document, have been made prior to the first database lock of the study data
for the primary  anal ysis.
1.1 Stud y design
This is a randomized,  Phase III , open -label,  active -controlled, multi- center study   comparing  
safet y and efficacy  ofasciminib tobosutinib inpatients with CML -CP, previously  treated with 
2 or more tyrosine kinase inhibitors (Figure 1-1). Approximately 220 patients will be 
randomized to one of the following treatment arms in 2:1ratio:
asciminib 40 mg BID
Bosutinib 500 mg QD
Randomization will be stratified by the following factor: cytogenetic respons
e status (with or 
without major cy togenetic response).
Figure 1-1 Schematic of Study  Design
Patients with documented treatment failure (as per the 2013 ELN guidelines, Baccarani et al 
2013) while on bosutinib treatment will have the option to switch to asciminib treatment within 

Novartis Confidential Page 14
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
96 weeks after the last patient has been randomized on study . The patients who switch to 
asciminib will be able to receive asciminib up to the e nd of study  treatment (EOsT) period.
Patients will be treated up to the EOsT defined as up to 96 weeks after the last patient received 
the first study  dose(LPFT) or up to 48 weeks after the last patient has switched to asciminib 
treatment whichever is longer, if they do not discontinue study  treatment earlier. After the EOsT, 
the assigned study  treatment will be made available to patients who in the opinion of the 
investigator sare still deriving clinical benefit. This may be outside of this study  through 
alternative options including, but not limited to, an expanded access/compassionate 
use/managed access program or access to commercial supplies in applicable countries.
Major Molecular Response (MMR) rate at 24 weeks is the primary  endpoint in this study . MMR 
rate at 96 weeks is the key secondary  endpoint.
Four analyses are planned for this study , including the 24 -week primary  analy sis, the 96 -week 
analysis, the End-of-Study -Treatment (EOsT) analy sis, and Progression- Free survival/Overall 
survival (PFS/OS) update analysis The timing when those analyses are conducted is 
summarized in Section 2.1. 
No formal interim efficacy  analysis is planned in this study . A data monitoring committee 
(DMC )will monitor unblinded safet y data approximately  6months after the first randomized 
patient has started study treatment. Subsequent reviews will be conducted approximately  ever y 
6 months and when needed thereafter (ie. if significant safety  findings are noted) until the 
primary  anal ysis.
1.2 Stud y objectives and endpoints
Table 1-1 Objectives and related endpoints
Objective Endpoint
Primary
To compare the MMR rate at 24 weeks of
asciminib versus bosutinib Major Molecular Response (MMR) rate at 24 weeks
Key secondary
To compare additional parameters of the 
efficacy of asciminib versus bosutinib MMR rate at 96 weeks
Other secondary
To compare additional parameters of the 
efficacy of asciminib versus bosutinibCytogenetic response rate (Complete, Partial, Major, 
Minor, Minimal, no response) at and by all scheduled 
data collection time points including 24, 48 and 96 weeks
MMR rate at all scheduled data collection time points  
(except 24 and 96 weeks which are already covered by 
primary an d key secondary endpoints)
MMR rate by all scheduled data collection time points 
including 24, 48 and 96 weeks
Time to MMR
Duration of MMR
Time to CCyR
Duration of CCyR
Time to treatment failure
Progression free survival
Novartis Confidential Page 15
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Objective Endpoint
Overall survival
To compare the sa fety and tolerability 
profile of asciminib versus bosutinibType, frequency and severity of adverse events,
changes in laboratory values that fall outside the pre -
determined ranges and clinically notable ECG and other 
safety data (vital signs)
To characterize the PK of asciminib in the 
CML-CP populationTrough plasma concentrations,
PK parameters in full PK group: Cmax, Tmax, AUC0 -12h, 
CL/F 
To assess the safety of asciminib when 
administered as treatment after bosutinib 
failure according to the 2 013 ELN 
GuidelinesType, frequency and severity of adverse events, changes in 
laboratory values that fall outside the pre -determined ranges 
and clinically notable ECG and other safety data (vital signs )
Novartis Confidential Page 16
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Objective Endpoint
Exploratory
To evaluate the influence of factors such 
as cytogenetic response at baseline, 
failure/intolerance to prior TKIs, line of 
therapy, gender, race and age on the 
effect of asciminib with respect to the 
primary efficacy endpoint Major Molecular Response (MMR) rate at 24 weeks
To explore the exposure -response 
relationships of asciminib ; evaluate the 
effect of population covariatesExposure -safety ,exposure -PDanalyses
To characterize mutations in the BCR -
ABL1 gene at Week 1 Day 1, upon 
confirmed loss of MMR and/orat end of 
treatment and examine their association 
with molecular and cytogenetic r esponse 
forasciminib vs bosutinibBCR -ABL1 gene mutations at Week 1 Day 1, upom confirmed 
loss of MMR and/orat end of treatment as determined by 
Sanger Sequencing
To und erstand biology of CML and bone 
marrow microenvironment on leukemic 
stem cells (LSCs) eradication, including 
patients’ immunogenicityBone marrow biopsies characterization for adaptive immune 
response by immunohistochemistry (IHC); bone marrow 
aspirates t o evaluate the effect of treatments on LSCs burden 
and immune cells subsets changes by flow cytometry
To assess clonal evolution during 
treatment with asciminib vs. bosutinibLow level BCR -ABL1 mutation profiles assessed by mass 
spectrometry at Week 1 Day 1, upon confirmed loss of MMR
and/orat EOT.  
Clonal evolution of several genes implicated in CML assessed 
by Next Generation Sequencing (NGS) methods 
To evaluate soluble /inflammarory factors 
that correlate with response to asciminib
vs. bosutinib trea tmentBaseline and changes from baseline of c ytokine expression in 
plasma  
To compare the impact of treatment on 
patient reported outcomes (PRO) 
including CML -specific symptoms, patient 
quality of life, and impact on work 
productivity and activity impairment from 
baseline and EOT between  treatment 
arms in all patientsChange in symptom burden and interference from baseline 
over time according to the MDASI-CM L PRO instrument
Change in patient’s impression of CML symptoms according 
to Patient Global Impression of Change ( PGIC )
Change in health utility from baseline over time according to 
EQ-5D-5L
Change in work productivity and activity impairment over time 
according to W PAI
To compare the impact of treatment on 
health care resource utilization between 
treatment arms in all patientsHealth care resource burden over time
2 Statistical methods
2.1 Data analy sisgeneral information
The planned analyses will be performed by Novartis and/or a designated CRO . SAS version 9.4 
or later will be used to perform all data anal yses and to generate tables, figures and listings.
There is no planned interim efficacy  analysis. Prior to the database lock for the primary  analysis, 
tables and figures aggregated by treatment arm for safet y data review by the data monitoring 
committee or for other reporting activities will be produced by  an independent statistician and 
independent statistical programmers.
Novartis Confidential Page 17
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
For between -treatment comparisons of efficacy  endpoints, randomization stratification factor, 
i.e. cytogenetic response status (MCyR vs no MCyR) at screening , will beincluded inrespective
stratified statistical tests.
Data included in the analy ses
The anal ysis data cut-off date s for the planned analy ses are:
Primary  anal ysis:After all randomized patients have been on stud y treatment for 24
weeks or  discontinued earlier , i.e., LPFT + 24 weeks . 
96-week analysis: After all randomized patients have been on study  treatment for 96
weeks or  discontinued earlier, i.e., LPFT + 96 weeks
End of study  treatment analy sis
:30 day s after the EOsT. (Note: After the study  
treatment period, the assigned stud y treatment will be made available, may be outside 
of this study , to patients who in the opinion of the investigators are still deriving 
clinical benefit. ) 
PFS/OS update analysis:5 years from the date when the last randomized patient 
received the first stud y dose (irrespective of treatment switch for patients failing 
bosutinib) .
All statistical analyseswill be performed using all data colle ctedinthe database upto th e
respective data cut-offdate. Alldata with an assessment date orevent start date (e.g. vital sign
assessment date orstart date ofanadverse event) prior toor
onthecut-offdate will beincluded
intheanalysis.Any data collected beyondthecut-offdate willnot be included in the analysis 
and will not be used for a ny derivations.
All events with start date before or on the respective cut-off date and end date after the 
respective cut-off date will be reported as ongoing . The same rule will be applied to events 
starting before or on the respective cut-off date and not having documented end date. This 
approach applies, in particular, to adverse event and concomitant medication reports. For these 
events, the end date will n ot be imputed and therefore will not appear in the listings.
General analy sis conventions
Pooling of center s:Unless specified otherwise, data from all study  centers will be pooled for 
the anal ysis. Due to expected small number of patients enrolled at centers, no center effect 
will be assessed. 
Qualitative data (e.g., gender, race, etc.) will be summarized by  means of contingency  tables
by treatment group; a missing category  will be included as applicable. Percentages will be
calculated using the number of patients in the relevant population or subgroup as the
denominator.
Quantitative data (e.g., age, bod y weight, etc.) will be summarized by  appropriate descriptive 
statistics (i.e. mean, standard deviation, median, minimum, and maximum) by treatment grou p.
For pharmacokinetics (PK)concentration and parameters descriptive statistics also include 
coefficient of variation ( CV)%, geo -mean and geo -CV%.
Novartis Confidential Page 18
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
2.1.1 General d efinition s
Investigational drug and study  treatment
Investigational drug , will refer to the asciminib only. Whereas, study treatment will refer to
asciminib orcontrol treatment , i.e. bosutinib, received during the treatment phase. Switched 
treatment will refer to asciminib received during treatment switch phase .
Treatment arms
Asciminib (Subjects randomized to asciminib arm at the beginning of the study )
Bosutinib (Subjects randomized to bosutinib arm at the beginning of the study )
Date of end of study  treatment (EOsT)
The EOsT date is the date that the study  treatment is ended for the entire study . On this date, 
patients are treated for at least 96 weeks if they are not eligible to switch study treatment or are 
treated for at least 48 weeks after they have switched to asciminib treatment, unless patients 
have discontinued stud y treatment earlier
Date of first administration of randomized study treatment 
The date of first administration of randomized study  treatment (FD) is derived as the first date 
when a non-zero dose of study  treatment was administered as per the Dosage Administration
Record (DAR) electronic case report form (eCRF )
. The date of first administration of study  
treatment will also be referred as start of study treatment .
The date of first administration of randomized study  treatment is the same as the date of first 
administration of investigational drug or control drug. 
Date of first administration of switched treatment 
For subjects switching from bosutinib to asciminib, the date of first administration of switched 
treatment (FD switch) is derived as the first date when a non-zero dose of asciminib was 
administered as per the DAR eCRF. The date of first administration of switched treatment 
(asciminib )will also be referred as start of switched treatment
.
Date of last administration o f randomized study treatment 
The date of last administration of randomized study  treatment (LD) is defined as the last date 
when a non-zero dose of study  treatment was administered as per DAR eCRF . For subjects 
switching 
from bosutinib to asciminib, this includes the dose of bosutinib administered as 
bridging therap y between their treatment failure and the first dose of asciminib administered .
The date of last administration of randomized study  treatment is the same as the date of last 
administration of in vestigational drug or control drug.
Novartis Confidential Page 19
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Date of last administration of switched treatment 
The date of last administration of switched treatment (LD switch) is defined as the last date when 
a non -zero dose of switched treatment (asciminib) was administered as per DAR eCRF .
Study day
The study  day, describes the day  of the event or assessment date, relative to the reference start 
date. 
The study  day is defined as:
The date of the event (visit date, onset date of an event, assessment date ,etc.)−
reference start date + 1 if event is on or after the reference start dat e;
The date of the event (visit date, onset date of an event, assessment date ,etc.) − 
reference start date if event precedes the reference start dat e.
Thereference start date for safety assessments (e.g.adverse event onset, laboratory  abnormality
occurrence, vital sign measurement, dose interruption, PK,etc.) isthestart ofstudy  treatment.
Thereference start date forallother, non -safety assessments (e.g.molecular response, survival 
time, disease progression, ECOG performance status, patient reported outcomes (PRO) , etc. )is
thedate ofrandomization.
The stud y day will be display ed in the data listings. If anevent starts before thereference start 
date, thestudy day displa yed on the listing will be negative.
Switch study  day
Theswitch study  day, describes the day  of the event or assessment date, relative to the start of 
switched treatment .
Switch study  day = date of event –start of switched treatment + 1, if event is on or after the
start of switched treatment
Switch study  day = date of event –start of switched treatment, if event precedes the start of
switched treatment
The switch study  day will be display ed in the data listings if an even t starts on or after the start 
of switched treatment.
Time unit
A year length is defined as 365.25 days. A month length is 30.4375  (=365.25/12) days. If 
duration is reported in months, duration in days will be divided by 30.4375.  If duration is  
reported in years, duration in day s will be divided by  365.25.
A week length is defined as 7 days. If duration is reported in weeks, duration in days will be 
divided by  7.
Baseline for the treatment period
For efficacy evaluations, the last non-missing assessment, including unscheduled assessments 
on or before the date of randomization is taken as “baseline” value or “baseline” assessment. In 
Novartis Confidential Page 20
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
the context of baseline definition, the efficacy  evaluations also include PRO andperforma nce 
status. 
For safet y evaluations, the last available assessment , including unscheduled assessments before 
the date of start of study  treatment is taken as‘‘baseline” assessment.
For pre-dose electrocardiogram (ECG ), the last available assessment befor e the treatment start 
date/time is used for baseline.
For ECGs, where study requires multiple replicates per time point, the average of theses 
measurements would be calculated for baseline (if not alread y available in the database).
For mutations, the Week 1 Day  1 assessment is taken as “baseline” assessment.
In rare cases where multiple laboratory
 measurements meet the baseline definition, with no 
further flag or label that can identify the chronological order, then the following rule should be 
applied: If values are from central and local laboratories, the value from central assessment 
should be considered as baseline.
If patients have no value as defined above , the baseline result will be missing .
Baseline for the treatment switch period
For subjects sw itching from bosutinib to asciminib, the last non- missing assessment, including
unscheduled assessments before the date of first administration of asciminib is taken as
‘‘baseline” assessment for the switched treatment period
, and denoted as baseline_switc h for 
short.
On-treatment assessment/event and observation periods
For adverse event reporting the overall observation period will be divided into three mutually 
exclusive segments for subjects without treatment switching and into up to five mutually  
exclusive segments for subjects switching treatment : 
For subjects without treatment switching:
1.pre-treatment period: from day of patient’s informed consent to the day before first 
administration of study  treatment (FD)
2.on-treatment period: from date of first administration of study  treatment to 30 days after 
date of last actual administration ofstudy  treatment (including start and stop date) (LD) . 
Note: Patients will be treated up to the end of study  treatment period (EOsT) . This will 
be the las t actual administration of study treatment for each patient if the patient hasnot 
discontinue dstudy  treatment earlier .On this date, all patients without treatment 
switching will have been treated for at least 96 weeks unless patients have discontinued 
study treatment earlier. After this period, the assigned study  treatment will be made 
available, may be outside of this study , to patients who in the opinion of the investigators 
are still deriving clinical benefit.
3.post-treatment period: starting at day  31 after last administration of study  treatment .
For subjects with treatment switching from bosutinib to asciminib:
Novartis Confidential Page 21
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
pre-treatment period: from day of patient’s informed consent to the day before first 
administration of study  treatment (FD)
on-treatment period: from date of first administration of study  treatment to either the day 
before the first administration of asciminib (FD switch) or  30 days after the date of last actual 
administration of bosutinib (L D), whichever comes first. 
post-treatment period
: from day 31 after last administration ofbosutinib to the day before  
the first administration of asciminib (FD switch)
.If the end date is before the start date, this 
period is not applicable.
on-switched treatment period : from date of first admin istration of asciminib (FD switch) to 
30 day s after date of last actual administration of asciminib (L Dswitch).
NOTE: Subjects are treated in the study  up to end of study  treatment period (EOsT). On 
this date, all subjects with treatment switching will hav e been treated for at least 48 weeks 
after switching unless they have discontinued the switched treatment earlier.
Post- switched treatment period :from day  31 after last actual administration of asciminib 
(LD switch). 
If dates are incomplete in a way thatclear assignment to pre-, on-, post- , on- switched -, post-
switched- treatment period cannot be made, then the respective data will be assigned to the on-
treatment period.
Safety  summaries (tables, figures) on the Safet y set (respectivel y on the Switch Anal ysis Set) 
include only data from the on-treatment (resp. on-switched treatment) period with the exception 
of baseline data which will also be summarized where appropriate (e.g. change from baseline 
summaries). In particular, summary  tables for adverse events (AEs) will summarize only on-
treatment (resp. on
-switched treatment) events, with a start date during the on-treatment (resp. 
on-switched treatment) period (treatment -emergent AEs) (resp. switched- treatment -emergent 
AEs) . In addition, a separate summary  for death including on-treatment and post-treatment 
deaths will be provided.
However, all safet y data (including those from the pre-treatment, post-treatment and post-
switched treatment period) will be listed and flagged as appropriate .
Efficacy  summa ries on the FAS (apart from OS and PFS) include data from baseline up to either 
the last assessment on or before the EoT visit or before or on treatment failure, whichever is the 
earliest .
Efficacy  summaries on the Switch Analy sis Set include data from baseline_switch up to the last 
assessment on or before the S
-EoT visit or before or on treatment failure during the switched
treatment period, whichever is the earliest .
The efficacy  assessments collected post-treatment failure, post-EoT or post S -EoT visit a re not 
included in any efficacy analyses(except for OS and PFS analyses).However, they will be 
listed and flagged as appropriate .
Novartis Confidential Page 22
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Windows for multiple assessments 
Data such as molecular response, cytogene tic response collected over time (including 
unscheduled visits) will be summarized by scheduled time point. As patients do not always 
adhere to the visit schedule, visits will be remapped according to visit windows defined in 
Table s 2-1 to Table 2-4of this document to enable by-visit analy sis. Only those protocol -
defined visits will have the visit window defined. Each assessment (including the end of 
treatment assessment) , either scheduled or unscheduled, will have a mapped visit assigned, as 
long as study  day is available, according to the defined visit window up to the date with data 
included. 
If more than oneassessment isassigned to thesametime window, theassessment performed 
closest tothetarget date willbeused for by -visit statistical analy ses. If 2 assessments within a 
visit window are equidistant from the target date, then theaverage of the 2 assessments will be 
used. If multiple assessments on the same date ,then the the average will be used. Data from all 
assessments (scheduled and unscheduled), including multiple assessments, will be listed.
Table 2-1 Time windows for molecular response
Assessment Target dayofassessment Time Interval
Baseline ≤ 1 ≤ Day 1#
Week 4 29 Day 2 to day 43
Week 8 57 Day 44 -71
Week 12 85 Day 72 - 99
Week 16 113 Day 100to day 141
Week 24 169 Day 142to day 211
Week k (k=36, 48, …) kx7 + 1 Day kx7-40 –kx7+43
# Day 1 = Date of randomization
EOT assessments are mapped to the time points as needed.
Novartis Confidential Page 23
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Table 2-2 Time windows for cy togenetic response
Assessment Target dayofassessment Time Interval
Baseline 1 ≤ Day 1#
Week 24 169 Day 2to day 253
Week 48 337 Day 254to day 421
Week 72 505 Day 422to day 589
Week 96 673 Day 590 to day 7 00
# Day 1 = Date of randomization
EOT assessments are mapped to the time points as needed.
For PRO data time windows will be defined for descriptive summary  by visit and longitudinal 
data analysis. If more than one assessment is available in the same time window, the assessment 
closest to the planned date will be considered. If two assessments are obtained with the same 
time difference compared to the scheduled visit day , the assessment obtained prior to visit will 
be considered.  
Table 2-3 Time windows for PRO : MDA SI-CML, EQ -5D-5L, PGIC
Assessment Target dayofassessment Time Interval
Baseline 1 ≤ Day 1#
Week 4 29 Day 2 -43
Week 8 57 Day 44 - 71
Week 12 85 Day 72 - 99
Week 16 113 Day 100 -141
Week 24 169 Day 142 -211
Week 36 253 Day 212 -295
Week 48 337 Day 296 -505
Week 96 673 Day 506 -700
# Day 1 = Date of randomization
Table 2-4 Time windows for PRO : WPA I-CML
Assessment Target dayofassessment Time Interval
Baseline 1 ≤ Day 1#
Week 4 29 Day 2 -57
Week 12 85 Day 58 - 127
Week 24 169 Day 128- 253
Week 48 337 Day 254 -505
Week 96 673 Day 506 -700
# Day 1 = Date of randomization
Here’s the general rule for the target day of assessment and time interval: For Week k visit, 
target day of assessment is defined ask*7+1. For the time interval, “Lower limit” = “upper limit 
Novartis Confidential Page 24
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
of prior applicable visit” +1. “Upper limit” = “target day of current visit” + integer part of 
(“target day  of next applicable visit” – “target day  of current visit”)/2. 
Visit window for the switched treatment period will use the same rules as described above but 
with Day 1 being the date of first administration of asciminib . Visit name for the switched 
treatment period will be defined similarly  with annotated by  beginning with “S -“ (e.g. S -Week 
4) to differentiate from those used for the randomized treatment period.
Novartis Confidential Page 25
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Last contact date 
The last contact date will be derived for patients not known to have died at the respective 
analysis data cut-off date using the last complete date among the following:
Table 2-5 Last contact date data sources
Source data Conditions
Date of random ization No condition
Last contac t date/last date patient was known to 
be alive from Survival Follow -up page Patient status is reported to be aliv e, lost to 
follow -up or unknown
Start/End dates from further antineoplastic 
therapyNon-missing medication/ procedure term
Start/End dates from drug administration record Non-missing dose. Doses of 0 are allowed
End of treatment date from end of treatment page No condition
Any speci fic efficacy  (molecular or cytogenetic) 
assessment date if availableEvaluation is marked as ‘done’
Laboratory/PK collection dates Sample collection marked as ‘done’
Vital signs da te At least one non -missing parameter value
Performance status date Non-missing performance status
Start/End dates of AE Non-missing verbatim term
The last contact date is defined as the latest complete date from the above list on or before the 
respective data cut-off date. The cut-offdate willnotbe used for last contact date, unless the
patient was seen or contacted on thatdate . No date post the cut-off date will be used. 
Completely  imputed dates (e.g. theanalysisdata cut-offdateprogrammaticall yimputed to
replac ethemissing enddate of adose administration record) willnot b e used toderive the last 
contact dat e. 
The last contact date will be used for censoring of patients in the anal ysis of overall survival.
Novartis Confidential Page 26
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
2.2 Analysis sets
Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all pati ents to whom study  treatment has been assigned 
by randomization. According to the intent to treat principle, patients will be analyzed according 
to the treatment and strat umthey have been assigned to during the randomization procedure.
Safety Set
The Safety Setincludes all subjects who received at least one dose of study  treatment. Subjects 
will be anal yzed according to the study  treatment actuall y received.
The actual treatment received corresponds to:
the randomized treatment if patients took at least one dose of that treatment;
the first treatment received if the randomized treatment was never received.
Pharmacokinetic Analysis Set
The Pharmacokinetic Analysis Set (PAS) includes all patients who provide at least one 
evaluable PK concentration. For a co ncentration to be evaluable, patients are required to:
Take a d ose of asciminib prior to sampling
Take the same dose of asciminib for at least 3 consecutive day s without dose 
interruption or dose modification prior to sampling
Have thepre-dose sample collected before thenext dose administration
Other analy sis sets
For duration of MMR and time to MMR (descriptive anal ysis), the MMR Responder 
Setwill be used that is a subset of FAS and includes patients who achieve MMR at 
any time on study  treatment .
For CCy R rates at and by scheduled time points and time to CCyR(Kaplan
-Meier 
analysis), the CCyR Analysis Set will be used that is a subset of FAS and includes 
patients who are not in CCy R at baseline.
For duration of CCy R and time to CCy R(descriptive anal ysis), the C CyR Responder 
Setwill be use that is a subset of FAS and includes patients who do not have CCy R at 
baseline and achieve CCy R at any  time on study  treatment .
For analy ses of patients switched to asciminib, the Switch Analysis S etwill be used 
that is a subset of FAS and includes patients who switched from bosutinib to 
asciminib and received at least one dose of asciminib.
Patient Classification
Patients may be excluded from the analysis populations defined above based on the protoc ol 
deviations entered in the database and/or on specific subject classification rules defined in Table 
2-6. 
Novartis Confidential Page 27
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Table 2-6 Subject classification based on protocol deviations and non protocol 
deviation criteria
Analy sis set Protocol deviations leading 
to exclusionNon protocol deviation 
leading to exclusion
FAS No written inform consent Not applicable
Safety  set No written inform consent No dose of stud y medication 
PK a nalysis set No written inform consent See definition of PAS
MMR Responder Set Not applicable See definition of MMR 
Responder Set
CCyR Anal ysis Set Not applicable See definition of CCyR 
Analy sis Set
CCyRResponder Set Not applicable See definition of CCyR
Responder Set
Switch Analy sis Set Not applicable See definition of Switch 
Analy sis Set
Withdrawal of Informed Consent
Any data collected in the clinical database after a subject withdraws informed consent from all 
further participation in the trial, will not be included in the analy sis.  The date on which a patient 
withdraws full consent is recorded in the eCRF. 
2.2.1 Subgrou p of interest
Subgroup analyses will use the same method as for the analysis in the respective overall analysis 
set. 
The objective forcarryingoutthese subgroup analysesis toidentif ypotential issues that
may belimited toasubgroup ofpatients, orthataremore commonly  observed in a subgroup 
of patients.
Summary  tables and figures will be generated only for subgroups with at least 1 5 patients. 
Efficacy
The primary  efficacy  endpoint will be summarized by  the following subgroups to examine the 
homogeneity  of treatment effect provided that the primary  efficacy  analysisbased on the FAS 
isstatistically  significant: 
Stratification factor (based on randomization data from Interactive Response 
Technology [IRT]): “Major Cy togenetic Response” or “No Major Cy togenetic 
Response”
Stratum reported in the CRF ( derived using the data collected on theBone Marrow 
Aspirate eCRF at baseline : see Appendix): “Major Cytogenetic Response” or “No 
Major Cy togenetic Response”
Novartis Confidential Page 28
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Sex: Female or male
Race : Asian, Caucasia n, or others
Age category  (≥18- < 65years, ≥65 years, ≥ 75 years, )
Reason for discontinuation of the last prior Tyrosine Kinase Inhibitor ( TKI): 
Failure (i.e. lack of efficacy ) or intolerance (i.e. adverse event, lack of tolerability ). 
Note: Only  one reason for discontinuation is allowed for each prior therap y.
Number of prior TKI therapies: 2 , 3or ≥4
Line of therap yof randomized treatment : 3rd, 4thor ≥5th
With or without Week 1 Day  1 BCR -ABL1 mutation (other than T315I or V299L) by 
Sanger Sequencing at central lab: W ild ty peor  mutan t
BCR -
ABL ratio at baseline ≥ 1% or <1%
No formal statistical test of hypotheses will be performed for the subgroups, only point estimate 
of the treatment effect and 95%- confidence intervals will be provided (see Section 2.14 for 
further analysis details) . The objective of the efficacy  subgroup analy sis is to demonstrate 
homogeneity  of treatment effect in the above subgroups.
Safety
Subgroup anal yses for select ed safet y endpoints will be defined when required.
Japan -specific subgroup analy ses
Two subgroups will be formed based on geographic region: Japan or other region (this is not 
based on ethinicity ). These subgroup anal yses will be only  used for submission t o Japan health 
authority .
Summary  tables and figures will be presented for the two subgroups for the following outcome 
measures:
Baseline characteristics :Tables of demographics, diagnosis and extent of cancer ,
extramedullary  involvement , bone marrow anal ysis, molecular response, prior TKI 
and non
-TKI, patient disposition, analy sis sets by stratum
Exposure: Tables of duration of exposure , dose received
Tables of c oncomitant medications as well as surgical and medical procedures
PK(only  inasciminib arm): Table and figure of asciminib concentration by time, 
table of asciminib PK parameters (patients with full PK sampling), figure of a verage 
trough asciminib concentration from week 2, 4, 12 and 24 vs. BCR -ABL ratio IS (%)
at 24 weeks
AEs: T ables of a ll AEs, treatment -related AEs, AEs requiring dose adjustment or 
interruption, AEs requiring additional therapies, serious adverse event s (SAEs ), 
adverse eve nts of special interest ( AESIs ), overview table of AEs and death
ECG: Tables of Notable ECG values , change from baseline in ECG parameters values
Lab: Hematology  shift table, biochemistry  shift table
Efficacy : Tables of m olecular response categories at and by  each time point, MMR 
rate at and b y each time point, time to MMR, duration of MMR, c ytogenetic response 
Novartis Confidential Page 29
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
categories at and by each time point , time to CCy R, duration of CCy R, TTF, PFS, OS . 
Figures of cumulative incidence of MMR and of CCy R, association between Week 1 
Day 1BCR -ABL1 gene mutation and clinical outcome .
2.3 Patient disposition, demographics and other baseline 
characteristics
The FAS will be used for all baseline and demographic summaries and listings unless otherwise 
specified. Summaries will be reported b y treatment arm and for all patients ,and listings will be 
reported by treatment arm to assess baseline comparability . No inferential statistics will be 
provided.
Basic demographic and background data
All demographic and baseline disease characteristics data will be summarized and listed by 
treatment arm. Categorical data (e.g. age groups: 18 - <65, 65 - <75, and ≥ 75yearsand 18 -
<65, ≥ 65 years, sex, race, ethnicity , ECOG performance status) will be summarized by 
frequency  counts and percentages ; the number and percentage of patients with missing data will 
be provided. Contin uous data (e.g. age, weight, height, body  mass index ) will be summarized 
by descriptive statistics (N,mean, median, standard deviation, minimum and maximum ), where
BMI (kg/m2) will be calculated as weight[kg] / (height[m]2) using weight at screening .
For the Switch Anal ysis Set, the initial baseline and “baseline_switch” value will be 
summarized. Weight, BMI , age and ECOG performance status will be summarized using the 
“baseline_switch” value defined in Section 2.1.2.
In addition , a summary  table by sex, age group (18 - <65, 65 -<85, and ≥ 85 years)and treatment 
group and another summary  table by race and treatment group will be generated using the safet y 
setfor DSUR/PSUR.
Baseline stratification factors
The number (%) of patients in each stratum ( “Major Cytogenetic Response” or “No Major 
Cytogenetic Response” ) based on data obtained from the IRT system will be summarized 
overall and by treatment arm for the FAS. Discordances between the stratum recorded in IRT 
at the time of randomization and the str atum recorded in the clinical database through the data 
collected on eCRF will be cross -tabulated and listed. In case the baseline bone marrow aspirate 
is missing or not evaluable (i.e. < 20 metaphases), the stratum recorded in the clinical database 
will b e imputed following the rule described in Appendix 5.1. 2.1.
Baseline cytogenetic response and molecular response
Baseline and Baseline_switch will be summarized for cytogenetic response and molecular 
response for the FAS and Switch Analy sis Set respectivel y.
Diagnosis and extent of cancer
All diagnosis and extent of cancer data will be summarized and listed by treatment arm. One
summary  table will include time (years) since initial diagnosis (descriptive statistics with N,
mean, median, standard deviation, minimum and maximum )andhistorical mutation : present 
Novartis Confidential Page 30
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
(unknown, yes, no), historical CML -associated mutation status (E225K, E255V, E355G, etc.)
(frequency  counts and percentages ). Another table will include e xtramedullary involvement : 
any extramedullary  involvement (Yes/No) and location of extramedullary  involvement (Spleen, 
Liver) (frequency  counts and percentages ).
For the Switch Analy sis Set, the above information will be based on the last observation prior 
to the Baseline_switch.
Medical history
Medical history  and ongoing conditions, including cancer -related conditions and symptoms 
entered on eCRF will be summarized and listed by treatment arm. The summar ywill be 
presented by primary  system organ class (SOC), preferred term (PT) and treatment arm. 
Medical history  and current medical conditions will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA) terminology . The MedDRA version used for reporting will 
be specified in the CSR and as a footnote in the applicable tables/listings.
In addition, separate listings will be produced for medical history  possibly  contributing to liver 
dysfunction ,and medical history  of protocol solicited cardi ovascular events .
The cardiovascular risk factors, heav y smoking, low physical activity , unhealthy  diet, and other, 
are collected prior to randomization and the EoT visit. A listing by treatment arm will be 
presented. 
Family  medical history  of each patien t for ischemic heart disease, cardiac arrhythmia, sudden 
death, high cholesterol, diabetes mellitus, heart defects (congenital heart disease), and heart 
failure is also collected prior to randomization and at the EoT visit. A listing by  treatment arm 
will be presented.
Other
All data collected at baseline , including child bearing potential as well as informed consent for 
additional research on study  data and biological samples ,will be listed.
2.3.1 Patient disposition
Enrollment bycountr y and center will besummarized forallscreened patients andalso by 
treatment arm using the FAS. The number (%) of randomized patients included in the FAS will 
be presented overall and by  treatment group. The number (%) of screened and not -randomized 
patients and the reasons for screening failure will also be displayed. The eligibility  criteria will 
be also summarized. The number (%) of patients in the FAS who are still on treatment, who 
discontinued the study  phases and the reason for discontinuation will be presented overal l and 
by treatment group.
The following summaries will be provided (with % based on the total number of FAS patients):
Number (%) of patients who were randomized (based on data from IRT s ystem)
Number (%) of patients who were randomized but not treated (based on DAR eCRF 
page not completed for any  study  treatment component)
Primary  reason for not being treated (based on “End of Treatment P hase Disposition” 
eCRF page)
Novartis Confidential Page 31
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Number (%) of patients who were treat ed (based on DAR eCRF pages of each study  
treatment completed with non-zero dose administered)
Number (%) of 
patient s who are still on -treatment ( based on the “ End of Treatment 
Phase Disposition” page not completed); 
Number (%) of patient s who discontinued the study  treatment phase overall, before 
Week 24,  Week 48 and Week 96 (based on the “ End of Treatment Phase 
Disposition” page) 
Primary  reason for study  treatment phase discontinuation overall, before Week 24,  
Week 48 and Week 96 (based on the “ End of Treatment Phase Disposition” page)
Number (%) of patient s who have entered the survival follow -up (based on the “ End 
of Treatment 
Phase Disposition” page)
Number (%) of patients in the FAS randomized to the bosutinib arm who switched to 
receive asciminib (based on DAR –ABL00 01eCRF page completed with non -zero 
dose administered during the Treatment switch phase );
The following summaries will be provided with % based on the total number patients in the 
Switch Analy sis Set :
Number (%) of patient s who switched from bosutinib arm to receive asciminib and are 
still receiving asciminib (based on the “ End of Treatment Disposition” eCRF not 
completed during the Treatment switch phase );Number (%) of patient s who switched from 
bosutinib arm to receive asciminib and discontinued asci minib (based on the “ End of 
Treatment 
Disposition” eCRF during the Treatment switch phase );
Primary  reason for  treatment switch phase discontinuation (based on the “End of 
Treatment Disposition” eCRF during the Treatment switch phase )
Number (%) of patient s who have entered the survival follow -up (based on the “ End of 
Treatment 
Disposition” eCRF during the Treatment switch phase )
Protocol de viations
The number (%) of patients in the FAS with any protocol deviation during the randomized 
treatment period will be tabulated by deviation category  (as specified in the Study Specification 
Document ) overall and by treatment group for the FAS. All protocol deviations will be listed.
In addition, the number (%) of patients in the FAS with any COVID -19 related protocol 
deviation (COVID -19 specific protocol deviations as well as non -specific COVID -19 protocol 
deviations with a COVID -19 relationship) during the randomized treatment period will be 
tabulated b y deviation category (as specified in the Study Specification Document ) overall and 
by treatment group .The same information will be tabulated for protocol deviations occuring 
during the treatment switch period for the switch analy sis set.
Analysis sets
The number (%) of patients in each anal ysis set (defined in Section 2.2 ) will be summarized  by 
treatment group and stratum. Reasons leading to exclusion from analy sis sets will be listed by 
treatment group and stratum as well as tabulated overall and b y treatment group .
Novartis Confidential Page 32
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
2.4 Treatments (study  treatment, rescue medication, concomitant 
therapies, compliance)
2.4.1 Study treatment / compliance
Duration of exposure, actual cumulative dose, average daily dose, dose intensity  (DI) and 
relative dose intensit y (RDI) will be summarized by treatment arm. Duration of exposure will 
be categorized into time intervals; frequency  counts and percentages will be presented for the 
number (%) of subjects in each interval. The number (%) of subjects who have dose reductions 
or interruptions, and the r easons, will be summarized by treatment group. 
Subject level listings of all doses 
administered on treatment along with dose change reasons 
will be produced.  
The safety  set and Switch Anal ysis Set will be used for all summaries and listings of randomize d 
and switched treatment s respectivel y. 
To summarize exposure data for the randomized treatment period, this will be based on patients 
in the Safet y set with the date of last administration of study  treatment and the date of first 
administration of stud y treatment being FD and LD respectively .
To summarize exposure data for the switched treatment period, this will be based on patients in 
the Switch Anal ysis Set with the date of last administration of  study  treatment and the date of 
first administration of stud y treatment being FD switchand LD switchrespectively.
Duration of exposure to study  treatment
Duration of exposure to study  treatment is considered by taking into account the duration of 
exposure to the investigational drug or control:
Duration of exposure to study treatment (weeks )= ((date of last administration of  study 
treatment) –(date of first administration of study  treatment) + 1) / 7. 
The duration of exposure in patient -years is thetotal of the duration of exposure in years 
from all the patients in a treatment group. 
The date of last administration of study  treatment is defined in Section 2.1.1 .
Summary  of duration of exposure to study treatment will include categorical summaries based 
on intervals (<24 weeks, ≥24 weeks, ≥48 weeks, ≥96 weeks) and continuous summaries (i.e. 
mean, standard deviation etc. ).
Cumulative dose
Cumulative dose of a study  treatment is defined as the total dose given during the study  
treatment 
exposure. 
The planned cumulative dose for a study  treatment refers to the total planned dose as per the 
protocol up to the last date of study  treatment administration. The calculations for the two study 
treatments are:
ABL001: 40 mg/administration × 2 (administration/day ) ×duration of exposure (day ) 
Novartis Confidential Page 33
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Bosutinib:  500 mg/day  × duration of exposure prior to dose escalation (day) 
+ 600 mg/day  
×duration of exposure since dose escalation (day ),
where the starting day  of dose escalation is identified as the first record in the DAR 
eCRF with dose increased and reason “As per protocol ”.
The actual cumulative dose refers to the total actual dose administered, over the duration for 
which the subject is on the study  treatment as documented in the DAR eCRF. It is the sum of 
the non-zero total daily doses recorded over the dosing period. For patients who did not take 
any drug the actual cumulative dose is by  definition equal to zero. The actual cumulative dose 
will be summarized for each of the study  treatment.
Dose intensity  and relative dose intensity
Average Daily Dose (ADD )is defined as:
ADD (mg/day ) = Actual cumulative dose (mg) / Time on treatment (day).
Time on treatment (weeks) = ((date of last administration of  study treatment) –(date of first 
administration of study  treatment) + 1 –number of day s with dose interruption*) / 7
*For subjects in the ascimin ib arm, this includes the half day s before and after the period with 
0 dose if the treatment was interrupted afte r the morning dose and/or resumed in the evening (1 
day record with QD dose administered before or after a record with 0 dose).
Dose intensity (DI) for patients with non- zero duration of exposure is defined as follows: 
DI (mg/day) = Actual c umulative dose (mg) / Duration of exposure to study  treatment ( day).
For patients who did not take any drug the DI is by definition equal to zero. 
Planned dose intensity (PDI ) is defined as:
PDI (mg/day) = Planned cumulative dose ( mg) / Duration of exposure ( day).
Relative dose intensity (RDI) is defined as follows:
RDI = DI ( mg/day)  / PDI ( mg/day ).  
ADD, DI and RDI will be summarized separatel y for the two study  treatment s . 
Dose change s, interruptions or permanent discontinuations
The number of subjects who have dose increase (allowed for bosutinib starting week 8, see 
protocol Section 6.2), dose reductions, dose interruptions or permanent discontinuations
, and 
the reasons, as well as the duration of dose interruption due to any  reason will be summarized 
separately  for the two study  treatment s. For any subjects, duration of dose interruption will be 
calculated b y adding all individual episodes of dose interruption for that pa tient. For subjects in 
the asciminb arm, this includes the half days before and after the period with 0 dose if the 
treatment was interrupted after the morning dose and/or resumed in the evening (1 day record 
with QD dose administered before or after a rec ord with 0 dose) . 
‘Dose Changed’, ‘Dose Interrupted’ and ‘Dose Permanently  Discontinued’ fields from the DAR 
eCRF pages will be used to determine the dose change s, dose interruptions, and permanent 
discontinuations, respectively .
Novartis Confidential Page 34
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
The corresponding fields ‘Reason for Dose Change/ Dose Interrupted’ and ‘Reason for 
Permanent D iscontinuation’ will be used to summarize the reasons.
A dose change occurs when total daily dose is different from the most recently  planned dose.
For patients inasciminib arm, there isonly one planned dose, i.e. 80 mg/day. For patients in 
bosutinib arm, the initial planned dose is 500 mg/day  and could be changed to 600 mg/day  in 
week 8 or later.
For the purpose of summarizing interruptions and reasons, multiple entries for interruption that 
are entered on consecutive days with different reasons will be counted as separate interruptions. 
However, if the reason is the same in th ementioned multiple entries on consecutive day s, then 
it will be counted as one interruption. 
Reduction : A dose change where the actual total daily  dose is lower than the most recently
planned dose. Therefore any dose change to correct a dosing error will not be considered a dose 
reduction. Only dose change is collected in the eCRF, while number of reductio ns will be 
derived programmatically  based on the change and the direction of the change.
Increase : A dose change where the actual total daily  dose is great er than the most recent ly
planned dose. Therefore any dose change to correct a dosing error will not be considered a dose 
increase . Onl y dose change is collected in the eCRF, while number of increase will be derived 
programmaticall y based on the change and the direction of the change.
2.4.2 Prior, concomitant and post therap ies
Prior anti -cancer thera py
The num ber and percentage of patients who received an y prior anti -neoplastic medications will 
be summarized by treatment arm forthelowest anatomical therapeutic classification (ATC )
class andpreferred term. A listing willalso be produced. 
Anti- neoplastic medications will be coded using the WHO Drug Dictionary  (WHO -DD). 
Details regarding WHO -DD version will be included in the footnote in the tables/listings. 
The above anal yses will be performed using the FAS.
The following information will be summarized for the FAS and Switch Analysis Set:
Prior TKI b y medication (e.g. imatinib, dasatinib, nilotinib, ponatinib, bosutinib, etc.) 
Number of prior TKI (e.g. 2, 3, 4, etc.) 
Number of lines of prior TKI therap y (2, 3, 4, 5+)
A new line of therap yis considered each time a change in TKI occured .Multiple entries 
for the same TKI will be counted as separate lines of therap yif a different TKI is received 
between the different entries.
Time on each line of prior TKI therapy (in years)
Time on last 
prior TKI (in years)
Reason to discontinue the most recent TKI therapy  at the time of screening
Prior non- TKI therapies (Yes, No). 
A Sankey -
like plot showing the sequence of prior TKIs will be provided.
Novartis Confidential Page 35
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Note: In case the last TKI given prior to enrollment in the study  was a bridging therapy  (i.e. 
reason for discontinuation includes a wording related to bridging), it will not be considered in 
the analy sis of prior TKIs. I n particular, it will not be considered as the last or most recent TKI 
therap y at the t ime of screening and will not count as an additional line of therapy .
For the Switch Anal ysis Set, bosutinib received during the randomized treatment period and 
other TKIs received since discontinuation of bosutinib and before first administration of 
asciminib ( FD switch) should be considered as prior TKIs.
Post treatment anti -cancer therapy
Anti- neoplastic therapies since discontinuation of study  treatment will be listed and summarized 
by thelowest anatomical therapeutic classification (ATC )class, preferred term, overall and by 
treatment group by means of frequency  counts and percentages using FAS.
Anti- neoplastic medications will be coded using the WHO -DD. Details regarding WHO -DD 
version will be included in the footnote in the tables/listi ngs. 
Concomitant therap ies
Concomitant therap ies aredefined as all interventions (therapeutic treatments and procedures) 
other than the study  treatment administered to a patient coinciding with the study  treatment 
period. Concomitant therap iesinclude medications (other than study  drugs) and medical 
procedures starting on or after the start date of study treatment ,or starting prior to the start date 
of study  treatment and continuing after the start date of study  treatment. 
Concomitant medications will be coded using the World Health Organization (WHO) Drug 
Reference  Listing  (DRL)  dictionary   that  employs  the  WHO  ATC classification system and 
summarized by the lowest ATC class and PTusing frequency  counts and percentages. Surgical 
and medical proc edures will be coded using MedDRA and summarized by SOC and PT . 
The summaries for the on -treatment period using the Safet y Set will includ e:
Therapies starting on or after the start of randomized study  treatment but no later than 
the end of the on-treatment period and
Therapies 
starting prior to start of randomized study  treatment and continuing after 
the start of randomized study  treatment .
These summaries for the on-switched treatment period using the Switch Analy sis Set will 
includ e
:
Medicatio ns starting on or after the start of switched treatment but no later than the 
end of the on- switched treatment period and
Medications starting prior to start of switched treatment and continuing after the start 
of switched treatment .
Allconcomitant therapies will belisted using the Safet y Set. Any concomitant therapies
starting andending prior to thestart ofrandomized study treatment or starting beyond end of 
the on-treatment period if not switched, or starting beyond end of on-switched treatment
period if switched will be flagged in the listin g. 
Novartis Confidential Page 36
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
The prohibited concomitant medications will be summarized by lowest ATC class and preferred 
term up to the end of on -treatment and on -switched treatment periods, respectivel y.Prohibited 
medications will be concomitant medications that led to the protocol deviation “Use of 
prohibited concomitant medication”.
2.5 Analysis of the primary  objective /estimand
In this section, the target edtreatment effect corresponding to the primary  objective as well as 
the primary  objective is clarified using the estimand language.
The primary  clinical question of interest is: Isthe efficacy of asciminib (40 mg bid) superior to 
bosutinib (500 mg qd) in CML  patients in chronic phase, previousl y treated with 2 or more 
tyrosine kinase inhibitors, with regards to achieving MMR at 24 weeks while on study  treatment
and without meeting any  treatment failure criteria (defined in section 5.4.4) prior to 24 weeks, 
regardless of dose 
modification,  dose interruption, or deviation in any intake of concomitant 
medications.
The primary  estimand is described by  the following attributes:
Population: CML  patients in chronic phase, previously  treated with 2 or more tyrosine kinase 
inhibitors. Further details about the population are provided in Section 5 of the protocol .
Endpoint: Major Molecular Response (MMR) achieved at 24 weeks while on study  treatment
without meeting any treatment failure criteria (defined in section 5.4.4) prior to 24 weeks . A 
patient will be counted as having achieved MMR at 24 weeks if he/shemeets 
the MMR criteri on
(BCR -ABL ratio ≤0.1%) at 24 weeks while on study  treatment unless the patient met any 
treatment failure criteria (defined in 
section 5.4.4 ) prior to 24 weeks .
Intercurrent events: 
Treatment discontinuation (i.e. having performed an EOT visit) prior to 24 weeks due to 
any reason (e.g. intolerance, treatment failure, death, etc.) : non response
Meeting any treatment failure criteria (defined in section 5.4.4 ) prior to 24 weeks: non 
response
D
ose modification,  dose interruption, or de viation in any  intake of concomitant 
medications: ignore (treatment policy  strategy )
Treatment of interest: the randomized treatment (the investigational treatment asciminib or the 
control treatment bosutinib) received for at least 24 weeks with or without dose modification, 
dose interruption or deviation in any intake of concomitant medications. Further details about 
the investigational treatment and control treatment are provided in Section 6 of the protocol.
Handling of remaining intercurrent events : noother IE foreseen
The summary  measure: difference in MMR rateand its 95% confidence interval at week 24 
between the two treatment arms .
2.5.1 Primary  endpoint /estimand
The primary  endpoint is Major Molecular Response (MMR) achieved at 24 weeks while on 
study  treatment withoutmeeting an ytreatment failure criteria (defined in section 5.4.4) prior to 
24 weeks . A patient will be counted as having achieved MMR at 24 weeks if he /shemeets the 
Novartis Confidential Page 37
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
MMR criteri on(BCR -ABL ratio ≤0.1%) at 24 weeks while on study  treatment unless the 
patient met an y treatment failure criteria (defined in section 5.4.4 ) prior to 24 weeks .
MMR will be considered as a binary  variable with patients achieving MMR grouped as 
‘responders’ and patients not achieving MMR grouped as ‘non responders’. Only patients with 
MMR at 24 weeks are considered responders. In other words, any  patient who achieves MMR 
before 24 weeks, but is no longer in MM R at 24 weeks, will be considered as a non -responder 
in this primary  analy sis.
Patients discontinuing treatment (i.e. having performed an EOT visit) prior to 24 weeks due to 
any reason (e.g. intolerance, treatment failure, death, etc.) and patients meeting any treatment 
failure criteria (defined in section 5.4.4 ) prior to 24 weeks will be considered as not having 
achieved MMR at 24 weeks.
Details of derivation of Polymerase Chain Reaction (PCR )results and calculation of BCR -ABL 
ratio are presented in Section 5.4 .
2.5.2 Statistical hy pothesis, model, and method of analy sis
The MMR rate at 24 weeks will be calculated based on the FAS and according to the I ntent To
Treat (ITT) principle. MMR rate and its 95% confidence interval based on the Pearson -Clopper 
method will be presented by  treatment group. The 95% confidence interval for the unstratified 
difference in MMR rate between treatment groups will be provided usi ng the Wald method.
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 24 weeks. The Cochrane -Mantel -Haenszel (CMH) chi-square test, stratified by 
the randomization stratification factor, i.e. cytogenetic response status ( MCyR vs no MCy R) at 
screening , will be used to compare MMR rate between the two treatment groups, at the two-
sided 5% level of significance. The Mantel -Haenszel estimate of the common risk difference 
and the corresponding 95% confidence interval will be presented. 
2.5.3 Handling of remaining intercurrent events of primary  estimand
No remaining intercurrent events.
2.5.4 Handling of missing values not related to intercurrent event
Patients with missing PCR evaluations at 24 weeks will be conside red as non-responders. 
However, if the 24-week PCR evaluation is missing, but both a PCR evaluation at 16 weeks 
and a PCR evaluation at 36 weeks indicate MMR, the 24-week assessment is imputed as a 
‘Response’ ,
assuming that MMR is maintained between 16 and 36 weeks.
2.5.5 Sensitivity analy ses
The following sensitivity anal yses will be performed:
The CMH chi-square test of MMR rate at 24 weeks will be repeated stratifying by the 
stratum recorded in the CRF (MCy R vs no MC yRat baseline) .
Due to the C OVID -19 (Coronavirus) pandemic, there is a risk that planned hospital visits 
are cancelled, potentially resulting in missing PCR evaluations. In order to assess the 
impact of C OVID-19 (including potential missing data) on the primary endpoint, the 
Novartis Confidential Page 38
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
CMH chi -square test of MMR rate at 24 weeks will be repeated on the FAS excluding the 
patients with planned 24 -week visit ( start of stud y treatment + 161 day s ) after the start 
date of COVID -19 epi demic. As per Novartis guidance, the start date, in a given country  
or region, is being defined as the approximate time point at which, according to the WHO 
situation reports and the Johns Hopkins database, the number of confirmed COVID -
19 
infections started to increase significantl y (around 100 confirmed cases) and/or 
govern ments started to take measures (such as stay -at-home orders) to contain the
epide mic, whichever occurred first (China: January  1, 2020; South Korea: February  20, 
2020; Japan: February  21, 2020; I taly: February  23, 2020 and Rest of the World: March 1, 
2020).
The CMH chi-square test of MMR rate at 24 weeks will be repeated without the 
imputation rule used in the main anal ysis in case of missing PCR evaluations at 24 weeks.
2.5.6 Supplementary  analyses
Additional supplemental logistic regression and subgroup analyses are described in Section 
2.14.
Assess whether the efficacy of asciminib (40 mg bid) is superior to bosutinib (500 mg qd) in 
CML  patients in chronic phase, without T315I or V299L  mutation detected at Week 1 Day 1 
visit and previously  treated with 2 or more tyrosine kinase inhibitors, with regards to achieving 
MMR at 24 weeks while on study  treatment and without meeting any  treatment failure criteria 
(defined in section 5.4.4) prior to 24 weeks, regardless of dose modification,  dose interruption, 
or deviation in an y intake of concomitant medications.
The corresponding estimand attributes are the same as the ones of the primary  estimand except 
that the population excludes patients detected with T315I  or V299L  at Week 1 Day  1 visit (As 
per protocol, these patients were discontinued from study  treatment when the mutation results 
became available ). 
The CMH chi-
square testof MMR rate at 24weeks will be repeated on the FAS excluding 
patients detected with T315I  or V299L at Week 1 Day  1visit.
2.6 Analysis of the key  secondary  
objective /estimand
The key secondary clinical question of interest is: Isthe efficacy of asciminib (40 mg bid) 
superior to bosutinib (500 mg qd) in CML patients in chronic phase, previously  treated with 2 
or more tyrosine kinase inhibitors, with regards to achieving MMR at 96weeks while on stud y 
treatment and without meeting any treatment failure criteria (defined in section 5.4.4 ) prior to 
96 weeks, regardless of dose modification,  dose interruption, or deviation in any intake of 
concomitant medications.
The key secondary estimand is described b y the following attributes:
Population: CML  patients in chronic phase, previously  treated with 2 or more tyrosine kinase 
inhibitors. Further details about the population are provided in Section 5 of the protocol .
Endpoint: Major Molecular Response (MMR) achieved at 96 weeks while being treated without 
meeting any treatment failure criteria (defined in section 5.4.4) prior to 96 weeks . A patient will 
be counted as having achieved MMR at 96weeks if he/she meets the MMR criteri on(BCR -
Novartis Confidential Page 39
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
ABL ratio ≤0.1%) at 96weeks while on study  treatment unless the patient met any treatment 
failure criteria (defined in section 5.4.4 ) prior to 96 weeks . 
Intercurrent events: 
Treatment dis continuation (i.e. having performed an EOT visit) prior to 96weeks due to 
any reason (e.g. intolerance, treatment failure, death, etc.): non response
Meeting an y treatment failure criteria (defined in section 5.4.4) prior to 96 weeks: non 
response
Dose modification,  dose interruption, or deviation in any  intake of concomitant 
medications
: ignore (treatment policy  strategy )
Treatment of interest: the randomized treatment (the investigational treatment asciminib or the 
control treatment bosutinib) received for at least 96 weeks with or without dose modification, 
dose interruption or deviation in any intake of concomitant medications. Further details about 
the investigational treatment and control treatme nt are provided in Section 6 of the protocol.
Handling of remaining intercurrent events : no other IE foreseen
The summary  measure: difference in MMR rateand its 95% confidence interval at week 96 
between the two treatment arms
The analy sis of the key secondary  objective will be performed at the time of the 96-week 
analysis.
2.6.1 Key secondary  endpoint /estimand
The key secondary  endpoint is MMR achieved at 96 weeks while on study  treatment without 
meeting any treatment failure criteria (defined in section 5.4.4) prior to96 weeks .A patient will 
be coun ted as having achieved MMR at 96weeks if he/she meets the MMR criteri on(BCR -
ABL ratio ≤0.1%) at 96weeks while on study  treatment unless the patient met any treatment 
failure criteria (defined in section 5.4.4 ) prior to 96 weeks .
MMR will be considered as a binary  variable with patients achieving MMR grouped as 
‘responders’ and patients not achieving MMR g rouped as ‘non responders’. Only patients with 
MMR at 96weeks are considered responders. In other words, any  patient who achieves MMR 
before 96weeks, but is no longer in MMR at 96weeks, will be considered as a non -responder 
in this key secondary analy sis.
Patients discontinuing treatment (i.e. having performed an EOT visit) prior to 96weeks due to 
any reason (e.g. intolerance, treatment failure, death, etc.) and patients meeting any treatment 
failure criteria (defined in section 5.4.4) prior to 96weeks will be considered as not having 
achieved MMR at 96 weeks.
2.6.2 Statistical hy pothesis, model, and method of analy sis
The null hypothesis is that there is no difference between the treatment groups with respect to 
MMR rate at 96 weeks. Following a gatekeeping procedure to control the overall alpha level , 
only if the primary  endpoint is significant , formal statistical testing of the key secondary 
endpoint with two-sided 5% level of significance will be performed using the CMH chi -square 
Novartis Confidential Page 40
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
test, stratified by the randomization stratification factor, i.e. cytogenetic response status (MCyR 
vs no MCy R) at screening .
MMR rate and its 95% confidence interval based on the Pearson- Clopper method will be 
presented by treatment group. The 95% confidence interval for the difference in MMR rate 
between treatment groups will be provided using the Wald method. The Mantel -Haenszel 
estimate of the common risk difference and the corresponding 95% confid ence interval will 
also be presented.
2.6.3 Handling of remaining intercurrent events of primary  estimand
No remaining intercurrent events.
2.6.4 Handling of missing values not related to intercurrent event
Patients with missing PCR evaluations at 96 weeks will be considered as non-responders. 
However, ifthe 96-week PCR evaluation is missing, but both a PCR evaluation at 84 weeks 
and a PCR evaluation at 108 weeks indicate MMR, the 96-week assessment is imputed as a 
‘Response’, assuming that MMR is maintained between 84 and 108 weeks.
2.6.5 Sensitivity analy sis
In order to assess the impact of COVID -
19 (including potential missing data )on the key  
secondary  endpoint , the CMH chi-square test of MMR rate at 96 weeks will be repeated 
on the FAS excluding the patients with planned 96- week visit (start of stud y treatment + 
665 day s) between the start date of the COVID -19 epid
emic (China: January  1, 2020; 
South Korea: February  20, 2020; Japan: February  21, 2020; I taly: February 23, 2020 and 
Rest of the World: March 1, 2020) and itsend date (to be defined in the future). 
The CMH chi-square test of MMR rate at 96 weeks will be repeated without the 
imputation rule used in the main anal ysis in case of missing PCR evaluations at 96 weeks.
2.7 Analysis of secondary  efficacy  objective (s)
The other secondary  efficacy  objective is to compare additional parameters (defined below) of 
the efficacy  ofasciminib versus bosutinib .
2.7.1 Secondary  endpoints
2.7.1.1 Molecular response
MMR ratesat all scheduled data collection tim e points, i.e., the protocol -planned visits 
except for 24 weeks and 96 weeks which are alread y covered by primary and key secondary 
endpoints. Such rates are defined as the proportion of patients with MMR atthe respective time 
points.
MMR ratesby all scheduled data collection time points, i.e., the protocol -planned visits .
These are cumulative MMR rates by time points and are defined as the proportion of patients 
who achieve MMR at or before specified visits, i.e. if a patient achieves an MMR but then loses 
it before or at a specific visit, he/she will still be classed as achieving MMR by that specific 
time point.
Novartis Confidential Page 41
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Molecular response category at specific time points, i.e., the protocol -planned visits. 
Categories of molecular response are defined in Appen dix. 
Molecular response category by specific time points , i.e., the protocol -planned visits. This is 
defined as the best (lowest) molecular response category  up to the specific time points.
Time to MMR (in weeks) is defined as: (date of first documented MMR -date of randomization 
+ 1)/ 7.
Duration of MMR is defined for patients in the MMR Responder Set as the time between the 
date of the first documented MMR and the end date of MMR, i.e. the earliest date of confirmed 
loss of MMR, progression to accelerated phase ( AP)/blast crisis ( BC), or CML -related death . 
Loss of MMR and progression to accelerated phase (AP)/blast crisis (BC) are defined in 
Appendix .
For patients for whom none of the events above is reported , the duration will be censored (see 
Section 2.7.3). The duration of MMR (in weeks) is calculated as: (end date or censoring date of 
MMR -date of first MMR +
1)/7.
2.7.1.2 Cytogenetic response
At ea
ch assessment time point the cytogenetic response status of each patient is classified as 
complete, partial, major, minor, minimal response and none(a review of a minimum of 20 
metaphases is required) :
Complete response (CCyR) :0% Philadelphia chromosome positive (Ph+)metaphases
Partial respons e(PCyR):>0 to 35% Ph+ metaphases
Major response (MCy R= CCy R + PCy R): 0 to 35% Ph+ metaphases
Minor response (mCyR) :>35 to 65% Ph+ metaphases
Minimal response: >65 to 95% Ph+ metaphases
None :>95 to 100% Ph+ metaphases.
As per protocol, bone marrow aspirate for cytogenetic analyses will be performed as long as 
subjects have not achieved MMR. Therefore, in case no bone marrow aspirate was performed 
but the subject is in MMR at a specific time-point, the subject is consider ed to have achieved
CCyR atthat time-point. The date of CCyR is imputed by the date of MMR at the same 
scheduled time -point.
CCyR rates at all scheduled data collection time points, i.e., the protocol -planned visits . 
Such rates are defined as the proporti on of patients in CCyR atthe respective time points among 
patients in the CCy R Analy sis Set, which excludes patients who are in CCy R at baseline .
CCyR ratesby all scheduled data collection time points ,i.e., the protocol -planned visits .
Such rates are defined as the proportion of patients who achieve CCyR at or before the 
respective time points among patients in the CCyR Analy sis Set .
Cytogenetic response category at specific time points, i.e., the protocol -planned visits. At 
each assess ment time point the cytogenetic response status of each patient is classified as 
complete, partial, major, minor, minimal response and none (a review of a minimum of 20 
metaphase is required) as defined in Appendix.
Novartis Confidential Page 42
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Cytogenetic response category by specifi c time points, i.e., the protocol -planned visits. This 
is defined as the best (lowest) cy togenetic response category  up to the specific time points.
Time to CCyR (in weeks) is defined for patients as: (date of first documented CCyR -date of 
randomization + 1)/7.
Duration of CCyR is defined for patients in the CCyRResponder Set as the time between date 
of first documented CCyR and the end date of CCyR, i.e. the earliest date of loss of CCyR, 
progression to AP/BC, or CML -
related death. Loss of CCyR and progression to AP/BC are 
defined in Appendix. For patients for whom none of the events above is reported , the duration
will be censored (see Section 2.7.3). The duration of CCyR (in w eeks) is calculated as: (end
date or censoring date of CCy R -date of first CCyR + 1)/7.
2.7.1.3
Other secondary  efficacy  endpoints
Time to treatment failure (TTF) is defined for patients in FAS as the time from date of 
randomization to an event of treatment failure. The events thatconstitute ‘treatment failure’ are 
described in the Appendix. They are based on the ELN criteria [Baccarani et al. 2013] defining 
failure of a second line treatment adapted to include discontinuation of randomized treatment 
as an event .
TTF (in months) is calculated as: (date of treatment failure or censoring date (see Section 2.7.3) 
-date of 
randomization + 1)/30.4375.
Progression -Free -Survival (PFS) is defined for patients in FAS 
as the time from the date of 
randomization to the earliest occurrence of documented disease progression to AP/BC or the 
date of death from any cause (including progressions and deaths observed during the survival 
follow -up period). 
PFS (in months) is calculated as: (date of disease progression/death or censoring date (see 
Section 2.7.3) -date of randomization + 1)/30.4375 .
Overall survival (OS) is defined for patients in FAS as the time from the date of randomization 
to the date of death (including 
the survival follow -up period).
OS (in months) is calculated as: (date of death or censoring date (see Section 2.7.3) -date of 
randomization +
1)/30.4375, regardless whether the patient switched from bosutinib to 
asciminib .
2.7.2 Statistical hy pothesis, model, and method of analy sis
No confirmatory  statistical testing of non- key secondary  efficacy  endpoints will be performed, 
however ,
nominal p -value swill be presented for exploratory  purposes (as specified in protocol 
Section 10.5.2)
.
MMR rates at and by  time points
The FAS will be used for these endpoints. For each time point the MMR rate and the associated 
95% confidence interval based on the Pearson -Clopper method will be presented by  treatment 
group. The descriptive p-value obtained via CMH chi-square tests stratified by the 
randomization strata ,i.e. MCyR vs no MCy R at screening , will be presented .A 95% confidence 
Novartis Confidential Page 43
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
interval for the difference in each MMR rate between treatment groups will be provided using 
the Wald method. The Mantel -Haenszel estimate of the common risk difference and the 
corresponding 95% confidence interval will also be provided .
A post-hoc analysis of the MMR rate will beperformed using the number of subjects with 
adequate follow -up as the denominator . Subjects will be included in the analysis at a timepoint 
whenever their time between the date of randomization and the cut-off date is equal or above 
this timepoint, regardless of whether they  discontinued before.
The cumulative incidence of MMR by treatment group will be graphically  display ed by an 
increasing step function. Each curve will increase each time (after randomization) at which a 
new responder is observed and thus will increase up to the best observed response rate (e.g. up 
to 50% if half of the patients in the anal ysis population are able to achieve MMR ).
Molecular response at and by  time points
Frequency  and percentage of all molecular response categories (defined 
in Appendix ) by 
treatment arm using FAS will be presented for each time point.
For the b y-time-points summary , the within -patient best molecular response category  up to the 
specific time poi nts is used to calculate the frequency and percentage.
Time to MMR
The MMR Responder Setwill be used. Descriptive statistics (minimum, maximum , median, 
quartiles, mean, sd) of time to MMR will be provided for the two treatment groups separately .
The FAS will be also used to perform similar Time -to-Event analy ses as described below for 
duration of MMR.
A post-hoc a nalysis of time to MMR will also be performed considering discontinuation from 
treatment due to an y reason, without prior achievement of MMR as acompeting risk.
Time to MMR will be censored at the last molecular assessment (PCR) date on treatment prior 
to or at the cut -off date, if no events/competing risk occurred before or at the cut- off date or the 
EOT. 
The estimated cumulative incidence rates and 95% confidence intervals at 12, 24, 48, 72 and 
96 weeks will be presented for each treatment group. The cumulative incidence curve will be 
plotted. 
Duration of MMR
The MMRResponder Setwill be used. The surviv al distribution of duration of MMR will be 
estimated using the Kaplan -Meier method, and Kaplan -Meier curves, medians and 95% 
confidence intervals [Brookmey er and Crowley  1982]of the medians, along with the proportion 
of patients who are still in MMR at 24, 48, 72 and 96 weeks and the associated 95% confidence 
intervals
, will be presented for each treatment group.
CCyR rates at and by time points
The CCyR Anal ysis Set will be used for these endpoints. 
Novartis Confidential Page 44
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
For each time point the CCyR rate and the associated 95% confidence interval based on the 
Pearson -Clopper method will be presented by treatment group. The descriptive p-value 
obtained via CMH chi-square tests stratified by the randomization strata ,i.e. MCyR vs no 
MCy R at screening , will be presented .A 95% confidence interval for the difference in each
CCyR rate between treatment groups will be provided using the Wald method. The Mantel -
Haenszel estimate of the common 
risk difference and the corresponding 95% confidence 
interval will also be provided.
The cumulative incidence of CCyR by treatment group will be graphically  display ed by an 
increasing step function. Each curve will increase each time (after randomization) at which a 
new responder is observed and thus will increase up to the best observed r esponse rate (e.g. up 
to 50% if half of the patients in the anal ysis population are able to achieve CCyR).
Cytogenetic response at and by  time points
Frequency  and percentage of all cytogenetic response categories (defined in Section 2.7.1.2) by 
treatment arm using FAS will be presented for each time point. A shift table comparing baseline 
and best post -baseline cytogenetic response categories by treatment will also be presented. All 
assessments of cy togenet ic response categories will also be listed by  treatment arm.
For the by-time-points summary , the within -patient best cytogenetic response category  up to 
the specific time points is used to calculate the frequency  and percentage.
Assessments of bone marrow aspirate at different time points will also be summarized.
Time to CCyR
The CCyRResponder Setwill be used. Descriptive statistics (minimum, maximum , median, 
quartiles, mean, sd) of time to CCyR will be provided for the two treatment groups separately .
The CCyR analysis set will be also used to perform similar Time -to-Event analy ses as described 
below for duration of CCyR. 
Duration of CCyR
The CCyRResponder Setwill be used. The survival distribution of duration of CCy
R will be 
estimated using the Kaplan -Meier method, and Kaplan -Meier curves, medians and 95% 
confidence intervals [Brookmey er and Crowley  1982]of the medians, along with the proportion 
of patients who are still in CCyRat 24, 48, 72 and 96 weeks and the associated 95% confidence 
intervals, w ill be presented for each treatment group.
TTF, PFS and O
S
For each endpoint t he survival distribution will be estimated using the Kaplan -Meier method, 
and Kaplan -Meier curves, medians and 95% confidence intervals [Brookmey er and Crowle y 
1982] of the medians, along with the proportion of patients who have not experienced the 
respective events at 1, 3 and 5 years and the associated 95% confidence intervals, will be 
presented for each treatment group. The hazard ratio between the two treatments will be 
calculated, along with its 95% confidence interval, using a stratified Cox model. The descriptive 
p-value obtained using astratified log-rank testwill be also presented. The stratification will be 
Novartis Confidential Page 45
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
based on the randomization stratification factor, i.e. cytogenetic response status (MCyR vs no 
MCy R) at screening .
2.7.3 Handling of missing values/censoring/discontinuations
MMR rate sat specific time points :Patients discontinuing the randomized treatment prior to 
a specific time point due to any  reason or patients without an available assessment at that time 
point will be considered as non -responders for that time point.
MMR rate s by specific time points : 
Patients without any documented response for which an evaluable response assessment was 
never provided will be considered as non-responders for the period of time up to that time point.
Molecular response atspecific time points :The category  “Missing” will be assigned to
Ongoing cases, i.e. patients 
without assessment at the specific time point who have 
not discontinued study  treatment and have not been treated sufficientl y long for a 
specific time point
Discontinued due to progressive disease /death prior to a specific time point
Discontinued due to other reasons prior to a specific time point
Molecular response category byspecific time points: The category  “Missing” will be 
assigned to p atients for whom an evaluable respons e assessment was never provided.
Time to MMR : For patients in the FAS who have not experienced an y MMR, the time will be 
censored as follows in the Kaplan- Meier anal ysis:
If a patient does not achieve the specified response before the cut -off date for the 
analysis,censoring time will be the last molecular assessment (PCR) date on treatment
prior to the cut -off date or the EoT visit, whichever comes first.
If a pat ient discontinues study  treatment prior to achieving a response for a reason 
other than disease progression or death, then the patient will be censored at the last 
molecular assessment (PCR) date on treatment prior to the cut -off date or the EoT 
visit, whichever comes first.
If a pat ient discontinues study  treatment prior to achieving a response due to 
progression or death, then the censoring time will be set to the longest follow -up time 
in the treatment group , that i s, consider the response is impossible to reach.
In case no on -treatment response assessment was performed, the patient will be 
censored at day  1.
Duration of MMR : For patients in the MMR responder set who have not experienced any event 
(loss of MMR, prog ression to AP/BC, or CML -related death ),the duration will be censored at 
the last molecular assessment (PCR) date on treatment.
CCyR rates at specific time points :Patients discontinuing the randomized treatment prior to 
a specific time point due to any reason will be considered as non -responders for that time point .
CCyR rates by specific time points: This will be handled similarly  as MMR, but with CCy R 
instead.
Novartis Confidential Page 46
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Cytogenetic response at specific time points: This will be handled similarly  as molecular 
response category .
Cytogenetic response category byspecific time points: This will be handled similarly  as 
molecular response category .
Time to CCyR : For patients in the CCyR analy sis setwho have not experienced any CCyR, 
the time will be censored in the same manner as Time to MMR.
Duration of CCyR: For patients in the CCyR responder set who have not experienced any 
event (loss of CCyR, progression to AP/BC, or CML -related death )the duration will be 
censored at the last cytogenetic assessment date on treatment or the last PCR evaluation on 
treatment indicating MMR, whichever is the latest . 
TTF :For patients in the FAS who have not reach edtreatment failure, their TTFs will be 
censored at the time of their last study  assessment (PCR, cytogenetic, hematologic or 
extramedullary ) before the cut- off date .
PFS:For patients who have not experienced an event (disease progression to AP/BC or death 
from any cause ), their PFS times will be censored at the date of last study  assessment (PCR, 
cytogenetic, hematologic or extramedullary )before the cut-off date, regardless of subsequent 
intake of treatment(s) after randomization .
OS:Patients who are alive at the time of the analy sis data cutoff date will be censored at the 
date of last contact (see Section 2.1.1) before the cut-off date,regardless of subsequent intake 
of treatment(s) after randomization
.
2.8 Safet y analyses
All safety  analyses will be based on the safety  set, except that the summary of safet y data during 
the switched treatment period will be based on the Switch Analy sis Set . All listings and tables 
will be presented b y treatment group.
2.8.1 Adverse events (A Es)
AE summaries will include all AEs occurring during the on-treatment period (or the on-
switched treatment period) . All AEs collected in the AE eCRF page will be listed along with 
the information collected on those AEs e.g. AE relationship to study  drug, AE outcome
,etc. 
AEs with start date outside of the on-t reatment period will be flagged in the listings.
AEs will be summarized by  number and percentage of subjects having at least one AE, having 
at least one AE in each primary  system organ class (SOC) and for each preferred term (PT) 
using MedDRA coding. A subject with multiple occurrences of an AE will be counted only 
once in the respective AE category . A subject with multiple CTCAE grades or the same 
preferred term will be summarized under the maximum CTCAE grade recorded for the event.
AE with missing CTCAE grade will be included in the ‘All grades’ column of the summary 
tables.
In AE summaries, the primary  system organ class will be presented alphabeticall y and the 
preferred terms will be sorted within primary  SOC in descending frequency . The sort ingorder 
for the preferred term will be based on their frequency  in the asciminib arm.
Novartis Confidential Page 47
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
The followi ng adverse event summaries will be produced by treatment armfor the Safet y set 
and Switch Analy sis Set:overview of adverse events and deaths, AEs by SOC and PT,
summari zedby relationship, seriousness, leading to treatment discontinuation, leading to dos e 
interruption/adjustment, requiring additional therapy ,and leading to fatal outcome. The study 
treatment -related AEs/SAEs/AEs leading to treatment discontinuation as well as SAE with fatal 
outcome are summarized for the Safet y set and Switch Anal ysis set. 
For posting to ClinTrial.gov and EudraCT , a summary table of on -treatment deaths and serious 
AEs and another summary  table of non serious AEs by treatment, both including occurrences 
(an occurrence is defined as >1 day between start and prior end date of record of same preferred 
term) and sorted b y SOC and PT, will be presented as well.
In order to account for differences in exposure between the treatment arms, incidence rates of 
AEs and SAEs will be presented by  adjusting for duration 
of treatment perio d in patient -years. 
They  will also be reported by time intervals (i.e. period of emergence : the event is assigned to 
the interval when it first started) : 0 to 2months, > 2months to 6 months, > 6 months to 12 
months, 
>12 months and more after the start of study  treatment . 
2.8.1.1 Adverse events of special interest / grouping of A Es
Data analy sis of AESIs
An adverse event of special interest (AESI) is a grouping of adverse events that are of scientific 
and medical concern specific to compound asciminib . These groupings are defined using 
MedDRA terms, SMQs (standardized MedDRA queries), HLGTs (high level group terms), 
HLT (high level terms) and PTs (preferred terms). Customized SMQs (Novartis MedDRA 
queries, NMQ) may also be used. A NMQ is a custo mized group of search terms which defines 
a medical concept for which there is no official SMQ available or the available SMQ does not 
completely  fit the need. It may  include a combination of single terms and/or an existing SMQ, 
narrow or broad. The latest approved version of CRS prior to the respective database lock will 
be used.
For each specified AESI, number and percentage of patients with at least one event of the AESI 
occurring during the on-treatment period (or the on-switched treatment period) will be 
summarized.
Summaries of these AESI s will be provided by treatment arm (specify ing grade, SAE, 
relationship, leading to treatment discontinuation, leading to dose adjustment/interruption, 
death ,etc.).If sufficient number of events occurred, analysis o f time to first occurrence will be 
applied.
A listing of all grouping levels down to the MedDRA PTs used to define each AESI will be 
generated.
2.8.2 Deaths
Separate 
summaries for on-treatment and all deaths (including post-treatment death s)will be 
produced on the Safet y set by  treatment arm, s ystem organ class and preferred term. 
Similarly , a separate summary  for on-switched treatment deaths will be produced on the Switch 
Analy sis Set.
Novartis Confidential Page 48
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
All deaths will be listed, where deaths occurring during the post-treatm ent, the on-switched 
treatment or post -switched treatment periods will be flagged.
A separate listing of deaths prior 
to starting treatment will be provided for all screened subjects.
2.8.3 Laboratory  data
Grading of laboratory  values will be assigned programmat ically  as per National Cancer Institute 
(NCI)Common Terminology  Criteria for Adverse Events (CTCAE) version 4.03.  The 
calculation of CTCAE grades will be based on the observed laboratory  values only, clinical 
assessments will not be taken into account.
CTCAE Grade 0 will be assigned for all non-missing 
values not graded as 1 or higher. Grade 5 will not be used. Details of CTC AEgrading and 
imputation rules are presented in Appendix 5.3
.
For laboratory  tests where grades are not defined by  CTCAE v4.03, results will be categorized 
as low/normal/high based on laboratory  normal ranges.
On anal yzing laboratory  data ,all sources (central and local laboratories) will be combined. The 
summaries will include allassessments available for the 
lab parameter collected no later than
30days after the last study  treatment administration date.
The following summaries will be produced on the Safet y set separatel y for hematology  and 
biochemistry  laboratory  data (by  labor atory  parameter and treatment ):
Worst post -baseline CTC AEgrade (regardless of the baseline status). Each subject will be 
counted only for the worst grade observed post -baseline in the on-treatment period.
Shift tables using CTC AEgrades to compare baseline to the worst on- treatment value . 
For laboratory  tests where CTC AEgrades are not defined, shift tables using the 
low/normal/high/(low and high) classification to compare baseline to the worst on-
treatment value.
The same summar ies will be produced on the Switch Anal ysis Set for the on-switched treatment 
period.
The following listings will be produced separately  for hematology  and biochemistry  for the 
laboratory  data:
Listing sof all 
laboratory data, with CTC AEgrades and classif ication relative to the 
laboratory  normal range. Lab data collected during the post -treatment period willbe 
flagged .
Listing of all CTC AEgrade 3 or 4 laboratory  toxicities
Liver function parameters
Liver function parameters of interest are total bilirubi n(TBL), Alanine aminotransferase
(ALT), Aspartate aminotransferase ( AST )and alkaline phosphatase (ALP). The number (%)
of patients with worst post -baseline values as per Novartis DILI Clinical safety  guidelines will 
be summarized for the criteria defined by single lab parameter. For combination of various 
parameters, the worst post-baseline values from each single parameter are taken into 
consideration, i.e. it may  not come from the concurrent measurement (i.e. same assessment). :
The following summaries will be produced:
Novartis Confidential Page 49
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
ALT or AST > 3x upper limit of norm ( ULN)
ALT or AST > 5xULN
ALT or AST > 10xULN
ALT or AST > 20xULN
TBL > 2xULN
TBL > 3xULN
ALT or AST > 3xULN & TBL > 2xULN
ALT or AST > 3xULN & TBL > 2xULN & AL P >=2xUL N
ALT or AST > 3xULN & TBL > 2xULN & AL P < 2xUL N  
2.8.4 Other safety  data
2.8.4.1 ECG and cardiac imaging data
12-lead ECGs including PR, QRS, QT, QTcF and RR intervals will be obtained centrall y for 
each subject during the study . ECG data will be read and interpreted centrally . 
The echocardiogram will be performed and evaluated locall y to assess the left ventricular 
ejection fraction (LVEF) .
Data handling
The average of the triplicate ECG parameters at each time point will be used in the anal yses.
For unscheduled visits, ECGs that are reported on the same day and within 30 minutes apart 
from each other will be assumed to be sequential ECGs and thus will be used to compute the 
mean of the ECG parameters.
Unscheduled ECG measurements will not be used in computing the summary  statistics for 
change from Baseline at each post-baseline time point. However, they will be used in the outlier 
analyses 
(e.g. QTc >450 ms, > 480 ms,or >500 ms at any time point, or an increase from 
Baseline in QTc > 30 ms or > 60 ms). End of treatment ECG measurements for discontinued 
patients will be considered as an unscheduled measurement in case it occurs outside a schedule d 
visit.
Data analy sis
The number and percentage of subjects with notable ECG values will be presented by treatment 
armfor the Safet y set and Switched Anal ysis Set . Notable values are defined below:
QT, QTcF
New value of > 450 and ≤ 480 ms
New value of > 480 and ≤ 500 ms
New value of > 500 ms
Increase from Baseline of > 30 ms to ≤  60ms
Increase from Baseline of > 60 ms
HR
Novartis Confidential Page 50
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Increase from baseline >25% and to a value > 100 bpm
Decrease from baseline >25% and to a value < 50 bpm
PR
Increase from baseline >25% and  to a value > 200 ms
New value of > 200 ms
QRS
Increase from baseline >25% and  to a value > 120 ms
New values of QRS > 120 ms
A listing of all ECG assessments will be produced by treatment arm and notable values will be 
flagged . A separate listing of only the subjects with notable ECG values willalso be produced.
In each listing the assessments collected during the post -treatment period willbe flagged.
Change from baseline ECG parameters b y timepoint will also be summariz ed by  treatment.
A listing of all LVEF assessments will be produced by treatment arm. In the listing, the 
assessments collected outside of on- treatment period will be flagged.
A summary  table by  treatment arm with descriptive statistics for LVEF at different timepoints
(baseline, week 20) and for change from baseline will be presented. A shift table for LVE F 
categories (
≤40%, 41-49%, ≥50%) at baseline versus worst value on treatment will also be 
presented.
2.8.4.2 Cardiovascular risk factor assessment
Prior to randomization and at the end of treatment, for each patient information of the following 
risk factors is collected: heav y smoking, low physical activity , unhealthy  diet, and other . A 
listing by  treatment arm will be presented. 
Family  medical history  of each patient for ischemic heart disease, cardiac arrhythmia, sudden 
death, high cholesterol, diabetes mellitus, heart defects (congenital heart disease), and heart 
failure is also collected prior to randomization and at the end of treatment .A listing by treatment 
arm will be presented.
2.8.4.3 Vital signs
Vital sign assessments are performed in order to characterize basic body  function. The 
following parameters were collected: height (cm), weight (kg), body  temperature (°C), heart 
rate (beats per minute), systolic and diastolic blood pressure (mmHg).
Data handling
Vital signs collected on treatment will be summarized. Values measured outside of on treatment 
period will be flagged in the listings.
Novartis Confidential Page 51
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Data analy sis
The number and percentage of subjects with notable vital sign values (high/low) in systolic 
blood pressure, diastolic blood pressure, pulse rate,weight and temperature will be presented 
by treatment arm.         
A listing of all vital sign assessments will be produced by treatment arm and notable values will 
be flagged. In the listing, the assessments collected outside of on-treatment period will be 
flagged. 
2.8.4.4 Liver events
There are separate eCRF pages to collect acetaminophen/paracetamol, autoimmune, drug use 6 
months prior to liver event, immunoglobulin, liver function tests, pathology , related imaging, 
viral serology  andpotential impact of alcohol use, and an overview eCRF page. Data on the 
overview e
CRF pag ewill be listed by treatment arm. A ssessments collected during the post-
treatment period willbe flagged.
2.8.4.5 Pulmonary  function tests
Data o f pulmonary  function tests will be listed by  treatment arm. Assessments collected during 
the post -treatment period willbeflagged .
2.8.5 Additional Analyses
2.8.5.1 ECOG performance status
ECOG performance status collected on treatment will be summarized. Shift tables will be 
provided comparing baseline with best and worst values during study for each treatment group.
2.9 Pharmacokinetic endpoints
PK parameters
The PK parameters that will be determined are shown inTable 2-7. The PK param eters for
asciminib are derived based on the non-compartmental methods using Phoenix WinNonlin®
software version 6.4in patients with full PK sampling in PAS .
Novartis Confidential Page 52
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Table 2-7 Non-compartmental PK parameters for asciminib in full PK group
AUC 0-12h The area under the plasma concentration -time curve from time zero to 12 
hours (ng*hr*mL-
1)
AUClast The AUC from time zero to the last measurable plasma concentration 
sampling time ( Tlast) (ng*hr*mL-1)
CtroughTrough plasma concentration (measured concentration at the end of a 
dosing interval at stead y state [taken directl y before next administration])
Cmax The maximum (peak) observed plasma concentration after dose 
administration (ng/mL)
Tmax The time to reach maximum (peak) plasma concentration after dose 
administration (hr)
Tlast The time to reach the last measurable plasma concentration after dose 
administration (hr)
CL/F The total apparent body clearance of drug from the plasma after oral 
administration (L *hr-1)
Descriptive statistics (n, arithmetic mean, CV% mean, standard deviation (SD) ,median, 
geometric mean, CV% geo- mean, minimum and maximum) will be presented by treatment for 
PASfor 
all PK parameters defined in Table 2 -7except Tmax, where only n, medi an, minimum 
and maximum will be presented. 
All individual PK parameters will be listed for patients treated with asciminib and with full PK 
sampling in the safety  set.
PK concentrations 
Descriptive statistics ( n, m (number of non -zero concentrations), arithmetic mean, CV% mean, 
SD,median, geometric mean, CV% geo-mean, minimum and maximum ) forasciminib
concentration will be presented at each scheduled time point for the PAS.
The mean (+/-SD) and geometric mean concentration -time profiles forasciminib over time will 
be display ed graphically  forPAS on the linear and semi -log view (Week 2 Day  1; for patients 
with full PK sampling only )
.
The mean (±SD) and median Ctrough values of asciminib over time will be display ed 
graphicall yfor PAS on the linear scale onl y (Patients with full and sparse PK sampling ).
All individual plasma asciminib concentration data will be listed forpatients treated with
asciminib inthe Safety  Set.
Handling of PK data below LLOQ or missing
All c oncentration values below the lower limit of quantitation (LLO Q, 1 ng/mL ) are set to zero 
by the Bioanaly st, and will be display ed in the listings as zero and flagged. LLOQ values will 
be treated as zero in any calculations of summary  statistics, and treated as missing for the 
Novartis Confidential Page 53
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
calcula tion of the geometric means and their CV%. The number of non-zero concentrations will 
also be reported in the summary  statistics.
Missing values for an y PK data will not be imputed and will be treated as missing.
2.10 PD and PK/PD analyses
The potential relationship between asciminib exposure (e.g. trough concentration) and efficacy ,
pharmacod ynamics (PD) or safet y endpoints may be assessed by graphic exploration and/or 
statistical modeling ,as appropriate ,including effect of population covariates. Additional 
exposure -response analyses for ECG may be conducted. The concentration data may be 
analyzed by  a population approach to evaluate the influence of covariates on drug exposure. If 
applicable, the details of the above -mentioned analy ses will be described in a separate analysis 
plan and reported separately .
The relationship between average trough plasma concentration up to 24 weeks and BCR-ABL 
ratio I S (%) at 24 weeks will be assessed by  graphic exploration. 
2.11 Patient-reported outcomes
The FAS will be used for analy zing PRO data unless specified differentl y. The MDASI CML, 
PGIC along with EQ-5D- 5L will be used to assess patient’s disease -related symptoms and 
health- related qualit y of life from baseline to EOT ; and the WPAI -CML will be us ed to assess 
work productivity  and activity  impairment related to the patient’s CML. All tools require 
patient’s direct completion and will be administered utilizing electronic device for data 
collection at scheduled time points from screening to end of tr eatment .
The baseline is defined in Section 2.1.1 . Patients with an evaluable baseline score and at least 
one evaluable post-baseline score during the treatment period will be included in the change 
from b aseline anal yses. Missing data items in a scale will be handled according to the manual 
for each instrument. No imputation will be applied if the total or subscale scores are missing 
at a visit. All measures will assess differences between the treatment ar ms.
Compliance to the schedule of administration of each PRO questionnaire will be summarized 
by treatment group, forbaseline and scheduled post-baseline assessment time points. The 
following categories, as collected on the eCRF, will be used to describe whether the 
questionnaire was completed at a specific time point:
1.yes, fully  completed
2.yes, partl y completed
3. no
Repeated measures model for continuous scores
Tobest utilize the repeated assessments of a given PRO score , a repeate d measures model for 
longitudinal data will be used toestimate differences between treatment arms. This repeated 
measures model will include terms for treatment, the stratification factor (major cytogenetic 
response status) , time, baseline value as main e ffects, and an interaction term for treatment b y 
time. 
This analy sis will be restricted to patients with an evaluable baseline score and at least 
Novartis Confidential Page 54
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
one evaluable post-baseline score. All data collected until end of treatment (including the end 
of treatment assessment) will be included in the analy sis. Note thatonly data collected under 
treatment (i.e. while the patient is treated) will be included. The end of treatment assessment 
will be included if collected within 7 day s of the last dose intake.
Time willbe considered as a contin uous variable expressed in weeks , i.e. considering 
thatthe 
PRO score follow a linear trend.
As a first approach, an unstructured correlation matrix will be used to model the correlation 
within patients. The structure of the corre lation matrix will be investigated and simplified using 
likelihood ratio tested if appropriate.
2.11.1 MDASI-CML
The M.D. Anderson Symptom Inventory  –Chronic Myeloid Leukemia (MDASI -CML)
questionnaire isplanned to be administered during screening, at weeks 4, 8, 12, 16, 24, 36, 48 
and 96 after randomization.
The MDASI -CML is a 26 item self-administered questionnaire for adult CML  patients. Twent y 
of the items measure the severit y of disease -related symptoms and are scored from 0 (Not 
present) to 10 (As bad as you can imagine) and 6 items that measure symptom interference with 
daily  life scored from 0 (Did not interfere) to 10 (Interfered completel y). 
The severit y score will be calculated when a patient s
cores at least 11 items out of the 20 
severit y items using the formula: (sum of scores for the items answered) / (number of items 
answered ).If a patient scores fewer than 11 items, the severit y score will be missing.
The interference score will be calcula ted when a patient scores at least 4 items out of the 6 
interference items using the formula: (sum of scores for the items answered) / (number of 
items answered ).If a patient scores fewer than 4 items, the interference score will be missing.
For the sever ity score and interference score , descriptive statistics (n, mean, SD, median, 25th 
and 75th percentiles) by treatment arm will be provided for the actual scores and change sfrom 
baseline scores at each scheduled assessment time point.
Between -treatment differences for the change in severit y and interference score s will be 
evaluated using the above -mentioned repeated measures model . 
2.11.2 EQ-5D-5L
EQ-5D- 5L is a two-part standardized instrument for measuring health outcomes in a wide range 
of health conditions and treatments. It consists of a descriptive system and a visual analogue 
scale (EQ VAS). The descriptive system comprises the following 5 dimensions: mobility , self -
care, usual activities, pain/discomfort and anxiety
/depression. Each dimension has 5 levels: no 
problems, slight problems, moderate problems, severe problems and extreme problems (or 
unable to perform the activity ). The EQ VAS records the respondent’s self-rated health on a 
vertical, visual analogue scale where the endpoints are labeled ‘Best imaginable health state’ 
and ‘worst imaginable health state’.
The EQ-5D- 5L data will be used to calcutae utility  values forthe economic evaluation of
asciminib and bosutinib i n a sepa rate anal ysis.
Novartis Confidential Page 55
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
The EQ -5D- 5L questionnaire is planned to be administered during screening, at weeks 4, 8, 12, 
16, 24, 36, 48 and 96 after randomization .
Descriptive sy stem
The number and percentage of subjects in the five levels of each EQ-5D demension will be 
presented b y treatment group at each assessment time point .
EQ VA S
The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale from 
0, labeled as ‘worst imaginable health state’, to 100, labeled as ‘best imaginable health state’.
For the EQ VAS, descriptive statistics (n, mean, SD, median, 25th and 75th percentiles) by 
treatment arm will be provided for actual values and forthe change from baseline at each 
assessment 
time point.
Between -treatment differences for the change sin EQ VAS score will be evaluated using the 
above -mentioned repeated measures model .
2.11.3 WPA I-CML
The Work Productivity  and Activity  Impairment Questionnaire –Chronic Myeloid Leukemia
(WPAI -CML ) questionnaire is planned to be administered during screening, at weeks 4, 12, 24, 
48 and 96 after randomization .
The WPAI -CMLis a six-item questionnaire which is intended to measure work and activit y 
impairment associated with CML  for those who self-identify  as currentl y employ ed for pay. 
This questionnaire measures self-reported productivity  loss associated with CML during the 
past seven days. It consists of questions about absence from work due to CML , hours spent at 
work, the reduction in productivity  at work attributed to CML , and the reduction in productivity 
while performing regular activities. WPAI -CML outcomes are expre ssed as impairment 
percentages, with higher numbers indicating greater impairment and less productivity , i.e., 
worse outcomes .Scoring will be done according to WPAI -CML instrument guidance resulting 
in four scores including: Percent work time missed due to problem; percent impairment while 
working due to problem; Percent overall work impairment due to problem; and, percent activ ity 
impairment due to problem.
Descriptive statistics (n, mean, SD, median, 25th and 75th percentiles) for each of the four 
derived outcome scores and change sfrom baseline scores will be presented by treatment arm 
ateach scheduled assessment time point with .
Between -treatment differences for the change sin each of the four outcome scores will be 
evaluated using the above -mentioned repeated measures model . 
2.11.4 PGIC
The Patient Global Impression of Change (PGIC ) instrument i s planned to be administered 
during at weeks 4, 8, 12, 16, 24, 36, 48 and 96 after randomization
The PGICis compr ised of a single question intended to measure a patient’s perspective of 
improvement or deterioration over time relative to treatment. The PGIC uses a seven -point scale 
Novartis Confidential Page 56
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
where one (1) equals very much improved and seven (7) equals very much worse. Missing 
values will not be imputed.
The number and percentage of subjects 
in each of the seven categories for PGIC will be 
presented b y treatment group at each assessment time point .
2.12 Resource utilization
Data relating to resource utilization (described in trial protocol Section 7.2.5) from the FAS will 
be used for the purpose of economic evaluation ,which will be carried out and reported as a 
separate activity  outside the CSR . 
The measures of healthcare resource utilization (HCRU) include: hospitalization (H), 
emergency  
room (ER) visit, general practitioner (GP) visits, specialist (Sp) visit and urgent care 
(UC) visit. HCRUwill be assessed as follows: frequency  and duration of hospitalization from 
baseline up to end of treatment ; frequency  of emergency room visi ts from baseline up to end of 
treatment ; frequency  of additional outpatient office visits general practitioner, specialist, and 
urgent care visits from baseline up to e nd of treatment . Hospitalization visits will also record 
the number of days on ward and the type of ward (hospital unit) and the discharge status. At 
each HCRU collected, the reason for the visit, i.e. related to CML, AE related to CML therapy  
or other reason, will be collected, in order to quantify  the impact of treatment on healthcare 
resou rces.
HCRU data by treatment arm will be summarized in the primary  analysis CSR and the end of 
study  treatment CSR, with descriptive statistics (n, mean, median, SD, min, max) for 
quantitative variables ,and count and percentage for qualitative variables .
2.13 Biomarkers
Asa
projec t standa rd,Novartiswillanalyze onl y biom arke rsc oll ected inthe clinical da tabase.
For ex ploratory ma rkers,since thestudies a renot adequa tel y po wered to assess specific
biomarker-related hy pothes es,thegoal of these e xploratorystatistical analyse s should be
considered as thegeneration of new sc ientific h ypothes es. Noadjustment formultiple
compa risons isusual ly planned for exploratory analyses. Fu rth ermore , addit ional post hoc
e
xploratory assessments areexpected and may beperfor med.
Therem
aybecircumstances when  a decis i on ismade tostop sample coll ection, or not 
perform or discontinue the ira nalysisdue toe ither p ractical or strategicreasons. Und e r such 
circumstance s,thenumber of sam ples may be inadequa te to perfor m a rigo rous da taa naly sis 
and the 
availa bledata will onlybe listed and potentially summa rized.
If not otherwise specified, the FASwillbe used for allbiomarker analyses on patie nts with 
biomar k er data.
Exploratory  biom
arkerobjectives
To characterize mutations in the BCR-ABL1 gene at Week 1 Day  1, upon confirmed 
loss of molecular response and/orat end of treatment and examine their association 
with molecular and cy togenetic r esponse for asciminib vs bosutinib
Novartis Confidential Page 57
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
To understand biology  of CML  and bone marrow microenvironment on leukemic 
stem cells (L SCs) eradication, including patients’ immunogenicit y
To assess clonal evolution during trea tment with asciminib vs. bosutinib
To evaluate soluble /inflammatory factors that correlate with respons e toasciminib vs. 
bosutinib treatment 
Only  some analyses for the first exploratory  biomarker objective about BCR-ABL1 mutation
listed above are described here and the results will be included in the respective CSRs. 
Additional analyses for this and other exploratory biomarker objectives will bedescribed in 
separate analy ses plans, w i
th results reported separa tely.
List ofbiom arkersevaluated a ndthecollection timepoints
The biomarkers evaluated in the study  are listed in Table 2-8 below.
Table 2-8 Sample biomarker summary  table
Biom arker Timep
oint Sample Method
Immune markers PD -L1 
and CD8Screening and 
end of treatmentBone marrow biops y Immunohisto -
chemistry
Leukemic stem cells
characterizationScreening, week 
24 and end of 
treatmentBone marrow aspirate Flow c ytometry
BCR -ABL1 gene mutation W1D1 pre-dose 
and end of 
treatment . If 
mutation is 
present at 
baseline, then 
also ever y 12 
weeks after 
baselinePeripheral blood Sanger 
Sequencing
Low level mutations in 
BCR -ABL1geneW1D1 pre-dose 
and end of 
treatmentPeripheral blood Mass 
spectrometry  
and NGS
Circulating cytokines in 
plasmaW1D1 pre -dose,
Week 48 and end 
of treatmentPeripheral blood MSD and ELISA
Genetic variant analysis of 
the UGT 2B7 and 
UGT2B17 geneW1D1 Peripheral blood Genechip
General data handling and preprocessing
For bone marrow samples the latest assessment during screening period will be used as the 
baseline value, while for blood samples the week 1 day  1 (W1D1) pre -dose assessment willbe
used as the baseline va lue.
Novartis Confidential Page 58
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Whenmore than onebiomarker da tav a lueare availa bleforasubjec t at an y timepoint,the 
mean of thereplicate va lues will be us ed for allstatistical analyse s.
2.13.1 Somatic mutation biomarker data handling and analy sis
Handli ng of somaticbiom ark
er data
Overall, somatic mutationstatus (wild ty pe or mutant) will be derivedfromthe mutationa l 
status oftheint
errogated exons fortheBCR -ABL1 gene by Sanger Sequencing .Thesemay
be non-exc lus ive and the p resence of mutation ac ross more than one exon will bereported in 
separate categori es.
Muta tion summary statistics
Allsomatic mutation data willbe reported using counts and pe rcentages b y themutation ty pe 
intheform of contingency ta bles with therows c ontaining thedifferent mutations a ssayed, 
and the treatment g roups inthe columns.Allthemutation categoriesfora gene will also be
aggreg a tedintomutant,wild type or missing/unknown groups and c ounts/pe rcentages willbe
reported b y thesethree categor iesas w ell. A summary  table will be presented for baseline 
mutations and another summary  table for post-baseline new mutations (not present at baseline) .
All themutation da ta will be listed for eac h subj ect ordered by tr eatment group.
Association be tweenbiom arkers a ndclinicaloutcome
This analy sisdoes not a djust formultiplecomp arisons and re sultsmay have higher fals e 
posit iverates.
The r elationship b etweenWeek 1 Day  1 BCR -ABL1 gene mutation data(wild ty pe or muta nt)
a
nd outcome data(with or without MMR atand by24 and 96 weeks using FAS, with or without 
CCyR at and by 
24 and 96 weeks using CCyR analysis set)will be explored b y reporti ng
contingency table s and by applying a logistic regression including treatment group, Week 1 
Day 1 BCR -
ABL1 gene mutation and their interaction as covariates . Treatment group willbe
includ ed in this summary table.
In addition, the same analy sis will be perform edfor
the relationship b etweenpost-baseline new BCR -ABL1 mutation (with or without 
new mutation) up to 48 weeks and outcome d ata(with or without MMR at 48 and 96 
weeks using FAS, with or without CCy R at 48 and 96 weeks using CCy Ranalysis 
set).
the relationship b etweenpost-baseline new BCR -ABL1 mutation (with or without 
new mutation) up to end of treatment and outcome d ata(with or without MMR at 96 
weeks using FAS, with or without CCy R at 96 weeks using CCy R anal ysis set).
The odds ratios bewteen treatment groups with 95% confidence intervals willbe reporte d, for 
each biomark ercategor y and ov erall. If treatme nt by biomarkerinteractionis significant (e.g.
when p < 0.1), overa llodds ratio for tr eatment will not be re ported.
Novartis Confidential Page 59
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
2.14 Other e xploratory  analy ses
MMR rate at 24 weeks
The FAS will be used for the following exploratory  analy ses:
1.A logistic regression model adjusted for the stratification factor (based on the 
randomization platform data IRT) will be fit to assess treatment effect. An adjusted 
odds ratio for the treatment effect with associated 95% confidence intervals will be 
presented. Mantel -Haenszel estimates of the common odds ratio and the 
corresponding 95% confidence interval will also be provided.
Some subje cts were mistratified . To assess the impact of this mistratification on the 
treatment effect assessment, alogistic regression adjusting for major cy togenetic
status at baseline based on CRF data will also be run .
2.Based on the subgroups specified in Section 2.2.1, the following analyses will be 
performed for each subgroup:
Proportion of patients with MMR at 24 weeks and its 95% confidence interval 
based on the Pearson -Clopper method within each treatment g roup
The difference in MMR rate at 24 weeks between treatment groups and the 
corresponding Wald 95% confidence interval
Efficacy  anal yses in subgroups will be purel y exploratory  and are intended to explore the 
consistency  of treatment effect. Forest plot ( n, risk difference, Wald 95% confidence 
interval ) will be produced to graphicall y depict the treatment effect estimates in 
different subgroups. No inferential statistics (p -values) will be produced for the 
subgroups.
Post-hoc exploration of the treatment e ffect in different subgroups and assessment of 
the possible effect of differences in distribution of baseline characteristics were 
conducted (e.g. distribution of reasons for discontinuation of last prior TKI by  gender 
and treatment, distribution of MCy R status at baseline by
 reasons for discontinuation 
of last prior TKI, distribution of mutation status at Week 1 Day  1 by  reasons for 
discontinuation of last prior TKI).
3.A logistic regression model adjusted for the stratification factor (baseline major 
cytogenetic response status based on randomization data ) and other important 
variables identified b y the subgroup anal yses above will be fit to assess treatment 
effect. An adjusted odds ratio for the treatment effect with associated 95% confidence 
interval s will be presented.
To assess the impact of mistratifications on the treatment effect assessment, the same 
analysis will be repeated, adjusting for major cy togenetic status at baseline based on 
CRF data instead of based on randomization data.
Novartis Confidential Page 60
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Influence of early  molecular response levels on long term molecular response 
levels
The r elationship betwee nMMR status at 24 weeks and MMR status at 48 and 96 weeks willbe 
exploredusing FAS by reporting contingency  tables and by applying a logistic regression
including treatment group, MMR status at 24 weeks and their interaction as covariates . 
T
reatment group will beinclud ed in this summary table. The odds ratios between treatment 
groups with 95% confidence intervals willbe repo rte d, for each categor y of MMR status at 24 
weeks a
nd overall. If the interaction of tre atme nt byMMR status at 24 weeks is significant
(e.g. when p < 0.1), overa llodds ratio for tr eatment will not be re ported.
Efficacy  Analysis on Switch A nalysis Set
Efficacy  analyses on the Switch Analy sis Set will be performed at the time of the 96-week 
analysis. Unless otherwise specified, endpoints are defined and anal yzed similarly  as specified 
in Sections 2.5, 2.6, and 2.7 
on Switch Analy sis Set, but with baseline, FD, LD, and EoT 
replaced by baseline_switch, FD switch, LD switch, and S-EoT. The below are the efficacy  endpoints 
to be anal yzed:
MMR rate at and b y all protocol -planned visits. 
CCyR rate at and by  all protocol -planned visits. 
Time to MMR
Duration of MMR
Time to CCy R
Duration of CCy R
Time to Treatment Failure
The analysis of time-to-event endpoints will be conducted only if at least 5 events are observed.
2.15 Interim analy sis
No formal interim anal ysis is planned for this trial.
Three to four analyses areplanned with the analy sis data cut-off dates and the scope of analyses 
as follows :
24-week Primary analysis :Formal testing of the primary  endpoint with full alpha will be 
performed. Anal yses of other efficacy  endpoints at and by  24 weeks will also be 
performed.
96-week analysis : Formal statistical testing of the key secondary endpoint will be 
performed with = 0.05 (two
-sided) onl y if the primary endpoint (i.e. MMR rate at 24 
weeks) is significant. Otherwise, no statistical testing will be performed, and any  anal ysis
will be considered exploratory . Anal yses of other efficacy  endpoints will also be 
performed.
End of study treatment (EO sT) analysis (if required) :similar to the 96 -week anal ysis 
without formal statistical testing.
NOTE: This anal ysis may  be conducted at the same time as 96- week analy sis.
Novartis Confidential Page 61
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
5-year PFS/OS update analysis :PFS and OS .
In addition, DMC s afety analyses will be conducted . Prior to the database lock for the primary 
analysis, tables and figures aggregated by  treatment arm for safety  data review by  the DMC or 
for other reporting activities will be produced by an independent statistician and independent 
statistical programmers.
3 Sample size calculation
3.1 Primary  analy sis
To test the null hypothesis that the MMR rateat 24 weeks is equal in the two treatment arms, 
based on  two -sided 5% level of significance and with 90% power, 222 patients will be needed 
in total (i.e. 148 patients in the asciminib arm and 74 patients in the bosutinib arm based on 2:1 
randomization allocation). The calculations were made using the software package PASS 
(2008).
It is assume dthatasciminib leads to a 20% improvement in the MMR rate at 24 weeks over 
bosutinib from 15% to 35% which corresponds to an odds ratio of 3.05. The assumed bosutinib
MMR rate of 15% at 24 weeks is based on previous trials evaluating bosutinib therap y ([Kuour y 
et al. 2012] , [Gambacorti -Passerini et al. 2014] , [García -Gutiérrez et al. 2015] ).
3.2 Power for analy sis of key
 secondary  variables
If the primary  analysis of MMR rate at 24 weeks is statistically  significant, then the key 
secondary  endpoint MMR rate at 96 weeks will be tested, with the overall alpha controlled at 
the 5% two- sided level using a gatekeeping strategy .
Table 3-1 below summarizes the treatment effects of the key  secondary  endpoint which can be 
detected with 80% and 90% power , based on the specified assumptions regarding the bosutinib 
effect. The calculations were made using the software package PASS (20 08).
Table 3-1 Detectable effect sizes for key  secondary  endpoint
Endpoint Anticipated effect 
with bosutinib2-sided alpha Power Detectable 
effect size§
MMR rate at 96 weeks 30%*0.05 90%
80%≥ 23%
≥ 20%
*:[Gambacorti -Passerini et al. 2014], Figure 1D.
§: Absolute difference from the anticipated effect with bosutinib.
For MMR rate at 96 weeks, if the anticipated effect with bosutinib is 30%, then the given sample 
size with 2 -sided alpha=0.05 would allow to detect an absolute difference of at least 23% (i.e. 
MMR rate at 96 weeks with asciminib is at least 53%) for 90% power and of at least 20% (i.e. 
MMR rate at 96 weeks with asciminib is at least 50%) for 80% power.
4 Change to protocol specified analyses
Pharmacokinetic analysis set: Removal of the condition related to vomiting to consider a 
concentration evaluable as the occurrence and time of vomiting is not collected in the CRF .
Novartis Confidential Page 62
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
The estimand langage was implemented in sections 2.5 and 2.6. Then, the PPS and analy ses 
based on PPS were removed.
The subgroup considering historical BCR -ABL1 mutations was removed as not considered 
clinically  relevant.
A definition for loss of CHR was provi ded.
Definition of loss of MMR: removed any reference to confirmation of CHR and CCyR as 
confirmation of CHR and CCyR was not mandated by protocol and was therefore not performed 
in practise.
The following anal yses were added:
ECOG status, time to event analyses for duration of MMR and CCyR, exposure adjusted AE 
incidence and yearly AE incidence , COVID -19 related sensitivity  analy ses. 
5 Appendix
5.1 Imputation rules
5.1.1 Study drug
The following rulesshould be used for the imputation of the dose end date for a given study 
treatment component.
Scenario 1: I f the dose end date is completely  missing and there is no EOT page and no death 
date, the patient is considered as on -going: 
The patient should be treated as on-going and the cut-off date should be used as the dose end 
date. 
Scenario 2: If the dose end date is completel y missing and the EOT page is available:
The EOT completion date should be used.  
All other cases should be considered as a data issue and the statistician should contact 
the data manager of the study .
After imputation, compare the imputed date with start date of treatment, if the 
imputed da te is < start date of treatment:
Use the treatment start date
Patients with missing start dates are to be considered missing for all study  treatment component 
related calculations and no imputation will be made. If start date is missing then end-date should 
not be imputed.
5.1.2 AE, ConMeds and safety  assessment date imputation
The imputations specified in this section are only used for analyses of time to and duration of 
AEs and concomitant medications. 
Novartis Confidential Page 63
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Table 5-1 Imputation of start dates (A E, CM) and assessments (LB, EG, VS)
Missing 
ElementRule
day, month, 
and y earNo imputation will be done for completely  missing dates
day, month If available year = year of study  treatment start date then 
oIf stop date contains a full date and stop date is earlier than 
study  treatment start date then set start date = 01JanYYYY
oElse set start date = stud y treatment start date. 
If available year > year of study  treatment start date then 01JanYYYY
If availabl e year < year of study  treatment start date then 01JulYYYY
day If available month and year = month and year of study  treatment start 
date then 
oIf stop date contains a full date and stop date is earlier than 
study  treatment start date then set start date= 01MONYYYY. 
oElse set start date = stud y treatment start date.
If available month and year > month and year of study  treatment start 
date then 01 MONYYYY  
If available month and year < month year of stud y treatment start date 
then 15MONYYYY  
Table 5-2 Imputation of end dates (A E, CM) 
Missing 
ElementRule
(*=last treatment date plus 30days not > (death date, cut -off date, 
withdraw al of consent date))
day, month, 
and y earCompletely  missing end dates (incl. ongoing events) will be imputed 
by the end date of the on -treatment period* 
day, month If partial end date contains y ear onl y, set end date = earliest of 
31DecYYYY or end date of the on -treatment period * 
day If partial end date contains month and y ear, set end date = earliest of 
last day  of the month or end date of the on -treatment period *
Any AEs and ConMeds with partial/missing dates wil l be displayed as such in the data listings .
Any AEs and ConMeds which are continuing as per data cut-off will be shown as ‘ongoing’ 
rather than the end date provided. 
Novartis Confidential Page 64
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
5.1.2.1 Other imputations
Incomplete date of initial diagnosis of cancer 
Missing day is defaul ted to the 15thof the month and missing month and day is defaulted to 01 -
Jan. 
Stratum reported in the CRF
This will be derived from the Bone Marrow Aspirate data recorded in the corresponding eCRF
pages at baseline. In some case the baseline sample may be missing or not evaluable (i.e. <20 
metaphases). 
The following imputation rule will be applied to derive the missing or non evaluable values:
Major cytogenetic response (MCy R)(0 to 35% Ph+ metaphases )will be assumed if
BCR -ABL1 levels ≤10% (I S).
Rationale :
ELN 2013 recommendations are providing treatment milestones with response categories for 
cytogenetic and molecular response, which we can refer to for the imputation:
MCy R is roughl y corresponding to BCR -ABL1 levels ≤10% (IS) (Ross et al 2009) .
5.2 AEs coding/grading
Adverse events are coded using the latest available version of Medical dictionary  for regulatory 
activities (MedDRA) terminology .
AEs will be assessed according to the Common Terminology  Criteria for Adverse Events 
(CTCAE) version 4.03. 
The CTCAE represents a comprehensive grading system for reporting the acute and late effects 
of cancer treatments. 
CTCAE grading is by definition a 5-point scale generally  corresponding 
to mild, moderate, severe, life threatening, and death. This grading system inherently  places a 
value on the importance of an event, although there is not necessaril y proportionality  among 
grades (a grade 2 is not nece ssarily  twice as bad as a grade 1). 
5.3 Laboratory  parameters derivations
Grade categorization of lab values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) version 4.03.The calculation of CTCAE 
grades will be based on the observed laboratory  values only, clinical assessments will not be 
taken into account. The criteria to assign CTCAE grades are given in Novartis internal criteria 

Novartis Confidential Page 65
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
for CTCAE grading of laboratory  parameters (embedded below) . The latest available version 
of the document based on the underly ing CTCAE version v4.03 at the time of analysis will be 
used. For laboratory  tests where grades are not defined by CTCAE v4.03, results will be graded 
by the low/normal/high (or other project -specific range s, if more suitable) classifications based 
on laboratory  normal ranges.
A severity  grade of 0 will be assigned for all non -missing lab values not graded as 1 or higher. 
Grade 5 will not be used. For laboratory  tests that are graded for both low and high values, 
summaries will be done separately  and labelled by direction, e.g., sodium will be summarized 
as hy
ponatremia and hy pernatremia.
EASE LAB - CTC 
grades in Novartis On  
Imputation Rules  
Hematology
Immature cells (prom yelocytes, my elocy tes, metamy elocy tes and blasts) will not be display ed 
in shift tables and will only  be listed.
Immature cells are manually  counted only if anomalies are detected during the automatic testing. 
Therefore, when the automatic testing was performed but no data is transferred for immature 
cells, this means there was no immature cells and theirvalue scan be imputed to 0. Note that 
there should not be any imputation in case the automatic testing was not performed or the test 
of immature cells is present with missing value in the data base (this would mean the test was to 
be performed but couldn’t).
CTC AEgrading for blood differentials is based on absolute values. However,  this data may 
not be reported as absolute counts but rather as percentage of white blood cells ( WBC ). 
If laboratory  values are provided as ‘<X’ (i.e. below limit of detection) or ‘>X’ , prior to 
conversion of laboratory  values to SI  unit, these numeric values are set to X. 
The following rules will be applied to derive the WBC differential counts when only 
percentages are available for a xxx differential
xxx count = (WBC count) * (xxx %value / 100)
The following rules will be applied to derive the WBC differential percentages when only 
differential counts are available for a xxx differential
xxx %value = (xxx count  100) / WBC count
Further derivation of laboratory  parameters might be required for CTCAE grading. For instance, 
corrected calcium can be derived using the reported total calcium value and albumin at the same 
assessment using the following fo rmula:
Corrected Calcium (mmol/ L) = Calcium (m mol/L) +0.02 (40 – [Albumin (g/L )]
Novartis Confidential Page 66
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
For calculation of laboratory  CTCAEgrades 0 and 1, the normal range for derived corrected 
calcium is set to the same limits (in mmol /L) as for calcium.
CTC AEgrades for the derived absolute WBC differential counts (neutrophils, lymphocy tes) 
and corrected calcium will be assigned as described above for grading .
Biochemistry
In order to avoid double reporting of the same information, all available values for BUN and 
UREA will be reported under the parameter name BUN (mmol/L) in listing using the following 
conversion rule: UREA (mmol/L)=2.14 BUN (mmol/L) ( [Lamb E et al 2012] ) . 
5.4 Efficacy  variables
5.4.1 Molecular response
Scaling towards an international standard will beperformed for all molecular results using 
laboratory  specific conversion factors. In this process, the raw ratio between BCR -ABL and the 
control gene ABL  is calculated and multiplied by  the lab -specific conversion factor ( [Branford 
and Hughes 2006] ). Therefore, using the international unit, the BCR -ABL ratio will be 
presented in %. The MRDx assay  using PAXgeneTMBlood RNA tubes from MMD laborator y 
will be used in this study . The lab conversion factor for this assay  was1.1until 1 June 2020 and 
1 there after.  
The BCR -ABL  ratio in IS % is calculated by m ultiply ingthe raw BCR -ABL ratio with the lab -
specific conversion factor and then b y 100: 
BCR -ABL ratio (in %) = ( BCR -
ABL / ABL) * conversion factor * 100
The BCR -ABL ratio in IS% provided by the centra l laboratory  will be use in the analyses. 
However, to calculate the fold change in BCR -ABL1/ABL used to derive the loss of MMR 
criteria, in case the BCR -ABL number of copies is reported as a 0 value and the patient doesn’t 
have atypical transcript at basel ine, then the value will be replaced by 1, and the BCR -ABL 
ratio will be calculated.
Molecular response is categorized as follows:
10% >BCR -ABL ratio
1% < BCR -ABL ratio ≤ 10%
0.1% < BCR -ABL ratio ≤ 1%
0.01% < BCR -ABL ratio ≤ 0.1%
0.0032% < BCR -ABL ratio ≤ 0.01%
BCR -ABL ratio 
≤ 0.0032%
Major molecular response (MMR)
Major molecular response (MMR) is defined as a value of ≤ 0.1% of BCR -ABL ratio on the IS. 
This endpoint corresponds to a ≥ 3 log reduction in BCR -ABL transcripts from a standardized 
baseline value for untreated CML  patients which was established in the IRIS study 
(STI5710106) . MMR will be considered as a binary  variable with patients achieving MMR 
Novartis Confidential Page 67
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
grouped as ‘responders’ and patients not achieving MMR or patients with missing PCR 
evaluations grouped as ‘non- responders’.
Loss of MMR
Loss of MMR is defined as an 
increase in BCR -ABL1/ABL  to > 0.1% by international scale 
(IS) in association with a ≥ 5-fold rise in BCR -ABL1 /ABL from the lowest value achieved up 
to that time point on study  treatment and replicated by a second analy sis of the same sample. 
Loss of MMR must be confirmed by a subsequent sample analysis within 4-6 weeks showing 
loss of MMR associated with a ≥ 5-fold rise in BCR -ABL1 /ABL from the lowest value achieved
up to that time point on study  treatment.
If there is any assessment in between indicating a BCR -ABL ratio of ≤ 0.1% or a < 5
-fold 
increase in BCR -ABL ratio from the lowest value achieved up to that time point on study  
treatment, then the initial indication of loss of MMR canno t be confirmed. However, an 
assessment indicating (unconfirmed) loss of MMR will be considered as confirmed loss of 
MMR if the patient had loss of CHR or loss of complete cytogenetic response (CCyR) after the 
achievement of MMR. CML -related death or progression to AP or BC will be considered as 
confirmed loss of MMR in any case (if they occurred on treatment) (given that the patient 
achieved prior MMR). 
5.4.2 Cytogenetic response
Cytogenetic response will be based on the percentage of Ph+ metaphases in the bone marrow. 
Cytogenetic evaluations will be considered for response assessment only if the number of 
metaphases examined is ≥20 in each bone marrow sample . As per protocol, f luorescent in-situ
hybridization (FISH) assessments will not be considered for any evaluation of cytogenetic 
response during treatment.
Cytogenetic response is categorized as follows (a review of a minimum of 20 metaphase sis 
required):
Complete response (CCyR) :0% Philadelphia chromosome positive (Ph+)metaphases
Partial response (PCyR):>0 to 35% Ph+ metaphases
Major response (MCy R= CCy R + PCy R): 0 to 35% Ph+ metaphases
Minor response (mCyR) :>35 to 65% Ph+ metaphases
Minimal response: >65 to 95% Ph+ metaphases
None :>95 to 100% Ph+ metaphases.
If bone marrow aspirate blast percentage is provided as ‘<X’ (i.e. below limit of detection), the 
numeric value isset to X for summary  tables. In the listing ‘<X’ will be presented.
Complete cy togenetic response (CCy R)
CCyR is defined as a value of 0% Ph+ metaphases in bone marrow.
CCyR will be considered as a binary  variable with patients achieving CCyR grouped as 
‘responders’ and patients not achieving CCyR, patients with missing cytogenetic evaluations 
grouped as ‘non -responders’.
Novartis Confidential Page 68
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Loss of CCyR
Loss of CC yR is defined as an increas e in the Ph+ bone marrow cells to > 0%.
Loss of CC yR must have led to treatment discontinuation because of lack of efficacy ( based on 
the “End of Treatment Phase Disposition” eCRF or “End of Treatment Disposition” eCRF 
during the Treatment switch phase with Subject status=”lack of efficacy ” and Reason of 
treatment failure = “After start of therap y, loss of CHR, CCy R or PCy R”).
In addition, CML -related death or progression to AP or BC will be considered as loss of CCyR 
in any  case (if they  occurred on treat ment) .
Major cytogenetic response (MCyR)
MCy R is defined as a value of 0% to 35% Ph+ metaphases in bone marrow.
MCyR will be considered as a binary  variable with patients achieving MCyRgrouped as 
‘responders’ and patients not achieving MCyR, patients with missing cytogenetic evaluations 
grouped as ‘non -responders’.
Loss of MCy Ris defined as an increase in the Ph+ bone marrow cells to > 35%. For patients 
with response = PCy R, this would constitute loss of PCy R.
CML -related death or progre ssion to AP or BC will be considered as confirmed loss of MCy R
in any  case (if they  occurred on treatment) .
5.4.3 Hematologic response
Loss of CHR
Loss of CHR isdefined by  meeting any  of the following :
WBC count > 20 × 109/L
Platelet count ≥ 600 × 109/L
Appearance of blasts or promy elocy tes in peripheral blood
Appearance of m yeloc ytes + metam yeloc ytes ≥ 5% in peripheral blood
Progressive splenomegaly refractory  to therapy (i.e. ≥5cm below left intercostal margin) 
Loss of CHR must have ledto treatment d iscontinu ation because of lack of efficacy  (based on 
the “End of Treatment Phase Disposition” eCRF or “End of Treatment Disposition” eCRF 
during the Treatment switch phase with Subject status=”lack of efficacy ” and Reason of 
treatment failure = “After sta rt of therap y, loss of CHR, CCy R or PCy R”).
In addition, CML -related death or progression to AP or BC will be considered as loss of CHR 
in any  case (if they  occurred on treatment) .
Complete hematologic response (CHR)
CHR is defined when all of the followin g criteria are present at any assessment which is
confirmed b y another assessment at least after 4 weeks:
White blood cells ( WBC ) count < 10 × 109/L
Platelet count < 450 × 109/L
Novartis Confidential Page 69
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Basophils < 5%
No blasts and prom yelocytes in peripheral blood
Myelocy tes + metam yelocytes < 5% in peripheral blood
No evidence of extramedullary  disease, including spleen and liver. As extramedullary
disease is evaluated less frequentl y than hematology, the results of these evaluations are
carried forward until the next assessmen t (unless extramedullary  disease was not present
at the current assessment but present at the next).
The assessment is not considered CHR, if there are any  values indicative of CML  in AP or BC 
(i.e. by blasts in bone marrow). The information used for hemat ological assessment will be
obtained from the laboratory , extramedullary  and bone marrow data, all merged b y patient and 
date. To accommodate for missing parameters, specific laboratory  results may be carried
forward up to 14 days such that assessments performed within a two-week period cancombined 
into one complete evaluation of hematological response. A value will be carried forward for no 
more than up to the subsequent valid assessment of the respective laborator yparameter. If even 
after apply ing this carry -forward algorithm, any of the above laboratory parameters is not 
available at a given assessment date, the response assessment will beconsidered missing, unless 
any of the available values (including those carried forward) indicates that there is no response 
in which case the assessment will be ‘No response’.
For confirmation of CHR, both the initial CHR as well as the confirming assessment (at least 4 
weeks after the initial assessment) must satisfy  all the criteria mentioned above and no
assessment in between indicates ‘No response’. The terms “confirmed CHR” and “CHR” are 
used as synony mous given that the definition of CHR mentioned above alread y includes a 
requirement for confirmation.
5.4.4 Treatment Failure
The following events will constitute ‘treatm ent failure’, and are based on the ELN criteria
(Baccarani et 
al 2013) defining failure of a second line treatment adapted to include 
discontinuation of randomized treatment as an event
:
No CHR or > 95% Ph+ metaphases at three months af ter initiation of therapy  or 
thereafter
BCR -ABL 1
ratio > 10% IS and/or > 65% Ph+ metaphases at six months af ter 
initiation of therapy or thereafter
BCR -ABL 1ratio > 10% IS and/or > 35% Ph+ metaphases at 12 months after 
initiation of therapy or thereafter
Loss of CHR, CCy R or PCy R at any  time after initiation of therap y
Detection of new BCR -ABL 1mutations which potentially  cause resistance to study  
treatment ( T315I and V299L ), at an y time after initiation of therap y  
Confi rmed loss of MMR in 2 consecutive tests
New clonal chromosome abnormalities in Ph+ cells: CCA/Ph+: at any  time after 
initiation of therapy
Novartis Confidential Page 70
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
Discontinuation from randomized treatment for any reason * (Note that Reason for 
treatment discontinuation= ”completed ” doesn’t indicate a premature treatment 
discontinuation )
5.4.5 CML progression to accelerated phase (AP) or blast crisis (BC)
For the evaluation of CML  progression to AP or BC, the following criteria will be used.
Accelerated phase (AP) isdefined b y any of th e following:
≥ 15% blasts in the peripheral blood or bone marrow aspirate, but < 30% blasts in 
both the peripheral blood and bone marrow aspirate
≥ 30% blasts plus promyelocy tes in peripheral blood or bone marrow aspirate, but < 
30% blasts in both the peripheral blood and bone marrow aspirate
≥ 20% basophils in the peripheral blood
Thrombocy topenia (<100 x 109/L) that is unrelated to therap y*
*As thrombocy topenia is a known adverse reaction to CML  therap y, platelets <100 × 109/L are 
only considered as CML -AP if the patient had these values within 30 days of treatment 
discontinuation due to disease progression. In this case, comments are to be provided on the 
termination page that thrombocy topenia is indicative of progression to AP and an adverse event 
(AE) entered with relationship to study treatment = ‘Not suspected’
Blast crisis (BC) is defined by  any of the following:
≥ 30% blasts in periphera l blood or bone marrow aspirate
Appearance of extramedullary  involvement other than hepatosplenomegal y proven b y 
biopsy  (i.e., chloroma).
The second bullet criteria can’t be considered in this study  as this information was not 
collected.
5.4.6 CML -related death s
CML -related death is considered as any death during treatment or follow -up(safet y or survival)
if the principal cause of death is marked as “stud y indication” in the eCRF by  the 
investigator,
or if the death occurred subsequent to documented progression to AP/BC and the cause of 
death is reported as “unknown” or not reported b y the investigator .
With respect to the second bullet, as “unknown” cause of death will be coded to the Medical 
Dictionary  for Regulatory  Activities (MedDRA) preferred term ‘Death’, this MedDRA coding 
will be used in the derivation of CML -related death.
5.4.7 Disease progression
The following events are considered disease progression
CML -related deaths
Accelerated phase (AP)
Blast crisis (BC)
Novartis Confidential Page 71
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
5.4.8 Overall survival
This includes all- cause deaths.
5.5 Derivation of response rates and categories 
5.5.1 Response rate at a specific time point
The molecular and cytogenetic response evaluations will be summarized by the following 
mutually  exclusive categories which are based on the respective assessment within the time 
window:
Response categories (sections 5.4.1 and 5.4.2 ) :Patients with an available assessment at 
that time point (+/
-time window) indicating an y of the response categories.
No response: Patients with assessment at that time point (+/- time window) indicating 'no 
response'
Missing: Patients without an evaluabl e response assessment at that time point (+/ -time 
window). This category  is then further split into patients who are ongoing without 
treatment failure at the beginning of the relevant time window, patients who are ongoing
with treatment failure at the beg inning of the relevant time window ,patients who 
discontinued due to lack of efficacy , disease progression (PD) or death and patients who 
discontinued due to other reasons.
5.5.2 Response rate by  a specific time point (best response)
In this analysis, patients w
ho had achieved any response at or before the time point will be 
display ed in their best response category , no matter if they lost the response/discontinued or not. 
Therefore this response rate represents the best observed response rate up to that specific time 
point (including the time window). 
Patients for whom an evaluable response assessment was never provided will be classified as 
‘Missing’. 
5.6 Statistical models
5.6.1 Primary  analy sis
The null hypothesis of equality  of MMR rate at 24 weeks in the two treatme nt armswill be 
tested against two -sided alternative. The statistical hy potheses are:
H0: RA 24wk= RB 24wkversus HA: RA 24wk≠ RB 24wk, for a two- sided test
where RA 24wkis the probability  of MMR rate at 24 weeks inasciminib arm and RB 24wkis the 
probability  of MMR rate at 24 weeks in bosutinib arm.
The Cochran- Mant e l- Haenszel chi-square testX2
CMH(im plement ed via S ASprocedure F REQ
withCMH option in t heT ABL ESstatem ent), stratified by the randomization stratification 
factor, i.e. cytogenetic response status ( MCyR vs no MCy R) at screening, willbeused totest
thediffer ence inresponse rates between the treatment arms. The p -value corresponding to the 
CMH test for “general association” will be used which follows a Chi -square distri bution with 
one degree of freedom.
Novartis Confidential Page 72
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
The 95% confidence interval for the unstratified difference in MMR rate at 24 weeks between 
treatment groups will be provided using the Wald method (implement ed via SASprocedure
F
REQ with RISKDIFF option in the TABL ES s tatem ent, under the default 
METHOD=WALD and VAR=SAMP LE).If the 2×2 table is with asciminib in row 1, 
bosutinib in row 2, MMR in column 1 and No MMR in column 2, then the SAS output will 
give the estimate of (risk for MMR at 24 weeks inasciminib –risk for MMR at 24 weeks in 
bosutinib) . The corresponding Mant el-Haenszel estimate of common risk difference and 95% 
confidence interval will also be presented (with RISKDIFF( COMMON )option in t
he
TABL ESstatem ent, taking the Mant el-Haenszel estimate from the SAS output table ).
If the sampling assumptions for chi -square test is not met (i.e. the expected frequencies should
e
xceed 5forall of tablecells), theexact Cochran- Mantel -Haenszel test will be use d 
(imple mented via SAS procedure MULTTEST). The testisperform edbyrunni ng a stra ti fied
version ofthe Cochran- Armitage permutation test [Armitage et al. 1969] . In s tudies w ith
stratified randomi zation, the chi-square appro ximation is considered appropr iate for the 
X2
CMHstatistics iftheruleofMantelandFleiss[Mantel and Fleiss 1980] issatisfied.
Confidence inter
valforMMR rate within each treatment arm
MMR will besummarizedinterms of per centagerates with 95% confidence int erva lusing
exact binomial confidence interval (implemented using SAS proced ure FREQwith EXACT
statement forone-way table [ Clopper and Pearson 1934] ).
5.6.2 Key secondary  analysis
The null hypothesis of equality  of MMR rate at 96weeks in the two treatment armswill be 
tested against two -sided alternative. The statistical hy potheses are:
H0: RA 96wk= RB 96wkversus HA: RA 96wk≠ RB 96wk, for a two- sided test
where RA 96wkis the probability  of MMR rate at 96weeks inasciminib arm and RB 96wkis the 
probability  of MMR rate at 96 weeks in bosutinib arm.
The same approaches as for the primary  endpoint (Section 5.5.1) will be applied here for the 
Cochra
n-Mant el-Haenszel chi-square test X2
CMH, the 95% Wald confidence interval for the 
difference in MMR rate at 96 weeks between treatment groups ,the Mant e
l-Haenszel estimate 
of common 
risk difference with 95% confidence interval , and the confidence interval for MMR 
rate within each treatment arm .
Multiplicity  adjustment
Formal statistical testing of the key  secondary  endpoint will be performed with = 0.05 (two -
sided) only if the primary  endpoint is significant by means of a gatekeeping procedure to control 
the overall alpha level.
Novartis Confidential Page 73
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
5.6.3 Other analy ses
Mantel -Haenszel comm on odds ratio
To obtain Mantel -Haenszel estimates of the common odds ratio and the corresponding 95% 
confidence interval in exploratory  analy ses,  it requires SASprocedure FREQwithCMHand 
RELR ISK options in the TABL ESstatem ent. 
Logistic Regression 
Odds ratio will beused as a me asure of associati onbetw een tr eatment and response in 
exploratory  anal yses (Section 2.14). The odds r atiowillbe derived from thelogisticregre ssion
model(impl emented usingSASprocedure LOGISTIC, w ith tr eatmentspecified as an
explanat ory vari abl e in the CLASS statem ent) which allows forincluding not only the
stratifi c
ation factor but also foradjustments forother covaria tes(both categoricaland
continuous). Theodds ratio willbepresented with 95% Wald confidence limits.
In ca ses wh ereanexact test hasbeen used tocompare response rates, the odds ratio should be 
determined using ex actlogisticregression, and theodds ratio presented with exact 95% 
confidence limits. I
nthesecases,SASPRO C LOGISTIC withEXACT ONLYoptio nwillbe 
used.
Kaplan -Meier estimates
Anestimate of the survival function in each treatment group w illbe constructed using Kaplan -
Meier (product-limit ) methodas implemented inPROC LIFETEST with METH OD=KM
option. The PROC LIFETEST statement will usetheoption CON FTYP E=LOGL OG.
Median survival foreachtreatment group will be obt ained along wit h 95% confide nce 
intervals ca lculated from PRO C LIFE TEST output using themethod of[Brookm eyer and 
Crowl ey 1982] . Kaplan- Mei er es timatesof the survivalfunction w ith 95% confidence
interval s atspecific timepoint swill besummarized.Thestandard error of the Kaplan-
Meier estimate will be calculated using Gr eenwood’s formula [Collett 1994].
Hazard ratio
Hazard ratio will be estimated by fitting the Cox proportional hazards model using SAS 
procedure PHREG (with TI ES=EXACT option in the MODEL statement). 
A stratified unadjusted Cox model willbe, i.e.theMOD ELstatement will include the
treatment group va riable astheonly covar iateand theSTRATA sta tement will include
stratification vari abl e(s). Hazard ratio with two-sided 95% confidence interval will be based 
on Wald test.
Cumulative incidence
The cumulative incidence proportion (CIP) will be estimated using SAS procedure LIFETEST 
or PHREG with EVENTCODE=Code for event of interest (e.g. MMR) as option in the 
MODEL  statement, whereas code=0 for censored subjects and any other code (e.g. code=2) 
for subjects who dropped out due to a competing risk. The estimated CIP at the defined time 
points will be presented with 95% CI together with number of subjects with events, number of 
subjects with competing risks, and number of subjects censored.
Novartis Confidential Page 74
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
5.6.4 Calculat ion of exposure -adjusted incidence rate
To adjust for different durations of exposure across treatment arms, the incidence rate per 100 
patient -years of exposure (exposure -adjusted incidence rates of adverse events) will be 
calculated.
The I R/100 py r is de fined as numerator/denominator, where
Numerator = number of patients with the adverse events of interest (not the number of 
events; one patient may  have more than one event).
Denominator = patient -years = total time at risk in y ears = among all patients in the 
population, sum of the duration of exposure (in day s) until the first onset of the event 
of interest, if the patient experienced the event, or until the date of last dose if the 
patient did not experience the event / 365.25.
The patient -years (i.e. total time at risk in y ears) will be calculated as the sum of times at risk 
in day s over all patients in the population / 365.25.
The time at risk for a patient in day s will be calculated as follows:
If the patient experienced the event of interest, the time at risk for this patient is the 
duration of exposure from the first dose of treatment until the first onset of the event.
For patients without an event of interest, the time at risk is the total duration of 
exposure during core study , as applicable.
6 Reference
1.Armitage P, McPherson CK and Rowe BC (1969). Repeated significance tests on 
accumulating data. J .R. Statist. Soc. A, 132, 232 -244. 
2.Baccarani M, Deininger DW, Rosti G, et al (2013). European LeukemiaNet 
recommendations for the management of chro nic my eloid leukemia: 2013. Blood;
122(6):872-84.
3.Branford S, Hughes T (2006) Diagnosis and monitoring of chronic m yeloid leukemia b y 
qualitative and quantitative RT -PCR. Methods Mol Med; 125:69 -92.
4.Brookmey
er R and Crowley  J (1982). A Confidence Interval for the Median Survival 
Time. Biometrics, 38, 29 - 41. 
5.Clopper CJ and Pearson ES (1934).  The use of confidence or fiducial limits illustrated in 
the case of the binomial.  Biometrical , 26, 404- 413.
6.
Collet D (1994). Modelling survival data in medical re search. London, Chapman & Hall.
7.Gambacorti -Passerini C, Brümmendorf TH, Kim DW, et al (2014). Bosutinib efficacy  and 
safet y in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: 
Minimum 24 -month follow -up. Am J Hematol; 89(7):732-42.
8.García -Gutiérrez V, Martinez -Trillos A, L opez Lorenzo JL , et al (2015) .Bosutinib shows 
low cross intolerance, in chronic m yeloid leukemia patients treated in fourth line. Results 
of the Spanish compassionate use program. Am J Hematol; 90(5): 429-33.
9.Khoury  HJ, Cortes JE, Kantarjian HM, et al (2012). Bosutinib is active in chronic phase 
chronic m yeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. 
Blood; 119(15):3403 -
12.
Novartis Confidential Page 75
SAP Addendum 1 14-Oct-2020 (2:27) CABL001A2301
10.Lamb E, et al (2012) Kidney  Function Tests  In Elsevier Health Sciences (Ed), Tietz 
Textbook of Clinical Chemistry and Molecular Diagnostics (Chapter 25). Also retrieved 
from 
https://books.google.es/books?id=BBLRUI4aHhkC&lpg=PA685&hl=es&pg=PA685#v=o
nepage& q&f=false
11.Mantel, N. and Joseph L  Fleisś (1980). Minimum expected cell size requirements for the 
Mantel -Haenszel one degree- of-freedom Chi -Square Test and a related rapid procedure. 
American Journal of Epidemiology , 112, 129- 134.
12.Ross DM, Branford S, Moore S, et al (2006) Limited clinical value of regular bone 
marrow cy togenetic analy sis in imatinib -treated chronic phase CML patients monitored by  
RQ-
PCR for BCR- ABL. Leukemia; 20(4):664 -70.
Novartis   Confidential  Page 2 
SAP Summary of changes   CABL001A2301  
 
 
Date  Time point  Reason for 
update  Outcome for update  Section and title impacted 
(Current)  
25-
Aug-
2017 Prior to 
DB lock  
for primary 
analysis  Creation of 
final version N/A - First version  NA 
     
26-Mar-
2020 Prior to 
DB lock 
for primary analysis  Implementation 
of protocol 
amendment s 2 
and 3.  ABL001 has been replaced by International Nonproprietary Name (INN) asciminib.  
Introduction of the switch to asciminib option for patients experiencing treatment failure on bosutinib treatment   Update of the definition of end of study treatment  
Added a potential End- of-
Study- Treatment analysis 
different from the 96 -week 
analysis  
Addition/removal of 
secondary safety objectives and exploratory efficacy 
objectives  Throughout the SAP amendment  
 
Section  1.1, 
Figure 1 -1 
Sections 2.1, 2.3 Analyses added throughout the document Section 1.1 
    
Table 1 -1 
 
  Additional analyses, clarification  
Clarification on which data are 
included in the analyses, 
which assessments are 
considered for safety  and 
efficacy analyses  
Addition of the treatment arms 
and definition of the date of 
end of study treatment  
Removal of windows defined 
for ECGs, LVEF and PK 
assessments as they are not 
needed.  
As per Health Authorities Section 2.1     
Section 2.1.1       
Section 2.3.1  
Novartis   Confidential  Page 3 
SAP Summary of changes   CABL001A2301  
 
request, a ddition  of the 
breakdown per different time 
points of the number (%) of 
patients who discontinued the 
study treatment phase and of 
the primary reason for study 
treatment phase 
discontinuation 
PAS: Removal of the 
condition related to vomiting to consider a concent ration 
evaluable as the occurrence 
and time of vomiting is not 
collected in the CRF.  
Addition of a subgroup 
“Stratum reported in the CRF ” 
for the analysis by subgroup of the primary endpoint (to take 
into account the 
mistratification  cases ) 
Removal of the subgroup 
“with or without historical 
BCR -ABL1 mutation by local 
lab” as this is not considered clinically relevant  
Additional analyses of prior 
TKI and non TKI 
antineoplastic therapies  
Implementation of the 
estimand language for the 
primary and key seconda ry 
objectives  
Addition of a sensitivity 
analysis of the primary 
estimand stratifying by the 
stratum recorded in the CRF  to 
take into account that many 
stratification errors occurred  
Addition of Time -to-event 
analyses for time to MMR and 
time to CCyR   
       
Section 2.2 
 
    Section 2.2.1      
 
    
Section  2.4.2 
 
 
Sections 2.5 and 
2.6   
Section 2.5.5 
     
Section 2.7.2  
 
Novartis   Confidential  Page 4 
SAP Summary of changes   CABL001A2301  
 
Added how time is censored 
for time to MMR/CCyR, 
clarification on how to handle 
missing BMA assessments 
due to MMR being achieved 
Added analyses AEs and 
SAEs incidence rates by 
adjusting for exposure and by 
reporting by time intervals  to 
account for  potential 
difference in exposure 
between the treatment arms  
Clarified handling of 
unscheduled ECG 
measurements in the analyses  Section 2.7.3     
Section 2.8.1 
      
Section 2.8.4.1  
4-
June-2020 Prior to 
DB lock 
for primary analysis   Creation of 
amendment 2.0 Clarified baseline for 
mutations  
Clarified EOT is mapped to 
defined time points 
Modified age subgroup, added Line of therapy subgroup and 
moved Without T315I/V299L to Supplementary analysis  
(All patients with 
T315I/V299L mutations 
identified at the Week 1 Day 1 
visit are discontinued from 
study treatment when the 
mutation results beco me 
available) . 
Clarified Mutation subgroup 
doesn’t include T315I/V299L mutations.  
Modified age categories  
Added COVID -19 related PDs 
analysis  
Added definitions of time on 
treatment, duration of 
exposure in patient -years and 
average daily dose   Section 2.1.1  
 
 
Section 2.2.1 
             
Section 2.3 Section 2.3.1 
 
Section 2.4.1   
 
Novartis   Confidential  Page 5 
SAP Summary of changes   CABL001A2301  
 
Additional a nalyses of prior 
TKI therap y 
Added summary of 
concomitant therapies for on-
switched treatment period.  
Added COVID -19 sensitivity 
analyses for the primary and 
key secondary endpoints 
Added a supplementary 
analysis to the primary 
endpoint (Patients without 
T315I/V299L mutations at 
Week 1 Day 1  visit) 
Added new graph for Ctrough values of asciminib  
Updated the list of changes to the protocol specified analyses  
Added imputation rules for 
immature cells  
Removed imputation rules for corrected calcium as corrected calcium is collected  
Clarified all available values 
for BUN and UREA will be 
reported under the parameter 
name BUN in listing to avoid 
double reporting of same 
information  
Definition of loss of MMR: Removed reference to confirmation of loss of CHR/CCyR  
Loss of CHR: clarified “Progressive splenomegaly refractory to therapy” is ≥ 5cm below left intercostal 
margin”  
Implemented change to definition of treatment failure 
(Protocol amendment 3)  Section 2.4.2  
Sections 2.5.5, 
2.6.5  
Section 2.5.6 
 
 
Section 2.9  
  Section 4  
 Section 5.3 
 
 
  
 
        Section 5.4.1    
Section 5.4.3 
    
Section 5.4.4  
 
Novartis   Confidential  Page 6 
SAP Summary of changes   CABL001A2301  
 
Clarified what 
“Thrombocytopenia (<100 x 109/L) that is unrelated t o 
therapy” is.  
Added derivation of response 
rates and categories section  Section 5.4.5     
Section 5.5. 
7-
Aug-
2020 Prior to 
DB lock 
for primary analysis   Creation of 
amendment 3.0 after FDA ty pe 
C teleconference on 28 July 020 As agreed with FDA, added 
sensitivity analyses of the 
primary and key secondary 
endpoints without the 
imputation rule used  in the 
main analyses  in case of 
missing PCR evaluations at 
24/96 weeks.  
Per FDA request, added 
another subgroup of interest: 
BCR -ABL ratio at baseline ≥ 
1% or <1%.  
Added calculation rules for 
duration of interrruption. 
Added derivation rule for 
corrected calcium using the 
reported total calcium value 
and albumin. 
Aligned the d efinition of loss 
of CCyR with the definition of 
loss of CHR by adding the 
requirement that loss of CCyR (Ph+ bone marrow cells to > 
0%) must have led to treatment 
discontinuation because of 
lack of efficacy.  Section 2.5.5        
Section 2.2.1 
   
Section 2.4.1 
 Section 5.3 
   
Section 5.4.2 
14-
Oct-
2020 
Post DB 
lock for 
primary analysis  Creation of 
addendum 1.0 
to include post-
hoc analyses  
added after FIR results review  Added that protocol deviations 
during the treatment switch 
period will be reported 
separately and clarified .  
Clarified how to identify prohibited concomitant medications.  
Added an analysis  of time to 
MMR considering Section 2.3.1    
Section 2.4.2 
  
Sections 2.7.2 
and 5.6.3  
Novartis   Confidential  Page 7 
SAP Summary of changes   CABL001A2301  
 
discontinuation from 
treatment due to any reason, 
without prior achievement of MMR as a competing risk. 
Added an analysis of the 
MMR rate using the number of subjects with adequate follow -
up as the denominator, i.e. for each time point (week x), only patie nts randomized at least x 
weeks prior to the cut -off date 
will be considered. 
Added that post-hoc 
exploration of the treatment effect in different subgroups and assessment of the possible effect of differences in distribution of baseline characteristics were conducted (e.g. distribution of reasons for discontinuation of last prior TKI by gender and treatment, distribution of MCyR status at baseline by reasons for discontinuation of last prior TKI, distribution of mutation status at Week 1 Day 1 by reasons f or 
discontinuation of last prior 
TKI).   
   
        
Section 2.14 
 
Novartis   Confidential  Page 8 
SAP Summary of changes   CABL001A2301  
 
 